PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Leblais, V; Demolombe, S; Vallette, G; Langin, D; Baro, I; Escande, D; Gauthier, C				Leblais, V; Demolombe, S; Vallette, G; Langin, D; Baro, I; Escande, D; Gauthier, C			beta(3)-adrenoceptor control the cystic fibrosis transmembrane conductance regulator through a cAMP/protein kinase A-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-3-ADRENERGIC RECEPTOR; FUNCTIONAL BETA(3)-ADRENOCEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; TRACHEAL EPITHELIUM; CHLORIDE CHANNEL; TRANSGENIC MICE; CL CHANNELS; CELL-LINE; CFTR	In human cardiac myocytes, we have previously identified a functional beta(3)-adrenoceptor in which stimulation reduces action potential duration. Surprisingly, in cardiac biopsies obtained hom cystic fibrosis patients, beta(3)-adrenoceptor agonists produced no effects on action potential duration. This result suggests the involvement of cystic fibrosis transmembrane conductance regulator (CFTR) chloride current in the electrophysiological effects of beta(3)-adrenoceptor stimulation in non-cystic fibrosis tissues. We therefore investigated the control of CFTR activity by human beta(3)-adrenoceptors in a recombinant system: A549 human cells were intranuclearly injected with plasmids encoding CFTR and beta(3)-adrenoceptors. CFTR activity was functionally assayed using the 6-methoxy-N-(3-sulfopropyl) quinolinium fluorescent probe and the patch-clamp technique. injection of CFTR-cDNA alone led to the expression of a functional CFTR protein activated by cAMP or cGMP. Co-expression of CFTR (but not of mutated Delta F508-CFTR) with high levels of beta(3)-adrenoceptor produced an increased halide permeability under base-line conditions that was not further sensitive to cAMP or beta(3)-adrenoceptor stimulation. Patch-clamp experiments confirmed that CFTR channels were permanently activated in cells co-expressing CFTR and a high level of beta(3)-adrenoceptor. Permanent CFTR activation was not associated with elevated intracellular cAMP or cGMP levels. When the expression level of beta(3)-adrenoceptor was lowered, CFTR was not activated under base-line conditions but became sensitive to beta(3)-adrenoceptor stimulation (isoproterenol plus nadolol, SR 58611, or CGP 12177). This later effect was not prevented by protein kinase A inhibitors. Our results provide molecular evidence that CFTR but not mutated Delta F508-CFTR is regulated by beta(3)-adrenoceptors expression through a protein kinase A-independent pathway.	Hotel Dieu, Lab Physiopathol & Pharmacol Cellulaires & Mol, INSERM, CJF 96 01, F-44093 Nantes, France; Hotel Dieu, INSERM, CJF 94 04, F-44093 Nantes, France; CHU Rangueil, INSERM, U317, F-31056 Toulouse, France; Univ Nantes, Fac Sci & Tech, F-44322 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Gauthier, C (corresponding author), Hotel Dieu, Lab Physiopathol & Pharmacol Cellulaires & Mol, INSERM, CJF 96 01, Bat HBN,BP 1005, F-44093 Nantes, France.		Baró, Isabelle/D-3604-2015; Baró, Isabelle/ABH-5667-2020; Gauthier, Chantal/D-6198-2015; LEBLAIS, Véronique/Q-3845-2018	Baró, Isabelle/0000-0003-4850-4171; Baró, Isabelle/0000-0003-4850-4171; LEBLAIS, Véronique/0000-0001-9934-8944; Langin, Dominique/0000-0002-2669-7825				BARO I, 1994, J PHYSIOL-LONDON, V478, P469, DOI 10.1113/jphysiol.1994.sp020266; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BLIN N, 1993, MOL PHARMACOL, V44, P1094; Bohm M, 1997, J MOL MED, V75, P842, DOI 10.1007/s001090050175; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DONG YJ, 1995, EMBO J, V14, P2700, DOI 10.1002/j.1460-2075.1995.tb07270.x; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; Gauthier C, 1998, J CLIN INVEST, V102, P1377, DOI 10.1172/JCI2191; GAUTHIER C, 1994, J MOL CELL CARDIOL, V26, P1267, DOI 10.1006/jmcc.1994.1146; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; GUILLAUME JL, 1994, EUR J BIOCHEM, V224, P761, DOI 10.1111/j.1432-1033.1994.00761.x; HOLLENGA C, 1991, EUR J PHARMACOL, V200, P325, DOI 10.1016/0014-2999(91)90590-M; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LEE RJ, 1975, EUR J PHARMACOL, V33, P371, DOI 10.1016/0014-2999(75)90182-X; LELIAS JM, 1993, FEBS LETT, V324, P127, DOI 10.1016/0014-5793(93)81377-C; LEVASSEUR S, 1995, GASTROEN CLIN BIOL, V19, P668; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILLIGAN G, 1994, BIOCHEM PHARMACOL, V48, P1059; Mohammad-Panah R, 1998, AM J PHYSIOL-CELL PH, V274, pC310, DOI 10.1152/ajpcell.1998.274.2.C310; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; REN Q, 1993, J BIOL CHEM, V268, P16483; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TAMAOKI J, 1993, LIFE SCI, V53, P1509, DOI 10.1016/0024-3205(93)90558-K; TIEN XY, 1994, J BIOL CHEM, V269, P51; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WEBBER SE, 1992, BRIT J PHARMACOL, V105, P857, DOI 10.1111/j.1476-5381.1992.tb09068.x; Wilson S, 1996, J PHARMACOL EXP THER, V279, P214; Wotta DR, 1997, MOL BRAIN RES, V44, P55, DOI 10.1016/S0169-328X(96)00189-1; Zilberfarb V, 1997, J CELL SCI, V110, P801	40	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6107	6113		10.1074/jbc.274.10.6107	http://dx.doi.org/10.1074/jbc.274.10.6107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037693	hybrid			2022-12-27	WOS:000078902800015
J	Kim, DY; Kam, Y; Koo, SK; Joe, CO				Kim, DY; Kam, Y; Koo, SK; Joe, CO			Gating connexin 43 channels reconstituted in lipid vesicles by mitogen-activated protein kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; EPIDERMAL GROWTH-FACTOR; INTERCELLULAR COMMUNICATION; SUBSTRATE RECOGNITION; EPITHELIAL-CELLS; HORIZONTAL CELLS; MEMBRANE CHANNEL; PLASMA-MEMBRANE; GLIOMA-CELLS; RAT-LIVER	The regulation of gap junctional permeability by phosphorylation was examined in a model system in which connexin 43 (Cx43) gap junction hemichannels were reconstituted in lipid vesicles. Cx43 was immunoaffinity-purified from rat brain, and Cx43 channels were reconstituted into unilamellar phospholipid liposomes. The activities of the reconstituted channels were measured by monitoring liposome permeability. Liposomes containing the Cx43 protein were fractionated on the basis of permeability to sucrose using sedimentation in an iso-osmolar density gradient. The gradient allowed separation of the sucrose-permeable and -impermeable liposomes. Liposomes that were permeable to sucrose were also permeable to the communicating dye molecule lucifer yellow. Permeability, and therefore activity of the reconstituted Cx43 channels, were directly dependent on the state of Cx43 phosphorylation. The permeability of liposomes containing Cx43 channels was increased by treatment of liposomes with calf intestinal phosphatase. Moreover, liposomes formed with Cx43 that had been dephosphorylated by calf intestinal phosphatase treatment showed increased permeability to sucrose. The role of phosphorylation in the gating mechanism of Cx43 channels was supported further by the observation that phosphorylation of Cx43 by mitogen-activated protein kinase reversibly reduced the permeability of liposomes containing dephosphorylated Cx43. Our results show a direct correlation between gap junctional permeability and the phosphorylation state of Cx43.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; NIH, Lab Genet Dis, Dept Biomed Sci, Seoul 122020, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH)	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	cojoe@sorak.kaist.ac.kr	Joe, Cheol O/C-1917-2011	Kam, Yoonseok/0000-0003-4712-9058				ALLEN F, 1990, DEVELOPMENT, V108, P623; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASMOTO M, 1991, MOL CARCINOG, V4, P322; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DONALDSON P, 1992, J MEMBRANE BIOL, V129, P155; DUPONT E, 1991, EUR J BIOCHEM, V200, P263, DOI 10.1111/j.1432-1033.1991.tb21075.x; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GUTHRIE S, 1988, DEVELOPMENT, V103, P769; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HEUSSEN GAH, 1992, CARCINOGENESIS, V13, P719, DOI 10.1093/carcin/13.4.719; Kanemitsu MY, 1998, CELL GROWTH DIFFER, V9, P13; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; Koo SK, 1997, MOL CELL BIOCHEM, V167, P41, DOI 10.1023/A:1006831114120; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MALCHOW RP, 1993, J NEUROSCI RES, V35, P237, DOI 10.1002/jnr.490350303; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NA MR, 1995, TOXICOLOGY, V98, P199, DOI 10.1016/0300-483X(94)02931-J; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; Saez JC, 1997, J MOL CELL CARDIOL, V29, P2131, DOI 10.1006/jmcc.1997.0447; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; TROSKO JE, 1990, PATHOBIOLOGY, V58, P265, DOI 10.1159/000163596; VanderMolen MA, 1996, J BIOL CHEM, V271, P12165, DOI 10.1074/jbc.271.21.12165; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Xie HQ, 1997, J CELL BIOL, V137, P203, DOI 10.1083/jcb.137.1.203; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	53	97	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5581	5587		10.1074/jbc.274.9.5581	http://dx.doi.org/10.1074/jbc.274.9.5581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026174	hybrid			2022-12-27	WOS:000078804400045
J	Neuhierl, B; Thanbichler, M; Lottspeich, F; Bock, A				Neuhierl, B; Thanbichler, M; Lottspeich, F; Bock, A			A family of S-methylmethionine-dependent thiol/selenol methyltransferases - Role in selenium tolerance and evolutionary relation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; TRIMETHYLSELENONIUM ION; ADENOSYLMETHIONINE; SELENOCYSTEINE; METABOLISM; TOXICITY; PROTEINS; PLANTS	Several plant species can tolerate high concentrations of selenium in the environment, and they accumulate organoselenium compounds. One of these compounds is Se-methylselenocysteine, synthesized by a number of species from the genus Astragalus (Fabaceae), like A. bisulcatus, An enzyme has been previously isolated from this organism that catalyzes methyl transfer from S-adenosylmethionine to selenocysteine. To elucidate the role of the enzyme in selenium tolerance, the cDNA coding for selenocysteine methyltransferase from A. bisulcatus was cloned and sequenced. Data base searches revealed the existence of several apparent homologs of hitherto unassigned function, The gene for one of them, yagD from Escherichia coli, was cloned, and the protein was overproduced and purified. A functional analysis showed that the YagD protein catalyzes methylation of homocysteine, selenohomocysteine, and selenocysteine with S-adenosylmethionine and S-methylmethionine as methyl group donors. S-Methylmethionine was now shown to be also the physiological methyl group donor for the A. bisulcatus selenocysteine methyltransferase. A model system was set up in E, coli which demonstrated that expression of the plant and, although to a much lesser degree, of the bacterial methyltransferase gene increases selenium tolerance and strongly reduces unspecific selenium incorporation into proteins, provided that S-methylmethionine is present in the medium, It is postulated that the selenocysteine methyltransferase under selective pressure developed from an S-methylmethionine-dependent thiol/selenol methyltransferase.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Max Planck Inst Biochem, Prot Chem Abt, D-82152 Martinsried, Germany	University of Munich; Max Planck Society	Bock, A (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.		Thanbichler, Martin/E-6035-2010					ABRAHAMSON L, 1965, ARCH BIOCHEM BIOPHYS, V109, P376, DOI 10.1016/0003-9861(65)90376-0; AIBA H, 1981, J BIOL CHEM, V256, P1905; BALISH E, 1967, ARCH BIOCHEM BIOPHYS, V119, P62, DOI 10.1016/0003-9861(67)90429-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BROWN TA, 1982, BIOL REV, V57, P59, DOI 10.1111/j.1469-185X.1982.tb00364.x; BROWN TA, 1981, PLANT PHYSIOL, V67, P1051, DOI 10.1104/pp.67.5.1051; BURNELL JN, 1981, PLANT PHYSIOL, V67, P316, DOI 10.1104/pp.67.2.316; CARRITHERS SL, 1994, BIOCHEM PHARMACOL, V48, P1017, DOI 10.1016/0006-2952(94)90373-5; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cournoyer B, 1998, BBA-GENE STRUCT EXPR, V1397, P161, DOI 10.1016/S0167-4781(98)00020-7; COX JC, 1981, J BACTERIOL, V145, P1317, DOI 10.1128/JB.145.3.1317-1324.1981; DEV IK, 1984, J BIOL CHEM, V259, P8402; GANTHER HE, 1966, BIOCHEMISTRY-US, V5, P1089, DOI 10.1021/bi00867a039; Goulding CW, 1997, BIOCHEMISTRY-US, V36, P8082, DOI 10.1021/bi9705164; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOFFMAN JL, 1987, ARCH BIOCHEM BIOPHYS, V254, P534, DOI 10.1016/0003-9861(87)90134-2; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HOLLOWAY CT, 1970, J BACTERIOL, V104, P734, DOI 10.1128/JB.104.2.734-747.1970; Huttenhofer A, 1998, COLD SPRING HARBOR M, P603; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; KUHN I, 1986, GENE, V42, P253, DOI 10.1016/0378-1119(86)90229-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUCHLI A, 1993, BOT ACTA, V106, P455; LOW B, 1968, P NATL ACAD SCI USA, V60, P160, DOI 10.1073/pnas.60.1.160; McConnell KP, 1942, J BIOL CHEM, V145, P55; Miller JH., 1992, SHORT COURSE BACTERI, P72; MOZIER NM, 1988, J BIOL CHEM, V263, P4527; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; Neuhierl B, 1996, EUR J BIOCHEM, V239, P235, DOI 10.1111/j.1432-1033.1996.0235u.x; PALMER IS, 1970, BIOCHIM BIOPHYS ACTA, V208, P260, DOI 10.1016/0304-4165(70)90244-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schultz J, 1940, J BIOL CHEM, V133, P199; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; SHAPIRO SK, 1965, J BIOL CHEM, V240, P2512; SHRIFT A, 1969, ANN REV PLANT PHYSIO, V20, P475, DOI 10.1146/annurev.pp.20.060169.002355; SHRIFT A, 1965, BIOCHIM BIOPHYS ACTA, V100, P65, DOI 10.1016/0304-4165(65)90428-9; SHRIFT A, 1963, BIOCHIM BIOPHYS ACTA, V71, P483, DOI 10.1016/0006-3002(63)91113-2; Spallholz JE, 1997, BIOMED ENVIRON SCI, V10, P260; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; TRELEASE SAM F., 1942, SCIENCE, V95, P656, DOI 10.1126/science.95.2478.656; TRELEASE SF, 1960, SCIENCE, V132, P618, DOI 10.1126/science.132.3427.618; Trossat C, 1998, PLANT PHYSIOL, V116, P165, DOI 10.1104/pp.116.1.165; VIRUPAKSHA TK, 1965, BIOCHIM BIOPHYS ACTA, V107, P69, DOI 10.1016/0304-4165(65)90389-2; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WU SE, 1983, BIOCHEMISTRY-US, V22, P2828, DOI 10.1021/bi00281a009; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; ZAPPIA V, 1969, BIOCHIM BIOPHYS ACTA, V178, P185, DOI 10.1016/0005-2744(69)90147-8	55	148	163	2	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5407	5414		10.1074/jbc.274.9.5407	http://dx.doi.org/10.1074/jbc.274.9.5407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026151	hybrid			2022-12-27	WOS:000078804400022
J	Cuenda, A; Cohen, P				Cuenda, A; Cohen, P			Stress-activated protein kinase-2 p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; P70 S6 KINASE; CELLULAR STRESSES; MAMMALIAN TARGET; SAP KINASES; KB CELLS; MAP; PHOSPHORYLATION; SPECIFICITY; MECHANISMS	The differentiation of C2C12 myoblasts to myotubes was found to be accompanied by a strong activation of p70 S6 kinase and the mitogen-activated protein kinase (MAPK) family member SAPK2/p38, without significant activation of p42 MAPK and only slight activation of SAPK1/JNK and protein kinase B alpha. Consistent with these findings, SE 203580 (a specific inhibitor of SAPK2/p38) or rapamycin (which blocks the activation of p70 S6 kinase) prevented the formation of multinucleated myotubes, as well as the expression of muscle-specific proteins that included SAPK3 (another MAPK family member). PD 098059 (which prevents the activation of p42 MAPK) had no effect on myotube formation. Surprisingly, the slow activation of p70 S6 kinase during differentiation was not only prevented by rapamycin but also by SE 203580, and the activation of MAPKAP kinase-2 (an in vivo substrate of SAPK2/p38) was not only prevented by SE 203580 but also by rapamycin. In contrast, the acute activation of p70 S6 kinase in C2C12 myoblasts induced by phorbol esters was unaffected by SE 203580 and the acute activation of MAPKAP kinase-g induced by anisomycin was unaffected by rapamycin, These results show for the first time that SAPK2/p38 plays an essential role in C2C12 cell differentiation.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee	Cuenda, A (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEHNER C, 1996, P NATL ACAD SCI USA, V93, P4355; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STOKOE D, 1993, BIOCHEM J, V296, P842; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794	36	271	279	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4341	4346		10.1074/jbc.274.7.4341	http://dx.doi.org/10.1074/jbc.274.7.4341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933636	hybrid			2022-12-27	WOS:000078575500060
J	Fletcher, AI; Shuang, RQ; Giovannucci, DR; Zhang, L; Bittner, MA; Stuenkel, EL				Fletcher, AI; Shuang, RQ; Giovannucci, DR; Zhang, L; Bittner, MA; Stuenkel, EL			Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CDC2-LIKE KINASE; DIRECTED PROTEIN-KINASE; UNC-18 GENE ENCODES; RAT-BRAIN; SYNAPTIC TRANSMISSION; CDK5 ACTIVATOR; SEC1 HOMOLOG; YEAST; SYNTAXIN; SECRETION	Munc18a, a mammalian neuronal homologue of Saccharomyces cerevisiae Sec1p protein, is essential for secretion, likely as a result of its high affinity interaction with the target SNARE protein syntaxin 1a (where SNARE is derived from SNAP receptor (the soluble N-ethylmaleimide-sensitive fusion protein)). However, this interaction inhibits vesicle SNARE interactions with syntaxin that are required for secretory vesicles to achieve competency for membrane fusion, As such, regulation of the interaction between Munc18a and syntaxin la may provide an important mechanism controlling secretory responsiveness. Cyclin-dependent kinase 5 (Cdk5), a member of the Cdc2 family of cell division kinases, co-purifies with Munc18a from rat brain, interacts directly with Munc18a in vitro, and utilizes Munc18a as a substrate for phosphorylation, We have now demonstrated that Cdk5 is capable of phosphorylating Munc18a in vitro within a preformed Munc18a syntaxin la heterodimer complex and that this results in the disassembly of the complex, Using site-directed mutagenesis, the Cdk5 phosphorylation site on Munc18a was identified as Thr(574). Stimulation of secretion from neuroendocrine cells produced a corresponding rapid translocation of cytosolic Cdk5 to a particulate fraction and an increase of Cdk5 kinase activity. Inhibition of Cdk5 with olomoucine decreased evoked norepinephrine secretion from chromaffin cells, an effect not observed with the inactive analogue iso-olomoucine, The effects of olomoucine were independent of calcium influx as evidenced by secretary inhibition in permeabilized chromaffin cells and in cells under whole-cell voltage clamp. Furthermore, transfection and expression in chromaffin cells of a neural specific Cdk5 activator, p25, led to a strong increase in nicotinic agonist-induced secretory responses. Our data suggest a model whereby Cdk5 acts to regulate Munc18a interaction with syntaxin la and thereby modulates the level of vesicle SNARE interaction with syntaxin 1a and secretory responsiveness.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Stuenkel, EL (corresponding author), Univ Michigan, Dept Physiol, 7804 Med Sci 2 Bldg, Ann Arbor, MI 48109 USA.	esterm@umich.edu	Giovannucci, David R/A-5657-2018	Stuenkel, Edward/0000-0001-8225-5725	NIDDK NIH HHS [DK50127] Funding Source: Medline; NINDS NIH HHS [NS36227] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; COWLES CR, 1994, J CELL SCI, V107, P3449; Dresbach T, 1998, J NEUROSCI, V18, P2923; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Graham ME, 1997, J NEUROCHEM, V69, P2369; Green SL, 1997, NEUROCHEM INT, V31, P617, DOI 10.1016/S0197-0186(97)00012-0; Guidato S, 1998, J NEUROCHEM, V70, P335; Halachmi N, 1996, J NEUROCHEM, V66, P889; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERRINGTON J, 1994, PULSE CONTROL VERSIO; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; QI Z, 1995, MOL CELL BIOCHEM, V149, P35, DOI 10.1007/BF01076561; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SUDHOF TC, 1993, CELL, V75, P1; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127	54	165	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4027	4035		10.1074/jbc.274.7.4027	http://dx.doi.org/10.1074/jbc.274.7.4027			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933594	hybrid			2022-12-27	WOS:000078575500018
J	Tlapak-Simmons, VL; Baggenstoss, BA; Clyne, T; Weigel, PH				Tlapak-Simmons, VL; Baggenstoss, BA; Clyne, T; Weigel, PH			Purification and lipid dependence of the recombinant hyaluronan syntheses from Streptococcus pyogenes and Streptococcus equisimilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; OLIGODENDROGLIOMA CELLS; BINDING-PROTEINS; ACID CAPSULE; SYNTHASE; GENE; IDENTIFICATION; SOLUBILIZATION; EXPRESSION; SYNTHETASE	The two hyaluronan synthases (HASs) from Streptococcus pyogenes (spHAS) and Streptococcus equisimilis (seHAS) were expressed in Escherichia coli as recombinant proteins containing His(6) tails. Both enzymes were expressed as major membrane proteins, accounting for similar to 5-8% of the total membrane protein. Using nickel chelate affinity chromatography, the HASs were purified to homogeneity from n-dodecyl beta-D-maltoside extracts, High levels of HAS activity could be achieved only if the purified enzymes were supplemented with either bovine or E. coli cardiolipin (CL), although bovine CL gave consistently greater activity. Mass spectroscopic analysis revealed that the fatty acid compositions of these two CL preparations did not overlap. The two HAS enzymes showed similar but distinct activation profiles with the 10 other lipids tested. For example, phosphatidic acid and phosphatidylethanolamine stimulated seHAS, but not spHAS, Phosphatidylserine stimulated both enzymes. spHAS appears to be more CL-specific than seHAS, although both purified enzymes still contain endogenous CL that can not easily be removed. Both seHAS and spHAS were inhibited by phosphatidylcholine, sphingomyelin, and sulfatides and were not substantially stimulated by cerebrosides, phosphatidylglycerol, or phosphatidylinositol. With both HASs, CL increased the K-m for UDP-GlcUA, but decreased the K-m for UDP-GlcNAc and gave an overall stimulation of V-max, A kinetic characterization of the two membrane-bound and purified HASs is presented in the accompanying paper (Tlapak-Simmons, V. L., Baggenstoss, B. A. Kumari, K., Heldermon, C., and Weigel, P. H. (1999) J. Biol. Chem, 274, 4246-4253), Both purified HASs became inactive after storage for similar to 5 days at 4 degrees C, Both purified enzymes also lost activity over 4-5 days when stored at -80 degrees C in the presence of CL, but reached a level of activity that then slowly decreased over a period of months. Although the purified enzymes stored in the absence of CL at -80 degrees C were much less active, the enzymes retained this same low level of activity for at least 5 weeks. When both spHAS and seHAS were stored without CL at -80 degrees C, even after 2 months, they could be stimulated by the addition of bovine CL to similar to 60% of the initial activity of the freshly purified enzyme.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.		Clyne, Bill/V-7473-2019		NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 1983, J SURG RES, V35, P410, DOI 10.1016/0022-4804(83)90030-6; BALAZS EA, 1993, J RHEUMATOL, V20, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EVERED D, 1989, CIBA F SYMP, V143, P1; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GRESSNER AM, 1995, DIGESTION, V56, P335, DOI 10.1159/000201257; HELDERMON C, 1996, MOL BIOL CELL, V7, P55; ILLUM L, 1994, J CONTROL RELEASE, V29, P133, DOI 10.1016/0168-3659(94)90129-5; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; JUBBELL JA, 1996, J CONTROL RELEASE, V39, P305; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1983, DEV BIOL, V99, P277, DOI 10.1016/0012-1606(83)90277-4; KUJAWA MJ, 1986, DEV BIOL, V114, P504, DOI 10.1016/0012-1606(86)90214-9; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer K, 1934, J BIOL CHEM, V107, P629; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NG KF, 1989, J BIOL CHEM, V264, P11776; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; TLAPAKSIMMONS VL, 1997, GLYCOBIOLOGY, V7, P1032; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305, DOI [10.1007/978-1-4615-3770-0_10, DOI 10.1007/978-1-4615-3770-0_10]; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; TURLEY EA, 1985, J CELL SCI, V78, P133; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	50	74	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4239	4245		10.1074/jbc.274.7.4239	http://dx.doi.org/10.1074/jbc.274.7.4239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933623	hybrid			2022-12-27	WOS:000078575500047
J	Lee, MG; Wigley, WC; Zeng, WZ; Noel, LE; Marino, CR; Thomas, PJ; Muallem, S				Lee, MG; Wigley, WC; Zeng, WZ; Noel, LE; Marino, CR; Thomas, PJ; Muallem, S			Regulation of Cl-/HCO3- exchange by cystic fibrosis transmembrane conductance regulator expressed in NIH 3T3 and HEK 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICARBONATE SECRETION; SULFONYLUREA RECEPTOR; MEMBRANE LOCALIZATION; SODIUM-CHANNELS; CFTR; TRANSPORTERS; BINDING; CL; K+; PATHWAY	A central function of cystic fibrosis transmembrane conductance regulator (CFTR)-expressing tissues is the secretion of fluid containing 100-140 mM HCO3-. High levels of HCO3- maintain secreted proteins such as mucins (all tissues) and digestive enzymes (pancreas) in a soluble and/or inactive state. HCO3- secretion is impaired in CF in all CFTR-expressing, HCO3--secreting tissues examined. The mechanism responsible for this critical problem in CF is unknown, Since a major component of HCO3- secretion in CFTR-expressing cells is mediated by the action of a Cl-/HCO3- exchanger (AE), in the present work we examined the regulation of AE activity by CFTR. In NIH 3T3 cells stably transfected with wild type CFTR and in HEK 293 cells expressing WT and several mutant CFTR, activation of CFTR by cAMP stimulated AE activity. Pharmacological and mutagenesis studies indicated that expression of CFTR in the plasma membrane, but not the Cl- conductive function of CFTR was required for activation of AE. Furthermore, mutations in NBD2 altered regulation of AE activity by CFTR independent of their effect on Cl- channel activity. At very high expression levels CFTR modified the sensitivity of AE to 4,4'-diisothiocyanatostilbene-2,2'-disulfonate, The novel finding of regulation of Cl-/HCO3- exchange by CFTR reported here may have important physiological implications and explain, at least in part, the impaired HCO3- secretion in CF.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Tennessee, Dept Physiol & Med, Memphis, TN 38163 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tennessee System; University of Tennessee Health Science Center	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Thomas, Philip J/F-7115-2012; Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK49835, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK038938, R01DK049835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARGENT BE, 1994, PHYSL GASTROINTESTIN, P1478; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; Cook D. I., 1994, P1061; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Gray MA, 1995, BIOSCIENCE REP, V15, P531, DOI 10.1007/BF01204355; Greger R, 1996, J MOL MED-JMM, V74, P527; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HADORN B, 1968, CAN MED ASSOC J, V98, P377; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hogan DL, 1997, GASTROENTEROLOGY, V113, P533, DOI 10.1053/gast.1997.v113.pm9247473; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ismailov II, 1996, J BIOL CHEM, V271, P4725; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; MUALLEM S, 1992, J BIOL CHEM, V267, P17658; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1989, ANN NY ACAD SCI, V574, P438; SATO K, 1990, J LAB CLIN MED, V115, P504; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; Sheppard DN, 1996, MOL MED TODAY, V2, P290, DOI 10.1016/1357-4310(96)10028-9; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Warth R, 1996, PFLUG ARCH EUR J PHY, V432, P81, DOI 10.1007/s004240050108; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wigley WC, 1998, BIOCHEMISTRY-US, V37, P844, DOI 10.1021/bi972293n; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	38	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3414	3421		10.1074/jbc.274.6.3414	http://dx.doi.org/10.1074/jbc.274.6.3414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920885	hybrid			2022-12-27	WOS:000078428200025
J	Pierik, AJ; Roseboom, W; Happe, RP; Bagley, KA; Albracht, SPJ				Pierik, AJ; Roseboom, W; Happe, RP; Bagley, KA; Albracht, SPJ			Carbon monoxide and cyanide as intrinsic ligands to iron in the active site of [NiFe]-hydrogenases - NiFe(CN)(2)CO, biology's way to activate H-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; CHROMATIUM-VINOSUM; MOLECULAR-BIOLOGY; NIFE HYDROGENASE; SULFUR CLUSTERS; FE-HYDROGENASE; NICKEL; DEHYDROGENASE; THIOCYANATE; COMPLEXES	Infrared-spectroscopic studies on the [NiFe]-hydrogenase of Chromatium vinosum enriched in N-15 Or C-13, as well as chemical analyses, show that this enzyme contains three non-exchangeable, intrinsic, diatomic molecules as ligands to the active site, one carbon monoxide molecule and two cyanide groups. The results form an explanation for the three non-protein ligands to iron detected in the crystal structure of the Desulfovibrio gigas hydrogenase (Volbeda, A., Garcin, E., Piras, C., De Lacey, A. I., Fernandez, V. M., Hatchikian, E. C., Frey, M., and Fontecilla-Camps, J. C. (1996) J. Am. Chem. Sec. 118, 12989-12996) and for the low spin character of the lone ferrous iron ion observed with Mossbauer spectroscopy (Surerus, K. K., Chen, M., Van der Zwaan, W., Rusnak, F. M., Kolk, M., Duin, E. C., Albracht, S. P. J., and Munck, E. (1994) Biochemistry 33, 4980-4993). The results do not support the notion, based upon studies of Desulfovibrio vulgaris [NiFe]-hydrogenase (Higuchi, Y., Yagi, T., and Noritake, Y. (1997) Structure 5, 1671-1680), that SO is a ligand to the active site. The occurrence of both cyanide and carbon monoxide as intrinsic constituents of a prosthetic group is unprecedented in biology.	Univ Amsterdam, EC Slater Inst Biochem Res, NL-1018 TV Amsterdam, Netherlands; SUNY Coll Buffalo, Dept Chem, Buffalo, NY 14222 USA	University of Amsterdam; State University of New York (SUNY) System; Buffalo State College	Albracht, SPJ (corresponding author), Univ Amsterdam, EC Slater Inst Biochem Res, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Pierik, Antonio J/G-1108-2010	Pierik, Antonio J/0000-0002-1509-6370; Roseboom, Winfried/0000-0002-4034-8330				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAGLEY KA, 1994, BIOCHEMISTRY-US, V33, P9229, DOI 10.1021/bi00197a026; BONAM D, 1984, J BACTERIOL, V159, P693, DOI 10.1128/JB.159.2.693-699.1984; BOXER GE, 1952, ARCH BIOCHEM BIOPHYS, V39, P292, DOI 10.1016/0003-9861(52)90338-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COREMANS JMCC, 1992, BIOCHIM BIOPHYS ACTA, V1119, P157, DOI 10.1016/0167-4838(92)90386-R; Cotton F. A., 1988, ADV INORG CHEM, P1021; Darensbourg DJ, 1997, J AM CHEM SOC, V119, P7903, DOI 10.1021/ja971559a; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; EPSTEIN J, 1947, ANAL CHEM, V19, P272, DOI 10.1021/ac60004a018; Frey M, 1998, STRUCT BOND, V90, P97; FRIEDRICH B, 1993, ANNU REV MICROBIOL, V47, P351, DOI 10.1146/annurev.mi.47.100193.002031; HAGEN WR, 1986, FEBS LETT, V203, P59, DOI 10.1016/0014-5793(86)81436-3; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; Hartmann GC, 1996, ARCH MICROBIOL, V165, P187, DOI 10.1007/s002030050314; Higuchi Y, 1997, STRUCTURE, V5, P1671, DOI 10.1016/S0969-2126(97)00313-4; Hsu HF, 1997, J AM CHEM SOC, V119, P8371, DOI 10.1021/ja971139l; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEEUSSEN JCL, 1989, ANALYST, V114, P959, DOI 10.1039/an9891400959; MITCHELL CA, 1930, ALLENS COMMERCIAL OR, V8, P492; NAGASHIMA S, 1978, ANAL CHIM ACTA, V99, P197, DOI 10.1016/S0003-2670(01)84514-1; NAKAMOTO K, 1997, INFRARED RAMAN SPECT, P95; PIERIK AJ, 1992, EUR J BIOCHEM, V209, P63, DOI 10.1111/j.1432-1033.1992.tb17261.x; Rey L, 1996, MOL GEN GENET, V252, P237; SHRIVER DF, 1966, J AM CHEM SOC, V88, P1672, DOI 10.1021/ja00960a018; STREKAS T, 1980, BIOCHIM BIOPHYS ACTA, V616, P1, DOI 10.1016/0005-2744(80)90257-0; SURERUS KK, 1994, BIOCHEMISTRY-US, V33, P4980, DOI 10.1021/bi00182a029; TANAKA A, 1992, ANAL CHIM ACTA, V261, P281, DOI 10.1016/0003-2670(92)80203-J; VanderSpek TM, 1996, EUR J BIOCHEM, V237, P629; VIGNAIS PM, 1994, ARCH MICROBIOL, V161, P1; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; ZIRNGIBL C, 1992, EUR J BIOCHEM, V208, P511, DOI 10.1111/j.1432-1033.1992.tb17215.x	36	203	210	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3331	3337		10.1074/jbc.274.6.3331	http://dx.doi.org/10.1074/jbc.274.6.3331			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920874	hybrid			2022-12-27	WOS:000078428200014
J	Fritsche, E; Humm, A; Huber, R				Fritsche, E; Humm, A; Huber, R			The ligand-induced structural changes of human L-arginine : glycine amidinotransferase - A mutational and crystallographic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY L-ARGININE; GYRATE ATROPHY; GROWTH-HORMONE; CREATINE; RAT; BIOSYNTHESIS; CLONING; MUSCLE; RETINA; HYPERORNITHINEMIA	Human L-arginine:glycine amidinotransferase (AT) shows large structural changes of the 300-flap and of helix H9 upon binding of L-arginine and L-ornithine, described as a closed and an open conformation (Humm, A, Fritsche, E., Steinbacher, S., and Huber, R. (1997) EMBO J. 16, 3373-3385), To elucidate the structural basis of these induced-fit movements, the x-ray structures of AT in complex with the amidino acceptor glycine and its analogs gamma-aminobutyric acid and delta-aminovaleric acid, as well as in complex with the amidino donor analogs L-alanine, L-alpha-aminobutyric acid, and L-norvaline, have been solved at 2.6-, 2.5-, 2.37-, 2.3-, 2.5-, and 2.4-Angstrom resolutions, respectively. The latter three compounds were found to stabilize the open conformer. The glycine analogs bind in a distinct manner and do not induce the transition to the open state. The complex with glycine revealed a third binding mode, reflecting the rather broad substrate specificity of AT. These findings identified a role for the cu-amino group of the ligand in stabilizing the open conformer. The kinetic, structural, and thermodynamic properties of the mutants AT Delta M302 and AT Delta 11 (lacks 11 residues of H9) confirmed the key role of Asn(300) and suggest that in mammalian amidinotransferases, the role of helix H9 is in accelerating amidino transfer by an induced-fit mechanism. Helix H9 does not add to the stability of the protein.	Max Planck Inst Biochem, Abt Strukturforsch, Dept Struct Res, D-82152 Martinsried, Germany	Max Planck Society	Fritsche, E (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Dept Struct Res, Klopferspitz 18a, D-82152 Martinsried, Germany.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, XPLOR VERSION 3 1; CONCONI F, 1964, J BIOL CHEM, V240, P2461; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fritsche E, 1997, EUR J BIOCHEM, V247, P483, DOI 10.1111/j.1432-1033.1997.00483.x; FRITSCHE E, 1999, IN PRESS BIOCHEMISTR; GRAZI E, 1968, J BIOL CHEM, V243, P538; GRAZI E, 1964, J BIOL CHEM, V240, P2465; GROSS MD, 1986, ARCH BIOCHEM BIOPHYS, V251, P747, DOI 10.1016/0003-9861(86)90385-1; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; GUTHMILLER P, 1994, J BIOL CHEM, V269, P17556; Humm A, 1997, BIOCHEM J, V322, P771, DOI 10.1042/bj3220771; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LASKOWSKI RA, 1992, PROCHECK VERSION 3 3; LESLIE A, 1994, MOSFLM USER GUIDE MO; LOIKE JD, 1988, P NATL ACAD SCI USA, V85, P807, DOI 10.1073/pnas.85.3.807; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGUIRE DM, 1980, J BIOL CHEM, V255, P1152; MCGUIRE DM, 1984, J BIOL CHEM, V259, P2034; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; Piepersberg W., 1997, BIOTECHNOLOGY ANTIBI, P81; RATNER S, 1956, ARCH BIOCHEM BIOPHYS, V63, P296, DOI 10.1016/0003-9861(56)90045-5; RONCA G, 1966, J BIOL CHEM, V241, P2589; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIH VE, 1978, AM J HUM GENET, V30, P174; SIPILA I, 1979, NEUROLOGY, V29, P996, DOI 10.1212/WNL.29.7.996; SIPILA I, 1980, BIOCHIM BIOPHYS ACTA, V613, P79, DOI 10.1016/0005-2744(80)90194-1; TAKEDA M, 1992, EUR J CLIN CHEM CLIN, V30, P325; TORMANEN CD, 1985, BIOSCIENCE REP, V5, P309, DOI 10.1007/BF01116902; VANPILSUM JF, 1968, ARCH BIOCHEM BIOPHYS, V124, P372, DOI 10.1016/0003-9861(68)90340-8; VANPILSUM JF, 1972, BIOCHEM J, V126, P325, DOI 10.1042/bj1260325; VANPILSUM JF, 1970, ANAL BIOCHEM, V35, P277, DOI 10.1016/0003-2697(70)90035-7; Walker J.B., 1973, ENZYMES, P497; WALKER JB, 1961, J BIOL CHEM, V236, P493; WALKER JB, 1958, J BIOL CHEM, V231, P1; WALKER JB, 1976, BIOCHEMISTRY-US, V15, P2519, DOI 10.1021/bi00657a004; WALKER JB, 1979, ADV ENZYMOL, V50, P172; WALKER JB, 1975, METHDOS ENZYMOL, V43, P41; WALKER MS, 1962, J BIOL CHEM, V237, P473; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3026	3032		10.1074/jbc.274.5.3026	http://dx.doi.org/10.1074/jbc.274.5.3026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915841	hybrid			2022-12-27	WOS:000078319500059
J	Mahata, SK; Mahata, M; Parmer, RJ; O'Connor, DT				Mahata, SK; Mahata, M; Parmer, RJ; O'Connor, DT			Desensitization of catecholamine release - The novel catecholamine release-inhibitory peptide catestatin (chromogranin A(344-364)) acts at the receptor to prevent nicotinic cholinergic tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT; PHEOCHROMOCYTOMA; SECRETION; CELLS; PC12; TRANSITIONS; SENSITIVITY; EXPRESSION; ANTAGONIST	Nicotinic cholinergic receptors undergo desensitization upon repeated or prolonged exposure to agonist, We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment, catestatin (chromogranin A(344-364)), on agonist-induced desensitization of catecholamine release from pheochromocytoma cells. In a dose-dependent fashion, the nicotinic antagonist catestatin blocked agonist desensitization of both catecholamine release (IC50 similar to 0.24 mu M) and Na-22(+) uptake (IC50 similar to 0.31 mu M), the initial step in nicotinic cationic signal transduction; both secretion inhibition and blockade of desensitization were noncompetitive with agonist, Desensitizing effects of the nicotinic agonists nicotine and epibatidine were blocked. This antagonist action was specific to desensitization by nicotinic agonists, since catestatin did not block desensitization of catecholamine release induced by agents which bypass the nicotinic receptor. Hill plots with slopes near unity suggested noncooperativity for catestatin effects on both nicotinic responses (secretory antagonism and blockade of desensitization). Human, bovine, and rat catestatins (as well as substance P) had similar potencies. IC50 values for secretion inhibition and blockade of desensitization paralleled each other (r = 0.76, n = 10 antagonists, p = 0.01) for several noncompetitive nicotinic antagonists. Peptide nicotinic antagonists (catestatins, substance P) were far more potent inhibitors of both secretion (p = 0.019) and desensitization (p = 0.005) than nonpeptide antagonists (trimethaphan, hexamethonium, procaine, phencyclidine, cocaine, or clonidine), and the peptides displayed enhanced selectivity to block desensitization versus secretion (p = 0.003). We conclude that catestatin is a highly potent, dose-dependent, noncompetitive, noncooperative, specific inhibitor of nicotinic desensitization, an effect which may have implications for control of catecholamine release.	Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Ctr Mol Genet, San Diego, CA 92161 USA; San Diego Vet Adm Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Mahata, SK (corresponding author), Univ Calif San Diego, Dept Med, 9111H,3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Mahata, Sushil/AAF-8781-2021		NHLBI NIH HHS [HL55583] Funding Source: Medline; NIDA NIH HHS [DA11311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011311, R29DA011311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Baenziger JE, 1997, BIOCHEMISTRY-US, V36, P3617, DOI 10.1021/bi962845m; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BOYD ND, 1987, J PHYSIOL-LONDON, V389, P45, DOI 10.1113/jphysiol.1987.sp016646; BROWN RD, 1983, MOL PHARMACOL, V23, P8; CONLEY EC, 1996, ION CHANNEL FACTS BO, V1; CONLEY EC, 1996, ION CHANNEL FACTS BO, V1, P36; Fenster CP, 1997, J NEUROSCI, V17, P5747; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROSS A, 1991, PFLUG ARCH EUR J PHY, V419, P545, DOI 10.1007/BF00370805; HSIAO RJ, 1991, MEDICINE, V70, P33, DOI 10.1097/00005792-199101000-00003; HSIAO RJ, 1990, KIDNEY INT, V37, P955, DOI 10.1038/ki.1990.71; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; LINDSTROM J, 1995, ANN NY ACAD SCI, V757, P100, DOI 10.1111/j.1749-6632.1995.tb17467.x; LIVETT BG, 1991, ANN NY ACAD SCI, V632, P249, DOI 10.1111/j.1749-6632.1991.tb33113.x; LIVETT BG, 1993, J ANAT, V183, P277; LIVETT BG, 1993, TRENDS PHARMACOL SCI, V14, P345, DOI 10.1016/0165-6147(93)90090-7; LUKAS RJ, 1989, J PHARMACOL EXP THER, V251, P175; LUKAS RJ, 1992, INT REV NEUROBIOL, V34, P25, DOI 10.1016/S0074-7742(08)60097-5; Mahata S K, 1998, Adv Pharmacol, V42, P260; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OCHOA ELM, 1989, CELL MOL NEUROBIOL, V9, P141, DOI 10.1007/BF00713026; OCONNOR DT, 1989, CLIN CHEM, V35, P1631; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Rogers S W, 1991, Protein Expr Purif, V2, P108, DOI 10.1016/1046-5928(91)90058-Q; ROWELL PP, 1994, J NEUROCHEM, V63, P561; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SIMASKO SM, 1986, MOL PHARMACOL, V30, P6; Tsigelny I, 1998, REGUL PEPTIDES, V77, P43, DOI 10.1016/S0167-0115(98)00040-8; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VIBAT CRT, 1995, CELL MOL NEUROBIOL, V15, P411, DOI 10.1007/BF02071877; WEILAND G, 1977, J BIOL CHEM, V252, P7648; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITING P, 1991, MOL PHARMACOL, V40, P463; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; ZHOU XF, 1991, J PHYSIOL-LONDON, V433, P393, DOI 10.1113/jphysiol.1991.sp018433	39	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2920	2928		10.1074/jbc.274.5.2920	http://dx.doi.org/10.1074/jbc.274.5.2920			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915830	hybrid			2022-12-27	WOS:000078319500048
J	Hamid, J; Nelson, D; Spaetgens, R; Dubel, SJ; Snutch, TP; Zamponi, GW				Hamid, J; Nelson, D; Spaetgens, R; Dubel, SJ; Snutch, TP; Zamponi, GW			Identification of an integration center for cross-talk between protein kinase C and G protein modulation of N-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CA2+ CHANNELS; SUBCELLULAR-DISTRIBUTION; RECEPTOR INHIBITION; INTRACELLULAR LOOP; DOMAIN-II; SUBUNIT; NEURONS; BRAIN; DETERMINANTS	The modulation of presynaptic calcium channel activity by second messengers provides a fine tuning mechanism for neurotransmitter release. In neurons, the activation of certain G protein-coupled receptors reduces N-type channel activity by similar to 60%. In contrast, activation of protein kinase C (PKC) results in an approximately 50% increase in N-type channel activity, and subsequent G protein inhibition is antagonized. Here, we describe the molecular determinants that control the dual effects of PKC-dependent phosphorylation. The double substitution of two adjacent PKC consensus sites in the calcium channel domain I-II linker (Thr(422), Ser(425)) to alanines abolished both PKC-dependent up-regulation and the PKC-G protein cross-talk. The single substitution of Ser(425) to glutamic acid abolished PRC up-regulation but had no effect on G protein modulation. Replacement of Thr(422) With glutamic acid eliminated PKC-dependent up-regulation and mimicked the effects of PKC phosphorylation on G protein inhibition. Our data suggest that Thr(422) mediates the antagonistic effect of PKC on G protein modulation, while phosphorylation of either Thr(422) or Ser(425) are sufficient to increase N-type channel activity. Thus, Thr(422) serves as a molecular switch by which PKC is able to simultaneously trigger the upregulation of channel activity and antagonize G protein inhibition.	Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of Calgary; University of British Columbia	Zamponi, GW (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@acs.ucalgary.ca	Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BOLAND LM, 1993, J NEUROSCI, V13, P515; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; Fisher SE, 1997, GENOMICS, V45, P340, DOI 10.1006/geno.1997.4941; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Page KM, 1998, J NEUROSCI, V18, P4815; Page KM, 1997, J NEUROSCI, V17, P1330; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; QUIN N, 1997, P NATL ACAD SCI USA, V95, P8866; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1994, P NATL ACAD SCI USA, V91, P10567; Stephens GJ, 1998, J PHYSIOL-LONDON, V509, P163, DOI 10.1111/j.1469-7793.1998.163bo.x; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	40	102	107	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6195	6202		10.1074/jbc.274.10.6195	http://dx.doi.org/10.1074/jbc.274.10.6195			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037705				2022-12-27	WOS:000078902800027
J	Bonaventura, C; Godette, G; Tesh, S; Holm, DE; Bonaventura, J; Crumbliss, AL; Pearce, LL; Peterson, J				Bonaventura, C; Godette, G; Tesh, S; Holm, DE; Bonaventura, J; Crumbliss, AL; Pearce, LL; Peterson, J			Internal electron transfer between hemes and Cu(II) bound at cysteine beta 93 promotes methemoglobin reduction by carbon monoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; INOSITOL HEXAPHOSPHATE; HUMAN-HEMOGLOBIN; OXIDATION; SPECTROSCOPY; BINDING; COPPER; HORSE; ION	Previous studies showed that CO/H2O oxidation provides electrons to drive the reduction of oxidized hemoglobin (metHb), We report here that Cu(II) addition accelerates the rate of metHb beta chain reduction by CO by a factor of about 1000, A mechanism whereby electron transfer occurs via an internal pathway coupling CO/H2O oxidation to Fe(III) and Cu(II) reduction is suggested by the observation that the copper-induced rate enhancement is inhibited by blocking Cys-beta 93 with N-ethylmaleimide. Furthermore, this internal electron-transfer pathway is more readily established at low Cu(II) concentrations in Hb Deer Lodge (beta 2His --> Arg) and other species lacking His-beta 2 than in Hb A(0). This difference is consistent with preferential binding of Cu(II) in Hb A(0) to a high affinity site involving His-beta 2, which is ineffective in promoting electron exchange between Cu(II) and the beta heme iron, Effective electron transfer is thus affected by Hb type but is not governed by the R <-> T conformational equilibrium. The beta hemes in Cu(II)-metHb are reduced under CO at rates close to those observed for cytochrome c oxidase, where heme and copper are present together in the oxygen-binding site and where internal electron transfer also occurs.	Duke Univ, Marine Lab, Marine Freshwater Biomed Ctr, Beaufort, NC 28516 USA; Univ Alabama, Dept Chem, Tuscaloosa, AL 35487 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Duke University; University of Alabama System; University of Alabama Tuscaloosa; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	Bonaventura, C (corresponding author), Duke Univ, Marine Lab, Marine Freshwater Biomed Ctr, Beaufort, NC 28516 USA.			Pearce, Linda/0000-0002-0940-965X; Peterson, James/0000-0002-7300-5887	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001908, P50ES001908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58248] Funding Source: Medline; NIEHS NIH HHS [ESO1908] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAYASH AI, 1993, ARCH BIOCHEM BIOPHYS, V303, P332, DOI 10.1006/abbi.1993.1292; ANTHOLINE WE, 1984, J INORG BIOCHEM, V21, P125, DOI 10.1016/0162-0134(84)85045-X; ANTHOLINE WE, 1985, J INORG BIOCHEM, V25, P95, DOI 10.1016/0162-0134(85)80018-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BEMSKI G, 1969, BIOCHEM BIOPH RES CO, V35, P599, DOI 10.1016/0006-291X(69)90446-X; BICKAR D, 1984, J BIOL CHEM, V259, P777; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; BONOMO RP, 1995, J INORG BIOCHEM, V59, P773, DOI 10.1016/0162-0134(94)00063-G; BRITTAIN T, 1976, BIOCHEM J, V155, P453, DOI 10.1042/bj1550453; CHIANCONE E, 1974, J BIOL CHEM, V249, P5689; CRUMBLISS AL, 1975, INORG CHEM, V14, P1529, DOI 10.1021/ic50149a017; DAY EP, 1993, BIOCHEMISTRY-US, V32, P7855, DOI 10.1021/bi00082a003; EVERSE J, 1994, METHOD ENZYMOL, V231, P547; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GERACI G, 1969, J BIOL CHEM, V244, P4664; GREENWOOD C, 1974, BIOCHEM J, V137, P205, DOI 10.1042/bj1370205; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; Hyde J. S., 1986, ADV MAGN RESON, P363; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KILMARTIN JV, 1973, BIOCHEM J, V133, P725, DOI 10.1042/bj1330725; LOURO SRW, 1986, STUD BIOPHYS, V113, P75; LOURO SRW, 1977, J MAGN RESON, V28, P427; MANSOURI A, 1979, BIOCHEM BIOPH RES CO, V89, P441, DOI 10.1016/0006-291X(79)90649-1; NAGEL RL, 1970, ARCH BIOCHEM BIOPHYS, V137, P428, DOI 10.1016/0003-9861(70)90459-5; NICHOLLS P, 1981, BIOCHIM BIOPHYS ACTA, V634, P256, DOI 10.1016/0005-2728(81)90144-4; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2187, DOI 10.1021/bi00707a028; RIFKIND JM, 1976, BIOCHEMISTRY-US, V15, P5337, DOI 10.1021/bi00669a021; RIFKIND JM, 1981, MET IONS BIOL SYST, P191; WHARTON DC, 1968, J BIOL CHEM, V243, P702; WINTERBOURN C C, 1977, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V70, P97; WINTERBOURN CC, 1977, BIOCHEM J, V165, P141, DOI 10.1042/bj1650141; YOUNG LJ, 1987, J BIOL CHEM, V262, P15019; YOUNG LJE, 1980, FED PROC, V39, P2090; YUBISUI T, 1977, BIOCHEM BIOPH RES CO, V76, P174, DOI 10.1016/0006-291X(77)91683-7	36	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5499	5507		10.1074/jbc.274.9.5499	http://dx.doi.org/10.1074/jbc.274.9.5499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026163	hybrid			2022-12-27	WOS:000078804400034
J	Cotten, JF; Welsh, MJ				Cotten, JF; Welsh, MJ			Cystic fibrosis-associated mutations at arginine 347 alter the pore architecture of CFTR - Evidence for disruption of a salt bridge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CHLORIDE CHANNEL; CL CHANNELS; POTASSIUM CHANNEL; ESCHERICHIA-COLI; LINING RESIDUES; ION-CHANNEL; GENE; IDENTIFICATION; MEMBRANE	Arginine 347 in the sixth transmembrane domain of cystic fibrosis transmembrane conductance regulator (CFTR) is a site of four cystic fibrosis-associated mutations. To better understand the function of Arg-347 and to learn how mutations at this site disrupt channel activity, we mutated Arg-347 to Asp, Cys, Glu, His, Leu, or Lys and examined single-channel function. Every Arg-347 mutation examined, except R347K, had a destabilizing effect on the pore, causing the channel to flutter between two conductance states. Chloride flow through the larger conductance state was similar to that of wildtype CFTR, suggesting that the residue at position 347 does not interact directly with permeating anions, We hypothesized that Arg-347 stabilizes the channel through an electrostatic interaction with an anionic residue in another transmembrane domain. To test this, we mutated anionic residues (Asp-924, Asp-993, and Glu-1104) to Arg in the context of either R347E or R347D mutations. Interestingly, the D924R mutation complemented R347D, yielding a channel that behaved Like wild-type CFTR, These data suggest that Arg-347 plays an important structural role in CFTR, at least in part by forming a salt bridge with Asp-924; cystic fibrosis-associated mutations disrupt this interaction.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.	mjwelsh@blue.weeg.uiowa.edu		Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029851, R37HL029851, P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29851, HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Antosiewicz J, 1996, BIOCHEMISTRY-US, V35, P7819, DOI 10.1021/bi9601565; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Cremonesi Laura, 1992, Human Mutation, V1, P314, DOI 10.1002/humu.1380010409; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; EIGEN M, 1960, J AM CHEM SOC, V82, P3482; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; Hille B., 1992, IONIC CHANNELS EXCIT; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUGER P, 1991, ELECTOGENIC ION PUMP; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; LU Z, 1995, BIOCHEMISTRY-US, V34, P13133, DOI 10.1021/bi00040a026; Mansoura MK, 1998, BIOPHYS J, V74, P1320, DOI 10.1016/S0006-3495(98)77845-2; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568	37	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5429	5435		10.1074/jbc.274.9.5429	http://dx.doi.org/10.1074/jbc.274.9.5429			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026154	hybrid			2022-12-27	WOS:000078804400025
J	Manna, PR; Tena-Sempere, M; Huhtaniemi, IT				Manna, PR; Tena-Sempere, M; Huhtaniemi, IT			Molecular mechanisms of thyroid hormone-stimulated steroidogenesis in mouse Leydig tumor cells - Involvement of the steroidogenic acute regulatory (StAR) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRIIODOTHYRONINE RECEPTORS; ADRENAL HYPOPLASIA CONGENITA; MESSENGER-RIBONUCLEIC-ACID; RAT TESTIS; MITOCHONDRIAL PROTEINS; GRANULOSA-CELLS; CONTACT SITES; TESTOSTERONE PRODUCTION; ENDOCRINE DEVELOPMENT; REPRODUCTIVE AXIS	Using a mouse Leydig tumor cell line, we explored the mechanisms involved in thyroid hormone-induced steroidogenic acute regulatory (StAR) protein gene expression, and steroidogenesis. Triiodothyronine (T-3) induced a similar to 3.6-fold increase in the steady-state level of StAR mRNA which paralleled with those of the acute steroid response (similar to 4.0-fold), as monitored by quantitative reverse transcriptase-polymerase chain reaction assay and progesterone production, respectively. The T-3-stimulated progesterone production was effectively inhibited by actinomycin-D or cycloheximide, indicating the requirement of on-going mRNA and protein synthesis. T-3 displayed the highest affinity of [I-125]iodo-T-3 binding and was most potent in stimulating StAR mRNA expression. In accordance, T-3 significantly increased testosterone production in primary cultures of adult mouse Leydig cells. The T-3 and human chorionic gonadotropin (hCG) effects on StAR expression were similar in magnitude and additive. Cells expressing steroidogenic factor 1 (SF-l) showed marginal elevation of StAR expression, but coordinately increased T-3-induced StAR mRNA expression and progesterone levels. In contrast, overexpression of DAX-1 markedly diminished the SF-1 mRNA expression, and concomitantly abolished T-3-mediated responses. Noteworthy, T-3 augmented the SF-1 mRNA expression while inhibition of the latter by DAX-1 strongly impaired T-3 action. Northern hybridization analysis revealed four StAR transcripts which increased 3-6-fold following T-3 stimulation. These observations clearly identified a regulatory cascade of thyroid hormone-stimulated StAR expression and steroidogenesis that provides novel insight into the importance of a thyroid-gonadal connection in the hormonal control of Leydig cell steroidogenesis.	Univ Turku, Dept Physiol, Inst Biomed, FIN-20520 Turku, Finland	University of Turku	Huhtaniemi, IT (corresponding author), Univ Turku, Dept Physiol, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	ilpo.huhtaniemi@utu.fi	Tena-Sempere, Manuel/AAX-3602-2021	Tena-Sempere, Manuel/0000-0002-4741-5567				Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; Bandyopadhyay A, 1996, J ENDOCRINOL, V150, P309, DOI 10.1677/joe.0.1500309; BHATTACHARYA S, 1988, EXPERIENTIA, V44, P1005, DOI 10.1007/BF01939903; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, STEROIDS, V62, P53, DOI 10.1016/S0039-128X(96)00159-6; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CHAN WK, 1986, ENDOCRINOLOGY, V119, P2353, DOI 10.1210/endo-119-5-2353; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; COOKE BA, 1975, BIOCHEM J, V150, P413, DOI 10.1042/bj1500413; DING YQ, 1989, ACTA ENDOCRINOL-COP, V121, P46, DOI 10.1530/acta.0.1210046; El-Gehani F, 1998, ENDOCRINOLOGY, V139, P1474, DOI 10.1210/en.139.4.1474; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; GERHARD I, 1991, HUM REPROD, V6, P338, DOI 10.1093/oxfordjournals.humrep.a137335; GOLDMAN S, 1993, MOL CELL ENDOCRINOL, V96, P125, DOI 10.1016/0303-7207(93)90102-P; HARTUNG S, 1995, BIOCHEM BIOPH RES CO, V215, P646, DOI 10.1006/bbrc.1995.2513; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; IIDA S, 1989, ENDOCRINOLOGY, V124, P2619, DOI 10.1210/endo-124-5-2619; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JANA NR, 1994, J ENDOCRINOL, V143, P549, DOI 10.1677/joe.0.1430549; JANNINI EA, 1995, ENDOCR REV, V16, P443, DOI 10.1210/er.16.4.443; JANS NR, 1996, BIOCHIM BIOPHYS ACTA, V1292, P209; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; LAWSON GM, 1987, LAB METHODS MANUAL H; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MENDELSON C, 1975, J BIOL CHEM, V250, P8818; MENDELSON C, 1975, BIOCHIM BIOPHYS ACTA, V411, P222, DOI 10.1016/0304-4165(75)90302-5; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; Nishikawa T, 1996, BIOCHEM BIOPH RES CO, V223, P12, DOI 10.1006/bbrc.1996.0838; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; OPPENHEIMER JH, 1979, SCIENCE, V203, P971, DOI 10.1126/science.218285; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; PALMERO S, 1993, J ENDOCRINOL, V136, P277, DOI 10.1677/joe.0.1360277; PALMERO S, 1992, J MOL ENDOCRINOL, V9, P55, DOI 10.1677/jme.0.0090055; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sandhoff TW, 1996, ENDOCRINE, V4, P259, DOI 10.1007/BF02738692; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMPSON ER, 1979, J BIOL CHEM, V253, P3135; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TAGAMI T, 1990, ENDOCRINOLOGY, V127, P1727, DOI 10.1210/endo-127-4-1727; TENASEMPERE M, 1994, ENDOCRINOLOGY, V135, P1018, DOI 10.1210/en.135.3.1018; VUORENTO T, 1989, SCAND J CLIN LAB INV, V49, P395, DOI 10.3109/00365518909089113; WAKIM AN, 1993, FERTIL STERIL, V59, P1187; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang FP, 1997, ENDOCRINOLOGY, V138, P2481, DOI 10.1210/en.138.6.2481	63	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5909	5918		10.1074/jbc.274.9.5909	http://dx.doi.org/10.1074/jbc.274.9.5909			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026215	hybrid			2022-12-27	WOS:000078804400086
J	Ozaki, I; Tani, E; Ikemoto, H; Kitagawa, H; Fujikawa, H				Ozaki, I; Tani, E; Ikemoto, H; Kitagawa, H; Fujikawa, H			Activation of stress-activated protein kinase/c-Jun NH2-terminal kinase and p38 kinase in calphostin C-induced apoptosis requires caspase-3-like proteases but is dispensable for cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; LYMPHOBLASTIC-LEUKEMIA CELLS; ICE/CED-3 FAMILY PROTEASES; FAS-MEDIATED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; SERINE PHOSPHORYLATION; JNK ACTIVATION; MAP KINASES	Apoptosis was induced in human glioma cell lines by exposure to 100 nM calphostin C, a specific inhibitor of protein kinase C, Calphostin C-induced apoptosis was associated with synchronous down-regulation of Bcl-2 and Bcl-x(L), as well as activation of caspase-3 but not caspase-1, The exposure to calphostin C led to activation of stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) and p38 kinase and concurrent inhibition of extracellular signal-regulated kinase (ERK). Upstream of ERK, Shc was shown to be activated, but its downstream Raf1 and ERR were inhibited. The pretreatment with acetyl-Tyr-Val-Ala-Asp-aldehyde, a relatively selective inhibitor of caspase-3, or benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD.fmk), a broad spectrum caspase inhibitor, similarly inhibited calphostin C-induced activation of SAPK/JNK and p38 kinase as well as apoptotic nuclear damages (chromatin condensation and DNA fragmentation) and cell shrinkage, suggesting that caspase-3 functions upstream of SAPK/JNR and p38 kinase, but did not block calphostin C-induced surface blebbing and cell death. On the other hand, the inhibition of SAPK/JNK by transfection of dominant negative SAPK/JNK: and that of p38 kinase by SB203580 induced similar effects on the calphostin C-induced apoptotic phenotypes and cell death as did z-VAD.fmk and acetyl-Tyr-Val-Ala-Asp-aldehyde, but the calphostin C-induced PARP cleavage was not changed, suggesting that SAPK/JNK and p38 kinase are involved in the DNA fragmentation pathway downstream of caspase-3. The present findings suggest, therefore, that the activation of SAPK/JNK and p38 kinase is dispensable for calphostin C-mediated and z-VAD.fmk-resistant cell death.	Hyogo Med Univ, Dept Neurosurg, Mol Biol Res Lab, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine; University of Hyogo	Tani, E (corresponding author), Hyogo Med Univ, Dept Neurosurg, Mol Biol Res Lab, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.							Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; RAPP UR, 1991, ONCOGENE, V6, P495; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	65	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5310	5317		10.1074/jbc.274.9.5310	http://dx.doi.org/10.1074/jbc.274.9.5310			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026138	hybrid			2022-12-27	WOS:000078804400009
J	Shen, AL; Sem, DS; Kasper, CB				Shen, AL; Sem, DS; Kasper, CB			Mechanistic studies on the reductive half-reaction of NADPH-cytochrome P450 oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHTHALATE DIOXYGENASE REDUCTASE; ADENINE-DINUCLEOTIDE PHOSPHATE; ALTERNATE SUBSTRATE INHIBITOR; ENZYME-CATALYZED REACTIONS; FUNCTION OXIDASE SYSTEM; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; SPECTRAL CHARACTERIZATION; FERREDOXIN REDUCTASE	Site-directed mutagenesis has been employed to study the mechanism of hydride transfer from NADPH to NADPH-cytochrome P450 oxidoreductase. Specifically, Ser(457), Asp(675), and Cys(630) have been selected because of their proximity to the isoalloxazine ring of FAD, Substitution of Asp(675) with asparagine or valine decreased cytochrome c reductase activities 17- and 677-fold, respectively, while the C630A substitution decreased enzymatic activity 49-fold. Earlier studies had shown that the S457A mutation decreased cytochrome c reductase activity 90-fold and also lowered the redox potential of the FAD semiquinone (Shen, A, and Kasper, C, B, (1996) Biochemistry 35, 9451-9459). The S457A/D675N and S457A/D675N/C630A mutants produced roughly multiplicative decreases in cytochrome c reductase activity (774- and 22000-fold, respectively) with corresponding decreases in the rates of flavin reduction. For each mutation, increases were observed in the magnitudes of the primary deuterium isotope effects with NADPD, consistent with decreased rates of hydride transfer from NADPH to FAD and an increase in the relative rate limitation of hydride transfer. Asp(675) substitutions lowered the redox potential of the FAD semiquinone. In addition, the C630A substitution shifted the pK(a) of an ionizable group previously identified as necessary for catalysis (Sem, D. S,, and Kasper, C, B. (1993) Biochemistry 32, 11539-11547) from 6.9 to 7.8, These results are consistent with a model in which Ser(457), Asp(675), and Cys(630) stabilize the transition state for hydride transfer. Ser(457) and Asp(675) interact to stabilize both the transition state and the FAD semiquinone, while Cys(630) interacts with the nicotinamide ring and the fully reduced FAD, functioning as a proton donor/acceptor to FAD.	Mcardle Lab Canc Res, Madison, WI 53706 USA		Kasper, CB (corresponding author), Mcardle Lab Canc Res, Madison, WI 53706 USA.			Sem, Daniel/0000-0002-2108-6646	NCI NIH HHS [CA0920, CA22484] Funding Source: Medline; NCRR NIH HHS [RR02301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484, K04CA000920] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hodgson AV, 1996, ARCH BIOCHEM BIOPHYS, V325, P99, DOI 10.1006/abbi.1996.0012; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1978, BIOCHEMISTRY-US, V17, P2224, DOI 10.1021/bi00604a032; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KAMIN H, 1966, FLAVINS FLAVOPROTEIN, P306; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIM JJP, 1997, FLAVINS FLAVOPROTEIN, P455; KUNKEL TA, 1989, SHORT PROTOCOLS MOL, P235; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KURZBAN GP, 1990, J BIOL CHEM, V265, P12272; KYTE J, 1995, MECH PROTEIN CHEM, P73; MASTERS BSS, 1965, J BIOL CHEM, V240, P921; MASTERS BSS, 1980, ENZYMATIC BASIS DETO, P183; MATTHEWS RG, 1991, FLAVINS AND FLAVOPROTEINS 1990, P593; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; NARAYANASAMI R, 1995, ARCH BIOCHEM BIOPHYS, V316, P267, DOI 10.1006/abbi.1995.1037; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SEM DS, 1994, BIOCHEMISTRY-US, V33, P12012, DOI 10.1021/bi00206a002; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11539, DOI 10.1021/bi00094a010; SEM DS, 1995, BIOCHEMISTRY-US, V34, P12768, DOI 10.1021/bi00039a037; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7058, DOI 10.1021/bi960060a; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Shen AL, 1996, BIOCHEMISTRY-US, V35, P9451, DOI 10.1021/bi960587n; SHEN AL, 1993, HDB EXPT PHARM, V105, P35; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWEET WL, 1991, BIOCHEMISTRY-US, V30, P8702, DOI 10.1021/bi00099a031; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; YASUKOCHI Y, 1979, J BIOL CHEM, V254, P7097	47	52	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5391	5398		10.1074/jbc.274.9.5391	http://dx.doi.org/10.1074/jbc.274.9.5391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026149	hybrid			2022-12-27	WOS:000078804400020
J	von Germar, F; Galan, A; Llorca, O; Carrascosa, JL; Valpuesta, JM; Mantele, W; Muga, A				von Germar, F; Galan, A; Llorca, O; Carrascosa, JL; Valpuesta, JM; Mantele, W; Muga, A			Conformational changes generated in GroEL during ATP hydrolysis as seen by time-resolved infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; CATALYTIC CYCLE; DIFFERENCE SPECTROSCOPY; SECONDARY STRUCTURE; PROTEIN-STRUCTURE; BINDING; CA2+-ATPASE; POLYPEPTIDE; ABSORPTION; MECHANISM	Changes in the vibrational spectrum of the chaperonin GroEL in the presence of ADP and ATP have been followed as a function of time using rapid scan Fourier transform infrared spectroscopy. The interaction of nucleotides with GroEL was triggered by the photochemical release of the ligands hom their corresponding biologically inactive precursors (caged nucleotides; P-3-1-(2-nitro)phenylethyl nucleotide). Binding of either ADP or ATP induced the appearance of small differential signals in the amide I band of the protein, sensitive to protein secondary structure, suggesting a subtle and localized change in protein conformation. Moreover, conformational changes associated with ATP hydrolysis were detected that differed markedly from those observed upon nucleotide binding. Both, high-amplitude absorbance changes and difference bands attributable to modifications in the interaction between oppositely charged residues were observed during ATP hydrolysis. Once this process had occurred, the protein relaxed to an ADP-like conformation. Our results suggest that the secondary structure as well as salt bridges of GroEL are modified during ATP hydrolysis, as compared with the ATP and ADP bound protein states.	Univ Basque Country, Consejo Super Invest Cient, Unidad Asociada, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Erlangen Nurnberg, Inst Phys & Theoret Chem, D-91058 Erlangen, Germany; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Consejo Super Invest Cient, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; University of Erlangen Nuremberg; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Muga, A (corresponding author), Univ Basque Country, Consejo Super Invest Cient, Unidad Asociada, Dept Bioquim & Biol Mol, Aptdo 644, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Llorca, Oscar/P-2784-2019; Valpuesta, José M/T-1977-2017; Llorca, Oscar/K-1144-2014; Muga, Arturo/N-1174-2014; Valpuesta, Jose M/AAA-6002-2019	Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Llorca, Oscar/0000-0001-5705-0699; Muga, Arturo/0000-0003-0345-6882; 				Aharoni A, 1997, P NATL ACAD SCI USA, V94, P1698, DOI 10.1073/pnas.94.5.1698; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; Fenton WA, 1997, PROTEIN SCI, V6, P743; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; Gorovits BM, 1997, J BIOL CHEM, V272, P6842, DOI 10.1074/jbc.272.11.6842; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; MANTELE W, 1993, TRENDS BIOCHEM SCI, V18, P197, DOI 10.1016/0968-0004(93)90186-Q; MCCRAY JA, 1980, P NATL ACAD SCI-BIOL, V77, P7237, DOI 10.1073/pnas.77.12.7237; Mendoza JA, 1996, J BIOL CHEM, V271, P16344, DOI 10.1074/jbc.271.27.16344; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	32	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5508	5513		10.1074/jbc.274.9.5508	http://dx.doi.org/10.1074/jbc.274.9.5508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026164	hybrid			2022-12-27	WOS:000078804400035
J	Xue, HW; Pical, C; Brearley, C; Elge, S; Muller-Rober, B				Xue, HW; Pical, C; Brearley, C; Elge, S; Muller-Rober, B			A plant 126-kDa phosphatidylinositol 4-kinase with a novel repeat structure - Cloning and functional expression in baculovirus-infected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PLASMA-MEMBRANE; PHOSPHOINOSITIDE 3-KINASE; INOSITOL TRISPHOSPHATE; ARABIDOPSIS-THALIANA; WORTMANNIN; PROTEIN; POLYPHOSPHOINOSITIDES; SEQUENCE; KINASE	Phosphatidylinositol metabolism plays a central role in signaling pathways in animals and is also believed to be of importance in signal transduction in higher plants, We report here the molecular cloning of a cDNA encoding a previously unidentified 126-kDa phosphatidylinositol (PI) 4-kinase (AtPI4K beta) from the higher plant Arabidopsis thaliana. The novel protein possesses the conserved domains present in animal and yeast PI 4-kinases, namely a lipid kinase unique domain and a catalytic domain. An additional domain, approximately 300 amino acids long, containing a high percentage (46%) of charged amino acids is specific to this plant enzyme. Recombinant AtPI4K beta expressed in baculovirus-infected insect (Spodoptera frugiperda) cells phosphorylated phosphatidylinositol exclusively at the D4 position of the inositol ring. Recombinant protein was maximally activated by 0.6% Triton X-100 but was inhibited by adenosine with an IC50 of similar to 200 mu M. Wortmannin at a concentration of 10 mu M inhibited AtPI4K beta activity by similar to 90%. AtPI4K beta transcript levels were similar in all tissues analyzed. Light or treatment with hormones or salts did not change AtPI4K beta transcript levels to a great extent, indicating constitutive expression of the AtPI4K beta gene.	Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany; Lund Univ, SE-22100 Lund, Sweden; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	Max Planck Society; Lund University; University of Cambridge	Muller-Rober, B (corresponding author), Max Planck Inst Mol Plant Physiol, Karl Liebknecht Str 25,Haus 20, D-14476 Golm, Germany.	mueller@mpimp-golm.mpg.de	Xue, Hao/GXV-4717-2022	Brearley, Charles/0000-0001-6179-9109				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brearley CA, 1997, BIOCHEM J, V324, P123, DOI 10.1042/bj3240123; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHEN QY, 1990, PLANT PHYSIOL, V94, P1820, DOI 10.1104/pp.94.4.1820; CHEN QY, 1991, PLANT PHYSIOL, V96, P340, DOI 10.1104/pp.96.1.340; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FIEUW S, 1995, PLANT PHYSIOL, V107, P905, DOI 10.1104/pp.107.3.905; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Hanenberg A, 1995, PLANT SCI, V112, P53, DOI 10.1016/0168-9452(95)04258-V; HENDRIX KW, 1989, PROTOPLASMA, V151, P62, DOI 10.1007/BF01403302; Hirayama T, 1997, PLANT MOL BIOL, V34, P175, DOI 10.1023/A:1005885230896; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kopka J, 1998, PLANT PHYSIOL, V116, P239, DOI 10.1104/pp.116.1.239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSCHUTZE V, 1995, EMBO J, V14, P660; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; MEMON AR, 1990, J BIOL CHEM, V265, P14817; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Mikami K, 1998, PLANT J, V15, P563, DOI 10.1046/j.1365-313X.1998.00227.x; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; OKPODU C M, 1990, Plant Physiology (Rockville), V93, P63; OKPODU CM, 1995, PLANT PHYSIOL, V107, P491, DOI 10.1104/pp.107.2.491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATTERLEE JS, 1997, PLANT PHYSIOL, V115, P864; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; Staiger CJ, 1997, TRENDS PLANT SCI, V2, P275, DOI 10.1016/S1360-1385(97)86350-9; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; WONG K, 1994, J BIOL CHEM, V269, P28878; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XU P, 1992, PLANT CELL, V4, P941, DOI 10.1105/tpc.4.8.941; YAMAMOTO YT, 1995, PLANT PHYSIOL, V107, P1029, DOI 10.1104/pp.107.3.1029; YANG W, 1994, J BIOL CHEM, V269, P3852; YANG WN, 1993, J BIOL CHEM, V268, P392; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	60	56	58	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5738	5745		10.1074/jbc.274.9.5738	http://dx.doi.org/10.1074/jbc.274.9.5738			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026194	hybrid			2022-12-27	WOS:000078804400065
J	Yegneswaran, S; Smirnov, MD; Safa, O; Esmon, NL; Esmon, CT; Johnson, AE				Yegneswaran, S; Smirnov, MD; Safa, O; Esmon, NL; Esmon, CT; Johnson, AE			Relocating the active site of activated protein C eliminates the need for its protein S cofactor - A fluorescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR VIIA; PEPTIDE-BOND CLEAVAGES; CLOTTING FACTOR-X; HUMAN FACTOR VA; BLOOD-COAGULATION; MEMBRANE-SURFACE; TISSUE FACTOR; CONFORMATIONAL SENSITIVITY; PHOSPHOLIPID SURFACE	The effect of replacing the gamma-carboxyglutamic acid domain of activated protein C (APC) with that of prothrombin on the topography of the membrane-bound enzyme was examined using fluorescence resonance energy transfer. The average distance of closest approach (assuming kappa(2) = 2/3) between a fluorescein in the active site of the chimera and octadecylrhodamine at the membrane surface was 89 Angstrom, compared with 94 Angstrom for wildtype APC, The gamma-carboxyglutamic acid domain substitution therefore lowered and/or reoriented the active site, repositioning it close to the 84 Angstrom observed for the APC protein S complex. Protein S enhances wild-type APC cleavage of factor Va at Arg(306), but the inactivation rate of factor Va Leiden by the chimera alone is essentially equal to that by wild-type APC plus protein S. These data suggest that the activities of the chimera and of the APC protein S complex are equivalent because the active site of the chimeric protein is already positioned near the optimal location above the membrane surface to cleave Arg(306). Thus, one mechanism by which protein S regulates APC activity is by relocating its active site to the proper position above the membrane surface to optimize factor Va cleavage.	Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, Rm 116,Reynolds Med Bldg, College Stn, TX 77843 USA.	aejohnson@tamu.edu	Johnson, Arthur E/G-3457-2012		NHLBI NIH HHS [R37 HL 30340, R01 HL 32934, R01 HL 29807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807, R01HL032934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESMON CT, 1995, HEMATOLOGY BASIC PRI, V2, P1597; Geng JP, 1997, THROMB HAEMOSTASIS, V77, P926; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; HOCHBERG Y, 1987, MULTIPLE COMP PROCED, P80; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LU RL, 1989, J BIOL CHEM, V264, P12956; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; OWEN WG, 1974, J BIOL CHEM, V249, P594; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1981, THROMB RES, V22, P321, DOI 10.1016/0049-3848(81)90125-0; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	43	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5462	5468		10.1074/jbc.274.9.5462	http://dx.doi.org/10.1074/jbc.274.9.5462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026158	hybrid			2022-12-27	WOS:000078804400029
J	Zizioli, D; Meyer, C; Guhde, G; Saftig, P; von Figura, K; Schu, P				Zizioli, D; Meyer, C; Guhde, G; Saftig, P; von Figura, K; Schu, P			Early embryonic death of mice deficient in gamma-adaptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-II PHOSPHORYLATION; CLATHRIN-COATED VESICLES; PREIMPLANTATION DEVELOPMENT; TARGETING SIGNAL; GOLGI MEMBRANES; PROTEIN; EXPRESSION; BINDING; COMPLEX; CELLS	Intracellular protein transport and sorting by vesicles in the secretory and endocytic pathways requires the formation of a protein coat on the membrane. The heterotetrameric adaptor protein complex 1 (AP-1) promotes the formation of clathrin-coated vesicles at the trans-Golgi network. AP-1 interacts with various sorting signals in the cytoplasmic tails of cargo molecules, thus indicating a function in protein sorting. We generated mutants of the gamma-adaptin subunit of AP-1 in mice to investigate its role in post-Golgi vesicle transport and sorting processes. gamma-Adaptin-deficient embryos develop until day 3.5 post coitus and die during the prenidation period, revealing that AP-1 is essential for viability. In heterozygous mice the amount of AP-1 complexes is reduced to half of controls. Free beta 1- or mu 1 chains were not detectable, indicating that they are unstable unless they are part of AP-1 complexes. Heterozygous mice weigh less then their wild-type littermates and show impaired T cell development.	Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Schu, P (corresponding author), Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, Gosslerstr 12D, D-37073 Gottingen, Germany.		Saftig, Paul/A-7966-2010	Zizioli, Daniela/0000-0003-0451-8029				Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DITTMER F, 1999, IN PRESS TRANSGENIC; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hogan B, 1994, MANIPULATING MOUSE E; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; KIDDER GM, 1992, DEV GENET, V13, P319, DOI 10.1002/dvg.1020130502; KORNFELD S, 1995, METABOLIC MOL BASES, P2495; LABORGNE R, 1997, J CELL BIOL, V137, P335; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ooi CE, 1997, EMBO J, V16, P4508; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PERONA RM, 1986, DEV BIOL, V114, P42, DOI 10.1016/0012-1606(86)90382-9; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; RAD MR, 1995, J CELL SCI, V108, P1605; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; Stewart CL, 1997, DEV GENET, V21, P91, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;91::AID-DVG11&gt;3.0.CO;2-D; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482	42	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5385	5390		10.1074/jbc.274.9.5385	http://dx.doi.org/10.1074/jbc.274.9.5385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026148	hybrid			2022-12-27	WOS:000078804400019
J	Cheshire, JL; Williams, BRG; Baldwin, AS				Cheshire, JL; Williams, BRG; Baldwin, AS			Involvement of double-stranded RNA-activated protein kinase in the synergistic activation of nuclear factor-kappa B by tumor necrosis factor-alpha and gamma-interferon in preneuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT EIF-2-ALPHA KINASE; IFN-GAMMA; ADHESION MOLECULE-1; GENE-EXPRESSION; 3T3-F442A CELLS; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; BETA DEGRADATION; PKR; INDUCTION	Tumor necrosis factor-alpha (TNF-alpha) and gamma-interferon (IFN-gamma) cooperate during a variety of biological responses and ultimately synergistically enhance the expression of genes involved in immune and inflammatory responses. Recently, we demonstrated that IFN-gamma can significantly potentiate TNF-alpha-induced nuclear factor (NF)-kappa B nuclear translocation in neuronal derived and endothelial cell lines. The mechanism by which these two cytokines exert their synergistic effect on NF-kappa B involves the de novo degradation of the NF-kappa B inhibitor, I kappa B beta. The double-stranded RNA-dependent kinase PKR is IFN-inducible and has been implicated in the activation of NF-kappa B; therefore, we examined the possibility that PKR may play a role in the synergistic activation of NF-kappa B during TNF-alpha/IFN-gamma cotreatment. The PKR inhibitor 2-aminopurine (2-AP) inhibited TNF-alpha/IFN-gamma-induced NF-kappa B nuclear translocation in neuronal derived cells but not in endothelial cells. The induced degradation of I kappa B beta, which is normally observed upon TNF-alpha/IFN-gamma cotreatment, was blocked completely by 2-AP in neuronal derived cells. Also, 2-AP treatment or overexpression of a catalytically inactive PKR inhibited the TNF-alpha/IFN-gamma-induced synergistic activation of kappa B-dependent gene expression. Our results suggest that the signal generated by IFN-gamma during TNF-alpha/IFN-gamma cotreatment may require PKR to elicit enhanced NF-kappa B activity, and this signal may affect the stability of the I kappa B beta protein.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cleveland Clinic Foundation	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NIAID NIH HHS [AI34039, AI35098] Funding Source: Medline; NIA NIH HHS [1 F32 AG05745] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039, R37AI035098, R01AI035098, R21AI034039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005745] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLANCHET O, 1991, INT J CANCER, P138; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KRAKAUER T, 1993, J IMMUNOL, V150, P1205; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Petryshyn R, 1996, ARCH BIOCHEM BIOPHYS, V326, P290, DOI 10.1006/abbi.1996.0078; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; SANCEAU J, 1992, J IMMUNOL, V149, P1671; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; Weil R, 1997, J BIOL CHEM, V272, P9942; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	66	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4801	4806		10.1074/jbc.274.8.4801	http://dx.doi.org/10.1074/jbc.274.8.4801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988719	Green Published, hybrid			2022-12-27	WOS:000078698200044
J	Miyagi, T; Wada, T; Iwamatsu, A; Hata, K; Yoshikawa, Y; Tokuyama, S; Sawada, M				Miyagi, T; Wada, T; Iwamatsu, A; Hata, K; Yoshikawa, Y; Tokuyama, S; Sawada, M			Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; CYTOSOLIC SIALIDASE; GROWTH-CONTROL; GM3 GANGLIOSIDE; MESSENGER-RNA; GENE-TRANSFER; RAT-LIVER; DIFFERENTIATION; FIBROBLASTS; ACID	Gangliosides are plasma membrane components thought to play important roles in cell surface interactions, cell differentiation, and transmembrane signaling. A mammalian sialidase located in plasma membranes is unique in specifically hydrolyzing gangliosides, suggesting crucial roles in regulation of cell surface functions. Here we describe the cloning and expression of a cDNA for the ganglioside sialidase, isolated from a bovine brain cDNA library based on the amino acid sequence of the purified enzyme from bovine brain. This cDNA encodes a 428-amino acid protein containing a putative transmembrane domain and the three Asp boxes characteristic of sialidases and sharing 19-38% sequence identity with other sialidases, Northern blot and polymerase chain reaction analyses revealed a general distribution of the gene in mammalian species, including man, and the mouse. In COS-7 cells transiently expressing the sialidase, the activity was found to be 40-fold that of the control level with ganglioside substrates in the presence of Triton X-100, and the hydrolysis was almost specific to gangliosides other than GM1 and GM2, both alpha 2-->3 and alpha 2-->8 sialyl linkages being susceptible. The major subcellular localization of the expressed sialidase was assessed to be plasma membrane by Percoll density gradient centrifugation of cell homogenates and by immunofluorescence staining of the transfected COS-7 cells. Analysis of the membrane topology by protease protection assay suggested that this sialidase has a type I membrane orientation with its amino terminus facing to the extracytoplasmic side and lacking a signal sequence.	Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 236, Japan	Kirin Brewery Company Limited	Miyagi, T (corresponding author), Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan.	tmiyagi@mcc.pref.miyagi.jp						Akita H, 1997, HISTOCHEM CELL BIOL, V107, P495, DOI 10.1007/s004180050137; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; Hata K, 1998, J BIOCHEM-TOKYO, V123, P899; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOYER LL, 1992, MOL MICROBIOL, V6, P873, DOI 10.1111/j.1365-2958.1992.tb01538.x; Igdoura SA, 1998, HUM MOL GENET, V7, P115, DOI 10.1093/hmg/7.1.115; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; Kopitz J, 1997, EUR J BIOCHEM, V248, P527, DOI 10.1111/j.1432-1033.1997.00527.x; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LIESER M, 1989, BIOCHEM J, V260, P69, DOI 10.1042/bj2600069; MACALA LJ, 1995, GLYCOBIOLOGY, V5, P67, DOI 10.1093/glycob/5.1.67; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; MIYAGI T, 1990, JPN J CANCER RES, V81, P1286, DOI 10.1111/j.1349-7006.1990.tb02692.x; OHMAN R, 1971, J NEUROCHEM, V18, P79, DOI 10.1111/j.1471-4159.1971.tb00168.x; OHMAN R, 1971, J NEUROCHEM, V18, P89, DOI 10.1111/j.1471-4159.1971.tb00169.x; Palestini P, 1998, BIOCHEMISTRY-US, V37, P3143, DOI 10.1021/bi971838a; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; ROST B, 1995, PROTEIN SCI, V4, P521; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHENGRUND CL, 1973, J BIOL CHEM, V248, P4424; Tatewaki K, 1997, EXP CELL RES, V233, P145, DOI 10.1006/excr.1997.3563; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; USUKI S, 1988, J BIOL CHEM, V263, P10595; USUKI S, 1988, J BIOL CHEM, V263, P6847; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; YOGEESWARAN G, 1975, BIOCHEMISTRY-US, V14, P2151, DOI 10.1021/bi00681a017; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; [No title captured]	47	152	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5004	5011		10.1074/jbc.274.8.5004	http://dx.doi.org/10.1074/jbc.274.8.5004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988745	hybrid			2022-12-27	WOS:000078698200070
J	Schwientek, T; Nomoto, M; Levery, SB; Merkx, G; van Kessel, AG; Bennett, EP; Hollingsworth, MA; Clausen, H				Schwientek, T; Nomoto, M; Levery, SB; Merkx, G; van Kessel, AG; Bennett, EP; Hollingsworth, MA; Clausen, H			Control of O-glycan branch formation - Molecular cloning of human cDNA encoding a novel beta 1,6-N-acetylglucosaminyltransferase forming core 2 and core 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; HUMAN COLONIC MUCIN; OLIGOSACCHARIDE STRUCTURES; CORRELATION SPECTROSCOPY; LINKED OLIGOSACCHARIDES; GENE FAMILY; UDP-GLCNAC; CELL-LINES; EXPRESSION	A novel human UDP-GlcNAc: Gal/GlcNAc beta 1-3GalNAc alpha beta 1,6GlcNAc-transferase, designated C2/4GnT, was identified by BLAST analysis of expressed sequence tags. The sequence of C2/4GnT encoded a putative type II transmembrane protein with significant sequence similarity to human C2GnT and IGnT, Expression of the secreted form of C2/4GnT in insect cells showed that the gene product had UDP-N-acetyl-alpha-D-glucosamine: acceptor beta 1,6-N-acetylglucosaminyltransferase (beta 1,6GlcNAc-transferase) activity. Analysis of substrate specificity revealed that the enzyme catalyzed O-glycan branch formation of the core 2 and core 4 type. NMR analyses of the product formed with core 3-para-nitrophenyl confirmed the product core 4-para-nitrophenyl, The coding region of C2/4GnT was contained in a single exon and located to chromosome 15q21.3. Northern analysis revealed a restricted expression pattern of C2/4GnT mainly in colon, kidney, pancreas, and small intestine. No expression of C2/4GnT was detected in brain, heart, liver, ovary, placenta, spleen, thymus, and peripheral blood leukocytes, The expression of core 2 O-glycans has been correlated with cell differentiation processes and cancer. The results confirm the predicted existence of a beta 1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation. The redundancy in beta 1,6Glc-NAc-transferases capable of forming core 2 O-glycans is important for understanding the mechanisms leading to specific changes in core 2 branching during cell development and malignant transformation.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	University of Copenhagen; University of Nebraska System; University of Nebraska Medical Center; University System of Georgia; University of Georgia; Radboud University Nijmegen	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		Bennett, Eric/AAG-6120-2020; van Kessel, Ad Geurts/A-2810-2010; clausen, henrik/AAD-8016-2021	Bennett, Eric/0000-0002-4976-0647; 	NCI NIH HHS [1 RO1 CA66234, 1RO1 CA66234] Funding Source: Medline; NCRR NIH HHS [5 P41 RR05351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1988, J MAGN RESON, V78, P186, DOI 10.1016/0022-2364(88)90172-2; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, GLYCOBIOLOGY, V8, P547, DOI 10.1093/glycob/8.6.547; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; Brockhausen I, 1997, BIOCHEM SOC T, V25, P871, DOI 10.1042/bst0250871; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; Bush CA, 1988, B MAGN RESON, V10, P73; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Fukuda M, 1996, CANCER RES, V56, P2237; HANISCH FG, 1993, EUR J BIOCHEM, V217, P645, DOI 10.1111/j.1432-1033.1993.tb18288.x; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HOUNSELL EF, 1989, EUR J BIOCHEM, V186, P597, DOI 10.1111/j.1432-1033.1989.tb15250.x; Karlsson NG, 1997, J BIOL CHEM, V272, P27025, DOI 10.1074/jbc.272.43.27025; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUHNS W, 1993, GLYCOCONJUGATE J, V10, P381, DOI 10.1007/BF00731043; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leppanen A, 1998, J BIOL CHEM, V273, P17399, DOI 10.1074/jbc.273.28.17399; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Natunen J, 1997, GLYCOBIOLOGY, V7, P711, DOI 10.1093/glycob/7.5.711; Olavesen MG, 1997, GENOMICS, V46, P303, DOI 10.1006/geno.1997.5032; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PILLER F, 1988, J BIOL CHEM, V263, P15146; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; POLLEXKRUGER A, 1993, GLYCOCONJUGATE J, V10, P365, DOI 10.1007/BF00731042; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SAITOH O, 1991, BLOOD, V77, P1491; SANGADALA S, 1991, MOL CELL BIOCHEM, V101, P125; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SCHACHTER H, 1971, J BIOL CHEM, V246, P5321; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SEKINE M, 1994, J BIOL CHEM, V269, P31143; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Sutherlin ME, 1997, CANCER RES, V57, P4744; Toki D, 1997, BIOCHEM J, V325, P63, DOI 10.1042/bj3250063; VanderElst IE, 1998, GLYCOBIOLOGY, V8, P731, DOI 10.1093/glycob/8.7.731; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	65	84	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4504	4512		10.1074/jbc.274.8.4504	http://dx.doi.org/10.1074/jbc.274.8.4504			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988682	hybrid			2022-12-27	WOS:000078698200007
J	Volkman, BF; Anderson, ME; Clark, KD; Hayakawa, Y; Strand, MR; Markley, JL				Volkman, BF; Anderson, ME; Clark, KD; Hayakawa, Y; Strand, MR; Markley, JL			Structure of the insect cytokine peptide plasmatocyte-spreading peptide 1 from Pseudoplusia includens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEINS; PROGRAM; SPECTROSCOPY; THROMBIN	The structure of the recently identified plasmatocyte spreading peptide from the moth Pseudoplusia includens (PSP1) has been determined by NMR spectroscopy. This novel insect cytokine consists of 23 amino acid residues and a single disulfide bond. Torsion angle dynamics calculations utilizing a total of 337 distance constraints yielded an ensemble of 30 structures with an average backbone root mean square deviation for residues 7-22 of 0.18 Angstrom from the mean structure. The structure consists of a disordered N-terminal region and a well defined core that is stabilized by numerous hydrophobic interactions and a short beta-hairpin. Structural comparisons confirm that PSP1 adopts an epidermal growth factor (EGF)-like fold with close similarity to the C-terminal subdomain of EGF-like module 5 of human thrombomodulin. The combination of the three-dimensional structure of PSP1 and the extensive literature on EGF-receptor interactions should accelerate the process of identifying the specific residues responsible for receptor binding activity of this family of immunoregulatory peptides.	Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA; Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Hokkaido University	Volkman, BF (corresponding author), Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil Madison, 433 Babcock Dr, Madison, WI 53706 USA.	volkman@nmrfam.wisc.edu	Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020; Clark, Kevin/GQA-9811-2022	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; 	NCRR NIH HHS [RR02781, RR02301] Funding Source: Medline; NIAID NIH HHS [AI32917] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Bartels C, 1996, J BIOMOL NMR, V7, P207, DOI 10.1007/BF00202037; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1991, J MAGN RESON, V91, P174, DOI 10.1016/0022-2364(91)90422-P; Benitez BAS, 1997, J MOL BIOL, V273, P913, DOI 10.1006/jmbi.1997.1356; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; Hrabal R, 1996, PROTEIN SCI, V5, P195; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Wuthrich K, 1986, NMR PROTEINS NUCL AC	20	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4493	4496		10.1074/jbc.274.8.4493	http://dx.doi.org/10.1074/jbc.274.8.4493			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988679	hybrid			2022-12-27	WOS:000078698200004
J	Gary, R; Kim, K; Cornelius, HL; Park, MS; Matsumoto, Y				Gary, R; Kim, K; Cornelius, HL; Park, MS; Matsumoto, Y			Proliferating cell nuclear antigen facilitates excision in long-patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; STRUCTURE-SPECIFIC ENDONUCLEASE; DEOXYRIBOSE PHOSPHATE RESIDUES; HUMAN APURINIC ENDONUCLEASE; HUMAN FLAP ENDONUCLEASE-1; MISMATCH REPAIR; HUMAN FEN-1; PCNA; REPLICATION; BINDING	There are two distinct pathways for the removal of modified DNA bases through base excision repair (BER) in vertebrates, Following 5' incision by AP endonuclease, the pathways diverge as two different excision mechanisms are possible, In short-patch repair, DNA polymerase beta accounts for both excision activity and single nucleotide repair synthesis. In long-patch repair, the damage-containing strand is excised by the structure-specific endonuclease FEN-1 and approximately 2-8 nucleotides are incorporated by proliferating cell nuclear antigen (PCNA)-dependent synthesis. PCNA is an accessory factor of DNA polymerases delta and epsilon that is required for DNA replication and repair. PCNA binds to FEN-1 and stimulates its nuclease activity, but the physiological significance of this interaction is unknown. The importance of the PCNA-FEN-1 interaction in BER was investigated, In a reconstituted BER assay system containing FEN-1, omission of PCNA caused the accumulation of pre-excision reaction intermediates which could be converted to completely repaired product by addition of PCNA. When dNTPs were omitted from the reaction to suppress repair synthesis, PCNA was required for the formation of excised reaction intermediates. In contrast, a PCNA mutant that could not bind to FEN-1 was unable to stimulate excision, To further study this effect, a mutant of FEN-T was identified that retained full nuclease activity but was specifically defective in binding to PCNA. The mutant FEN-1 exhibited one-tenth the specific activity of wild type FEN-1 in the reconstituted BER assay, and this repair defect was due to a kinetic block at the excision step as evidenced by the accumulation of pre-excision intermediates when dNTPs were omitted, These results indicate that PCNA facilitates excision during long-patch BER through its interaction with FEN-1.	Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA; Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Fox Chase Cancer Center	Gary, R (corresponding author), Univ Calif Los Alamos Natl Lab, Div Life Sci, M888, Los Alamos, NM 87545 USA.		Park, Min Sung/HCH-2207-2022; Gary, Ronald K/A-8650-2008	Gary, Ronald K/0000-0001-5079-1953; Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL CANCER INSTITUTE [R29CA063154, R29CA071630, R01CA063154] Funding Source: NIH RePORTER; NCI NIH HHS [CA71630, CA63154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henderson DS, 1998, MUTAGENESIS, V13, P57; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P172; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713	45	141	143	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4354	4363		10.1074/jbc.274.7.4354	http://dx.doi.org/10.1074/jbc.274.7.4354			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933638	hybrid			2022-12-27	WOS:000078575500062
J	Kishi, A; Kato, M; Shimizu, T; Kato, K; Matsumoto, K; Yoshida, S; Shiosaka, S; Hakoshima, T				Kishi, A; Kato, M; Shimizu, T; Kato, K; Matsumoto, K; Yoshida, S; Shiosaka, S; Hakoshima, T			Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SERINE-PROTEASE; X-RAY; CRYSTALLOGRAPHIC REFINEMENT; NEURITE OUTGROWTH; NERVOUS-SYSTEM; MOUSE-BRAIN; TRYPSIN; EXPRESSION; CRYSTALLIZATION	Neuropsin is a novel serine protease, the expression of which is highly localized in the limbic areas of the mouse brain and which is suggested to be involved in kindling epileptogenesis and hippocampal plasticity, The 2.1-Angstrom resolution crystal structure of neuropsin provides the first three-dimensional view of one of the serine proteases highly expressed in the nervous system, and reveals a serine protease fold that exhibits chimeric features between trypsin and nerve growth factor-gamma (NGF gamma), a member of the kallikrein family. Neuropsin possesses an N-glycosylated "kallikrein loop" but forms six disulfide bonds corresponding to those of trypsin, The ordered kallikrein loop projects proline toward the active site tee restrict smaller residues or proline at the P2 position of substrates. Loop F, which participates in forming the S3/S4 sites, is similar to trypsin rather than NGF gamma. The unique conformations of loops G and H form an S1 pocket specific for both arginine and lysine, These characteristic loop structures forming the substrate-binding site suggest the novel substrate specificity of neuropsin and give a clue to the design of its specific inhibitors.	Nara Inst Sci & Technol, Dept Mol Biol, Nara 6300101, Japan; Nara Inst Sci & Technol, Dept Cell Biol, Nara 6300101, Japan	Nara Institute of Science & Technology; Nara Institute of Science & Technology	Hakoshima, T (corresponding author), Nara Inst Sci & Technol, Dept Mol Biol, 8916-5 Takayama, Nara 6300101, Japan.	hakosima@bs.aist-nara.ac.jp	Shiosaka, Sadao/B-1142-2008					Akita H, 1997, BRAIN RES, V769, P86, DOI 10.1016/S0006-8993(97)00674-4; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN ZL, 1995, J NEUROSCI, V15, P5088; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; FRIEDRICH A, 1996, TRENDS GLYCOSCI GLYC, V40, P101; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kishi T, 1997, J STRUCT BIOL, V118, P248, DOI 10.1006/jsbi.1997.3862; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okabe A, 1996, BRAIN RES, V728, P116, DOI 10.1016/S0006-8993(96)00473-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Shimizu C, 1998, J BIOL CHEM, V273, P11189, DOI 10.1074/jbc.273.18.11189; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X	29	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4220	4224		10.1074/jbc.274.7.4220	http://dx.doi.org/10.1074/jbc.274.7.4220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933620	hybrid			2022-12-27	WOS:000078575500044
J	Coy, DL; Wagenbach, M; Howard, J				Coy, DL; Wagenbach, M; Howard, J			Kinesin takes one 8-nm step for each ATP that it hydrolyzes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA KINESIN; MOLECULAR MOTORS; SLIDING DISTANCE; MICROTUBULES; FORCE; MOVEMENT; MUSCLE; ACTIN; TRANSPORT; MECHANISM	Conventional kinesin is a motor protein that moves stepwise along microtubules carrying membrane-bound organelles toward the periphery of cells. The steps are of amplitude 8.1 nm, the distance between adjacent tubulin binding sites, and are powered by the hydrolysis of ATP, We have asked: how many steps does kinesin take for each molecule of ATP that it hydrolyzes? To answer this question, the motility and ATP hydrolysis of recombinant, heterotetrameric and homodimeric conventional Drosophila kinesins adsorbed to 200-nm-diameter casein-coated silica beads were assayed under identical, single-molecule conditions. Division of the speed by the maximum microtubule-activated ATPase rate gave a stoichiometry of 1.08 +/- 0.09 steps for each ATP hydrolyzed at 1 mM ATP, Therefore, under low loads in which the drag force much less than 1 pN, coupling between the chemical and mechanical cycles of kinesin is tight, consistent with conventional power stroke models. Our results rule out models that require two or more ATPs/step, such as some thermal ratchet models, or that propose multiple steps powered by single ATPs.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Howard, J (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	johoward@u.washington.edu	Howard, Jonathon/J-7492-2016; Howard, Jonathon/D-4229-2011	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196	NIAMS NIH HHS [AR40593] Funding Source: Medline; NIGMS NIH HHS [GM08268] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR040593, R01AR040593] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Astumian RD, 1996, BIOPHYS J, V70, P637, DOI 10.1016/S0006-3495(96)79605-4; BERG H, 1983, RANDOM WALKS BIOL, P56; BLOCK SM, 1990, NATURE, V348, P284; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; Coy David L., 1994, Current Opinion in Neurobiology, V4, P662, DOI 10.1016/0959-4388(94)90007-8; EISENBERG E, 1978, PROG BIOPHYS MOL BIO, V33, P55; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HOWARD J, 1993, METHOD CELL BIOL, V39, P138; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	34	291	296	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3667	3671		10.1074/jbc.274.6.3667	http://dx.doi.org/10.1074/jbc.274.6.3667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920916	hybrid			2022-12-27	WOS:000078428200056
J	Ricci, MS; Toscano, DG; Mattingly, CJ; Toscano, WA				Ricci, MS; Toscano, DG; Mattingly, CJ; Toscano, WA			Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; XENOBIOTIC RESPONSIVE ELEMENT; ARYL-HYDROCARBON HYDROXYLASE; O-DEETHYLASE ACTIVITY; AH RECEPTOR; FUNCTIONAL-ANALYSIS; GENE-EXPRESSION; MESSENGER-RNA; INVITRO TRANSCRIPTION; REGULATORY ELEMENTS	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exerts its toxic action via the aryl hydrocarbon (Ah) receptor, which induces a battery of xenobiotic-metabolizing enzymes, including the cytochrome P450 isozyme, CYP1A1, TCDD-induced 7-ethoxycoumarin-O-deethylase activity was reduced 75% in cultured human endometrial ECC-1 cells exposed to various concentrations of 17 beta-estradiol for up to 72 h, with a half-maximal effective concentration (EC50) of 0.9 nM. Reduced enzyme activity was correlated with decreased CYP1A1 mRNA levels, and transcription. Exposure to TCDD plus 17 beta-estradiol also reduced CYP1A1 activity in MCF-7 breast cancer cells but not in Hep-3B human liver cells or HuE primary human keratinocytes, suggesting that the effect was specific to estrogen-regulated cells. Estrogen receptor antagonists 4-hydroxytamoxifen and 7 alpha-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]estra-1,3,5(10)-triene3,17 beta-diol restored TCDD-induced CYP1A1 transcription, steady-state mRNA levels, and enzymatic activity in ECC-1 cells. Gel mobility shift assay showed that 17 beta-estradiol had little effect on Ah receptor binding to its DNA-responsive element. 17 beta-Estradiol did not alter the induction of another Ah receptor-regulated gene, CYP1B1, suggesting that altered Ah receptor binding to DNA does not mediate reduced CYP1A1 transcription, Transfecting ECC-1 cells with a general transcription factor involved in CYP1A1 induction, nuclear factor-1, reversed 17 beta-estradiol antagonism of dioxin induced-CYP1A1, The data suggest that 17 beta-estradiol reduced CYP1A1 expression at the transcriptional level by squelching available nuclear factor-1, a transcription factor that interacts with both Ah and estrogen receptors.	Tulane Univ, Sch Publ Hlth & Trop Med SL29, Dept Environm Hlth Sci, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med SL29, Ctr Bioenvironm Res, New Orleans, LA 70112 USA	Tulane University; Tulane University	Toscano, WA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med SL29, Dept Environm Hlth Sci, 1430 Tulane Ave, New Orleans, LA 70112 USA.	wtoscan@tmc.tulane.edu		Mattingly, Carolyn/0000-0002-2146-9436				ASTROFF B, 1988, TOXICOL APPL PHARM, V95, P435, DOI 10.1016/0041-008X(88)90361-4; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BOIS FY, 1994, ENVIRON HEALTH PERSP, V102, P476, DOI 10.2307/3432044; BOULET AP, 1987, IN VITRO CELL DEV B, V23, P93; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DENISON MS, 1988, J BIOL CHEM, V263, P17221; Devito Michael J., 1994, P139; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLO MA, 1986, TOXICOL LETT, V32, P123, DOI 10.1016/0378-4274(86)90058-5; GASIEWICZ TA, 1991, BIOCHEMISTRY-US, V30, P2909, DOI 10.1021/bi00225a026; GREENLEE WF, 1978, J PHARMACOL EXP THER, V205, P596; HARRIS M, 1990, CANCER RES, V50, P3579; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HIRSCH V, 1986, P NATL ACAD SCI USA, V83, P9754, DOI 10.1073/pnas.83.24.9754; Hoivik D, 1997, J BIOL CHEM, V272, P30270, DOI 10.1074/jbc.272.48.30270; HORWITZ KB, 1975, STEROIDS, V26, P785, DOI 10.1016/0039-128X(75)90110-5; HUDSON LG, 1983, BIOCHEM BIOPH RES CO, V115, P611, DOI 10.1016/S0006-291X(83)80188-0; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; KONINCKX PR, 1994, HUM REPROD, V9, P1001, DOI 10.1093/oxfordjournals.humrep.a138623; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; KUBOTA M, 1991, J BIOCHEM-TOKYO, V110, P232, DOI 10.1093/oxfordjournals.jbchem.a123562; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lavin AL, 1998, ARCH BIOCHEM BIOPHYS, V352, P9, DOI 10.1006/abbi.1998.0587; Li Jonathan J., 1995, P397; LIEHR JG, 1995, P NATL ACAD SCI USA, V92, P9220, DOI 10.1073/pnas.92.20.9220; Liehr JG, 1996, P NATL ACAD SCI USA, V93, P3294, DOI 10.1073/pnas.93.8.3294; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; Miller CA, 1997, J BIOL CHEM, V272, P32824, DOI 10.1074/jbc.272.52.32824; MOORE M, 1993, J STEROID BIOCHEM, V44, P251, DOI 10.1016/0960-0760(93)90085-B; MOORE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P483, DOI 10.1006/abbi.1993.1451; NEBERT DW, 1970, INT J CANCER, V6, P470, DOI 10.1002/ijc.2910060318; OLIVE DL, 1993, NEW ENGL J MED, V328, P1759, DOI 10.1056/NEJM199306173282407; OMALLEY B, 1993, STEROID HORMONE ACTI, P44; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; Pink JJ, 1996, CANCER RES, V56, P2321; POLAND A, 1976, J BIOL CHEM, V251, P4936; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; Prough RA, 1996, FASEB J, V10, P1369, DOI 10.1096/fasebj.10.12.8903507; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; RICCI MS, 1999, IN PRESS IN VITRO CE; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; RODRIGUES AD, 1991, METHOD ENZYMOL, V206, P423; Safe S, 1995, TOXICOL LETT, V82-3, P731, DOI 10.1016/0378-4274(95)03591-5; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400, DOI 10.1111/j.1600-0773.1991.tb01321.x; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATYASWAROOP PG, 1983, SCIENCE, V219, P58, DOI 10.1126/science.6849115; SATYASWAROOP PG, 1986, PROGR CANC RES THERA, P430; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WAKELING AE, 1991, CANCER RES, V51, P3867; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; WHITLOCK JP, 1994, TRENDS ENDOCRIN MET, V5, P183, DOI 10.1016/1043-2760(94)90075-2; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Wo YYP, 1997, J BIOL CHEM, V272, P26702, DOI 10.1074/jbc.272.42.26702; ZACHAREWSKI T, 1998, REPROD DEV TOXICOLOG, P431	79	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3430	3438		10.1074/jbc.274.6.3430	http://dx.doi.org/10.1074/jbc.274.6.3430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920887	hybrid			2022-12-27	WOS:000078428200027
J	Swanson, KD; Taylor, LK; Haung, L; Burlingame, AL; Landreth, GE				Swanson, KD; Taylor, LK; Haung, L; Burlingame, AL; Landreth, GE			Transcription factor phosphorylation by pp90(rsk2) - Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; COFFIN-LOWRY SYNDROME; RIBOSOMAL S6 KINASE; DNA-BINDING DOMAIN; C-FOS; PHORBOL ESTER; MAP KINASES; INHIBITOR; POTENT	The in vitro phosphorylation of transcription factors by growth factor-activated protein kinases has resulted in the discovery of a number of activities whose identities and relationships to one another are unclear. Fos kinase is a growth factor-stimulated serine/threonine protein kinase that phosphorylates c-Fos at serine 362 within the carboxyl-terminal regulatory domain. Fos kinase activation is dependent on p21(ras) and mitogen-activated protein kinase/ERK kinase kinase (MEK) activity and is independent of phosphatidylinositol 3-kinase activity. We have purified Fos kinase by affinity chromatography using the Sepharose-linked protein kinase inhibitor, bisindolylmaleimide (BIM), Fos kinase has an apparent molecular mass of 88 kDa, and mass spectrophotometric analysis of the isolated protein showed that it produced tryptic fragments identical to those predicted for pp90(rsk2), Fos kinase isolated from nerve growth factor-stimulated PC12 cells is indistinguishable from NGFI-B kinase I, based on their chromatographic behavior, substrate specificities, and relative sensitivity to BIM, Furthermore, we have distinguished Fos kinase from calcium/cAMP response element-binding protein (CREB) kinase, Therefore, Fos kinase and NGFI-B kinase I and pp90(rsk2) represent the same protein kinase species, Moreover, we report that pp90(rsk2) exists within nerve growth factor-stimulated PC12 cells as two chromatographically and immunologically distinct species, Finally, we demonstrate that CREB kinase is distinct from pp90(rsk2).	Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, Dept Neurol, Cleveland, OH 44106 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco	Landreth, GE (corresponding author), Case Western Reserve Univ, Sch Med E504, Alzheimers Lab, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NIA NIH HHS [AG-00105] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; CURRAN T, 1984, CELL, V36, P259; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Grammer TC, 1996, J BIOL CHEM, V271, P23650, DOI 10.1074/jbc.271.39.23650; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIRATA Y, 1995, J NEUROCHEM, V65, P1780; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Pende M, 1997, J NEUROSCI, V17, P1291; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	39	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3385	3395		10.1074/jbc.274.6.3385	http://dx.doi.org/10.1074/jbc.274.6.3385			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920881	hybrid			2022-12-27	WOS:000078428200021
J	Matsui, T; Ozaki, S; Liong, E; Phillips, GN; Watanabe, Y				Matsui, T; Ozaki, S; Liong, E; Phillips, GN; Watanabe, Y			Effects of the location of distal histidine in the reaction of myoglobin with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; HORSERADISH-PEROXIDASE; HEME IRON; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; ACTIVE-SITE; COMPOUND-I	To clarify how the location of distal histidine affects the activation process of H2O2 by heme proteins, we have characterized reactions with H2O2 for the L29H/H64L and F43H/H64L mutants of sperm whale myoglobin (Mb), designed to locate the histidine farther from the heme iron. Whereas the L29H/H64L double substitution retarded the reaction with H2O2, an 11-fold rate increase versus wild-type Mb was observed for the F43H/H64L mutant. The V-max values for 1-electron oxidations by the myoglobins correlate well with the varied reactivities with H2O2. The functions of the distal histidine as a general acid-base catalyst were examined based on the reactions with cumene hydroperoxide and cyanide, and only the histidine in F43H/H64L Mb was suggested to facilitate heterolysis of the peroxide bond. The x-ray crystal structures of the mutants confirmed that the distal histidines in F43H/H64L Mb and peroxidase are similar in distance from the heme iron, whereas the distal histidine in L29H/H64L Mb is located too far to enhance heterolysis. Our results indicate that the proper positioning of the distal histidine is essential for the activation of H2O2 by heme enzymes.	Inst Mol Sci, Okazaki, Aichi 444, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 444, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Graduate University for Advanced Studies - Japan; Rice University	Watanabe, Y (corresponding author), Inst Mol Sci, Okazaki, Aichi 444, Japan.	yoshi@ims.ac.jp	Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40252] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ALLENTOFF AJ, 1992, J AM CHEM SOC, V114, P9744, DOI 10.1021/ja00051a003; BRANCACCIO A, 1994, J BIOL CHEM, V269, P13843; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARVER TE, 1990, J BIOL CHEM, V265, P20007; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; EVERSE J, 1994, METHOD ENZYMOL, V231, P547; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; KING NK, 1963, J BIOL CHEM, V238, P1520; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; MEEHAN EJ, 1961, J AM CHEM SOC, V83, P2232, DOI 10.1021/ja01471a004; Mukai M, 1997, J AM CHEM SOC, V119, P1758, DOI 10.1021/ja962551o; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 1996, J AM CHEM SOC, V118, P9784, DOI 10.1021/ja961223l; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAMETTE RW, 1965, J AM CHEM SOC, V87, P5001, DOI 10.1021/ja00950a005; RAO SI, 1993, J BIOL CHEM, V268, P803; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; YONETANI T, 1967, J BIOL CHEM, V242, P1974	43	174	178	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2838	2844		10.1074/jbc.274.5.2838	http://dx.doi.org/10.1074/jbc.274.5.2838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915818	hybrid			2022-12-27	WOS:000078319500036
J	Miele, C; Caruso, M; Calleja, V; Auricchio, R; Oriente, F; Formisano, P; Condorelli, G; Cafieri, A; Sawka-Verhelle, D; Van Obberghen, E; Beguinot, F				Miele, C; Caruso, M; Calleja, V; Auricchio, R; Oriente, F; Formisano, P; Condorelli, G; Cafieri, A; Sawka-Verhelle, D; Van Obberghen, E; Beguinot, F			Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg(1152)-> Gln insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; MICE; SHC; PHOSPHORYLATION; ASSOCIATION; INHIBITOR	In L6 muscle cells expressing the Arg(1152) --> Gln insulin receptor (Mut), basal tyrosine phosphorylation of insulin receptor substrate (IRS)-1 was increased by 35% compared with wild-type cells (WT), Upon exposure to insulin, IRS-1 phosphorylation increased by 12-fold in both the Mut and WT cells. IRS-2 was constitutively phosphorylated in Mut cells and not further phosphorylated by insulin. The maximal phosphorylation of IRS-S in basal Mut cells was paralleled by a 4-fold increased binding of the kinase regulatory loop binding domain of IRS-S to the Arg(1152) --> Gln receptor. Grb2 and phosphatidylinositol 3-kinase association to IRS-1 and IRS-2 reflected the phosphorylation levels of the two IRSs, Mitogen-activated protein kinase activation and [H-3]thymidine incorporation closely correlated with IRS-1 phosphorylation in Mut and WT cells, while glycogen synthesis and synthase activity correlated with IRS-S phosphorylation, The Arg(1152) Gln mutant did not signal Shc phosphorylation or Shc-Grb2 association in intact L6 cells, while binding Shc in a yeast two-hybrid system and phosphorylating Shc in vitro. Thus, IRS-2 appears to mediate insulin regulation of glucose storage in Mut cells, while insulin-stimulated mitogenesis correlates with the activation of the IRS-1/mitogen-activated protein kinase pathway in these cells. IRS-1 and She-mediated mitogenesis may be redundant in muscle cells.	Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples, Ctr Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; INSERM, U145, F-06107 Nice, France	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Beguinot, F (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; ORIENTE, Francesco/J-6652-2018	Condorelli, Gerolama/0000-0003-0177-8829; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; Denton R.M., 1997, INT TXB DIABETES MEL, P469; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HARADA S, 1995, J BIOL CHEM, V270, P26632, DOI 10.1074/jbc.270.44.26632; HARPER JW, 1993, CELL, V75, P805; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KAHN CR, 1997, INT TXB DIABETES MEL, P437; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MATSUOKA K, 1993, EMBO J, V12, P3467; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; Miller J.H., 1972, EXPT MOL GENETICS; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OKADA T, 1994, J BIOL CHEM, V269, P3568; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOBE K, 1993, J BIOL CHEM, V268, P11167; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; WHITE MF, 1994, J BIOL CHEM, V268, P1; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	49	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3094	3102		10.1074/jbc.274.5.3094	http://dx.doi.org/10.1074/jbc.274.5.3094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915848	hybrid			2022-12-27	WOS:000078319500066
J	Becker, DL; Fredenburgh, JC; Stafford, AR; Weitz, JI				Becker, DL; Fredenburgh, JC; Stafford, AR; Weitz, JI			Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARIN; TERNARY COMPLEX; DERMATAN SULFATE; ALPHA-THROMBIN; FACTOR-XA; MECHANISM; KINETICS; BINDING; GLYCOSAMINOGLYCANS; IDENTIFICATION	Assembly of ternary thrombin-heparin-fibrin complexes, formed when fibrin binds to exosite 1 on thrombin and fibrin-bound heparin binds to exosite 2, produces a 58- and 247-fold reduction in the heparin-catalyzed rate of thrombin inhibition by antithrombin and heparin cofactor II, respectively. The greater reduction for heparin cofactor II reflects its requirement for access to exosite 1 during the inhibitory process. Protection from inhibition by antithrombin and heparin cofactor II requires ligation of both exosites 1. and 2 because minimal protection is seen when exosite 1 variants (gamma-thrombin and thrombin Quick 1) or an exosite 2 variant (Arg(93) --> Ala, Arg(97) --> Ala, and Arg(101) --> Ala thrombin) is substituted for thrombin, Likewise, the rate of thrombin inhibition by the heparin-independent inhibitor, alpha(1)-antitrypsin Met(358) --> Arg, is decreased less than 2-fold in the presence of soluble fibrin and heparin, In contrast, thrombin is protected from inhibition by a covalent antithrombin-heparin complex, suggesting that access of heparin to exosite 2 of thrombin is hampered when ternary complex formation occurs. These results reveal the importance of exosites 1 and 2 of thrombin in assembly of the ternary complex and the subsequent protection of thrombin from inhibition by heparin-catalyzed inhibitors.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	jweitz@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Becker DL, 1997, ADV EXP MED BIOL, V425, P55; BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576; Berry L, 1998, J BIOL CHEM, V273, P34730, DOI 10.1074/jbc.273.52.34730; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BRIGINSHAW GF, 1974, ARCH BIOCHEM BIOPHYS, V161, P683, DOI 10.1016/0003-9861(74)90354-3; Chan A, 1997, J BIOL CHEM, V272, P22111, DOI 10.1074/jbc.272.35.22111; Cosmi B, 1997, CIRCULATION, V95, P118, DOI 10.1161/01.CIR.95.1.118; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; ELION J, 1986, ANN NY ACAD SCI, V485, P16, DOI 10.1111/j.1749-6632.1986.tb34564.x; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; Granger CB, 1998, J AM COLL CARDIOL, V31, P497, DOI 10.1016/S0735-1097(97)00539-1; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HATTON MWC, 1978, THROMB RES, V13, P655, DOI 10.1016/0049-3848(78)90155-X; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; Hermann JPR, 1997, THROMB HAEMOSTASIS, V78, P367; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HOGG PJ, 1990, J BIOL CHEM, V265, P241; Hogg PJ, 1997, THROMB HAEMOSTASIS, V77, P424; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HORTIN G, 1986, J BIOL CHEM, V261, P5827; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; McKenzie CR, 1996, ARTERIOSCL THROM VAS, V16, P1285, DOI 10.1161/01.ATV.16.10.1285; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; RAGG H, 1990, J BIOL CHEM, V265, P5211; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WEITZ J, 1993, J LAB CLIN MED, V122, P364; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WHINNA HC, 1993, J PROTEIN CHEM, V12, P677, DOI 10.1007/BF01024926; YE J, 1994, J BIOL CHEM, V269, P17965; YOUNG E, 1990, THROMB HAEMOSTASIS, V64, P559	50	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6226	6233		10.1074/jbc.274.10.6226	http://dx.doi.org/10.1074/jbc.274.10.6226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037709	hybrid			2022-12-27	WOS:000078902800031
J	Moche, M; Schneider, G; Edwards, P; Dehesh, K; Lindqvist, Y				Moche, M; Schneider, G; Edwards, P; Dehesh, K; Lindqvist, Y			Structure of the complex between the antibiotic cerulenin and its target, beta-ketoacyl-acyl carrier protein synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; MACROMOLECULAR STRUCTURES; ESCHERICHIA-COLI; INHIBITION; SYNTHETASE; MUTANTS; PROGRAM; CELLS; GENE	In the biosynthesis of fatty acids, the beta-ketoacyl-acyl carrier protein (ACP) synthases catalyze chain elongation by the addition of two-carbon units derived from malonyl-ACP to an acyl group bound to either ACP or CoA. The enzyme is a possible drug target for treatment of certain cancers and for tuberculosis. The crystal structure of the complex of the enzyme from Escherichia coli, and the fungal mycotoxin cerulenin reveals that the inhibitor is bound in a hydrophobic pocket formed at the dimer interface. Cerulenin is covalently attached to the active site cysteine through its C2 carbon atom. The fit of the inhibitor to the active site is not optimal, and there is thus room for improvement through structure based design.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Calgene Inc, Oils Div, Davis, CA 95616 USA	Karolinska Institutet	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Doktorsringen 9A1, S-17177 Stockholm, Sweden.	ylva@alfa.mbb.ki.se	Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Schneider, Gunter/0000-0003-0622-5713; Moche, Martin/0000-0002-4834-7076				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Child CJ, 1998, BIOCHEM J, V330, P933; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; Dehesh K, 1998, PLANT J, V15, P383, DOI 10.1046/j.1365-313X.1998.00218.x; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; INOKOSHI J, 1994, MOL GEN GENET, V244, P90, DOI 10.1007/BF00280191; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAWAGUCHI A, 1979, ARCH BIOCHEM BIOPHYS, V197, P30, DOI 10.1016/0003-9861(79)90214-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORISAKI N, 1993, EUR J BIOCHEM, V211, P111, DOI 10.1111/j.1432-1033.1993.tb19876.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P2745; Rastogi N, 1998, FEMS IMMUNOL MED MIC, V21, P149, DOI 10.1111/j.1574-695X.1998.tb01161.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; TOMODA H, 1984, J BIOCHEM-TOKYO, V995, P1712; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001	35	177	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6031	6034		10.1074/jbc.274.10.6031	http://dx.doi.org/10.1074/jbc.274.10.6031			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037680	hybrid			2022-12-27	WOS:000078902800002
J	Furstenau, U; Schwaninger, M; Blume, R; Jendrusch, EM; Knepel, W				Furstenau, U; Schwaninger, M; Blume, R; Jendrusch, EM; Knepel, W			Characterization of a novel calcium response element in the glucagon gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; PIG PANCREATIC-ALPHA-2 CELLS; TRANSCRIPTION FACTOR NFATP; NUCLEAR FACTOR; NF-AT; CYCLOSPORINE-A; BETA-CELL; IMMUNOSUPPRESSIVE DRUGS; PHOSPHATASE CALCINEURIN; MEMBRANE DEPOLARIZATION	To maintain blood glucose levels within narrow limits, the synthesis and secretion of pancreatic islet hormones is controlled by a variety of extracellular signals. Depolarization-induced calcium influx into islet cells has been shown to stimulate glucagon gene transcription through the transcription factor cAMP response element-binding protein that binds to the glucagon cAMP response element. By transient transfection of glucagon-reporter fusion genes into islet cell lines, this study identified a second calcium response element in the glucagon gene (G2 element, from -165 to -200), Membrane depolarization was found to induce the binding of a nuclear complex with NFATp-like immunoreactivity to the G2 element, Consistent with nuclear translocation, a comigrating complex was found in cytosolic extracts of unstimulated cells, and the induction of nuclear protein binding was blocked by inhibition of calcineurin phosphatase activity by FK506, A mutational analysis of G2 function and nuclear protein binding as well as the effect of FK506 indicate that calcium responsiveness is conferred to the G2 element by NFATp, functionally interacting with HNF-3 beta binding to a closely associated site. Transcription factors of the NFAT family are known to cooperate with AP-1 proteins in T cells for calcium-dependent activation of cytokine genes. This study shows a novel pairing of NFATp with the cell lineage-specific transcription factor HNF-3 beta in islet cells to form a novel calcium response element in the glucagon gene.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany	University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40, D-37070 Gottingen, Germany.	wknepel@med.uni-goettingen.de		Schwaninger, Markus/0000-0002-4510-9718				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; Diedrich T, 1997, BIOL CHEM, V378, P89, DOI 10.1515/bchm.1997.378.2.89; DIEM P, 1990, ENDOCRINOLOGY, V127, P1609, DOI 10.1210/endo-127-4-1609; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HO AM, 1994, J BIOL CHEM, V269, P28181; HOCHHUTH C, 1994, ENDOCRINE, V2, P833; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOHANSSON H, 1989, CELL CALCIUM, V10, P205, DOI 10.1016/0143-4160(89)90003-1; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Luo C, 1996, MOL CELL BIOL, V16, P3955; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Nirula A, 1997, J BIOL CHEM, V272, P7736, DOI 10.1074/jbc.272.12.7736; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OETJEN E, 1994, J BIOL CHEM, V269, P27036; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RORSMAN P, 1988, J GEN PHYSIOL, V91, P223, DOI 10.1085/jgp.91.2.223; RORSMAN P, 1988, J GEN PHYSIOL, V91, P243, DOI 10.1085/jgp.91.2.243; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCHWANINGER M, 1993, N-S ARCH PHARMACOL, V348, P541; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SUN P, 1996, J BIOL CHEM, V271, P30066; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Wrege Antje, 1995, Gene Expression, V4, P205; YANEY GC, 1992, MOL ENDOCRINOL, V6, P2143, DOI 10.1210/me.6.12.2143	73	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5851	5860		10.1074/jbc.274.9.5851	http://dx.doi.org/10.1074/jbc.274.9.5851			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026208	hybrid			2022-12-27	WOS:000078804400079
J	Itoh, M; Morita, K; Tsukita, S				Itoh, M; Morita, K; Tsukita, S			Characterization of ZO-2 as a MAGUK family member associated with tight as well as adherens junctions with a binding affinity to occludin and alpha catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE UVOMORULIN; POLARIZED EPITHELIAL-CELLS; TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; GUANYLATE KINASES; NONEPITHELIAL CELLS; CYTOPLASMIC DOMAIN; ZONULA OCCLUDENS; CDNA CLONING; E-CADHERIN	ZO-2, a member of the MAGUK family, was thought to be specific for tight junctions (TJs) in contrast to ZO-1, another MAGUK family member, which is localized at TJs and adherens junctions (AJs) in epithelial and nonepithelial cells, respectively. Mouse ZO-2 cDNA was isolated, and a specific polyclonal antibody was generated using corresponding synthetic peptides as antigens. Immunofluorescence microscopy with this polyclonal antibody revealed that, similarly to ZO-1, in addition to TJs in epithelial cells, ZO-2 was also concentrated at AJs in nonepithelial cells such as fibroblasts and cardiac muscle cells lacking TJs. When NH2-terminal dig-like and COOH-terminal non-dig-like domains of ZO-2 (N-ZO-2 and C-ZO-2, respectively) were separately introduced into cultured cells, N-ZO-2 was colocalized with endogenous ZO-1/ZO-2, i.e. at TJs in epithelial cells and at AJs in non-epithelial cells, whereas C-ZO-2 was distributed along actin filaments. Consistently, occludin as well as a: catenin directly bound to N-ZO-2 as well as the NH2-terminal dig-like portion of ZO-1 (N-ZO-1) in vitro. Furthermore, immunoprecipitation experiments revealed that the second PDZ domain of ZO-2 was directly associated with N-ZO-1. These findings indicated that ZO-2 forms a complex with ZO-1/occludin or ZO-1/alpha catenin to establish TJ or AJ domains, respectively.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Med, Dept Dermatol, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 606, Japan.							ABERLE H, 1994, J CELL SCI, V107, P3655; ANDERSON JM, 1995, BIOCHEM SOC T, V23, P470, DOI 10.1042/bst0230470; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOLTON JL, 1990, J CELL SCI, V97, P239; HOWARTH AG, 1994, J MEMBRANE BIOL, V137, P261; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kemler R, 1992, Semin Cell Biol, V3, P149; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Niethammer M, 1996, J NEUROSCI, V16, P2157; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YONEMURA S, 1995, J CELL SCI, V108, P127	45	239	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5981	5986		10.1074/jbc.274.9.5981	http://dx.doi.org/10.1074/jbc.274.9.5981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026224	hybrid			2022-12-27	WOS:000078804400095
J	Shi, YG; An, J; Liang, JD; Hayes, SE; Sandusky, GE; Stramm, LE; Yang, NN				Shi, YG; An, J; Liang, JD; Hayes, SE; Sandusky, GE; Stramm, LE; Yang, NN			Characterization of a mutant pancreatic eIF-2 alpha kinase, PEK, and co-localization with somatostatin in islet delta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STRANDED-RNA-BINDING; INSULIN GENE-EXPRESSION; INITIATION FACTOR-II; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; MOLECULAR-CLONING; INTERFERON ACTION; PKR; CDNA	Phosphorylation of eukaryotic translation initiation factor-2 alpha (eIF-2 alpha) is one of the key steps where protein synthesis is regulated in response to changes in environmental conditions. The phosphorylation is carried out in part by three distinct eIF-2 alpha kinases including mammalian double-stranded RNA-dependent eIF-2 alpha: kinase (PKR) and heme-regulated inhibitor kinase (HRI), and yeast GCN2. We report the identification and characterization of a related kinase, PEK, which shares common features with other eIF-2 alpha kinases including phosphorylation of eIF-2 alpha in vitro, We show that human PEK is regulated by different mechanisms than PKR or HRI, In contrast to PKR or HRI, which are dependent on autophosphorylation for their kinase activity, a point mutation that replaced the conserved Lys-614 with an alanine completely abolished the eIF-2 alpha: kinase activity, whereas the mutant PEK was still autophosphorylated when expressed in Sf-9 cells. Northern blot analysis indicates that PEK mRNA was predominantly expressed in pancreas, though low expression was also present in several tissues. Consistent with the high levels of mRNA in pancreas, the PEK protein was only detected in human pancreatic islets, and the kinase co-localized with somatostatin, a pancreatic delta cell-specific hormone. Thus PEK is believed to play an important role in regulating protein synthesis in the pancreatic islet, especially in islet delta cells.	Eli Lilly & Co, Diabet Res, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Diabet Res, Lilly Res Labs, Div Endocrine, DC 0545, Indianapolis, IN 46285 USA.							BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BONNERWEIR S, 1994, JOSLINS DIABETES MEL; Cai RR, 1998, J BIOL CHEM, V273, P11274, DOI 10.1074/jbc.273.18.11274; CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Dever TE, 1998, P NATL ACAD SCI USA, V95, P4164, DOI 10.1073/pnas.95.8.4164; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; FELDHOFF RC, 1993, PREP BIOCHEM, V23, P363, DOI 10.1080/10826069308544562; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HIDDINGA HJ, 1988, SCIENCE, V241, P451, DOI 10.1126/science.3393910; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; ICELY PL, 1991, J BIOL CHEM, V266, P16073; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; Merrick WC., 1996, TRANSLATION CONTROL, P31; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Mohrle JJ, 1997, BIOCHEM J, V328, P677; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; OLMSTED EA, 1993, J BIOL CHEM, V268, P12552; Olsen DS, 1998, GENETICS, V149, P1495; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Samuel CE, 1997, INT J HEMATOL, V65, P227; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; SARRE TF, 1989, BIOCHEM J, V262, P569, DOI 10.1042/bj2620569; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	57	55	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5723	5730		10.1074/jbc.274.9.5723	http://dx.doi.org/10.1074/jbc.274.9.5723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026192	hybrid			2022-12-27	WOS:000078804400063
J	Takeo, J; Yamashita, S				Takeo, J; Yamashita, S			Two distinct isoforms of cDNA encoding rainbow trout androgen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-TFIIB; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; SEX CONTROL; FISH; GENE; BINDING; CLONING; SUPERFAMILY; COACTIVATOR	Androgens play an important role in male sexual differentiation and development, The activity of androgens is mediated by an androgen receptor (AR), which binds to specific DNA recognition sites and regulates transcription. We describe here the isolation of two distinct rainbow trout cDNA clones, designated rtAR-alpha: and rtAR-beta, which contain the entire androgen receptor coding region. Comparison of the predicted amino acid sequence of rtAR-alpha to that of rtAR-beta revealed 85% identity. interestingly, despite this high homology, rtAR-alpha activated transcription of an androgen-responsive reporter gene in co-transfection assays, but rtAR-beta did not. These results suggest that rainbow trout contains two distinct isoforms of androgen receptors whose functions differ. The region of rtAR-beta responsible for its inactivity was mapped to its ligand binding domain by analyzing chimeras of the rtAR-alpha, rtAR-beta, and rtGR-I (glucocorticoid) receptors. Alteration of any one of three out of four segments within this domain restored activity. Extracts made from COS-I cells transfected with an rtAR-alpha expression plasmid produced a high level of [H-3]mibolerone binding, whereas no binding was observed by extracts of cells transfected with an rtAR-beta expression plasmid. These data demonstrate that the lack of transactivation activity of rtAR-beta is due to its inability to bind hormone.	Nippon Suisan Kaisha Ltd, Cent Res Lab, Hachioji, Tokyo 1920906, Japan	Nippon Suisan Kaisha, Ltd.	Yamashita, S (corresponding author), Nippon Suisan Kaisha Ltd, Cent Res Lab, 559-6 Kitanomachi, Hachioji, Tokyo 1920906, Japan.	KYE00332@nifty.ne.jp						BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; DONALDSON EM, 1982, CAN J FISH AQUAT SCI, V39, P99, DOI 10.1139/f82-012; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1991, BIOCHEM J, V278, P269, DOI 10.1042/bj2780269; FIJAN N, 1983, ANN INST PASTEUR VIR, V134, P207, DOI 10.1016/S0769-2617(83)80060-4; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Hata J, 1997, J BIOL CHEM, V272, P7285, DOI 10.1074/jbc.272.11.7285; Hata J, 1997, FISHERIES SCI, V63, P1050, DOI 10.2331/fishsci.63.1050; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HUNTER GA, 1983, FISH PHYSIOL, V9, P223; HUNTER GA, 1982, T AM FISH SOC, V111, P367, DOI 10.1577/1548-8659(1982)111&lt;367:POAASC&gt;2.0.CO;2; JOHNSTONE R, 1979, AQUACULTURE, V18, P13, DOI 10.1016/0044-8486(79)90096-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; Takeo J, 1996, FEBS LETT, V389, P244, DOI 10.1016/0014-5793(96)00596-0; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; YAMADA S, 1993, J BIOL CHEM, V268, P24361; Yamamoto T. O., 1969, P117; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	28	98	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5674	5680		10.1074/jbc.274.9.5674	http://dx.doi.org/10.1074/jbc.274.9.5674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026186	hybrid			2022-12-27	WOS:000078804400057
J	Urban, S; Kruse, C; Multhaup, G				Urban, S; Kruse, C; Multhaup, G			A soluble form of the avian hepatitis B virus receptor - Biochemical characterization and functional analysis of the receptor ligand complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-D; INFECTION; PROTEIN; SEQUENCE; GLYCOPROTEIN; HEPATOCYTES; REPLICATION; PARTICLES; BINDING; MEMBER	Avian hepatitis B virus infection is initiated by the specific interaction of the extracellular preS part of the large viral envelope protein with carboxypeptidase D (gp180), the primary cellular receptor. To functionally and biochemically characterize this interaction, we purified a soluble form of duck carboxypeptidase D from a baculovirus expression system, confirmed its receptor function, and investigated the contribution of different preS sequence elements to receptor binding by surface plasmon resonance analysis. We found that preS binds duck carboxypeptidase D with a 1:1 stoichiometry, thereby inducing conformational changes but not oligomerization, The association constant of the complex was determined to be 2.2 x 10(7) M-1 at 37 degrees C, pH 7.4, with an association rate of 4.0 x 10(4) M-1 s(-1) and a dissociation rate of 1.9 x 10(-3) s(-1), substantiating high affinity interaction of avihepadnaviruses with their receptor carboxypeptidase D, The separately expressed receptor-binding domain, comprising about 50% of preS as defined by mutational analysis, exhibits similar constants. The domain consists of an essential element, probably responsible for the initial receptor contact and a part that contributes to complex stabilization in a conformation sensitive manner. Together with previous results from cell biological studies these data provide new insights into the initial step of hepadnaviral infection.	Univ Heidelberg, Zentrum Mol Biol, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Urban, S (corresponding author), Univ Heidelberg, Zentrum Mol Biol, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.							Breiner KM, 1998, J VIROL, V72, P8098, DOI 10.1128/JVI.72.10.8098-8104.1998; Bruns M, 1998, J VIROL, V72, P1462, DOI 10.1128/JVI.72.2.1462-1468.1998; DeMeyer S, 1997, J VIRAL HEPATITIS, V4, P145, DOI 10.1046/j.1365-2893.1997.00126.x; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; HITCHCOCK M, 1964, BIOCHEM J, V93, P392, DOI 10.1042/bj0930392; ISHIKAWA T, 1994, VIROLOGY, V202, P1061, DOI 10.1006/viro.1994.1440; Jilbert AR, 1996, VIROLOGY, V226, P338, DOI 10.1006/viro.1996.0661; KLINGMULLER U, 1993, J VIROL, V67, P7414; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON WS, 1991, CURRENT TOP MICROBIO, V168; McGwire GB, 1997, LIFE SCI, V60, P715, DOI 10.1016/S0024-3205(96)00642-X; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; RIGG RJ, 1992, J VIROL, V66, P2829, DOI 10.1128/JVI.66.5.2829-2836.1992; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; TONG SP, 1995, J VIROL, V69, P7106, DOI 10.1128/JVI.69.11.7106-7112.1995; TUTTLEMAN JS, 1986, J VIROL, V58, P17, DOI 10.1128/JVI.58.1.17-25.1986; Urban S, 1998, J VIROL, V72, P8089, DOI 10.1128/JVI.72.10.8089-8097.1998; Varlamov O, 1998, J CELL SCI, V111, P877; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897	30	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5707	5715		10.1074/jbc.274.9.5707	http://dx.doi.org/10.1074/jbc.274.9.5707			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026190	hybrid			2022-12-27	WOS:000078804400061
J	Adderley, SR; Fitzgerald, DJ				Adderley, SR; Fitzgerald, DJ			Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FREE-RADICALS; REPERFUSION INJURY; INDUCED APOPTOSIS; CARDIAC MYOCYTES; RAT-HEART; EXPRESSION; STRESS; CELLS; SUPEROXIDE	Oxidative stress causes cardiac damage following ischemia/reperfusion and in response to anthracyclines. Extracellular signal-regulated kinases (ERK) 1/2 are activated by oxidative stress in cardiac myocytes and protect cardiac myocytes from apoptosis. Prostaglandins (PG) also protect cells from injury in a number of tissues, including the cardiomyocyte, Cyclooxygenase (COX) the rate-limiting enzyme in PG biosynthesis has two isoforms, the constitutive COX-1 and an inducible COX-2. Here, we examined the effects of two oxidative stresses, hydrogen peroxide (H2O2) and the anthracycline doxorubicin on the activity of ERK1/2 and the expression of COX isoforms and PG formation in neonatal rat primary cardiomyocytes. These cells expressed COX-1 at rest and both COX isoforms on treatment with phorbol 12-myristate 13-acetate. Exposure to 50 mu M H2O2 for 10 min or doxorubicin at 10 and 100 mu g/ml caused expression of COX-2 that was prevented by free radical scavengers. COX-2 induction was associated with activation of ERK1/2 and the specific ERK-inhibitor PD098059 abolished COX-2 expression. Treatment of cells with decoy oligonucleotides corresponding to COX-2 promoter elements implicated the AP-1 and NF kappa B-2 but not the NF-kappa B-1 in the transcription of COX-2. Induction of COX-2 mRNA and protein was accompanied by increased prostacyclin formation, which was abolished by the selective COX-2 inhibitor, NS-398, and PD098059. H2O2 and doxorubicin enhanced the release of lactate dehydrogenase and free radical scavengers prevented this. NS-398 enhanced the release of lactate dehydrogenase in response to H2O2 and doxorubicin, whereas the injury was prevented by iloprost, a stable prostacyclin analogue. In cardiomyocytes cell injury by H2O2 and doxorubicin is limited by an increase in prostacyclin formation that reflects induction of COX-2 mediated by ERK1/2 activation.	Royal Coll Surgeons Ireland, Ctr Cardiovasc Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin	Fitzgerald, DJ (corresponding author), Royal Coll Surgeons Ireland, Ctr Cardiovasc Sci, 123 St Stephens Green, Dublin 2, Ireland.	dfitzgerald@rcsi.ie						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BAKER CW, 1994, J BIOL CHEM, V269, P3985; BALINT GA, 1994, EXP TOXICOL PATHOL, V46, P37, DOI 10.1016/S0940-2993(11)80011-4; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Boveris A, 1977, Adv Exp Med Biol, V78, P67; BRISTOW MR, 1983, J CARDIOVASC PHARM, V5, P913, DOI 10.1097/00005344-198311000-00002; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; CHURCH DJ, 1994, BIOCHEM J, V303, P217, DOI 10.1042/bj3030217; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEMPLE B, 1996, ANNU REV GENET, V25, P315; DOROSHOW JH, 1983, CANCER RES, V43, P4543; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Feng LL, 1997, ADV EXP MED BIOL, V407, P281; Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67; Goppelt-Struebe M, 1998, J CELL PHYSIOL, V175, P341, DOI 10.1002/(SICI)1097-4652(199806)175:3<341::AID-JCP12>3.0.CO;2-8; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HEARSE DJ, 1975, J MOL CELL CARDIOL, V7, P315, DOI 10.1016/0022-2828(75)90121-2; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hoshida S, 1996, J MOL CELL CARDIOL, V28, P1845, DOI 10.1006/jmcc.1996.0177; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; JADINE L, 1996, AM J PHYSIOL, V271, P12197; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kostic MM, 1997, J MOL CELL CARDIOL, V29, P3135, DOI 10.1006/jmcc.1997.0544; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Morecki S, 1998, INT J CANCER, V75, P894, DOI 10.1002/(SICI)1097-0215(19980316)75:6<894::AID-IJC12>3.0.CO;2-3; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pang LH, 1998, AM J PHYSIOL-LUNG C, V275, pL322, DOI 10.1152/ajplung.1998.275.2.L322; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Reiser COA, 1998, BIOCHEM J, V330, P1107; SARVAZYAN NA, 1995, LIFE SCI, V57, P1003, DOI 10.1016/0024-3205(95)02036-I; SATO A, 1995, EMBO J, V12, P2005; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SIGNAL PK, 1998, NEW ENGL J MED, V339, P900; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Soler HM, 1997, J SURG RES, V67, P46, DOI 10.1006/jsre.1996.4917; Song W, 1996, BRIT J PHARMACOL, V118, P2157, DOI 10.1111/j.1476-5381.1996.tb15657.x; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VonKnethen A, 1997, FASEB J, V11, P887; WERNS SW, 1986, CIRCULATION, V74, P1, DOI 10.1161/01.CIR.74.1.1; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamazaki T, 1997, CIRCULATION, V95, P1260; YANHNA H, 1997, ARTERIOSCL THROM VAS, V17, P2808; Zerrouk A, 1998, J CARDIOVASC PHARM, V31, P525, DOI 10.1097/00005344-199804000-00009; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353	59	325	341	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5038	5046		10.1074/jbc.274.8.5038	http://dx.doi.org/10.1074/jbc.274.8.5038			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988750	hybrid			2022-12-27	WOS:000078698200075
J	Henstra, SA; Tuinhof, M; Duurkens, RH; Robillard, GT				Henstra, SA; Tuinhof, M; Duurkens, RH; Robillard, GT			The Bacillus stearothermophilus mannitol regulator, MtlR, of the phosphotransferase system - A DNA-binding protein, regulated by HPr and IICBmtl-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; SUBTILIS LEVANASE OPERON; GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; CATABOLITE REPRESSION; NUCLEOTIDE-SEQUENCE; LACTOCOCCUS-LACTIS; TRANSCRIPTIONAL ANTITERMINATORS; STREPTOCOCCUS-MUTANS; RNA-POLYMERASE	D-Mannitol is taken up by Bacillus stearothermophilus and phosphorylated via a phosphoenolpyruvate-dependent phosphotransferase system (PTS). The genes involved in the mannitol uptake were recently cloned and sequenced. One of the genes codes for a putative transcriptional regulator, MtlR. The presence of a DNA binding helix-turn-helix motif and two antiterminator-like PTS regulation domains, suggest that MtlR is a DNA-binding protein, the activity of which can be regulated by phosphorylation by components of the PTS. To demonstrate DNA binding of MtIR to a region upstream of the mannitol promoter, by DNA footprinting, MtlR was overproduced and purified. EI, HPr, IIA(mtl), and IICBmtl of B. stearothermophilus were purified and used to demonstrate that MtlR can be phosphorylated and regulated by HPr and IICBmtl, in vitro. Phosphorylation of MtlR by HPr increases the affinity of MtlR for its binding site, whereas phosphorylation by IICBmtl results in a reduction of this affinity. The differential effect of phosphorylation, by two different proteins, on the DNA binding properties of a bacterial transcriptional regulator has not, to our knowledge, been described before. Regulation of MtlR by two components of the PTS is an example of an elegant control system sensing both the presence of mannitol and the need to utilize this substrate.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARDOWSKI J, 1994, J BACTERIOL, V176, P5681, DOI 10.1128/JB.176.18.5681-5685.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HANSEN PV, 1985, NUCLEIC ACIDS RES, V13, P5927; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; Henstra SA, 1996, J BACTERIOL, V178, P5586, DOI 10.1128/jb.178.19.5586-5591.1996; HONEYMAN AL, 1992, INFECT IMMUN, V60, P3369, DOI 10.1128/IAI.60.8.3369-3375.1992; HUECK CJ, 1994, RES MICROBIOL, V145, P503, DOI 10.1016/0923-2508(94)90028-0; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; Idelson M, 1998, J BACTERIOL, V180, P660, DOI 10.1128/JB.180.3.660-666.1998; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; Kruger S, 1996, J BACTERIOL, V178, P2637; Lai Xiaokuang, 1995, Microbiology (Reading), V141, P1443, DOI 10.1099/13500872-141-6-1443; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; LU Z, 1989, NUCLEIC ACIDS RES, V17, P4883, DOI 10.1093/nar/17.12.4883; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; MARTINVERSTRAETE I, 1995, J BACTERIOL, V177, P6919, DOI 10.1128/jb.177.23.6919-6927.1995; NOVOTNY MJ, 1984, J BACTERIOL, V159, P986, DOI 10.1128/JB.159.3.986-990.1984; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REESE MG, 1996, P PAC S BIOC 1996; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1996, TRANSPORT PROCESSES, P549; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; ROSEY EL, 1992, J BACTERIOL, V174, P6159, DOI 10.1128/JB.174.19.6159-6170.1992; Sambrook J., 2002, MOL CLONING LAB MANU; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STULKE J, 1995, J BACTERIOL, V177, P6928; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; Stulke J, 1997, MOL MICROBIOL, V25, P65, DOI 10.1046/j.1365-2958.1997.4351797.x; Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; VANROOIJEN RJ, 1990, J BIOL CHEM, V265, P18499; VANROOIJEN RJ, 1992, J BACTERIOL, V174, P2273, DOI 10.1128/JB.174.7.2273-2280.1992; YAMADA M, 1988, J MOL BIOL, V203, P569, DOI 10.1016/0022-2836(88)90193-3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKOWSKI MM, 1990, GENE, V90, P153, DOI 10.1016/0378-1119(90)90453-X	49	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4754	4763		10.1074/jbc.274.8.4754	http://dx.doi.org/10.1074/jbc.274.8.4754			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988713	Green Published, hybrid			2022-12-27	WOS:000078698200038
J	Meivar-Levy, I; Futerman, AH				Meivar-Levy, I; Futerman, AH			Up-regulation of neutral glycosphingolipid synthesis upon long term inhibition of ceramide synthesis by fumonisin B-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGANINE N-ACYLTRANSFERASE; BURKITTS-LYMPHOMA CELLS; RAT-LIVER; GOLGI-APPARATUS; SHIGA TOXIN; EXPRESSION; DIFFERENTIATION; SPHINGOLIPIDS; GANGLIOSIDES; APOPTOSIS	In a previous study we observed that long term (5 days) incubation with fumonisin B-1 (FB1), an inhibitor of acylation of sphingoid long chain bases to (dihydro)ceramide, resulted in morphological and biochemical changes in 3T3 fibroblasts (Meivar-Levy, I., Sabanay, Il,, Bershadsky, A. D,, and Futerman, A. H. (1997) J, Biol, Chem, 272, 1558-1564). Among these were changes in the profile of synthesis of sphingolipids (SLs) and glycosphingolipids (GSLs), Whereas [H-3]globotriaosylceramide ([H-3]Gb(3)) comprised 1.9% of the total [H-3]SLs and [H-3]GSLs synthesized in control cells, it comprised 16.5% in FB1-treated cells. We now demonstrate by in vitro analysis that inhibition of ceramide synthesis by FB1 for 5 days results in up-regulation of the activities of three enzymes in the pathway of Gb(3) synthesis, namely glucosylceramide, lactosylceramide, and Gb(3) synthases; up-regulation is due to an increase in V-max, with no change in K-m values toward lipid substrates, Moreover, molecular analysis (reverse transcriptase-polymerase chain reaction) of glucosylceramide synthase indicated that this enzyme is up regulated at the transcriptional level. No changes in either the V-max or K-m values of sphingomyelin or of GM(3) synthase were detected after FB1 treatment. Analysis of SL and GSL synthesis in cultured cells using [4,5-H-3]sphinganine as a metabolic precursor demonstrated that at low substrate concentrations, Gb(3) synthesis is favored over GM(3) synthesis and glucosylceramide synthesis is favored over sphingomyelin synthesis, whereas the opposite is true at high substrate concentrations. These data demonstrate that GSL synthesis and in particular Gb(3) synthesis are tightly regulated in fibroblasts, presumably so as to maintain constant levels of Gb(3) on the cell surface.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmfuter@weizmann.weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUHOURS JF, 1976, BIOCHIM BIOPHYS ACTA, V441, P123, DOI 10.1016/0005-2760(76)90287-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; FUTERMAN AH, 1992, METHOD ENZYMOL, V209, P437; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HAKOMORI S, 1984, TRENDS BIOCHEM SCI, V9, P453, DOI 10.1016/0968-0004(84)90156-7; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MANGENEY M, 1993, CANCER RES, V53, P5314; MeivarLevy I, 1997, J BIOL CHEM, V272, P1558, DOI 10.1074/jbc.272.3.1558; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; NAIKI M, 1974, BIOCHEM BIOPH RES CO, V60, P1105, DOI 10.1016/0006-291X(74)90426-4; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Sando GN, 1996, J BIOL CHEM, V271, P22044, DOI 10.1074/jbc.271.36.22044; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; STULTS CLM, 1995, GLYCOCONJUGATE J, V12, P680, DOI 10.1007/BF00731265; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; WIELS J, 1984, J BIOL CHEM, V259, P4783; YAMASHIRO S, 1993, CANCER RES, V53, P5395	42	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4607	4612		10.1074/jbc.274.8.4607	http://dx.doi.org/10.1074/jbc.274.8.4607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988695	hybrid			2022-12-27	WOS:000078698200020
J	Walker, JB; Nesheim, ME				Walker, JB; Nesheim, ME			The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED FIBRIN; A-ALPHA-CHAIN; CROSSLINKED FIBRIN; SUBUNIT STRUCTURE; FACTOR-XIII; GEL ELECTROPHORESIS; ELECTRON-MICROSCOPY; FRAGMENT-D; PURIFICATION; COMPLEXES	We used a perfused clot system to study the degradation of cross-linked fibrin, Multiangle laser light scattering showed that plasmin-mediated cleavage caused the release of noncovalently associated fibrin degradation products (FDPs) with a weight-averaged molar mass (M-w) of similar to 6 x 10(6) g/mol. The M-w of FDPs is dependent on ionic strength, and the M-w observed at 0.15 M NaCl resulted from the self-association of FDPs having M, of similar to 3.8 x 10(6) g/mol. Complete solubilization required the cleavage of similar to 25% of fragment D/fragment E connections, with 48% alpha-, 62% beta-, and 42% gamma-chains cleaved. These results showed that D-E cleavage cannot be explained by a random mechanism, implying cooperativity. Gel filtration and multiangle laser light scattering showed that FDPs range from 2.5 x 10(5) to 1 x 10(7) g/mol. In addition to fragment E, FDPs are composed of fragments ranging from 2 x 10(5) Da (D-dimer, or DD) to at least 2.3 x 10(6) Da (DX8D). FDP mass distribution is consistent with a model whereby FDPs bind to fibrin with affinities proportional to fragment mass. Root mean square radius analysis showed that small FDPs approximate rigid rods, but this relationship breaks down as FDPs size increases, suggesting that large FDPs possess significant flexibility.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NHLBI NIH HHS [HL 46703-6] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU I, 1992, BIOCHIM BIOPHYS ACTA, V1119, P268, DOI 10.1016/0167-4838(92)90213-W; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARADET TC, 1995, BIOPHYS J, V68, P1551, DOI 10.1016/S0006-3495(95)80327-9; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARR ME, 1980, MACROMOLECULES, V13, P1473, DOI 10.1021/ma60078a022; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHASE T, 1970, METHOD ENZYMOL, V19, P20; COLLEN D, 1975, J BIOL CHEM, V250, P5808; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FERGUSON EW, 1975, J BIOL CHEM, V250, P7210; FRANCIS CW, 1987, J CLIN INVEST, V80, P1459, DOI 10.1172/JCI113226; FRANCIS CW, 1986, ANNU REV MED, V37, P187; FRANCIS CW, 1982, SEMIN THROMB HEMOST, V8, P25, DOI 10.1055/s-2007-1005040; FRANCIS CW, 1980, BLOOD, V56, P456; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1983, THROMB RES, P27; HOLM B, 1985, THROMB RES, V37, P165, DOI 10.1016/0049-3848(85)90043-X; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; LIU CY, 1986, THROMB HAEMOSTASIS, V56, P100; LORAND L, 1981, METHOD ENZYMOL, V80, P333; Lundblad R L, 1976, Methods Enzymol, V45, P156; Marder V J, 1967, Trans Assoc Am Physicians, V80, P156; MARDER VJ, 1983, ANN NY ACAD SCI, V408, P397, DOI 10.1111/j.1749-6632.1983.tb23260.x; MIHALYI E, 1983, ANN NY ACAD SCI, V408, P60, DOI 10.1111/j.1749-6632.1983.tb23234.x; MONTEJO JM, 1992, BIOCHEMISTRY-US, V31, P7580, DOI 10.1021/bi00148a020; MOSESSON MW, 1973, J BIOL CHEM, V248, P7913; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; Pfitzner SA, 1997, THROMB HAEMOSTASIS, V78, P1069; PIZZO SV, 1972, J BIOL CHEM, V247, P636; PIZZO SV, 1973, J BIOL CHEM, V248, P4584; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; Rudchenko S, 1996, J BIOL CHEM, V271, P2523, DOI 10.1074/jbc.271.5.2523; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; Tanford C., 1961, PHYS CHEM MACROMOLEC; Toyosawa M, 1997, ELECTROPHORESIS, V18, P118, DOI 10.1002/elps.1150180122; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; WEISEL JW, 1987, P NATL ACAD SCI USA, V84, P8991, DOI 10.1073/pnas.84.24.8991; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3; ZHANG JZ, 1994, J BIOL CHEM, V269, P652	52	97	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5201	5212		10.1074/jbc.274.8.5201	http://dx.doi.org/10.1074/jbc.274.8.5201			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988770	hybrid			2022-12-27	WOS:000078698200095
J	Warner, DR; Romanowski, R; Yu, SH; Weinstein, LS				Warner, DR; Romanowski, R; Yu, SH; Weinstein, LS			Mutagenesis of the conserved residue Glu(259) of G(s)alpha demonstrates the importance of interactions between switches 2 and 3 for activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; GS-ALPHA; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; HEREDITARY OSTEODYSTROPHY; ESCHERICHIA-COLI; GTP HYDROLYSIS; G(S-ALPHA); RECEPTOR; MUTATION	We previously reported that substitution of Arg(258) within the switch 3 region of G(s)alpha impaired activation and increased basal GDP release due to loss of an interaction between the helical and GTPase domains (Warner, D. R., Weng, G., Yu, S., Matalon, R., and Weinstein, L. S. (1998) J Biol. Chem. 273, 23976-23983). The adjacent residue (Glu(259)) is strictly conserved in G protein alpha-subunits and is predicted to be important in activation. To determine the importance of Glu(259), this residue was mutated to Ala (G(s)alpha-E259A), Gln (G(s)alpha-E259Q), Asp (G(s)alpha-E259D), or Val (G(s)alpha-E259V), and the properties of in vitro translation products were examined. The G(s)alpha-E259V was studied because this mutation was identified in a patient with Albright hereditary osteodystrophy. 549 eye reconstitution assays demonstrated that G(s)alpha-E259D stimulated adenylyl cyclase normally in the presence of GTP gamma S but was less efficient with isoproterenol or AlF4-. The other mutants had more severely impaired effector activation, particularly in response to AlF4-. In trypsin protection assays, GTP gamma S was a more effective activator than AlF4- for all mutants, with G(s)alpha-E259D being the least severely impaired. For G(s)alpha-E259D, the AlF4--induced activation defect was more pronounced at low Mg2+ concentrations. G(s)alpha-E259D and G(s)alpha-E259A purified from Escherichia coli had normal rates of GDP release (as assessed by the rate GrT gamma S binding). However, for both mutants, the ability of AlF4- to decrease the rate of GTP gamma S binding was impaired, suggesting that they bound AlF4- more poorly. GrTP gamma S bound to purified G(s)alpha-E259D irreversibly in the presence of 1 mM free Mg2+, but dissociated readily at micromolar concentrations. Sucrose density gradient analysis of in, vitro translates demonstrated that all mutants except G(s)alpha-E259V bind to beta gamma at 0 degrees C and were stable at higher temperatures. In the active conformation Glu(259) interacts with conserved residues in the switch 2 region that are important in maintaining both the active state and AlF4- in the guanine nucleotide binding pocket. Although both G(s)alpha Arg(258) and Glu(259) are critical for activation, the mechanisms by which these residues affect G(s)alpha. protein activation are distinct.	NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Warner, DR (corresponding author), NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bldg 49,Rm 2A28, Bethesda, MD 20892 USA.	dwarner@helix.nih.gov	Weinstein, Lee S/I-5575-2015	Weinstein, Lee/0000-0002-1899-5152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043302, ZIADK043302] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed SF, 1998, CLIN ENDOCRINOL, V49, P525, DOI 10.1046/j.1365-2265.1998.00572.x; Basi NS, 1997, ANAL BIOCHEM, V251, P103, DOI 10.1006/abio.1997.2255; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CARTY DJ, 1994, METHOD ENZYMOL, V237, P38; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LAMBRIGHT DG, 1996, NATURE, V379, P297; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE E, 1992, J BIOL CHEM, V267, P1212; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P276; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Warner DR, 1997, MOL ENDOCRINOL, V11, P1718, DOI 10.1210/me.11.11.1718; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4977	4984		10.1074/jbc.274.8.4977	http://dx.doi.org/10.1074/jbc.274.8.4977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988742	hybrid			2022-12-27	WOS:000078698200067
J	Schmidt, A; Grimm, R; Schmidt, J; Scheel, D; Strack, D; Rosahl, S				Schmidt, A; Grimm, R; Schmidt, J; Scheel, D; Strack, D; Rosahl, S			Cloning and expression of a potato cDNA encoding hydroxycinnamoyl-CoA : Tyramine N-(hydroxycinnamoyl)transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION-CULTURES; SOLANUM-TUBEROSUM L; PHENYLALANINE AMMONIA-LYASE; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; PHYTOPHTHORA-INFESTANS; NICOTIANA-TABACUM; PURIFICATION; COENZYME; LEAVES; ACCUMULATION	Hydroxycinnamoyl-CoA:tyramine N-(hydroxycinnamoyl)transferase (THT; EC 2.3.1.110) catalyzes the transfer of hydroxycinnamic acids from the respective CoA esters to tyramine and other amines in the formation of N-(hydroxycinnamoyl)amines. Expression of THT is induced by Phytophthora infestans, the causative agent of late blight disease in potato. The amino acid sequences of nine endopeptidase LysC-liberated peptides from purified potato THT were determined. Using degenerate primers, a THT-specific fragment was obtained by reverse transcription-polymerase chain reaction, and THT cDNA clones were isolated from a library constructed from RNA of elicitor-treated potato cells. The open reading frame encoding a protein of 248 amino acids was expressed in Escherichia coli, Recombinant THT exhibited a broad substrate specificity, similar to that of native potato THT, accepting cinnamoyl-, 4-coumaroyl-, caffeoyl-, feruloyl- and sinapoyl-CoA as acyl donors and tyramine, octopamine, and noradrenalin as accepters tested. Elicitor-induced THT transcript accumulation in cultured potato cells peaked 5 h after initiation of treatment, whereas enzyme activity was highest from 5 to 30 h after elicitation, In soil-grown potato plants, THT mRNA was most abundant in roots. Genomic Southern analyses indicate that, in potato, THT is encoded by a multigene family.	Inst Biochem Pflanzen, Abt Sekundarstoffwechsel, D-06120 Halle, Germany; Inst Biochem Pflanzen, Abt Nat Stoff Chem, D-06120 Halle, Germany; Inst Biochem Pflanzen, Abt Stress & Entwicklungsbiol, D-06120 Halle, Germany; Hewlett Packard GMBH, Waldbronn Analyt Div, D-76337 Waldbronn, Germany	Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzenbiochemie; Hewlett-Packard	Strack, D (corresponding author), Inst Biochem Pflanzen, Abt Sekundarstoffwechsel, Weinberg 3, D-06120 Halle, Germany.	dstrack@ipb.uni-halle.de						BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; BEIMEN A, 1992, BOT ACTA, V105, P152, DOI 10.1111/j.1438-8677.1992.tb00281.x; Clarke D. D., 1982, ACTIVE DEFENSE MECH, P321; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DUNSMUIR P, 1988, PLANT MOL BIOL MAN C, V1, P1; Eckerskorn C, 1996, ELECTROPHORESIS, V17, P899, DOI 10.1002/elps.1150170511; FRITZEMEIER KH, 1987, PLANT PHYSIOL, V85, P34, DOI 10.1104/pp.85.1.34; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; Fry WE, 1997, PLANT DIS, V81, P1349, DOI 10.1094/PDIS.1997.81.12.1349; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; GRANDMAISON J, 1993, MYCORRHIZA, V3, P155, DOI 10.1007/BF00203609; GROSS GG, 1966, Z NATURFORSCH PT B, VB 21, P683; Hohlfeld H, 1996, PLANTA, V199, P166, DOI 10.1007/BF00196893; HOHLFELD H, 1995, PLANT PHYSIOL, V107, P545, DOI 10.1104/pp.107.2.545; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; JOOS HJ, 1992, EUR J BIOCHEM, V204, P621, DOI 10.1111/j.1432-1033.1992.tb16675.x; Keller H, 1996, PHYTOCHEMISTRY, V42, P389, DOI 10.1016/0031-9422(95)00866-7; KUC J, 1985, ARCH BIOCHEM BIOPHYS, V236, P455; KUC J, 1982, PHYTOALEXINS, P81; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MATERN U, 1995, CAN J BOT, V73, pS511, DOI 10.1139/b95-290; Miersch O, 1998, PHYTOCHEMISTRY, V47, P327, DOI 10.1016/S0031-9422(97)00617-1; Negrel J, 1996, PHYTOCHEMISTRY, V43, P1195, DOI 10.1016/S0031-9422(96)00500-6; NEGREL J, 1993, J PLANT PHYSIOL, V142, P518, DOI 10.1016/S0176-1617(11)80392-5; Negrel J, 1997, EUR J BIOCHEM, V247, P1127, DOI 10.1111/j.1432-1033.1997.01127.x; Negrel J, 1995, PHYSIOL PLANTARUM, V95, P569, DOI 10.1111/j.1399-3054.1995.tb05524.x; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P2797, DOI 10.1016/0031-9422(84)83018-6; NICHOLSON RL, 1992, ANNU REV PHYTOPATHOL, V30, P369, DOI 10.1146/annurev.py.30.090192.002101; Pearce G, 1998, PHYTOCHEMISTRY, V47, P659, DOI 10.1016/S0031-9422(97)00620-1; ROHWER F, 1987, PLANTA, V170, P556, DOI 10.1007/BF00402991; Schmidt A, 1998, PLANTA, V205, P51, DOI 10.1007/s004250050295; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STRACK D, 1987, J PLANT PHYSIOL, V131, P61, DOI 10.1016/S0176-1617(87)80268-7; VILLEGAS M, 1990, PHYSIOL PLANTARUM, V78, P414, DOI 10.1111/j.1399-3054.1990.tb09057.x	36	88	93	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4273	4280		10.1074/jbc.274.7.4273	http://dx.doi.org/10.1074/jbc.274.7.4273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933628	hybrid			2022-12-27	WOS:000078575500052
J	Iyer, RR; Wells, RD				Iyer, RR; Wells, RD			Expansion and deletion of triplet repeat sequences in Escherichia coli occur on the leading strand of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; FRAGILE-X-SYNDROME; CENTER-DOT-CAG; HEREDITARY-DISEASE GENES; SYNTHESIS IN-VITRO; TRINUCLEOTIDE REPEATS; HAIRPIN STRUCTURES; CTG; INSTABILITY; FORM	Expansions and deletions of triplet repeat sequences that cause human hereditary neurological diseases were previously suggested to be mediated by the formation of DNA hairpins on the lagging strand during replication. The replication properties of CTG.CAG, CGG.CCG, and TTC.GAA repeats were studied in Escherichia coli using an in vivo phagemid system as a model for continuous leading strand synthesis. The repeats were substantially deleted when the CTG, CGG, and GAA repeats were the templates for rolling circle replication from the fl phage origin, The deletions may be mediated by hairpins formed by these repeat tracts. The distributions of the deletion products of the CTG.CAG and CGG.CCG tracts indicated that hairpins of discrete sizes mediate deletions during complementary strand synthesis. Deletions during rolling circle synthesis are caused by larger hairpins of specific sizes. Thus, most deletion products were of defined lengths, suggesting a preference for specific hairpin intermediates. Small expansions of the CTG.CAG and CGG.CCG repeats were also observed, presumably due to the formation of CTG and CGG hairpins on the nascent complementary strand. Since rolling circle replication has been established in vitro as a model for leading strand synthesis, we conclude that triplet repeat instability can also occur on the leading strand of DNA replication.	Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol,Dept Biochem & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol,Dept Biochem & Biophys, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	RWELLS@IBT.TAMU.EDU			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAAS PD, 1988, CURR TOP MICROBIOL, V136, P31; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P467; BAUMEL I, 1984, EUR J BIOCHEM, V138, P247, DOI 10.1111/j.1432-1033.1984.tb07908.x; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Darlow JM, 1998, J MOL BIOL, V275, P3, DOI 10.1006/jmbi.1997.1453; Denhardt D.T., 1978, SINGLE STRANDED DNA; ENEA V, 1975, J MOL BIOL, V96, P495, DOI 10.1016/0022-2836(75)90175-8; Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; Gao XL, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P623; GAO XL, 1995, J AM CHEM SOC, V117, P8883, DOI 10.1021/ja00139a035; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; HIASA H, 1998, GENETIC INSTABILITIE, P732; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; Hoogeveen AT, 1997, J INHERIT METAB DIS, V20, P139, DOI 10.1023/A:1005392319533; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; MOK M, 1987, J BIOL CHEM, V262, P16644; MOK M, 1987, J BIOL CHEM, V262, P2304; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; PIECZENIK G, 1975, NATURE, V253, P131, DOI 10.1038/253131a0; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; Strong PN, 1997, J INHERIT METAB DIS, V20, P159, DOI 10.1023/A:1005396420442; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; Zheng MX, 1996, J MOL BIOL, V264, P323, DOI 10.1006/jmbi.1996.0643	72	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3865	3877		10.1074/jbc.274.6.3865	http://dx.doi.org/10.1074/jbc.274.6.3865			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920942	hybrid			2022-12-27	WOS:000078428200082
J	Scheidegger, KJ; Du, J; Delafontaine, P				Scheidegger, KJ; Du, J; Delafontaine, P			Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RAT CARDIAC FIBROBLASTS; PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; LOW-DENSITY-LIPOPROTEIN; KINASE-C ACTIVATION; KAPPA-B-ALPHA; IGF-I; 3T3 CELLS; DIFFERENTIAL ACTIVATION	Angiotensin II (Ang II) and basic fibroblast growth factor (bFGF) are important modulators of cell growth under physiological and pathophysiological conditions. We and others have previously shown that these growth factors increase insulin-like growth factor-1 receptor (IGF-1R) number and mRNA in vascular smooth muscle cells and that this effect is transcriptionally regulated. To study the mechanisms and the signaling pathways involved, IGF-1R promoter reporter constructs were transiently transfected in CHO-AT, cells that overexpress angiotensin AT(1) receptors. Our findings indicate that Ang II and bFGF significantly increased IGF-1R promoter activity up to 7- and 3-fold, respectively. The effect induced by Ang II was mediated via a tyrosine kinase-dependent mechanism, since tyrphostin A25 largely inhibited the Ang II-induced increase in promoter activity. In addition, co-transfection of dominant negative Ras, Raf, and MEK1 or pretreatment with the MEK inhibitor PD 98059 dose-dependently decreased both the Ang II- and bFGF-induced increase in IGF-1R transcription and protein expression, suggesting that the Ras-Raf-mitogen-activated protein kinase kinase pathway is required for both growth factors. Reactive oxygen species have been shown to act as second messengers in Ang II-induced signaling, and activation of the transcription factor NF-kappa B is redox-sensitive. While co-transfection of dominant negative I kappa B alpha mutant completely inhibited the Ang II-induced increase in transcription, it had no effect on the bFGF signaling. In contrast, co-transfection studies indicated that the transcription factors STAT1, STAT3, and c-Jun and the Janus kinase 2 kinase are required in the signaling pathway of bFGF, whereas only dominant c-Jun inhibited the Ang II-induced effect. In summary, these data demonstrate that Ang II and bFGF increase IGF-1R gene transcription via distinct as well as shared pathways and have important implications for understanding growth-stimulatory effects of these growth factors on vascular cells.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Emory Univ, Dept Med, Atlanta, GA 30322 USA	University of Geneva; Emory University	Delafontaine, P (corresponding author), Univ Hosp Geneva, Div Cardiol, Rue Micheli Crest 24, CH-1211 Geneva 14, Switzerland.	Patrice.Delafontaine@hcuge.ch		Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL047035, R01HL045317] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45317, HL 47035] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1980, P NATL ACAD SCI-BIOL, V77, P6644, DOI 10.1073/pnas.77.11.6644; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELAFONTAINE P, 1995, J BIOL CHEM, V270, P14383, DOI 10.1074/jbc.270.24.14383; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; Delafontaine P, 1996, J CLIN INVEST, V97, P139, DOI 10.1172/JCI118381; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Du J, 1996, ENDOCRINOLOGY, V137, P1378, DOI 10.1210/en.137.4.1378; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1995, CARDIOVASC RES, V30, P511, DOI 10.1016/0008-6363(95)00088-7; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROSENTHAL SM, 1991, MOL ENDOCRINOL, V5, P678, DOI 10.1210/mend-5-5-678; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; SA G, 1994, J BIOL CHEM, V269, P3219; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; VILLASCHI S, 1993, AM J PATHOL, V143, P181; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	85	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3522	3530		10.1074/jbc.274.6.3522	http://dx.doi.org/10.1074/jbc.274.6.3522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920898	hybrid			2022-12-27	WOS:000078428200038
J	Chang, BHJ; Liao, W; Li, L; Nakamuta, M; Mack, D; Chan, L				Chang, BHJ; Liao, W; Li, L; Nakamuta, M; Mack, D; Chan, L			Liver-specific inactivation of the abetalipoproteinemia gene completely abrogates very low density lipoprotein low density lipoprotein production in a viable conditional knockout mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-TRANSFER-PROTEIN; B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; INTRACELLULAR DEGRADATION; EXPRESSION; CELLS; SECRETION; SUBUNIT; CLONING; DEFECTS	Conventional knockout of the microsomal triglyceride transfer protein large subunit (lMTP) gene is embryonic lethal in the homozygous state in mice. We have produced a conditional lMTP knockout mouse by inserting loxP sequences flanking exons 5 and 6 by gene targeting. Homozygous flexed mice were born live with normal plasma lipids. Intravenous injection of an adenovirus harboring Cre recombinase (AdCre1) produced deletion of exons 5 and 6 and disappearance of lMTP mRNA and immunoreactive protein in a liver-specific manner. There was also disappearance of plasma apolipoprotein (apo) B-100 and marked reduction in apoB-48 levels. Wild-type mice showed no response, and heterozygous mice, an intermediate response, to AdCre1. Wild-type mice doubled their plasma cholesterol level following a high cholesterol diet. This hypercholesterolemia was abolished in AdCre1-treated lMTP(-/-) mice, the result of a complete absence of very low/intermediate/low density lipoproteins and a slight reduction in high density lipoprotein. Heterozygous mice showed an intermediate lipoprotein phenotype. The rate of accumulation of plasma triglyceride following Triton WR1339 treatment in lMTP(-/-) mice was <10% that in wild-type animals, indicating a failure of triglyceride-rich lipoprotein production. Pulse-chase experiments using hepatocytes isolated from wild-type and lMTP(-/-) mice revealed a failure of apoB secretion in lMTP(-/-) animals. Therefore, the liver-specific inactivation of the lMTP gene completely abrogates apoB 100 and very low/intermediate/low density lipoprotein production. These conditional knockout mice are a useful in vivo model for studying the role of MTP in apoB biosynthesis and the biogenesis of apoB-containing lipoproteins.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Cell Biol, MS112A,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; CHAN L, 1995, CURR OPIN LIPIDOL, V6, P335, DOI 10.1097/00041433-199510000-00014; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; KANE JP, 1995, METABOLIC MOL BASES, P1853; KOBAYASHI K, 1996, J BIOL CHEM, V271, P6851; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1995, J LIPID RES, V36, P1073; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; Nakamuta M, 1996, GENOMICS, V33, P313, DOI 10.1006/geno.1996.0200; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; White AL, 1997, CLIN GENET, V52, P326; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	25	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6051	6055		10.1074/jbc.274.10.6051	http://dx.doi.org/10.1074/jbc.274.10.6051			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037685	hybrid			2022-12-27	WOS:000078902800007
J	Abraham, N; Stojdl, DF; Duncan, PI; Methot, N; Ishii, T; Dube, M; Vanderhyden, BC; Atkins, HL; Gray, DA; McBurney, MW; Koromilas, AE; Brown, EG; Sonenberg, N; Bell, JC				Abraham, N; Stojdl, DF; Duncan, PI; Methot, N; Ishii, T; Dube, M; Vanderhyden, BC; Atkins, HL; Gray, DA; McBurney, MW; Koromilas, AE; Brown, EG; Sonenberg, N; Bell, JC			Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS VAI RNA; NF-KAPPA-B; 58,000-DALTON CELLULAR INHIBITOR; IMMUNODEFICIENCY-VIRUS TYPE-1; REGULATED EIF-2-ALPHA KINASE; INITIATION-FACTOR 2-ALPHA; TUMOR NECROSIS FACTOR; MALIGNANT TRANSFORMATION; TRANSLATIONAL CONTROL; VACCINIA VIRUS	The interferon-inducible, double-stranded RNA dependent protein kinase PKR has been implicated in anti-viral, anti-tumor, and apoptotic responses, Others have attempted to examine the requirement of PKR in these roles by targeted disruption at the amino terminal-encoding region of the Phr gene. By using a strategy that aims at disruption of the catalytic domain of PHR, we have generated mice that are genetically ablated for functional PKR Similar to the other mouse model of Pkr disruption, we have observed no consequences of loss of PKR on tumor suppression. Anti-viral response to influenza and vaccinia also appeared to be normal in mice and in cells lacking PKR Cytokine signaling in the type I interferon pathway is normal but may be compromised in the erythropoietin pathway in erythroid bone marrow precursors. Contrary to the aminoterminal targeted Phr mouse, tumor necrosis factor alpha-induced apoptosis and the anti-viral apoptosis response to influenza is not impaired in catalytic domain-targeted Pkr-null cells. The observation of intact eukaryotic initiation factor-2 alpha phosphorylation in these Pkr-null cells provides proof of rescue by another eukaryotic initiation factor-2 alpha kinase(s).	Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; Ottawa Gen Hosp, Div Hematol, Ottawa, ON K1H 8L6, Canada; Lady Davis Inst Med Res, Dept Oncol & Med, Montreal, PQ H3T 1E2, Canada; Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Geneva; University of Ottawa; Ottawa Hospital Research Institute; Lady Davis Institute; McGill University; University of Ottawa; McGill University	Bell, JC (corresponding author), Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada.		Abraham, Ninan/K-5572-2012; /U-3554-2018	Abraham, Ninan/0000-0002-2747-1246; /0000-0002-8634-4984				BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; BROWN EG, 1990, J VIROL, V64, P4523, DOI 10.1128/JVI.64.9.4523-4533.1990; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEMENS MJ, 1994, BIOCHIMIE, V76, P770, DOI 10.1016/0300-9084(94)90081-7; COLBY C, 1969, NATURE, V222, P940, DOI 10.1038/222940a0; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; ICELY PL, 1991, J BIOL CHEM, V266, P16073; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LEIST M, 1994, J IMMUNOL, V153, P1778; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHIFF LA, 1988, MOL CELL BIOL, V8, P273, DOI 10.1128/MCB.8.1.273; SEN GC, 1992, J BIOL CHEM, V267, P5017; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SMEENK CA, 1994, J VIROL, V68, P530, DOI 10.1128/JVI.68.1.530-534.1994; SONENBERG N, 1990, New Biologist, V2, P402; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; TANAKA H, 1995, GENE, V153, P283, DOI 10.1016/0378-1119(94)00821-9; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	77	193	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5953	5962		10.1074/jbc.274.9.5953	http://dx.doi.org/10.1074/jbc.274.9.5953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026221	hybrid			2022-12-27	WOS:000078804400092
J	Gao, ZH; Chen, TS; Weber, MJ; Linden, J				Gao, ZH; Chen, TS; Weber, MJ; Linden, J			A(2B) adenosine and P2Y(2) receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells - Cross-talk between cyclic AMP and protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MAP KINASE; MAST-CELLS; COUPLED RECEPTORS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CALCIUM MOBILIZATION; DISTINCT PATHWAYS; PHOSPHOLIPASE-C; NEURONAL CELLS	Mitogen-activated protein kinase (MAPK) cascades underlie long-term mitogenic, morphogenic, and secretory activities of purinergic receptors. In HEK-293 cells, N-ethylcarboxamidoadenosine (NECA) activates endogenous A(2B)ARs that signal through G(s) and G(q)/11. UTP activates P2Y(2) receptors and signals only through G(q)/11. The MAPK isoforms, extracellular-signal regulated kinase 1/2 (ERK), are activated by NECA and UTP. H-89 blocks ERR activation by forskolin, but weakly affects the response to NECA or UTP. ERR activation by NECA or UTP is unaffected by a tyrosine kinase inhibitor (genistein), attenuated by a phospholipase C inhibitor (U73122), and is abolished by a MEK inhibitor (PD098059) or dominant negative Ras. Inhibition of protein kinase C (PRC) by GF 109203X failed to block ERK activation by NECA or UTP, however, another PRC inhibitor, Ro 31-8220, which unlike GF 109203X, can block the zeta-isoform, and prevents UTP- but not NECA-induced ERK activation. In the presence of forskolin, Ro 31-8220 loses its ability to block UTP-stimulated ERR activation. PRA has opposing effects on B-Raf and c-Raf-1, both of which are found in HEK-293 cells. The data are explained by a model in which ERK activity is modulated by differential effects of PRC zeta and PRA on Raf isoforms.	Univ Virginia, Hlth Sci Ctr 6012, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Linden, J (corresponding author), Univ Virginia, Hlth Sci Ctr 6012, Dept Mol Physiol & Biol Phys, Box MR4, Charlottesville, VA 22908 USA.		Chen, Taosheng/I-6351-2013	Chen, Taosheng/0000-0001-6420-3809	NHLBI NIH HHS [R01-HL37942] Funding Source: Medline; NIGMS NIH HHS [GM 47332] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbracchio MP, 1996, DRUG DEVELOP RES, V39, P393, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<393::AID-DDR21>3.0.CO;2-1; ABBRACCHIO MP, 1995, BIOCHEM BIOPH RES CO, V213, P908, DOI 10.1006/bbrc.1995.2215; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALI H, 1990, J BIOL CHEM, V265, P745; ANTONYSAMY MA, 1995, J IMMUNOL, V155, P2813; Auchampach JA, 1997, MOL PHARMACOL, V52, P846, DOI 10.1124/mol.52.5.846; BROOKER G, 1979, SCIENCE, V184, P270; BUDWORTH J, 1995, FEBS LETT, V362, P139, DOI 10.1016/0014-5793(95)00227-Z; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Das M, 1997, AM J PHYSIOL-LUNG C, V273, pL1276, DOI 10.1152/ajplung.1997.273.6.L1276; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hoffman HM, 1997, INFLAMMATION, V21, P55, DOI 10.1023/A:1027390825353; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUGHES PJ, 1986, AGENTS ACTIONS, V18, P81, DOI 10.1007/BF01987989; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; ISN AJ, 1993, BIOCHEM SOC T, V21, pS386; JIN WZ, 1994, BRAIN RES, V642, P237, DOI 10.1016/0006-8993(94)90927-X; Jones T, 1997, BIOCHEM PHARMACOL, V53, P1413, DOI 10.1016/S0006-2952(96)00863-5; Jordan NJ, 1996, BRIT J PHARMACOL, V117, P1245, DOI 10.1111/j.1476-5381.1996.tb16722.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; Neary JT, 1996, DRUG DEVELOP RES, V39, P407, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<407::AID-DDR22>3.0.CO;2-X; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Robeva AS, 1996, DRUG DEVELOP RES, V39, P243, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<243::AID-DDR3>3.0.CO;2-R; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWNSENDNICHOLS.A, 1997, RRECEPTOR SIGNAL TRA, P45; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG YZ, 1993, J CARDIOVASC PHARM, V22, pS164, DOI 10.1097/00005344-199322008-00044; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WINITZ S, 1993, J BIOL CHEM, V268, P19196	61	126	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5972	5980		10.1074/jbc.274.9.5972	http://dx.doi.org/10.1074/jbc.274.9.5972			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026223	hybrid			2022-12-27	WOS:000078804400094
J	Grigoryev, SA; Bednar, J; Woodcock, CL				Grigoryev, SA; Bednar, J; Woodcock, CL			MENT, a heterochromatin protein that mediates higher order chromatin folding, is a new serpin family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION EFFECT VARIEGATION; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; ELECTRON-MICROSCOPY; GENE-EXPRESSION; NUCLEAR MATRIX; DNA; NUCLEOSOME; BINDING; CELLS	Terminal cell differentiation is correlated with the extensive sequestering of previously active genes into compact transcriptionally inert heterochromatin. In vertebrate blood cells, these changes can be traced to the accumulation of a developmentally regulated heterochromatin protein, MENT. Cryoelectron microscopy of chicken granulocyte chromatin, which is highly enriched with MENT, reveals exceptionally compact polynucleosomes, which maintain a level of higher order folding above that imposed by linker histones. The amino acid sequence of MENT reveals a close structural relationship with serpins, a large family of proteins known for their ability to undergo dramatic conformational transitions. Conservation of the "hinge region" consensus in MENT indicates that this ability is retained by the protein. MENT is distinguished from the other serpins by being a basic protein, containing several positively charged surface clusters, which are likely to be involved in ionic interactions with DNA. One of the positively charged domains bears a significant similarity to the chromatin binding region of nuclear lamina proteins and with the A T-rich DNA-binding motif, which may account for the targeting of MENT to peripheral heterochromatin. MENT ectopically expressed in a mammalian cell Line is transported into nuclei and is associated with intranuclear foci of condensed chromatin.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Grigoryev, SA (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	sergei@bio.umass.edu	Bednar, Jan/K-2162-2012; Bednar, Jan/H-3648-2017	Bednar, Jan/0000-0003-0879-6405	NIGMS NIH HHS [GM-43786, GM-51352] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786, R55GM051352] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BEAULIEU AD, 1992, J BIOL CHEM, V267, P426; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BEDNAR J, 1995, J CELL BIOL, V131, P1365, DOI 10.1083/jcb.131.6.1365; BJELLQVIST B, 1994, ELECTROPHORESIS, V15, P529, DOI 10.1002/elps.1150150171; BURLEY SK, 1993, COLD SPRING HARB SYM, V58, P123, DOI 10.1101/SQB.1993.058.01.016; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; FRENSTER JH, 1974, CELL NUCLEUS, P565; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Girard F, 1998, EMBO J, V17, P2079, DOI 10.1093/emboj/17.7.2079; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grigoryev SA, 1998, J BIOL CHEM, V273, P3082, DOI 10.1074/jbc.273.5.3082; GRIGORYEV SA, 1993, EXP CELL RES, V206, P335, DOI 10.1006/excr.1993.1154; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heitz E., 1928, JAHRB WISS BOT, V69, P762; Henikoff S, 1997, CURR OPIN CELL BIOL, V9, P388, DOI 10.1016/S0955-0674(97)80012-9; HILWIG I, 1971, CHROMOSOMA, V34, P243; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8952; John B, 1988, HETEROCHROMATIN MOL, P1; JORCANO JL, 1980, P NATL ACAD SCI-BIOL, V77, P6443, DOI 10.1073/pnas.77.11.6443; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOMAIKO W, 1985, BIOCHEMISTRY-US, V24, P1186, DOI 10.1021/bi00326a020; LAFOND RE, 1983, EXP CELL RES, V147, P31, DOI 10.1016/0014-4827(83)90268-9; Lauber AH, 1997, J BIOL CHEM, V272, P24657, DOI 10.1074/jbc.272.39.24657; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Lohe A., 1988, HETEROCHROMATIN MOL, P148; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pollard KM, 1997, J IMMUNOL, V158, P3521; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROWLEY AF, 1988, VERTEBRATE BLOOD CEL; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; Singh PB, 1998, DEV GENET, V22, P85, DOI 10.1002/(SICI)1520-6408(1998)22:1<85::AID-DVG9>3.0.CO;2-3; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TOBIN AJ, 1978, DEV BIOL, V67, P11, DOI 10.1016/0012-1606(78)90296-8; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WEITH A, 1985, CHROMOSOMA, V91, P287, DOI 10.1007/BF00328224; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WILKIE TM, 1994, METHOD ENZYMOL, V237, P327; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1993, COLD SPRING HARB SYM, V58, P225, DOI 10.1101/SQB.1993.058.01.027; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CL, 1995, TRENDS CELL BIOL, V5, P272, DOI 10.1016/S0962-8924(00)89038-8; Woodcock CL, 1997, METHODS, V12, P84, DOI 10.1006/meth.1997.0450; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Zou S, 1997, P NATL ACAD SCI USA, V94, P7412, DOI 10.1073/pnas.94.14.7412; [No title captured]	88	93	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5626	5636		10.1074/jbc.274.9.5626	http://dx.doi.org/10.1074/jbc.274.9.5626			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026180	hybrid			2022-12-27	WOS:000078804400051
J	Sei, Y; Gallagher, KL; Basile, AS				Sei, Y; Gallagher, KL; Basile, AS			Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SARCOPLASMIC-RETICULUM; RELEASE CHANNEL; CA-2+ RELEASE; CA2+ RELEASE; SURFACE-IMMUNOGLOBULIN; MALIGNANT HYPERTHERMIA; MOLECULAR-CLONING; BRAIN; ACTIVATION	The regulation of intracellular free Ca2+ concentration ([Ca2+](i)) in B cells remains poorly understood and is presently explained almost solely by inositol 1,4,5-triphosphate (IP3)-mediated Ca2+ release, followed by activation of a store-operated channel mechanism. In fact, there are reports indicating that IP3 production does not always correlate with the magnitude of Ca2+ release. We demonstrate here that human B cells ex press a ryanodine receptor (RYR) that functions as a Ca2+ release channel during the B cell antigen receptor (BCR)-stimulated Ca2+ signaling process. Immunoblotting studies showed that both human primary CD19(+) B and DAHIKI cells express a 565-kDa immunoreactive protein that is indistinguishable in molecular size and immunoreactivity from the RYR. Selective reverse transcription-polymerase chain reaction, restriction fragment length polymorphism, and sequencing of cloned cDNA indicated that the major isoform of the RYR expressed in primary CD19(+) B and DAKIKI cells is identical to the skeletal muscle type (RYR1). Saturation analysis of [H-3]ryanodine binding yielded B-max = 150 fmol/mg of protein and K-d = 110 nM in DAKIKI cells. In fluo-3-loaded CD19(+) B and DAKIKI cells, 4-chloro-m-cresol, a potent activator of Ca2+ release mediated by the ryanodine-sensitive Ca2+ release channel, induced Ca2+ release in a dose-dependent and ryanodine-sensitive fashion. Furthermore, BCR-mediated Ca2+ release in CD19(+) B cells was significantly altered by 4-chloro-m-cresol and ryanodine. These results indicate that RYR1 functions as a Ca2+ release channel during BCR-stimulated Ca2+ signaling and suggest that complex Ca2+ signals that control the cellular activities of B cells may be generated by cooperation of the IP3 receptor and RYR1.	Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; NIDDK, NIH, Bioorgan Chem Lab, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sei, Y (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	ysei@mx3.usuhs.mil						Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUIXERAS E, 1993, IMMUNOL REV, V132, P5; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DELMETSCH RE, 1997, NATUIRE, V386, P855; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MILLET I, 1988, EUR J IMMUNOL, V18, P545, DOI 10.1002/eji.1830180409; Ono Atsuko, 1995, Bulletin of Tokyo Medical and Dental University, V42, P9; OTSU K, 1990, J BIOL CHEM, V265, P13472; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PEAKER CJG, 1994, CURR OPIN IMMUNOL, V6, P359, DOI 10.1016/0952-7915(94)90113-9; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROIFMAN CM, 1987, EUR J IMMUNOL, V17, P1737, DOI 10.1002/eji.1830171209; SEI Y, 1991, J IMMUNOL METHODS, V137, P237; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192; Zucchi R, 1997, PHARMACOL REV, V49, P1; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	39	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5995	6002		10.1074/jbc.274.9.5995	http://dx.doi.org/10.1074/jbc.274.9.5995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026226	hybrid			2022-12-27	WOS:000078804400097
J	Thankavel, K; Shah, AH; Cohen, MS; Ikeda, T; Lorenz, RG; Curtiss, R; Abraham, SN				Thankavel, K; Shah, AH; Cohen, MS; Ikeda, T; Lorenz, RG; Curtiss, R; Abraham, SN			Molecular basis for the enterocyte tropism exhibited by Salmonella typhimurium type 1 fimbriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; FAMILY ENTEROBACTERIACEAE; ADHESION PROTEIN; URINARY-TRACT; CELLS; EXPRESSION; ADHERENCE; SURFACE; BINDING	Salmonella typhimurium exhibits a distinct tropism for mouse enterocytes that is linked to their expression of type 1 fimbriae, The distinct binding traits of Salmonella type 1 fimbriae is also reflected in their binding to selected mannosylated proteins and in their ability to promote secondary bacterial aggregation on enterocyte surfaces. The determinant of binding in Salmonella type I fimbriae is a 35-kDa structurally distinct fimbrial subunit, FimHs, because inactivation of fimHs abolished binding activity in the resulting mutant without any apparent effect on fimbrial expression. Surprisingly, when expressed in the absence of other fimbrial components and as a translational fusion protein with MalE, FimHs failed to demonstrate any specific binding tropism and bound equally to all cells and mannosylated proteins tested. To determine if the binding specificity of Salmonella type 1 fimbriae was determined by the fimbrial shaft that is intimately associated with FimHs, we replaced the amino-terminal half of FimHs with the corresponding sequence from Escherichia coli FimH (FimHE) that contains the receptor binding domain of FimHE, The resulting hybrid fimbriae bearing FimHES on a Salmonella fimbrial shaft exhibited binding traits that resembled that of Salmonella rather than E, coli fimbriae, Apparently, the quaternary constraints imposed by the fimbrial shaft on the adhesin determine the distinct binding traits of S. typhimurium type 1 fimbriae.	Duke Univ, Med Ctr, Dept Pathol & Microbiol, Durham, NC 27710 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA; Azabu Univ, Sch Vet Med, Dept Vet Med, Kanagawa 229, Japan; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Duke University; Washington University (WUSTL); Azabu University; Washington University (WUSTL); Washington University (WUSTL)	Thankavel, K (corresponding author), Duke Univ, Med Ctr, Dept Pathol & Microbiol, Campus Box 3020, Durham, NC 27710 USA.	krishnan@acpub.duke.edu	Lorenz, Robin G/AAJ-1499-2021	Lorenz, Robin G/0000-0002-2514-9819	NIAID NIH HHS [AI 35678] Funding Source: Medline; NIDDK NIH HHS [DK 508141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035678] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; CLEGG S, 1985, INFECT IMMUN, V48, P275, DOI 10.1128/IAI.48.2.275-279.1985; Clegg S., 1994, FIMBRIAE ADHESION GE, P105; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DODD DC, 1982, INFECT IMMUN, V38, P764, DOI 10.1128/IAI.38.2.764-773.1982; DUGUID JP, 1976, J MED MICROBIOL, V9, P459, DOI 10.1099/00222615-9-4-459; DUGUID JP, 1966, J PATHOL BACTERIOL, V92, P107, DOI 10.1002/path.1700920113; DUGUID JP, 1980, BACTERIAL ADHERENC B, V6, P185; Ewen SWB, 1997, FEMS IMMUNOL MED MIC, V18, P185, DOI 10.1016/S0928-8244(97)00038-2; FAVREBONTE S, 1995, INFECT IMMUN, V63, P1318, DOI 10.1128/IAI.63.4.1318-1328.1995; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Hancox LS, 1997, FEMS IMMUNOL MED MIC, V19, P289, DOI 10.1016/S0928-8244(97)00095-3; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; LOCKMAN HA, 1992, MOL MICROBIOL, V6, P933, DOI 10.1111/j.1365-2958.1992.tb01543.x; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; PECK R, 1985, J IMMUNOL METHODS, V82, P131, DOI 10.1016/0022-1759(85)90232-7; PONNIAH S, 1991, J BACTERIOL, V173, P4195, DOI 10.1128/jb.173.13.4195-4202.1991; Sambrook J., 1989, MOL CLONING, pA1; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; Sukupolvi S, 1997, INFECT IMMUN, V65, P5320, DOI 10.1128/IAI.65.12.5320-5325.1997; Svanborg C, 1996, ANN NY ACAD SCI, V797, P177, DOI 10.1111/j.1749-6632.1996.tb52959.x; SWENSON DL, 1994, MOL GEN GENET, V244, P216, DOI 10.1007/BF00283525; Thankavel K, 1997, J CLIN INVEST, V100, P1123, DOI 10.1172/JCI119623; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van der Velden AWM, 1998, INFECT IMMUN, V66, P2803, DOI 10.1128/IAI.66.6.2803-2808.1998; YEH KS, 1995, J BACTERIOL, V177, P6861, DOI 10.1128/jb.177.23.6861-6865.1995; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	41	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5797	5809		10.1074/jbc.274.9.5797	http://dx.doi.org/10.1074/jbc.274.9.5797			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026202	hybrid			2022-12-27	WOS:000078804400073
J	Hamik, A; Setiadi, H; Bu, GJ; McEver, RP; Morrissey, JH				Hamik, A; Setiadi, H; Bu, GJ; McEver, RP; Morrissey, JH			Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SEPTIC SHOCK; FACTOR-XA; CELL-SURFACE; FACTOR-VIIA; COAGULATION INHIBITOR; BLOOD-COAGULATION; INTRAVASCULAR COAGULATION; PLASMINOGEN-ACTIVATOR; MONOCLONAL-ANTIBODY; UROKINASE RECEPTOR	Inflammatory mediators like bacterial lipopolysaccharide induce monocytes to express tissue factor (TF), the cell-surface protein that triggers the blood clotting cascade in hemostasis and thrombotic disease. The physiologic ligand for TF is the serine protease, factor VIIa (FVIIa), and the resulting bimolecular enzyme, TF/FVIIa, can be reversibly inhibited by tissue factor pathway inhibitor (TFPI), Culturing monocytic cells in the presence of both FVIIa and TFPI caused down-regulation of TF expression via reducing its half-life. To exert this effect, FVIIa had to be competent to bind both TF and TFPI, and TFPI had to contain the C-terminal domain required for binding to other cell-surface receptors, including the low density lipoprotein receptor-related protein (LRP), TF down-regulation by FVIIa plus TFPI was abrogated by the 39-kDa receptor-associated protein, which blocks binding of all known ligands to LRP, Furthermore, treatment with FVIIa plus TFPI caused monocyte TF to colocalize with alpha-adaptin, a component of clathrin-coated pits. Thus, in addition to reversibly inhibiting TF/FVIIa catalytic activity, TFPI also mediates the permanent down-regulation of cell-surface TF in monocytic cells via LRP-dependent internalization and degradation. This represents an unusual mechanism for receptor internalization, requiring ligand-dependent bridging of one cell-surface receptor (TF) to a second cell-surface receptor (LRP), the latter being capable of clathrin-mediated internalization.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); Washington University (WUSTL)	Morrissey, JH (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	morrissey@scientist.com	Morrissey, James H/H-4933-2011; Setiadi, Hendra/ACQ-9386-2022; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; Setiadi, Hendra/0000-0002-0570-1354	NHLBI NIH HHS [P50 HL54502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; BROZE GJ, 1987, BLOOD, V69, P150; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; CARR C, 1994, CIRC SHOCK, V44, P126; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; CZEKAY RP, 1995, J CELL SCI, V108, P1433; DAY KC, 1990, BLOOD, V76, P1538; DRAKE TA, 1993, AM J PATHOL, V142, P1458; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GIRARD TJ, 1993, METHOD ENZYMOL, V222, P195; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; Girard TJ, 1997, NEW THERAPEUTIC AGEN, P225; Goretzki L, 1997, J CELL SCI, V110, P1395; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HELINSKI EH, 1988, J LEUKOCYTE BIOL, V44, P111, DOI 10.1002/jlb.44.2.111; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; Jesty J, 1976, Methods Enzymol, V45, P95; KAZAMA Y, 1993, BLOOD, V81, P676; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; Mulder AB, 1996, BLOOD, V88, P1306, DOI 10.1182/blood.V88.4.1306.bloodjournal8841306; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NERI SG, 1990, LANCET, V336, P1444; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NIEMETZ J, 1971, NATURE-NEW BIOL, V232, P247, DOI 10.1038/newbio232247a0; NOVOTNY WF, 1988, BLOOD, V72, P2020; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OKAJIMA K, 1991, AM J HEMATOL, V36, P265, DOI 10.1002/ajh.2830360408; OSTERUD B, 1995, THROMB HAEMOSTASIS, V73, P873; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; RIVERS RPA, 1975, BRIT J HAEMATOL, V30, P311, DOI 10.1111/j.1365-2141.1975.tb00547.x; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCHWARTZ BS, 1982, J EXP MED, V155, P1464, DOI 10.1084/jem.155.5.1464; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Solberg S, 1990, Blood Coagul Fibrinolysis, V1, P595; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Tenno T, 1997, THROMB RES, V88, P215, DOI 10.1016/S0049-3848(97)00232-6; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; Wang PY, 1996, J INFLAMM, V47, P126; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	70	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4962	4969		10.1074/jbc.274.8.4962	http://dx.doi.org/10.1074/jbc.274.8.4962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988740	hybrid			2022-12-27	WOS:000078698200065
J	Koppelman, SJ; Bruijnzeel-Koomen, CAFM; Hessing, M; de Jongh, HHJ				Koppelman, SJ; Bruijnzeel-Koomen, CAFM; Hessing, M; de Jongh, HHJ			Heat-induced conformational changes of Ara h 1, a major peanut allergen, do not affect its allergenic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOPIC-DERMATITIS; IGE-BINDING; THERMAL-DENATURATION; SECONDARY STRUCTURE; PROTEIN STRUCTURE; DOUBLE-BLIND; HYPERSENSITIVITY; CHALLENGE; IDENTIFICATION; STABILIZATION	Ara h 1, a major peanut allergen was isolated, and its structure on secondary, tertiary, and quaternary level at ambient temperature was investigated using spectroscopic and biochemical techniques. Ara h 1 appeared to be a highly structured protein on a secondary level, possesses a clear tertiary fold, and is present as a trimeric complex. Heat treatment of purified Ara h 1 results in an endothermic, irreversible transition between 80 and 90 degrees C, leading to an increase in beta-structures and a concomitant aggregation of the protein. Ara h 1 from peanuts that were heat-treated prior to the purification procedure exhibited a similar denatured state with an increased secondary folding and a decreased solubility, The effect of heat treatment on the in vitro allergenic properties of Ara h 1 was investigated by means of a fluid-phase IgE binding assay using serum from patients with a clinically proven peanut allergy. Ara h 1 purified from peanuts heated at different temperatures exhibited IgE binding properties similar to those found for native Ara h 1, indicating that the allergenicity of Ara h 1 is heat-stable. We conclude that the allergenicity of Ara h 1 is unaffected by heating, although native Ara h 1 undergoes a significant heat-induced denaturation on a molecular level, indicating that the recognition of conformational epitopes of Ara h 1 by IgE either is not a dominant mechanism or is restricted to parts of the protein that are not sensitive to heat denaturation.	TNO, Nutr & Food Res Inst, Dept Prot Technol, NL-3700 AJ Zeist, Netherlands; Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Wageningen Univ Agr, TNO, Ctr Prot Technol, NL-6700 EV Wageningen, Netherlands	Netherlands Organization Applied Science Research; Utrecht University; Netherlands Organization Applied Science Research; Wageningen University & Research	Koppelman, SJ (corresponding author), TNO, Nutr & Food Res Inst, Dept Prot Technol, POB 360, NL-3700 AJ Zeist, Netherlands.	koppelman@voeding.tno.nl						BARNETT D, 1986, BIOCHIM BIOPHYS ACTA, V882, P97, DOI 10.1016/0304-4165(86)90060-7; BERKHOUT TA, 1987, BIOCHIM BIOPHYS ACTA, V897, P1, DOI 10.1016/0005-2736(87)90308-7; BURKS AW, 1995, INT ARCH ALLERGY IMM, V107, P248, DOI 10.1159/000236993; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; Buschmann L, 1996, MONOGR ALLERGY, V32, P92; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; deJongh HHJ, 1996, ANAL BIOCHEM, V242, P95, DOI 10.1006/abio.1996.0434; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hourihane JO, 1997, BRIT MED J, V314, P1084, DOI 10.1136/bmj.314.7087.1084; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; KALNIN NN, 1990, BIOPOLYMERS, V30, P1273, DOI 10.1002/bip.360301311; KOPPELMAN SJ, 1996, WORLD INGREDIENTS, V12, P35; LAPANJE S, 1989, BIOPHYS CHEM, V34, P155, DOI 10.1016/0301-4622(89)80053-5; LAWRENCE MC, 1990, EMBO J, V9, P9, DOI 10.1002/j.1460-2075.1990.tb08074.x; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Phillips R. D., 1981, ACS Symposium Series, V147, P275; Pots AM, 1998, EUR J BIOCHEM, V252, P66, DOI 10.1046/j.1432-1327.1998.2520066.x; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Smith J., 1997, International Food Ingredients, P13; Stanley JS, 1996, ADV EXP MED BIOL, V409, P213; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VUILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303, DOI 10.1021/bi00090a005; Yeung JM, 1996, J AOAC INT, V79, P1411	38	144	157	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4770	4777		10.1074/jbc.274.8.4770	http://dx.doi.org/10.1074/jbc.274.8.4770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988715	hybrid, Green Published			2022-12-27	WOS:000078698200040
J	Till, JH; Chan, PM; Miller, WT				Till, JH; Chan, PM; Miller, WT			Engineering the substrate specificity of the Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE; CRYSTAL-STRUCTURE; PROTEIN-KINASES; MUTATION; BINDING; DOMAIN; PHOSPHORYLATION; PEPTIDES; LEUKEMIA; ONCOGENE	c-Abl is a non-receptor tyrosine kinase that is involved in a variety of signaling pathways. Activated forms of c-Abl are associated with some forms of human leukemia. Presently, no high resolution structure of the tyrosine kinase domain of Abl is available. We have developed a structural homology model of the catalytic domain of Abl based on the crystal structure of the insulin receptor tyrosine kinase, Using this model as a guide, we selected residues near the active site predicted to play a role in peptide/protein substrate recognition. We expressed and purified 15 mutant forms of Abl with single amino acid substitutions at these positions and tested their peptide substrate specificity. We report here the identification of seven residues involved in recognition of the P-1, P+1, and P+3 positions of bound peptide substrate. Mutations in these residues cause distinct changes in substrate specificity. The results suggest features of Abl substrate recognition that may be relevant to related tyrosine kinases.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA58530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen PB, 1996, J BIOL CHEM, V271, P19585, DOI 10.1074/jbc.271.32.19585; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; Moro Marina, 1997, Leukemia (Basingstoke), V11, P313; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SURLES MC, 1994, PROTEIN SCI, V3, P198; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4471, DOI 10.1021/bi00388a043; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILL JH, 1994, J BIOL CHEM, V269, P7423; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; XU W, 1997, NATURE, V385, P596; Zhou Songyang, 1995, Nature (London), V373, P536	34	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4995	5003		10.1074/jbc.274.8.4995	http://dx.doi.org/10.1074/jbc.274.8.4995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988744	hybrid			2022-12-27	WOS:000078698200069
J	van Leeuwen, JEM; Paik, PK; Samelson, LE				van Leeuwen, JEM; Paik, PK; Samelson, LE			Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol S-kinase association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED CBL; OF-FUNCTION MUTATION; PROTOONCOGENE C-CBL; EGF RECEPTOR; V-CBL; BCR-ABL; CELLS; CRKL; C3G; TRANSFORMATION	The Cbl proto-oncogene product is a complex adapter protein that functions as a negative regulator of protein tyrosine kinases. It is rapidly tyrosine-phosphorylated and associates with Crk(L) and p85 phosphatidylinositol 3-kinase (PI3K) upon engagement of numerous receptors linked to tyrosine kinases. Elucidation of the mechanism(s) underlying Cbl deregulation is therefore of considerable interest. The 70Z Cbl oncoprotein shows increased baseline tyrosine phosphorylation in fibroblasts and enhances nuclear factor of activated T cells (NFAT) activity in Jurkat T cells. Its transforming ability has been proposed to relate to its increased phosphotyrosine content. We demonstrate that 70Z Cbl shows increased basal and activation-induced tyrosine phosphorylation and association with Crk(L) and p85 PI3K in Jurkat T cells. 70Z Cbl, however, retains the ability to enhance NFAT and activating protein 1 (AP1) activity in the absence of Crk(L)/p85 PI3K association. In contrast, the G306E mutation, which inactivates the phosphotyrosine binding domain of CM, blocks NFAT/AP1 activation by 70Z Cbl. We conclude that 70Z Cbl-induced NFAT/AP1 activation requires the phosphotyrosine binding domain but not Crk(L)/p85 PI3K association. We hypothesize that 70Z Cbl acts as a dominant negative by blocking the negative regulatory function of the Cbl phosphotyrosine binding domain on protein-tyrosine kinases.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	van Leeuwen, JEM (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	vanleeuj@box-v.nih.gov	van Leeuwen, Jeroen/G-3555-2010		NATIONAL CANCER INSTITUTE [Z01BC010304, ZIABC010304] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; KEANE MM, 1995, ONCOGENE, V10, P2367; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5153	5162		10.1074/jbc.274.8.5153	http://dx.doi.org/10.1074/jbc.274.8.5153			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988765	hybrid			2022-12-27	WOS:000078698200090
J	Goudet, G; Delhalle, S; Biemar, F; Martial, JA; Peers, B				Goudet, G; Delhalle, S; Biemar, F; Martial, JA; Peers, B			Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; HUMAN PROTOONCOGENE PBX1; DNA-BINDING SPECIFICITY; CAMP RESPONSE ELEMENT; HOMEOBOX GENES; HOX PROTEINS; TRANSCRIPTIONAL ACTIVATOR; FACTOR STF-1; EXTRADENTICLE; EXPRESSION	Expression of the somatostatin gene in endocrine pancreatic cells is controlled by several regulatory cis-elements located in the promoter region. Among these, the adjacent UE-A and TSEI elements, located from -113 to -85 relative to the transcription initiation site, function in combination and act as a pancreas-specific mini-enhancer. The TSEI element is recognized by the pancreatic homeodomain factor PDX1. In the present study, we show that the UE-A element binds a heterodimeric complex composed of a Pbx factor and the Prep1 protein, both belonging to the atypical three-amino acid loop extension homeodomain family. Recombinant Pbx1 and Prep1 proteins bind cooperatively to the UE-A site, whereas neither protein can bind this site alone. Transient transfection experiments reveal that both Pbx1 and Prep1 are required to generate a strong transcriptional activation from the UE-A element when this element is inserted close to the TATA box. In contrast, in the context of the intact somatostatin promoter or mini-enhancer, Pbx1 and Prep1 alone have no effect, but they produce a drastic activation when the pancreatic homeodomain factor PDX1 is also coexpressed. Thus, the activity of the somatostatin mini-enhancer is mediated by a cooperative interaction between the Pbx-Prep1 heterodimeric complex and the pancreatic factor PDX1.	Univ Liege, Inst Chim, Lab Biol Mol & Genie Genet, B-4000 Sart Tilman, Belgium	University of Liege	Peers, B (corresponding author), Univ Liege, Inst Chim, Lab Biol Mol & Genie Genet, Batiment B6, B-4000 Sart Tilman, Belgium.							Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chen HM, 1997, GENOMICS, V41, P193, DOI 10.1006/geno.1997.4632; DeCesare D, 1996, ONCOGENE, V13, P2551; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kurant E, 1998, DEVELOPMENT, V125, P1037; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Montminy M R, 1990, Recent Prog Horm Res, V46, P219; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6	44	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4067	4073		10.1074/jbc.274.7.4067	http://dx.doi.org/10.1074/jbc.274.7.4067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933599	hybrid			2022-12-27	WOS:000078575500023
J	Bevans, CG; Harris, AL				Bevans, CG; Harris, AL			Direct high affinity modulation of connexin channel activity by cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTION MEMBRANE CHANNELS; MAJOR COAT PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTOR; CGMP-BINDING-SITES; GAP-JUNCTIONS; ASPARTIC-ACID; ION CHANNELS; CAMP; COMMUNICATION; DICTYOSTELIUM	Connexin channels mediate molecular communication between cells. However, positive identification of biological ligands that directly and noncovalently modulate their activity has been elusive. This study demonstrates a high affinity inhibition of connexin channels by the purine cyclic monophosphates cAMP and cGMP, Purified homomeric connexin-32 and heteromeric connexin-32/connexin-26 channels were inhibited by exposure to nanomolar levels of the nucleotides prior to incorporation into membranes. Access to the site of action, or affinity for the nucleotides, was greatly reduced following incorporation of the connexin channels into membranes, where inhibition required millimolar concentrations of the nucleotides, The high affinity inhibition did not occur with similar concentrations of AMP, ADP, ATP, cTMP, or cCMP. This is the first report of a direct ligand effect on connexin channel function, The high affinity and specificity of the inhibition suggest a biological role in control of connexin channels and also may lead to the application of affinity reagents to study of connexin channel structure-function.	Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University	Harris, AL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.		Bevans, Carville/C-6651-2009	Bevans, Carville/0000-0001-7389-2124; Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastiaanse EML, 1997, CARDIOVASC RES, V33, P272, DOI 10.1016/S0008-6363(96)00193-9; Bevans C. G., 1996, Molecular Biology of the Cell, V7, p281A; Bevans C. G., 1996, Biophysical Journal, V70, pA32; Bevans C. G., 1997, Biophysical Journal, V72, pA272; Bevans C. G., 1995, Molecular Biology of the Cell, V6, p190A; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CAVALIERI SJ, 1976, J MOL BIOL, V102, P713, DOI 10.1016/0022-2836(76)90287-4; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P118; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARRIS AL, 1981, J GEN PHYSIOL, V77, P95, DOI 10.1085/jgp.77.1.95; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HARRIS AL, 1997, GAP JUNCTIONS, P60; HARRIS AL, 1994, BIOMEMBRANE ELECTROC, P197; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; Kalman L, 1997, BIOCHEMISTRY-US, V36, P4489, DOI 10.1021/bi961860o; Kim JY, 1997, J BIOL CHEM, V272, P2060; KIM JY, 1994, J BIOL CHEM, V269, P28724; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KURAOKA A, 1993, J HISTOCHEM CYTOCHEM, V41, P971, DOI 10.1177/41.7.8390496; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; LEHNINGER AL, 1974, P NATL ACAD SCI USA, V71, P1520, DOI 10.1073/pnas.71.4.1520; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MAKINO S, 1975, J BIOL CHEM, V250, P4327; MATTHEWS BW, 1982, LIPID PROTEIN INTERA, P1; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORENO AP, 1992, BIOPHYS J, V62, P51, DOI 10.1016/S0006-3495(92)81775-7; MORENO AP, 1991, BIOPHYS J, V59, P920, DOI 10.1016/S0006-3495(91)82305-0; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; Nicholson BJ, 1998, GAP JUNCTIONS, P3; NORTH RA, 1994, LIGAND VOLTAGE GATED; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PERACCHIA C, 1995, HDB MEMBRANE CHANNEL, P361; PICCOLINO M, 1984, J NEUROSCI, V4, P2477; PITTS JD, 1977, EXP CELL RES, V104, P153, DOI 10.1016/0014-4827(77)90078-7; PRASAD K, 1994, J BIOL CHEM, V269, P6931; REYNOLDS JA, 1982, LIPID PROTEIN INTERA, P193; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; RISEK B, 1995, J CELL SCI, V108, P1017; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; Spray David C., 1994, P195; SPRAY DC, 1979, SCIENCE, V204, P432, DOI 10.1126/science.312530; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Spruijt RB, 1996, BIOCHEMISTRY-US, V35, P10383, DOI 10.1021/bi960410t; Stopar D, 1997, BIOCHEMISTRY-US, V36, P12268, DOI 10.1021/bi970747a; Stopar D, 1996, BIOCHEMISTRY-US, V35, P15467, DOI 10.1021/bi961770j; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; TAKENSKWAK BR, 1992, PFLUG ARCH EUR J PHY, V422, P198, DOI 10.1007/BF00370421; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; TSIEN RW, 1976, J PHYSIOL-LONDON, V260, P117, DOI 10.1113/jphysiol.1976.sp011507; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; VANHAASTERT PJM, 1983, J BIOL CHEM, V258, P9636; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WIERENGA RK, 1992, FEBS LETT, V307, P34, DOI 10.1016/0014-5793(92)80897-P; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; Zanello LP, 1996, BIOPHYS J, V70, P2155, DOI 10.1016/S0006-3495(96)79781-3; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	74	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3720	3725		10.1074/jbc.274.6.3720	http://dx.doi.org/10.1074/jbc.274.6.3720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920924	hybrid			2022-12-27	WOS:000078428200064
J	Kekuda, R; Wang, HP; Huang, W; Pajor, AM; Leibach, FH; Devoe, LD; Prasad, PD; Ganapathy, V				Kekuda, R; Wang, HP; Huang, W; Pajor, AM; Leibach, FH; Devoe, LD; Prasad, PD; Ganapathy, V			Primary structure and functional characteristics of a mammalian sodium-coupled high affinity dicarboxylate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; BRUSH-BORDER MEMBRANES; EXPRESSION CLONING; UPHILL TRANSPORT; SEQUENCE; IDENTIFICATION; COTRANSPORTER; SPECIFICITY; SUCCINATE; GRADIENT	We have cloned a Na+-dependent, high affinity dicarboxylate transporter (NaDC3) from rat placenta. NaDC3 exhibits 48% identity in amino acid sequence with rat NaDC1, a Na+-dependent, low affinity dicarboxylate transporter. NaDC3-specific mRNA is detectable in kidney, brain, liver, and placenta. When expressed in mammalian cells, NaDC3 mediates Na+-dependent transport of succinate with a K-t of 2 mu M. The transport function of NaDC3 shows a sigmoidal relationship with regard to Na+ concentration, with a Hill coefficient of 2.7. NaDC3 accepts a number of dicarboxylates including dimethylsuccinate as substrates and excludes monocarboxylates. Li+ inhibits NaDC3 in the presence of Na+. Transport of succinate by NaDC3 is markedly influenced by pH, the transport function gradually decreasing when pH is acidified from 8.0 to 5.5. In contrast, the influence of pH on NaDC3-mediated transport of citrate is biphasic in which a pH change from 8.0 to 6.5 stimulates the transport and any further acidification inhibits the transport. In addition, the potency of citrate to compete with NaDC3-mediated transport of succinate increases 25-fold when pH is changed from 7.5 to 5.5. These data show that NaDC3 interacts preferentially with the divalent anionic species of citrate. This represents the first report on the cloning and functional characterization of a mammalian Na+-dependent, high affinity dicarboxylate transporter.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Texas System; University of Texas Medical Branch Galveston	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mai.mcg.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 33347] Funding Source: Medline; NIDA NIH HHS [DA 10045] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BALKOVETZ DF, 1988, J BIOL CHEM, V263, P13823; Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BROWNE JL, 1978, PROC R SOC SER B-BIO, V200, P117, DOI 10.1098/rspb.1978.0010; BURCKHARDT G, 1984, PFLUG ARCH EUR J PHY, V401, P254, DOI 10.1007/BF00582592; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; GANAPATHY V, 1988, BIOCHEM J, V249, P179, DOI 10.1042/bj2490179; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Khatri IA, 1996, BBA-GENE STRUCT EXPR, V1309, P58, DOI 10.1016/S0167-4781(96)00138-8; KIPPEN I, 1979, P NATL ACAD SCI USA, V76, P3397, DOI 10.1073/pnas.76.7.3397; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MOSELEY RH, 1992, AM J PHYSIOL, V263, pG871, DOI 10.1152/ajpgi.1992.263.6.G871; Pajor AM, 1998, J BIOL CHEM, V273, P18923, DOI 10.1074/jbc.273.30.18923; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PAJOR AM, 1996, AM J PHYSIOL, V270, pF462; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRASAD PD, 1998, TROPHOBLAST RES, V11, P243; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; SMITH CH, 1992, ANNU REV NUTR, V12, P183, DOI 10.1146/annurev.nu.12.070192.001151; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VOGELI G, 1987, METHOD ENZYMOL, V152, P407; WOLFFRAM S, 1992, COMP BIOCHEM PHYS A, V101, P759, DOI 10.1016/0300-9629(92)90355-T; WRIGHT EM, 1993, SOC GEN PHY, V48, P229; WRIGHT SH, 1981, BIOCHIM BIOPHYS ACTA, V640, P767, DOI 10.1016/0005-2736(81)90107-3; WRIGHT SH, 1980, J MEMBRANE BIOL, V57, P73, DOI 10.1007/BF01868987; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF432, DOI 10.1152/ajprenal.1987.253.3.F432; ZIMMERLI B, 1992, PFLUG ARCH EUR J PHY, V421, P329, DOI 10.1007/BF00374220	31	91	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3422	3429		10.1074/jbc.274.6.3422	http://dx.doi.org/10.1074/jbc.274.6.3422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920886	hybrid			2022-12-27	WOS:000078428200026
J	Lin, D; Gish, GD; Songyang, Z; Pawson, T				Lin, D; Gish, GD; Songyang, Z; Pawson, T			The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; DENSITY PROTEIN PSD-95; EPH-FAMILY; TRANSMEMBRANE LIGANDS; MOLECULAR-CLONING; COMMISSURAL AXONS; K+ CHANNELS; IN-VITRO; NUK; PHOSPHATASE	Ephrin B proteins function as ligands for B class Eph receptor tyrosine kinases and are postulated to possess an intrinsic signaling function. The sequence at the carboxyl terminus of B-type ephrins contains a putative PDZ binding site, providing a possible mechanism through which transmembrane ephrins might interact with cytoplasmic proteins. To test this notion, a day 10.5 mouse embryonic expression library was screened with a biotinylated peptide corresponding to the carboxyl terminus of ephrin B3. Three of the positive cDNAs encoded polypeptides with multiple PDZ domains, representing fragments of the molecule GRIP, the protein syntenin, and PHIP, a novel PDZ domain-containing protein related to Caenorhabditis elegans PAR-3. In addition, the binding specificities of PDZ domains previously predicted by an oriented library approach (Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997) Science 275, 73-77) identified the tyrosine phosphatase FAP-1 as a potential binding partner for B ephrins. In vitro studies demonstrated that the fifth PDZ domain of FAP-I and full-length syntenin bound ephrin B1 via the carboxyl-terminal motif. Lastly, syntenin and ephrin B1 could be co-immunoprecipitated from transfected COS-1 cells, suggesting that PDZ domain binding of B ephrins can occur in cells. These results indicate that the carboxyl-terminal motif of B ephrins provides a binding site for specific PDZ domain-containing proteins, which might localize the transmembrane ligands for interactions with Eph receptors or participate in signaling within ephrin B-expressing cells.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Massachusetts Institute of Technology (MIT)	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					[Anonymous], 1997, Cell, V90, P403; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHAO HN, 1994, J BIOL CHEM, V269, P26606; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6	55	211	216	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3726	3733		10.1074/jbc.274.6.3726	http://dx.doi.org/10.1074/jbc.274.6.3726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920925	hybrid			2022-12-27	WOS:000078428200065
J	Agarwal, C; Efimova, T; Welter, JF; Crish, JF; Eckert, RL				Agarwal, C; Efimova, T; Welter, JF; Crish, JF; Eckert, RL			CCAAT/enhancer-binding proteins - A role in regulation of human involucrin promoter response to phorbol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATIN INTERMEDIATE FILAMENTS; TRANSCRIPTION FACTORS C/EBP; ADIPOCYTE DIFFERENTIATION; TRANSGENIC MICE; EXPRESSION; GENE; ENVELOPE; FAMILY; ALPHA; CELLS	The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) is a potent inducer of keratinocyte differentiation and of involucrin gene expression. In the present study we show that a CCAAT/enhancer-binding protein (C/EBP) site in the proximal regulatory region is required for the phorbol ester response. Mutation of the C/EBP site results in the loss of basal and TPA-responsive activity. Gel mobility supershift analysis shows that C/EBP alpha binding to this site is increased by TPA treatment. Moreover, cotransfection of the human involucrin reporter plasmid with C/EBP alpha increases promoter activity to an extent comparable with TPA treatment. Mutation of the C/EBP-binding site eliminates these responses. Transfection experiments using GADD153 to create C/EBP-null conditions confirm that C/EBP factors are absolutely required for promoter activity and TPA responsiveness. C/EBP alpha and C/EBP delta inhibit both TPA- and C/EBP alpha-dependent promoter activation, indicating functional differences among C/EBP family members. These results suggest that C/EBP transcription factor activity is necessary for basal promoter activity and TPA response of the involucrin gene.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm 532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu		Efimova, Tatiana/0000-0002-9869-1545	NIAMS NIH HHS [AR41456, AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, R55AR041456, P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Chowdhury S, 1996, EUR J BIOCHEM, V236, P500, DOI 10.1111/j.1432-1033.1996.00500.x; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P407; Lane MD, 1996, INT J OBESITY, V20, pS91; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 1998, J INVEST DERMATOL, V110, P493; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT LM, 1992, BLOOD, V80, P1725; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1994, J INVEST DERMATOL, V103, pS19, DOI 10.1111/1523-1747.ep12398900; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; Sun TT, 1984, CANCER CELLS, V1, P169; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang H, 1996, J VIROL, V70, P4839, DOI 10.1128/JVI.70.7.4839-4844.1996; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	43	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6190	6194		10.1074/jbc.274.10.6190	http://dx.doi.org/10.1074/jbc.274.10.6190			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037704	hybrid			2022-12-27	WOS:000078902800026
J	Ali, H; Richardson, RM; Haribabu, B; Snyderman, R				Ali, H; Richardson, RM; Haribabu, B; Snyderman, R			Chemoattractant receptor cross-desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PLATELET-ACTIVATING-FACTOR; PHOSPHOLIPASE-C; PEPTIDE CHEMOATTRACTANTS; INTERLEUKIN-8 RECEPTOR; LEUKOCYTE ACTIVATION; RBL-2H3 CELLS; IL-8 RECEPTOR; GAMMA-SUBUNIT; G-PROTEINS; PHOSPHORYLATION		Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Snyderman, R (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3701, Durham, NC 27710 USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038910, R29AI038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-037838] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; Ali H, 1997, MED CLIN N AM, V81, P1, DOI 10.1016/S0025-7125(05)70503-4; Ali H, 1996, J BIOL CHEM, V271, P3200, DOI 10.1074/jbc.271.6.3200; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Blackwood RA, 1996, J LEUKOCYTE BIOL, V60, P88, DOI 10.1002/jlb.60.1.88; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Choe H, 1998, SEMIN IMMUNOL, V10, P249, DOI 10.1006/smim.1998.0127; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HENSON PM, 1981, J IMMUNOL, V127, P754; HIDE M, 1991, MOL PHARMACOL, V40, P473; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LIGGETT SB, 1994, REGULATION CELLULAR, V3, P71; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; MOSER B, 1991, J BIOL CHEM, V266, P10666; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NACCACHE PH, 1979, J CELL PHYSIOL, V100, P239, DOI 10.1002/jcp.1041000205; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PHILIPS MR, 1995, P NATL ACAD SCI USA, V92, P2283, DOI 10.1073/pnas.92.6.2283; PIKE MC, 1982, CELL, V28, P107, DOI 10.1016/0092-8674(82)90380-4; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Reed Randall R., 1994, Seminars in Cell Biology, V5, P33, DOI 10.1006/scel.1994.1005; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Snyderman R, 1984, Contemp Top Immunobiol, V14, P1; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P412; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; WILDE MW, 1989, J BIOL CHEM, V264, P190; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	52	226	233	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6027	6030		10.1074/jbc.274.10.6027	http://dx.doi.org/10.1074/jbc.274.10.6027			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037679	hybrid, Green Published			2022-12-27	WOS:000078902800001
J	Al-Shami, A; Naccache, PH				Al-Shami, A; Naccache, PH			Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils - Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GM-CSF; PROTEIN-TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE; BETA-SUBUNIT; CELL-LINE; CYTOPLASMIC DOMAINS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; FAMILY MEMBERS; JANUS KINASES	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates many of the biological activities of human neutrophils. The signaling pathways via which these effects are mediated are not fully understood. We have shown previously that GM-CSF treatment of human neutrophils activates the Janus kinase/signal transducers and activators of transcription (Jak/STAT) pathway and, more specifically, Jak2, STAT3, and STAT5B in neutrophils. GM-CSF also stimulates the activity of the phosphatidylinositol 3-kinase (PI3-kinase) in a tyrosine kinase-dependent manner. Here we report that pretreating the cells with a Jak2 inhibitor (AG-490) abolishes tyrosine phosphorylation of the p85 subunit of PI3-kinase induced by GM CSF. Furthermore, p85 was found to associate with Jak2, but not with Lyn, in stimulated cells in situ and with its autophosphorylated form in vitro; however, Jak2 did not bind to either of the two Src homology 2 (SH2) domains of the p85 subunit of PI3-kinase. Although STAT5B bound to the carboxyl-terminal SH2 domain of p85, it was absent from the complex containing PI3-kinase and Jak2. These results suggest that stimulation of the activity of PI3-kinase induced by GM-CSF is mediated by Jak2 and that the association between Jak2 and p85 depends on an adaptor protein yet to be identified.	CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Med, Fac Med, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Naccache, PH (corresponding author), CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		Al-Shami, Amin/D-3889-2009					Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; ATKINSON YH, 1988, IMMUNOLOGY, V64, P519; Belova LA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P563; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CLARK SC, 1988, INT J CELL CLONING, V6, P365, DOI 10.1002/stem.5530060602; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1993, BIOCHEM J, V291, P211, DOI 10.1042/bj2910211; Hallett MB, 1997, BIOESSAYS, V19, P615, DOI 10.1002/bies.950190712; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LI Y, 1995, J IMMUNOL, V155, P2165; LINNEKIN D, 1995, J BIOL CHEM, V270, P4950, DOI 10.1074/jbc.270.9.4950; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MCCOLL SR, 1991, BLOOD, V78, P1842; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; Naccache PH, 1997, J LEUKOCYTE BIOL, V62, P901, DOI 10.1002/jlb.62.6.901; NACCACHE PH, 1991, CELL SIGNAL, V3, P635, DOI 10.1016/0898-6568(91)90040-2; NACCACHE PH, 1988, J IMMUNOL, V140, P3541; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NATHAN CF, 1989, BLOOD, V73, P301; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POWIS G, 1994, CANCER METAST REV, V13, P91, DOI 10.1007/BF00690420; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAPOPORT AP, 1992, BLOOD REV, V6, P43, DOI 10.1016/0268-960X(92)90007-D; ROBERTS PJ, 1994, BLOOD, V84, P1064; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; THOMPSON NT, 1995, BIOCHEM SOC T, V23, pS196, DOI 10.1042/bst023196s; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WIESBART RH, 1985, NATURE, V314, P361; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YANO H, 1993, J BIOL CHEM, V268, P25846; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220	76	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5333	5338		10.1074/jbc.274.9.5333	http://dx.doi.org/10.1074/jbc.274.9.5333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026141	hybrid			2022-12-27	WOS:000078804400012
J	Che, SL; El-Hodiri, HM; Wu, CF; Nelman-Gonzalez, M; Weil, MM; Etkin, LD; Clark, RB; Kuang, J				Che, SL; El-Hodiri, HM; Wu, CF; Nelman-Gonzalez, M; Weil, MM; Etkin, LD; Clark, RB; Kuang, J			Identification and cloning of Xp95, a putative signal transduction protein in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; CELL-CYCLE; MAP KINASE; MEIOTIC MATURATION; PHOSPHORYLATION; CDC25; ACTIVATION; MPM-2; GENE; MOS	A 95-kDa protein in Xenopus oocytes, Xp95, was shown to be phosphorylated from the first through the second meiotic divisions during progesterone-induced oocyte maturation. Xp95 was purified and cloned. The Xp95 protein sequence exhibited homology to mouse Rhophilin, budding yeast Bro1, and Aspergillus PalA, all of which are implicated in signal transduction. It also contained three conserved features including seven conserved tyrosines, a phosphorylation consensus sequence for the Src family of tyrosine kinases, and a proline-rich domain near the C terminus that contains multiple SH3 domain-binding motifs. me showed the following: 1) that both Xp95 isolated from Xenopus oocytes and a synthetic peptide containing the Src phosphorylation consensus sequence of Xp95 were phosphorylated in vitro by Src kinase and to a lesser extent by Fyn kinase; 2) Xp95 from Xenopus oocytes or eggs was recognized by an anti-phosphotyrosine antibody, and the relative abundance of tyrosine-phosphorylated Xp95 increased during oocyte maturation; and 3) microinjection of deregulated Src mRNA into Xenopus oocytes increased the abundance of tyrosine-phosphorylated Xp95, These results suggest that Xp95 is an element in a tyrosine kinase signaling pathway that may be involved in progesterone-induced Xenopus oocyte maturation.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Kuang, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.		El-hodiri, Heithem/E-3019-2011		NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048457] Funding Source: NIH RePORTER; NCI NIH HHS [CA09299] Funding Source: Medline; NIGMS NIH HHS [R-29 GM48457-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; COOK R, 1994, PROTEIN BLOTTING PRA, V1, P207; Cork R. John, 1994, Zygote, V2, P289; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GEAHLEN RL, 1990, PEPT PROT PHOSPH, P239; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUANG J, 1991, DEV BIOL, V144, P54, DOI 10.1016/0012-1606(91)90478-L; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; MILLER M, 1991, DEVELOPMENT, V113, P569; MOSES RM, 1989, EXP CELL RES, V185, P271, DOI 10.1016/0014-4827(89)90055-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; Nigg E A, 1991, Semin Cell Biol, V2, P261; PASADA J, 1993, MOL CELL BIOL, V13, P2546; PENG HB, 1991, METHOD CELL BIOL, V36, P657; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SMITH LD, 1989, DEVELOPMENT, V107, P685; SPIVACK JG, 1984, MOL CELL BIOL, V4, P1631, DOI 10.1128/MCB.4.8.1631; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	46	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5522	5531		10.1074/jbc.274.9.5522	http://dx.doi.org/10.1074/jbc.274.9.5522			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026166	hybrid			2022-12-27	WOS:000078804400037
J	Endrich, MM; Gehrig, P; Gehring, H				Endrich, MM; Gehrig, P; Gehring, H			Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CRYSTAL-STRUCTURE; GAG PROTEINS; VIRIONS; CORE; RP24	Viral incorporation of cyclophilin A (CS PA) during the assembly of human immunodeficiency virus type-1 (HIV-1) is crucial for efficient viral replication, CyPA binds to the previously identified Gly-Pro(90) site of the capsid protein p24, but its role remained unclear. Here we report two new interaction sites between cyclophilins and p24, Both are located in the C-terminal domain of p24 around Gly-Pro(157) and Gly-Pro(224). Peptides corresponding to these regions showed higher affinities (K-d similar to 0.3 mu M) for both CyPA and cyclophilin B than the best peptide derived from the Gly-Pro(90) site (similar to 8 mu M) and thus revealed new sequence motifs flanking Gly-Pro that are important for tight interaction of peptide ligands with cyclophilins. Between CS PA and an immature (unprocessed) form of p24, a K-d of similar to 8 mu M was measured, which corresponded with the K-d of the best of the Gly-Pro(90) peptides, indicating an association via this site, Processing of immature p24 by the viral protease, yielding mature p24, elicited a conformational change in its C-terminal domain that was signaled by the covalently attached fluorescence label acrylodan. Consequently, CyPA and cyclophilin B bound with much higher affinities (similar to 0.6 and 0.25 mu M) to the new, i.e. maturation-generated sites. Since this domain is essential for p24 oligomerization and capsid cone formation, CyPA bound to the new sites might impair the regularity of the capsid cone and thus facilitate in vivo core disassembly after host infection.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Gehring, H (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gehring@bioc.unizh.ch						Accola MA, 1998, J VIROL, V72, P2072, DOI 10.1128/JVI.72.3.2072-2078.1998; Ackerson B, 1998, J VIROL, V72, P303, DOI 10.1128/JVI.72.1.303-308.1998; Agresta BE, 1997, J VIROL, V71, P6921, DOI 10.1128/JVI.71.9.6921-6927.1997; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; EHRLICH LS, 1992, J VIROL, V66, P4874, DOI 10.1128/JVI.66.8.4874-4883.1992; Endrich MM, 1998, EUR J BIOCHEM, V252, P441, DOI 10.1046/j.1432-1327.1998.2520441.x; Endrich MM, 1996, BIOL CELL, V88, P15, DOI 10.1016/S0248-4900(97)86826-8; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Gay B, 1998, VIROLOGY, V247, P160, DOI 10.1006/viro.1998.9237; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HAUSDORF G, 1994, J VIROL METHODS, V50, P1, DOI 10.1016/0166-0934(94)90158-9; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Jones I, 1996, NAT STRUCT BIOL, V3, P818, DOI 10.1038/nsb1096-818; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Luhan J, 1996, CELL, V87, P1157; McDermott J, 1996, J VIROL, V70, P5106, DOI 10.1128/JVI.70.8.5106-5114.1996; MISSELWITZ R, 1995, BBA-PROTEIN STRUCT M, V1250, P9, DOI 10.1016/0167-4838(95)00041-R; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Vajdos FE, 1997, PROTEIN SCI, V6, P2297; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhao YD, 1997, STRUCTURE, V5, P139, DOI 10.1016/S0969-2126(97)00172-X	34	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5326	5332		10.1074/jbc.274.9.5326	http://dx.doi.org/10.1074/jbc.274.9.5326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026140	hybrid			2022-12-27	WOS:000078804400011
J	Negrutskii, BS; Shalak, VF; Kerjan, P; El'skaya, AV; Mirande, M				Negrutskii, BS; Shalak, VF; Kerjan, P; El'skaya, AV; Mirande, M			Functional interaction of mammalian valyl-tRNA synthetase with elongation factor EF-1 alpha in the complex with EF-1H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; PROTEIN-SYNTHESIS; FACTOR-I; RABBIT LIVER; FACTOR 1-ALPHA; PHOSPHORYLATION; CELLS; FACTOR-1-BETA; PURIFICATION	In mammalian cells valyl-tRNA synthetase (ValRS) forms a high M-r complex with the four subunits of elongation factor EF-1H. The beta, gamma, and delta subunits, that contribute the guanine nucleotide exchange activity of EF-1H, are tightly associated with the NH2-terminal polypeptide extension of valyl-tRNA synthetase, In this study, we have examined the possibility that the functioning of the companion enzyme EF-1 alpha could regulate valyl-tRNA synthetase activity. We show here that the addition of EF-1 alpha and GTP in excess in the aminoacylation mixture is accompanied by a 2-fold stimulation of valyl-tRNA(Val) synthesis catalyzed by the vall-tRNA synthetase component of the ValRS EF-1H complex. This effect is not observed in the presence of EF-1 alpha and GDP or EF-Tu GTP and requires association of valyl-tRNA synthetase within the ValRS EF-1H complex. Since valyl-tRNA synthetase and elongation factor EF-1 alpha catalyze two consecutive steps of the in vivo tRNA cycle, aminoacylation and formation of the ternary complex EF-1 alpha.GTP.Val-tRNA(Val) that serves as a vector of tRNA from the synthetase to the ribosome, the data suggest a coordinate regulation of these two successive reactions. The EF-1 alpha.GTP-dependent stimulation of valyl-tRNA synthetase activity provides further evidence for tRNA channeling during protein synthesis in mammalian cells.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Natl Acad Sci Ukraine, Inst Mol Biol & Genet, UA-232143 Kiev, Ukraine	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	marc.mirande@lebs.cnrs-gif.fr	Shalak, Vyacheslav F/D-3707-2015; Negrutskii, Boris/G-6439-2016	Shalak, Vyacheslav F/0000-0001-6114-6482; Negrutskii, Boris/0000-0001-5974-1629; El'skaya, Anna/0000-0002-7327-4075				ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P293, DOI 10.1093/oxfordjournals.jbchem.a130571; BARBARESE E, 1995, J CELL SCI, V108, P2781; BEC G, 1994, J BIOL CHEM, V269, P2086; BEC G, 1989, J BIOL CHEM, V264, P21131; BEC G, 1989, J BIOL CHEM, V264, P21138; CRECHET JB, 1986, EUR J BIOCHEM, V161, P655, DOI 10.1111/j.1432-1033.1986.tb10490.x; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; Kawaguchi Y, 1998, J VIROL, V72, P1731, DOI 10.1128/JVI.72.3.1731-1736.1998; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Minella O, 1996, EUR J BIOCHEM, V237, P685, DOI 10.1111/j.1432-1033.1996.0685p.x; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1985, EXP CELL RES, V156, P91, DOI 10.1016/0014-4827(85)90264-2; MOTORIN YA, 1991, EUR J BIOCHEM, V201, P325, DOI 10.1111/j.1432-1033.1991.tb16289.x; Negrutskii BS, 1996, FEBS LETT, V382, P18, DOI 10.1016/0014-5793(96)00128-7; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; PALEN E, 1994, BIOCHEMISTRY-US, V33, P8515, DOI 10.1021/bi00194a016; Petrushenko ZM, 1997, FEBS LETT, V407, P13, DOI 10.1016/S0014-5793(97)00242-1; REED VS, 1994, J BIOL CHEM, V269, P32932; Sanders J, 1996, J CELL SCI, V109, P1113; Sheu GT, 1997, J BIOL CHEM, V272, P33290, DOI 10.1074/jbc.272.52.33290; SLOBIN LI, 1981, BIOCHEM BIOPH RES CO, V101, P1388, DOI 10.1016/0006-291X(81)91601-6; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	31	72	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4545	4550		10.1074/jbc.274.8.4545	http://dx.doi.org/10.1074/jbc.274.8.4545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988688	hybrid			2022-12-27	WOS:000078698200013
J	Zong, H; Raman, N; Mickelson-Young, LA; Atkinson, SJ; Quilliam, LA				Zong, H; Raman, N; Mickelson-Young, LA; Atkinson, SJ; Quilliam, LA			Loop 6 of RhoA confers specificity for effector binding, stress fiber formation, and cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ACTIN POLYMERIZATION; INDEPENDENT PATHWAYS; POTENTIAL EFFECTOR; CYCLE PROGRESSION; CRYSTAL-STRUCTURE; RAC REGULATION; INSERT REGION; ACTIVATION; GTPASES	Rho family GTPases regulate multiple cellular processes, including cytoskeletal organization, gene expression, and transformation. These effects are achieved through the interaction of GTP-bound proteins with various downstream targets. A series of RhoA/Rad and Rho/Ras chimeras was generated to map the domain(s) of RhoA involved in its association with two classes of effector kinase, represented by PRK2 and ROCK-I, Although the switch 1 domain was required for effector binding, the N terminus of Rho (residues 1-75) was interchangeable with that of Rac, This suggested that the region of Rho that confers effector binding specificity lay further C-terminal, Subsequent studies indicated that the "insert domain" (residues 123-137), a region unique to Rho family GTPases, is not the specificity determinant. However, a determinant for effector binding was identified between Rho residues 75-92, Rac to Rho point mutations (V85D or A88D) within loop 6 of Rac promoted its association with PRK2 and ROCK, whereas the reciprocal Rho(D87V/D90A) double mutant significantly reduced effector binding capacity. In vivo studies showed that microinjection of Rac(Q6IL/V85D/ A88D) but not Rac(Q6IL)) induced stress fiber formation in LLC-PK epithelial cells, suggesting that loop 6 residues conferred the ability of Rac to activate ROCK. On the other hand, the reciprocal Rho (Q6IL/D87V/D90A) mutant was defective in its ability to transform NM 3T3 cells. These data suggest that although Rho effecters can utilize a Rho or Rac switch I domain to sense the GTP-bound state of Rho, unique residues within loop 6 are essential for determining both effector binding specificity and cellular function.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Div Nephrol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS 4053, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019					Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leung T, 1996, MOL CELL BIOL, V16, P5313; LI L, 1997, J BIOL CHEM, V272, P32830; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MOODIE SA, 1995, ONCOGENE, V11, P447; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SELF AJ, 1993, ONCOGENE, V8, P655; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1993, CIBA F SYMP, V176, P6; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU XM, 1994, J BIOL CHEM, V269, P23569; Yu WP, 1997, J BIOL CHEM, V272, P10030	51	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4551	4560		10.1074/jbc.274.8.4551	http://dx.doi.org/10.1074/jbc.274.8.4551			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988689	hybrid			2022-12-27	WOS:000078698200014
J	Alzuherri, HM; White, RJ				Alzuherri, HM; White, RJ			Regulation of RNA polymerase I transcription in response to F9 embryonal carcinoma stem cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; RIBOSOMAL-RNA; FACTOR UBF; SPECIES-SPECIFICITY; TBP; INDUCTION; SUBUNITS; COMPLEX; GENES; SL1	Dramatic changes in the patterns of transcription are a common feature of early development, We have used F9 embryonal carcinoma cells as a model system to study gene regulation during an early stage of murine embryogenesis, We find that transcription by RNA polymerase I decreases when F9 cells differentiate into parietal endoderm, The reduced rate of transcription is associated with a down-regulation of several components of the Glass I transcription apparatus. The most substantial change involves the essential factor SL1, which is a multisubunit complex that contains the TATA-binding protein and three TATA-binding protein-associated factors (TAFs), The abundance of two of these TAFs, TAAF(I)48 and TAF(I)95, decreases during F9 cell differentiation. Developmental regulation of a specific class of genes may therefore be achieved through changes in the availability of TAFs.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Alzuherri, HM (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland.							Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; CAIRNS C, 1995, NUCLEIC ACIDS RES, V23, P4583, DOI 10.1093/nar/23.22.4583; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAREY MF, 1986, MOL CELL BIOL, V6, P3068, DOI 10.1128/MCB.6.9.3068; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; PAULE MR, 1998, TRANSCRIPTION RIBOSO, pR1; Reeder R. H., 1995, NUCL ACIDS MOL BIOL, V9, P251; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SEGALL J, 1980, J BIOL CHEM, V255, P1986; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VASSEUR M, 1985, EMBO J, V4, P1749, DOI 10.1002/j.1460-2075.1985.tb03846.x; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	29	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4328	4334		10.1074/jbc.274.7.4328	http://dx.doi.org/10.1074/jbc.274.7.4328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933634	hybrid			2022-12-27	WOS:000078575500058
J	Kwong, PD; Wyatt, R; Desjardins, E; Robinson, J; Culp, JS; Hellmig, BD; Sweet, RW; Sodroski, J; Hendrickson, WA				Kwong, PD; Wyatt, R; Desjardins, E; Robinson, J; Culp, JS; Hellmig, BD; Sweet, RW; Sodroski, J; Hendrickson, WA			Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN CRYSTALLIZATION; HUMAN CD4; VARIABLE REGIONS; ATOMIC-STRUCTURE; BINDING; RECEPTOR; RETROVIRUS; INFECTION; ANTIBODY	The extensive glycosylation and conformational mobility of gp120, the envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1), pose formidable barriers for crystallization. To surmount these difficulties, we used probability analysis to determine the most effective crystallization approach and derive equations which show that a strategy, which we term variational crystallization, substantially enhances the overall probability of crystallization for gp120, Variational crystallization focuses on protein modification as opposed to crystallization screening. Multiple variants of gp120 were analyzed with an iterative cycle involving a limited set of crystallization conditions and biochemical feedback on protease sensitivity, glycosylation status, and monoclonal antibody binding. Sources of likely conformational heterogeneity such as N-linked carbohydrates, flexible or mobile N and C termini, and variable internal loops were reduced or eliminated, and ligands such as CD4 and antigen-binding fragments (Fabs) of monoclonal antibodies were used to restrict conformational mobility as well as to alter the crystallization surface. Through successive cycles of manipulation involving 18 different variants, we succeeded in growing six different types of gp120 crystals. One of these, a ternary complex composed of gp120, its receptor CD4, and the Fab of the human neutralizing monoclonal antibody 17b, diffracts to a minimum Bragg spacing of at least 2.2 Angstrom and is suitable for structural analysis.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Dana Farber Canc Inst, Div Human Retrovirol, Boston, MA 02115 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Tulane University; GlaxoSmithKline	Kwong, PD (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Binley JM, 1998, AIDS RES HUM RETROV, V14, P191, DOI 10.1089/aid.1998.14.191; BRAND CM, 1972, NATURE, V87, P713; CARTER CW, 1979, J BIOL CHEM, V254, P2219; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUCRUIX A, CRYSTALLIZATION NUCL; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JARVEST RL, 1993, BIOORG MED CHEM LETT, V3, P2851, DOI 10.1016/S0960-894X(01)80778-2; JORDAN SR, 1985, SCIENCE, V230, P1383; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KELDERS HA, 1987, PROTEIN ENG, V1, P301, DOI 10.1093/protein/1.4.301; KENDREW JC, 1956, P ROY SOC          A, V238, P305; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kovari LC, 1995, STRUCTURE, V3, P1291, DOI 10.1016/S0969-2126(01)00266-0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; KWONG PD, 1999, IN PRESS J APPL CRYS; LANGEDIJK JPM, 1992, ARCH VIROL, V126, P129, DOI 10.1007/BF01309690; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUSTBADER JW, 1989, BIOCHEMISTRY-US, V28, P9239, DOI 10.1021/bi00450a001; LUSTY CJ, 1999, IN PRESS J APPL CRYS; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MORRIS DW, 1989, BIOTECHNIQUES, V7, P522; MYERS G, 1996, HUMAN RETROVIRUSES A; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STURA EA, 1992, J CRYST GROWTH, V122, P273, DOI 10.1016/0022-0248(92)90256-I; TEETER MM, 1979, J MOL BIOL, V127, P219, DOI 10.1016/0022-2836(79)90242-0; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WUKOVITZ SW, 1995, NAT STRUCT BIOL, V2, P1062, DOI 10.1038/nsb1295-1062; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150	63	101	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4115	4123		10.1074/jbc.274.7.4115	http://dx.doi.org/10.1074/jbc.274.7.4115			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933605	hybrid			2022-12-27	WOS:000078575500029
J	Tlapak-Simmons, VL; Baggenstoss, BA; Kumari, K; Heldermon, C; Weigel, PH				Tlapak-Simmons, VL; Baggenstoss, BA; Kumari, K; Heldermon, C; Weigel, PH			Kinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; OLIGODENDROGLIOMA CELLS; BINDING-PROTEINS; ACID SYNTHASE; DG42 GENE; XENOPUS; IDENTIFICATION; SOLUBILIZATION; EXPRESSION; SYNTHETASE	The two hyaluronan synthases (HASs) from Streptococcus pyogenes (spHAS) and Streptococcus equisimilis (seHAS) were expressed in Escherichia colt as recombinant proteins containing His(6) tails, The accompanying paper has described the purification and lipid dependence of both HASs, their preference for cardiolipin, and their stability during storage (Tlapak-Simmons, V. L., Baggenstoss, B. A. Clyne, T., and Weigel, P. H. (1999) J. Biol. Chem. 274, 4239-4245). Kinetic characterization of the enzymes in isolated membranes gave K-m values for UDP-GlcUA of 40 +/- 4 mu M for spHAS and 51 +/- 5 mu M for seHAS, In both cases, the V-max profiles at various concentrations of UDP-GlcNAc were hyperbolic, with no evidence of cooperativity. In contrast, membrane-bound spHAS, but not seHAS, showed sigmoidal behavior as the UDP-GlcNAc concentration was increased, with a Hill number of similar to 2, indicating significant cooperativity, The Hill number for UDP-GlcNAc utilization by seHAS was I, confirming the lack of cooperativity for UDP-GlcNAc in this enzyme. The K-m values for UDP-GlcNAc were 60 +/- 7 mu M for seHAS and 149 +/- 3 mu M for spHAS in the isolated membranes. The kinetic characteristics of the two affinity-purified HAS enzymes were assessed in the presence of cardiolipin after 8-9 days of storage at -80 degrees C without cardiolipin. With increasing storage time, the enzymes showed a gradual increase in their K-m values for both substrates and a decrease in V-max. Even in the presence of cardiolipin, the detergent-solubilized; purified HASs had substantially higher K-m values for both substrates than the membrane-bound enzymes, The KUDP-GlcUA for purified spHAS and seHAS increased 2-4-fold. The KUDP-GlcNAc for spHAS and seHAS increased 4- and 5-fold, respectively. Despite the higher K-m values, the V-max values for the purified HASs were only similar to 50% lower than those for the membrane-bound enzymes. Significantly, purified spHAS displayed the same cooperative interaction with UDP-GlcNAc (n(H) similar to 2), whereas purified seHAS showed no cooperativity.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu		Heldermon, Coy/0000-0002-2148-2868	NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 1983, J SURG RES, V35, P410, DOI 10.1016/0022-4804(83)90030-6; Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; BALAZS EA, 1993, J RHEUMATOL, V20, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cartee RT, 1998, GLYCOBIOLOGY, V8, P1123; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DeAngelis PL, 1995, DEV BIOL STAND, V85, P225; EVERED D, 1989, CIBA F SYMP, V143, P1; FEINBERG RN, 1983, SCIENCE, V220, P1177, DOI 10.1126/science.6857242; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GRESSNER AM, 1995, DIGESTION, V56, P335, DOI 10.1159/000201257; Harwood C., 1990, MOL BIOL METHODS BAC, P1; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAURENT TC, 1987, ACTA OTO-LARYNGOL, P7; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NG KF, 1989, J BIOL CHEM, V264, P11776; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SEMINO AM, 1996, P NATL ACAD SCI USA, V93, P47; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; TlapakSimmons VL, 1997, GLYCOBIOLOGY, V7, P71; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; TURLEY EA, 1985, J CELL SCI, V78, P133; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	51	56	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4246	4253		10.1074/jbc.274.7.4246	http://dx.doi.org/10.1074/jbc.274.7.4246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933624	hybrid			2022-12-27	WOS:000078575500048
J	Chen, YR; Gunther, MR; Mason, RP				Chen, YR; Gunther, MR; Mason, RP			An electron spin resonance spin-trapping investigation of the free radicals formed by the reaction of mitochondrial cytochrome c oxidase with H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE-INDUCED PEROXIDATION; RAT-LIVER MITOCHONDRIA; BOVINE SERUM-ALBUMIN; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; NITRIC-OXIDE; FATTY-ACIDS; OXYGEN; PROTEIN	The reaction of purified bovine mitochondrial cytochrome c oxidase (CcO) and hydrogen peroxide was studied using the ESR spin-trapping technique. A protein-centered radical adduct was trapped by 5,5-dimethyl-1-pyrroline N-oxide and was assigned to a thiyl radical adduct based on its hyperfine coupling constants of a(N) = 14.7 G and a(beta)(H) = 15.7 G. The ESR spectra obtained using the nitroso spin traps 3,5-dibromo-4-nitrosobenzenesulfonic acid (DBNBS) and 2-methyl-2-nitrosopropane (MNP) indicated that both DBNBS/.CcO and MNP/.CcO radical adducts are immobilized nitroxides formed by the trapping of protein-derived radicals. Alkylation of the free thiols on the enzyme with N-ethylmaleimide (NEM) prevented 5,5 dimethyl-1-pyrroline N-oxide adduct formation and changed the spectra of the MNP and DBNBS radical adducts, Nonspecific protease treatment of MNP-d(9)/(NEM)-N-.-CcO converted its spectrum from that of an immobilized nitroxide to an isotropic three-line spectrum characteristic of rapid molecular motion, Super-hyperfine couplings were detected in this spectrum and assigned to the MNP/.tyrosyl adduct(s), The inhibition of either CcO or NEM-CcO with potassium cyanide prevented detectable MNP adduct formation, indicating heme involvement in the reaction. The results indicate that one or more cysteine residues are the preferred reductant of the presumed ferryl porphyrin cation radical residue intermediate. When the cysteine residues are blocked with NEM, one or more tyrosine residues become the preferred reductant, forming the tyrosyl radical.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chen, YR (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	chen6@niehs.nih.gov	Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Brigellius R., 1985, OXIDATIVE STRESS, P243; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Deterding LJ, 1998, J BIOL CHEM, V273, P12863, DOI 10.1074/jbc.273.21.12863; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; GRACEFFA P, 1983, ARCH BIOCHEM BIOPHYS, V225, P802, DOI 10.1016/0003-9861(83)90092-9; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HE DY, 1994, J BIOL CHEM, V269, P2292; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KALYANARAMAN B, 1979, TETRAHEDRON LETT, P4809; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; Konstantinov AA, 1998, BBA-BIOENERGETICS, V1363, P11, DOI 10.1016/S0005-2728(97)00087-X; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P8580, DOI 10.1021/bi952096t; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Prutz W A, 1986, Free Radic Res Commun, V2, P69, DOI 10.3109/10715768609088056; PRUTZ WA, 1990, NATO ADV SCI I A-LIF, V197, P389; PRUTZ WA, 1987, RADIAT RES, V2, P134; REINHECKEL T, 1995, BBA-BIOMEMBRANES, V1239, P45, DOI 10.1016/0005-2736(95)00142-P; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; SCHONEICH C, 1989, BIOCHEM BIOPH RES CO, V161, P113, DOI 10.1016/0006-291X(89)91568-4; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; THOMAS JW, 1994, BIOCHEMISTRY-US, V33, P13013, DOI 10.1021/bi00248a010; TRUMPER L, 1988, BIOMED BIOCHIM ACTA, V47, P933; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; Verkhovsky MI, 1996, P NATL ACAD SCI USA, V93, P12235, DOI 10.1073/pnas.93.22.12235; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WISWEDEL I, 1988, BIOCHIM BIOPHYS ACTA, V934, P80, DOI 10.1016/0005-2728(88)90122-3; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YU CA, 1975, J BIOL CHEM, V250, P1383; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P3062, DOI 10.1021/bi971877m; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	53	69	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3308	3314		10.1074/jbc.274.6.3308	http://dx.doi.org/10.1074/jbc.274.6.3308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920871	hybrid			2022-12-27	WOS:000078428200011
J	Garton, AJ; Tonks, NK				Garton, AJ; Tonks, NK			Regulation of fibroblast motility by the protein tyrosine phosphatase PTP-PEST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; SWISS 3T3 CELLS; PHOSPHOTYROSINE-CONTAINING PROTEINS; V-CRK ONCOGENE; GROWTH-FACTOR; SUBSTRATE P130(CAS); SH3 DOMAINS; SRC KINASE; C-SRC	The protein tyrosine phosphatase PTP-PEST is a cytosolic enzyme that displays a remarkable degree of selectivity for tyrosine-phosphorylated p130(Cas) as a substrate, both in vitro and in intact cells, We have investigated the physiological role of PTP-PEST using Rat1 fibroblast-derived stable cell lines that we have engineered to overexpress PTP-PEST. These cell lines exhibit normal levels of tyrosine phosphorylation of the majority of proteins but have significantly lower levels of tyrosine phosphorylation of p130(Cas) than control cells. Initial cellular events occurring following integrin-mediated attachment to fibronectin (cell attachment and spreading) are essentially unchanged in cells overexpressing PTP-PEST; similarly, the extent and time course of mitogen-activated protein kinase activation in response to integrin engagement is unchanged. In contrast, the reduced phosphorylation state of p130(Cas) is associated with a considerably reduced rate of cell migration and a failure of cells overexpressing PTP-PEST to accomplish the normally observed redistribution of p130(Cas) to the leading edge of migrating cells. Furthermore, cells overexpressing PTP-PEST demonstrate significantly reduced levels of association of p130(Cas) with the Crk adaptor protein. Our results suggest that one physiological role of PTP-PEST is to dephosphorylate p130(Cas), thereby controlling tyrosine phosphorylation dependent signaling events downstream of p130(Cas) and regulating cell migration.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.org			NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FINCHAM VJ, EMBO J, V1781, P98; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HABIB T, 1994, J BIOL CHEM, V269, P25243; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; ILLC D, 1995, NATURE, V377, P539; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nievers MG, 1997, J CELL SCI, V110, P389; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RANKIN S, 1994, J BIOL CHEM, V269, P704; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	66	115	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3811	3818		10.1074/jbc.274.6.3811	http://dx.doi.org/10.1074/jbc.274.6.3811			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920935	hybrid			2022-12-27	WOS:000078428200075
J	Shahrestanifar, M; Fan, XM; Manning, DR				Shahrestanifar, M; Fan, XM; Manning, DR			Lysophosphatidic acid activates NF-kappa B in fibroblasts - A requirement for multiple inputs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; RIBOSOMAL S6 KINASE; SWISS 3T3 CELLS; GROWTH-FACTOR; SIGNALING PATHWAYS; MOLECULAR-CLONING; RAT-1 FIBROBLASTS; GENE-EXPRESSION; COUPLED PATHWAY	Lysophosphatidic acid (LPA) is a growth factor that exerts a number of well characterized biological actions on fibroblasts and other cells. In the present study, we investigated the possibility that LPA activates the transcription factor NF-kappa B. NF-kappa B is a target of cytokines, but its activation by other classes of agonists has raised considerable interest in the control of processes such as inflammation and wound healing through varied mechanisms. We find that LPA causes a marked activation of NF-kappa B in Swiss 3T3 fibroblasts as determined by the degradation of I kappa B-alpha in the cytosol and the emergence of kappa B binding activity in nuclear extracts. The EC50 for activation of NF-kappa B is 1-5 mu M, a range similar to that reported for reinitiation of DNA synthesis and activation of the serum response element. Activation of NF-kappa B is attenuated by pertussis toxin and inhibitors of protein kinase C, and it is completely blocked by the Ca2+ chelator BAPTA-AM, The combination of phorbol ester and thapsigargin promotes an activation comparable with that of LPA Activation by LPA is additionally inhibited by tyrphostin A25 but not genistein or AG1478, indicating a selective utilization of protein-tyrosine kinases, and by certain antioxidants, implying a role for reactive oxygen species. The activation is also inhibited by tricyclodecan-9-yl-xanthogenate (D609), implying a requirement for hydrolysis of phosphatidylcholine. The data demonstrate the utilization of multiple pathways in the activation of NF-kappa B by LPA, not inconsistent with the relevance of several families of GTP-binding regulatory proteins.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	manning@pharm.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1990, J BIOL CHEM, V265, P12232; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MARI B, 1994, J BIOL CHEM, V269, P8517; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NOBES CD, 1995, J CELL SCI, V108, P225; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; PERKINS LM, 1994, NUCLEIC ACIDS RES, V22, P450, DOI 10.1093/nar/22.3.450; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHUTZE S, 1992, CELL, V71, P765; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3828	3833		10.1074/jbc.274.6.3828	http://dx.doi.org/10.1074/jbc.274.6.3828			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920937	hybrid			2022-12-27	WOS:000078428200077
J	Yamaguchi, K; Yamaguchi, F; Miyamoto, O; Sugimoto, K; Konishi, R; Hatase, O; Tokuda, M				Yamaguchi, K; Yamaguchi, F; Miyamoto, O; Sugimoto, K; Konishi, R; Hatase, O; Tokuda, M			Calbrain, a novel two EF-hand calcium-binding protein that suppresses Ca2+/calmodulin-dependent protein kinase II activity in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; CALMODULIN-BINDING; RAT-BRAIN; AUTOPHOSPHORYLATION; RELEASE; CELLS; PHOSPHORYLATION; EVOLUTIONARY; ACTIVATION; EXPRESSION	A cDNA clone that encodes a novel Ca2+-binding protein was isolated from a human brain cDNA library. The gene for this clone, termed calbrain, encodes a 70-amino acid polypeptide with a predicted molecular mass of 8.06 kDa, The analysis of deduced amino acid sequence revealed that calbrain contains two putative EF-hand motifs that show significantly high homology to those of the calmodulin (CaM) family rather than two EF-hand protein families. By Northern hybridization analysis, an approximate 1.5-kilobase pair transcript of calbrain was detected exclusively in the brain, and in situ hybridization study revealed its abundant expression in the hippocampus, habenular area in the epithalamus, and in the cerebellum. A recombinant calbrain protein showed a Ca2+ binding capacity, suggesting the functional potency as a regulator of Ca2+-mediated cellular processes. Ca2+/calmodulin-dependent kinase II, the most abundant protein kinase in the hippocampus and strongly implicated in the basic neuronal functions, was used to evaluate the physiological roles of calbrain, Studies in vitro revealed that calbrain competitively inhibited CaM binding to Ca2+/calmodulin-dependent kinase II (K-i = 129 nM) and reduced its kinase activity and autophosphorylation.	Kagawa Med Univ, Fac Med, Dept Physiol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Biol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Pharmacobioinformat, Miki, Kagawa 7610793, Japan	Kagawa University; Kagawa University; Kagawa University	Tokuda, M (corresponding author), Kagawa Med Univ, Fac Med, Dept Physiol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	tokuda@kms.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRESSEN C, 1993, CELL TISSUE RES, V271, P181, DOI 10.1007/BF00318606; BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BRAUN K, 1990, PROG HISTOCHEM CYTOC, V21, pU1; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1980, BIOCHEM J, V258, P313; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DELORENZO RJ, 1981, CELL CALCIUM, V2, P365, DOI 10.1016/0143-4160(81)90026-9; DELORENZO RJ, 1979, P NATL ACAD SCI USA, V76, P1838, DOI 10.1073/pnas.76.4.1838; DESILVA JJR, 1991, BIOL CHEM ELEMENTS, P269; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FISCHER R, 1988, J BIOL CHEM, V263, P17055; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; HAGIWARA T, 1991, J BIOL CHEM, V266, P16401; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HUNTER T, 1991, METHOD ENZYMOL, P274; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOSAKA T, 1993, EXP BRAIN RES, V93, P483; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OCHIISHI T, 1993, BRAIN RES, V610, P97, DOI 10.1016/0006-8993(93)91222-E; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PARMENTIER M, 1987, EUR J BIOCHEM, V170, P207, DOI 10.1111/j.1432-1033.1987.tb13688.x; PERRET C, 1988, J MOL EVOL, V27, P351, DOI 10.1007/BF02101198; RASMUSSEN H, 1977, PHYSIOL REV, V57, P421, DOI 10.1152/physrev.1977.57.3.421; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; RUBIN RP, 1970, PHARMACOL REV, V22, P389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Segel I.H., 1975, ENZYME KINETICS; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; Siesjo B K, 1986, Adv Neurol, V44, P813; VANAMAN TC, 1980, CALCIUM CELL FUNCTIO, V1, P41; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1991, BRAIN RES, V541, P198, DOI 10.1016/0006-8993(91)91019-W; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108; Yoshimura Y, 1997, J BIOL CHEM, V272, P26354, DOI 10.1074/jbc.272.42.26354	60	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3610	3616		10.1074/jbc.274.6.3610	http://dx.doi.org/10.1074/jbc.274.6.3610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920909	hybrid			2022-12-27	WOS:000078428200049
J	Park, PW; Broekelmann, TJ; Mecham, BR; Mecham, RP				Park, PW; Broekelmann, TJ; Mecham, BR; Mecham, RP			Characterization of the elastin binding domain in the cell-surface 25-kDa elastin-binding protein of Staphylococcus aureus (EbpS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; INTEGRIN ALPHA-4-BETA-1; STREPTOCOCCUS-PYOGENES; FIBRONECTIN RECEPTOR; COLLAGEN-BINDING; HEPARAN-SULFATE; IIICS REGION; ADHESIN; DEGRADATION; SEQUENCE	Our previous studies have established that a cell-surface 25-kDa elastin-binding protein of Staphylococcus aureus (EbpS) mediates binding of this pathogen to the extracellular matrix protein elastin. Results from binding assays examining the activity of various EbpS fragments suggested that the elastin recognition domain is contained within the first 59 amino acids. In this report, we have used functional analyses with synthetic peptides and recombinant truncated forms of EbpS to localize the elastin binding domain to a 21-amino acid region contained within residues 14-34 of EbpS. Further evidence for the importance of this domain was obtained by demonstrating that the inhibitory activity of anti-EbpS antibodies on staphylococcal elastin binding was neutralized when these antibodies were pre-absorbed with a truncated recombinant EbpS construct containing residues 1-34. Overlapping synthetic peptides corresponding to EbpS residues 14-36 were then generated and tested for elastin binding activity to define further the elastin binding domain, and results from these studies showed that sequences spanning amino acids Gln(14)-Asp(23), Asp(17)-Asp(23), and Thr(18)-Glu(34) inhibit binding of Staphylococcus aureus to elastin. Our analyses indicate that the hexameric sequence Thr(18)-Asn-Ser-His-Gln-Asp(23) is the minimal sequence common to all active synthetic peptides, proteolytic fragments, and recombinant constructs of EbpS. Furthermore, substitution of Asp(23) with Asn abrogated the blocking activity of the synthetic peptides, demonstrating the requirement for a charged amino acid at this location. The composite data indicate that staphylococcal elastin binding is mediated by a discrete domain defined by short peptide sequences in the amino-terminal extracellular region of EbpS.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.			Park, Pyong Woo/0000-0002-7979-4979	NHLBI NIH HHS [HL41926, HL53325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL053325, R01HL041926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BADDOUR LM, 1994, INFECT IMMUN, V62, P2143, DOI 10.1128/IAI.62.6.2143-2148.1994; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; FLETCHER TS, 1987, BIOCHEMISTRY-US, V26, P7256, DOI 10.1021/bi00397a010; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HOLDERBAUM D, 1986, INFECT IMMUN, V54, P359, DOI 10.1128/IAI.54.2.359-364.1986; HOOK M, 1990, CELL DIFFER DEV, V32, P433, DOI 10.1016/0922-3371(90)90060-A; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0; LIANG OD, 1992, INFECT IMMUN, V60, P899, DOI 10.1128/IAI.60.3.899-906.1992; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; Park PW, 1996, J INVEST DERMATOL, V106, P1075, DOI 10.1111/1523-1747.ep12339292; PARK PW, 1991, J BIOL CHEM, V266, P23399; PARK PW, 1995, INT J BIOCHEM CELL B, V27, P139, DOI 10.1016/1357-2725(94)00086-Q; Park PW, 1996, J BIOL CHEM, V271, P15803, DOI 10.1074/jbc.271.26.15803; PARK PW, 1993, INTERACTIONS ELASTIN; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RAJA RH, 1990, INFECT IMMUN, V58, P2593, DOI 10.1128/IAI.58.8.2593-2598.1990; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SJOBRING U, 1992, INFECT IMMUN, V60, P3601; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; STEFFENSEN B, 1995, J BIOL CHEM, V270, P1155; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x	39	19	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2845	2850		10.1074/jbc.274.5.2845	http://dx.doi.org/10.1074/jbc.274.5.2845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915819	Green Submitted, hybrid			2022-12-27	WOS:000078319500037
J	Armah, DA; Mensa-Wilmot, K				Armah, DA; Mensa-Wilmot, K			S-myristoylation of a glycosylphosphatidylinositol-specific phospholipase C in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; ADENYLATE-CYCLASE; MEMBRANE-FORM; PROTEINS; PALMITOYLATION; PURIFICATION; ANCHOR; ACTIVATION; ACYLATION; MYRISTATE	Covalent modification with lipid can target cytosolic proteins to biological membranes. With intrinsic membrane proteins, the role of acylation can be elusive. Herein, we describe covalent lipid modification of an integral membrane glycosylphosphatidylinositol-specific phospholipase C (GPI-PLC) from the kinetoplastid Trypanosoma brucei. Myristic acid was detected on cysteine residue(s) (i.e. thiomyristoylation). Thiomyristoylation occurred both co- and post-translationally Acylated GPI-PLC was active against variant surface glycoprotein (VSG). The half-life of fatty acid on GPI-PLC was 45 min, signifying the dynamic nature of the modification. Deacylation in vitro decreased activity of GPI-PLC 18-30-fold. Thioacylation, from kinetic analysis, activated GPI-PLC by accelerating the conversion of a GPI-PLC VSG complex to product. Reversible thioacylation is a novel mechanism for regulating the activity of a phospholipase C.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Armah, DA (corresponding author), Univ Georgia, Dept Cellular Biol, 724 Biol Sci, Athens, GA 30602 USA.				NIAID NIH HHS [AI33383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1986, J BIOL CHEM, V261, P1918; Buxbaum LU, 1996, P NATL ACAD SCI USA, V93, P1178, DOI 10.1073/pnas.93.3.1178; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DOERING TL, 1993, J BIOL CHEM, V268, P9215; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FOX JA, 1986, J BIOL CHEM, V261, P5767; Garg N, 1997, J BIOL CHEM, V272, P12482, DOI 10.1074/jbc.272.19.12482; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HEISE N, 1995, MOL BIOCHEM PARASIT, V70, P71, DOI 10.1016/0166-6851(95)00009-P; HERELD D, 1986, J BIOL CHEM, V261, P3813; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; KNOLL LJ, 1995, METHOD ENZYMOL, V250, P405; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; Morris JC, 1997, J BIOL CHEM, V272, P29554, DOI 10.1074/jbc.272.47.29554; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; PATNAIK PK, 1993, MOL BIOCHEM PARASIT, V58, P97, DOI 10.1016/0166-6851(93)90094-E; Rolin S, 1996, J BIOL CHEM, V271, P10844, DOI 10.1074/jbc.271.18.10844; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333	28	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5931	5938		10.1074/jbc.274.9.5931	http://dx.doi.org/10.1074/jbc.274.9.5931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026218	hybrid			2022-12-27	WOS:000078804400089
J	Kaminski, MJ; MacKenzie, CR; Mooibroek, MJ; Dahms, TES; Hirama, T; Houghton, AN; Chapman, PB; Evans, SV				Kaminski, MJ; MacKenzie, CR; Mooibroek, MJ; Dahms, TES; Hirama, T; Houghton, AN; Chapman, PB; Evans, SV			The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces - Demonstration of an intermolecular beta-sheet interaction between V(H) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MALIGNANT-MELANOMA; PLASMON RESONANCE; HUMAN MELANOCYTES; GD3 GANGLIOSIDE; FAB; AFFINITY; IMMUNOTHERAPY	The murine antibody R24 and mouse-human Fv-IgG1(kappa) chimeric antibody chR24 are specific for the cell-surface tumor antigen disialoganglioside GD3. X-ray diffraction and surface plasmon resonance experiments have been employed to study the mechanism of "homophilic binding," in which molecules of R24 recognize and bind to other molecules of R24 though their heavy chain variable domains. R24 exhibits strong binding to liposomes containing disialoganglioside GD3; however, the kinetics are unusual in that saturation of binding is not observed. The binding of chR24 to GD3-bearing liposomes is significantly weaker, suggesting that cooperative interactions involving antibody constant regions contribute to R24 binding of membrane-bound GD3. The crystal structures of the Fabs from R24 and chR24 reveal the mechanism for homophilic binding and confirm that the homophilic and antigen-binding idiotopes are distinct. The homophilic binding idiotope is formed largely by an anti-parallel beta-sheet dimerization between the H2 complementarity determining region (CDR) loops of two Fabs, while the antigen-binding idiotope is a pocket formed by the three CDR loops on the heavy chain. The formation of homophilic dimers requires the presence of a canonical conformation for the H2 CDR in conjunction with participation of side chains. The relative positions of the homophilic and antigen-binding sites allows for a lattice of GD3-specific antibodies to be constructed, which is stabilized by the presence of the cell membrane. This model provides for the selective recognition by R24 of cells that overexpress GD3 on the cell surface.	Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Ottawa; National Research Council Canada; Memorial Sloan Kettering Cancer Center	Evans, SV (corresponding author), Univ Ottawa, Dept Biochem, 451 Smyth, Ottawa, ON K1H 8M5, Canada.	evans@uottawa.ca		Evans, Stephen/0000-0002-0366-4027				ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOON T, 1993, INT J CANCER, V54, P177, DOI 10.1002/ijc.2910540202; BRADY RL, 1992, J MOL BIOL, V227, P253, DOI 10.1016/0022-2836(92)90695-G; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CARUBIA JM, 1984, BIOCHEM BIOPH RES CO, V120, P500, DOI 10.1016/0006-291X(84)91282-8; CAULFIELD MJ, 1990, J BIOL RESP MODIF, V9, P319; CHAPMAN PB, 1990, CANCER RES, V50, P1503; CHAPMAN PB, 1990, J IMMUNOL, V145, P891; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COOPER LJN, 1994, MOL IMMUNOL, V31, P577, DOI 10.1016/0161-5890(94)90165-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GREENSPAN NS, 1987, J IMMUNOL, V138, P285; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; HAKAMORI S, 1981, ANNU REV BIOCHEM, V50, P733; HAMILTON WB, 1993, INT J CANCER, V53, P566, DOI 10.1002/ijc.2910530407; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P614; IRIE RF, 1990, THERAPEUTIC MONOCLON, P75; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kievit E, 1996, BRIT J CANCER, V73, P457, DOI 10.1038/bjc.1996.81; LLOYD KO, 1993, ANN NY ACAD SCI, V690, P50; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; RAYMOND J, 1991, P AN M AM SOC CLIN, V10, P298; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; Sheriff S, 1996, J MOL BIOL, V259, P938, DOI 10.1006/jmbi.1996.0371; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; THURIN J, 1985, J BIOL CHEM, V260, P4556; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; VELDERS MP, 1995, CANCER RES, V55, P4398; YAMAGUCHI Y, 1995, J IMMUNOL METHODS, V181, P259, DOI 10.1016/0022-1759(95)00010-8; Yan XY, 1996, J IMMUNOL, V157, P1582	37	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5597	5604		10.1074/jbc.274.9.5597	http://dx.doi.org/10.1074/jbc.274.9.5597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026176	hybrid			2022-12-27	WOS:000078804400047
J	Liu, Y; Choudhury, P; Cabral, CM; Sifers, RN				Liu, Y; Choudhury, P; Cabral, CM; Sifers, RN			Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glycoprotein for degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT ALPHA-MANNOSIDASE; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; LINKED OLIGOSACCHARIDES; PROTEIN-DEGRADATION; INTRACELLULAR DEGRADATION; MEMBRANE-PROTEIN; HUMAN-DISEASE; CALNEXIN; ASSOCIATION	The role of conformation-based quality control in the early secretory pathway is to eliminate misfolded polypeptides and unassembled multimeric protein complexes from the endoplasmic reticulum, ensuring the deployment of only functional molecules to distal sites. The intracellular fate of terminally misfolded human alpha(1)-antitrypsin was examined in hepatoma cells to identify the functional role of asparagine-linked oligosaccharide modification in the selection of glycoproteins for degradation by the cytosolic proteasome. Proteasomal degradation required physical interaction with the molecular chaperone calnexin. Altered sedimentation of intracellular complexes following treatment with the specific proteasome inhibitor lactacystin, and in combination with mannosidase inhibition, revealed that the removal of mannose from attached oligosaccharides abrogates the release of misfolded alpha(1)-antitrypsin from calnexin prior to proteasomal degradation. Intracellular turnover was arrested with kifunensine, implicating the participation of endoplasmic reticulum mannosidase I in the disposal process. Accelerated degradation occurred in a mannosidase-independent manner and was arrested by lactacystin, in response to the posttranslational inhibition of glucosidase II, demonstrating that the attenuated removal of glucose from attached oligosaccharides functions as the underlying rate-limiting step in the proteasome-mediated pathway. A model is proposed in which the removal of mannose from multiple attached oligosaccharides directs calnexin in the selection of misfolded alpha(1)-antitrypsin for degradation by the proteasome.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Sifers, RN (corresponding author), Baylor Coll Med, Dept Pathol, One Baylor Plaza, Houston, TX 77030 USA.	rsifers@bcm.tmc.edu	Sifers, Richard Norman/AGQ-7262-2022					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; Choudhury P, 1997, NEWS PHYSIOL SCI, V12, P162; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SIFERS RN, 1989, MOL BIOL MED, V6, P127; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; SU K, 1993, J BIOL CHEM, V268, P14301; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	49	207	211	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5861	5867		10.1074/jbc.274.9.5861	http://dx.doi.org/10.1074/jbc.274.9.5861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026209	hybrid			2022-12-27	WOS:000078804400080
J	Wiegmann, K; Schwandner, R; Krut, O; Yeh, WC; Mak, TW; Kronke, M				Wiegmann, K; Schwandner, R; Krut, O; Yeh, WC; Mak, TW; Kronke, M			Requirement of FADD for tumor necrosis factor-induced activation of acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NIEMANN-PICK DISEASE; SIGNALS CELL-DEATH; FACTOR RECEPTOR; TNF-RECEPTOR; NEUTRAL SPHINGOMYELINASE; CYTOPLASMIC DOMAIN; DEFICIENT MICE; PROTEIN; APOPTOSIS	The generation of mice strains deficient for select members of the signaling complex of the 55-kDa tumor necrosis factor receptor (TNF-R55) has allowed the assignment of specific cellular responses to distinct TNF-R55-associated proteins. In particular, the TNF-R55-associated protein FADD seems to be responsible for recruitment and subsequent activation of caspase 8. In this report we demonstrate the requirement of FADD for TNF-induced activation of endosomal acid sphingomyelinase (A-SMase), In primary embryonic fibroblasts from FADD-deficient mice the activation of A-SMase by TNF-R55 ligation was almost completely impaired. This effect is specific in that other TNF responses like activation of NF-kappa B or neutral (N-)SMase remained unaffected. In addition, interleukin-l-induced activation of A-SMase in FADD-deficient cells was unaltered. In FADD(-/-) embryonic fibroblasts reconstituted by transfection with a FADD cDNA expression construct, the TNF responsiveness of A-SMase was restored. The results of this study suggest that FADD, in addition to its role in triggering a proapoptotic caspase cascade, is required for TNF-induced activation of A-SMase.	Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Univ Toronto, Amgen Inst, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Kiel; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Kronke, M (corresponding author), Univ Kiel, Inst Immunol, Brunswiker Str 4, D-24105 Kiel, Germany.							ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; ADAM D, 1995, J BIOL CHEM, V270, P17482; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHUTZE S, 1999, IN PRESS J BIOL CHEM, V274; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	24	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5267	5270		10.1074/jbc.274.9.5267	http://dx.doi.org/10.1074/jbc.274.9.5267			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026132	hybrid			2022-12-27	WOS:000078804400003
J	Bernish, B; van de Rijn, I				Bernish, B; van de Rijn, I			Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GRAM-POSITIVE BACTERIA; MOLECULAR CHARACTERIZATION; M-PROTEIN; SIGNAL-TRANSDUCTION; RNA-POLYMERASE; CLONED GENES; EXPRESSION; CAPSULE; VIRULENCE	Hyaluronic acid production by group A streptococci is regulated by transcriptional control. In this study, transposon mutagenesis of an unencapsulated strain yielded an encapsulated mutant. Two genes homologous to sensors and response regulators of bacterial two-component systems were identified downstream of the transposon insertion. Inactivation of the putative sensor gene, csrS, in three different unencapsulated strains yielded encapsulated mutant strains. Electrophoretic mobility shift assays determined factor(s) in a cytoplasmic extract of an unencapsulated group A streptococcal strain was binding to a double-stranded DNA fragment derived from the has operon promoter. In contrast, similarly prepared cytoplasmic extracts from a csrS deletion mutant did not shift the fragment. The putative response regulator, CsrR, was partially purified and was shown to bind the has operon promoter fragment, The affinity and specificity of CsrR for the fragment were increased significantly after incubation with acetyl phosphate. DNase I footprinting determined that the acetyl phosphate-treated CsrR was binding to key sequences in the promoter and the coding region of hasA. Therefore, a two-component system is repressing the production of hyaluronic acid in group A streptococci using a phosphorylation-dependent binding interaction between the response regulator CsrR and the promoter region of the has operon.	Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University	van de Rijn, I (corresponding author), Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ivr@fubmc.edu	Bernish, Brian/J-9447-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037320] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [AI37320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti S, 1998, MOL MICROBIOL, V28, P343, DOI 10.1046/j.1365-2958.1998.00800.x; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; CHODOSH LA, 1995, CURRENT PROTOCOLS MO, P1; Cleary PP, 1998, MOL MICROBIOL, V28, P157, DOI 10.1046/j.1365-2958.1998.00786.x; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; CRATER DL, 1995, J BIOL CHEM, V270, P28676, DOI 10.1074/jbc.270.48.28676; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; DUNNY GM, 1991, APPL ENVIRON MICROB, V57, P1194, DOI 10.1128/AEM.57.4.1194-1201.1991; GAWRONBURKE C, 1984, J BACTERIOL, V159, P214, DOI 10.1128/JB.159.1.214-221.1984; HEATH A, 1997, 97 GEN M AM SOC MICR, V36, pB45; Husmann LK, 1997, INFECT IMMUN, V65, P1422, DOI 10.1128/IAI.65.4.1422-1430.1997; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; McCleary WR, 1996, MOL MICROBIOL, V20, P1155, DOI 10.1111/j.1365-2958.1996.tb02636.x; Moore DD, 1995, GLOB MOB SURV; Moses AE, 1997, INFECT IMMUN, V65, P64, DOI 10.1128/IAI.65.1.64-71.1997; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PEREZCASAL J, 1992, RES MICROBIOL, V143, P549, DOI 10.1016/0923-2508(92)90112-2; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Podbielski A, 1996, GENE, V177, P137, DOI 10.1016/0378-1119(96)84178-3; PODBIELSKI A, 1995, INFECT IMMUN, V63, P9, DOI 10.1128/IAI.63.1.9-20.1995; RICCI ML, 1994, FEMS MICROBIOL LETT, V119, P47; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; SCOPES RK, 1994, PROTEIN PURIFICATION, P347; SIMPSON WJ, 1990, J BACTERIOL, V172, P696, DOI 10.1128/jb.172.2.696-700.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VANDERIJN I, 1979, INFECT IMMUN, V26, P883, DOI 10.1128/IAI.26.3.883-891.1979; WESSELS MR, 1994, P NATL ACAD SCI USA, V91, P12238, DOI 10.1073/pnas.91.25.12238; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4786	4793		10.1074/jbc.274.8.4786	http://dx.doi.org/10.1074/jbc.274.8.4786			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988717	hybrid			2022-12-27	WOS:000078698200042
J	Paka, L; Kako, Y; Obunike, JC; Pillarisetti, S				Paka, L; Kako, Y; Obunike, JC; Pillarisetti, S			Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains - A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; DEACETYLASE N-SULFOTRANSFERASE; FIBROBLAST GROWTH-FACTOR; CORONARY HEART-DISEASE; SUBENDOTHELIAL MATRIX; CELL-PROLIFERATION; MOLECULAR-CLONING; HUMAN AORTA; PROTEOGLYCAN; ATHEROSCLEROSIS	Reduced heparin and heparan sulfate (HS) proteoglycans (PG) have been observed in both inflammation and atherosclerosis. Methods to increase endogenous heparin and heparan sulfate are not known. We found that incubation of endothelial cells with 500-1,000 mu g/ml high density lipoprotein (HDL) increased (SO4)-S-35 incorporation into PG by 1.5-2.5-fold. A major portion of this increase was in HS and was the result of increased synthesis. Total PG core proteins were not altered by HDL; however, the ratio of (SO4)-S-35 to [H-3]glucosamine was increased by HDL, suggesting increased sulfation of glycosaminoglycans. In addition, HDL increased the amount of highly sulfated heparin-like HS in the subendothelial matrix, HS from HDL-treated cells bound 40 +/- 5% more I-125-antithrombin III (requires 3-O sulfated HS) and 49 +/- 3% fewer monocytes. Moreover, the HS isolated from HDL-treated cells inhibited smooth muscle cell proliferation (by 83 +/- 5%) better than control HS (56 +/- 6%) and heparin (42 +/- 6%). HDL isolated from apolipoprotein E (apoE)-null mice did not stimulate HS production unless apoE was added. ApoE also stimulated HS production in the absence of HDL. ApoE did not increase (SO4)-S-35 incorporation in macrophages and fibroblasts, suggesting that this is an endothelial cell-specific process. Receptor-associated protein inhibited apoE-mediated stimulation of HS only at higher (20 mu g/ml) doses, suggesting the involvement of a receptor-associated protein-sensitive pathway in mediating apoE actions. In summary, our data identify a novel mechanism by which apoE and apoE-containing HDL can be antiatherogenic. Identification of specific apoE peptides that stimulate endothelial heparin/HS production may have important therapeutic applications.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Div Prevent Med, New York, NY 10032 USA	Columbia University; Columbia University	Pillarisetti, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, BB 901,630 W 168th St, New York, NY 10032 USA.	heparin@email.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, R37HL045095] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Alston WK, 1997, J CELL PHYSIOL, V173, P102, DOI 10.1002/(SICI)1097-4652(199710)173:1<102::AID-JCP12>3.3.CO;2-5; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DESILVA HV, 1994, J LIPID RES, V35, P1297; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ENGELBERG H, 1991, SEMIN THROMB HEMOST, V17, P5; Engelberg H, 1997, SEMIN THROMB HEMOST, V23, P159, DOI 10.1055/s-2007-996085; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; GALLIS ZS, 1994, J CLIN INVEST, V94, P2493; GURETZKI HJ, 1994, ATHEROSCLEROSIS, V107, P15, DOI 10.1016/0021-9150(94)90137-6; HOFF HF, 1986, ATHEROSCLEROSIS, V61, P231, DOI 10.1016/0021-9150(86)90143-7; HOLLMANN J, 1989, ARTERIOSCLEROSIS, V9, P154, DOI 10.1161/01.ATV.9.2.154; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kruse R, 1996, BASIC RES CARDIOL, V91, P344; LANIR N, 1988, J IMMUNOL, V140, P2340; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P3; MURATA K, 1989, ATHEROSCLEROSIS, V78, P69, DOI 10.1016/0021-9150(89)90160-3; MURATA K, 1985, STROKE, V16, P687, DOI 10.1161/01.STR.16.4.687; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Patsch W, 1995, Adv Pharmacol, V32, P375, DOI 10.1016/S1054-3589(08)61018-2; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Pillarisetti S, 1997, J CLIN INVEST, V100, P867, DOI 10.1172/JCI119602; Pillarisetti S, 1995, J BIOL CHEM, V270, P29760; PILLARISETTI S, 1992, J BIOL CHEM, V267, P16517; PINHAL MAS, 1995, THROMB HAEMOSTASIS, V74, P1169; PYE DA, 1995, BBA-MOL CELL RES, V1266, P235, DOI 10.1016/0167-4889(95)00012-H; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; RAMASAMY S, 1995, J CELL PHYSIOL, V162, P119, DOI 10.1002/jcp.1041620114; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; RICHARDSON M, 1982, ARTERIOSCLEROSIS, V2, P369, DOI 10.1161/01.ATV.2.5.369; Riddell DR, 1997, J BIOL CHEM, V272, P89; ROSENBERG RD, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)80523-6; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SRINIVASAN SR, 1991, ADV EXP MED BIOL, V285, P373; STINS MF, 1993, J LIPID RES, V34, P1853; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1995, THROMB HAEMOSTASIS, V74, P534; VOLKER W, 1990, EUR HEART J, V11, P29, DOI 10.1093/eurheartj/11.suppl_E.29; WAGNER WD, 1985, ANN NY ACAD SCI, V454, P52, DOI 10.1111/j.1749-6632.1985.tb11844.x; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WIGHT TN, 1985, FED PROC, V44, P381; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1020; WILLIAMS DL, 1985, ANN NY ACAD SCI, V454, P222, DOI 10.1111/j.1749-6632.1985.tb11861.x; WILSON HM, 1993, CLIN CHIM ACTA, V220, P175, DOI 10.1016/0009-8981(93)90046-7	63	39	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4816	4823		10.1074/jbc.274.8.4816	http://dx.doi.org/10.1074/jbc.274.8.4816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988721	hybrid			2022-12-27	WOS:000078698200046
J	Velasco, G; Pendas, AM; Fueyo, A; Knauper, V; Murphy, G; Lopez-Otin, C				Velasco, G; Pendas, AM; Fueyo, A; Knauper, V; Murphy, G; Lopez-Otin, C			Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; HUMAN STROMELYSIN-3; IV COLLAGENASE; CLEAVAGE SITES; GENE FAMILY; SUBSTRATE-SPECIFICITY; CHROMOSOMAL LOCATION; BREAST CARCINOMAS	A cDNA encoding a new human matrix metalloproteinase (MMP), tentatively called MMP-23, has been cloned from an ovary cDNA Library. This protein exhibits sequence similarity with MMPs, but displays a different domain structure. Thus, MMP-23 lacks a recognizable signal sequence and has a short prodomain, although it contains a single cysteine residue that can be part of the cysteine-switch mechanism operating for maintaining enzyme latency. The C-terminal domain is considerably shortened and shows no sequence similarity to hemopexin, whereas all human MMPs, with the exception of matrilysin, contain four hemopexin-like repeats. Furthermore, MMP-23 is devoid of structural features distinctive of the diverse MMP subclasses, including the specific residues located close to the zinc-binding site in collagenases, the transmembrane domain of membrane-type MMPs, or the fibronectin-like domain of gelatinases. Fluorescent in situ hybridization experiments showed that the human MMP-23 gene maps to 1p36, a location which differs from all MMP genes mapped to date. Recombinant MMP-23 produced in Escherichia coli exhibits low, but significant proteolytic activity against a synthetic substrate commonly used for assaying MMPs. Northern blot analysis demonstrated that MMP-23 is predominantly expressed in ovary, testis, and prostate, suggesting that this new MMP may play a specialized role in reproductive processes.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oviedo; University of East Anglia	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	clo@dwarf1.quimica.uniovi.es	Pendas, Alberto M/L-1017-2014; Velasco, Gloria/AAS-5842-2021; López-Otín, Carlos/AAB-2106-2020; Fueyo, Antonio/ABH-3243-2020	Velasco, Gloria/0000-0001-8032-5056; López-Otín, Carlos/0000-0001-6964-1904; Fueyo, Antonio/0000-0002-7121-9398; Knauper, Vera/0000-0002-3965-9924; Pendas, Alberto M/0000-0001-9264-3721				Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Couet J, 1996, J BIOL CHEM, V271, P4545; DEVEREUX J, NUCLEIC ACIDS RES, V12, P387; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Gururajan R, 1998, GENOMICS, V52, P101, DOI 10.1006/geno.1998.5401; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Hulboy DL, 1997, MOL HUM REPROD, V3, P27, DOI 10.1093/molehr/3.1.27; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KINOSHITA T, 1992, P NATL ACAD SCI USA, V89, P4693, DOI 10.1073/pnas.89.10.4693; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LEVY A, 1992, GENOMICS, V13, P881, DOI 10.1016/0888-7543(92)90175-R; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Maniatis T., 1982, MOL CLONING LAB MANU; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MAST AE, 1991, J BIOL CHEM, V266, P15810; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mattei MG, 1997, GENOMICS, V40, P168, DOI 10.1006/geno.1996.4559; MIGNON C, 1995, GENOMICS, V28, P360, DOI 10.1006/geno.1995.1159; MITCHELL TI, 1993, BIOCHIM BIOPHYS ACTA, V1156, P245, DOI 10.1016/0304-4165(93)90038-A; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PENDAS AM, 1994, CYTOGENET CELL GENET, V67, P31, DOI 10.1159/000133792; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; Pendas AM, 1996, GENOMICS, V37, P266, DOI 10.1006/geno.1996.0557; Puente XS, 1996, CANCER RES, V56, P944; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STJEAN PL, 1995, ANN HUM GENET, V59, P17; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yang MZ, 1998, J BIOL CHEM, V273, P17893, DOI 10.1074/jbc.273.28.17893; Yang MZ, 1997, J BIOL CHEM, V272, P13527, DOI 10.1074/jbc.272.21.13527	61	164	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4570	4576		10.1074/jbc.274.8.4570	http://dx.doi.org/10.1074/jbc.274.8.4570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988691	hybrid			2022-12-27	WOS:000078698200016
J	Haggie, PM; Brindle, KM				Haggie, PM; Brindle, KM			Mitochondrial citrate synthase is immobilized in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID CYCLE ENZYMES; P-31 NMR VISIBILITY; SACCHAROMYCES-CEREVISIAE; TCA CYCLE; MALATE-DEHYDROGENASE; FUSION PROTEIN; YEAST; ORGANIZATION; TRANSFORMATION; METABOLITES	The enzymes of the tricarboxylic acid cycle in the mitochondrial matrix are proposed to form a multienzyme complex, in which there is channeling of substrates between enzyme active sites. However no direct evidence has been obtained in vivo for the involvement of these enzymes in such a complex. We have labeled the tricarboxylic acid cycle enzyme, citrate synthase 1, in the yeast Saccharomyces cerevisiae, by biosynthetic incorporation of Fi-fluorotryptophan. Comparison of the F-19 NMR resonance intensities from the labeled enzyme in the intact cell and in cell-free lysates indicated that the enzyme is motionally restricted in vivo, consistent with its participation in a multienzyme complex.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Brindle, KM (corresponding author), Univ Cambridge, Dept Biochem, Old Addenbrookes Site,80 Tennis Court Rd, Cambridge CB2 1GA, England.							ARAGON JJ, 1991, FASEB J, V5, P2945, DOI 10.1096/fasebj.5.14.1752361; BARNES SJ, 1986, FEBS LETT, V201, P267, DOI 10.1016/0014-5793(86)80621-4; Braden M, 1976, Front Oral Physiol, V2, P1; BRINDLE K, 1989, FEBS LETT, V255, P121, DOI 10.1016/0014-5793(89)81073-7; Cantor C.R., 1980, BIOPHYS CHEM; COUSENS DJ, 1990, NUCLEIC ACIDS RES, V18, P1308, DOI 10.1093/nar/18.5.1308; Elcock AH, 1996, BIOCHEMISTRY-US, V35, P12652, DOI 10.1021/bi9614747; FREIFELDER D, 1982, PHYSICAL BIOCH; FUSHIMI K, 1991, J CELL BIOL, V112, P719, DOI 10.1083/jcb.112.4.719; GANCEDO JM, 1973, BIOCHIMIE, V55, P205, DOI 10.1016/S0300-9084(73)80393-1; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; Hubbard SJ, 1993, NACCESS COMPUTER PRO; HUTSON SM, 1989, BIOCHEMISTRY-US, V28, P4325, DOI 10.1021/bi00436a030; HUTSON SM, 1992, BIOCHEMISTRY-US, V31, P1322, DOI 10.1021/bi00120a007; JEFFREY FM, 1989, BIOCHEMISTRY-US, V28, P5323, DOI 10.1021/bi00439a003; Jia YK, 1997, MOL MICROBIOL, V24, P53, DOI 10.1046/j.1365-2958.1997.3011669.x; JONES EW, 1991, J BIOL CHEM, V266, P7963; KISPAL G, 1989, J BIOL CHEM, V264, P11204; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11684, DOI 10.1021/bi00205a003; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11692, DOI 10.1021/bi00205a004; LopezBeltran EA, 1996, J BIOL CHEM, V271, P10648, DOI 10.1074/jbc.271.18.10648; MASSON S, 1992, BIOCHEMISTRY-US, V31, P7488, DOI 10.1021/bi00148a008; McAlisterHenn L, 1997, PROG NUCLEIC ACID RE, V57, P317, DOI 10.1016/S0079-6603(08)60285-8; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; Mitchell CG, 1996, BIOCHEM J, V313, P769, DOI 10.1042/bj3130769; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCALETTAR BA, 1991, P NATL ACAD SCI USA, V88, P8057, DOI 10.1073/pnas.88.18.8057; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; SRERE PA, 1993, BIOL CHEM H-S, V374, P833; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRERE PA, 1995, ADV MOL CEL, V11, P125; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; SUISSA M, 1984, EMBO J, V3, P1781; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; SUMEGI B, 1993, BIOCHEMISTRY-US, V32, P12725, DOI 10.1021/bi00210a022; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Velot C, 1997, BIOCHEMISTRY-US, V36, P14271, DOI 10.1021/bi972011j; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WESTERHOFF HV, 1992, CURR TOP CELL REGUL, V33, P361; Williams SP, 1997, BIOPHYS J, V72, P490, DOI 10.1016/S0006-3495(97)78690-9; WILLIAMS SP, 1993, BIOCHEMISTRY-US, V32, P4895, DOI 10.1021/bi00069a026	46	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3941	3945		10.1074/jbc.274.7.3941	http://dx.doi.org/10.1074/jbc.274.7.3941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933583	hybrid			2022-12-27	WOS:000078575500007
J	Ritz-Laser, B; Estreicher, A; Klages, N; Saule, S; Philippe, J				Ritz-Laser, B; Estreicher, A; Klages, N; Saule, S; Philippe, J			Pax-6 and Cdx-2/3 interact to activate glucagon gene expression on the G(1) control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEIN CDX-2/3; CELL-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENE; PROMOTER ELEMENT; DNA-BINDING; INSULIN GENE; TRANSCRIPTION; IDENTIFICATION; SEQUENCES; CLONING	The promoter element G(1), critical for alpha-cell-specific expression of the glucagon gene, contains two AT-rich sequences important for transcriptional activity. Pax-6, a paired homeodomain protein previously shown to be required for normal alpha-cell development and to interact with the enhancer element G(3) of the glucagon gene, binds as a monomer to the distal AT-rich site of G(1), However, although the paired domain of Pax-6 is sufficient for interaction with the G(3) element, the paired domain and the homeodomain are required for high affinity binding to G(1), In addition to monomer formation, Pax-6 interacts with Cdx-2/3, a caudal-related homeodomain protein binding to the proximal AT-rich site, to form a heterodimer on G(1), Both proteins are capable of directly interacting in the absence of DNA. In BHK-21 cells, Pax-6 activates glucagon gene transcription both through G(1) and G(3), and heterodimerization with Cdx-2/3 on G(1) leads to more than additive transcriptional activation, In glucagon-producing cells, both G(3) and G(1) are critical for basal transcription, and the Pax-6 and Cdx-2/3 binding sites are required for activation. We conclude that Pax-6 is not only critical for cu-cell development but also for glucagon gene transcription by its independent interaction with the two DNA control elements, G(1) and G(3).	Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland; Inst Pasteur, CNRS EP56, Lab Differentiat Cellulaire & Mol, F-59019 Lille, France	University of Geneva; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Ritz-Laser, B (corresponding author), Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland.			Estreicher, Anne/0000-0001-6828-2508				Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; Jin TR, 1996, MOL CELL BIOL, V16, P19; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1991, DNA CELL BIOL, V10, P119, DOI 10.1089/dna.1991.10.119; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584	29	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4124	4132		10.1074/jbc.274.7.4124	http://dx.doi.org/10.1074/jbc.274.7.4124			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933606	hybrid			2022-12-27	WOS:000078575500030
J	Scholz, A; Truss, M; Beato, M				Scholz, A; Truss, M; Beato, M			Hormone-dependent recruitment of NF-Y to the uteroglobin gene enhancer associated with chromatin remodeling in rabbit endometrial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR VIRUS PROMOTER; LIGATION MEDIATED PCR; BINDING FACTOR CBF; TRANSCRIPTIONAL ACTIVATION; MMTV PROMOTER; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; DNA-BINDING; FUNCTIONAL DOMAINS	Expression of the rabbit uteroglobin gene is hormonally induced in cells of the endometrial epithelium during the preimplantation phase of pregnancy. Here we show that progesterone activation of the gene is mediated by two clusters of hormone responsive elements located between 2.4 and 2.7 kilobase pairs upstream of the transcriptional start site. Between these two clusters, genomic footprinting studies in the intact endometrial epithelium reveal the hormone-inducible occupancy of several cis-acting elements. One of the protected elements shows sequence homology to the consensus binding site of the transcription factor NF-Y, which binds to the element in gel shift experiments. This uteroglobin Y box is essential for enhancer activity in transient transfection experiments with endometrial and non-endometrial cell lines, in accordance with the ubiquitous expression of NF-Y. To understand why binding of this ubiquitous factor to the uteroglobin Y box in endometrium depends on hormone induction, we examined the chromatin structure of the relevant gene region. In the uninduced state, the enhancer region appears to be organized into positioned nucleosomes. Upon hormone induction, this nucleosomal pattern is lost and the enhancer region becomes hypersensitive to nucleases, suggesting that a hormone-induced change in the local chromatin structure unmasks previously unaccessible binding sites for transcription factors. Our results emphasize the limitations of using transient transfection assays for the functional analysis of cis-acting elements and underline the need for including the native chromatin organization in this kind of studies.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	beato@imt.uni-marburg.de	Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BEATO M, 1976, EUR J BIOCHEM, V64, P15, DOI 10.1111/j.1432-1033.1976.tb10270.x; BEATO M, 1983, REGULATION GENE EXPR, P151; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1975, CELL TISSUE RES, V165, P1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BLENDY JA, 1995, RECENT PROG HORM RES, V50, P97; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BONDY KL, 1993, NUCLEIC ACIDS RES, V21, P5277, DOI 10.1093/nar/21.22.5277; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CATO ACB, 1984, EMBO J, V3, P2771, DOI 10.1002/j.1460-2075.1984.tb02208.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Eisfeld K, 1997, NUCLEIC ACIDS RES, V25, P3733, DOI 10.1093/nar/25.18.3733; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HEINS B, 1981, MOL CELL ENDOCRINOL, V21, P139, DOI 10.1016/0303-7207(81)90051-4; HELFTENBEIN G, 1993, ONCOGENE, V8, P2075; HELFTENBEIN G, 1991, ANN NY ACAD SCI, V622, P69; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAY E, 1972, BIOCHIM BIOPHYS ACTA, V271, P436, DOI 10.1016/0005-2795(72)90219-X; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENNE C, 1982, P NATL ACAD SCI-BIOL, V79, P4853, DOI 10.1073/pnas.79.16.4853; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUKHERJEE AB, 1993, MOL CELL ENDOCRINOL, V94, pR15, DOI 10.1016/0303-7207(93)90176-K; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; NEULEN J, 1982, MOL CELL ENDOCRINOL, V25, P183, DOI 10.1016/0303-7207(82)90051-X; NISHIDA M, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P1103; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOSKE IG, 1976, BIOL REPROD, V15, P704, DOI 10.1095/biolreprod15.5.704; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RAJKUMAR K, 1983, ENDOCRINOLOGY, V112, P1490, DOI 10.1210/endo-112-4-1490; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVOURET JF, 1980, J BIOL CHEM, V255, P4131; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; SHEN XZ, 1983, ENDOCRINOLOGY, V112, P871, DOI 10.1210/endo-112-3-871; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; Spangenberg C, 1998, J MOL BIOL, V278, P725, DOI 10.1006/jmbi.1998.1718; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WHITSON GL, 1974, SCIENCE, V183, P668, DOI 10.1126/science.183.4125.668; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	86	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4017	4026		10.1074/jbc.274.7.4017	http://dx.doi.org/10.1074/jbc.274.7.4017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933593	hybrid			2022-12-27	WOS:000078575500017
J	Tanaka, K; Horiguchi, K; Yoshida, T; Takeda, M; Fujisawa, H; Takeuchi, K; Umeda, M; Kato, S; Ihara, S; Nagata, S; Fukui, Y				Tanaka, K; Horiguchi, K; Yoshida, T; Takeda, M; Fujisawa, H; Takeuchi, K; Umeda, M; Kato, S; Ihara, S; Nagata, S; Fukui, Y			Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE THYMUS; KINASE-B; 3-KINASE; CELLS; ACTIVATION; ALPHA; PURIFICATION; RECEPTOR; SYSTEM; BRAIN	PIP3BP is a phosphatidylinositol 3,4,5-trisphosphate-binding protein (PIP3BP) abundant in brain, containing a zinc: finger motif and two pleckstrin homology (PH) domains. Staining of rat brain cells with anti-PIP3BP antibody and determination of localization of PIP3BP fused to the green fluorescent protein (GFP-PIP3BP) revealed that PIP3BP was targeted to the nucleus. Targeting was dependent on a putative nuclear localization signal in PIP3BP. Generation of PIP3 in the nucleus was detected in H2O2-treated 293T cells, nerve growth factor (NGF)-treated PC12 cells, and platelet-derived growth factor (PDGF)-treated NIH 3T3 cells. Translocation of phosphatidylinositol 3-kinase (PI 3-kinase) to the nucleus and enhanced activity of PI 3-kinase in the nucleus fraction were observed after H2O2 treatment of 293T cells, suggesting that PI 3-kinase can be activated in the nucleus as well as in the membrane after appropriate stimulation of the cells, Go-expression of the constitutively active PI 3-kinase with PIP3BP resulted in exportation of the protein from the nucleus to the cytoplasm, suggesting that PIP3BP can function as a PIP3-binding protein in the intact cells. These results imply that there may be an unknown function of PI 3-kinase in the nucleus.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, Tokyo 1130032, Japan; Inst Environm Toxicol, Div Toxicol, Mitsukaido, Ibaraki 3030043, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Fukui, Y (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ayfukui@hongo.ecc.u-tokyo.ac.jp	Yoshida, Toshinori/B-7255-2015; Fukui, Yasuhisa/E-8806-2010; Nagata, Satoshi/B-5781-2008	Nagata, Satoshi/0000-0001-9156-5215; Yamada, Kaori/0000-0003-4075-9866				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; FUKUI Y, 1991, ONCOGENE, V6, P407; Fukui Y, 1998, J BIOCHEM-TOKYO, V124, P1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kabuyama Y, 1996, EUR J BIOCHEM, V238, P350, DOI 10.1111/j.1432-1033.1996.0350z.x; Kita Y, 1998, J CELL SCI, V111, P907; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NAGATA S, 1991, HYBRIDOMA, V10, P317, DOI 10.1089/hyb.1991.10.317; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yoshida T, 1998, TOXICOL PATHOL, V26, P411, DOI 10.1177/019262339802600316	30	115	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3919	3922		10.1074/jbc.274.7.3919	http://dx.doi.org/10.1074/jbc.274.7.3919			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933577	hybrid			2022-12-27	WOS:000078575500001
J	Hong, H; Darimont, BD; Ma, H; Yang, L; Yamamoto, KR; Stallcup, MR				Hong, H; Darimont, BD; Ma, H; Yang, L; Yamamoto, KR; Stallcup, MR			An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; RETINOIC ACID; ACTIVATION; SUPERFAMILY; PROTEIN; SRC-1	Transcriptional coactivators of the p160 family (SRC-1, GRIP1, and p/CIP) associate with DNA-bound nuclear receptors (NRs) and help the NRs to recruit an active transcription initiation complex to the promoters of target genes. Previous studies have demonstrated the importance of the NR interaction domain (NID) of p160 proteins containing three NR box motifs (LXXLL) for the interaction with the hormone-binding domains of NRs, Here we report that, in addition to NID, another region of coactivator GRIP1 (amino acids 1011-1121), called the auxiliary NID (NIDaux), is required in vitro and in vivo for efficient interaction with a subset of NRs, including the glucocorticoid receptor (GR), androgen receptor, and retinoic acid receptor cu, A second group of NRs, which includes the progesterone receptor, retinoid X receptor alpha, thyroid hormone receptor beta 1, and vitamin D receptor, required only NID for efficient interaction. For binding to GR, the MD and NIDaux of GRIP1 must act in cis, but deletion of up to 144 amino acids between the two regions did not reduce binding efficiency. Amino acids 1011-1121 of GRIP1 also contain a p300 interaction domain, but mutational analysis indicated that the p300 interaction function within this region is separable from the ability to contribute to GR hormone-binding domain binding. SRC-1 lacks an NIDaux activity equivalent to that in GRIP1.	Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of Southern California; University of California System; University of California San Francisco	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R37CA020535, R01CA020535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NCI NIH HHS [CA20535] Funding Source: Medline; NIDDK NIH HHS [DK43093] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN DG, 1994, MOL ENDOCRINOL, V8, P422, DOI 10.1210/me.8.4.422; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	48	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3496	3502		10.1074/jbc.274.6.3496	http://dx.doi.org/10.1074/jbc.274.6.3496			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920895	hybrid			2022-12-27	WOS:000078428200035
J	Murakami, A; Kimura, K; Nakano, A				Murakami, A; Kimura, K; Nakano, A			The inactive form of a yeast casein kinase I suppresses the secretory defect of the sec12 mutant - Implication of negative regulation by the Hrr25 kinase in the vesicle budding from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MEMBRANE GLYCOPROTEIN; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; STATIONARY-PHASE; GOLGI-APPARATUS; MAP KINASE; TRANSPORT; GENE	Sec12p is the guanine nucleotide exchange factor of Sari GTPase and functions at the very upstream in the vesicle budding reactions from the endoplasmic reticulum (ER). We previously identified three yeast loci, RST1, RST2, and RST3, whose mutations suppressed the temperature-sensitive growth of the sec12-4 mutant (Nakano, A. (1996) J. Biochem. (Tokyo) 120, 642-646). In the present study, we cloned the wild-type RST2 gene by complementation of the cold-sensitive phenotype of the rst2-1 mutant. RST2 turned out to be identical to HRR25, a gene encoding a dual-specificity casein kinase I in yeast. The rst2-1 mutation, which is now renamed hrr25-2, was due to the T176I amino acid replacement in the kinase domain. This mutation remedied not only the temperature-sensitive growth but also the defect of ER-to-Golgi protein transport of sec12. Immunoprecipitation of the hemagglutinin-tagged Hrr25-2 protein and a subsequent protein kinase assay showed that the kinase activity of the mutant protein was markedly reduced. The overproduction of another kinase-minus mutant of Hrr25p (Hrr25p K38A) slightly suppressed the growth defect of sec12-4 as well. These observations suggest that the reduction of the kinase activity in the mutant protein is important for the suppression of sec12. We propose that Hrr25p negatively regulates the vesicle budding from the ER.	RIKEN, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan; Natl Food Res Inst, Genet Engn Lab, Tsukuba, Ibaraki 305, Japan	RIKEN; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Nakano, A (corresponding author), RIKEN, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan.	nakano@postman.riken.go.jp	Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Kimura, Keitarou/B-1589-2010; Nakano, Akihiko/C-6185-2009	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; Kimura, Keitarou/0000-0003-4641-4041; Murakami-Sekimata, Akiko/0000-0002-9417-2377				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Nakano A, 1996, J BIOCHEM-TOKYO, V120, P642; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWELS J, 1991, P NATL ACAD SCI USA, V88, P9548; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANCURA A, 1994, J BIOL CHEM, V269, P19271; Wang XM, 1996, MOL CELL BIOL, V16, P5375; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	34	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3804	3810		10.1074/jbc.274.6.3804	http://dx.doi.org/10.1074/jbc.274.6.3804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920934	hybrid			2022-12-27	WOS:000078428200074
J	Werten, S; Wechselberger, R; Boelens, R; van der Vliet, PC; Kaptein, R				Werten, S; Wechselberger, R; Boelens, R; van der Vliet, PC; Kaptein, R			Identification of the single-stranded DNA binding surface of the transcriptional coactivator PC4 by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSED-FIELD GRADIENTS; RELAXATION; DOMAIN; SPECTROSCOPY; SENSITIVITY; ACTIVATION; HOMOLOGY	The C-terminal domain of the eukaryotic transcriptional cofactor PC4 (PC4(CTD)) is known to bind with nanomolar affinity to single-stranded (ss)DNA. Here, NMR is used to study DNA binding by this domain in more detail. Amide resonance shifts that were observed in a (HN)-H-1-N-15-HSQC-monitored titration of N-15-labeled protein with the oligonucleotide dT(18) indicate that binding of the nucleic acid occurs by means of two anti-parallel channels that were previously identified in the PC4(CTD) crystal structure. The beta-sheets and loops that make up these channels exhibit above average flexibility in the absence of ssDNA, which is reflected in higher values of T-1 rho, reduced heteronuclear nuclear Overhauser effects and faster deuterium exchange rates for the amides in this region. Upon ssDNA binding, this excess flexibility is significantly reduced. The binding of ssDNA by symmetry-related channels reported here provides a structural rationale for the preference of PC4(CTD) for juxtaposed single-stranded regions (e.g. in heteroduplexes) observed in earlier work.	Univ Utrecht, Bijvoet Centrum Biomol Onderzoek, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Lab Fysiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University	Kaptein, R (corresponding author), Univ Utrecht, Bijvoet Centrum Biomol Onderzoek, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Werten, Sebastiaan/AAU-9011-2021; Boelens, Rolf/B-4702-2009	Werten, Sebastiaan/0000-0003-2244-9688; Boelens, Rolf/0000-0002-6939-8913				BALLARD DW, 1988, J BIOL CHEM, V263, P8450; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CAVANAGH J, 1991, J MAGN RESON, V91, P429, DOI 10.1016/0022-2364(91)90209-C; Cavanagh J., 1996, PROTEIN NMR SPECTROS; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; PENG JW, 1994, METHOD ENZYMOL, V239, P563; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Suck D, 1997, NAT STRUCT BIOL, V4, P161, DOI 10.1038/nsb0397-161; Vis H, 1998, J BIOMOL NMR, V11, P265, DOI 10.1023/A:1008208615714; VIS H, 1995, Q MAGN RES BIOL MED, V2, P107; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492	28	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3693	3699		10.1074/jbc.274.6.3693	http://dx.doi.org/10.1074/jbc.274.6.3693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920920	hybrid			2022-12-27	WOS:000078428200060
J	Borland, G; Murphy, G; Ager, A				Borland, G; Murphy, G; Ager, A			Issue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE; TISSUE INHIBITOR; CELL-SURFACE; CHEMOTACTIC FACTORS; TERMINAL DOMAIN; MEL-14 ANTIGEN; IN-VITRO; IDENTIFICATION; DISINTEGRIN	Although the enzyme or enzymes mediating shedding of L-selectin have not yet been identified, this activity can be blocked by synthetic hydroxamic acid-based inhibitors of metalloproteinases such as Ro 31-9790, However, the endogenous matrix metalloproteinase inhibitor tissue inhibitor of metalloproteinases (TIMP)-1 does not block L-selectin shedding. Here, we report that TIMP-3, but not TIMP-2, inhibits L-selectin shedding from mouse and human lymphocytes, Jurkat T cells, and human monocytes, TIMP-3 has an IC50 of 0.3-0.4 mu M on these cell types compared with 0.7-4.8 mu M for Ro 31-9790, A metalloproteinase (tumor necrosis factor-alpha (TNF-alpha)converting enzyme; ADAM17) has recently been identified which cleaves the pro-form of TNF-alpha to produce soluble cytokine, We compared inhibition of L-selectin shedding by TIMPs and Ro 31-9790 with inhibition of TNF-alpha shedding from human monocytes, TIMP-3 inhibited TNF-alpha shedding (IC50 of 0.1 mu M), as did Ro 31-9790 (IC50 of 0.4 mu M). TIMP-2 had a partial effect, and TIMP-1 did not inhibit. This study confirms that L-selectin sheddase is a metalloproteinase, but not a matrix metalloproteinase, and investigates the relationship between shedding of L-selectin and TNF-alpha.	Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	MRC National Institute for Medical Research; University of East Anglia	Ager, A (corresponding author), Natl Inst Med Res, Div Cellular Immunol, Mill Hill,The Ridgeway, London NW7 1AA, England.			Ager, Ann/0000-0002-5763-8908				Ager A, 1997, BIOCHEM SOC T, V25, P421, DOI 10.1042/bst0250421; Allport JR, 1997, J IMMUNOL, V158, P4365; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bennett TA, 1996, J IMMUNOL, V156, P3093; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BORLAND G, 1999, IN PRESS METALLOPROT; BUHRER C, 1992, SCAND J IMMUNOL, V35, P107, DOI 10.1111/j.1365-3083.1992.tb02839.x; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Solomon KA, 1997, J IMMUNOL, V159, P4524; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275	37	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2810	2815		10.1074/jbc.274.5.2810	http://dx.doi.org/10.1074/jbc.274.5.2810			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915814	hybrid			2022-12-27	WOS:000078319500032
J	Mains, RE; Alam, MR; Johnson, RC; Darlington, DN; Back, N; Hand, TA; Eipper, BA				Mains, RE; Alam, MR; Johnson, RC; Darlington, DN; Back, N; Hand, TA; Eipper, BA			Kalirin, a multifunctional PAM COOH-terminal domain interactor protein, affects cytoskeletal organization and ACTH secretion from AtT-20 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PEPTIDE-PROCESSING ENZYME; PLECKSTRIN HOMOLOGY DOMAIN; ROUTING DETERMINANTS; SIGNALING MOLECULES; CYTOSOLIC DOMAIN; MESSENGER-RNA; TUMOR-CELLS; EXPRESSION; MEMBRANE	The production and regulated secretion of bioactive peptides require a series of lumenal enzymes to convert inactive precursors into bioactive peptides plus several cytosolic proteins to govern granule formation, maturation, translocation, and exocytosis. Peptidylglycine alpha-amidating monooxygenase (PAM), an enzyme essential for biosynthesis of many peptides, is an integral membrane protein with trafficking information in both its lumenal and cytosolic domains. Kalirin, a PAM cytosolic domain interactor protein with spectrin-like repeats and GDP/GTP exchange factor activity for Rad, is expressed with PAM in neurons but is not expressed in the anterior pituitary or AtT-20 corticotrope cells. Expression of Kalirin alters the cytoskeletal organization of Chinese hamster ovary and AtT-20 cells expressing membrane PAM. Expression of membrane PARI also alters cytoskeletal organization, demonstrating the presence of endogenous proteins that can mediate this effect. Significant amounts of both PAM and Kalirin fractionate with cytoskeletal elements. Since cytoskeletal organization is critical for exocytosis, constitutive-like and regulated secretions were evaluated. Whereas the constitutive-like secretion of adrenocorticotropic hormone (ACTH) is increased by expression of membrane PAM, regulated secretion is eliminated. Expression of Kalirin in AtT-20 cells expressing membrane PAM restores stimulated secretion of ACTH. Thus, Kalirin or its homologue may be essential for regulated secretion, and the PAM-Kalirin interaction may coordinate intragranular with cytosolic events.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Helsinki, Dept Anat, Inst Biomed, Helsinki 00014, Finland	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Helsinki	Eipper, BA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	beipper@jhmi.edu	Darlington, Daniel/CAG-1917-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R01DK032948, R37DK032948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; ALAM MR, SOC NEUR ABST; ARVAN P, 1991, J BIOL CHEM, V266, P14171; BACK N, 1995, NEUROSCI RES, V22, P267, DOI 10.1016/0168-0102(95)00903-7; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRION C, 1992, J BIOL CHEM, V267, P1477; Calakos N, 1996, PHYSIOL REV, V76, P1; Carbajal ME, 1997, ENDOCRINOLOGY, V138, P5374, DOI 10.1210/en.138.12.5374; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; CUTTITTA F, 1993, ANAT REC, V236, P87, DOI 10.1002/ar.1092360112; Darlington DN, 1997, J HISTOCHEM CYTOCHEM, V45, P1265, DOI 10.1177/002215549704500910; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DEBOLD AJ, 1973, CARDIOVASC RES, V7, P351; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; GEE P, 1993, BRAIN RES, V617, P238, DOI 10.1016/0006-8993(93)91091-6; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; Klumperman J, 1996, J NEUROSCI, V16, P7930; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MAINS RE, 1984, ENDOCRINOLOGY, V115, P1683, DOI 10.1210/endo-115-5-1683; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MAINS RE, 1991, MOL ENDOCRINOL, V5, P187, DOI 10.1210/mend-5-2-187; MARTINEZ A, 1993, J HISTOCHEM CYTOCHEM, V41, P375, DOI 10.1177/41.3.8094086; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NAIK DV, 1973, Z ZELLFORSCH MIK ANA, V142, P305, DOI 10.1007/BF00307355; NER A, 1998, NATURE, V391, P195; Oldham CD, 1997, AM J PHYSIOL-CELL PH, V273, pC1908, DOI 10.1152/ajpcell.1997.273.6.C1908; Paquet L, 1996, MOL CELL ENDOCRINOL, V120, P161, DOI 10.1016/0303-7207(96)03834-8; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHAFER MKH, 1992, J NEUROSCI, V12, P222; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; STEEL JH, 1994, CELL TISSUE RES, V276, P197, DOI 10.1007/BF00354800; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YUN HY, 1995, J BIOL CHEM, V270, P30075; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	74	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2929	2937		10.1074/jbc.274.5.2929	http://dx.doi.org/10.1074/jbc.274.5.2929			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915831	hybrid			2022-12-27	WOS:000078319500049
J	Cranmer, SL; Ulsemer, P; Cooke, BM; Salem, HH; de la Salle, C; Lanza, F; Jackson, SP				Cranmer, SL; Ulsemer, P; Cooke, BM; Salem, HH; de la Salle, C; Lanza, F; Jackson, SP			Glycoprotein (GP) Ib-IX-transfected cells roll on a von Willebrand factor matrix under flow - Importance of the GPIb/actin-binding protein (ABP-280) interaction in maintaining adhesion under high shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(IIB)BETA(3); VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAIN; PLATELETS; COMPLEX; ALPHA; IDENTIFICATION; ATTACHMENT; EXPRESSION; FIBRINOGEN	Adhesion of platelets to sites of vascular injury is critical for hemostasis and thrombosis and is dependent on the binding of the vascular adhesive protein von Willebrand factor (vWf) to the glycoprotein (GP) Ib-V-M complex on the platelet surface. A unique but poorly defined characteristic of this receptor/ligand interaction is its ability to support platelet adhesion under conditions of high shear stress. To examine the structural domains of the GPIb-V-IX complex involved in mediating cell adhesion under flow, we have expressed partial (GPIb-IX), complete (GPIb-V-IX), and mutant (GPIb alpha cytoplasmic tail mutants) receptor complexes on the surface of Chinese hamster ovary (CHO) cells and examined their ability to adhere to a vWf matrix in flow-based adhesion assays. Our studies demonstrate that the partial receptor complex (GPIb-IX) supports CHO cell tethering and rolling on a bovine or human vWf matrix under flow. The adhesion was specifically inhibited by an antiGPI alpha blocking antibody (AK2) and was not observed with CHO cells expressing GPIb beta and GPIX alone. The velocity of rolling was dependent on the level of shear stress, receptor density, and matrix concentration and was not altered by the presence of GPV. In contrast to selectins, which mediate cell rolling under conditions of low shear (20-200 s(-1)), GPIb-IX was able to support cell rolling at both venous (150 s(-1)) and arterial (1500-10,500 s(-1)) shear rates. Studies with a mutant GPIba receptor subunit lacking the binding domain for actin-binding protein demonstrated that the association of the receptor complex with the membrane skeleton is not essential for cell tethering or rolling under low shear conditions, but is critical for maintaining adhesion at high shear rates (3000-6000 s(-1)). These studies demonstrate that the GPIb-IX complex is sufficient to mediate cell rolling on a vWf matrix at both venous and arterial levels of shear independent of other platelet adhesion receptors. Furthermore, our results suggest that the association between GPIb alpha and actin-binding protein plays an important role in enabling cells to remain tethered to a vWf matrix under conditions of high shear stress.	Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia; Monash Univ, Dept Microbiol, Box Hill, Vic 3128, Australia; Box Hill Hosp, Dept Pathol, Box Hill, Vic 3128, Australia; Etablissement Transfus Sanguine, INSERM, U311, F-67065 Strasbourg, France	Monash University; Monash University; Box Hill Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Jackson, SP (corresponding author), Box Hill Hosp, Monash Med Sch, Australian Ctr Blood Dis, Dept Med, Arnold St, Box Hill, Vic 3128, Australia.		Lanza, Francois/H-9252-2016	Lanza, Francois/0000-0002-5802-4748; Jackson, Shaun/0000-0002-4750-1991				ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; COOKE BM, 1993, MICROVASC RES, V45, P33, DOI 10.1006/mvre.1993.1004; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; HUBBE MA, 1981, PROG SURF SCI, V11, P65, DOI 10.1016/0079-6816(81)90009-5; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; Kroll MH, 1996, BLOOD, V88, P1525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MOAKE JL, 1980, THROMB RES, V19, P21, DOI 10.1016/0049-3848(80)90400-4; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; PUSZKIN EG, 1990, BLOOD, V76, P1572; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TURRITO VT, 1980, SCIENCE, V207, P541; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	24	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6097	6106		10.1074/jbc.274.10.6097	http://dx.doi.org/10.1074/jbc.274.10.6097			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037692	hybrid			2022-12-27	WOS:000078902800014
J	Chavin, KD; Yang, SQ; Lin, HZ; Chatham, J; Chacko, VP; Hoek, JB; Walajtys-Rode, E; Rashid, A; Chen, CH; Huang, CC; Wu, TC; Lane, MD; Diehl, AM				Chavin, KD; Yang, SQ; Lin, HZ; Chatham, J; Chacko, VP; Hoek, JB; Walajtys-Rode, E; Rashid, A; Chen, CH; Huang, CC; Wu, TC; Lane, MD; Diehl, AM			Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE; FACTOR-ALPHA; MITOCHONDRIAL; METABOLISM; INTERLEUKIN-6; TRANSPORT; HOMOLOG; INJURY; MICE	Uncoupling protein 2 (UCP2) uncouples respiration from oxidative phosphorylation and may contribute to obesity through effects on energy metabolism. Because basal metabolic rate is decreased in obesity, UCP2 expression is predicted to be reduced. Paradoxically, hepatic expression of UCP2 mRNA is increased in genetically obese (ob/ob) mice, In situ hybridization and immunohistochemical analysis of ob/ob livers demonstrate that UCP2 mRNA and protein expression are increased in hepatocytes, which do not express UCP2 in lean mice. Mitochondria isolated from ob/ob livers exhibit an increased rate of H+ leak which partially dissipates the mitochondrial membrane potential when the rate of electron transport is suppressed. In addition, hepatic ATP stores are reduced and these livers are more vulnerable to necrosis after transient hepatic ischemia. Hence, hepatocytes adapt to obesity by up-regulating UCP2. However, because this decreases the efficiency of energy trapping, the cells become vulnerable to ATP depletion when energy needs increase acutely.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Jefferson University	Diehl, AM (corresponding author), Johns Hopkins Univ, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.	amdiehl@welchlink.welch.jhu.edu			NIAAA NIH HHS [AA09347, AA00173, AA08714] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714, R01AA009347] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Boss O, 1998, LANCET, V351, P1933, DOI 10.1016/S0140-6736(05)78617-7; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; BRADY LJ, 1985, BIOCHEM J, V231, P439, DOI 10.1042/bj2310439; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; Camargo CA, 1997, HEPATOLOGY, V26, P1513, DOI 10.1002/hep.510260619; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FRASER DR, 1983, BIOCHEM J, V214, P163, DOI 10.1042/bj2140163; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Hatano E, 1996, HEPATOLOGY, V24, P663, DOI 10.1002/hep.510240332; KATYARE SS, 1978, ARCH BIOCHEM BIOPHYS, V188, P15, DOI 10.1016/0003-9861(78)90349-1; Keller JN, 1998, J NEUROSCI, V18, P687; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; LEE FYJ, 1999, IN PRESS HEPATOLOGY; MCCULLOUGH AJ, 1991, SEMIN LIVER DIS, V11, P265, DOI 10.1055/s-2008-1040445; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Nedergaard J., 1992, MOL MECH BIOENERGETI, P385; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nicholls DG, 1997, BIOSCIENCE REP, V17, P251, DOI 10.1023/A:1027376426860; NICHOLLS DG, 1992, BIOENERGETICS INTRO; Nordfors L, 1998, DIABETOLOGIA, V41, P935, DOI 10.1007/s001250051010; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; PORTER RK, 1995, AM J PHYSIOL-REG I, V269, pR1213, DOI 10.1152/ajpregu.1995.269.5.R1213; Ricquier D, 1998, BIOCHEM SOC T, V26, P120, DOI 10.1042/bst0260120; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; SAAD B, 1995, EUR J BIOCHEM, V229, P349, DOI 10.1111/j.1432-1033.1995.0349k.x; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALAJTYSRHODE E, 1992, J BIOL CHEM, V267, P370; Walder K, 1998, HUM MOL GENET, V7, P1431, DOI 10.1093/hmg/7.9.1431; WASSERMAN DH, 1991, AM J PHYSIOL, V260, pE811, DOI 10.1152/ajpendo.1991.260.6.E811; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	48	366	391	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5692	5700		10.1074/jbc.274.9.5692	http://dx.doi.org/10.1074/jbc.274.9.5692			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026188	hybrid			2022-12-27	WOS:000078804400059
J	Galbiati, F; Volonte, D; Meani, D; Milligan, G; Lublin, DM; Lisanti, MP; Parenti, M				Galbiati, F; Volonte, D; Meani, D; Milligan, G; Lublin, DM; Lisanti, MP; Parenti, M			The dually acylated NH2-terminal domain of G(i1 alpha) is sufficient to target a green fluorescent protein reporter to caveolin-enriched plasma membrane domains - Palmitoylation of caveolin-1 is required for the recognition of dually acylated G-protein alpha subunits in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL MOTIF; TYROSINE KINASES; FATTY ACYLATION; CARDIAC MYOCYTES; RECEPTOR; ACTIVATION; LOCALIZATION; CELLS; MYRISTOYLATION; PALMITYLATION	Here we investigate the molecular mechanisms that govern the targeting of G-protein cr subunits to the plasma membrane. For this purpose, we used G(i1 alpha), as a model dually acylated G-protein, We fused full-length G(i1 alpha) or its extreme NH2-terminal domain (residues 1-32 or 1-122) to green fluorescent protein (GFP) and analyzed the subcellular localization of these fusion proteins. We show that the first 32 amino acids of G(i1 alpha) are sufficient to target GFP to caveolin-enriched domains of the plasma membrane in vivo, as demonstrated by cofractionation and co-immunoprecipitation with caveolin-1, Interestingly, when dual acylation of this 32-amino acid domain was blocked by specific point mutations (G2A or C3S), the resulting GFP fusion proteins were localized to the cytoplasm and excluded from caveolin-rich regions. The myristoylated but nonpalmitoylated (C3S) chimera only partially partitioned into caveolin-containing fractions. However, both nonacylated GFP fusions (G2A and C3S) no longer co-immunoprecipitated with caveolin-1, Taken together, these results indicate that lipid modification of the NH2-terminal of G(i1 alpha) is essential for targeting to its correct destination and interaction with caveolin-1, Also, a caveolin-1 mutant lacking all three palmitoylation sites (C133S, C143S, and C156S) was unable to co-immunoprecipitate these dually acylated GFP-G-protein fusions, Thus, dual acylation of the NH2-terminal domain of G(i1 alpha) and palmitoylation of caveolin-1 are both required to stabilize and perhaps regulate this reciprocal interaction at the plasma membrane in vivo. Our results provide the first demonstration of a functional role for caveolin-1 palmitoylation in its interaction with signaling molecules.	Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Mol Biol & Biochem, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Milan; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Glasgow; Washington University (WUSTL)	Parenti, M (corresponding author), Univ Milan, Sch Med, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	marco.parenti@unimi.it	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Milligan, Graeme/F-9426-2011; Galbiati, Ferruccio/AAF-3527-2020	Lisanti, Michael/0000-0003-2034-1382; Milligan, Graeme/0000-0002-6946-3519; 				ALLAND L, 1994, J BIOL CHEM, V269, P16701; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Brown RE, 1998, J CELL SCI, V111, P1; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MAGEE AI, 1995, METHOD ENZYMOL, V250, P330; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, CELL MOL BIOL, V43, P293; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wise A, 1997, BIOCHEMISTRY-US, V36, P10620, DOI 10.1021/bi9702997; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zlatkine P, 1997, J CELL SCI, V110, P673	43	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5843	5850		10.1074/jbc.274.9.5843	http://dx.doi.org/10.1074/jbc.274.9.5843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026207	hybrid			2022-12-27	WOS:000078804400078
J	Garcia-Guzman, M; Dolfi, F; Russello, M; Vuori, K				Garcia-Guzman, M; Dolfi, F; Russello, M; Vuori, K			Cell adhesion regulates the interaction between the docking protein p130(Cas) and the 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; SH3 DOMAINS; T-CELLS; V-CRK; SUBSTRATE P130(CAS); DIRECT BINDING; SRC KINASE	Integrin Ligand binding induces a signaling complex formation via the direct association of the docking protein p130(Cas) (Cas) with diverse molecules. We report here that the 14-3-3 zeta protein interacts with Cas in the yeast two-hybrid assay, we also found that the two proteins associate in mammalian cells and that this interaction takes place in a phosphoserine-dependent manner, because treatment of Cas with a serine phosphatase greatly reduced its ability to bind 14-3-3 zeta. Furthermore, the Cas-14-3-3 zeta interaction was found to be regulated by integrin-mediated cell adhesion. Thus, when cells are detached from the extracellular matrix, the binding of Cas to 14-3-3 zeta is greatly diminished, whereas replating the cells onto fibronectin rapidly induces the association. Consistent with these results, we found that the subcellular localization of Cas and 14-3-3 is also regulated by integrin ligand binding and that the two proteins display a significant co-localization during cell attachment to the extracellular matrix. In conclusion, our results demonstrate that 14-3-3 proteins participate in integrin-activated signaling pathways through their interaction with Gas, which, in turn, may contribute to important biological responses regulated by cell adhesion to the extracellular matrix.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@ljcrf.edu			NATIONAL CANCER INSTITUTE [R01CA071560] Funding Source: NIH RePORTER; NCI NIH HHS [CA71560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Burnham MR, 1996, ONCOGENE, V12, P2467; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Golemis EA, 1997, YEAST 2 HYBRID SYSTE, P43; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Ishino M, 1995, ONCOGENE, V11, P2331; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Law SF, 1996, MOL CELL BIOL, V16, P3327; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nojima Y, 1996, Hum Cell, V9, P169; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINGER II, 1982, J CELL BIOL, V92, P398, DOI 10.1083/jcb.92.2.398; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	63	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5762	5768		10.1074/jbc.274.9.5762	http://dx.doi.org/10.1074/jbc.274.9.5762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026197	hybrid			2022-12-27	WOS:000078804400068
J	Grant, PA; Eberharter, A; John, S; Cook, RG; Turner, BM; Workman, JL				Grant, PA; Eberharter, A; John, S; Cook, RG; Turner, BM; Workman, JL			Expanded lysine acetylation specificity of Gcn5 in native complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVE X-CHROMOSOME; HISTONE ACETYLATION; CHROMATIN STRUCTURE; YEAST; TRANSCRIPTION; H4; H3; REPRESSION; IDENTIFICATION; PROTEINS	The coactivator/adaptor protein Gcn5 is a conserved histone acetyltransferase, which functions as the catalytic subunit in multiple yeast transcriptional regulatory complexes. The ability of Gcn5 to acetylate nucleosomal histones is significantly reduced relative to its activity on free histones, where it predominantly modifies histone H3 at lysine 14. However, the association of Gcn5 in multisubunit complexes potentiates its nucleosomal histone acetyltransferase activity. Here, we show that the association of Gcn5 with other proteins in two native yeast complexes, Ada and SAGA (Spt-Ada-Gcn5-acetyltransferase), directly confers upon Gcn5 the ability to acetylate an expanded set of lysines on H3. Furthermore Ada and SAGA have overlapping, yet distinct, patterns of acetylation, suggesting that the association of specific subunits determines site specificity.	Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Baylor College of Medicine; University of Birmingham	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jlw10@psu.edu			NIGMS NIH HHS [GM47867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047867, R37GM047867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belyaev ND, 1996, HUM GENET, V97, P573; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Candau R, 1996, MOL CELL BIOL, V16, P593; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Stein P, 1997, MOL REPROD DEV, V47, P421, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;421::AID-MRD8&gt;3.0.CO;2-M; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	48	285	304	5	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5895	5900		10.1074/jbc.274.9.5895	http://dx.doi.org/10.1074/jbc.274.9.5895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026213	hybrid			2022-12-27	WOS:000078804400084
J	Kuzuguchi, T; Morita, Y; Sagami, I; Sagami, H; Ogura, K				Kuzuguchi, T; Morita, Y; Sagami, I; Sagami, H; Ogura, K			Human geranylgeranyl diphosphate synthase - cDNA cloning and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL PYROPHOSPHATE SYNTHETASE; NUCLEAR RECEPTOR; ALPHA-SUBUNIT; PROTEINS; PURIFICATION; CELLS; CHROMATOGRAPHY; IDENTIFICATION; TRANSFERASE; STIMULATION	Geranylgeranyl diphosphate (GGPP) synthase (GGPPSase) catalyzes the synthesis of GGPP, which is an important molecule responsible for the C-20-prenylated protein biosynthesis and for the regulation of a nuclear hormone receptor (LXR.RXR). The human GGPPSase cDNA encodes a protein of 300 amino acids which shows 16%, sequence identity with the known human farnesyl diphosphate (FPP) synthase (FPPSase). The GGPPSase expressed in Escherichia coli catalyzes the GGPP formation (240 nmol/min/mg) from FPP and isopentenyl diphosphate. The human GGPPSase behaves as an oligomeric molecule with 280 kDa on a gel filtration column and cross-reacts with an antibody directed against bovine brain GGPPSase, which differs immunochemically from bovine brain FPPSase. Northern blot analysis indicates the presence of two forms of the mRNA.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, H (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	yasagami@icrs.tohoku.ac.jp	fujimura, yuiko/M-7393-2013; Morita-fujimura, Yuiko/N-4804-2014					ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARTLETT DL, 1985, METHOD ENZYMOL, V110, P171; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; ITOH T, 1993, J BIOL CHEM, V268, P3025; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LUTZ RJ, 1992, J BIOL CHEM, V267, P7983; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RINE J, 1990, New Biologist, V2, P219; SAGAMI H, 1993, J BIOCHEM-TOKYO, V114, P118, DOI 10.1093/oxfordjournals.jbchem.a124125; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SAGAMI H, 1992, J LIPID RES, V33, P1857; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEPPLORENZINO L, 1991, EUR J BIOCHEM, V200, P579, DOI 10.1111/j.1432-1033.1991.tb16221.x; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	36	46	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5888	5894		10.1074/jbc.274.9.5888	http://dx.doi.org/10.1074/jbc.274.9.5888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026212	hybrid			2022-12-27	WOS:000078804400083
J	Munaut, C; Salonurmi, T; Kontusaari, S; Reponen, P; Morita, T; Foidart, JM; Tryggvason, K				Munaut, C; Salonurmi, T; Kontusaari, S; Reponen, P; Morita, T; Foidart, JM; Tryggvason, K			Murine matrix metalloproteinase 9 gene - 5 '-upstream region contains cis-acting elements for expression in osteoclasts and migrating keratinocytes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; BASEMENT-MEMBRANE COLLAGEN; HUMAN COLON-CANCER; MESSENGER-RNA; MOUSE DEVELOPMENT; GELATINASE-B; TUMOR-CELLS; ALVEOLAR MACROPHAGES; MOLECULAR-CLONING; EPITHELIAL-CELLS	Knowledge about the regulation of cell lineage-specific expression of extracellular matrix metalloproteinases is limited. In the present work, the murine matrix metalloproteinase 9 (MMP-9) gene was shown to contain 13 exons, and the 2.8-kilobase pair upstream region was found to contain several common promoter elements including a TATA boxlike motif, three GC boxes, four AP-1-like binding sites, an AP-2 site, and three PEA3 consensus sequences that may be important for basic activity of the gene. In order to identify cell-specific regulatory elements, constructs containing varying lengths of the upstream region in front of a LacZ reporter gene were made and studied for expression in transgenic mice generated by microinjection into fertilized oocytes. Analyses of the mice revealed that the presence of sequences between -2722 and -7745 allowed for expression in osteoclasts and migrating keratinocytes, ie. cells that have been shown to normally express the enzyme in vivo. The results represent the first in vivo demonstration of the location of cell-specific control elements in a matrix metalloproteinase gene and show that element(s) regulating most cell-specific activities of 92-kDa type collagenase are located in the -2722 to -7745 base pair region.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Liege, Dept Biol, B-4000 Liege, Belgium; Univ Oulu, Bioctr, FIN-90570 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland	Karolinska Institutet; University of Liege; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.	karl.tryggvason@mbh.ki.se	Salonurmi, Tuire/L-3637-2018; Munaut, Carine/K-8138-2019	Salonurmi, Tuire/0000-0001-5104-5792; 				BANCROFT JD, 1990, THEORY PRATICE HISTO; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DREWS R, 1994, BIOTECHNIQUES, V17, P866; FINI ME, 1994, J BIOL CHEM, V269, P28620; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hogan B, 1986, MANIPULATING MOUSE E, P1; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; METSARANTA M, 1995, DEV DYNAM, V204, P202, DOI 10.1002/aja.1002040211; MUNAUT C, 1994, ANN NY ACAD SCI, V732, P369, DOI 10.1111/j.1749-6632.1994.tb24756.x; Nielsen BS, 1996, INT J CANCER, V65, P57, DOI 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F; POULSOM R, 1992, AM J PATHOL, V141, P389; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1992, CANCER RES, V52, P1336; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1992, J BIOL CHEM, V267, P7856; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; SALO T, 1994, LAB INVEST, V70, P176; SALO T, 1983, J BIOL CHEM, V258, P3058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YOKOO T, 1996, J PHYSL, V270, pF123	56	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5588	5596		10.1074/jbc.274.9.5588	http://dx.doi.org/10.1074/jbc.274.9.5588			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026175	Green Published, hybrid			2022-12-27	WOS:000078804400046
J	Nishitani, J; Nishinaka, T; Cheng, CH; Rong, W; Yokoyama, KK; Chiu, R				Nishitani, J; Nishinaka, T; Cheng, CH; Rong, W; Yokoyama, KK; Chiu, R			Recruitment of the retinoblastoma protein to c-jun enhances transcription activity mediated through the AP-1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; SUSCEPTIBILITY GENE; SP1-MEDIATED TRANSCRIPTION; NEGATIVE REGULATOR; CELLULAR PROTEINS; FOS; EXPRESSION; CELLS; DIFFERENTIATION	The retinoblastoma susceptibility gene product (RB) is a transcriptional modulator. One of the targets for this modulator effect is the AP-1 binding site within the c-jun and collagenase promoters. The physical interactions between RE and c-Jun were demonstrated by coimmunoprecipitation of these two proteins using anti-c-Jun or anti-RE antisera, glutathione S-transferase affinity matrix binding assays in vitro, and electrophoretic mobility shift assays. The C-terminal site of the leucine zipper of c-Jun mediated the interaction with RB. Although the B-pocket domain of RE alone bound to c-Jun, a second c-Jun binding site in the RE was also suggested. Mammalian two-hybrid-based assay provided corroborative evidence that transactivation of gene expression by RE required the C-terminal region of c-Jun. me conclude that RE enhances transcription activity mediated through the AP-1 binding site. Adenovirus E1A or human papillomavirus E7 inhibits RE-mediated transcription activity. These data reveal that the interactions between these two distinct classes of oncoproteins RE and c-Jun may be involved in controlling cell growth and differentiation mediated by transcriptional regulation.	Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; RIKEN, Tsukuba Life Sci Ctr, Ibaraki, Osaka 305, Japan	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; RIKEN	Chiu, R (corresponding author), Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Box 951668, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA 66746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2847; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Welter JF, 1995, ONCOGENE, V11, P2681; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANG-YEN H-F, 1990, New Biologist, V2, P351; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	46	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5454	5461		10.1074/jbc.274.9.5454	http://dx.doi.org/10.1074/jbc.274.9.5454			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026157	hybrid			2022-12-27	WOS:000078804400028
J	Trinh, KY; Jin, TR; Drucker, DJ				Trinh, KY; Jin, TR; Drucker, DJ			Identification of domains mediating transcriptional activation and cytoplasmic export in the caudal homeobox protein Cdx-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGLUCAGON GENE-TRANSCRIPTION; HOMEODOMAIN PROTEIN; EPITHELIAL-CELLS; ISLET CELLS; EXPRESSION; INTESTINE; PROMOTER; EXTRADENTICLE; TRANSLOCATION; DOPAMINE	The caudal genes have important functions in embryonic development and cell differentiation. The caudal-related protein Cdx-2/3 (the protein designated Cdx-2 in the mouse and Cdx-3 in the hamster) is expressed in the gastrointestinal epithelium and in islet and enteroendocrine cells, where it activates proglucagon gene transcription. We show here that Cdx-3 sequences aminoterminal to the homeodomain (amino acids 1-180) function as a heterologous transcriptional activation domain when fused to the LexA. DNA binding domain, A Cdx-3-Pit-1 fusion protein containing only the first 83 amino acids of Cdx-3 linked to the POU domain of Pit-1 markedly stimulated the transcriptional activity of a Pit-1-responsive promoter. Analysis of the transcriptional properties of Cdx-3 mutants in fibroblasts and islet cells revealed distinct amino-terminal subdomains that function in a cell-specific manner. Point mutations within the amino-terminal A domain were associated with reduced transcriptional activity. Furthermore, internal deletions and selected point mutations within domain A, but not the B or C domains, resulted in accumulation of mutant Cdx-3 in the cytoplasm, Unexpectedly, mutation of an Asp-Lys-Asp motif within domain A identified a putative cytoplasmic membrane-associated export signal that mediates Cdx-3 compartmentalization, These experiments delineate unique activities for specific amino-terminal sequences that are functionally important for Cdx-3 biological activity.	Univ Toronto, Toronto Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Drucker, DJ (corresponding author), Univ Toronto, Toronto Hosp, Dept Med, Banting & Best Diabet Ctr, 200 Elizabeth St,CCRW3-838, Toronto, ON M5G 2C4, Canada.		Drucker, Daniel J/A-4092-2010					BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen XN, 1997, NUCLEIC ACIDS RES, V25, P682, DOI 10.1093/nar/25.3.682; Doll U, 1996, EUR J CELL BIOL, V70, P260; DRUCKER DJ, 1988, ENDOCRINOLOGY, V123, P1861, DOI 10.1210/endo-123-4-1861; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HORN JM, 1995, HUM MOL GENET, V4, P1041, DOI 10.1093/hmg/4.6.1041; HU YL, 1993, J BIOL CHEM, V268, P27214; Jin TR, 1996, MOL CELL BIOL, V16, P19; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; Joliot A, 1997, DEVELOPMENT, V124, P1865; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; LEW AM, 1995, J BIOL CHEM, V270, P7156, DOI 10.1074/jbc.270.13.7156; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					6011	6019		10.1074/jbc.274.9.6011	http://dx.doi.org/10.1074/jbc.274.9.6011			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026228	hybrid			2022-12-27	WOS:000078804400099
J	de Cock, H; Brandenburg, K; Wiese, A; Holst, O; Seydel, U				de Cock, H; Brandenburg, K; Wiese, A; Holst, O; Seydel, U			Non-lamellar structure and negative charges of lipopolysaccharides required for efficient folding of outer membrane protein PhoE of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE LIPID-A; CHEMICAL-STRUCTURE; INVITRO TRIMERIZATION; SALMONELLA-MINNESOTA; MOLECULAR-BASIS; OMPF; TRANSLOCATION; INSERTION; SYSTEMS; PORIN	Lipopolysaccharides (LPS) are amphiphilic molecules in the outer leaflet of the bacterial outer membrane. Recently, an early role for LPS in the folding of outer membrane porin PhoE was demonstrated in vitro, In order to elucidate the molecular mechanism of LPS-protein interactions, folding of PhoE protein was studied with a large set of well characterized LPS chemotypes. We demonstrate that negative charges in the inner core region contribute to the high efficiency of folding of PhoE protein. In addition, the supramolecular structure of the LPS aggregate seems to be important. LPS with a lipid A part that prefers a lamellar or a direct micellar structure and a high state of order of its acyl chains is much less efficient to support folding as compared with LPS with lipid A that prefers a non-lamellar structure and a low acyl chain order. These in vitro data indicate that extensive interactions between the core and lipid A region of LPS with the protein are required to support protein folding. The LPS-PhoE binding might be promoted by the presence of hydroxy fatty acids in the lipid A moiety of LPS.	Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Res Ctr Borstel, Dept Immunochem, D-23845 Borstel, Germany; Res Ctr Borstel, Dept Biochem Microbiol, D-23845 Borstel, Germany	Utrecht University; Forschungszentrum Borstel; Forschungszentrum Borstel	de Cock, H (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	J.J.P.A.deCock@Bio.UU.NL	de Cock, Hans/B-7790-2011	de Cock, Hans/0000-0002-8420-6764				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCQUETPAGES C, 1981, EUR J BIOCHEM, V118, P105, DOI 10.1111/j.1432-1033.1981.tb05491.x; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOLLA JM, 1988, EMBO J, V7, P3595, DOI 10.1002/j.1460-2075.1988.tb03237.x; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; BRANDENBURG K, 1992, J STRUCT BIOL, V108, P93, DOI 10.1016/1047-8477(92)90010-8; BRANDENBURG K, 1984, BIOCHIM BIOPHYS ACTA, V775, P225, DOI 10.1016/0005-2736(84)90174-3; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; BRANDENBURG K, 1995, BACTERIAL ENDOTOXINS, P167; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; deCock H, 1996, J BIOL CHEM, V271, P12885, DOI 10.1074/jbc.271.22.12885; DECOCK H, 1990, BIOCHIMIE, V72, P177, DOI 10.1016/0300-9084(90)90143-5; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EISELE JL, 1990, J BIOL CHEM, V265, P10217; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HOLST O, 1993, EUR J BIOCHEM, V214, P695, DOI 10.1111/j.1432-1033.1993.tb17970.x; HOLST O, 1998, ENDOTOXINS HLTH DIS; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KAWAHARA K, 1991, FEBS LETT, V292, P107, DOI 10.1016/0014-5793(91)80845-T; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; KOPLOW J, 1974, J BACTERIOL, V117, P527, DOI 10.1128/JB.117.2.527-543.1974; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; Lasch P, 1998, BIOPHYS J, V75, P840, DOI 10.1016/S0006-3495(98)77573-3; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; LUZZATI V, 1993, J MOL BIOL, V229, P540, DOI 10.1006/jmbi.1993.1053; MAYER H, 1990, ADV EXP MED BIOL, V256, P45; MULLERLOENNIES S, 1994, EUR J BIOCHEM, V224, P751, DOI 10.1111/j.1432-1033.1994.t01-1-00751.x; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAGES C, 1982, EUR J BIOCHEM, V122, P381, DOI 10.1111/j.1432-1033.1982.tb05892.x; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415; RIED G, 1990, J BACTERIOL, V172, P6048, DOI 10.1128/jb.172.10.6048-6053.1990; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; SEYDEL U, 1993, J STRUCT BIOL, V110, P232, DOI 10.1006/jsbi.1993.1026; SEYDEL U, 1998, ENDOTOXIN HLTH DIS; SEYDEL U, 1992, BACTERIAL ENDOTOXIC, V1, P225; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; TOMMASSEN J, 1981, J BACTERIOL, V147, P118, DOI 10.1128/JB.147.1.118-123.1981; WEISS MS, 1991, SCIENCE, V254, P1727; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILKINSON BJ, 1986, FEMS MICROBIOL LETT, V37, P63, DOI 10.1111/j.1574-6968.1986.tb01767.x	55	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5114	5119		10.1074/jbc.274.8.5114	http://dx.doi.org/10.1074/jbc.274.8.5114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988760	hybrid			2022-12-27	WOS:000078698200085
J	Dirnbach, E; Steel, DG; Gafni, A				Dirnbach, E; Steel, DG; Gafni, A			Proline isomerization is unlikely to be the cause of slow annealing and reactivation during the folding of alkaline phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BETA-LACTOGLOBULIN; ESCHERICHIA-COLI; RIBONUCLEASE-A; PHOSPHOGLYCERATE KINASE; PROLYL ISOMERASE; CYCLOSPORINE-A; PROTEIN; CYCLOPHILIN; MECHANISM; CATALYSIS	The in vitro folding of Escherichia coli alkaline phosphatase (AP) from the guanidine hydrochloride (GdnHCl) denatured state is characterized by a significant slow phase in the post activational recovery of native protein lability (probed by the susceptibility to GdnHCl denaturation and occurring on the time scale of days) as well as a slow phase in the recovery of activity ton the time scale of minutes). Slow folding events have often been attributed to cis-trans isomerizations of X-Pro peptide bonds, a plausible explanation for AP, which contains 21 prolines per subunit, To investigate the role of proline isomerization in the two measures of refolding mentioned above, we have performed "double-jump" GdnHCl denaturation/renaturation experiments, with a third jump, where the rate of unfolding of refolded protein upon exposure to denaturant was added to assess the rate of change of lability, Our measurements of the time evolution of both the lability and the reactivation of refolded AP as a function of denaturation time show that proline isomerization is unlikely to be the cause of either of these slow events in the refolding of AP. The conclusions are further confirmed by the absence of proline isomerization effects when AP is refolded in the presence of human and periplasmic E, coli peptidyl-prolyl isomerase.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gafni, A (corresponding author), Univ Michigan, Div Biophys Res, Rm 913,N Ingalls Bldg, Ann Arbor, MI 48109 USA.	arigafni@umich.edu			NIA NIH HHS [T32AG00114, AG09761] Funding Source: Medline; NIGMS NIH HHS [5T32GM08270-66] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114, R01AG009761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CHLEBOWSKI JF, 1977, J BIOL CHEM, V252, P7042; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; COOK KH, 1979, P NATL ACAD SCI USA, V76, P6157, DOI 10.1073/pnas.76.12.6157; CREIGHTON TE, 1980, J MOL BIOL, V137, P431, DOI 10.1016/0022-2836(80)90167-9; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GETTINS P, 1983, J BIOL CHEM, V258, P396; HATTORI M, 1993, J BIOL CHEM, V268, P22414; HIREMATH LS, 1982, J GERONTOL, V37, P680, DOI 10.1093/geronj/37.6.680; KEIFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEVITT M, 1981, J MOL BIOL, V145, P251, DOI 10.1016/0022-2836(81)90342-9; LIN LN, 1983, BIOCHEMISTRY-US, V22, P564, DOI 10.1021/bi00272a007; LIN LN, 1983, BIOCHEMISTRY-US, V22, P559, DOI 10.1021/bi00272a006; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MALAMY MH, 1964, BIOCHEMISTRY-US, V3, P1893, DOI 10.1021/bi00900a018; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Reimer U, 1997, BIOCHEMISTRY-US, V36, P13802, DOI 10.1021/bi9713916; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P3552, DOI 10.1021/bi00863a029; ROTHSTEIN M, 1985, REV BIOL RES AGING, V2, P421; Schmid F X, 1986, Methods Enzymol, V131, P70; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STRAMBINI GB, 1985, CHEM PHYS LETT, V115, P196, DOI 10.1016/0009-2614(85)80678-3; SUBRAMANIAM V, 1995, BIOCHEMISTRY-US, V34, P1133, DOI 10.1021/bi00004a005; Subramaniam V, 1996, PROTEIN SCI, V5, P2089, DOI 10.1002/pro.5560051015; Veeraraghavan S, 1997, BIOCHEMISTRY-US, V36, P15134, DOI 10.1021/bi971357r; YUH KCM, 1987, P NATL ACAD SCI USA, V84, P7458, DOI 10.1073/pnas.84.21.7458; ZUNIGA A, 1988, BIOCHIM BIOPHYS ACTA, V955, P50, DOI 10.1016/0167-4838(88)90178-1	39	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4532	4536		10.1074/jbc.274.8.4532	http://dx.doi.org/10.1074/jbc.274.8.4532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988686	hybrid			2022-12-27	WOS:000078698200011
J	Kim, M; Thum, KE; Morishige, DT; Mullet, JE				Kim, M; Thum, KE; Morishige, DT; Mullet, JE			Detailed architecture of the barley chloroplast psbD-psbC blue light-responsive promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSTARD SINAPIS-ALBA; POLYMERASE-ALPHA-SUBUNIT; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; LEAF DEVELOPMENT; PROTEIN-KINASE; SIGMA-FACTORS	The photosystem II reaction center chlorophyll protein D2, is encoded by the chloroplast gene psbD. PsbD is transcribed from at least three different promoters, one which is activated by high fluence blue light. Sequences within 130 base pairs (bp) of the psbD blue light-responsive promoter (BLRP) are highly conserved in higher plants. In this study, the structure of the psbD BLRP was analyzed in detail using deletion and site-directed mutagenesis and in vitro transcription. Deletion analysis showed that a 53-bp DNA region of the psbD BLRP, from -57 to -5, was sufficient for transcription in vitro. Mutation of a putative prokaryotic -10 element (TATTCT) located from -7 to -12 inhibited transcription from the psbD BLRP. In contrast, mutation of a putative prokaryotic -35 element, had no influence on transcription. Mutation of a TATATA sequence located between the barley psbA -10 and -35 elements significantly reduced transcription from this promoter. However, site-directed mutation of sequences located between -35 and -10 had no effect on transcription from the psbD BLRP. Transcription from the psbD BLRP was previously shown to require a 22-bp sequence, termed the AAG-box, located between -36 and -57. The AAG-box specifically binds the protein complex AGF. Site-directed mutagenesis identified two different sequence motifs in the AAG-box that are important for transcription in vitro. Based on these results, we propose that positive factors bind to the AAG-box and interact with the chloroplast-encoded RNA polymerase to promote transcription from the psbD BLRP. Transcription from the psbD BLRP is thus similar to type II bacterial promoters that use activating proteins to stimulate transcription. Transcription of the psbD BLRP was similar to 6.5-fold greater in plastid extracts from illuminated versus dark-grown plants. This suggests that light-induced activation of this promoter in vivo involves factors interacting with the 53-bp psbD BLRP in vitro.	Texas A&M Univ, Crop Biotechnol Ctr, Dept Biochem & Biophys, College Stn, TX 77843 USA; Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Chem, Div Appl Biol & Chem, Suwon 441744, South Korea	Texas A&M University System; Texas A&M University College Station; Seoul National University (SNU)	Mullet, JE (corresponding author), Texas A&M Univ, Crop Biotechnol Ctr, Dept Biochem & Biophys, College Stn, TX 77843 USA.				NIGMS NIH HHS [GM 37987] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1995, EMBO J, V14, P3721, DOI 10.1002/j.1460-2075.1995.tb00042.x; Baginsky S, 1997, PLANT MOL BIOL, V34, P181, DOI 10.1023/A:1005802909902; BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHEN SCG, 1995, PHYSIOL PLANTARUM, V93, P617, DOI 10.1111/j.1399-3054.1995.tb05108.x; CHRISTOPHER DA, 1994, PLANT PHYSIOL, V104, P1119, DOI 10.1104/pp.104.4.1119; Christopher DA, 1997, PLANT PHYSIOL, V113, P1273, DOI 10.1104/pp.113.4.1273; CHRISTOPHER DA, 1992, PLANT CELL, V4, P785, DOI 10.1105/tpc.4.7.785; Christopher DA, 1996, PHOTOSYNTH RES, V47, P239, DOI 10.1007/BF02184285; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DEPAMPHILIS CW, 1990, NATURE, V348, P337, DOI 10.1038/348337a0; EISERMANN A, 1990, EMBO J, V9, P3981, DOI 10.1002/j.1460-2075.1990.tb07619.x; GAMBLE PE, 1989, EMBO J, V8, P2785, DOI 10.1002/j.1460-2075.1989.tb08424.x; GAMBLE PE, 1988, EMBO J, V7, P1289, DOI 10.1002/j.1460-2075.1988.tb02943.x; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GRUISSEM W, 1986, NUCLEIC ACIDS RES, V14, P7541, DOI 10.1093/nar/14.19.7541; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Hajdukiewicz PTJ, 1997, EMBO J, V16, P4041, DOI 10.1093/emboj/16.13.4041; HANLEYBOWDOIN L, 1987, TRENDS BIOCHEM SCI, V12, P67, DOI 10.1016/0968-0004(87)90033-8; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubschmann T, 1998, PLANT MOL BIOL, V36, P493, DOI 10.1023/A:1005924502336; IGLOI GL, 1992, CRIT REV PLANT SCI, V10, P525, DOI 10.1080/07352689209382326; IRATNI R, 1994, GENE DEV, V8, P29228; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; Isono K, 1997, P NATL ACAD SCI USA, V94, P14948, DOI 10.1073/pnas.94.26.14948; Kapoor S, 1997, PLANT J, V11, P327, DOI 10.1046/j.1365-313X.1997.11020327.x; KIM MY, 1993, PLANT MOL BIOL, V22, P447, DOI 10.1007/BF00015975; KIM MY, 1995, PLANT CELL, V7, P1445, DOI 10.1105/tpc.7.9.1445; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; LANDINI P, 1995, EMBO J, V14, P4329, DOI 10.1002/j.1460-2075.1995.tb00107.x; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; LINK G, 1994, PLANT PROMOTERS TRAN, P63; Liu B, 1996, P NATL ACAD SCI USA, V93, P3313, DOI 10.1073/pnas.93.8.3313; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1993, PLANT PHYSIOL, V103, P309, DOI 10.1104/pp.103.2.309; NEUHAUS H, 1989, CURR GENET, V15, P63, DOI 10.1007/BF00445753; OHAD I, 1985, EMBO J, V4, P1655, DOI 10.1002/j.1460-2075.1985.tb03833.x; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RAPP JC, 1992, J BIOL CHEM, V267, P21404; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SEXTON TB, 1990, EMBO J, V9, P4485, DOI 10.1002/j.1460-2075.1990.tb07899.x; SEXTON TB, 1990, CURR GENET, V17, P445, DOI 10.1007/BF00334526; SIMONS RW, 1983, CELL, V34, P673, DOI 10.1016/0092-8674(83)90400-2; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; Tanaka K, 1997, FEBS LETT, V413, P309, DOI 10.1016/S0014-5793(97)00906-X; Tanaka K, 1996, SCIENCE, V272, P1932, DOI 10.1126/science.272.5270.1932; TILLER K, 1993, EMBO J, V12, P1745, DOI 10.1002/j.1460-2075.1993.tb05822.x; TILLER K, 1993, PLANT MOL BIOL, V21, P503, DOI 10.1007/BF00028807; Tozawa Y, 1998, NUCLEIC ACIDS RES, V26, P415, DOI 10.1093/nar/26.2.415; TROXLER RF, 1994, PLANT PHYSIOL, V104, P753, DOI 10.1104/pp.104.2.753; Vera A, 1996, MOL GEN GENET, V251, P518, DOI 10.1007/s004380050197; WADA T, 1994, PLANT PHYSIOL, V104, P1259, DOI 10.1104/pp.104.4.1259; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x; ZURAWSKI G, 1987, ANNU REV PLANT PHYS, V38, P391, DOI 10.1146/annurev.pp.38.060187.002135; ZURAWSKI G, 1984, GENETICS, V106, P735	72	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4684	4692		10.1074/jbc.274.8.4684	http://dx.doi.org/10.1074/jbc.274.8.4684			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988705	hybrid			2022-12-27	WOS:000078698200030
J	Perrone, L; Tell, G; Di Lauro, R				Perrone, L; Tell, G; Di Lauro, R			Calreticulin enhances the transcriptional activity of thyroid transcription factor-1 by binding to its homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; PROTEIN-KINASE-A; FACTOR-I TTF-1; GENE-EXPRESSION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; REDOX REGULATION; FRTL-5 CELLS; B GENE; ACTIVATION	Transcription factors are often regulated by associated protein cofactors that are able to modify their activity by several different mechanisms. In this study we show that calreticulin, a Ca2+-binding protein with chaperone activity, binds to thyroid transcription factor-1 (TTF-1), a homeodomain-containing protein implicated in the differentiation of lung and thyroid. The interaction between calreticulin and TTF-1 appears to have functional significance because it results in increased transcriptional stimulation of TTF-1-dependent promoters. Calreticulin binds to the TTF-1 homeodomain and promotes its folding, suggesting that the mechanism involved in stimulation of transcriptional activity is an increase of the steady-state concentration of active TTF-1 protein in the cell. We also demonstrate that calreticulin mRNA levels in thyroid cells are under strict control by the thyroid-stimulating hormone, thus implicating calreticulin in the modulation of thyroid gene expression by thyroid-stimulating hormone.	Staz Zool Anton Dohrn, I-80121 Naples, Italy; Fac Med, Dipartimento Sci & Tecnol Biomed, Udine, Italy	Stazione Zoologica Anton Dohrn di Napoli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, Villa Comunale, I-80121 Naples, Italy.	rdilauro@unina.it	Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; Perrone, Lorena/0000-0001-5399-9397; Tell, Gianluca/0000-0001-8845-6448	Telethon [D.067] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; Aurisicchio L, 1998, J BIOL CHEM, V273, P1477, DOI 10.1074/jbc.273.3.1477; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burns K, 1997, MOL CELL BIOCHEM, V171, P37, DOI 10.1023/A:1006865108833; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, FEBS LETT, V354, P293, DOI 10.1016/0014-5793(94)01145-1; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Desai D, 1996, J BIOL CHEM, V271, P15153, DOI 10.1074/jbc.271.25.15153; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JEROEN EM, 1996, P NATL ACAD SCI USA, V93, P13997; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KHANNA NC, 1986, BIOCHEMISTRY-US, V25, P1078, DOI 10.1021/bi00353a020; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lai JS, 1997, MOL CELL BIOL, V17, P3937, DOI 10.1128/MCB.17.7.3937; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Oguchi H, 1998, ENDOCRINOLOGY, V139, P1999, DOI 10.1210/en.139.4.1999; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Saito T, 1997, ENDOCRINOLOGY, V138, P602, DOI 10.1210/en.138.2.602; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shago M, 1997, EXP CELL RES, V230, P50, DOI 10.1006/excr.1996.3408; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHERMAN F, 1986, METHODS YEAST GENETI, P207; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	56	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4640	4645		10.1074/jbc.274.8.4640	http://dx.doi.org/10.1074/jbc.274.8.4640			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988700	hybrid			2022-12-27	WOS:000078698200025
J	Zetser, A; Gredinger, E; Bengal, E				Zetser, A; Gredinger, E; Bengal, E			p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation - Participation of the MEF2C transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR STRESSES; GENE-EXPRESSION; MOUSE MUSCLE; FACTOR MEF-2; MYOD; ENHANCER; GROWTH; DOMAIN; FAMILY; BINDS	Differentiation of muscle cells is regulated by extracellular growth factors that transmit largely unknown signals into the cells. Some of these growth factors induce mitogen-activated protein kinase (MAPK) cascades within muscle cells, In this work we show that the kinase activity of p38 MAPK is induced early during terminal differentiation of L8 cells. Addition of a specific p38 inhibitor SE 203580 to myoblasts blocked their fusion to multinucleated myotubes and prevented the expression of MyoD and MEF2 family members and myosin light chain 2, The expression of MKK6, a direct activator of p38, or of p38 itself enhanced the activity of MyoD in converting 10T1/2 fibroblasts to muscle, whereas treatment with SE 203580 inhibited MyoD, Several lines of evidence suggesting that the involvement of p38 in MyoD activity is mediated via its co-activator MEF2C, a known substrate of p38, are presented. In these experiments we show that MEF2C protein and MEF2-binding sites are necessary for the p38 MAPK pathway to regulate the transcription of muscle creatine kinase reporter gene. Our results indicate that the p38 MAPK pathway promotes skeletal muscle differentiation at least in part via activation of MEF2C.	Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Family Inst Res Med Sci, POB 9649, IL-31096 Haifa, Israel.	Bengal@tx.technion.ac.il						AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; TAHA C, 1997, AM J PHYSIOL, V273, P68; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	44	365	384	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5193	5200		10.1074/jbc.274.8.5193	http://dx.doi.org/10.1074/jbc.274.8.5193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988769	hybrid			2022-12-27	WOS:000078698200094
J	Chadli, A; Ladjimi, MM; Baulieu, EE; Catelli, MG				Chadli, A; Ladjimi, MM; Baulieu, EE; Catelli, MG			Heat-induced oligomerization of the molecular chaperone Hsp90 - Inhibition by ATP and geldanamycin and activation by transition metal oxyanions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; SHOCK-PROTEIN; MUTATIONAL ANALYSIS; ESTROGEN-RECEPTOR; STEROID-RECEPTOR; BINDING; INVITRO; PURIFICATION; REACTIVATION	It has been previously reported that heat shock protein 90 (Hsp90) oligomerizes at high temperatures and displays concomitantly a novel chaperone activity (Yonehara, M., Minami, Y., Kawata, Y., Nagai, J., and Yahara, I. (1996) J. Biol. Chem., 271, 2641-2645). In order to better define these oligomerization properties at high temperatures and to know whether they are influenced by modulators of Hsp90 function, heat-induced oligomerization of highly purified dimeric Hsp90 has been investigated over a wide range of temperature and protein concentrations by native polyacrylamide gel electrophoresis and size exclusion chromatography. Whereas below 50 degrees C, the dimeric form is maintained over a large range of concentrations, at the critical temperature of 50 degrees C, a sharp transition from dimeric to higher order oligomeric species takes place within minutes, in a highly ordered process, suggesting that a conformational change, leading to the appearance of a new oligomerization site, occurs in Hsp90 dimer. Moreover, at and above the critical temperature, the extent of oligomerization increases with Hsp90 concentration. Formation of high order oligomers at high temperatures is sensitive to modulators of Hsp90 function. ATP and geldanamycin, both known to bind to the same pocket of Hsp90, are inhibitors of this process, whereas molybdate, vanadate, and Nonidet P-40, which are thought to increase surface hydrophobicity of the protein, are activators. Thus, oligomerization of Hsp90 at high temperatures may be mediated through hydrophobic interactions that are hindered by ligands and favored by transition metal oxyanions. The fact that the heat-induced oligomerization of Hsp90 is affected by specific ligands that modulate its properties also suggests that this process may be involved in cell protection during heat shock.	INSERM U488, F-94276 Le Kremlin Bicetre, France; CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, F-75006 Paris, France; CHU Cochin Port Royal, CNRS, Lab Endocrinol Metab & Dev, UPR 1524, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Catelli, MG (corresponding author), INSERM U488, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	Catelli@icgm.cochin.inserm.fr						BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CORNILLOT JD, 1992, INT J BIOCHEM, V24, P1585, DOI 10.1016/0020-711X(92)90174-Y; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ellis RJ, 1996, CELL STRESS CHAPERON, V1, P155, DOI 10.1379/1466-1268(1996)001<0155:DOMC>2.3.CO;2; Freitag DG, 1997, BIOCHEMISTRY-US, V36, P10221, DOI 10.1021/bi963030g; Garnier C, 1998, BIOCHEM BIOPH RES CO, V249, P197, DOI 10.1006/bbrc.1998.9108; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LANKS KW, 1992, BIOCHEM BIOPH RES CO, V184, P394, DOI 10.1016/0006-291X(92)91206-6; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; Meng X, 1996, J CELL SCI, V109, P1677; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MORIMOTO R I, 1990, P1; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADANYI C, 1989, J BIOL CHEM, V264, P2568; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Soti C, 1998, EUR J BIOCHEM, V255, P611, DOI 10.1046/j.1432-1327.1998.2550611.x; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X	45	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4133	4139		10.1074/jbc.274.7.4133	http://dx.doi.org/10.1074/jbc.274.7.4133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933607	hybrid			2022-12-27	WOS:000078575500031
J	Mahon, MG; Lindstedt, KA; Hermann, M; Nimpf, J; Schneider, WJ				Mahon, MG; Lindstedt, KA; Hermann, M; Nimpf, J; Schneider, WJ			Multiple involvement of clusterin in chicken ovarian follicle development - Binding to two oocyte-specific members of the low density lipoprotein receptor gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS AMYLOID-BETA; APOLIPOPROTEIN-J; SULFATED GLYCOPROTEIN-2; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; GRANULOSA-CELLS; TESTIS FLUID; HUMAN PLASMA; LAYING HEN; EXPRESSION	The interaction of the female germ cell with somatic cells during the development of the ovarian follicle in the chicken provides a prime system to study gene expression. Here, we have uncovered the involvement of clusterin, the function(s) of which is still poorly understood, in this complex process. As revealed by molecular cloning, chicken clusterin is a 428-residue protein that migrates at 70 kDa on SDS-polyacrylamide gel electrophoresis and possesses most of the structural features of its mammalian successors. However, in contrast to mammalian clusterin, the chicken protein appears not to be cleaved intracellularly into a disulfide-linked heterodimer; possibly as a consequence thereof, it is not secreted constitutively and is absent from the circulation, where most of clusterin is found in mammals. In the ovary, clusterin is a major product of the somatic granulosa cells, in a pattern correlating with the developmental phases of individual follicles. In that, transcript levels are high not only at onset of vitellogenesis, but also in atretic follicles and in the postovulatory follicle sac, ie. in situations characterized by apoptotic events. Yolk of growing oocytes contains a 43-kDa truncated form of clusterin that does not appear to be synthesized within the oocyte, Rather, we here show for the first time that 70-kDa clusterin interacts not only with megalin, but also with two chicken oocyte-specific members of the low density lipoprotein receptor (LDLR) gene family. These receptors, termed LDLR-related protein with eight ligand binding repeats (LR8) and LDLR-related protein (380 kDa), likely internalize granulosa cell-derived 70-kDa clusterin, which may subsequently be processed to the 43-kDa product. Thus, chicken clusterin could serve as a marker for follicular atresia and resorption, and, based on its ability to bind several other proteins, it may serve as carrier for the receptor-mediated endocytosis into oocytes of components important for embryonic development, two hitherto unknown functions of this intriguing protein.	Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schneider, WJ (corresponding author), Univ Vienna, Dept Mol Genet, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wjs@mol.univie.ac.at		Hermann, Marcela/0000-0003-2298-4269; Nimpf, Johannes/0000-0002-9273-3492				ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; BURKEY BF, 1991, J LIPID RES, V32, P1039; BUTTERWORTH GE, 1989, REV INT PSYCHOL SOC, V2, P9; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DESILVA HV, 1990, J BIOL CHEM, V265, P14292; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GILBERT AB, 1978, J REPROD FERTIL, V52, P227, DOI 10.1530/jrf.0.0520227; GILBERT AB, 1983, J REPROD FERTIL, V69, P221, DOI 10.1530/jrf.0.0690221; GILBERT AB, 1980, BRIT POULTRY SCI, V21, P257, DOI 10.1080/00071668008416667; Harlow E., 1988, ANTIBODIES LAB MANUA; Hermann M, 1998, FASEB J, V12, P897, DOI 10.1096/fasebj.12.10.897; HSUEH AJW, 1994, ENDOCR REV, V15, P707, DOI 10.1210/er.15.6.707; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Johnson AL, 1996, ENDOCRINOLOGY, V137, P2059, DOI 10.1210/en.137.5.2059; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; Lindstedt KA, 1997, J BIOL CHEM, V272, P30221, DOI 10.1074/jbc.272.48.30221; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MICHEL D, 1989, ONCOGENE RES, V4, P127; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1994, J BIOL CHEM, V269, P212; PALUMBO A, 1995, J SOC GYNECOL INVEST, V2, P565, DOI 10.1016/1071-5576(94)00062-6; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; STIFANI S, 1991, J BIOL CHEM, V266, P19079; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; TILLY JL, 1991, ENDOCRINOLOGY, V129, P2799, DOI 10.1210/endo-129-5-2799; TILLY JL, 1991, BIOL REPROD, V44, P305, DOI 10.1095/biolreprod44.2.305; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; [No title captured]	57	51	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4036	4044		10.1074/jbc.274.7.4036	http://dx.doi.org/10.1074/jbc.274.7.4036			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933595	hybrid			2022-12-27	WOS:000078575500019
J	Toth, I; Yuan, LP; Rogers, JT; Boyce, H; Bridges, KR				Toth, I; Yuan, LP; Rogers, JT; Boyce, H; Bridges, KR			Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; RESPONSIVE ELEMENT; NITRIC-OXIDE; OXIDATIVE STRESS; METABOLISM; TRANSLATION; ACTIVATION; ACONITASE; ERYTHROPOIETIN	Ferritin and transferrin receptor expression is posttranscriptionally regulated by a conserved mRNA sequence termed the iron-responsive element (IRE), to which a transacting protein called the iron-regulatory protein (IRP) is bound. Our data demonstrate that hypoxia powerfully enhances IRE/IRP-1 binding in human cell lines. Using the human hepatoma cell line Hep3B as a model, we found that 16 h in a 1% oxygen atmosphere markedly increases IRE/IRP-1 binding as assessed by electromobility shift assay. Hypoxia also decreased cytosolic aconitase activity. The hypoxia-enhanced IRE/IRP-1 binding stabilized the transferrin receptor message, increased the cellular mRNA content by over 10-fold, and doubled surface receptor expression. Simultaneously, hypoxia suppressed ferritin message translation. Hypoxia's effect was most strikingly depicted by the absence of ferritin synthesis in cells challenged with inorganic iron. Our results contrast with previously reported data (Hanson, E. S., and Leibold, E. A. (1998) J. Biol. Chem, 273, 7588-7593) in which a 3% oxygen atmosphere reduced IRE/IRP-1 binding in rat hepatoma cells. We discuss some possible reasons for the differences. In aggregate with other investigations involving responses to hypoxia, iron, or nitric oxide, our data indicate that cellular iron metabolic responses are complex and that IRE/IRP-1 interactions vary between cell lines and perhaps between species.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Hematol Div,Joint Ctr Sickle Cell & Thal, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bridges, KR (corresponding author), Joint Ctr Sickle Cell & Thalassem Disorders, BLI 327,221 Longwood Ave, Boston, MA 02115 USA.	bridges@calvin.bwh.harvard.edu		Rogers, Jack/0000-0003-1262-8578	NHLBI NIH HHS [HL 457940] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Constanzo F, 1986, NUCLEIC ACIDS RES, V14, P721; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GOLBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; Kuriyama-Matsumura K, 1998, BIOCHEM BIOPH RES CO, V249, P241, DOI 10.1006/bbrc.1998.9046; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MORRIS CJ, 1995, INT J BIOCHEM CELL B, V27, P109, DOI 10.1016/1357-2725(94)00084-O; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; QI Y, 1994, J NEUROCHEM, V63, P1485; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TOTH I, 1995, J BIOL CHEM, V270, P2846, DOI 10.1074/jbc.270.6.2846; TOTH I, 1995, J BIOL CHEM, V270, P19540, DOI 10.1074/jbc.270.33.19540; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	43	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4467	4473		10.1074/jbc.274.7.4467	http://dx.doi.org/10.1074/jbc.274.7.4467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933651	hybrid			2022-12-27	WOS:000078575500075
J	Giordano, R; Fouts, DL; Tewari, D; Colli, W; Manning, JE; Alves, MJM				Giordano, R; Fouts, DL; Tewari, D; Colli, W; Manning, JE; Alves, MJM			Cloning of a surface membrane glycoprotein specific for the infective form of Trypanosoma cruzi having adhesive properties to laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPOMASTIGOTE STAGE; BASEMENT-MEMBRANES; MAMMALIAN-CELLS; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; MONOCLONAL-ANTIBODIES; PROTEIN; BINDING; INVASION; FAMILY; ENTRY	Trypomastigotes of Trypanosoma cruzi express a set of surface glycoproteins known, collectively, as Tc-85. A monoclonal antibody to these proteins, named H1A10, inhibits (50-90%) in vitro parasite interiorization into host cells, thus implicating these glycoproteins in the infection process. Two DNA inserts, a genomic DNA fragment and a full-length cDNA encoding the H1A10 epitope, have now been cloned and characterized. Results show that both have high sequence identity with all reported members of the gp85/trans-sialidase gene family, although the H1A10 epitope exists only in the Tc-85 subset of the family. The epitope has been mapped by competition of antibody binding to a Tc-85 recombinant protein with peptides having sequences predicted by the Tc-85 DNA sequence, which contains also putative N-glycosylation sites and COOH-terminal glycosylphosphatidylinositol anchor insertion sites, as expected, since an N-glycan chain and a glycosylphosphatidylinositol anchor have been characterized previously in the Tc-85 subset. The protein encoded by the full-length cDNA insert binds to cells and in vitro to laminin, but not to gelatin or fibronectin, in a saturable manner. For the first time it was possible to assign a defined ligand to a sequenced glycoprotein belonging to the gp85 family, This fact, together with the reported binding of family members to cell surfaces, reinforces the hypothesis that this family encodes glycoproteins with similar sequences but differing enough as to bind to different ligands and thus forming a family of adhesion glycoproteins enabling the parasite to overcome the barriers interposed by cell membranes, extracellular matrices, and basal laminae.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, SP, Brazil; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	Universidade de Sao Paulo; University of California System; University of California Irvine	Alves, MJM (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05599970 Sao Paulo, SP, Brazil.	mjmalves@quim.iq.usp.br	Colli, Walter/G-1188-2012; Alves, Maria Julia/K-8976-2012; Giordano, Ricardo/A-2074-2010; Colli, Walter/ABA-5440-2021; Colli, Walter/AAW-7649-2021	Alves, Maria Julia/0000-0001-7211-9631; Giordano, Ricardo/0000-0001-8116-6771; Colli, Walter/0000-0001-7305-4673	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018873] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18873] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abuin G, 1996, EXP PARASITOL, V82, P290, DOI 10.1006/expr.1996.0036; ALVES MJM, 1986, MOL BIOCHEM PARASIT, V21, P75, DOI 10.1016/0166-6851(86)90081-2; ANDREWS NW, 1984, EUR J BIOCHEM, V140, P599, DOI 10.1111/j.1432-1033.1984.tb08144.x; ARAGUTH MF, 1988, PARASITE IMMUNOL, V10, P707, DOI 10.1111/j.1365-3024.1988.tb00256.x; AUBIN G, 1989, MOL BIOCHEM PARASIT, V35, P229; BEARD CA, 1985, MOL BIOCHEM PARASIT, V16, P199, DOI 10.1016/0166-6851(85)90087-8; BEARD CA, 1988, MOL BIOCHEM PARASIT, V28, P227, DOI 10.1016/0166-6851(88)90007-2; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOSCHETTI MA, 1987, MOL BIOCHEM PARASIT, V24, P175, DOI 10.1016/0166-6851(87)90104-6; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; CANO MI, 1995, MOL BIOCHEM PARASIT, V71, P273, DOI 10.1016/0166-6851(95)00066-A; Cazzulo JJ, 1997, BIOL CHEM, V378, P1; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; COLLI W, 1993, FASEB J, V7, P1257, DOI 10.1096/fasebj.7.13.8405811; COUTO AS, 1987, MOL BIOCHEM PARASIT, V26, P145, DOI 10.1016/0166-6851(87)90138-1; COUTO AS, 1993, EUR J BIOCHEM, V217, P597, DOI 10.1111/j.1432-1033.1993.tb18282.x; COUTO AS, 1990, MOL BIOCHEM PARASIT, V39, P101, DOI 10.1016/0166-6851(90)90012-B; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; FERNANDEZ MA, 1993, EUR J IMMUNOL, V23, P552, DOI 10.1002/eji.1830230238; Finlay BB, 1990, CURR OPIN CELL BIOL, V2, P815, DOI 10.1016/0955-0674(90)90078-S; FURTADO GC, 1992, INFECT IMMUN, V60, P2337, DOI 10.1128/IAI.60.6.2337-2342.1992; GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1; GONCALVES MF, 1991, EXP PARASITOL, V72, P43, DOI 10.1016/0014-4894(91)90119-H; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hall B. Fenton, 1993, Seminars in Cell Biology, V4, P323, DOI 10.1006/scel.1993.1039; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAHN S, 1990, J EXP MED, V172, P589, DOI 10.1084/jem.172.2.589; Kahn SJ, 1997, J IMMUNOL, V159, P4444; KATZIN AM, 1983, BIOCHIM BIOPHYS ACTA, V727, P403, DOI 10.1016/0005-2736(83)90425-X; LEBLOND CP, 1989, AM J ANAT, V185, P367, DOI 10.1002/aja.1001850403; LIMA MF, 1989, MOL BIOCHEM PARASIT, V33, P159, DOI 10.1016/0166-6851(89)90030-3; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; Mercurio AM, 1990, CURR OPIN CELL BIOL, V2, P845, DOI 10.1016/0955-0674(90)90082-P; ORTEGABARRIA E, 1992, INFECT AGENT DIS, V1, P136; RAMIREZ MI, 1993, INFECT IMMUN, V61, P3636, DOI 10.1128/IAI.61.9.3636-3641.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTANA JM, 1997, BIOCHEM J, V324, P129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Williams JA, 1995, DNA CLONING, P15; WRIGHTSMAN RA, 1994, J IMMUNOL, V153, P3148; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; Zhang LH, 1997, MOL BIOCHEM PARASIT, V87, P183, DOI 10.1016/S0166-6851(97)00066-2; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129; ZINGALES B, 1982, MOL BIOCHEM PARASIT, V6, P111, DOI 10.1016/0166-6851(82)90069-X	50	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3461	3468		10.1074/jbc.274.6.3461	http://dx.doi.org/10.1074/jbc.274.6.3461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920891	hybrid, Green Published			2022-12-27	WOS:000078428200031
J	Kuo, SY; Chesrown, SE; Mellott, JK; Rogers, RJ; Hsu, JL; Nick, HS				Kuo, SY; Chesrown, SE; Mellott, JK; Rogers, RJ; Hsu, JL; Nick, HS			In vivo architecture of the manganese superoxide dismutase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-LESS PROMOTER; LIGATION-MEDIATED PCR; TUMOR NECROSIS FACTOR; TNF-ALPHA; MALIGNANT PHENOTYPE; INITIATOR ELEMENT; EPITHELIAL-CELLS; GENE-EXPRESSION; RECEPTOR GENE; DNASE-I	Mitochondrial manganese superoxide dismutase (Mn-SOD) is the primary cellular defense against damaging superoxide radicals generated by aerobic metabolism and as a consequence of inflammatory disease. Elevated expression of Mn-SOD therefore provides a potent cytoprotective advantage during acute inflammation. Mn SOD contains a GC-rich and TATA/CAAT-less promoter characteristic of a housekeeping gene. In contrast, however, Mn-SOD expression is dramatically regulated in a variety of cells by numerous proinflammatory mediators, including lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1. To understand the underlying regulatory mechanisms controlling Mn-SOD expression, me utilized DNase I-hypersensitive (HS) site analysis, which revealed seven hypersensitive sites throughout the gene. Following high resolution DNase I HS site analysis, the promoter was found to contain five HS subsites, including a subsite that only appears following stimulus treatment. Dimethyl sulfate in vivo footprinting identified 10 putative constitutive protein-DNA binding sites in the proximal Mn-SOD promoter as well as two stimulus-specific enhanced guanine residues possibly due to alterations in chromatin structure. In vitro footprinting data implied that five of the binding sites may be occupied by a combination of Sp1 and gut-enriched Kruppel-like factor. These studies have revealed the complex promoter architecture of a highly regulated cytoprotective gene.	Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Nick, HS (corresponding author), Univ Florida, Coll Med, Dept Neurosci, POB 100244,JHMHC, Gainesville, FL 32610 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39593] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BORG LAH, 1992, ENDOCRINOLOGY, V130, P2851, DOI 10.1210/en.130.5.2851; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EGGERS B, 1994, AM J HUM GENET, V55, P183; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; JACOBY DB, 1994, FREE RADICAL BIO MED, V16, P821, DOI 10.1016/0891-5849(94)90198-8; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI JJ, 1995, ONCOGENE, V10, P1989; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; MCCORD JM, 1982, CAN J PHYSIOL PHARM, V60, P1346, DOI 10.1139/y82-201; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SHAFFER JB, 1990, FREE RADICAL BIO MED, V8, P497, DOI 10.1016/0891-5849(90)90064-P; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Toda H, 1997, J BIOCHEM-TOKYO, V121, P1035; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; VALENTINE JF, 1992, GASTROENTEROLOGY, V103, P905, DOI 10.1016/0016-5085(92)90024-S; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WARD PA, 1988, FREE RADICAL BIO MED, V5, P403, DOI 10.1016/0891-5849(88)90114-1; WERNER H, 1993, ADV EXP MED BIOL, V343, P91; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YAHARA O, 1991, RES COMMUN CHEM PATH, V72, P315; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	52	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3345	3354		10.1074/jbc.274.6.3345	http://dx.doi.org/10.1074/jbc.274.6.3345			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920876	hybrid			2022-12-27	WOS:000078428200016
J	Tomitori, H; Kashiwagi, K; Sakata, K; Kakinuma, Y; Igarashi, K				Tomitori, H; Kashiwagi, K; Sakata, K; Kakinuma, Y; Igarashi, K			Identification of a gene for a polyamine transport protein in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES SPERMINE UPTAKE; TISSUE-CULTURE CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ORNITHINE DECARBOXYLASE; ANTIZYME; KINASE; GROWTH	Properties of a membrane protein encoded by YLL028w were examined using yeast cells transformed with the gene. The transformed cells became resistant to polyamine toxicity, and the resistance was overcome by bafilomycin A(1), an inhibitor of vacuolar H+-ATPase. Although spermine uptake activity of the transformed cells was almost the same as that of wild type cells, the uptake activity of vacuolar membrane vesicles from the transformed cells was higher than that from wild type cells. The transformed cells became resistant to MGBG (methylglyoxal bis(guanylhydrazone)) and paraquat, but not Ni2+ and Co2+, suggesting that the protein encoded by YLL028w is a transport protein specific for polyamines. When the YLL028w gene was disrupted by inserting the HIS3 gene, the cells became sensitive to polyamines, and spermine uptake activity of the vacuolar membrane vesicles decreased significantly. The accumulated spermine in YLL028w gene-disrupted cells decreased greatly compared with that in wild type cells. The results indicate that a membrane protein encoded by YLL028w (TPO1) is a polyamine transport protein on the vacuolar membrane.	Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER C, 1994, METHODS YEAST GENETI, P141; KAKINUMA Y, 1995, BIOCHEM BIOPH RES CO, V216, P985, DOI 10.1006/bbrc.1995.2717; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Nozaki T, 1996, BIOCHEM BIOPH RES CO, V228, P452, DOI 10.1006/bbrc.1996.1681; PEGG AE, 1988, CANCER RES, V48, P759; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Woolridge DP, 1997, J BIOL CHEM, V272, P8864	24	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3265	3267		10.1074/jbc.274.6.3265	http://dx.doi.org/10.1074/jbc.274.6.3265			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920864	hybrid			2022-12-27	WOS:000078428200004
J	Jung, YS; Roberts, VA; Stout, CD; Burgess, BK				Jung, YS; Roberts, VA; Stout, CD; Burgess, BK			Complex formation between Azotobacter vinelandii ferredoxin I and its physiological electron donor NADPH-ferredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; ANABAENA SP PCC-7119; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; 7FE FERREDOXIN; ANGSTROM RESOLUTION; SULFOLOBUS-ACIDOCALDARIUS; ENCODING FLAVODOXIN; SPINACH FERREDOXIN; 3FE-4S CLUSTER	In Azotobacter vinelandii, deletion of the fdxA gene, which encodes ferredoxin I (FdI), leads to activation of the expression of the fpr gene, which encodes NADPH-ferredoxin reductase (FPR), In order to investigate the relationship of these two proteins further, the interactions of the two purified proteins have been examined, AvFdI forms a specific 1:1 cross-linked complex with AvFPR through ionic interactions formed between the Lys residues of FPR and Asp/Glu residues of FdI, The Lys in FPR has been identified as Lys(258), a residue that forms a salt bridge with one of the phosphate oxygens of FAD in the absence of FdI. UV-Vis and circular dichroism data show that on binding FdI, the spectrum of the FPR flavin is hyperchromatic and red-shifted, confirming the interaction region close to the FAD, Cytochrome c reductase assays and electron paramagnetic resonance data show that electron transfer between the two proteins is pH-dependent and that the [3Fe-4S](+) cluster of FdI is specifically reduced by NADPH via FPR, suggesting that the [3Fe-4S] cluster is near FAD in the complex. To further investigate the FPR:FdI interaction, the electrostatic potentials for each protein were calculated. Strongly negative regions around the [3Fe-4S] cluster of FdI are electrostatically complementary with a strongly positive region overlaying the FAD of FPR, centered on Lys(258). These proposed interactions of FdI with FPR are consistent with cross-linking, peptide mapping, spectroscopic, and electron transfer data and strongly support the suggestion that the two proteins are physiological redox partners.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of California System; University of California Irvine; Scripps Research Institute	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu						ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; AONO S, 1994, BIOCHEM BIOPH RES CO, V201, P938, DOI 10.1006/bbrc.1994.1792; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BENEMANN JR, 1971, BIOCHIM BIOPHYS ACTA, V226, P205, DOI 10.1016/0005-2728(71)90087-9; BENNETT LT, 1988, J BIOL CHEM, V263, P1364; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; BOHME H, 1987, BIOCHIM BIOPHYS ACTA, V891, P1, DOI 10.1016/0005-2728(87)90076-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Coligan JE, 1995, CURRENT PROTOCOLS PR; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; DUPORT C, 1990, NUCLEIC ACIDS RES, V18, P4618, DOI 10.1093/nar/18.15.4618; FILLAT MF, 1990, NUCLEIC ACIDS RES, V18, P7161, DOI 10.1093/nar/18.23.7161; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GomezMoreno C, 1996, BIOCHEM SOC T, V24, P111, DOI 10.1042/bst0240111; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; HARDER J, 1992, J BIOL CHEM, V267, P25548; HOWARD JB, 1983, J BIOL CHEM, V258, P508; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; Macedo AL, 1996, BIOCHEM BIOPH RES CO, V229, P524, DOI 10.1006/bbrc.1996.1837; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MOUESCA JM, 1994, J AM CHEM SOC, V116, P11898, DOI 10.1021/ja00105a033; Nishida H, 1996, PROTEINS, V26, P32, DOI 10.1002/(SICI)1097-0134(199609)26:1<32::AID-PROT3>3.0.CO;2-I; OHMORI D, 1976, BIOCHEM BIOPH RES CO, V72, P566, DOI 10.1016/S0006-291X(76)80078-2; Prasad GS, 1998, PROTEIN SCI, V7, P2541, DOI 10.1002/pro.5560071207; PUEYO JJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P367, DOI 10.1016/0003-9861(92)90697-U; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schmitz S, 1998, BBA-BIOENERGETICS, V1363, P85, DOI 10.1016/S0005-2728(97)00085-6; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; TROWER MK, 1990, BIOCHIM BIOPHYS ACTA, V1037, P281, DOI 10.1016/0167-4838(90)90026-C; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; WADSWORTH CL, 1992, TECHNIQUES PROTEIN C, V3, P61; WANG SP, 1995, J BACTERIOL, V177, P2901, DOI 10.1128/jb.177.10.2901-2907.1995; Wang XZ, 1997, APPL ENVIRON MICROB, V63, P1623, DOI 10.1128/AEM.63.4.1623-1626.1997; Yannone SM, 1998, J BIOL INORG CHEM, V3, P253, DOI 10.1007/s007750050229; Yannone SM, 1997, J BIOL CHEM, V272, P14454, DOI 10.1074/jbc.272.22.14454; YOCH DC, 1972, J BIOL CHEM, V247, P4514	63	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2978	2987		10.1074/jbc.274.5.2978	http://dx.doi.org/10.1074/jbc.274.5.2978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915836	hybrid			2022-12-27	WOS:000078319500054
J	McCloskey, DE; Coleman, CS; Pegg, AE				McCloskey, DE; Coleman, CS; Pegg, AE			Properties and regulation of human spermidine/spermine N-1-acetyltransferase stably expressed in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SPERMINE N1-ACETYLTRANSFERASE; POLYAMINE ANALOG; GROWTH-INHIBITION; LUNG-CANCER; INDUCTION; METABOLISM; INCREASES	Spermidine/spermine N-1-acetyltransferase (SSAT) appears to be the rate-limiting enzyme of polyamine catabolism, yet studies of its regulation have been limited by the low amounts of SSAT in uninduced cells. A system for studying SSAT was established by stably transfecting Chinese hamster ovary cells with a construct where SSAT cDNA was under control of the cytomegalovirus promoter. Thirteen of 44 clones expressed significantly increased SSAT activity (650-1900 compared with 24 pmol/min/mg protein in control cells). SSAT activity was directly proportional to SSAT protein, which turned over very rapidly (t(1/2) of 29 min) and was degraded through the ubiquitin/proteasomal pathway. The increased SSAT activity caused perturbations in polyamine homeostasis and led to a reduction in the rate of growth under clonal conditions. N-1-N-12-bis(ethyl)spermine greatly increased SSAT activity in controls and SSAT transfected clones (to about 10 and 60 nmol/min/mg protein, respectively). N-1,N-12-Bis(ethyl) spermine caused an increase in the SSAT half-life and a slight increase in SSAT mRNA, but these changes were insufficient to account for the increase in SSAT protein suggesting that translational regulation of SSAT must also occur.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pegg, AE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.	aep1@psu.edu			NIGMS NIH HHS [GM-26290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1994, CANCER RES, V54, P3955; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; DAVIDSON NE, 1993, CANCER RES, V53, P2071; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; ERWIN BG, 1986, BIOCHEM J, V238, P581, DOI 10.1042/bj2380581; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LIBBY PR, 1989, CANCER RES, V49, P6226; MAKI C, 1996, CANCER RES, V56, P2469; MATSUI I, 1981, BIOCHIM BIOPHYS ACTA, V675, P373; MATSUI I, 1981, J BIOL CHEM, V256, P2454; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1985, BIOCHEM J, V231, P285, DOI 10.1042/bj2310285; PORTER CW, 1991, CANCER RES, V51, P3716; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6	26	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6175	6182		10.1074/jbc.274.10.6175	http://dx.doi.org/10.1074/jbc.274.10.6175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037702	hybrid			2022-12-27	WOS:000078902800024
J	Zhang, Y; Lee, YC				Zhang, Y; Lee, YC			Acid-catalyzed lactonization of alpha 2,8-linked oligo/polysialic acids studied by high performance anion-exchange chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; NEISSERIA-MENINGITIDIS; GANGLIOSIDE LACTONES; SIALIC ACIDS; POLYSACCHARIDE; GD1B; POLYSIALYLTRANSFERASE; POLYSIALYLATION; IDENTIFICATION	Recent studies from many laboratories revealed remarkable structural, distributional, and functional diversities of oligo/polysialic acids (OSA/PSA) that exist in organisms ranging from bacteria to man. These diversities are further complicated by the fact that OSA/PSA spontaneously form lactones under even mildly acidic conditions. By using high performance anion-exchange chromatography (HPAEC) with nitrate eluents, we found that lactonization of alpha 2,8-linked OSA/PSA (oligo/poly-Neu5Ac, oligo/poly-Neu5Gc and oligo/poly-KDN) proceeds readily, and the lactonization process displays three discrete stages. The initial stage is characterized by limited lactonization occurring between two internal sialic acid residues, reflected by a regular pattern of lactone peaks interdigitated with non-lactonized peaks on HPAEC. In the middle stage, multiple lactonized species are formed from a molecule with a given degree of polymerization (DP), in which the maximum number of lactone rings formed equals DP minus 2. At the final stage, completely lactonized species become the major components, resulting in drastic changes in the physicochemical properties of the sample. Interestingly, the smallest lactonizable OSA are tetramer, trimer, and dimer at the initial, middle, and final stages, respectively. At any of the stages, OSA/PSA of higher DP lactonize more rapidly, but all the lactone rings rapidly open up when exposed 60 mild alkali. Lactonized OSA/PSA are resistant to both enzyme- and acid-catalyzed glycosidic bond cleavage. The latter fact was utilized to obtain more high DP oligo/poly(alpha 2,8-Neu5Gc) chains from a polysialoglycoprotein. Our results should be useful in preparation, storage, and analysis of OSA/PSA. Possible biological significance and bioengineering potentials of lactonization are discussed.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.							ACQUOTTI D, 1991, CHEM PHYS LIPIDS, V59, P107, DOI 10.1016/0009-3084(91)90001-R; ANDO S, 1989, J BIOL CHEM, V264, P3478; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; BASSI R, 1989, CARBOHYD RES, V193, P141, DOI 10.1016/0008-6215(89)85113-4; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; Cheng MC, 1998, ANAL BIOCHEM, V260, P154, DOI 10.1006/abio.1998.2701; Fernandes AI, 1997, BBA-PROTEIN STRUCT M, V1341, P26, DOI 10.1016/S0167-4838(97)00056-3; Fernandes AI, 1996, BBA-PROTEIN STRUCT M, V1293, P90, DOI 10.1016/0167-4838(95)00227-8; GROSS SK, 1975, CARBOHYD RES, V41, P344, DOI 10.1016/S0008-6215(00)87038-X; GROSS SK, 1980, J NEUROCHEM, V34, P1351, DOI 10.1111/j.1471-4159.1980.tb11215.x; Ijuin T, 1996, GLYCOCONJUGATE J, V13, P401, DOI 10.1007/BF00731473; KAWAKAMI H, 1994, BIOSCI BIOTECH BIOCH, V58, P1314, DOI 10.1271/bbb.58.1314; KAWASHIMA I, 1994, INT J CANCER, V58, P263, DOI 10.1002/ijc.2910580220; KIELCZYNSKI W, 1994, GLYCOBIOLOGY, V4, P791, DOI 10.1093/glycob/4.6.791; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; Kitazume S, 1996, J BIOL CHEM, V271, P6694, DOI 10.1074/jbc.271.12.6694; LEE YC, 1966, J BIOL CHEM, V241, P1899; LIFELY MR, 1984, CARBOHYD RES, V134, P229, DOI 10.1016/0008-6215(84)85040-5; LIFELY MR, 1981, CARBOHYD RES, V94, P193, DOI 10.1016/S0008-6215(00)80717-X; MANZI AE, 1994, J BIOL CHEM, V269, P23617; MCGUIRE EJ, 1964, BIOCHEMISTRY-US, V3, P247, DOI 10.1021/bi00890a017; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; OConnell AW, 1997, J NEUROCHEM, V68, P2538; Ogawa T, 1996, J CHROMATOGR A, V741, P295, DOI 10.1016/0021-9673(96)00217-8; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Qu BX, 1996, P NATL ACAD SCI USA, V93, P8995, DOI 10.1073/pnas.93.17.8995; RIBONI L, 1986, J BIOL CHEM, V261, P8514; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; SATO C, 1993, J BIOL CHEM, V268, P23675; Shen HM, 1997, J NEUROSCI, V17, P5221; Shi WX, 1996, J BIOL CHEM, V271, P31517, DOI 10.1074/jbc.271.49.31517; Terabayashi T, 1996, CARBOHYD POLYM, V29, P35, DOI 10.1016/0144-8617(95)00153-0; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TSUDA M, 1994, CHEM PHYS LIPIDS, V70, P95, DOI 10.1016/0009-3084(94)90051-5; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WEI XS, 1998, GLYCOBIOLOGY, V8, P199; YANG PF, 1994, J BIOL CHEM, V269, P23039; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZHANG Y, 1997, GLYCOBIOLOGY, V7, P1027	42	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6183	6189		10.1074/jbc.274.10.6183	http://dx.doi.org/10.1074/jbc.274.10.6183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037703	hybrid			2022-12-27	WOS:000078902800025
J	Kloeker, S; Wadzinski, BE				Kloeker, S; Wadzinski, BE			Purification and identification of a novel subunit of protein serine/threonine phosphatase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; AFFINITY-CHROMATOGRAPHY; CATALYTIC SUBUNIT; 2A; PHOSPHORYLATION; EXPRESSION; FAMILY	The catalytic subunit of protein serine/threonine phosphatase 4 (PP4(C)) has greater than 65% amino acid identity to the catalytic subunit of protein phosphatase 2A (PP2A(C)). Despite this high homology, PP4 does not appear to associate with known PP2A regulatory subunits. As a first step toward characterization of PP4 holoenzymes and identification of putative PP4 regulatory subunits, PP4 was purified from bovine testis soluble extracts, PP4 existed in two complexes of approximately 270-300 and 400-450 kDa as determined by gel filtration chromatography. The smaller PP4 complex was purified by sequential phenyl-Sepharose, Source 15Q, DEAE2, and Superdex 200 gel filtration chromatographies, The final product contained two major proteins: the PP4 catalytic subunit plus a protein that migrated as a doublet of 120-125 kDa on SDS-polyacrylamide gel electrophoresis. The associated protein, termed PP4(R1), and PP4(C) also bound to microcystin-Sepharose, Mass spectrometry analysis of the purified complex revealed two major peaks, at 35 (PP4(C)) and 105 kDa (PP4(R1)). Amino acid sequence information of several peptides derived from the 105 kDa protein was utilized to isolate a human cDNA clone. Analysis of the predicted amino acid sequence revealed 13 nonidentical repeats similar to repeats found in the A subunit of PP2A (PP2A(A)). The PP4(R1) cDNA clone engineered with an N-terminal Myc tag was expressed in COS M6 cells and PP4(C) co-immunoprecipitated with Myc-tagged PP4,,. These data indicate that one form of PP4 is similar to the core complex of PP2A in that it consists of a catalytic subunit and a "PP2A(A)-like" structural subunit.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Wadzinski, BE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Rm 421 MRBI, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSCH M, 1995, EUR J BIOCHEM, V230, P1037, DOI 10.1111/j.1432-1033.1995.tb20653.x; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHEN MX, 1992, FEBS LETT, V306, P54, DOI 10.1016/0014-5793(92)80836-6; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DING JB, 1992, BIOCHIM BIOPHYS ACTA, V1133, P235, DOI 10.1016/0167-4889(92)90074-L; Farmer TB, 1998, J MASS SPECTROM, V33, P697, DOI 10.1002/(SICI)1096-9888(199808)33:8<697::AID-JMS711>3.0.CO;2-H; FAVRE B, 1994, J BIOL CHEM, V269, P16311; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E., 1988, ANTIBODIES LAB MANUA; Helps NR, 1998, J CELL SCI, V111, P1331; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; Kloeker S, 1997, BIOCHEM J, V327, P481, DOI 10.1042/bj3270481; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NISHIWAKI S, 1991, FEBS LETT, V279, P115, DOI 10.1016/0014-5793(91)80264-4; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SELDEN RF, 1995, CURRENT PROTOCOLS MO, V1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1997, J NEUROCHEM, V68, P2119; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	39	63	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5339	5347		10.1074/jbc.274.9.5339	http://dx.doi.org/10.1074/jbc.274.9.5339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026142	hybrid			2022-12-27	WOS:000078804400013
J	Manabe, R; Oh-e, N; Sekiguchi, K				Manabe, R; Oh-e, N; Sekiguchi, K			Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; MAP KINASE; INTEGRINS; ACTIVATION; P130(CAS); ISOFORM; DOMAIN; ALPHA-5-BETA-1	Fibronectin (FN) is comprised of multiple isoforms arising from alternative splicing of a single gene transcript. One of the alternatively spliced segments, EDA, is expressed prominently in embryonic development, malignant transformation, and wound healing. We showed previously that EDA(+) FN was more potent than EDA(-) FN in promoting cell spreading and cell migration because of its enhanced binding affinity to integrin alpha 5 beta 1 (Manabe, R., Oh-e, N., Maeda, T., Fukuda, T., and Sekiguchi, K. (1997) J. Cell Biol. 139, 295-307). In this study, we compared the cell cycle progression and its associated signal transduction events induced by FN isoforms with or without the EDA segment to examine whether the EDA segment modulates the cell proliferative potential of FN. We found that EDA(+) FN was more potent than EDA- FN in inducing G(1)-S phase transition. Inclusion of the EDA segment potentiated the ability of FN to induce expression of cyclin D1, hyperphosphorylation of pRb, and activation of mitogen-activated protein kinase extracellular signal regulated kinase 2 (ERK2). EDA(+) FN was also more potent than EDA(-) FN in promoting FN-mediated tyrosine phosphorylation of p130(Cas), but not focal adhesion kinase, which occurred in parallel with the activation of ERK2, suggesting that p130(Cas) may be involved in activation of ERK2, These results indicated that alternative splicing at the EDA region is a novel mechanism that promotes FN-induced cell cycle progression through up-regulation of integrin-mediated mitogenic signal transduction.	Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 5941101, Japan		Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp						Arai H, 1997, AM J PATHOL, V151, P403; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; BROWN LF, 1993, AM J PATHOL, V142, P793; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; MAEDA T, 1989, J BIOL CHEM, V264, P15165; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MULLER U, 1995, MOL BIOL CELL, V6, P433; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; OYAMA F, 1993, CANCER RES, V53, P2005; OYAMA F, 1989, BIOCHEMISTRY-US, V28, P3293; PATCH LA, 1995, J CELL SCI, V108, P1371; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; VARTIO T, 1987, J CELL SCI, V88, P419; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	55	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5919	5924		10.1074/jbc.274.9.5919	http://dx.doi.org/10.1074/jbc.274.9.5919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026216	hybrid, Green Published			2022-12-27	WOS:000078804400087
J	Shibata, Y; Hayakawa, M; Takiguchi, H; Shiroza, T; Abiko, Y				Shibata, Y; Hayakawa, M; Takiguchi, H; Shiroza, T; Abiko, Y			Determination and characterization of the hemagglutinin-associated short motifs found in Porphyromonas gingivalis multiple gene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-GINGIVALIS; CYSTEINE PROTEINASE; ARG-GINGIPAIN; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; STRUCTURAL CHARACTERIZATION; PERIODONTAL-DISEASE; MOLECULAR-CLONING; PROTEASE; COLONIZATION; MELANINOGENICUS	Porphyromonas gingivalis is a Gram-negative anaerobic bacterial species implicated as an important pathogen in the development of adult periodontitis, In our studies of P. gingivalis and ways to protect against periodontal disease, we have prepared the monoclonal antibody mAb-Pg-vc and its recombinant antibody, which are capable of inhibiting the hemagglutinating activity of P. gingivalis (Shibata, Y,, Kurihara, K,, Takiguchi, H., and Abiko, Y, (1998) Infect. Immun, 66, 2207-2212), To clarify the antigenically related hemagglutinating do. mains, we attempted to determine the minimum motifs responsible for P, gingivalis hemagglutinin, Initially, the 9-kilobase EcoRI fragment encoding the 130-kDa protein was cloned from the P, gingivalis chromosome using mAb-Pg-vc, Western blot analysis of nested deletion clones, the competition experiments using synthetic peptides, and the binding assay of the phage-displayed peptides using the mAb-Pg-vc allowed us to identify the minimum motifs, PVQNLT, Furthermore, the presence of multi-gene family coding for this epitope was confirmed via Southern blot analysis and PCR using the primers complementary to the domain corresponding to this epitope, It is suggested that the hemagglutinin-associated motif may be PVQNLT and that the gene families specifying this motif found in P, gingivalis chromosome encode many hemagglutinin and/or hemagglutinin-related proteases.	Nihon Univ, Sch Dent Matsudo, Dept Biochem, Chiba 2718587, Japan	Nihon University	Abiko, Y (corresponding author), Nihon Univ, Sch Dent Matsudo, Dept Biochem, 2-870-1 Sakaecho Nishi, Chiba 2718587, Japan.							AduseOpoku J, 1997, J BACTERIOL, V179, P4778, DOI 10.1128/jb.179.15.4778-4788.1997; ADUSEOPOKU J, 1995, INFECT IMMUN, V63, P4744, DOI 10.1128/IAI.63.12.4744-4754.1995; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; BEDI GS, 1994, J BIOL CHEM, V269, P599; BOYD J, 1984, INFECT IMMUN, V45, P403, DOI 10.1128/IAI.45.2.403-409.1984; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; CHU L, 1991, INFECT IMMUN, V59, P1932, DOI 10.1128/IAI.59.6.1932-1940.1991; Curtis MA, 1996, INFECT IMMUN, V64, P2532, DOI 10.1128/IAI.64.7.2532-2539.1996; DONIS RO, 1989, VIROLOGY, V169, P408, DOI 10.1016/0042-6822(89)90166-9; FLETCHER HM, 1994, INFECT IMMUN, V62, P4279, DOI 10.1128/IAI.62.10.4279-4286.1994; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; HIRATSUKA K, 1992, ARCH ORAL BIOL, V37, P717, DOI 10.1016/0003-9969(92)90078-M; HOLT S C, 1991, Critical Reviews in Oral Biology and Medicine, V2, P177; ISOGAI H, 1988, ARCH ORAL BIOL, V33, P479, DOI 10.1016/0003-9969(88)90028-3; Kelly CG, 1997, CLIN EXP IMMUNOL, V110, P285; Kiyama M, 1998, BBA-GENE STRUCT EXPR, V1396, P39, DOI 10.1016/S0167-4781(97)00225-X; Kuramitsu H K, 1995, Adv Dent Res, V9, P37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ MS, 1991, J BACTERIOL, V173, P4263, DOI 10.1128/JB.173.14.4263-4270.1991; LANTZ MS, 1991, J BACTERIOL, V173, P495, DOI 10.1128/jb.173.2.495-504.1991; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; MALEY J, 1994, FEMS MICROBIOL LETT, V123, P219, DOI 10.1016/0378-1097(94)90298-4; NAITO Y, 1988, J DENT RES, V67, P1075, DOI 10.1177/00220345880670080301; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V178, P336, DOI 10.1016/0006-291X(91)91819-X; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; OKUDA K, 1974, ARCH ORAL BIOL, V19, P415, DOI 10.1016/0003-9969(74)90184-8; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; PIKE R, 1994, J BIOL CHEM, V269, P406; POTEMPA J, 1995, TRENDS MICROBIOL, V3, P430, DOI 10.1016/S0966-842X(00)88996-9; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; Shibata Y, 1998, INFECT IMMUN, V66, P2207, DOI 10.1128/IAI.66.5.2207-2212.1998; Slakeski N, 1996, BIOCHEM BIOPH RES CO, V224, P605, DOI 10.1006/bbrc.1996.1073; SLOTS J, 1984, J DENT RES, V63, P412, DOI 10.1177/00220345840630031101; SLOTS J, 1978, INFECT IMMUN, V19, P254, DOI 10.1128/IAI.19.1.254-264.1978; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; Yoneda M, 1996, ORAL MICROBIOL IMMUN, V11, P129, DOI 10.1111/j.1399-302X.1996.tb00347.x	42	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5012	5020		10.1074/jbc.274.8.5012	http://dx.doi.org/10.1074/jbc.274.8.5012			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988746	hybrid			2022-12-27	WOS:000078698200071
J	Frohnert, BI; Hui, TY; Bernlohr, DA				Frohnert, BI; Hui, TY; Bernlohr, DA			Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; RETINOID-X RECEPTOR; COA OXIDASE GENE; BINDING-PROTEIN; PPAR-GAMMA; PREADIPOCYTE DIFFERENTIATION; ADIPOCYTE; EXPRESSION; INDUCTION; MEMBRANE	Fatty acid transport protein (FATP), a plasma membrane protein implicated in controlling adipocyte transmembrane fatty acid flux, is up-regulated as a consequence of adipocyte differentiation and down-regulated by insulin, Based upon the sequence of the FATP gene upstream region (Hui, T. Y,, Frohnert, B. I., Smith, A. J., Schaffer, J. A, and Bernlohr, D, A, (1998) J. Biol, Chem. 273, 27420-27429) a putative peroxisome proliferator-activated receptor response element (PPRE) is present from -458 to -474. To determine whether the FATP PPRE was functional, and responded to lipid activators, transient transfection of FATP-luciferase reporter constructs into CV-1 and 3T3-L1 cells was carried out. In CV-1 cells, FATP-luciferase activity was up-regulated 4- and 5.5-fold, respectively, by PPAR alpha and PPAR gamma in the presence of their respective activators in a PPRE-dependent mechanism. PPAR delta, however, was unable to mediate transcriptional activation under any condition. In 3T3-L1 cells, the PPRE conferred a small but significant increase in expression in preadipocytes, as well as a more robust up-regulation of FATP expression in adipocytes. Furthermore, the PPRE conferred the ability for luciferase expression to be up-regulated by activators of both PPAR gamma and retinoid X receptor alpha (RXR alpha) in a synergistic manner. PPAR alpha and PPAR delta activators did not up-regulate FATP expression in 3T3-L1 adipocytes, however, suggesting that these two subtypes do not play a significant role in differentiation-dependent activation in fat cells. Electromobility shift assays showed that all three PPAR subtypes were able to bind specifically to the PPRE as heterodimers with RXR alpha. Nuclear extracts from 3T3-L1 adipocytes also showed a specific gel-shift complex with the FATP PPRE. To correlate the expression of FATP to its physiological function, treatment of 3T3-L1 adipocytes with PPAR gamma and RXR alpha activators resulted in an increased uptake of oleate. Moreover, linoleic acid, a physiological ligand, up-regulated FATP expression 2-fold in a PPRE-dependent manner. These results demonstrate that the FATP gene possesses a functional PPRE and is up-regulated by activators of PPAR alpha and PPAR gamma, thereby linking the activity of the protein to the expression of its gene. Moreover, these results have implications for the mechanism by which certain PPAR gamma activators such as the antidiabetic thiazolidinedione drugs affect adipose lipid metabolism.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA.			Frohnert, Brigitte/0000-0002-6636-4048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fitscher BA, 1996, P SOC EXP BIOL MED, V212, P15; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FUJII S, 1987, J BIOCHEM-TOKYO, V101, P679, DOI 10.1093/jb/101.3.679; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Hui TY, 1998, J BIOL CHEM, V273, P27420, DOI 10.1074/jbc.273.42.27420; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Montague CT, 1998, DIABETES, V47, P1384, DOI 10.2337/diabetes.47.9.1384; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, BIOCHIM BIOPHYS ACTA, V877, P191, DOI 10.1016/0005-2760(86)90134-7; STREMMEL W, 1985, J CLIN INVEST, V75, P1068, DOI 10.1172/JCI111769; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; TURCOTTE LP, 1991, FEBS LETT, V279, P327, DOI 10.1016/0014-5793(91)80180-B; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	57	203	218	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3970	3977		10.1074/jbc.274.7.3970	http://dx.doi.org/10.1074/jbc.274.7.3970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933587	hybrid			2022-12-27	WOS:000078575500011
J	Kraev, A; Kraev, N; Carafoli, E				Kraev, A; Kraev, N; Carafoli, E			Identification and functional expression of the plasma membrane calcium ATPase gene family from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; CA-2+ PUMP; CA2+ PUMP; LIMITED PROTEOLYSIS; MESSENGER-RNAS; TRANSPORT; HOMOLOG; CA2+-ATPASE	Calcium-pumping ATPases are an essential component of the intracellular calcium homeostasis system and have been characterized in a large variety of species and cell types. In mammalian genomes, these proteins are encoded by gene families whose individual members feature complex: tissue-specific expression and alternative splicing. ale the search for a less complex system that is more amenable to genetic manipulation, we have identified a family of three genes (mca-1, mca-2, rand mca-3) encoding putative calcium ATPases in the Caenorhabditis elegans Genome Project data and completed their transcript structure. In this work, we report the cloning and functional expression of the mca-l gene, which encodes a calcium-stimulated ATPase whose features resemble those of the plasma membrane calcium adenosine triphosphatase family of mammalian cells and appears to be regulated by a multipartite promoter.	ETH Zurich, Lab Biochem 3, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Padua, Dept Biol Chem, I-35121 Padua, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Padua	Carafoli, E (corresponding author), ETH Zurich, Lab Biochem 3, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	carafoli@bc.biol.ethz.ch	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				Ahringer J, 1997, CURR OPIN GENET DEV, V7, P410, DOI 10.1016/S0959-437X(97)80157-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BAYLIS H, 1998, EUR WORM M SANG CT T, V7; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Catty P, 1996, BIOSCIENCE REP, V16, P75, DOI 10.1007/BF01206198; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davis RE, 1996, PARASITOL TODAY, V12, P33, DOI 10.1016/0169-4758(96)80643-0; DAVIS RE, 1994, J BIOL CHEM, V269, P20026; DEMENDONCA RL, 1995, MOL BIOCHEM PARASIT, V72, P129, DOI 10.1016/0166-6851(95)00078-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Korswagen HC, 1996, P NATL ACAD SCI USA, V93, P14680, DOI 10.1073/pnas.93.25.14680; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maryon EB, 1996, J CELL BIOL, V134, P885, DOI 10.1083/jcb.134.4.885; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PLASTERK RH, 1998, EUR WORM M SANG CT T, V17; Sakube Y, 1997, J MOL BIOL, V267, P849, DOI 10.1006/jmbi.1997.0910; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008	43	15	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4254	4258		10.1074/jbc.274.7.4254	http://dx.doi.org/10.1074/jbc.274.7.4254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933625	hybrid			2022-12-27	WOS:000078575500049
J	Thompson, SJ; Robinson, C; Mant, A				Thompson, SJ; Robinson, C; Mant, A			Dual signal peptides mediate the signal recognition particle Sec-independent insertion of a thylakoid membrane polyprotein, psbY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-TRANSPORT; TRANSIT PEPTIDE; PHOTOSYSTEM-II; INTEGRATION; PATHWAY; REQUIREMENTS; POLYPEPTIDE; COMPONENT; MACHINERY	The nuclear psbY gene (formerly ycf32) encodes two distinct single-spanning chloroplast thylakoid membrane proteins in Arabidopsis thaliana, After import into the chloroplast, the precursor protein is processed to a polyprotein in which each "mature" protein is preceded by an additional hydrophobic region; we show that these regions function as signal peptides that are cleaved after insertion into the thylakoid membrane. Inhibition of the first or second signal cleavage reaction by enlargement of the -1 residues leads in each case to the accumulation of a thylakoid-integrated intermediate containing three hydrophobic regions after import into chloroplasts; a double mutant is converted to a protein containing all four hydrophobic regions. We propose that the overall insertion process involves (i) insertion as a double-loop structure, (ii) two cleavages by the thylakoidal processing peptidase on the lumenal face of the membrane, and (iii) cleavage by an unknown peptidase on the stromal face on the membrane between the first mature protein and the second signal peptide. We also show that this polyprotein can insert into the thylakoid membrane in the absence of stromal factors, nucleoside triphosphates, or a functional Sec apparatus; this effectively shows for the first time that a multispanning protein can insert posttranslationally without the aid of signal recognition particle, SecA, or the membrane-bound Sec machinery.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	CG@dna.bio.warwick.ac.uk		Thompson, Simon/0000-0003-0769-8555; Mant, Alexandra/0000-0001-7169-209X				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRASSILANA M, 1996, EMBO J, V15, P5202; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLINE K, 1992, J BIOL CHEM, V267, P2688; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DeGier JWL, 1997, FEBS LETT, V408, P1, DOI 10.1016/S0014-5793(97)00402-X; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Gau AE, 1998, MOL GEN GENET, V260, P56, DOI 10.1007/s004380050870; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENRY R, 1994, J BIOL CHEM, V269, P10189; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 1998, FEBS LETT, V423, P183, DOI 10.1016/S0014-5793(98)00089-1; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; Robinson C, 1998, PLANT MOL BIOL, V38, P209, DOI 10.1023/A:1006041917853; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4059	4066		10.1074/jbc.274.7.4059	http://dx.doi.org/10.1074/jbc.274.7.4059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933598	hybrid			2022-12-27	WOS:000078575500022
J	Melkonian, KA; Ostermeyer, AG; Chen, JZ; Roth, MG; Brown, DA				Melkonian, KA; Ostermeyer, AG; Chen, JZ; Roth, MG; Brown, DA			Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts - Many raft proteins are acylated, while few are prenylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; KIDNEY EPITHELIAL-CELLS; GPI-ANCHORED PROTEINS; TYROSINE KINASE; PLASMA-MEMBRANE; TRANSMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; T-CELLS; CAVEOLAE; CHOLESTEROL	Sphingolipid and cholesterol-rich Triton X-100-insoluble membrane fragments (detergent-resistant membranes, DRMs) containing lipids in a state similar to the liquid-ordered phase can be isolated from mammalian cells, and probably exist as discrete domains or rafts in intact membranes. We postulated that proteins with a high affinity for such an ordered lipid environment might be targeted to rafts. Saturated acyl chains should prefer an extended conformation that would fit well in rafts. In contrast, prenyl groups, which are as hydrophobic as acyl chains but have a branched and bulky structure, should be excluded from rafts. Here, we showed that at least half of the proteins in Madin-Darby canine kidney cell DRMs (other than cytoskeletal contaminants) could be labeled with [H-3]palmitate. Association of influenza hemagglutinin with DRMs required all three of its palmitoylated Cys residues. Prenylated proteins, detected by [H-3]mevalonate labeling or by blotting for Rap1, Rab5, G(beta), or Ras, were excluded from DRMs. Rab5 and H-Ras each contain more than one lipid group, showing that hydrophobicity alone does not target multiply lipid-modified proteins to DRMs. Partitioning of covalently linked saturated acyl chains into liquid-ordered phase domains is likely to be an important mechanism for targeting proteins to DRMs.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	dbrown@mcbsgi.bio.sunysb.edu		Roth, Michael/0000-0002-9056-332X; Chen, Zhe/0000-0002-1668-4051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897, R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47897, GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DOERING TL, 1990, J BIOL CHEM, V265, P611; Draberova L, 1996, IMMUNOLOGY, V87, P141; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FAUST J, 1987, J BIOL CHEM, V262, P1996; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JONES PP, 1984, METHOD ENZYMOL, V108, P452; JONES PP, 1980, SELECTED METHODS CEL, P398; KIM CM, 1992, J BIOL CHEM, V267, P23113; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NAIM HY, 1992, J VIROL, V66, P7585, DOI 10.1128/JVI.66.12.7585-7588.1992; NEAME SJ, 1995, J CELL SCI, V108, P3127; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; PERSCHL A, 1995, J CELL SCI, V108, P1033; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHERNOYSCARIA AM, 1994, J CELL BIOL, V126, P353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SPIEGEL S, 1984, J CELL BIOL, V99, P1575, DOI 10.1083/jcb.99.5.1575; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHAO YH, 1990, ONCOGENE, V5, P1629	77	536	544	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3910	3917		10.1074/jbc.274.6.3910	http://dx.doi.org/10.1074/jbc.274.6.3910			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920947	hybrid			2022-12-27	WOS:000078428200087
J	Schindler, T; Graumann, PL; Perl, D; Ma, SF; Schmid, FX; Marahiel, MA				Schindler, T; Graumann, PL; Perl, D; Ma, SF; Schmid, FX; Marahiel, MA			The family of cold shock proteins of Bacillus subtilis - Stability and dynamics in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-BOX PROTEINS; ESCHERICHIA-COLI; MESSENGER-RNA; CRYSTAL-STRUCTURE; CSPA; BINDING; DOMAIN; EXPRESSION; ACID; DNA	Bacillus subtilis possesses three homologous small cold shock proteins (CSPs; CspB, CspC, CspD, sequence identity >72%). They share a similar beta-sheet structure, as shown by circular dichroism, and have a very low conformational stability, with CspC being the least stable. Similar to CspB, CspC and CspD unfold and refold extremely fast in a N reversible arrow U two-state reaction with average lifetimes of only 100-150 ms for the native state and 1-6 ms for the unfolded states at 25 degrees C. As a consequence of their low stability and low kinetic protection against unfolding, all three cold shock proteins are rapidly degraded by proteases in vitro, Analysis of the CSP stabilities in vivo by pulse-chase experiments revealed that CspB and CspD are stable during logarithmic growth at 37 degrees C as well as after cold shock. The cellular half-life of CspC is shortened at 37 degrees C, but under cold shock conditions CspC becomes stable. The proteolytic susceptibility of the CSPs in vitro was strongly reduced in the presence of a nucleic acid ligand, suggesting that the observed stabilization of CSPs in vivo is mediated by binding to their substrate mRNA at 37 degrees C and, in particular, under cold shock conditions.	Univ Bayreuth, Biochem Lab, D-95440 Bayreuth, Germany; Univ Marburg, Fachbereich Chem, D-35032 Marburg, Germany	University of Bayreuth; Philipps University Marburg	Graumann, PL (corresponding author), Harvard Univ, Biol Labs, Cambridge, MA 02138 USA.	graumann@fas.harvard.edu		Graumann, Peter/0000-0002-8033-5171				Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandi A, 1996, MOL MICROBIOL, V19, P231, DOI 10.1046/j.1365-2958.1996.362897.x; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; Graumann P, 1997, MOL GEN GENET, V253, P745, DOI 10.1007/s004380050379; GRAUMANN P, 1994, FEBS LETT, V338, P157, DOI 10.1016/0014-5793(94)80355-2; Graumann P, 1996, J BACTERIOL, V178, P4611, DOI 10.1128/jb.178.15.4611-4619.1996; Graumann P, 1997, MOL MICROBIOL, V25, P741, DOI 10.1046/j.1365-2958.1997.5121878.x; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; JIANG WN, 1993, J BACTERIOL, V175, P5824, DOI 10.1128/JB.175.18.5824-5828.1993; Jiang WN, 1997, J BIOL CHEM, V272, P196; Jones PG, 1996, MOL MICROBIOL, V21, P1207, DOI 10.1111/j.1365-2958.1996.tb02582.x; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Mayr B, 1996, J BACTERIOL, V178, P2916, DOI 10.1128/jb.178.10.2916-2925.1996; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Reid KL, 1998, PROTEIN SCI, V7, P470; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; Schindler T, 1996, BIOCHEMISTRY-US, V35, P16833, DOI 10.1021/bi962090j; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x	34	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3407	3413		10.1074/jbc.274.6.3407	http://dx.doi.org/10.1074/jbc.274.6.3407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920884	hybrid			2022-12-27	WOS:000078428200024
J	Mazzucato, M; Spessotto, P; Masotti, A; De Appollonia, L; Cozzi, MR; Yoshioka, A; Perris, R; Colombatti, A; De Marco, L				Mazzucato, M; Spessotto, P; Masotti, A; De Appollonia, L; Cozzi, MR; Yoshioka, A; Perris, R; Colombatti, A; De Marco, L			Identification of domains responsible for von Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; HUMAN VASCULAR SUBENDOTHELIUM; MEMBRANE GLYCOPROTEIN-IB; A3 DOMAIN; A1 DOMAIN; EXTRACELLULAR-MATRIX; MULTIPLE FORMS; FIBRINOGEN; DISEASE; LOCALIZATION	We have identified type VI collagen (Col VI) as a primary subendothelial extracellular matrix component responsible for von Willebrand factor (vWF)-dependent platelet adhesion and aggregation under high tensile strength. Intact tetrameric Col VI was the form of the collagen found to be capable of promoting vWF-mediated platelet adhesion/aggregation under this shear condition, whereas removal of the predominant portion of the terminal globules by pepsin treatment abrogated its activity. The inability of the pepsin-digested Col VI to support any platelet interaction at high flow was because of the failure of the A3(vWF) domain to bind to this form of collagen, suggesting a stringent requirement of a tridimensional conformation or of intactness of its macromolecular structure. In contrast, the A1(vWF) domain bound to both intact and pepsin-digested Col VI tetramers but, in accordance with the cooperating function of the two vWF domains, failed to support platelet adhesion/aggregation under high shear onto Col VI by itself. The putative A1(vWF) binding site resided within the A7(VI) module (residues 413-613) of the globular amino-terminal portion of the alpha 3(VI) chain. Soluble recombinant A7(VI) poly-peptide strongly perturbed the vWF-mediated platelet adhesion to Col VI under high shear rates, without affecting the binding of the vWF platelet receptor glycoprotein Ib alpha to its cognate ligand A1(vWF), The findings provide evidence for a concerted action of the A1(vWF) and A3(vWF) domains in inducing platelet arrest on Col VI, This is accomplished via an interaction of the A1(vWF) domain with a site contained in the alpha 3 chain A7(VI) domain and via a conformation-dependent interaction of the A3(vWF) domain with the intact tetrameric collagen, The data further emphasize that Col VI microfilaments linking the subendothelial basement membrane to the interstitial collagenous network may play a pivotal role in the hemostatic process triggered upon damage of the blood vessel wall.	Ctr Riferimento Oncol, Serv Immunotrasfus & Anal Clin, Inst Nazl Tumori Ctr Europeo, I-33081 Aviano, PN, Italy; Ctr Riferimento Oncol, Div Oncol Sperimentale 2, Inst Nazl Tumori Ctr Europeo, I-33081 Aviano, PN, Italy; Nara Med Univ, Dept Pediat, Kashihara, Nara 634, Japan; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Parma, Dept Evolutionary & Funct Biol, I-43100 Parma, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO); Nara Medical University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Parma	De Marco, L (corresponding author), Ctr Riferimento Oncol, Serv Immunotrasfus & Anal Clin, Inst Nazl Tumori Ctr Europeo, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	ldemarco@ets.it	Mazzucato, Mario/ABF-5472-2020; Cozzi, Maria Rita/ABD-7970-2020; Spessotto, Paola/K-5005-2012	Mazzucato, Mario/0000-0001-8319-053X; Cozzi, Maria Rita/0000-0001-6841-2632; Spessotto, Paola/0000-0002-3033-404X; colombatti, alfonso/0000-0002-3676-2379				AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; BAHNAK BR, 1989, J CELL PHYSIOL, V138, P305, DOI 10.1002/jcp.1041380212; BARUCH D, 1991, BLOOD, V77, P519; BEUMER S, 1995, BLOOD, V86, P3452, DOI 10.1182/blood.V86.9.3452.bloodjournal8693452; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CHRISTOPHE O, 1995, BRIT J HAEMATOL, V90, P195, DOI 10.1111/j.1365-2141.1995.tb03400.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; COLOMBATTI A, 1996, SUPERFAMILY VONWILLE; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DEMARCO L, 1987, J CLIN INVEST, V80, P475, DOI 10.1172/JCI113095; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; Doliana R, 1998, MATRIX BIOL, V16, P427, DOI 10.1016/S0945-053X(98)90015-4; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; Galbusera M, 1997, BLOOD, V90, P1558, DOI 10.1182/blood.V90.4.1558.1558_1558_1564; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Godyna S, 1996, BLOOD, V88, P2569, DOI 10.1182/blood.V88.7.2569.bloodjournal8872569; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Gralnick HR, 1996, THROMB RES, V81, P113, DOI 10.1016/0049-3848(95)00219-7; HANDA M, 1986, J BIOL CHEM, V261, P2579; HILBERT L, 1994, BLOOD, V83, P1542; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Keene DR, 1998, J HISTOCHEM CYTOCHEM, V46, P215, DOI 10.1177/002215549804600210; KEHREL B, 1993, BLOOD, V82, P3364; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; KUO HJ, 1989, BIOCHEMISTRY-US, V28, P3757, DOI 10.1021/bi00435a020; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; Lankhof H, 1997, BLOOD, V89, P2766, DOI 10.1182/blood.V89.8.2766; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; MOHRI H, 1989, J BIOL CHEM, V264, P17361; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIJA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; Pareti FI, 1996, THROMB HAEMOSTASIS, V76, P460; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; PERRIS R, 1993, DEV DYNAM, V198, P135, DOI 10.1002/aja.1001980207; POLANOWSKAGRABOWSKA R, 1992, P NATL ACAD SCI USA, V89, P5754, DOI 10.1073/pnas.89.13.5754; RAND JH, 1993, AM J PATHOL, V142, P843; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; ROSS JM, 1995, BLOOD, V85, P1826, DOI 10.1182/blood.V85.7.1826.bloodjournal8571826; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SAELMAN EUM, 1994, BLOOD, V83, P1244; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SEGAT D, 1994, BLOOD, V83, P1586; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SINHA D, 1994, BIOCHEM BIOPH RES CO, V203, P881, DOI 10.1006/bbrc.1994.2265; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; Tsuji S, 1996, BLOOD, V88, P3854, DOI 10.1182/blood.V88.10.3854.bloodjournal88103854; VANGENDEREN PJJ, 1994, BLOOD, V84, P3378; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; Wu XX, 1996, AM J PATHOL, V149, P283; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967; [No title captured]	65	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3033	3041		10.1074/jbc.274.5.3033	http://dx.doi.org/10.1074/jbc.274.5.3033			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915842	hybrid			2022-12-27	WOS:000078319500060
J	Neptune, ER; Iiri, T; Bourne, HR				Neptune, ER; Iiri, T; Bourne, HR			G alpha(i) is not required for chemotaxis mediated by G(i)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEINS; SPECIFICITY; RESPONSIVENESS; INTERLEUKIN-8; ACTIVATION; LEUKOCYTE; CELLS	Pertussis toxin inhibits chemotaxis of neutrophils by preventing chemoattractant receptors from activating trimeric G proteins in the G(i) subfamily. In HEK293 cells expressing recombinant receptors, directional migration toward appropriate agonist ligands requires release of free G protein beta gamma subunits and can be triggered by agonists for receptors coupled to G(i) but not by agonists for receptors coupled to two other G proteins, G(s) and G(q). Because activation of any G protein presumably releases free G beta gamma, we tested the hypothesis that chemotaxis also requires activated alpha subunits (G alpha(i)) of G(i) proteins. HEK293 cells were stably cotransfected with the G(i)-coupled receptor for interleukin-8, CXCR1, and with a chimeric G alpha G alpha(qz5) which resembles G alpha(i) in susceptibility to activation by G(i)-coupled receptors but cannot regulate the G alpha(i) effector, adenylyl cyclase, These cells, unlike cells expressing CXCR1 alone, migrated toward interleukin-8 even after treatment with pertussis toxin, which prevents activation of endogenous G alpha(i) but not that of G alpha(qz5). We infer that chemotaxis does not require activation of G alpha(i). Because chemotaxis is mediated by G beta gamma subunits released when G(i)-coupled receptors activate G alpha(qz5) but not when G(q)- or G(s)-coupled receptors activate their respective G proteins, we propose that G(i)-coupled receptors transmit a necessary chemotactic signal that is independent of G alpha(i).	Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, S-1212,Box 04500, San Francisco, CA 94143 USA.				NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DAI YL, 1994, J LEUKOCYTE BIOL, V56, P776, DOI 10.1002/jlb.56.6.776; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Elferink JGR, 1996, GEN PHARMACOL-VASC S, V27, P387, DOI 10.1016/0306-3623(95)00070-4; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARVATH L, 1991, J IMMUNOL, V146, P224; IIRI T, 1995, J BIOL CHEM, V270, P5901, DOI 10.1074/jbc.270.11.5901; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAW SF, 1993, J BIOL CHEM, V268, P10721; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Ueda H, 1997, J CELL SCI, V110, P1503; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197	32	111	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2824	2828		10.1074/jbc.274.5.2824	http://dx.doi.org/10.1074/jbc.274.5.2824			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915816	hybrid			2022-12-27	WOS:000078319500034
J	Pei, L				Pei, L			Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MESSENGER-RNAS; CDNA CLONE; YEAST; EXPRESSION; PHOSPHOPROTEIN; PURIFICATION	Pituitary tumor-transforming gene (PTTG) is a recently characterized proto-oncogene that is expressed specifically in adult testis, In this study, we have used in situ hybridization and developmental Northern blot assays to demonstrate that PTTG mRNA is expressed stage-specifically in spermatocytes and spermatids during rat spermatogenic cycle. We have used the yeast two-hybrid system to identify proteins that interact with PTTG in testicular cells. Two positive clones were characterized. One of the clones is the ribosomal protein S10, the other encodes a novel human DnaJ homologue designated HSJ2. Northern blot analysis showed that testis contains higher levels of HSJ2 mRNA than other tissues examined, and the expression pattern of HSJ2 mRNA in postnatal rat testis is similar to PTTG. S10 mRNA levels do not vary remarkably among different tissues and remains unchanged during testicular germ cell differentiation. In vitro binding assays demonstrated that both S10 and HSJ2 bind to PTTG specifically and that PTTG can be co-immunoprecipitated with S10 and HSJ2 from transfected cells. Moreover, the binding sites for both proteins were located within the C-terminal 75 amino acids of the PTTG protein. These results suggest that PTTG may play a role in spermatogenesis.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, 8700 Beverly Blvd,D-3066, Los Angeles, CA 90048 USA.	pei@cshs.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BARNARD GF, 1992, CANCER RES, V52, P3067; Berruti G, 1998, EXP CELL RES, V239, P430, DOI 10.1006/excr.1997.3879; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; GATEFF E, 1994, INT J DEV BIOL, V38, P565; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDSTONE SD, 1993, BIOCHEM BIOPH RES CO, V196, P619, DOI 10.1006/bbrc.1993.2294; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KONDOH N, 1992, CANCER RES, V52, P791; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MAHESHWARI Y, 1993, CELL GROWTH DIFFER, V4, P745; Malkov M, 1998, BIOL REPROD, V59, P84, DOI 10.1095/biolreprod59.1.84; MANOVA K, 1990, DEVELOPMENT, V110, P1057; OHKI M, 1986, J BIOL CHEM, V261, P1778; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHARP MGF, 1990, BRIT J CANCER, V61, P83, DOI 10.1038/bjc.1990.19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WESTERMANN P, 1983, BIOCHIM BIOPHYS ACTA, V741, P103, DOI 10.1016/0167-4781(83)90015-5; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	40	37	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3151	3158		10.1074/jbc.274.5.3151	http://dx.doi.org/10.1074/jbc.274.5.3151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915854	hybrid			2022-12-27	WOS:000078319500072
J	Hao, WS; Fong, HKW				Hao, WS; Fong, HKW			The endogenous chromophore of retinal G protein-coupled receptor opsin from the pigment epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; VITAMIN-A; BOVINE RETINA; RETINOCHROME; DEHYDROGENASE; RHODOPSIN; 11-CIS-RETINOL; CLONING; HOMOLOG; PINEAL	The recent identification of nonvisual opsins has revealed an expanding family of vertebrate opsin genes. The retinal pigment epithelium (RPE) and Muller cells contain a blue and UV light-absorbing opsin, the RPE retinal G protein-coupled receptor (RGR, or RGR opsin). The spectral properties of RGR purified from bovine RPE suggest that RGR is conjugated in vivo to a retinal chromophore through a covalent Schiff base bond. In this study, the isomeric structure of the endogenous chromophore of RGR was identified by the hydroxylamine derivatization method. The retinaloximes derived from RGR in the dark consisted predominantly of the all-trans isomer. Irradiation of RGR with 470-nm monochromatic or near-UV light resulted in stereospecific isomerization of the bound all-trans-retinal to an 11-cis configuration. The stereospecificity of photoisomerization of the all-trans-retinal chromophore of RGR was lost by denaturation of the protein in SDS. Under the in vitro conditions, the photosensitivity of RGR is at least 34% that of bovine rhodopsin. These results provide evidence that RGR is bound in vivo primarily to all-transretinal and is capable of operating as a stereospecific photoisomerase that generates 11-cis-retinal in the pigment epithelium.	Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	Doheny Eye Institute; University of Southern California; University of Southern California	Fong, HKW (corresponding author), Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.	hfong@hsc.usc.edu			NATIONAL EYE INSTITUTE [R01EY008364, P30EY003040] Funding Source: NIH RePORTER; NEI NIH HHS [EY03040, EY08364] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERMAN ER, 1985, CURR EYE RES, V4, P867, DOI 10.3109/02713688509095254; BLANER WS, 1987, J BIOL CHEM, V262, P53; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; Dartnall H. J. A., 1972, HDB SENSORY PHYSIOLO, V7, P122; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; FUTTERMAN S, 1977, J BIOL CHEM, V252, P3267; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; HARA T, 1982, METHOD ENZYMOL, V81, P190; HARA T, 1987, RETINAL PROTEINS, P457; HARANISHIMURA I, 1990, FEBS LETT, V271, P106, DOI 10.1016/0014-5793(90)80383-T; HONG K, 1982, METHOD ENZYMOL, V81, P144; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; Mata NL, 1998, INVEST OPHTH VIS SCI, V39, P1312; MAX M, 1995, SCIENCE, V267, P1502, DOI 10.1126/science.7878470; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OZAKI K, 1986, VISION RES, V26, P691, DOI 10.1016/0042-6989(86)90083-0; OZAKI K, 1983, BIOPHYS J, V44, P127, DOI 10.1016/S0006-3495(83)84285-4; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RANDO RR, 1991, PROGR RETINAL RES, V10, P161; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; TERAKITA A, 1989, VISION RES, V29, P639, DOI 10.1016/0042-6989(89)90026-6; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	38	110	110	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6085	6090		10.1074/jbc.274.10.6085	http://dx.doi.org/10.1074/jbc.274.10.6085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037690	hybrid			2022-12-27	WOS:000078902800012
J	Joyce, JG; Tung, JS; Przysiecki, CT; Cook, JC; Lehman, ED; Sands, JA; Jansens, KU; Keller, PM				Joyce, JG; Tung, JS; Przysiecki, CT; Cook, JC; Lehman, ED; Sands, JA; Jansens, KU; Keller, PM			The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-SUPEROXIDE-DISMUTASE; CERVICAL INTRAEPITHELIAL NEOPLASIA; FIBROBLAST GROWTH-FACTOR; BETA-D-XYLOSIDES; SACCHAROMYCES-CEREVISIAE; SULFATE PROTEOGLYCANS; ANTITHROMBIN-III; INSECT CELLS; IN-VITRO; BINDING	The L1 major capsid protein of human papillomavirus (HPV) type 11, a 55-kDa polypeptide, forms particulate structures resembling native virus with an average particle diameter of 50-60 nm when expressed in the yeast Saccharomyces cerevisiae. me show in this report that these virus-like particles (VLPs) interact with heparin and with cell-surface glycosaminoglycans (GAGs) resembling heparin on keratinocytes and Chinese hamster ovary cells. The binding of VLPs to heparin is shown to exhibit an affinity comparable to that of other identified heparin-binding proteins. Immobilized heparin chromatography and surface plasmon resonance were used to show that this interaction can be specifically inhibited by free heparin and dextran sulfate and that the effectiveness of the inhibitor is related to its molecular weight and charge density. Sequence comparison of nine human L1 types revealed a conserved region of the carboxyl terminus containing clustered basic amino acids that bear resemblance to proposed heparin-binding motifs in unrelated proteins. Specific enzymatic cleavage of this region eliminated binding to both immobilized heparin and human keratinocyte (HaCaT) cells. Removal of heparan sulfate GAGs on keratinocytes by treatment with heparinase or heparitinase resulted in an 80-90% reduction of VLP binding, whereas treatment of cells with laminin, a substrate for cu, integrin receptors, provided minimal inhibition. Cells treated with chlorate or substituted beta-D-xylosides, resulting in under-sulfation or secretion of GAG chains, also showed a reduced affinity for VLPs. Similarly, binding of VLPs to a Chinese hamster ovary cell mutant deficient in GAG synthesis was shown to be only 10% that observed for wild type cells. This report establishes for the first time that the carboxyl-terminal portion of HPV L1 interacts with heparin, and that this region appears to be crucial for interaction with the cell surface.	Merck Res Labs, Dept Virus & Cell Biol, West Point, PA 19486 USA; Merck Res Labs, Dept Bioproc & Bioanalyt Res, Rahway, NJ 07065 USA; Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA	Merck & Company; Merck & Company; Lehigh University	Joyce, JG (corresponding author), Merck Res Labs, Dept Virus & Cell Biol, Sumneytown Pike, West Point, PA 19486 USA.							ABBOTT NL, 1993, ACS SYM SER, V532, P53; BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARLSON TH, 1995, BLOOD COAGUL FIBRIN, V6, P474, DOI 10.1097/00001721-199507000-00016; CARTER JJ, 1991, VIROLOGY, V182, P513, DOI 10.1016/0042-6822(91)90592-Y; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; DILLNER J, 1995, INT J CANCER, V60, P377; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; FRITZ TA, 1994, J BIOL CHEM, V269, P300; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; HAGENSEE ME, 1993, J VIROL, V67, P315, DOI 10.1128/JVI.67.1.315-322.1993; HAGGERTY JG, 1994, J CELL PHYSIOL, V158, P39, DOI 10.1002/jcp.1041580106; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOFMANN KJ, 1995, VIROLOGY, V209, P506, DOI 10.1006/viro.1995.1283; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; HOVINGH P, 1993, EUR J BIOCHEM, V211, P771, DOI 10.1111/j.1432-1033.1993.tb17608.x; HOWLEY PM, 1990, VIROLOGY, P1625; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; KLUG A, 1965, J MOL BIOL, V11, P403, DOI 10.1016/S0022-2836(65)80066-3; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LIANG XP, 1993, VIROLOGY, V194, P233, DOI 10.1006/viro.1993.1254; Linker A., 1972, METHODS ENZYMOL, P902; Lowe RS, 1997, J INFECT DIS, V176, P1141, DOI 10.1086/514105; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MULLER M, 1995, J VIROL, V69, P948; MURRAY E, 1983, BIOCHIM BIOPHYS ACTA, V763, P299, DOI 10.1016/0167-4889(83)90138-6; Neeper MP, 1996, GENE, V180, P1, DOI 10.1016/S0378-1119(96)00388-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFISTER H, 1994, INTERVIROLOGY, V37, P143, DOI 10.1159/000150372; PIEPKORN M, 1995, IN VITRO CELL DEV-AN, V31, P536; ROSE RC, 1993, J VIROL, V67, P1936, DOI 10.1128/JVI.67.4.1936-1944.1993; SANDSTROM J, 1993, BIOCHEM J, V294, P853, DOI 10.1042/bj2940853; SAPP M, 1995, J GEN VIROL, V76, P2407, DOI 10.1099/0022-1317-76-9-2407; SASAGAWA T, 1995, VIROLOGY, V206, P126, DOI 10.1016/S0042-6822(95)80027-1; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Secchiero P, 1997, J VIROL, V71, P4571, DOI 10.1128/JVI.71.6.4571-4580.1997; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SLUZKY V, 1994, PHARMACEUT RES, V11, P485, DOI 10.1023/A:1018946011652; SMITH LH, 1995, J INVEST DERMATOL, V105, P438, DOI 10.1111/1523-1747.ep12321173; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TALSINGER R, 1995, J VIROL, V69, P4471, DOI 10.1128/JVI.69.7.4471-4483.1995; TOKUNAGA F, 1994, J BIOCHEM-TOKYO, V116, P1164, DOI 10.1093/oxfordjournals.jbchem.a124644; VOLPERS C, 1994, VIROLOGY, V200, P504, DOI 10.1006/viro.1994.1213; VOLPERS C, 1995, J VIROL, V69, P3258, DOI 10.1128/JVI.69.6.3258-3264.1995; WU HF, 1995, BLOOD, V85, P421; YOSHIDA T, 1993, POLYM J, V25, P1069, DOI 10.1295/polymj.25.1069; Zhu Z, 1995, NEUROLOGY, V45, pS15, DOI 10.1212/WNL.45.12_Suppl_8.S15	56	291	309	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5810	5822		10.1074/jbc.274.9.5810	http://dx.doi.org/10.1074/jbc.274.9.5810			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026203	hybrid			2022-12-27	WOS:000078804400074
J	Radisky, DC; Babcock, MC; Kaplan, J				Radisky, DC; Babcock, MC; Kaplan, J			The yeast frataxin homologue mediates mitochondrial iron efflux - Evidence for a mitochondrial, iron cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAA TRIPLET REPEAT; FRIEDREICH-ATAXIA; ABC TRANSPORTER; DESFERRIOXAMINE; ACCUMULATION; DEFICIENCY	Mutations in the nuclear gene encoding the mitochondrial protein frataxin are responsible for the neurological disorder Friedreich ataxia (FA). Yeast strains with a deletion in the frataxin homologue YFH1 accumulate excess iron in mitochondria and demonstrate mitochondrial damage. We show that in the absence of YFH1, mitochondrial damage is proportional to the concentration and duration of exposure to extracellular iron, establishing mitochondrial iron accumulation as causal to mitochondrial damage. Reintroduction of YFH1 results in the rapid export of accumulated mitochondrial iron into the cytosol as free, non-heme bound iron, demonstrating that mitochondrial iron in the yeast FA model can be made bioavailable. These results demonstrate a mitochondrial iron cycle in which Yfh1p regulates mitochondrial iron efflux.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.	kaplan@bioscience.biology.utah.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	NCI NIH HHS [CA42014] Funding Source: Medline; NIDDK NIH HHS [DK52380, DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219, R01DK052380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P3018; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972; GIARDINA PJ, 1995, SEMIN HEMATOL, V32, P304; HARDING AE, 1993, ADV NEUROL, V61, P1; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; KUSHNER JP, 1971, MEDICINE, V50, P139, DOI 10.1097/00005792-197105000-00001; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Miyajima H, 1997, ANN NEUROL, V41, P404, DOI 10.1002/ana.410410318; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Ponka P, 1997, BLOOD, V89, P1; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352	19	225	234	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4497	4499		10.1074/jbc.274.8.4497	http://dx.doi.org/10.1074/jbc.274.8.4497			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988680	hybrid			2022-12-27	WOS:000078698200005
J	Sartori, G; Aldegheri, L; Mazzotta, G; Lanfranchi, G; Tournu, H; Brown, AJP; Carignani, G				Sartori, G; Aldegheri, L; Mazzotta, G; Lanfranchi, G; Tournu, H; Brown, AJP; Carignani, G			Characterization of a new hemoprotein in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; GENE-EXPRESSION; STRESS-RESPONSE; FLAVOHEMOGLOBIN GENE; BACTERIAL HEMOGLOBIN; RHIZOBIUM-MELILOTI; RNA-POLYMERASE; OXYGEN SENSOR; PROTEIN; BINDING	The Saccharomyces cerevisiae gene YNL234w encodes a 426-amino acid-long protein that shares significant similarities with the globin family. Compared with known globins from unicellular organisms, the Ynl234wp polypeptide is characterized by an unusual structure. In this protein, a central putative heme-binding domain of about 140 amino acids is flanked by two sequences of about 160 and 120 amino acids, respectively, which share no similarity with known polypeptides. Northern analysis indicates that YNL234w transcription is very low in cells grown under normal aerobic conditions but is induced by oxygen-limited growth conditions and by other stress conditions such as glucose repression, heat shock, osmotic stress, and nitrogen starvation. However the deletion of the gene had no detectable effect on yeast growth. The Ynl234wp polypeptide has been expressed in Escherichia coli, and the hemoprotein nature of the recombinant protein was demonstrated by heme staining after SDS/polyacrylamide gel electrophoresis and spectroscopic analysis. Our data indicate that purified recombinant Ynl234wp possesses a noncovalently bound heme molecule that is predominantly found in a low spin form.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Padua; University of Padua; University of Aberdeen	Carignani, G (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	carigna@civ.bio.unipd.it	Brown, Alistair J.P./B-6627-2014	MAZZOTTA, GABRIELLA MARGHERITA/0000-0001-5461-6837				BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; BROWN AJP, 1995, METHODS YEAST MOL BI, P269; Buisson N, 1998, J BIOL CHEM, V273, P9527, DOI 10.1074/jbc.273.16.9527; Chantrel Y, 1998, GENETICS, V148, P559; Couture M, 1996, EUR J BIOCHEM, V242, P779, DOI 10.1111/j.1432-1033.1996.0779r.x; CRAMM R, 1994, J BIOL CHEM, V269, P7349; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Drabkin David L., 1942, JOUR BIOL CHEM, V146, P605; Evangelista CC, 1996, GENETICS, V142, P1083; GIETZ RD, 1995, YEAST, V11, P335; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1225, DOI 10.1021/bi00677a021; MARCHLER G, 1998, EMBO J, V14, P1997; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; NISHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P8863, DOI 10.1021/bi00085a018; OHANIANCE L, 1966, BIOCHIM BIOPHYS ACTA, V128, P228, DOI 10.1016/0926-6593(66)90170-6; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pandolfo D, 1996, YEAST, V12, P1071; PILLAR TM, 1991, CURR GENET, V20, P185, DOI 10.1007/BF00326230; PLANTA RJ, 1999, IN PRESS YEAST; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; Sambrook J., 2002, MOL CLONING LAB MANU; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAGI T, 1993, CURR OPIN STRUC BIOL, V3, P413, DOI 10.1016/S0959-440X(05)80115-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Thorsteinsson MV, 1996, BBA-PROTEIN STRUCT M, V1292, P133, DOI 10.1016/0167-4838(95)00178-6; TSUBAMOTO Y, 1990, EUR J BIOCHEM, V193, P55, DOI 10.1111/j.1432-1033.1990.tb19303.x; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71	46	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5032	5037		10.1074/jbc.274.8.5032	http://dx.doi.org/10.1074/jbc.274.8.5032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988749	hybrid			2022-12-27	WOS:000078698200074
J	Hoffmeyer, A; Grosse-Wilde, A; Flory, E; Neufeld, B; Kunz, M; Rapp, UR; Ludwig, S				Hoffmeyer, A; Grosse-Wilde, A; Flory, E; Neufeld, B; Kunz, M; Rapp, UR; Ludwig, S			Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor a gene expression in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION PATHWAY; TNF-ALPHA; CELLS; P38; MAP; PROMOTER; PHOSPHORYLATION	Tumor necrosis factor a (TNF-alpha) is a potent proinflammatory cytokine and plays a crucial role in early events of inflammation. TNF-alpha is primarily produced by monocytes and T lymphocytes, In particular, T-cell-derived TNF-alpha plays a critical role in autoimmune inflammation and superantigen-induced septic shock. However, little is known about the intracellular signaling pathways that regulate TNF expression in T cells. Here we show that extracellular signal-regulated kinase (ERK), c-dun N-terminal kinase (JNK), and p38-mitogen-activated protein kinase (MaPK) pathways control the transcription and synthesis of TNF-alpha in A3.01 T cells that produce the cytokine upon T cell activation by costimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and ionomycin, Selective activation of each if the distinct MaPK pathways by expression of constitutively active kinases is sufficient for TNF-alpha promoter induction. Furthermore, blockage of all three pathways almost abolishes TPA/ionomycin-induced transcriptional activation of the TNF-alpha promoter. Selective inhibition of one or more MATH pathways impairs TNF-alpha induction by TPA/ionomycin, indicating a cooperation between these signal transduction pathways. Our approach revealed that the MAPK kinase 6 (MKK6)/p38 pathway is involved in both transcriptional and posttranscriptional regulation of TNF expression. Moreover, analysis of the progressive 5' deletion mutants of the TNF-cr promoter indicates that distinct promoter regions are targeted by either ERK-, JNK-, or p38-activating pathways. Thus, unlike what has been reported for other TNF-alpha-producing cells, all three MAPK pathways are critical and cooperate to regulate transcription of the TNF-alpha gene in T lymphocytes, suggesting a T-cell-specific regulation of the cytokine.	Inst Med Strahlenkunde & Zellforsch MSZ, D-97078 Wurzburg, Germany; Univ Wurzburg, Klin & Poliklin Haut & Geschlechtskrankheiten, D-97078 Wurzburg, Germany	University of Wurzburg	Ludwig, S (corresponding author), Inst Med Strahlenkunde & Zellforsch MSZ, Versbacherstr 5, D-97078 Wurzburg, Germany.	IMSD019@rzbox.uni-wuerzburg.de		Ludwig, Stephan/0000-0003-4490-3052				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; DROUET C, 1991, J IMMUNOL, V147, P1694; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HAGEMANN D, 1999, IN PRES ONCOGENE; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jongeneel C V, 1994, Prog Clin Biol Res, V388, P367; Korner H, 1997, J EXP MED, V186, P1585, DOI 10.1084/jem.186.9.1585; KRAMER B, 1995, J INFLAMM, V45, P183; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Parry SL, 1997, J IMMUNOL, V158, P3673; PAUL S, 1994, INT J SOFTW ENG KNOW, V4, P325, DOI 10.1142/S0218194094000167; Prieschl EE, 1996, J IMMUNOL, V157, P2645; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Taupin VR, 1997, EUR J IMMUNOL, V27, P905, DOI 10.1002/eji.1830270416; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	56	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4319	4327		10.1074/jbc.274.7.4319	http://dx.doi.org/10.1074/jbc.274.7.4319			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933633	hybrid			2022-12-27	WOS:000078575500057
J	Hurst, ST; Rivier, DH				Hurst, ST; Rivier, DH			Identification of a compound origin of replication at the HMR-E locus in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-REPLICATION; FISSION YEAST; ARS ELEMENTS; RECOGNITION COMPLEX; CHROMOSOMAL DNA; FUNCTIONAL ELEMENTS; GENE AMPLIFICATION; SEQUENCE-ANALYSIS; DROSOPHILA	Eukaryotic chromosomal origins of replication are best defined in Saccharomyces cerevisiae. Previous analysis of yeast origins suggests that they are relatively simple structures comprised of three or four small DNA sequence elements contained within approximately 100-200-base pair regions (Gilbert, D. M. (1998) Curr. Opin. Genet. Dev. 8, 194-199). In contrast, the sequence elements that may comprise origins in multicellular eukaryotes are largely unknown. The yeast HMR-E region is both a chromosomal origin of replication and a silencer that represses transcription of adjacent genes through a position effect. The analysis presented here indicated that HMR-E had a novel DNA structure that was more complex than defined for other yeast origins, and thus revealed that there is variation in the structural complexity of yeast origins. In contrast to "simple" yeast origins, the origin at HMR-E consisted of at least three independent subregions that had the capacity to initiate replication. We have termed HMR-E a compound origin to reflect its structural complexity. Furthermore, only one origin within the compound origin was a silencer.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Rivier, DH (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin Ave, Urbana, IL 61801 USA.	rivier@uiuc.edu			NIGMS NIH HHS [5T32-GM07283, GM52103] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283, R01GM052103] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENBOW RM, 1992, BIOESSAYS, V14, P661, DOI 10.1002/bies.950141004; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; Donovan S, 1996, CURR OPIN GENET DEV, V6, P203; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; Gerbi SA, 1997, METHODS, V13, P271, DOI 10.1006/meth.1997.0526; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gilbert DM, 1998, CURR OPIN GENET DEV, V8, P194; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; Huang RY, 1996, NUCLEIC ACIDS RES, V24, P816, DOI 10.1093/nar/24.5.816; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; JAMES CD, 1986, MOL CELL BIOL, V6, P976, DOI 10.1128/MCB.6.4.976; JOHNSTON LH, 1987, MOL GEN GENET, V207, P161, DOI 10.1007/BF00331504; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; LEWIS EB, 1995, P NATL ACAD SCI USA, V92, P8403, DOI 10.1073/pnas.92.18.8403; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; LIANG C, 1993, GENE DEV, V7, P1072, DOI 10.1101/gad.7.6.1072; Lin S, 1997, MOL CELL BIOL, V17, P5473, DOI 10.1128/MCB.17.9.5473; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; Zhang Z, 1997, MOL CELL BIOL, V17, P6147, DOI 10.1128/MCB.17.10.6147; ZHU JG, 1994, CHROMOSOMA, V103, P414, DOI 10.1007/s004120050050	58	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4155	4159		10.1074/jbc.274.7.4155	http://dx.doi.org/10.1074/jbc.274.7.4155			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933610	hybrid			2022-12-27	WOS:000078575500034
J	Yu, LX; DeLeo, FR; Biberstine-Kinkade, KJ; Renee, J; Nauseef, WM; Dinauer, MC				Yu, LX; DeLeo, FR; Biberstine-Kinkade, KJ; Renee, J; Nauseef, WM; Dinauer, MC			Biosynthesis of flavocytochrome b(558) - gp91(phox) is synthesized as a 65-kDa precursor (p65) in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; NEUTROPHIL CYTOCHROME-B; PHAGOCYTE NADPH OXIDASE; CYTOSOLIC COMPONENT; PLASMA-MEMBRANE; ACTIVATION; EXPRESSION; MYELOPEROXIDASE; PROTEIN	The redox center of the phagocyte NADPH oxidase is flavocytochrome b(558), a transmembrane protein with two subunits, gp91(phox) and p22(phox). In this study we investigated the identity, subcellular localization, and maturation of a putative 65-kDa gp91(phox) precursor (p65), Expressing the gp91(phox) cDNA in an in vitro transcription and translation system, we found that synthesis of p65 required endoplasmic reticulum (ER) microsomes, Sucrose density gradient centrifugation of postnuclear supernatants obtained from a PLB-985 derived cell line with a constitutively expressed gp91(phox) transgene demonstrated that p65 co-sedimented with the ER marker protein calreticulin and myeloperoxidase precursors, Unexpectedly the majority of p22(phox) was found in subcellular compartments containing the mature 91-kDa form of gp91(phox) and not with p65, suggesting that heterodimer formation may occur in a post-ER compartment, The heme synthesis inhibitor, succinyl acetone, reduced the abundance of mature gp91(phox) and p22(phox) but had little or no impact on p65, These studies demonstrate (a) gp91(phox) is synthesized as a glycosylated 65-kDa precursor in the ER, (b) heterodimer formation is not a co-translational process, and (c) heme insertion is a determinant in the formation of a stable heterodimer but does not appear to affect the stability of p65.	Indiana Univ Sch Med, Riley Hosp Hosp, Wells Ctr Pedit Res, Indianapolis, IN 46202 USA; Vet Adm Med Ctr, Inflammat Program, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA	Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	Dinauer, MC (corresponding author), Indiana Univ Sch Med, Riley Hosp Hosp, Wells Ctr Pedit Res, Canc Res Bldg,Rm 466,1044 W Walnut St, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu		DeLeo, Frank/0000-0003-3150-2516; Nauseef, William/0000-0003-4032-757X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007343] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL45635, P01 HL 35386] Funding Source: Medline; NIAID NIH HHS [5-T32-AI07343-09] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DeLeo FR, 1998, J CLIN INVEST, V101, P2900, DOI 10.1172/JCI2649; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MIZUNO Y, 1988, J PEDIATR-US, V113, P458, DOI 10.1016/S0022-3476(88)80628-0; NAKAMURA M, 1987, BLOOD, V69, P1404; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1992, BLOOD, V80, P2622; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; PORTER CD, 1994, BLOOD, V84, P2767; Porter CD, 1996, BIOCHEM J, V315, P571, DOI 10.1042/bj3150571; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; Zhen L, 1998, J BIOL CHEM, V273, P6575, DOI 10.1074/jbc.273.11.6575; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	41	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4364	4369		10.1074/jbc.274.7.4364	http://dx.doi.org/10.1074/jbc.274.7.4364			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933639	hybrid			2022-12-27	WOS:000078575500063
J	Brodsky, JL; Werner, ED; Dubas, ME; Goeckeler, JL; Kruse, KB; McCracken, AA				Brodsky, JL; Werner, ED; Dubas, ME; Goeckeler, JL; Kruse, KB; McCracken, AA			The requirement for molecular chaperones during endoplasmic reticulum-associated protein degradation demonstrates that protein export and import are mechanistically distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ER QUALITY-CONTROL; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; STRESS PROTEINS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; BINDING-SPECIFICITY; SECRETORY PROTEIN; IN-VITRO; BIP	Polypeptide import into the yeast endoplasmic reticulum (ER) requires two hsp70s, Ssa1p in the cytosol and BiP (Kar2p) in the ER lumen. After import, aberrant polypeptides may be exported to the cytoplasm for degradation by the proteasome, and defects in the ER chaperone calnexin (Cne1p) compromise their degradation. Both import and export require BiP and the Sec61p translocation complex, suggesting that import and export may be mechanistically related. We now show that the cne1 Delta and two kar2 mutant alleles exhibit a synthetic interaction and that the export and degradation of pro-alpha factor is defective in kar2 mutant microsomes. Pulse-chase analysis indicates that A1PiZ, another substrate for degradation, is stabilized in the kar2 strains at the restrictive temperature. Because two of the kar2 mutants examined are proficient for polypeptide import, the roles of BiP during ER protein export and import differ, indicating that these processes must be mechanistically distinct. To examine whether Ssa1p drives polypeptides from the ER and is also required for degradation, we assembled reactions using strains either containing a mutation in SSA1 or in which the level of Ssa1p could be regulated. We found that pro-alpha factor and A1PiZ were degraded normally, indicating further that import and export are distinct and that other cytosolic factors may pull polypeptides from the ER.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nevada System of Higher Education (NSHE); University of Nevada Reno	Brodsky, JL (corresponding author), Univ Pittsburgh, Dept Biol Sci, 267 Crawford Hall, Pittsburgh, PA 15260 USA.			Goeckeler-Fried, Jennifer/0000-0001-5940-9917				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Becker J, 1996, MOL CELL BIOL, V16, P4378; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BRODSKY JL, 1996, TRENDS BIOCHEM SCI, V21, P121; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHIRICO WJ, 1992, BIOCHEM BIOPH RES CO, V189, P1150, DOI 10.1016/0006-291X(92)92324-Q; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LE AQ, 1994, J BIOL CHEM, V269, P7514; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; McCracken AA, 1998, ADV MOL CEL, V27, P165, DOI 10.1016/S1569-2558(08)60461-0; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OH HJ, 1997, J BIOL CHEM, V272, P3636; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; Paunola E, 1998, MOL BIOL CELL, V9, P817, DOI 10.1091/mbc.9.4.817; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P1555, DOI 10.1172/JCI114332; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rose MD., 1990, METHODS YEAST GENETI; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHMITZ A, 1995, EMBO J, V14, P1091, DOI 10.1002/j.1460-2075.1995.tb07092.x; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; VOGEL J, 1993, THESIS PRINCETON U; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	62	214	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3453	3460		10.1074/jbc.274.6.3453	http://dx.doi.org/10.1074/jbc.274.6.3453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920890	hybrid			2022-12-27	WOS:000078428200030
J	Inamori, K; Saito, T; Iwaki, D; Nagira, T; Iwanaga, S; Arisaka, F; Kawabata, S				Inamori, K; Saito, T; Iwaki, D; Nagira, T; Iwanaga, S; Arisaka, F; Kawabata, S			A newly identified horseshoe crab lectin with specificity for blood group A antigen recognizes specific O-antigens of bacterial lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; CDNA CLONING; BIG DEFENSIN; SUBCELLULAR-LOCALIZATION; ANTIBACTERIAL ACTIVITY; PROCLOTTING ENZYME; BINDING-PROTEIN; IMMUNE-SYSTEM; LIMULUS; PURIFICATION	A 14-kDa lectin, named tachylectin-3, was newly identified from hemocytes of the Japanese horseshoe crab, Tachypleus tridentatus. This lectin exhibited hemagglutinating activity against human A-type erythrocytes, but not against the B- and O-types of erythrocytes and animal erythrocytes, including those of sheep, rabbit, horse, and bovine. The hemagglutinating activity of tachylectin-3 was equivalent to that of a previously identified lectin, named tachylectin-2, with affinity for N-acetyl-D-glucosamine or N-acetyl-D-galactosamine. However, the activity of tachylectin-3 was not inhibited by these two N-acetylhexosamines at 100 mM but was inhibited by a blood group A-pentasaccharide at a minimum inhibitory concentration of 0.16 mM. Furthermore, the hemagglutinating activity was strongly inhibited by bacterial S-type lipopolysaccharides (LPSs) from Gramnegative bacteria but not by R-type LPSs lacking O-antigens, One of the most effective S-type LPSs was from Escherichia coli O111:B4, with a minimum inhibitory concentration of 6 ng/ml, These data suggest that tachylectin-3 specifically recognizes Gram-negative bacteria through the unique structural units of O-antigens, Ultracentrifugation analysis revealed that tachylectin-3 is present in dimer in solution. A cDNA coding for tachylectin-3 was isolated from a hemocyte cDNA library. Tachylectin-3 consisted of two repeating sequences, each with a partial sequence similarity to rinderpest virus neuraminidase. Tachylectin-3 and three previously isolated types of tachylectins were all predominantly expressed in hemocytes and released from hemocytes in response to external stimuli. These lectins present at injured sites suggest that they probably serve synergitically to accomplish an effective host defense against invading microbes.	Kyushu Univ, Fac Sci, Dept Biol, Grad SCh Med Sci, Fukuoka 8128581, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Tokyo Inst Technol, Fac Biosci & Bioengn, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan	Kyushu University; Kyushu University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Kawabata, S (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Grad SCh Med Sci, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp		Inamori, Kei-ichiro/0000-0002-5947-3633; Saito, Tetsu/0000-0002-9045-6743				ARMSTRONG PB, 1982, EXP CELL RES, V140, P15, DOI 10.1016/0014-4827(82)90150-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOLDMAN RC, 1982, J BACTERIOL, V151, P1210, DOI 10.1128/JB.151.3.1210-1221.1982; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; Iwanaga S, 1998, J BIOCHEM, V123, P1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kawabata S, 1997, BIOL CHEM, V378, P289, DOI 10.1515/bchm.1997.378.3-4.289; Kawabata S, 1997, Methods Mol Biol, V78, P51; Kawabata Shun-ichiro, 1996, P255; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langedijk JPM, 1997, J VIROL, V71, P6155, DOI 10.1128/JVI.71.8.6155-6167.1997; LEFFLER H, 1986, J BIOL CHEM, V261, P119; MANDRELL RE, 1994, METHOD ENZYMOL, V236, P231; Mey A, 1996, J IMMUNOL, V156, P1572; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO S, 1994, J BIOL CHEM, V269, P4424; SENGUPTA P, 1995, CARBOHYD RES, V277, P283, DOI 10.1016/0008-6215(95)00215-F; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SIKDER SK, 1986, CARBOHYD RES, V151, P247, DOI 10.1016/S0008-6215(00)90345-8; SODERHALL K, 1994, ANN NY ACAD SCI, V712, P155, DOI 10.1111/j.1749-6632.1994.tb33570.x; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMANAKA M, 1988, VIROLOGY, V166, P251, DOI 10.1016/0042-6822(88)90168-7	40	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3272	3278		10.1074/jbc.274.6.3272	http://dx.doi.org/10.1074/jbc.274.6.3272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920866	hybrid			2022-12-27	WOS:000078428200006
J	Osheroff, WP; Jung, HK; Beard, WA; Wilson, SH; Kunkel, TA				Osheroff, WP; Jung, HK; Beard, WA; Wilson, SH; Kunkel, TA			The fidelity of DNA polymerase beta during distributive and processive DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HIV-1 REVERSE-TRANSCRIPTASE; TEMPLATE-PRIMER; TRANSIENT MISALIGNMENT; MUTATIONAL SPECIFICITY; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CROSS-LINKING; DNTP BINDING	During base excision repair, DNA polymerase beta fills 1-6-nucleotide gaps processively, reflecting a contribution of both its 8- and 31-kDa domains to DNA binding. Here we report the fidelity of pol beta during synthesis to fill gaps of 1, 5, 6, or >300 nucleotides. Error rates during distributive synthesis by recombinant rat and human polymerase (pol) beta with a 390-base gap are similar to each other and to previous values with pol beta purified from tissues. The base substitution fidelity of human pol beta when processively filling a 5-nucleotide gap is similar to that with a 361-nucleotide gap, but "closely-spaced" substitutions are produced at a rate at least 60-fold higher than for distributive synthesis, Base substitution fidelity when filling a 1-nucleotide gap is higher than when filling a 5-nucleotide gap, suggesting a contribution of the 8-kDa domain to the dNTP binding pocket and/or a difference in base stacking or DNA structure imposed by pol beta. Nonetheless, 1-nucleotide gap filling is inaccurate, even generating complex substitution-addition errors. Finally, the single-base deletion error rate during processive synthesis to fill a 6-nucleotide gap is indistinguishable from that of distributive synthesis to fill a 390-nucleotide gap. Thus the mechanism of processivity by pol beta does not allow the enzyme to suppress template misalignments.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Natl Inst Safety Res, Div Mutagenesis, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRAEMER KH, 1989, MUTAT RES, V220, P61, DOI 10.1016/0165-1110(89)90011-0; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; Kunkel TA, 1998, NAT STRUCT BIOL, V5, P95, DOI 10.1038/nsb0298-95; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; NOWAK R, 1990, EXP CELL RES, V191, P51, DOI 10.1016/0014-4827(90)90034-8; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PROTICSABLJIC M, 1986, MOL CELL BIOL, V6, P3349, DOI 10.1128/MCB.6.10.3349; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEETHARAM S, 1991, MUTAT RES, V254, P97, DOI 10.1016/0921-8777(91)90045-Q; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; STALKER DM, 1976, BIOCHEMISTRY-US, V15, P3114, DOI 10.1021/bi00659a027; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Winter DB, 1998, P NATL ACAD SCI USA, V95, P6953, DOI 10.1073/pnas.95.12.6953	63	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3642	3650		10.1074/jbc.274.6.3642	http://dx.doi.org/10.1074/jbc.274.6.3642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920913	hybrid			2022-12-27	WOS:000078428200053
J	Kang, JJ; Schaber, MD; Srinivasula, SM; Alnemri, ES; Litwack, G; Hall, DJ; Bjornsti, MA				Kang, JJ; Schaber, MD; Srinivasula, SM; Alnemri, ES; Litwack, G; Hall, DJ; Bjornsti, MA			Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-I; CELL-DEATH; CAMPTOTHECIN SENSITIVITY; CYSTEINE PROTEASES; SIGNALING COMPLEX; APOPTOSIS; FAMILY; FLICE; RESISTANCE; PATHWAY	Caspases (aspartate-specific cysteine proteases) play a critical role in the execution of the mammalian apoptotic program. To address the regulation of human caspase activation, we used the yeast Saccharomyces cerevisiae, which is devoid of endogenous caspases. The apical procaspases, -8 beta and -10, were efficiently processed and activated in yeast. Although protease activity, per se, was insufficient to drive cell death, caspase-10 activity had little effect on cell viability, whereas expression of caspase-8 beta was cytotoxic. This lethal phenotype was abrogated by co-expression of the pan-caspase inhibitor, baculovirus p35, and by mutation of the active site cysteine of procaspase-8 beta. In contrast, autoactivation of the executioner caspase-3 and -6 zymogens was not detected. Procaspase-3 activation required co-expression of procaspase-8 or -10. Surprisingly, activation of procaspase-6 required proteolytic activities other than caspase-8, -10, or -3. Caspase-8 beta or -10 activity was insufficient to catalyze the maturation of procaspase-6, Moreover, a constitutively active caspase-3, although cytotoxic in its own right, was unable to induce the processing of wild-type procaspase-6 and vice versa, These results distinguish sequential modes of activation for different caspases in vivo and establish a yeast model system to examine the regulation of caspase cascades. Moreover, the distinct terminal phenotypes induced by various caspases attest to differences in the cellular targets of these apoptotic proteases, which may be defined using this system.	Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Bjornsti, MA (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, 233 S 10th St, Philadelphia, PA 19107 USA.	bjornsti@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010		NATIONAL CANCER INSTITUTE [R01CA067032, R01CA070406] Funding Source: NIH RePORTER; NCI NIH HHS [CA67032, CA70406] Funding Source: Medline; NIAID NIH HHS [AI14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dixit VM, 1996, ADV EXP MED BIOL, V406, P113; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shaham S, 1998, CELL, V92, P425, DOI 10.1016/S0092-8674(00)80934-4; SHERMAN F, 1986, LAB COURSE MANUAL ME, P61; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; TALANIAN RV, 1997, J BIOL CHEM, V272, P6977; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; [No title captured]	52	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3189	3198		10.1074/jbc.274.5.3189	http://dx.doi.org/10.1074/jbc.274.5.3189			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915859	hybrid			2022-12-27	WOS:000078319500077
J	Affourtit, C; Albury, MS; Krab, K; Moore, AL				Affourtit, C; Albury, MS; Krab, K; Moore, AL			Functional expression of the plant alternative oxidase affects growth of the yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANIDE-INSENSITIVE RESPIRATION; METABOLIC CONTROL ANALYSIS; QUINONE POOL; ELECTRON-TRANSFER; REDOX POISE; ACTIVE-SITE; MITOCHONDRIA; PROTEIN; PATHWAYS; KINETICS	We have investigated the extent to which functional expression of the plant alternative oxidase (from Sauromatum guttatum) in Schizosaccharomyces pombe affects yeast growth. When cells are cultured on glycerol, the maximum specific growth rate is decreased from 0.13 to 0.11 h(-1) while growth yield is lowered by 20% (from 1.14 x 10(8) to 9.12 x 10(7) cells ml(-1)). Kinetic studies suggest that the effect on growth is mitochondrial in origin. In isolated mitochondria we found that the alternative oxidase actively competes with the cytochrome pathway for reducing equivalents and contributes up to 24% to the overall respiratory activity. Metabolic control analysis reveals that the alternative oxidase exerts a considerable degree of control (22%) on total electron flux. Furthermore, the negative control exerted by the alternative oxidase on the flux ratio of electrons through the cytochrome and alternative pathways is comparable with the positive control exerted on this flux-ratio by the cytochrome pathway. To our knowledge, this is the first paper to report a phenotypic effect because of plant alternative oxidase expression. We suggest that the effect on growth is the result of high engagement of the non-protonmotive alternative oxidase in yeast respiration that, consequently, lowers the efficiency of energy conservation and hence growth.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England; Free Univ Amsterdam, IMBW, Microbiol Sect, NL-1081 HV Amsterdam, Netherlands	University of Sussex; Vrije Universiteit Amsterdam	Moore, AL (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	a.l.moore@susx.ac.uk	Affourtit, Charles/I-3958-2019	Affourtit, Charles/0000-0003-1776-9943				Albury MS, 1998, J BIOL CHEM, V273, P30301, DOI 10.1074/jbc.273.46.30301; Albury MS, 1996, J BIOL CHEM, V271, P17062, DOI 10.1074/jbc.271.29.17062; Brand MD, 1996, J THEOR BIOL, V182, P351, DOI 10.1006/jtbi.1996.0174; DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GEIER BM, 1995, EUR J BIOCHEM, V227, P296, DOI 10.1111/j.1432-1033.1995.tb20388.x; GUTMAN, 1971, BIOCHEMISTRY-US, V10, P4763, DOI 10.1021/bi00801a025; Hiser C, 1996, PLANT PHYSIOL, V110, P277, DOI 10.1104/pp.110.1.277; HOEFNAGEL MHN, 1995, EUR J BIOCHEM, V233, P531, DOI 10.1111/j.1432-1033.1995.531_2.x; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; JAULT JM, 1994, J BIOENERG BIOMEMBR, V26, P447, DOI 10.1007/BF00762785; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; KRAB K, 1995, BIOCHEM SOC T, V23, pS289, DOI 10.1042/bst023289s; LJUNGDAHL PO, 1986, METHOD ENZYMOL, V126, P181; Millar AH, 1997, PLANT CELL ENVIRON, V20, P1273, DOI 10.1046/j.1365-3040.1997.d01-25.x; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MOORE AL, 1994, BBA-BIOENERGETICS, V1187, P145, DOI 10.1016/0005-2728(94)90101-5; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; MOORE AL, 1978, ARCH BIOCHEM BIOPHYS, V186, P298, DOI 10.1016/0003-9861(78)90439-3; MOORE AL, 1982, PLANT PHYSIOL, V70, P1271, DOI 10.1104/pp.70.5.1271; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; OESTREIC.G, 1973, PLANT PHYSIOL, V52, P622, DOI 10.1104/pp.52.6.622; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; SIEDOW JN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P165, DOI 10.1016/0005-2728(93)90098-Z; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; UMBACH AL, 1994, FEBS LETT, V348, P181, DOI 10.1016/0014-5793(94)00600-8; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; VANLERBERGHE GC, 1994, PLANT PHYSIOL, V106, P1503, DOI 10.1104/pp.106.4.1503; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; WAGNER AM, 1995, PHYSIOL PLANTARUM, V95, P318, DOI 10.1111/j.1399-3054.1995.tb00844.x; WESTERHOFF HV, 1987, BIOTECHNOL BIOENG, V30, P101, DOI 10.1002/bit.260300115	37	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6212	6218		10.1074/jbc.274.10.6212	http://dx.doi.org/10.1074/jbc.274.10.6212			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037707	hybrid, Green Published			2022-12-27	WOS:000078902800029
J	Daniels, RH; Zenke, FT; Bokoch, GM				Daniels, RH; Zenke, FT; Bokoch, GM			alpha Pix stimulates p21-activated kinase activity through exchange factor-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; PROTEIN-KINASE; RHO; PAK1; RAS; TRANSFORMATION; REGULATORS; PLECKSTRIN	Activation of pal-activated kinases (Paks) is achieved through binding of the GTPases Rac or Cdc42 to a conserved domain in the N-terminal regulatory region of Pak. Additional signaling components are also likely to be important in regulating Pak activation. Recently, a family of Pak-interacting guanine nucleotide exchange factors (Pix) have been identified and which are good candidates for regulating Pak activity. Using an active, truncated form of alpha Pix (amino acids 155-545), we observe stimulation of Pak1 kinase activity when alpha Pix(155-545) is co-expressed with Cdc42 and wild-type Pak1 in COS-1 cells. This activation does not occur when we co-express a Pak1 mutant unable to bind alpha Pix. The activation of wild-type Pak1 by alpha Pix(155-545) also requires that alpha Pix(155-545) retain functional exchange factor activity. However, the Pak1(H83,86L) mutant that does not bind Rac or Cdc42 is activated in the absence of GTPase by alpha Pix(155-545) and by a mutant of alpha Pix(155-545) that no longer has exchange factor activity. Pak1 activity stimulated in vitro using GTP gamma S-loaded Cdc42 was also enhanced by recombinant alpha Pix(155-545) in a binding-dependent manner. These data suggest that Pak activity can be modulated by physical interaction with alpha Pix and that this specific effect involves both exchange factor-dependent and -independent mechanisms.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Daniels, RH (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Zenke, Frank/0000-0002-2226-3755	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45738] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	27	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6047	6050		10.1074/jbc.274.10.6047	http://dx.doi.org/10.1074/jbc.274.10.6047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037684	hybrid			2022-12-27	WOS:000078902800006
J	Cens, T; Restituito, S; Galas, S; Charnet, P				Cens, T; Restituito, S; Galas, S; Charnet, P			Voltage and calcium use the same molecular determinants to inactivate calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; BETA-SUBUNIT; XENOPUS-OOCYTES; CA2+-DEPENDENT INACTIVATION; ALPHA(1C) SUBUNIT; CA2+-SENSITIVE INACTIVATION; MEDIATED INACTIVATION; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; SNAIL NEURONS	During sustained depolarization, voltage-gated Ca2+ channels progressively undergo a transition to a nonconducting, inactivated state, preventing Ca2+ overload of the cell. This transition can be triggered either by the membrane potential (voltage-dependent inactivation) or by the consecutive entry of Ca2+ (Ca2+-dependent inactivation), depending on the type of Ca2+ channel. These two types of inactivation are suspected to arise from distinct underlying mechanisms, relying on specific molecular sequences of the different pore-forming Ca2+ channel subunits. Here we report that the voltage-dependent inactivation (of the alpha(1A) Ca2+ channel) and the Ca2+-dependent inactivation (of the alpha(1C) Ca2+ channel) are similarly influenced by Ca2+ channel beta subunits. The same molecular determinants of the beta subunit, and therefore the same subunit interactions, influence both types of inactivation. These results strongly suggest that the voltage and the Ca2+-dependent transitions leading to channel inactivation use homologous structures of the different cu, subunits and occur through the same molecular process. A model of inactivation taking into account these new data is presented.	CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Charnet, P (corresponding author), CNRS, UPR 1086, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34293 Montpellier, France.	charnet@crbm.cnrs-mop.fr	Cens, Thierry/M-3337-2017; Galas, Simon/X-1312-2019	Cens, Thierry/0000-0002-4109-2779; Galas, Simon/0000-0002-1717-1266; Charnet, Pierre/0000-0003-4692-528X				Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; ADAMS BA, 1994, J GEN PHYSIOL, V104, P985, DOI 10.1085/jgp.104.5.985; BEAN BP, 1991, AM J HYPERTENS, V4, pS406, DOI 10.1093/ajh/4.7.406S; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BREHM P, 1980, J PHYSIOL-LONDON, V306, P193, DOI 10.1113/jphysiol.1980.sp013391; BROWN AM, 1984, J GEN PHYSIOL, V83, P751, DOI 10.1085/jgp.83.5.751; BROWN AM, 1986, MEMBRANE BIOCHEM, V6, P73, DOI 10.3109/09687688609065444; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cens T, 1996, FEBS LETT, V391, P232, DOI 10.1016/0014-5793(96)00704-1; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; Cens T, 1998, PFLUG ARCH EUR J PHY, V435, P865, DOI 10.1007/s004240050595; CHAD J, 1989, COMP BIOCHEM PHYS A, V93, P95, DOI 10.1016/0300-9629(89)90196-5; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHARNET P, 1994, FEBS LETT, V344, P87, DOI 10.1016/0014-5793(94)00357-2; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; GUTNICK MJ, 1989, J PHYSIOL-LONDON, V412, P197, DOI 10.1113/jphysiol.1989.sp017611; HADLEY RW, 1998, J PHYSIOL-LONDON, V444, P257; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOFMANN F, 1988, J CARDIOVASC PHARM, V12, pS25, DOI 10.1097/00005344-198806121-00005; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IMREDY JP, 1992, NEURON, V9, P197, DOI 10.1016/0896-6273(92)90159-B; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; LUX HD, 1984, SCIENCE, V225, P432, DOI 10.1126/science.6330896; Mangoni ME, 1997, RECEPTOR CHANNEL, V5, P1; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MENTRARD D, 1984, J GEN PHYSIOL, V83, P105, DOI 10.1085/jgp.83.1.105; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; NASTAINCZYK W, 1990, GEN PHYSIOL BIOPHYS, V9, P321; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PARENT L, 1995, FEBS LETT, V360, P144, DOI 10.1016/0014-5793(95)00090-V; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Qin N, 1996, AM J PHYSIOL-CELL PH, V271, pC1539, DOI 10.1152/ajpcell.1996.271.5.C1539; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; REYES EP, 1992, J BIOL CHEM, V267, P1790; REYES EP, 1994, DRUG DEVELOP RES, V33, P295; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SATHER WA, 1994, ANN NY ACAD SCI, V747, P294; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; SHIROKOV R, 1993, J GEN PHYSIOL, V102, P1005, DOI 10.1085/jgp.102.6.1005; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1994, RECEPTOR CHANNEL, V2, P215; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; VASSORT G, 1994, J CARDIOVASC ELECTR, V5, P376, DOI 10.1111/j.1540-8167.1994.tb01175.x; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zong XG, 1996, FEBS LETT, V378, P121, DOI 10.1016/0014-5793(95)01434-9	75	85	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5483	5490		10.1074/jbc.274.9.5483	http://dx.doi.org/10.1074/jbc.274.9.5483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026161	hybrid			2022-12-27	WOS:000078804400032
J	Gross, BS; Lee, JR; Clements, JL; Turner, M; Tybulewicz, VLJ; Findell, PR; Koretzky, GA; Watson, SP				Gross, BS; Lee, JR; Clements, JL; Turner, M; Tybulewicz, VLJ; Findell, PR; Koretzky, GA; Watson, SP			Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; PHOSPHOLIPASE C-GAMMA-2; MOLECULAR-CLONING; T-CELLS; ACTIVATION; PROTEIN; SUBSTRATE; INTERLEUKIN-2; PURIFICATION; PHOSPHATASE	Collagen-related peptide (CRP), a collagen homologue, induces platelet activation through a tyrosine kinase-dependent pathway, leading to sequential tyrosine phosphorylation of Pc receptor (FcR) gamma-chain, Syk, and phospholipase C-gamma(2). Here we report that CRP and the platelet low affinity immune receptor Fc gamma RIIA stimulate tyrosine phosphorylation of the T cell adapter SLP-76, whereas the G protein-coupled receptor agonist thrombin induces only minor tyrosine phosphorylation. This suggests that SLP-76 has a specific role downstream of receptors that signal via an immunoreceptor tyrosine-based activation motif, Immunoprecipitation studies demonstrate association of SLP-76 with SLAP-130, Vav, Fyn, Lyn, and the FcR gamma-chain in CRP-stimulated platelets. Several of these proteins, including SLP-76, undergo tyrosine phosphorylation in in vitro kinase assays performed on SLP-76 immunoprecipitates. Tyrosine phosphorylation of all of these proteins in the in vitro kinase assay was abrogated by the Src family kinase inhibitor PP1, suggesting that it is mediated by either Fyn or Lyn, The physiological significance of this is uncertain, however, since tyrosine phosphorylation of SLP-76 in vivo is not altered in either Fyn- or Lyn-deficient platelets, CRP stimulation of Syk-deficient platelets demonstrated that in vivo tyrosine phosphorylation of SLP-76 is downstream of Syk, The absence of Syk in the SLP-76 immunoprecipitates raises the possibility that another protein is responsible for bringing SLP-76 to Syk, Candidates for this include those proteins that co-immunoprecipitate with SLP-76, including the FcR gamma-chain, Tyrosine phosphorylation of PLC-gamma(2) and Ca2+ mobilization is markedly attenuated in SLP-76-deficient platelets following CRP stimulation, suggesting that the adapter plays a critical role in the regulation of the phospholipase. The increase in tyrosine phosphorylation of SLAP-130 in response to CRP is also inhibited in SLP-76-deficient platelets, placing it downstream of SLP-76, This work identifies SLP-76 as an important adapter molecule that is regulated by Syk and lies upstream of SLAP-130 and PLC-gamma(2) in CRP-stimulated platelets.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Iowa, Coll Med, Dept Internal Med Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Immunol Program, Iowa City, IA 52242 USA; Roche Biosci, Palo Alto, CA 94304 USA; Natl Inst Med Res, London NW7 1AA, England	University of Oxford; University of Iowa; University of Iowa; Roche Holding; MRC National Institute for Medical Research	Gross, BS (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	barbara.gross@users.jesus.ox.ac.uk	Turner, Martin/N-9976-2014; Watson, Stephen P/Q-6292-2016; Koretzky, Gary/AAU-5381-2021	Turner, Martin/0000-0002-3801-9896; Watson, Stephen P/0000-0002-7846-7423; GROSS, BARBARA/0000-0001-5566-0004				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Fang N, 1996, J IMMUNOL, V157, P3769; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V353, P239, DOI 10.1006/abbi.1998.0598; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kehrel B, 1998, BLOOD, V91, P491; Law CL, 1996, MOL CELL BIOL, V16, P1305; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; RodriguezLinares B, 1996, BIOCHEM J, V316, P93, DOI 10.1042/bj3160093; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413	37	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5963	5971		10.1074/jbc.274.9.5963	http://dx.doi.org/10.1074/jbc.274.9.5963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026222	hybrid			2022-12-27	WOS:000078804400093
J	Zimmermann, B; Chiorini, JA; Ma, YL; Kotin, RM; Herberg, FW				Zimmermann, B; Chiorini, JA; Ma, YL; Kotin, RM; Herberg, FW			PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR-CLONING; INHIBITOR PROTEIN; IDENTIFICATION; EXPRESSION; NUCLEUS; DOMAINS; GENE; RESONANCE; STABILITY	The human X chromosome-encoded protein kinase X (PrKX) belongs to the family of cAMP-dependent protein kinases, The catalytically active recombinant enzyme expressed in COS cells phosphorylates the heptapeptide Kemptide (LRRASLG) with a specific activity of 1.5 mu mol/(min.mg). Using surface plasmon resonance, high affinity interactions were demonstrated with the regulatory subunit type I (RIalpha) of cAMP-dependent protein kinase (K-D = 10 nM) and the heat-stable protein kinase inhibitor (K-D = 15 nM), but not with the type II regulatory subunit (RIIalpha, K-D = 2.3 mu M) under physiological conditions. Kemptide and autophosphorylation activities of PrKX are strongly inhibited by the RIalpha subunit and by protein kinase inhibitor in vitro, but only weakly by the RIIalpha subunit. The inhibition by the RIalpha subunit is reversed by addition of nanomolar concentrations of cAMP (K-alpha = 40 nM), thus demonstrating that PrKX is a novel, type I cAMP-dependent protein kinase that is activated at lower cAMP concentrations than the holoenzyme with the C-alpha subunit of cAMP-dependent protein kinase. Microinjection data clearly indicate that the type I R subunit but not type II binds to PrKX in vivo, preventing the translocation of PrKX to the nucleus in the absence of cAMP. The RIIalpha subunit is an excellent substrate far PrKX and is phosphorylated in vitro in a cAMP-independent manner, me discuss how PrKX can modulate the cAMP-mediated signal transduction pathway by preferential binding to the RIalpha subunit and by phosphorylating the RIIalpha subunit in the absence of cAMP.	Ruhr Univ Bochum, Fak Med, Biochem Supramolek Syst Abt, Inst Physiol Chem 1, D-44801 Bochum, Germany; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; NHLBI, Mol Hematol Branch, NIH, Bethesda, MD 20892 USA	Ruhr University Bochum; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Herberg, FW (corresponding author), Ruhr Univ Bochum, Fak Med, Biochem Supramolek Syst Abt, Inst Physiol Chem 1, MA 2-40, D-44801 Bochum, Germany.	friedrich.w.herberg@ruhr-uni-bochum.de	kotin, robert/B-8954-2008; Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002231] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; CADD GG, 1990, J BIOL CHEM, V265, P19502; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chiorini JA, 1998, MOL CELL BIOL, V18, P5921, DOI 10.1128/MCB.18.10.5921; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Herberg FW, 1997, PROTEIN SCI, V6, P569; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; HERBERG FW, 1996, BIOCHEMISTRY-US, V35, P29834; Hermanns J, 1997, J VIROL, V71, P6020, DOI 10.1128/JVI.71.8.6020-6027.1997; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MELENDEZ A, 1995, GENETICS, V141, P1507; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; Schiebel K, 1997, HUM MOL GENET, V6, P1985, DOI 10.1093/hmg/6.11.1985; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581	48	79	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5370	5378		10.1074/jbc.274.9.5370	http://dx.doi.org/10.1074/jbc.274.9.5370			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026146	hybrid			2022-12-27	WOS:000078804400017
J	Bigey, P; Knox, JD; Croteau, S; Bhattacharya, SK; Theberge, J; Szyf, M				Bigey, P; Knox, JD; Croteau, S; Bhattacharya, SK; Theberge, J; Szyf, M			Modified oligonucleotides as bona fide antagonists of proteins interacting with DNA - Hairpin antagonists of the human DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SIGNALING PATHWAY; IN-VIVO; METHYLATION; CELLS; ANTISENSE; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; TUMORIGENESIS; RECOGNITION	The study of the biological role of DNA methyltransferase (DNA MeTase) has been impeded by the lack of direct and specific inhibitors. This report describes the design of potent DNA based antagonists of DNA MeTase and their utilization to define the interactions of DNA MeTase with its substrate and to study its biological role. We demonstrate that the size, secondary structure, hemimethylation, and phosphorothioate modification strongly affect the antagonists interaction with DNA MeTase whereas base substitutions do not have a significant effect. To study whether DNA MeTase is critical for cellular transformation, human lung non-small carcinoma cells were treated with the DNA MeTase antagonists. Ex vivo, hairpin inhibitors of DNA MeTase are localized to the cell nucleus in lung cancer cells. They inhibit DNA MeTase, cell growth, and anchorage independent growth tan indicator of tumorigenesis in cell culture) in a dose-dependent manner. The inhibitors developed in this study are the first documented example of direct inhibitors of DNA MeTase in living cells and of modified oligonucleotides as bona fide antagonists of critical cellular proteins.	McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Bhattacharya, Sanjoy K/B-2001-2008	bigey, pascal/0000-0002-6795-8569				Akhtar S, 1997, TRENDS PHARMACOL SCI, V18, P12, DOI 10.1016/S0165-6147(96)01002-4; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BOLDEN AH, 1986, MOL CELL BIOL, V6, P1135, DOI 10.1128/MCB.6.4.1135; BOULARD Y, 1991, NUCLEIC ACIDS RES, V19, P5159, DOI 10.1093/nar/19.19.5159; CHIANG PK, 1992, J BIOL CHEM, V267, P4988; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ERIE DA, 1993, BIOCHEMISTRY-US, V32, P436, DOI 10.1021/bi00053a008; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HANCK T, 1993, NUCLEIC ACIDS RES, V21, P303, DOI 10.1093/nar/21.2.303; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESTRE B, 1995, BIOCONJUGATE CHEM, V6, P466, DOI 10.1021/bc00034a017; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Reale A, 1995, BIOCHEM J, V312, P855, DOI 10.1042/bj3120855; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SPROAT BS, 1995, J BIOTECHNOL, V41, P221, DOI 10.1016/0168-1656(95)00012-F; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; Tracewell W, 1995, TOXICOL APPL PHARM, V135, P179, DOI 10.1006/taap.1995.1221; Wu J C, 1985, Prog Clin Biol Res, V198, P119; Yang J, 1997, J IMMUNOL, V159, P1303; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	35	28	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4594	4606		10.1074/jbc.274.8.4594	http://dx.doi.org/10.1074/jbc.274.8.4594			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988694	hybrid			2022-12-27	WOS:000078698200019
J	Tcheperegine, SE; Marelli, M; Wozniak, RW				Tcheperegine, SE; Marelli, M; Wozniak, RW			Topology and functional domains of the yeast pore membrane protein Pom152p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; COMPLEX GLYCOPROTEIN; NUCLEAR-ENVELOPE; NUCLEOPORINS; SACCHAROMYCES; POLYPEPTIDE; INTERACTS; NUP188P; GP210	Integral membrane proteins associated with the nuclear pore complex (NPC) are likely to play an important role in the biogenesis of this structure. Here we have examined the functional roles of domains of the yeast pore membrane protein Pom152p in establishing its topology and its interactions with other NPC proteins. The topology of Pom152p was evaluated by alkaline extraction, protease protection, and endoglycosidase H sensitivity assays. The results of these experiments suggest that Pom152p contains a single transmembrane segment with its N terminus (amino acid residues 1-175) extending into the nuclear pore and its C terminus (amino acid residues 196-1337) positioned in the lumen of the nuclear envelope. The functional role of these different domains was investigated in mutants that are dependent on Pom152p for viability. The requirement for Pom152p in strains containing mutations allelic to the NPC protein genes NIC96 and NUP59 could be alleviated by Pom152p's N terminus, independent of its integration into the membrane. However, complementation of a mutation in NUP170 required both the N terminus and the transmembrane segment. Furthermore, mutations in NUP188 were rescued only by full-length Pom152p, suggesting that the lumenal structures play an important role in the function of pore-side NPC structures.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2A7, Canada	University of Alberta	Wozniak, RW (corresponding author), Univ Alberta, Dept Cell Biol, 5-14 Med Sci Bldg, Edmonton, AB T6G 2A7, Canada.		Cheperegin, Sergey/R-6594-2018	Marelli, Marcello/0000-0001-7095-8263				AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BERRIOS M, 1995, EUR J CELL BIOL, V67, P1; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; KILMARTIN JV, 1982, MICROTUBULES MICROOR, P157; KIM H, 1994, MOL MICROBIOL, V11, P819, DOI 10.1111/j.1365-2958.1994.tb00360.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Marelli M, 1998, J CELL BIOL, V143, P1813, DOI 10.1083/jcb.143.7.1813; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; SIKORSKI RS, 1989, GENETICS, V122, P19; Soderqvist H, 1997, EUR J BIOCHEM, V250, P808, DOI 10.1111/j.1432-1033.1997.00808.x; SODERQVIST H, 1994, EUR J CELL BIOL, V64, P186; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141	24	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5252	5258		10.1074/jbc.274.8.5252	http://dx.doi.org/10.1074/jbc.274.8.5252			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988776	hybrid			2022-12-27	WOS:000078698200101
J	Baird, NR; Orlowski, J; Szabo, EZ; Zaun, HC; Schultheis, PJ; Menon, AG; Shull, GE				Baird, NR; Orlowski, J; Szabo, EZ; Zaun, HC; Schultheis, PJ; Menon, AG; Shull, GE			Molecular cloning, genomic organization, and functional expression of Na+/H+ exchanger isoform 5 (NHE5) from human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; MAMMALIAN-CELLS; GENE; SEQUENCES	To isolate a cDNA encoding Na+/H+ exchanger isoform 5 (NHE5), we screened a human spleen library using exon sequences of the NHE5 gene. Clones spanning 2.9 kilobase pairs were isolated; however, they contained several introns and were missing coding sequences at both the 5' and 3' ends. The missing 5' sequences were obtained by 5'-rapid amplification of cDNA ends and by analysis of an NHE5 genomic clone, and the missing 3' sequences were obtained by 3'-rapid amplification of cDNA ends. Polymerase chain reaction amplification of brain cDNA yielded products in which each of the introns had been correctly excised, whereas the introns were retained in products from spleen and testis, suggesting that the NHE5 transcripts expressed in these organs do not encode a functional transporter. The intron/exon organization of the NHE5 gene was analyzed and found to be very similar to that of the NHE3 gene. The NHE5 cDNA, which encodes an 896-amino acid protein that is most closely related to NHE3, was expressed in Na+/H+ exchanger-deficient fibroblasts and shown to mediate Na+/H+ exchange activity. Northern blot analysis demonstrated that the mRNA encoding NHE5 is expressed in multiple regions of the brain, including hippocampus, consistent with the possibility that it regulates intracellular pH in hippocampal and other neurons.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; McGill University	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu		Orlowski, John/0000-0001-7371-175X	NIDDK NIH HHS [DK41496, DK50594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHEARN JM, 1987, J BIOL CHEM, V262, P10695; Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Kandasamy RA, 1996, J BIOL CHEM, V271, P10551, DOI 10.1074/jbc.271.18.10551; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MILLER RT, 1991, J BIOL CHEM, V266, P10813; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pathak BG, 1996, GENOMICS, V31, P261, DOI 10.1006/geno.1996.0045; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG Z, 1993, J BIOL CHEM, V268, P11925; YU FH, 1993, J BIOL CHEM, V268, P25536	28	133	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4377	4382		10.1074/jbc.274.7.4377	http://dx.doi.org/10.1074/jbc.274.7.4377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933641	hybrid			2022-12-27	WOS:000078575500065
J	Jans, DA; Sutton, VR; Jans, P; Froelich, CJ; Trapani, JA				Jans, DA; Sutton, VR; Jans, P; Froelich, CJ; Trapani, JA			BCL-2 blocks perforin-induced nuclear translocation of granzymes concomitant with protection against the nuclear events of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MEDIATED CYTOTOXICITY; DEPENDENT PROTEIN-KINASE; DNA BREAKDOWN; TARGET-CELLS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ENDOPLASMIC-RETICULUM; IN-VITRO; C-MYC; LOCALIZATION; MICE	Cytolytic granule-mediated target cell killing is effected in part through the synergistic action of the membrane-acting protein perforin and serine proteases such as granzymes (Gr) A and B, In this study, we examine the subcellular distribution of granzymes in the presence of perforin and the induction of apoptosis in mouse FDC-P1 myeloid and YAC-1 lymphoma cells that express the proto-oncogene bcl2, Using confocal laser scanning microscopy to visualize and quantitate subcellular transport of fluoresceinated granzyme, we find that granzyme entry into the cytoplasm in the absence of perforin is not impaired in the bcl2-expressing lines. However, perforin-dependent enhancement of granzyme cellular uptake and, importantly, granzyme redistribution to the nucleus were strongly inhibited in the bcl2-expressing lines, concomitant with greatly increased resistance to granzyme/perforin-induced cell death, DNA fragmentation induced by granzyme/perforin was severely reduced in the bcl2-expressing lines, implying that prevention of granzyme nuclear translocation blocks the nuclear events of apoptosis, The kinetics of GrB nuclear uptake and induction of apoptosis were faster than for GrA, whereas YAC-1 cells showed greater resistance to granzyme nuclear uptake and apoptosis than FDC-P1 cells. In all cases, granzyme nuclear accumulation in the presence of perforin correlated precisely with ensuing apoptosis. All results supported the idea that GrA and GrB share a common, specific nuclear targeting pathway that contributes significantly to the nuclear changes of apoptosis.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Northwestern Univ, Sch Med, Dept Med, Evanston, IL 60201 USA; Austin Res Inst, Cellular Cytotox Lab, Heidelberg, Vic, Australia	Australian National University; John Curtin School of Medical Research; Northwestern University; Austin Research Institute	Jans, DA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, POB 334, Canberra, ACT 2601, Australia.	David.Jans@anu.edu.au		Trapani, Joseph/0000-0003-0983-1532				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU VK, 1995, J IMMUNOL, V154, P2023; DEJONG D, 1994, CANCER RES, V54, P256; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HANNA W, 1996, PROTEIN EXPRES PURIF, V4, P398; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MUNGER WE, 1988, IMMUNOL REV, V103, P99, DOI 10.1111/j.1600-065X.1988.tb00752.x; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; POE M, 1991, J BIOL CHEM, V266, P98; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schroter M, 1995, EUR J IMMUNOL, V25, P3509, DOI 10.1002/eji.1830251245; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Sutton VR, 1997, J IMMUNOL, V158, P5783; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451	50	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3953	3961		10.1074/jbc.274.7.3953	http://dx.doi.org/10.1074/jbc.274.7.3953			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933585	hybrid			2022-12-27	WOS:000078575500009
J	Liu, CT; Yao, J; de Belle, I; Huang, RP; Adamson, E; Mercola, D				Liu, CT; Yao, J; de Belle, I; Huang, RP; Adamson, E; Mercola, D			The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta(1), fibronectin, and plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WT1 GENE-PRODUCT; FACTOR-BETA; EXTRACELLULAR-MATRIX; CANCER CELLS; DNA-BINDING; EPITHELIAL-CELLS; CARCINOMA CELLS; MESSENGER-RNA; EXPRESSION; ADHESION	Re-expression of EGR-1 in fibrosarcoma HT1080 suppresses transformation including tumorigenicity (Huang, R-P., Liu, C., Fan, Y., Mercola, D., and Adamson, E. (1995) Cancer Res. 55, 5054-5062) owing in part to up-regulation of the transforming growth factor (TGF)-beta 1 promoter by EGR-1 which suppresses growth by an autocrine mechanism (Liu, C., Adamson, E., and Mercola, D. (1996) Proc. Natl. Acad. Sci U. S. A. 93, 11831-11836), Here we show that enhanced cell attachment contributes to the suppression via increased secretion of fibronectin (FN) and also of plasminogen activator inhibitor-1 (PAI-1), The secretion of FN and PAI-1 is strongly correlated with EGR-1 expression (R-PEARSON = 0.971 and 0.985, respectively). Addition of authentic TGF-beta 1 to parental cells greatly stimulated secretion of PAI-1 but not FN, whereas addition of TGF-P antibody or lipofection with specific antisense TGF-PI oligonucleotides to EGR-1-regulated cells completely inhibits the secretion of PAI-1 but not FN, However, in gel mobility shift assays pure EGR-1 or nuclear extracts of EGR-1-regulated cells specifically bind to two GC-rich elements of the human FN promoter at positions -75/-52 and -4/+18, indicating that the increased secretion of FN is likely due to direct up-regulation by EGR-1, Moreover, adhesion was greatly enhanced in EGR-1-regulated cells and was reversed by treatment with Arg-Gly-Asp (RGD) or PAI-1 antibody indicating that the secreted proteins are functional, We conclude that EGR-1 regulates the coordinated expression of gene products important for cell attachment ("oikis" factor) and normal growth control.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA; NW Canc Res Ctr, Seattle, WA 98125 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Mercola, D (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	danmercola@skcc.org	mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA63783, CA67888, CA76173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067888, R01CA063783, R01CA076173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Akamatsu H, 1996, CANCER RES, V56, P4541; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHAKRABARTY S, 1989, INT J CANCER, V44, P325, DOI 10.1002/ijc.2910440223; CHAKRABARTY S, 1987, J CELL PHYSIOL, V133, P415, DOI 10.1002/jcp.1041330302; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHAKRABARTY S, 1990, INT J CANCER, V46, P493, DOI 10.1002/ijc.2910460328; CHANDLER LA, 1991, CELL GROWTH DIFFER, V2, P379; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEBELLE I, 1999, IN PRESS ONCOGENE; DEBHAR S, 1990, BIOESSAYS, V12, P583; DER CJ, 1981, J CELL SCI, V52, P151; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GALLIMORE PH, 1977, CELL, V10, P669, DOI 10.1016/0092-8674(77)90100-3; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOGUEL AF, 1995, CANCER GENET CYTOGEN, V80, P47, DOI 10.1016/0165-4608(94)00154-4; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HARRIS H, 1990, J CELL SCI, V97, P5; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; HUANG S, 1994, J CELL PHYSIOL, V161, P470, DOI 10.1002/jcp.1041610310; HUANG S, 1994, INT J CANCER, V57, P742, DOI 10.1002/ijc.2910570522; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Kagami S, 1996, EXP CELL RES, V229, P1, DOI 10.1006/excr.1996.0336; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LAIHO M, 1989, CANCER RES, V49, P2533; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LeRoy C, 1996, J BIOL CHEM, V271, P11027, DOI 10.1074/jbc.271.18.11027; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NAGARAJAN L, 1994, BLOOD, V83, P199, DOI 10.1182/blood.V83.1.199.bloodjournal831199; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; OYAMA F, 1989, J BIOL CHEM, V264, P10331; PAULUS W, 1995, J NEUROPATH EXP NEUR, V54, P236, DOI 10.1097/00005072-199503000-00010; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Planus E, 1997, J CELL SCI, V110, P1091; Powell CT, 1996, CANCER RES, V56, P4137; QUAX PHA, 1992, DEV BIOL, V151, P161; RAMSEY WS, 1984, IN VITRO CELL DEV B, V20, P802; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHREINER C, 1991, CANCER RES, V51, P1738; SCOTT DL, 1981, J IMMUNOL METHODS, V43, P29, DOI 10.1016/0022-1759(81)90033-8; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; VARANI J, 1991, MICROCIRCULATION CAN, P2; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WILSON TE, 1992, J BIOL CHEM, V267, P3718; WIRTH PJ, 1992, ELECTROPHORESIS, V13, P305, DOI 10.1002/elps.1150130163; Xue W, 1997, CANCER RES, V57, P1682; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	79	113	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4400	4411		10.1074/jbc.274.7.4400	http://dx.doi.org/10.1074/jbc.274.7.4400			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933644	hybrid			2022-12-27	WOS:000078575500068
J	Barath, P; Albert-Fournier, B; Luciakova, K; Nelson, BD				Barath, P; Albert-Fournier, B; Luciakova, K; Nelson, BD			Characterization of a silencer element and purification of a silencer protein that negatively regulates the human adenine nucleotide translocator 2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; CYCLE-DEPENDENT GENES; ADP ATP TRANSLOCASE; TRANSFERASE-P GENE; ADP/ATP TRANSLOCASE; CELL-CYCLE; DIFFERENTIAL REGULATION; ERYTHROID PROMOTER; MOLECULAR-CLONING; BINDING-PROTEINS	Expression of adenine nucleotide translocator isoform 2 (ANT2) is growth regulated. In the present study, we report the presence of a silencer region in the human ANTS promoter and the purification of a two-component factor that recognizes a specific hexanucleotide element, GTCCTG, of the silencer. Transfection of deletion constructs shows that ANTS silencer activity extends over a region of at least 310 nts, However, mutating the GTCCTG element completely relieves silencing activity in the context of the human ANTS promoter. The data suggest that the GTCCTG element might be required for maintaining silencer activity of the extended silencer region. The ANTS silencer region cloned in front of the herpes simplex virus thymidine kinase promoter confers nearly complete inhibition to the heterologous promoter, However, unlike the ANTS promoter, mutating the GTCCTG element restores only partial activity to the herpes simplex virus thymidine kinase promoter. A protein complex consisting of two major polypeptides of 37 and 49 kDa was isolated from HeLa nuclear extracts by affinity chromatography using the GTCCTG element as the affinity resin. Cross-linking studies and Southwestern analysis indicate that p37 binds DNA. p49 appears to be loosely associated with the p37/DNA complex but is necessary for strong binding of p37, Our data implicating the GTCCTG element directly in silencing of the ANT2 promoter, together with data from the literature reporting the presence of this element within the silencer region of several additional promoters, suggest a general role of the GTCCTG element in transcriptional silencing.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden	Stockholm University	Nelson, BD (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden.		Barath, Peter/T-7563-2019	Barath, Peter/0000-0001-7330-955X				Ausubel R.B., 1994, CURRENT PROTOCOLS MO; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Dummler K, 1996, BIOCHEM J, V317, P913; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HAUN RS, 1990, J BIOL CHEM, V265, P15455; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JabraneFerrat N, 1996, MOL CELL BIOL, V16, P4683; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; KU DH, 1990, J BIOL CHEM, V265, P16060; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Ogbourne S, 1998, BIOCHEM J, V331, P1; Osada S, 1997, J BIOCHEM, V121, P355; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; *PROM, 1991, PROM PROT APPL GUID; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RITTLING SR, 1985, BIOCHEM BIOPH RES CO, V132, P327, DOI 10.1016/0006-291X(85)91026-5; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; WONG NCW, 1990, J BIOL CHEM, V265, P8775	48	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3378	3384		10.1074/jbc.274.6.3378	http://dx.doi.org/10.1074/jbc.274.6.3378			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920880	hybrid			2022-12-27	WOS:000078428200020
J	Medvedev, A; Saunders, NA; Matsuura, H; Chistokhina, A; Jetten, AM				Medvedev, A; Saunders, NA; Matsuura, H; Chistokhina, A; Jetten, AM			Regulation of the transglutaminase I gene - Identification of DNA elements involved in its transcriptional control in tracheobronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; INVITRO SQUAMOUS DIFFERENTIATION; MOUSE EPIDERMAL-KERATINOCYTES; RETINOIC ACID; TERMINAL DIFFERENTIATION; TISSUE TRANSGLUTAMINASE; PROXIMAL PROMOTER; BINDING PROTEINS; RESPONSE ELEMENT; LINKING ENZYMES	The transglutaminase I (TGase I) gene encodes an enzyme that catalyzes the cross-linking of structural proteins involved in the formation of the cornified envelope during squamous cell differentiation. To identify DNA elements important for the transcriptional control of the TGase I gene, we analyzed the ability of a 2.9-kilobase pair (kb) upstream regulatory region to control the expression of a reporter gene in vivo and in vitro. Transgenic mice bearing the pTG(-2.9kb)CAT construct exhibited the same pattern of tissue-specific expression of CAT as reported for TGase I. Deletion analysis in transiently transfected rabbit tracheal epithelial cells indicated that two sequences from bp -490 to -470 and from -54 to -37 are involved in the activation of TGase I transcription. Point mutation analysis and mobility shift assays showed that the sequence located between -54 and -37 is a functional Spl-like transcription element. Sp1 and Sp3, but not Sp2, are part of nuclear protein complexes from differentiated RbTE cells binding to this site. The element TGATGTCA between bp -490 and -470 is contained in a larger 22-bp palindrome and resembles the consensus cAMP response element-binding protein (CREB)/AP-1 element recognized by dimeric complexes of members of the CREB, ATF, Fos, and Jun families, Mutations in this sequence greatly reduced promoter activity. Supershift analysis identified CREB1; JunB, c-Fos, Fra-1, and c-Jun in protein complexes isolated from differentiated rabbit tracheal epithelial cells binding to this site. Our study shows that the Sp1- and CREB/AP-1-like sites act in concert to stimulate transcription of the TGase I gene. The 2.9-kb promoter region could guide expression of specific genes in the granular layer of the epidermis and could be useful in gene therapy.	NIEHS, Cell Biol Sect, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jetten, AM (corresponding author), NIEHS, Cell Biol Sect, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA.	jetten@niehs.nih.gov	Jetten, Anton/C-3736-2019; McTaggart, Jill/G-4696-2010; saunders, nicholas/AAJ-6101-2020	Jetten, Anton/0000-0003-0954-4445; McTaggart, Jill/0000-0002-9000-8529; saunders, nicholas/0000-0002-2478-3420; Medvedev, Alexander/0000-0001-6983-1687				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; Choate KA, 1997, HUM GENE THER, V8, P1659, DOI 10.1089/hum.1997.8.14-1659; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FISHER DF, 1996, MOL CELL BIOL, V16, P5365; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; HOHL D, 1991, J BIOL CHEM, V266, P6626; HUANG FL, 1986, IN VITRO CELL DEV, V22, P230; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1989, EXP CELL RES, V182, P622, DOI 10.1016/0014-4827(89)90264-4; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1992, CELL GROWTH DIFFER, V3, P549; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; Jetten Anton M., 1997, Journal of Dermatology (Tokyo), V24, P711; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; Lee JH, 1996, J BIOL CHEM, V271, P4561; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU B, 1994, J BIOL CHEM, V269, P7443; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MARVIN KW, 1995, J BIOL CHEM, V270, P28910, DOI 10.1074/jbc.270.48.28910; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Matsuura Hironori, 1994, Journal of Dermatological Science, V8, P25, DOI 10.1016/0923-1811(94)90317-4; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Parameswaran KN, 1997, J BIOL CHEM, V272, P10311; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; REARICK JI, 1987, J BIOL CHEM, V262, P13069; REARICK JI, 1986, J BIOL CHEM, V261, P13898; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Reichert Uwe, 1993, P107; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; Rutberg SE, 1996, ONCOGENE, V13, P167; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; SMITS HL, 1987, MOL CELL BIOL, V7, P4017, DOI 10.1128/MCB.7.11.4017; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; TARCSA E, 1992, J BIOL CHEM, V267, P25648; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	73	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3887	3896		10.1074/jbc.274.6.3887	http://dx.doi.org/10.1074/jbc.274.6.3887			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920944	hybrid			2022-12-27	WOS:000078428200084
J	Tamaru, M; Narumi, S				Tamaru, M; Narumi, S			E-selectin gene expression is induced synergistically with the coexistence of activated classic protein kinase C and signals elicited by interleukin-1 beta but not tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MURINE PERITONEAL-MACROPHAGES; ISCHEMIA-REPERFUSION INJURY; TISSUE-SPECIFIC EXPRESSION; CELL-ADHESION MOLECULE-1; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL REGULATION; GROWTH-FACTOR; IFN-GAMMA	We have examined the effect of protein kinase C (PKC) on the expression of the E-selectin and intercellular adhesion molecule-1 (ICAM-1) mRNAs in human umbilical vein endothelial cells. The lower classic PKC activity on pretreatment with phorbol ester (phorbol 12-myristate 13-acetate (PMA)) for 24 h markedly decreased IL-1 beta-induced E-selectin mRNA expression in the presence of fetal calf serum and basic fibroblast growth factor, although the induction of ICAM-1 mRNA expression was only influenced a little by the PKC down-regulation. On the other hand, tumor necrosis factor-alpha (TNF alpha)-induced gene expression of these adhesion molecules was unaffected by such PKC modulation. The intracellular signals generated by interleukin (IL)-1 beta and TNF alpha themselves are not mediated through classic PKC activation, because the response to neither stimulant was inhibited by the PKC down-regulation in the absence of fetal calf serum and basic fibroblast growth factor. Simultaneous treatment with IL-1 beta and PMA synergistically induced E-selectin gene expression but not when TNFa was substituted for IL-1 beta. ICAM-1 mRNA expression was only additively induced on the cotreatment. The synergistic effect on E-selectin mRNA induction was independent of de novo protein synthesis and mediated by elevated transcriptional activity. Promoter analysis of E-selectin indicated that the NF-ELAM1/activating transcription factor element is critical for the synergistic effect of the cotreatment with IL-1 beta and PMA.	Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 1130033, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Pharmaceut Frontier Res Labs, Kanagawa 2360004, Japan	University of Tokyo; Japan Tobacco Inc.	Narumi, S (corresponding author), Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	snarumi@tka.att.ne.jp						CARLOS TM, 1994, BLOOD, V84, P2068; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUKAS J, 1990, J IMMUNOL, V145, P1727; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; GIMOND C, 1992, EXP CELL RES, V203, P365, DOI 10.1016/0014-4827(92)90010-6; GREEN J, 1995, AM J PHYSIOL-CELL PH, V268, pC1090, DOI 10.1152/ajpcell.1995.268.5.C1090; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HA KS, 1993, J BIOL CHEM, V268, P10534; HAMILTON TA, 1986, J CELL PHYSIOL, V128, P9, DOI 10.1002/jcp.1041280103; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORGAN MJ, 1990, AM J PHYSIOL, V259, pL315, DOI 10.1152/ajplung.1990.259.4.L315; INTRONA M, 1987, J CELL PHYSIOL, V131, P36, DOI 10.1002/jcp.1041310107; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; NARUMI S, 1992, J LEUKOCYTE BIOL, V52, P27, DOI 10.1002/jlb.52.1.27; NARUMI S, 1992, J IMMUNOL, V149, P529; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHMORI Y, 1993, AM J PATHOL, V142, P861; Perbal B., 1988, PRACTICAL GUIDE MOL; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REPINE JE, 1987, AM REV RESPIR DIS, V136, P483, DOI 10.1164/ajrccm/136.2.483; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; SWERLICK RA, 1992, J IMMUNOL, V149, P698; Tamaru M, 1998, ARTERIOSCL THROM VAS, V18, P1292, DOI 10.1161/01.ATV.18.8.1292; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VORABERGER G, 1991, J IMMUNOL, V147, P2777; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	52	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3753	3763		10.1074/jbc.274.6.3753	http://dx.doi.org/10.1074/jbc.274.6.3753			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920928	hybrid			2022-12-27	WOS:000078428200068
J	Or, E; Goldshleger, R; Karlish, SJD				Or, E; Goldshleger, R; Karlish, SJD			Characterization of disulfide cross-links between fragments of proteolyzed Na,K-ATPase - Implications for spatial organization of trans-membrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; BETA-SUBUNIT; CATION OCCLUSION; ADENOSINE-TRIPHOSPHATASE; SENSITIVE INTERACTIONS; TRANSMEMBRANE DOMAIN; MOLECULAR-WEIGHT; PROTEIN-KINASE	This study characterizes disulfide cross-links between fragments of a well defined tryptic preparation of Na,K-ATPase, 19-kDa membranes solubilized with C12E10 in conditions preserving an intact complex of fragments and Rb occlusion (Or, E., Goldshleger, R., Tal, D. M., and Karlish, S. J. D. (1996) Biochemistry 35, 6853-6864). Upon solubilization, cross-links form spontaneously between the beta subunit, 19- and 11.7-kDa fragments of the alpha subunit, containing trans-membrane segments M7-M10 and M1/M2, respectively. Treatment with Cu2+-phenanthroline (CuP) improves efficiency of cross-linking, Sequencing and immunoblot analysis have shown that the crosslinked products consist of a mixture of beta-19 kDa dimers (approximate to 65%) and beta-19 kDa-11.7 kDa trimers (approximate to 35%). The alpha-beta cross-link has been located within the 19-kDa fragment to a 6.5-kDa chymotryptic fragment containing M8, indicating that beta Cys(44) is cross-linked to either Cys(911) or Cys(930). In addition, an internal cross-link between M9 and M10, Cys(964)-Cys(983), has,, been found by sequencing tryptic fragments of the cross-linked product. The M1/M2-M7/M10 cross-link has not been identified directly. However, we propose that Cys(983) in M10 is cross-linked either to Cys(104) in M1 or internally to Cys(964) in M9. Based on this study, cross-linking induced by o-phthal-aldehyde (Or, E., Goldshleger, R., and Karlish, S. J. D. (1998) Biochemistry 37, 8197-8207), and information from the literature, we propose an approximate spatial organization of trans-membrane segments of the alpha and beta subunits.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bckarlis@weizmann.weizmann.ac.il						ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; EFREMOV RG, 1993, J PROTEIN CHEM, V12, P143, DOI 10.1007/BF01026035; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HARLOW E, 1988, ANTIBODIES LAB MANUA, P509; HUANG WH, 1979, BIOCHIM BIOPHYS ACTA, V578, P547, DOI 10.1016/0005-2795(79)90186-7; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIANG SM, 1977, J BIOL CHEM, V252, P8278; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NAGAI M, 1986, J BIOL CHEM, V261, P3197; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; OR E, 1993, J BIOL CHEM, V268, P16929; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SARVAYAN NA, 1992, J BIOL CHEM, V270, P26528; Sarvazyan NA, 1997, J BIOL CHEM, V272, P7855, DOI 10.1074/jbc.272.12.7855; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWAPPACH B, 1994, J BIOL CHEM, V269, P21620; Shainskaya A, 1998, J BIOL CHEM, V273, P7311, DOI 10.1074/jbc.273.13.7311; SHIN JM, 1994, J BIOL CHEM, V269, P8642; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	47	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2802	2809		10.1074/jbc.274.5.2802	http://dx.doi.org/10.1074/jbc.274.5.2802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915813	hybrid			2022-12-27	WOS:000078319500031
J	Slavik, JM; Hutchcroft, JE; Bierer, BE				Slavik, JM; Hutchcroft, JE; Bierer, BE			CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; VAV PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; T-LYMPHOCYTES; COSTIMULATORY RECEPTOR; KINASE SUBSTRATE; B7-2 REGULATION; CLONAL ANERGY; ACTIVATION		Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Bierer, BE (corresponding author), NHLBI, Bldg 10,Rm 5D49,10 Ctr Dr, Bethesda, MD 20892 USA.	BiererB@nih.gov		Bierer, Barbara/0000-0001-6448-8170				BOUSSIOTIS VA, 1993, P NATL ACAD SCI USA, V90, P11059, DOI 10.1073/pnas.90.23.11059; Boutin Y, 1997, J IMMUNOL, V159, P5802; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Eck SC, 1997, TRANSPLANTATION, V64, P1497, DOI 10.1097/00007890-199711270-00025; Ellis JH, 1996, J IMMUNOL, V156, P2700; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; Gajewski TF, 1996, J IMMUNOL, V156, P465; GhiottoRagueneau M, 1996, EUR J IMMUNOL, V26, P34, DOI 10.1002/eji.1830260106; GILLIS S, 1978, J IMMUNOL, V120, P2027; Greene JAL, 1996, J BIOL CHEM, V271, P26762, DOI 10.1074/jbc.271.43.26762; Hatchcock Karen S., 1994, Journal of Experimental Medicine, V180, P631; Hutchcroft JE, 1996, J BIOL CHEM, V271, P13362, DOI 10.1074/jbc.271.23.13362; JUNE CH, 1994, CHEM IMMUNOL, V59, P62; Kariv I, 1996, J IMMUNOL, V157, P29; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Matulonis U, 1996, J IMMUNOL, V156, P1126; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; Nunes JA, 1996, MOL IMMUNOL, V33, P63, DOI 10.1016/0161-5890(95)00121-2; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RACKE MK, 1995, J CLIN INVEST, V96, P2195, DOI 10.1172/JCI118274; ROONEY JW, 1995, MOL CELL BIOL, V15, P6269; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; UEDA Y, 1995, INT IMMUNOL, V7, P957, DOI 10.1093/intimm/7.6.957; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WEISS M, 1993, BLOOD, V82, P3298; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	54	61	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3116	3124		10.1074/jbc.274.5.3116	http://dx.doi.org/10.1074/jbc.274.5.3116			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915850	hybrid			2022-12-27	WOS:000078319500068
J	van Geest, M; Nilsson, I; von Heijne, G; Lolkema, JS				van Geest, M; Nilsson, I; von Heijne, G; Lolkema, JS			Insertion of a bacterial secondary transport protein in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; IN-VITRO TRANSLATION; ESCHERICHIA-COLI; TRANSMEMBRANE TOPOLOGY; INTERNAL SIGNAL; TRANSLOCATION; SEQUENCE; INTEGRATION; RECEPTOR; COMPLEX	The sodium ion-dependent citrate carrier of Klebsiella pneumoniae (CitS) contains 12 hydrophobic potential transmembrane domains. Surprisingly, an alkaline phosphatase fusion study in Escherichia coli has suggested that only 9 of these domains are embedded in the membrane, and 3 are translocated to the periplasm (van Geest, M., and Lolkema, J. S. (1996) J. Biol. Chem. 271, 25582-25589), To provide independent data on the topology and mode of membrane insertion of CitS, we have investigated its insertion into the endoplasmic reticulum (ER) membrane. By using in vitro translation of model proteins in the presence of dog pancreas microsomes, each of the putative transmembrane segments of CitS was assayed for its potency to insert into the ER membrane, both as an isolated segment as well as in the context of COOH-terminal truncation mutants. All 12 segments were able to insert into the membrane as N-cyt- C-lum signal anchor sequences, In a series of COOH-terminal truncation mutants, the segments inserted in a sequential way except for one segment, segment Vb, which was translocated to the lumen. Hydrophobic segments VIII and M, which, according to the alkaline phosphatase fusion study, are in the periplasm off, coli, form a helical hairpin in the ER membrane. These observations suggest a topology for CitS with 11 transmembrane segments and also demonstrate that the sequence requirements for signal anchor and stop transfer function are different.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden	University of Groningen; Stockholm University	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklann 30, NL-9751 NN Haren, Netherlands.	j.s.lolkema@biol.rug.nl	Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Erickson B. W., 1976, PROTEINS, VII, P255; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILJESTROM P, 1991, J VIROL, V65, P4107; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Saaf A, 1998, EUR J BIOCHEM, V251, P821, DOI 10.1046/j.1432-1327.1998.2510821.x; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; YANNISCHPERRON C, 1985, GENE, V33, P103	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2816	2823		10.1074/jbc.274.5.2816	http://dx.doi.org/10.1074/jbc.274.5.2816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915815	hybrid, Green Published			2022-12-27	WOS:000078319500033
J	Gutknecht, R; Flukiger, K; Lanz, R; Erni, B				Gutknecht, R; Flukiger, K; Lanz, R; Erni, B			Mechanism of phosphoryl transfer in the dimeric IIAB(Man) subunit of the Escherichia coli mannose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; MANNITOL TRANSPORT; ENZYME-III; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ANTITERMINATOR PROTEIN; KLEBSIELLA-PNEUMONIAE; GLUCOSE-TRANSPORT; SITE MUTANTS; PHOSPHOENOLPYRUVATE	The mannose transporter of bacterial phosphoenolpyruvate:sugar phosphotransferase system (PTS) mediates uptake of mannose, glucose, and related hexoses by a mechanism that couples translocation with phosphorylation of the substrate. It consists of the transmembrane IICMan IIDMan complex and the cytoplasmic ILAB(Man) subunit. IIAB(Man) has two domains (IIA and IIB) that are linked by a 60-Angstrom long alanine-proline-rich linker. ILAB(Man) transfers phosphoryl groups from the phospho-histidine-containing phospho-carrier protein of the PTS to His-10 on IIA, hence to His-175 on IIB, and finally to the 6'-OH of the transported hexose. IIAB(Man) occurs as a stable homodimer. The subunit contact is mediated by a swap of beta-strands and an extensive contact area between the IIA domains. The H10C and H175C single and the H10C/H175C double mutants were used to characterize the phosphoryl transfer between IIA to IIB. Subunits do not exchange between dimers under physiological conditions, but slow phosphoryl transfer can take place between subunits from different dimers. Heterodimers of different subunits were produced in vitro by GuHCl-induced unfolding and refolding of mixtures of two different homodimers. With respect to wild-type homodimers, the heterodimers have the following activities: wild-type.H10C, 50%; wild-type.H175C 45%; H10C.H175C, 37%; and wild-type.H1OC/H175C (double mutant), 29%. Taken together, this indicates that both cis and trans pathways contribute to the maximal phosphotransferase activity of IIAB(Man). A phosphoryl group on a IIA domain can be transferred either to the IIB domain on the same or on the second subunit in the dimer, and interruption of one of the two pathways results in a reduction of the activity to 70-80% of the control.	Univ Bern, Dept Biochem & Chem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Biochem & Chem, Freiestr 3, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						BOER H, 1995, BIOCHEMISTRY-US, V34, P3239, DOI 10.1021/bi00010a013; BOER H, 1994, J BIOL CHEM, V269, P17863; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P557; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P308; Gutknecht R, 1998, J BIOL CHEM, V273, P12234, DOI 10.1074/jbc.273.20.12234; Huber F, 1996, EUR J BIOCHEM, V239, P810, DOI 10.1111/j.1432-1033.1996.0810u.x; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JIA ZC, 1993, J BIOL CHEM, V268, P22490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MARKOVICHOUSLEY Z, 1994, BIOCHEMISTRY-US, V33, P10977, DOI 10.1021/bi00202a017; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; MARTINVERSTRAETE I, 1994, J MOL BIOL, V241, P178, DOI 10.1006/jmbi.1994.1487; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meijberg W, 1996, BIOCHEMISTRY-US, V35, P2759, DOI 10.1021/bi952567b; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; MEINS M, 1988, J BIOL CHEM, V263, P12986; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; OSUMI T, 1982, P NATL ACAD SCI-BIOL, V79, P1457, DOI 10.1073/pnas.79.5.1457; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PETERKOFSKY A, 1995, BIOCHEMISTRY-US, V34, P8950, DOI 10.1021/bi00028a003; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RHIEL E, 1994, BIOL CHEM H-S, V375, P551, DOI 10.1515/bchm3.1994.375.8.551; SAIER MH, 1983, J BACTERIOL, V155, P1351, DOI 10.1128/JB.155.3.1351-1357.1983; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; STOLZ B, 1993, J BIOL CHEM, V268, P27094; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VANDERVLAG J, 1994, J BACTERIOL, V176, P3518, DOI 10.1128/JB.176.12.3518-3526.1994; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; VEYRAT A, 1994, MICROBIOL-UK, V140, P1141, DOI 10.1099/13500872-140-5-1141; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535	54	17	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6091	6096		10.1074/jbc.274.10.6091	http://dx.doi.org/10.1074/jbc.274.10.6091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037691	hybrid			2022-12-27	WOS:000078902800013
J	Masuko, N; Makino, K; Kuwahara, H; Fukunaga, K; Sudo, T; Araki, N; Yamamoto, H; Yamada, Y; Miyamoto, E; Saya, H				Masuko, N; Makino, K; Kuwahara, H; Fukunaga, K; Sudo, T; Araki, N; Yamamoto, H; Yamada, Y; Miyamoto, E; Saya, H			Interaction of NE-dlg/SAP102, a neuronal and endocrine tissue-specific membrane-associated guanylate kinase protein, with calmodulin and PSD-95/SAP90 - A possible regulatory role in molecular clustering at synaptic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR; BINDING DOMAIN; PDZ DOMAINS; FAMILY; IDENTIFICATION; RECOGNITION; SUBSTRATE; HOMOLOG	NE-dlg/SAP102, a neuronal and endocrine tissue-specific membrane-associated guanylate kinase family protein, is known to bind to C-terminal ends of N-methyl-D-aspartate receptor 2B (NR2B) through its PDZ (PSD-95/Dlg/ZO-1) domains. NE-dlg/SAP102 and NR2B colocalize at synaptic sites in cultured rat hippocampal neurons, and their expressions increase in parallel with the onset of synaptogenesis, me have identified that NE-dlg/SAP102 interacts with calmodulin in a Ca2+-dependent manner. The binding site for calmodulin has been determined to he at the putative basic cr-helix region located around the src homology 3 (SH3) domain of NE-dlg/SAP102. Using a surface plasmon resonance measurement system, we detected specific binding of recombinant NE-dlg/SAP102 to the immobilized calmodulin with a K-d value of 44 nM. However, the binding of Ca2+/calmodulin to NE-dlg/SAP102 did not modulate the interaction between PDZ domains of NE-dlg/SAP102 and the C-terminal end of rat NR2B. We have also identified that the region near the calmodulin binding site of NE-dlg/SAP102 interacts with the GUK-like domain of PSD-95/SAP90 by two-hybrid screening. Pull down assay revealed that NE-dlg/SAP102 can interact with PSD-95/SAP90 in the presence of both Ca2+ and calmodulin. These findings suggest that the Ca2+/calmodulin modulates interaction of neuronal membrane-associated guanylate kinase proteins and regulates clustering of neurotransmitter receptors at central synapses.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan; Taisho Pharmaceut Co Ltd, Hanno Res Ctr, Canc Res Lab, Hanno, Saitama 3578527, Japan	Kumamoto University; Kumamoto University; Taisho Pharmaceutical Holdings Co Ltd	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Baird DH, 1996, J NEUROSCI, V16, P2642; BASARSKY TA, 1994, J NEUROSCI, V14, P6402; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; KELLY GM, 1991, J BIOL CHEM, V266, P12469; KELLY PT, 1978, J CELL BIOL, V79, P173, DOI 10.1083/jcb.79.1.173; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lin SY, 1998, J NEUROSCI, V18, P3725; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; OROURKE NA, 1994, NEURON, V12, P921, DOI 10.1016/0896-6273(94)90343-3; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	40	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5782	5790		10.1074/jbc.274.9.5782	http://dx.doi.org/10.1074/jbc.274.9.5782			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026200	hybrid			2022-12-27	WOS:000078804400071
J	Yan, D; Schulte, MK; Bloom, KE; White, MM				Yan, D; Schulte, MK; Bloom, KE; White, MM			Structural features of the ligand-binding domain of the serotonin 5HT(3) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; N1E-115 NEUROBLASTOMA-CELLS; GATED ION-CHANNEL; FUNCTIONAL EXPRESSION; SEQUENCE; SUBUNIT; SITES	The nicotinic acetylcholine receptor (AChR) and the serotonin type 3 receptor (5HT(3)R) are members of the Ligand-gated ion channel gene family, Both receptors are inhibited by nanomolar concentrations of d-tubocurarine (curare) in a competitive fashion. Chemical labeling studies on the AChR have identified tryptophan residues on the gamma (gamma Trp-55) and delta (delta Trp-57) subunits that interact with curare, Comparison of the sequences of these two subunits with the 5HT(3)R shows that a tryptophan residue is found in the homologous position in the 5HT(3)R (Trp-89), suggesting that this residue may be involved in curare-5HT(3)R interactions. Site-directed mutagenesis at position Trp-89 markedly reduces the affinity of the 5HT(3)R for the antagonists curare and granisetron but has little effect on the affinity for the agonist serotonin, To further examine the role of this region of the receptor in ligand-receptor interactions, alanine-scanning mutagenesis analysis of the region centered on Trp-89 (Thr-85 to Trp-94) was carried out, and the ligand binding properties of the mutant receptors were determined. Within this region of the receptor, curare affinity is reduced by substitution only at Trp-89, whereas serotonin affinity is reduced only by substitution at Arg-91, On the other hand, granisetron affinity is reduced by substitutions at Trp-89, Arg-91, and Tyr-93, This differential effect of substitutions on ligand affinity suggests that different ligands may have different points of interaction within the ligand-binding pocket. In addition, the every-other-residue periodicity of the effects on granisetron affinity strongly suggests that this region of the ligand-binding site of the 5HT(3)R (and by inference, other members of the ligand-gated ion channel family) is in a beta-strand conformation.	Med Coll Penn & Hahnemann Univ, Dept Pharmacol, Philadelphia, PA 19129 USA; Med Coll Penn & Hahnemann Univ, Dept Physiol, Philadelphia, PA 19129 USA	Drexel University; Drexel University	White, MM (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Pharmacol, 3300 Henry Ave, Philadelphia, PA 19129 USA.			Schulte, Marvin/0000-0002-8141-041X	NINDS NIH HHS [T32 NS09618, R01 NS23885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023885] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GAMIER J, 1978, J MOL BIOL, V120, P97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPE AG, 1993, EUR J PHARM-MOLEC PH, V245, P187, DOI 10.1016/0922-4106(93)90128-V; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LUMMIS SCR, 1993, EUR J PHARMACOL, V243, P7, DOI 10.1016/0014-2999(93)90160-J; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIQUEL MC, 1991, BIOCHEM PHARMACOL, V42, P1453, DOI 10.1016/0006-2952(91)90459-I; OELARY ME, 1994, AM J PHYSIOL, V266, pC648; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PETERS JA, 1990, NEUROSCI LETT, V110, P107, DOI 10.1016/0304-3940(90)90796-C; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1993, NEURON S, V10, P31; Yan D, 1998, NEUROPHARMACOLOGY, V37, P251, DOI 10.1016/S0028-3908(98)00010-0	23	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5537	5541		10.1074/jbc.274.9.5537	http://dx.doi.org/10.1074/jbc.274.9.5537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026168	hybrid			2022-12-27	WOS:000078804400039
J	Aarts, MM; Levy, D; He, B; Stregger, S; Chen, TP; Richard, S; Henderson, JE				Aarts, MM; Levy, D; He, B; Stregger, S; Chen, TP; Richard, S; Henderson, JE			Parathyroid hormone-related protein interacts with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DSRNA BINDING DOMAIN; KH-DOMAIN; GENE-EXPRESSION; TAT; LOCALIZATION; PEPTIDE; NUCLEAR; KINASE; TRANSACTIVATION	Parathyroid hormone-related protein (PTHrP) is a secreted protein that acts as an autocrine and paracrine mediator of cell proliferation and differentiation. In addition to its biological activity that is mediated through signal transduction cascades, there is evidence for an intracellular role for PTHrP in cell cycle progression and apoptosis. These effects are mediated through a mid-region nuclear targeting sequence (NTS) that localizes PTHrP to the region of the nucleolus where ribonucleoprotein complexes form in vivo. In this work, we show that endogenous, transfected, and in vitro translated PTHrP proteins bind homopolymeric and total cellular RNAs at salt concentrations up to 1 M. A peptide representing the PTHrP NTS was effective in competing with the wild-type protein for RNA binding, whereas a similar peptide representing the nucleolin NTS was not. Bite-directed mutagenesis revealed that the binding of PTHrP to RNA was direct and was dependent on preservation of a core GXKKXXK motif, embedded in the PTHrP NTS, which is shared with other RNA-binding proteins. The current observations are the first to document RNA binding by a secreted cellular protein and predict a role for PTHrP in regulating RNA metabolism that may be related to its localization in the nucleolus of cells in vivo.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Henderson, JE (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Rm 602,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Aarts, Michelle/C-5766-2008	Aarts, Michelle/0000-0002-9171-0571				ASA SL, 1990, J CLIN ENDOCR METAB, V71, P1112, DOI 10.1210/jcem-71-5-1112; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Broadus Arthur E., 1994, P259; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chorev Michael, 1994, P139; DANG CV, 1989, J BIOL CHEM, V264, P18019; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; Goltzman David, 1996, P809; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; HENDERSON JE, 1995, J BONE MINER RES  S1, V10, pS286; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.3.CO;2-D; Lazdins IB, 1997, CHROMOSOMA, V105, P481, DOI 10.1007/BF02510485; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	33	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4832	4838		10.1074/jbc.274.8.4832	http://dx.doi.org/10.1074/jbc.274.8.4832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988723	hybrid			2022-12-27	WOS:000078698200048
J	Blum, E; Carpousis, AJ; Higgins, CF				Blum, E; Carpousis, AJ; Higgins, CF			Polyadenylation promotes degradation of 3 '-structured RNA by the Escherichia coli mRNA degradosome in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RPSO MESSENGER-RNA; POLY(A) POLYMERASE; G-QUARTET; DECAY; GENE; IDENTIFICATION; STABILITY; PLASMIDS; PROTEINS; COMPLEX	Polyadenylation contributes to the destabilization of bacterial mRNA We have investigated the role of polyadenylation in the degradation of RNA by the purified Eseherichia coil degradosome in vitro. RNA molecules with 3'-ends incorporated into a stable stem-loop structure could not readily be degraded by purified polynucleotide phosphorylase or by the degradosome, even though the degradosome contains active RhlB helicase which normally facilitates degradation of structured RNA. The exoribonucleolytic activity of the degradosome was due to polynucleotide phosphorylase, rather than the recently reported exonucleolytic activity exhibited by a purified fragment of RNase E (Huang, H,, Liao, J., and Cohen, S, N. (1998) Nature 391, 99-102), Addition of a 3'-poly(A) tail stimulated degradation by the degradosome, As few as 5 adenosine residues were sufficient to achieve this stimulation, and generic sequences were equally effective. The data show that the degradosome requires a single-stranded "toehold" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end. Significantly, oligo(a) and oligo(U) tails were unable to stimulate degradation; for oligo(a), at least, this is probably due to the formation of a G quartet structure which makes the 3'-end inaccessible. The inaccessibility of 3'-oligo(U) sequences is likely to have a role in stabilization of RNA molecules generated by Rho-independent terminators.	Hammersmith Hosp, Imperial Coll, Sch Med, MRC,Clin Sci Ctr, London W12 0NN, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Clin Biochem, Oxford OX3 9DS, England; CNRS, Lab Microbiol & Genet Mol, F-31062 Toulouse, France	Imperial College London; University of Oxford; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Higgins, CF (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, MRC,Clin Sci Ctr, Du Cane Rd, London W12 0NN, England.		Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				Baker EJ, 1993, CONTROL MESSENGER RN, P367; Bishop JS, 1996, J BIOL CHEM, V271, P5698, DOI 10.1074/jbc.271.10.5698; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; Cao GJ, 1996, P NATL ACAD SCI USA, V93, P11580, DOI 10.1073/pnas.93.21.11580; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HaugelNielsen J, 1996, EMBO J, V15, P3144, DOI 10.1002/j.1460-2075.1996.tb00677.x; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NEWBURY SF, 1987, CELL, V48, P297, DOI 10.1016/0092-8674(87)90433-8; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PIRTLE RM, 1980, J BIOL CHEM, V255, P199; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR N, 1996, MICROBIOLOGY, V142, P3126; Sugimoto N, 1996, NUCLEOS NUCLEOT NUCL, V15, P559, DOI 10.1080/07328319608002405; SUNDQUIST WI, 1993, CURR BIOL, V3, P893, DOI 10.1016/0960-9822(93)90229-H; TALJANIDISZ J, 1987, J MOL BIOL, V193, P507, DOI 10.1016/0022-2836(87)90263-4; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	32	88	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4009	4016		10.1074/jbc.274.7.4009	http://dx.doi.org/10.1074/jbc.274.7.4009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933592	hybrid			2022-12-27	WOS:000078575500016
J	Rodighiero, C; Aman, AT; Kenny, MJ; Moss, J; Lencer, WI; Hirst, TR				Rodighiero, C; Aman, AT; Kenny, MJ; Moss, J; Lencer, WI; Hirst, TR			Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin - Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; VIBRIO-CHOLERAE; ENDOPLASMIC-RETICULUM; B-SUBUNIT; RIBOSYLATION FACTORS; RECEPTOR; PROTEIN; SEQUENCE; BINDING; ACTIVATION	Cholera toxin (Ctx) and E. coli heat-labile enterotoxin (Etx) are structurally and functionally similar AB, toxins with over 80% sequence identity. When their action in polarized human epithelial (T84) cells was monitored by measuring toxin-induced Cl- ion secretion, Ctx was found to be the more potent of the two toxins. Here, we examine the structural basis for this difference in toxicity by engineering a set of mutant and hybrid toxins and testing their activity in T84 cells, This revealed that the differential toxicity of Ctx and Etx was (i) not due to differences in the A-subunit's C-terminal KDEL targeting motif (which is RDEL in Etx), as a RDEL to RDEL substitution had no effect on cholera toxin activity; (ii) not attributable to the enzymatically active AI-fragment, as hybrid toxins in which the Al-fragment in Ctx was substituted for that of Etx (and vice versa) did not alter relative toxicity; and (iii) not due to the B-subunit, as the replacement of the B-subunit in Ctx for that of Etx caused no alteration in toxicity, thus excluding the possibility that the broader receptor specificity of EtxB is responsible for reduced activity. Remarkably, the difference in toxicity could be mapped to a 10-amino acid segment of the A2-fragment that penetrates the central pore of the B-subunit pentamer, A comparison of the in vitro stability of two hybrid toxins, differing only in this 10-amino acid segment, revealed that the Ctx A2-segment conferred a greater stability to the interaction between the A- and B-subunits than the corresponding: segment from Etx A2. This suggests that the reason for the relative potency of Ctx compared with Etx stems from the increased ability of the A2-fragment of Ctx to maintain holotoxin stability during uptake and transport into intestinal epithelia.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; NHLBI, NIH, Bethesda, MD 20892 USA; Childrens Hosp, Combined Program Pediat Gastroenterol & Nutr, Boston, MA 02115 USA	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Boston Children's Hospital	Hirst, TR (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Univ Walk, Bristol BS8 1TD, Avon, England.	t.r.hirst@bristol.ac.uk	Aman, Abu Tholib/GLV-5081-2022	Aman, Abu Tholib/0000-0002-8634-7624; Lencer, Wayne/0000-0001-7346-2730	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000622] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; Backstrom M, 1997, MOL MICROBIOL, V24, P489, DOI 10.1046/j.1365-2958.1997.3541721.x; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; BLACK RE, 1985, DEV VACCINES DRUGS D, P23; BOOTH BA, 1984, INFECT IMMUN, V45, P558, DOI 10.1128/IAI.45.3.558-560.1984; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DHARMSATHAPHORN K, 1988, METHOD ENZYMOL, V192, P354; DOMENIGHINI M, 1995, MOL MICROBIOL, V15, P1165, DOI 10.1111/j.1365-2958.1995.tb02289.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOL WGJ, 1995, HANDB NAT T, V8, P185; HOLMGREN J, 1985, GASTROENTEROLOGY, V89, P27, DOI 10.1016/0016-5085(85)90741-3; HOLMGREN J, 1982, INFECT IMMUN, V38, P424, DOI 10.1128/IAI.38.2.424-433.1982; HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973; HOLMGREN J, 1983, INFECT IMMUN, V39, P147, DOI 10.1128/IAI.39.1.147-154.1983; HUNT PD, 1991, INFECT IMMUN, V59, P168, DOI 10.1128/IAI.59.1.168-171.1991; KAPER JB, 1984, NATURE, V308, P655, DOI 10.1038/308655a0; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MARCELLO A, 1994, THESIS U YORK YORK; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1988, METHOD ENZYMOL, V165, P169; MOON HW, 1993, VACCINE, V11, P213, DOI 10.1016/0264-410X(93)90020-X; MOSS J, 1994, METHOD ENZYMOL, V235, P640; MOSS J, 1992, BACTERIAL PROTEINS T, V23, P220; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; ORLANDI PA, 1993, J BIOL CHEM, V268, P17038; ORLANDI PA, 1994, BIOCHEMISTRY-US, V33, P12886, DOI 10.1021/bi00209a021; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RUDDOCK LW, 1995, J BIOL CHEM, V270, P29953; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; Sandvig K, 1996, P NATL ACAD SCI USA, V93, P12339, DOI 10.1073/pnas.93.22.12339; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TENEBERG S, 1994, GLYCOCONJUGATE J, V11, P533, DOI 10.1007/BF00731304; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456	47	46	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3962	3969		10.1074/jbc.274.7.3962	http://dx.doi.org/10.1074/jbc.274.7.3962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933586	hybrid			2022-12-27	WOS:000078575500010
J	Sung, TC; Zhang, Y; Morris, AJ; Frohman, MA				Sung, TC; Zhang, Y; Morris, AJ; Frohman, MA			Structural analysis of human phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; D DEFINES; SUPERFAMILY; FAMILY; INHIBITION; EXPRESSION; SYNTHASES; CLONING	Activation of phosphatidylcholine-specific phospholipase D (PLD) has been proposed to play roles in numerous cellular pathways including signal transduction and membrane vesicular trafficking. We previously reported the cloning of two mammalian genes, PLD1 and PLDS, that encode PLD activities. We additionally reported that PLD1 is activated in a synergistic manner by protein kinase c-alpha (PKC-alpha), ADP-ribosylation factor 1 (ARF1), and Rho family members. We describe here molecular analysis of PLD1 using a combination of domain deletion and mutagenesis. We show that the amino-terminal 325 amino acids are required for PKC-alpha activation of PLD1 but not for activation by ARF1 and RhoA This region does not contain the sole PKC-alpha interaction site and additionally functions to inhibit basal PLD activity in vivo. Second, a region of sequence unique to PLD1 las compared with other PLDs) known as the "loop" region had been proposed to serve as an effector regulatory region but is shown here only to mediate inhibition of PLD1. Finally, we show that modification of the amino terminus, but not of the carboxyl terminus, is compatible with PLD enzymatic function and propose a simple model for PLD activation.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Frohman, MA (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	michael@pharm.som.sunysb.edu	Morris, Andrew/B-7869-2010		NIGMS NIH HHS [GM54813, GM50388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388, R01GM054813] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cao JX, 1997, VIRUS RES, V48, P11, DOI 10.1016/S0168-1702(96)01422-0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; FROHMAN MA, 1999, PHOSPHOLIPASE D BIOC; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Katayama K, 1998, BIOCHEM J, V329, P647, DOI 10.1042/bj3290647; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 1996, PROTEIN SCI, V5, P914; REDINA O, 1998, GENE AMST, V22, P53; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Wakelam M J, 1995, Methods Mol Biol, V41, P271; Wang XM, 1997, TRENDS PLANT SCI, V2, P261, DOI 10.1016/S1360-1385(97)86348-0	29	140	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3659	3666		10.1074/jbc.274.6.3659	http://dx.doi.org/10.1074/jbc.274.6.3659			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920915	hybrid			2022-12-27	WOS:000078428200055
J	Xu, X; Zeng, WH; Popov, S; Berman, DM; Davignon, I; Yu, K; Yowe, D; Offermanns, S; Muallem, S; Wilkie, TM				Xu, X; Zeng, WH; Popov, S; Berman, DM; Davignon, I; Yu, K; Yowe, D; Offermanns, S; Muallem, S; Wilkie, TM			RGS proteins determine signaling specificity of G(q)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; INOSITOL TRISPHOSPHATE; ACINAR-CELLS; CORE DOMAIN; IN-VITRO; GAIP; EXPRESSION; CHANNELS; FAMILY	Regulators of G protein signaling (RGS) proteins accelerate GTP hydrolysis by G alpha subunits, thereby attenuating signaling. RGS4 is a GTPase-activating protein for G(i) and G(q) class alpha subunits. In the present study, we used knockouts of G(q) class genes in mice to evaluate the potency and selectivity of RGS4 in modulating Ca2+ signaling transduced by different G(q)-coupled receptors. RGS4 inhibited phospholipase C activity and Ca2+ signaling in a receptor-selective manner in both permeabilized cells and cells dialyzed with RGS4 through a patch pipette. Receptor-dependent inhibition of Ca2+ signaling by RGS4 was observed in acini prepared from the rat and mouse pancreas. The response of mouse pancreatic acini to carbachol was about 4- and 33-fold more sensitive to RGS4 than that of bombesin and cholecystokinin (CCK), respectively. RGS1 and RGS16 were also potent inhibitors of G(q)-dependent Ca2+ signaling and acted in a receptor-selective manner. RGS1 showed approximately 1000-fold higher potency in inhibiting carbachol than CCK-dependent signaling. RGS16 was as effective as RGS1 in inhibiting carbachol-dependent signaling but only partially inhibited the response to CCK. By contrast, RGS2 inhibited the response to carbachol and CCK with equal potency. The same pattern of receptor-selective inhibition by RGS4 was observed in acinar cells from wild type and several single and double G(q) class knockout mice. Thus, these receptors appear to couple G(q) class alpha subunit isotypes equally. Difference in receptor selectivity of RGS proteins action indicates that regulatory specificity is conferred by interaction of RGS proteins with receptor complexes.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Millenium Pharmaceut Inc, Cambridge, MA 02139 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmacol, D-14159 Berlin, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Gold SJ, 1997, J NEUROSCI, V17, P8024; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ingi T, 1998, J NEUROSCI, V18, P7178; JENSEN R T, 1984, Journal of Pediatric Gastroenterology and Nutrition, V3, pS25, DOI 10.1097/00005176-198400031-00007; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Saugstad JA, 1998, J NEUROSCI, V18, P905; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Williams John A., 1993, P167; Xu X, 1998, J BIOL CHEM, V273, P27275, DOI 10.1074/jbc.273.42.27275; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	47	228	232	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3549	3556		10.1074/jbc.274.6.3549	http://dx.doi.org/10.1074/jbc.274.6.3549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920901	hybrid			2022-12-27	WOS:000078428200041
J	Lucero, HA; Kaminer, B				Lucero, HA; Kaminer, B			The role of calcium on the activity of ERcalcistorin protein-disulfide isomerase and the significance of the C-terminal and its calcium binding - A comparison with mammalian protein-disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALSEQUESTRIN-LIKE PROTEIN; PANCREATIC TRYPSIN-INHIBITOR; ANTI-CHAPERONE ACTIVITY; SEA-URCHIN EGGS; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; MULTIFUNCTIONAL PROTEIN; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; PLASMA-MEMBRANE	ERcalcistorin/protein-disulfide isomerase (ECaSt/PDI) shows a 55% identity with mammalian protein-disulfide isomerase (PDI) (Lucero, H. A., Lebeche, D., and Kaminer, B. (1994) J. Biol. Chem. 269, 23112-23119) is a high capacity low affinity Ca2+-binding protein and behaves as a Ca2+ storage protein in the ER of a living cell (Lucero, H, A., Lebeche, D,, and Kaminer, B. (1998) J. Biol. Chem. 273, 9857-9863), Here we show that recombinant ECaSt/PDI bound 26 mol of Ca2+/mol and a C-terminal truncated mutant bound 14 mol of Ca2+/mol, both with a K-d of 2.8 mM in 50 mM KCl and 5.2 mM in 150 mM KCl, The percentage reduction in Ca2+ binding in the mutant corresponded with the percentage reduction of deleted pairs of acidic residues, postulated low affinity Ca2+-binding sites. 5 mM Ca2+ moderately increased the PDI activity of both ECaSt/PDI and the C-terminal truncated mutant on reduced RNase and insulin. Surprisingly, ECaSt/PDI in the absence of Ca2+ prevented the spontaneous reactivation of reduced bovine pancreatic trypsin inhibitor. In the presence of 1-5 mat Ca2+ (or 10 mu M polylysine) ECaSt/PDI augmented the bovine pancreatic trypsin inhibitor reactivation rate, In contrast, the C-terminal truncated ECaSt/PDI augmented rBPTI reactivation in the absence of Ca2+ and 1-5 mM Ca2+ further accelerated the reactivation rate, responses similar to those obtained with mammalian PDI.	Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA	Boston University	Lucero, HA (corresponding author), Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA.							AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1069, DOI 10.1177/36.8.3292644; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; CARMICHAEL DF, 1977, J BIOL CHEM, V252, P7163; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; Dai Y, 1997, J BIOL CHEM, V272, P27572, DOI 10.1074/jbc.272.44.27572; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; DOERING D, 1992, THESIS MIT CAMBRIDGE; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Guthapfel R, 1996, EUR J BIOCHEM, V242, P315, DOI 10.1111/j.1432-1033.1996.0315r.x; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; KAPPLA P, 1998, EMBO J, V17, P927; Kassell B., 1970, METHODS ENZYMOLOGY, VVolume 19, P844, DOI [10.1016/0076-6879(70)19074-4, DOI 10.1016/0076-6879(70)19074-4]; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; KOCH G, 1986, J CELL SCI, V86, P217; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LEBECHE D, 1992, BIOCHEM J, V287, P741, DOI 10.1042/bj2870741; LEBECHE D, 1994, BIOCHEM BIOPH RES CO, V202, P556, DOI 10.1006/bbrc.1994.1964; LEE AS, 1984, J BIOL CHEM, V259, P4616; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LUCERO HA, 1994, J BIOL CHEM, V269, P23112; Lucero HA, 1998, J BIOL CHEM, V273, P9857, DOI 10.1074/jbc.273.16.9857; Luz J M, 1996, EXS, V77, P97; MACER DRJ, 1988, J CELL SCI, V91, P61; MacLennan DH, 1998, NAT STRUCT BIOL, V5, P409, DOI 10.1038/nsb0698-409; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OBERDORF JA, 1988, J BIOL CHEM, V263, P6806; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; VAN PN, 1989, J BIOL CHEM, V264, P17494; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; Wang SR, 1998, NAT STRUCT BIOL, V5, P476, DOI 10.1038/nsb0698-476; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2; ZAPUN A, 1995, PROTEIN-STRUCT FUNCT, V14, P10; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	75	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3243	3251		10.1074/jbc.274.5.3243	http://dx.doi.org/10.1074/jbc.274.5.3243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915866	hybrid			2022-12-27	WOS:000078319500084
J	Schwartz, T; Lowenhaupt, K; Kim, YG; Li, LY; Brown, BA; Herbert, A; Rich, A				Schwartz, T; Lowenhaupt, K; Kim, YG; Li, LY; Brown, BA; Herbert, A; Rich, A			Proteolytic dissection of Zab, the Z-DNA-binding domain of human ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA ADENOSINE-DEAMINASE; RECEPTOR CHANNELS; CONFORMATIONAL CHANGE; SECONDARY STRUCTURE; ESCHERICHIA-COLI; EDITING ENZYME; ION FLOW; Z-FORM; PROTEIN; ACID	Z alpha is a peptide motif that binds to Z-DNA with high affinity. This motif binds to alternating dC-dG sequences stabilized in the Z-conformation by means of bromination or supercoiling, but not to B-DNA. Z alpha is part of the N-terminal region of double-stranded RNA adenosine deaminase (ADAR1) , a candidate enzyme for nuclear pre-mRNA editing in mammals. Z alpha is conserved in ADAR1 from many species; in each case, there is a second similar motif, Z beta, separated from Z alpha by a more divergent linker. To investigate the structure-function relationship of Z alpha, its domain structure was studied by limited proteolysis. Proteolytic profiles indicated that Z alpha is part of a domain, Zab, of 229 amino acids (residues 133-361 in human ADAR1), This domain contains both Z alpha and Z beta as well as a tandem repeat of a 49-amino acid linker module. Prolonged proteolysis revealed a minimal core domain of 77 amino acids (positions 133-209), containing only Z alpha, which is sufficient to bind left-handed Z-DNA; however, the substrate binding is strikingly different from that of Zab. The second motif, Z beta, retains its structural integrity only in the context of Zab and does not bind Z-DNA as a separate entity. These results suggest that Z alpha and Z beta act as a single bipartite domain. In the presence of substrate DNA, Zab becomes more resistant to proteases, suggesting that it adopts a more rigid structure when bound to its substrate, possibly with conformational changes in parts of the protein.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Herbert, Alan/AAY-4286-2020; Schwartz, Thomas/ABA-1770-2021	Schwartz, Thomas/0000-0001-8012-1512; Herbert, Alan/0000-0002-0093-1572; /0000-0002-8187-6498				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JANIN J, 1985, METHOD ENZYMOL, V115, P420; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kim YG, 1997, P NATL ACAD SCI USA, V94, P12875, DOI 10.1073/pnas.94.24.12875; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lilley D. M. J., 1995, DNA PROTEIN STRUCTUR; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MALFOY B, 1982, BIOCHEMISTRY-US, V21, P5463, DOI 10.1021/bi00265a013; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Nakagawa N, 1997, J BIOL CHEM, V272, P22703, DOI 10.1074/jbc.272.36.22703; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Petschek JP, 1996, J MOL BIOL, V259, P885, DOI 10.1006/jmbi.1996.0365; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; RIAZANCELAWRENCE JH, 1992, BIOPOLYMERS, V32, P271, DOI 10.1002/bip.360320307; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Roy R, 1996, J BIOL CHEM, V271, P23690, DOI 10.1074/jbc.271.39.23690; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHADE M, 1999, IN PRESS EMBO J; Schulz G. E., 1979, PRINCIPLES PROTEIN S; Seeburg PH, 1996, J NEUROCHEM, V66, P1; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TAL M, 1985, J BIOL CHEM, V260, P9976; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443	39	51	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2899	2906		10.1074/jbc.274.5.2899	http://dx.doi.org/10.1074/jbc.274.5.2899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915827	hybrid			2022-12-27	WOS:000078319500045
J	Zhong, M; Kim, SJ; Wu, C				Zhong, M; Kim, SJ; Wu, C			Sensitivity of Drosophila heat shock transcription factor to low pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; GENE-TRANSCRIPTION; ACTIVATION DOMAIN; INTRACELLULAR PH; INFLUENZA-VIRUS; COILED-COIL; TRANSACTIVATION DOMAIN; NUCLEAR-LOCALIZATION; PROTEIN-SYNTHESIS	The heat shock transcription factor (HSF) mediates the induction of heat shock gene expression. The activation of HSF involves heat shock-induced trimerization, binding to its cognate DNA sites, and the acquisition of transcriptional competence. In this study, the oligomeric properties of Drosophila HSF were analyzed by equilibrium analytical ultracentrifugation and gel filtration chromatography. Previous findings showed that trimerization of purified Drosophila HSF was directly sensitive to heat and oxidation (1). Here we report that low pH, in the physiological range, also directly induces HSF trimerization and DNA binding in vitro. Furthermore, the induction of HSF trimerization by low pH is synergistic with the actions of heat and oxidation, Since heat or chemical stress leads to a moderate decrease of intracellular pH, we suggest that intracellular acidification may contribute to activating the heat shock response in vivo.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bldg 37,Rm 5E26, Bethesda, MD 20892 USA.							ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BURDON R H, 1990, P19; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DIXON SJ, 1995, METH NEUROSCI, V27, P196; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOJ A, 1994, EMBO J, V13, P2617; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KIANG JG, 1990, AM J PHYSIOL, V259, pC727, DOI 10.1152/ajpcell.1990.259.5.C727; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1901; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Orosz A, 1996, MOL CELL BIOL, V16, P7018; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RITOSSA FM, 1964, EXP CELL RES, V35, P601, DOI 10.1016/0014-4827(64)90147-8; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHLESINGER MJ, 1993, PROTEIN SCI, V2, P1356, DOI 10.1002/pro.5560020819; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TREUTER E, 1993, MOL GEN GENET, V240, P113, DOI 10.1007/BF00276890; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; WEITZEL G, 1985, EXP CELL RES, V159, P252, DOI 10.1016/S0014-4827(85)80054-9; WESTWOOD JT, 1989, J CELL PHYSL, V139, P106; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Winegarden NA, 1996, J BIOL CHEM, V271, P26971, DOI 10.1074/jbc.271.43.26971; Wisniewski J, 1996, NUCLEIC ACIDS RES, V24, P367, DOI 10.1093/nar/24.2.367; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zhong M, 1996, METHOD ENZYMOL, V274, P113; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	69	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3135	3140		10.1074/jbc.274.5.3135	http://dx.doi.org/10.1074/jbc.274.5.3135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915852	hybrid			2022-12-27	WOS:000078319500070
J	Ichtchenko, K; Bittner, MA; Krasnoperov, V; Little, AR; Chepurny, O; Holz, RW; Petrenko, AG				Ichtchenko, K; Bittner, MA; Krasnoperov, V; Little, AR; Chepurny, O; Holz, RW; Petrenko, AG			A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; TRANSMITTER RELEASE; TOXIN; DEPENDENCE; CATIONS	Poisoning with alpha-latrotoxin, a neurotoxic protein from black widow spider venom, results in a robust increase of spontaneous synaptic transmission and subsequent degeneration of affected nerve terminals. The neurotoxic action of alpha-latrotoxin involves extracellular binding to its high affinity receptors as a first step. One of these proteins, GIRL, is a neuronal G-protein-coupled receptor implicated in the regulation of secretion. We now demonstrate that GIRL has two close homologs with a similar domain structure and high degree of overall identity. These novel receptors, which we propose to name CIRL-2 and CIRL-3, together with CIRL (CIRL-1) belong to a recently identified subfamily of large orphan receptors with structural features typical of both G-protein-coupled receptors and cell adhesion proteins. Northern blotting experiments indicate that CIRL-2 is expressed ubiquitously with highest concentrations found in placenta, kidney, spleen, ovary, heart, and lung whereas CIRL-3 is expressed predominantly in brain similarly to CIRL-1, It appears that CIRL-2 can also bind alpha-latrotoxin, although its affinity to the toxin is about 14 times less than that of CIRL-1, When overexpressed in chromaffin cells, CIRL-2 increases their sensitivity to alpha-latrotoxin stimulation but also inhibits Ca2+-regulated secretion, Thus, CIRL-2 is a functionally competent receptor of alpha-latrotoxin. Our findings suggest that although the nervous system is the primary target of low doses of alpha-latrotoxin, cells of other tissues are also susceptible to the toxic effects of alpha-latrotoxin because of the presence of CIRL-2, a low affinity receptor of the toxin.	NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Med Ctr, Dept Physiol & Neurosci, New York, NY 10016 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; NYU, Med Ctr, Dept Environm Med, New York, NY 10016 USA	New York University; New York University; University of Michigan System; University of Michigan; New York University	Ichtchenko, K (corresponding author), NYU, Med Ctr, Dept Pharmacol, 550 1st Ave,MSB-202, New York, NY 10016 USA.		Little, A/O-6191-2014	Little, A/0000-0001-6831-0177; Petrenko, Alexander/0000-0002-6689-6546; Ichtchenko, Konstantin/0000-0002-2198-1325	NIDDK NIH HHS [R01DK27959] Funding Source: Medline; NINDS NIH HHS [R01NS34937, R01NS35098] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098, R01NS034937] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnett DW, 1996, PFLUG ARCH EUR J PHY, V432, P1039, DOI 10.1007/s004240050232; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CLARK AW, 1970, NATURE, V225, P703, DOI 10.1038/225703a0; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; GRASSO A, 1976, BIOCHIM BIOPHYS ACTA, V439, P406, DOI 10.1016/0005-2795(76)90077-5; Gray JX, 1996, J IMMUNOL, V157, P5438; KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Petrenko AG, 1996, J NEUROSCI, V16, P4360; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124	25	86	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5491	5498		10.1074/jbc.274.9.5491	http://dx.doi.org/10.1074/jbc.274.9.5491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026162	hybrid			2022-12-27	WOS:000078804400033
J	Shinoda, E; Yui, Y; Hattori, R; Tanaka, M; Inoue, R; Aoyama, T; Takimoto, Y; Mitsui, Y; Miyahara, K; Shizuta, Y; Sasayama, S				Shinoda, E; Yui, Y; Hattori, R; Tanaka, M; Inoue, R; Aoyama, T; Takimoto, Y; Mitsui, Y; Miyahara, K; Shizuta, Y; Sasayama, S			Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR XA; EXPRESSION; CLONING; INJURY	A mitogen for growth-arrested cultured bovine aortic smooth muscle cells was purified to homogeneity from the supernatant of cultured human umbilical vein endothelial cells by heparin affinity chromatography and reverse-phase high performance liquid chromatography, This mitogen was revealed to be tissue factor pathway inhibitor-2 (TFPI-2), which is a Kunitz-type serine protease inhibitor. TFPI-2 was expressed in baby hamster kidney cells using a mammalian expression vector. Recombinant TFPI-2 (rTFPI-2) stimulated DNA synthesis and cell proliferation in a dose-dependent manner (1-500 nM). rTFPI-2 activated mitogen-activated protein kinase (MAPK) activity and stimulated early proto-oncogene c-fos mRNA expression in smooth muscle cells. MAPK, c-fos expression and the mitogenic activity were inhibited by a specific inhibitor of MAPK kinase, PD098059, Thus, the mitogenic function of rTFPI-2 is considered to be mediated through MAPK pathway, TFPI has been reported to exhibit antiproliferative action after vascular smooth muscle injury in addition to the ability to inhibit activation of the extrinsic coagulation cascade. However, structurally similar TFPI-2 was found to have a mitogenic activity for the smooth muscle cell.	Kyoto Univ Hosp, Dept Internal Med, Div 3, Kyoto 6068507, Japan; Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Kochi Med Sch, Dept Med Chem, Nanko Ku, Kochi 7838505, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Kochi University	Yui, Y (corresponding author), 26-4 Maehagicho,Sakyo Ku, Kyoto 6060833, Japan.							Brown DM, 1996, ARCH SURG-CHICAGO, V131, P1086; JANG YS, 1995, CIRCULATION, V92, P3041, DOI 10.1161/01.CIR.92.10.3041; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; Kamikubo Y, 1997, FEBS LETT, V407, P116, DOI 10.1016/S0014-5793(97)00312-8; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; NIIDOME T, 1994, BIOCHEM BIOPH RES CO, V203, P1821, DOI 10.1006/bbrc.1994.2399; Oltrona L, 1997, CIRCULATION, V96, P646; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEIICHIRO W, 1995, BIOCHEM BIOPH RES CO, V216, P729; SHIROTANI M, 1991, J PHARMACOL EXP THER, V259, P738; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STRAATEN F, 1983, P NATL ACAD SCI USA, V80, P3183; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248	16	29	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5379	5384		10.1074/jbc.274.9.5379	http://dx.doi.org/10.1074/jbc.274.9.5379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026147	Green Submitted, hybrid			2022-12-27	WOS:000078804400018
J	Stemmer, C; Quesnel, A; Prevost-Blondel, A; Zimmermann, C; Muller, S; Briand, JP; Pircher, H				Stemmer, C; Quesnel, A; Prevost-Blondel, A; Zimmermann, C; Muller, S; Briand, JP; Pircher, H			Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2D(b)-restricted CD8(+) T cell epitope GP33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRO-INVERSO-PEPTIDOMIMETICS; PSEUDOPEPTIDE ANALOGS; ANTIGENIC PEPTIDES; LIVING CELLS; MOLECULES; SELECTION; BINDING; REQUIREMENTS; EXPLORATION; HEXAPEPTIDE	Recent investigations have suggested that pseudopeptides containing modified peptide bonds might advantageously replace natural peptides in therapeutic strategies. We have generated eight reduced peptide bond psi(CH2-NH) analogues corresponding to the H-2D(b)-restricted CD8(+) T cell epitope (called GP33) of the glycoprotein of the lymphocytic choriomeningitis virus. One of these pseudopeptides, containing a reduced peptide bond between residues 6 and 7 (psi(6-7)), displayed very similar properties of binding to major histocompatibility complex (MHC) and recognition by T cell receptor transgenic T cells specific for GP33 when compared with the parent peptide. We assessed in vitro and in vivo the proteolytic resistance of GP33 and psi(6-7) and analyzed its contribution to the priming properties of these peptides. The psi(6-7) analogue exhibited a dramatically increased proteolytic resistance when compared with GP33, and we show for the first time that MHC-peptide complexes formed in vivo with a pseudopeptide display a sustained half-life compared with the complexes formed with the natural peptide. Furthermore, in contrast to immunizations with GP33, three injections of psi(6-7) in saline induced significant antiviral protection in mice. The enhanced ability of psi(6-7) to induce antiviral protection may result from the higher stability of the analogue and/or of the MHC-analogue complexes.	Univ Freiburg, Dept Immunol, Inst Med Microbiol & Hyg, D-79104 Freiburg, Germany; CNRS, UPR 9021, Inst Biol Mol & Cellulaire, F-67000 Strasbourg, France	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pircher, H (corresponding author), Univ Freiburg, Dept Immunol, Inst Med Microbiol & Hyg, Hermann Herder Str 11, D-79104 Freiburg, Germany.	pircher@ukl.uni-freiburg.de	Prevost-Blondel, Armelle/N-7643-2017; Muller, Sylviane/J-5319-2014	Prevost-Blondel, Armelle/0000-0002-7268-5905				AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Azay J, 1998, PEPTIDES, V19, P57, DOI 10.1016/S0196-9781(97)00275-1; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Benkirane N, 1996, J BIOL CHEM, V271, P33218, DOI 10.1074/jbc.271.52.33218; Bianco A, 1998, J BIOL CHEM, V273, P28759, DOI 10.1074/jbc.273.44.28759; Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; Cotton J, 1998, INT IMMUNOL, V10, P159, DOI 10.1093/intimm/10.2.159; Eberl G, 1996, EUR J IMMUNOL, V26, P1993, DOI 10.1002/eji.1830260904; Ettouati L, 1996, PEPTIDE RES, V9, P248; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; GANTE J, 1994, ANGEW CHEM INT EDIT, V33, P1699, DOI 10.1002/anie.199416991; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; GUICHARD G, 1994, PEPTIDE RES, V7, P308; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HILL CM, 1994, J IMMUNOL, V152, P2890; Kagi D, 1996, CURR OPIN IMMUNOL, V8, P472, DOI 10.1016/S0952-7915(96)80033-1; Liu MA, 1998, NAT MED, V4, P515, DOI 10.1038/nm0598supp-515; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; Meziere C, 1997, J IMMUNOL, V159, P3230; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; Muller S., 1998, Research in Immunology, V149, P55, DOI 10.1016/S0923-2494(98)80046-1; Ostankovitch M, 1998, J IMMUNOL, V161, P200; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Quesnel A, 1998, J PEPT RES, V52, P107; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; Sebzda E, 1996, J EXP MED, V183, P1093, DOI 10.1084/jem.183.3.1093; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; Stemmer C, 1998, EXPERT OPIN THER PAT, V8, P819, DOI 10.1517/13543776.8.7.819; Teal PEA, 1997, REGUL PEPTIDES, V72, P161, DOI 10.1016/S0167-0115(97)01053-7; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VERDINI AS, 1991, J MED CHEM, V34, P3372, DOI 10.1021/jm00116a005; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125	38	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5550	5556		10.1074/jbc.274.9.5550	http://dx.doi.org/10.1074/jbc.274.9.5550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026170	hybrid			2022-12-27	WOS:000078804400041
J	Berfield, JL; Wang, LJC; Reith, MEA				Berfield, JL; Wang, LJC; Reith, MEA			Which form of dopamine is the substrate for the human dopamine transporter: The cationic or the uncharged species?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT STRIATAL MEMBRANES; IDENTICAL CONDITIONS; IONIC REQUIREMENTS; COCAINE BINDING; NEURONAL UPTAKE; NA+ CHANNELS; GBR 12783; CATECHOLAMINES; DEPENDENCE; INHIBITION	The question of which is the active form of dopamine for the neuronal dopamine transporter is addressed in HEK-293 cells expressing the human dopamine transporter. The K-m value for [H-3]dopamine uptake fell sharply when the pH was increased from 6.0 to 7.4 and then changed less between pH 7.4 and 8.2. The K-I for dopamine in inhibiting the cocaine analog [H-3]2 beta-carbomethoxy-3 beta- (4-fluorophenyl) tropane binding displayed an identical pH dependence, suggesting that changes in uptake result from changes in dopamine recognition. Dopamine can exist in the anionic, neutral, cationic, or zwitterionic form, and the contribution of each form was calculated. The contribution of the anion is extremely low (less than or equal to 0.1%), and its pH dependence differs radically from that of dopamine binding, The increase in the neutral form upon raising the pH can model the results only when the pK(a1) (equilibrium neutral-charged) is set to a much lower value (6.8) than reported for dopamine in solution (8.86). The sum of cationic and zwitterionic dopamine concentrations remained constant over the entire pH range studied. These forms are the likely transporter substrates with pH-dependent changes occurring in their interaction with the transporter. The binding of dopamine, a hydroxylated phenylethylamine derivative, displays the same pH dependence as guanethidine, a heptamethyleniminoethylguanidine derivative fully protonated under our conditions. An ionizable residue in the transporter could be involved that does not interact with or impact the binding of bretylium, a quaternary ammonium phenylmethylamine derivative that is always positively charged and shows only a minor reduction in K-I upon increasing pH.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria	Reith, MEA (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.		Reith, Maarten E./AAD-2303-2019; Reith, Maarten E/A-4601-2008	Reith, Maarten E./0000-0002-1900-842X; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008379] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 08379] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMEJDKICHAB N, 1992, J NEUROCHEM, V59, P1795, DOI 10.1111/j.1471-4159.1992.tb11012.x; AMEJDKICHAB N, 1992, J NEUROCHEM, V58, P793, DOI 10.1111/j.1471-4159.1992.tb09327.x; ANDERSEN PH, 1987, J NEUROCHEM, V48, P1887, DOI 10.1111/j.1471-4159.1987.tb05752.x; ARMSTRONG J, 1976, BRIT J PHARMACOL, V57, P501, DOI 10.1111/j.1476-5381.1976.tb10377.x; BONNET JJ, 1988, J NEUROCHEM, V50, P759, DOI 10.1111/j.1471-4159.1988.tb02979.x; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS GGS, 1968, BRIT J PHARMACOL, V34, P514, DOI 10.1111/j.1476-5381.1968.tb08480.x; COURTNEY KR, 1987, HDB EXPT PHARM, V81, P53; DARCHEN F, 1988, BIOCHEM PHARMACOL, V37, P4381, DOI 10.1016/0006-2952(88)90621-1; EDVARDSEN O, 1994, MOL BRAIN RES, V27, P265, DOI 10.1016/0169-328X(94)90009-4; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; Eshleman AJ, 1997, J NEUROCHEM, V69, P1459; GARRIS PA, 1994, J NEUROSCI, V14, P6084; GU H, 1994, J BIOL CHEM, V269, P7124; Gu H. H., 1996, Society for Neuroscience Abstracts, V22, P370; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; HILLE B, 1984, IONIC CHANNELS EXCIT, P287; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KAMAL LA, 1983, J PHARMACOL EXP THER, V227, P446; KAMMERER RC, 1979, J MED CHEM, V22, P352, DOI 10.1021/jm00190a004; Katzung B. G., 1995, BASIC CLIN PHARM, P1; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KRUEGER BK, 1990, J NEUROCHEM, V55, P260, DOI 10.1111/j.1471-4159.1990.tb08847.x; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LEWIS GP, 1954, BRIT J PHARM CHEMOTH, V9, P488, DOI 10.1111/j.1476-5381.1954.tb00866.x; MACK F, 1979, N-S ARCH PHARMACOL, V310, P1, DOI 10.1007/BF00499868; Masuda M, 1998, AM J PHYSIOL-GASTR L, V274, pG29, DOI 10.1152/ajpgi.1998.274.1.G29; MAXWELL RA, 1976, MECHANISM NEURONAL E, P95; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; MEIERGERD SM, 1994, J NEUROCHEM, V62, P998; MOLINOFF PB, 1971, BIOCHEM J, V123, pP32, DOI 10.1042/bj1230032P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NETTLETON J, 1990, BIOPHYS J, V58, P95, DOI 10.1016/S0006-3495(90)82356-0; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; Reith MEA, 1996, N-S ARCH PHARMACOL, V354, P295; REITH MEA, 1992, EUR J PHARM-MOLEC PH, V227, P417, DOI 10.1016/0922-4106(92)90160-W; RUDNICK G, 1989, J BIOL CHEM, V264, P14865; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sachs C, 1970, Acta Physiol Scand Suppl, V341, P1; SILINSKY EM, 1974, BRIT J PHARMACOL, V51, P367, DOI 10.1111/j.1476-5381.1974.tb10671.x; Sonders MS, 1997, J NEUROSCI, V17, P960; STEINMETZ PR, 1973, NEW ENGL J MED, V289, P141; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; WALL SC, 1993, MOL PHARMACOL, V43, P264; Wu Q, 1997, J NEUROCHEM, V69, P1106; XU C, 1995, BIOCHEM PHARMACOL, V49, P339, DOI 10.1016/0006-2952(94)00485-5; Xu C, 1996, J PHARMACOL EXP THER, V278, P1340; ZIMANYI I, 1989, N-S ARCH PHARMACOL, V340, P626, DOI 10.1007/BF00717737; [No title captured]	51	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4876	4882		10.1074/jbc.274.8.4876	http://dx.doi.org/10.1074/jbc.274.8.4876			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988729	hybrid			2022-12-27	WOS:000078698200054
J	Fox, BA; Yee, VC; Pedersen, LC; Le Trong, I; Bishop', PD; Stenkamp, RE; Teller, DC				Fox, BA; Yee, VC; Pedersen, LC; Le Trong, I; Bishop', PD; Stenkamp, RE; Teller, DC			Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by X-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-XIII; PROTEIN STRUCTURES; CROSS-LINKING; CRYSTAL-STRUCTURE; HUMAN-PLACENTA; TRANSGLUTAMINASE; FIBRIN; THROMBIN; DEFICIENCY; ACTIVATION	The presence or absence of calcium determines the activation, activity, oligomerization, and stability of blood coagulation factor XIII. To explore these observed effects, we have determined the x-ray crystal structure of recombinant factor XIII A(2) in the presence of calcium, strontium, and ytterbium. The main calcium binding site within each monomer involves the main chain oxygen atom of Ala-457, and also the side chains from residues Asn-436, Asp-438, Glu-485, and Glu-490. Calcium and strontium bind in the same location, while ytterbium binds several angstroms removed. A novel ytterbium binding site is also found at the dimer two-fold axis, near residues Asp-270 and Glu-272, and this site may be related to the reported inhibition by lanthanide metals (Achyuthan, K. E., Mary, A., and Greenberg, C. S. (1989) Biochem. J. 257, 331-338). The overall structure of ion-bound factor XIII is very similar to the previously determined crystal structures of factor XIII zymogen, likely due to the constraints of this monoclinic crystal form. We have merged the three independent sets of water molecules in the structures to determine which water molecules are conserved and possibly structurally significant.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Zymogenet Inc, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Washington; University of Washington Seattle; Zymogenet Inc.	Teller, DC (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	teller@u.washington.edu	Pedersen, Lars/C-6173-2019	Pedersen, Lars/0000-0002-4488-4077; Fox, Brian/0000-0001-6620-3853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50355] Funding Source: Medline; NIGMS NIH HHS [GM08268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1989, BIOCHEM J, V257, P331, DOI 10.1042/bj2570331; ANWAR R, 1995, BRIT J HAEMATOL, V91, P728, DOI 10.1111/j.1365-2141.1995.tb05376.x; Aslam S, 1997, BRIT J HAEMATOL, V98, P346, DOI 10.1046/j.1365-2141.1997.2263043.x; Bardos H, 1996, BLOOD COAGUL FIBRIN, V7, P536; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BOARD PG, 1993, BLOOD REV, V7, P229, DOI 10.1016/0268-960X(93)90010-2; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; Carmassi Franco, 1996, Seminars in Thrombosis and Hemostasis, V22, P489, DOI 10.1055/s-2007-999049; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; COOKE RD, 1974, BIOCHEM J, V141, P79, DOI 10.1042/bj1410079; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3774, DOI 10.1021/bi00715a024; DEBACKERROYER C, 1992, INT J BIOCHEM, V24, P637, DOI 10.1016/0020-711X(92)90340-7; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; GREENBERG CS, 1987, BLOOD, V69, P867; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HORNYAK TJ, 1991, BIOCHEMISTRY-US, V30, P6175, DOI 10.1021/bi00239a014; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; IKURA K, 1995, ARCH BIOCHEM BIOPHYS, V318, P307, DOI 10.1006/abbi.1995.1234; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITCHENS CS, 1979, MEDICINE, V58, P413, DOI 10.1097/00005792-197911000-00002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI TS, 1994, J BIOL CHEM, V269, P24596; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis KB, 1997, BIOCHEMISTRY-US, V36, P995, DOI 10.1021/bi961636z; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V261, P112, DOI 10.1016/0003-9861(88)90110-5; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mikkola Hanna, 1996, Seminars in Thrombosis and Hemostasis, V22, P393, DOI 10.1055/s-2007-999037; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; MUSZBEK L, 1995, THROMB HAEMOSTASIS, V73, P702; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PEDERSEN LC, 1994, XRAY STRUCTURE DETER, V13; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIPPL MJ, 1993, J COMPUT AID MOL DES, V7, P473, DOI 10.1007/BF02337562; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; Takahashi N, 1998, BLOOD, V91, P2830, DOI 10.1182/blood.V91.8.2830.2830_2830_2838; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; Weiss MS, 1998, FEBS LETT, V423, P291, DOI 10.1016/S0014-5793(98)00098-2; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	49	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4917	4923		10.1074/jbc.274.8.4917	http://dx.doi.org/10.1074/jbc.274.8.4917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988734	hybrid			2022-12-27	WOS:000078698200059
J	Peng, Y; Du, KY; Ramirez, S; Diamond, RH; Taub, R				Peng, Y; Du, KY; Ramirez, S; Diamond, RH; Taub, R			Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1 - Egr-1 activation is an early event in liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; RAPID ACTIVATION; PRIMARY RESPONSE; CELL-GROWTH; 3T3 CELLS; KAPPA-B; EXPRESSION; BINDING; DIFFERENTIATION; COMPLEX	The cellular signals that initiate cell growth are incompletely understood. Insight could be provided by understanding the signals regulating the transcriptional induction of immediate-early genes which occurs within minutes of the growth stimulus. The expression of the PRL-1 gene, which encodes a unique nuclear protein-tyrosine phosphatase, is rapidly induced in regenerating liver and mitogen-treated cells. Transcription of the PRL-1 gene increased in the rat liver remnant within a few minutes after partial hepatectomy and largely explained the increase in steady-state PRL-1 mRNA in the first few hours posthepatectomy. Egr-1 (early growth response factor) specifically bound a region of the proximal PRL-1 promoter P1 (-99), Egr-1 binding activity was more rapidly induced in regenerating liver than mitogen-treated H35 and NIH 3T3 cells, remained elevated through 4 h posthepatectomy, and appeared to be dependent not only on new Egr-1 protein synthesis but on post-translational regulation of Egr-1. Egr-1 efficiently transactivated a PRL-1 promoter re porter construct containing an intact not mutant Egr-1 site, and the Egr-1 site largely accounted for PRL-1 gene up-regulation in response to mitogen stimulation. These data predict that Egr-1 activation is an early event in liver regeneration and mitogen-activated cells that provides a regulatory stimulus for a subset of immediate early genes.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Taub, R (corresponding author), Univ Penn, Sch Med, Dept Genet, 705A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK 49629, DK 44237, DK49210] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044237, P01DK049210, R01DK049629] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO X, 1994, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHRISTY BA, 1989, P NATL ACAD SCI USA, V85, P7857; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIAMOND HR, 1996, AM J PHYSIOL, V271, pG121; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Higgins GM, 1931, ARCH PATHOL, V12, P186; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V86, P8737; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LIM RW, 1987, ONCOGENE, V1, P263; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Moore DD, 1995, GLOB MOB SURV; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Peng Y, 1998, J BIOL CHEM, V273, P17286, DOI 10.1074/jbc.273.27.17286; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Suh E, 1996, MOL CELL BIOL, V16, P619; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; TAUB R, 1996, PROTEIN PHOSPHORYLAT, P59; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381	39	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4513	4520		10.1074/jbc.274.8.4513	http://dx.doi.org/10.1074/jbc.274.8.4513			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988683	hybrid			2022-12-27	WOS:000078698200008
J	Kanamaru, K; Wang, RC; Su, WP; Crawford, NM				Kanamaru, K; Wang, RC; Su, WP; Crawford, NM			Ser-534 in the hinge 1 region of Arabidopsis nitrate reductase is conditionally required for binding of 14-3-3 proteins and in vitro inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; POSTTRANSLATIONAL REGULATION; FUNCTIONAL DOMAINS; 14-3-3-PROTEIN; LEAVES; LIGHT; PHOSPHORYLATION; PATHWAYS; SEQUENCE; THALIANA	14-3-3 proteins bind to the hinge 1 region of nitrate reductase (NR) and inhibit its activity. To determine which residues of NR are required for 14-3-3-inhibitory interactions, wild-type and mutant forms of Arabidopsis NR were examined in the yeast two-hybrid system and in vitro inhibition assays, NR fragments with or without hinge 1 were introduced into yeast with one of seven Arabidopsis 14-3-3 isoforms (called GF14s), NR fragments (residues 1-562 or 487-562) containing hinge 1 interacted with all GF-14s tested; an NR fragment (residues 1-487) lacking hinge 1 did not. GF14 binding to NR fragments was dependent on Ser-534, since Asp or Ala substitutions at this site blocked the interaction. Revertants with second site substitutions restoring interaction between GF14 omega and the Ala- or Asp-substituted NR fragments were identified. One isolate had a Lys to Glu substitution at position 531, which is in hinge 1, and six isolates had lie to Leu or Phe substitutions at 561 in the heme binding region. Double mutant forms of holo-NR (S534D plus K531E, I561F, or I561L) were constructed and found to be partially inhibited by protein extracts from Arabidopsis containing 14-3-3 proteins. Wild-type NR is phosphorylated and inhibited by these extracts, but S534D single mutant forms are not. These results show that inhibitory NR/14-3-3 interactions are dependent on Ser-534 but only in the context of the wild-type sequence, since substitutions at second sites render 14-3-3 binding and in vitro NR inhibition independent of Ser-534.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Crawford, NM (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ncrawford@ucsd.edu	Kanamaru, Kengo/GNP-8187-2022	Kanamaru, Kengo/0000-0002-6844-0841	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Athwal GS, 1998, PLANT PHYSIOL, V118, P1041, DOI 10.1104/pp.118.3.1041; BACHMANN M, 1995, PLANT PHYSIOL, V108, P1083, DOI 10.1104/pp.108.3.1083; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; Campbell WH, 1996, PLANT PHYSIOL, V111, P355, DOI 10.1104/pp.111.2.355; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Ferl RJ, 1996, ANNU REV PLANT PHYS, V47, P49, DOI 10.1146/annurev.arplant.47.1.49; HOFF T, 1994, PLANT CELL ENVIRON, V17, P489, DOI 10.1111/j.1365-3040.1994.tb00145.x; Huber SC, 1996, TRENDS PLANT SCI, V1, P432, DOI 10.1016/S1360-1385(96)10046-7; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; KAISER WM, 1994, PLANT PHYSIOL, V106, P817, DOI 10.1104/pp.106.3.817; Kohalmi SE, 1998, PLANT MOL BIOL MAN M, P1; Lillo C, 1997, PLANT PHYSIOL, V114, P1377, DOI 10.1104/pp.114.4.1377; LILLO C, 1994, PHYSIOL PLANTARUM, V90, P616, DOI 10.1111/j.1399-3054.1994.tb08822.x; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NUSSAUME L, 1995, PLANT CELL, V7, P611, DOI 10.1105/tpc.7.5.611; PELSY F, 1992, ADV GENET, V30, P1, DOI 10.1016/S0065-2660(08)60317-X; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SU W, 1997, PLANT PHYSIOL, V155, P1135; Su WP, 1996, PLANT CELL, V8, P519, DOI 10.1105/tpc.8.3.519; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Wu K, 1997, PLANT PHYSIOL, V114, P1421, DOI 10.1104/pp.114.4.1421; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4160	4165		10.1074/jbc.274.7.4160	http://dx.doi.org/10.1074/jbc.274.7.4160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933611	hybrid			2022-12-27	WOS:000078575500035
J	Milewski, S; Kuszczak, D; Jedrzejczak, R; Smith, RJ; Brown, AJP; Gooday, GW				Milewski, S; Kuszczak, D; Jedrzejczak, R; Smith, RJ; Brown, AJP; Gooday, GW			Oligomeric structure and regulation of Candida albicans glucosamine-6-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-TUBE FORMATION; ESCHERICHIA-COLI; BLASTOCLADIELLA-EMERSONII; FRUCTOSE 6-PHOSPHATE; CHITIN SYNTHESIS; YEAST; AMIDOTRANSFERASE; BINDING; GENE; EFFICIENCY	Candida albicans glucosamine-6-phosphate (GlcN-6-P) synthase was purified to apparent homogeneity with 52% yield from recombinant yeast YRSC-65 cells efficiently overexpressing the GFA1 gene. The pure enzyme exhibited K-m(Gln) = 1.56 mM and Km(Fru-6-P) = 1.41 mM and catalyzed GlcN-6-P formation with k(cat) = 1150 min(-1). The isoelectric point of 4.6 +/- 0.05 was estimated from isoelectric chromatofocusing, Gel filtration, native polyacrylamide gel electrophoresis, subunit cross-linking, and SDS-polyacrylamide gel electrophoresis showed that the native enzyme was a homotetramer of 79.5-kDa subunits, with an apparent molecular mass of 330-340 kDa, Results of chemical modification of the enzyme by group-specific reagents established an essential role of a cysteinyl residue at the glutamine-binding site and histidyl, lysyl, arginyl, and tyrosyl moieties at the Flu-6-P-binding site. GlcN-6-P synthase in crude extract was effectively inhibited by UDP-GlcNAc (IC50 = 0.67 mM). Purification of the enzyme markedly decreased the sensitivity to the inhibitor, but this could be restored by addition of another effector, glucose g-phosphate. Binding of UDP-GlcNAc to the pure enzyme in the presence of Glc-6-P showed strong negative cooperativity, with RN = 0.54, whereas in the absence of this sugar phosphate no cooperative effect was observed. Pure enzyme was a substrate for cAMP-dependent protein kinase, the action of which led to the substantial increase of GlcN-6-P synthase activity, correlated with an extent of protein phosphorylation, The maximal level of activity was observed for the enzyme molecules containing 1.21 +/- 0.08 mol of phosphate/mol of GlcN-6-P synthase, Monitoring of GlcN-6-P synthase activity and its sensitivity to UDP-GlcNAc during yeast --> mycelia transformation of C, albicans cells, under in situ conditions, revealed a marked increase of the former and a substantial fall of the latter.	Gdansk Tech Univ, Dept Pharmaceut Technol & Biochem, PL-80952 Gdansk, Poland; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	Fahrenheit Universities; Gdansk University of Technology; University of Aberdeen	Milewski, S (corresponding author), Gdansk Tech Univ, Dept Pharmaceut Technol & Biochem, 11-12 Narutowicza St, PL-80952 Gdansk, Poland.	milewski@altis.chem.pg.gda.pl	Brown, Alistair J.P./B-6627-2014	Milewski, Slawomir/0000-0003-2616-4495				BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BADETDENISOT MA, 1993, B SOC CHIM FR, V130, P249; BadetDenisot MA, 1997, ARCH BIOCHEM BIOPHYS, V337, P129, DOI 10.1006/abbi.1996.9741; BADETDENISOT MA, 1992, ARCH BIOCHEM BIOPHYS, V292, P475, DOI 10.1016/0003-9861(92)90018-R; Bollag DM, 1992, PROTEIN METHODS, P143; BORGIA PT, 1992, J BACTERIOL, V174, P384, DOI 10.1128/jb.174.2.384-389.1992; BOROWSI E, 1988, 8 INT S FUT TRENDS C, P158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTAWAY FW, 1968, J GEN MICROBIOL, V51, P367, DOI 10.1099/00221287-51-3-367; CHIEW YY, 1980, ARCH MICROBIOL, V125, P97, DOI 10.1007/BF00403204; CIGAN AM, 1987, GENE, V59, P1; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; EGIDY G, 1990, CELL BIOL INT REP, V14, P59, DOI 10.1016/0309-1651(90)90071-6; ELLIS DB, 1972, BIOCHIM BIOPHYS ACTA, V267, P105; ENDO A, 1970, J BACTERIOL, V103, P588, DOI 10.1128/JB.103.3.588-594.1970; ETCHEBEHERE LC, 1989, ARCH BIOCHEM BIOPHYS, V272, P301, DOI 10.1016/0003-9861(89)90223-3; ETCHEBEHERE LC, 1993, J BACTERIOL, V175, P5022, DOI 10.1128/JB.175.16.5022-5027.1993; FRISA PS, 1982, P NATL ACAD SCI-BIOL, V79, P6289, DOI 10.1073/pnas.79.20.6289; Gadd G.M., 1995, GROWING FUNGUS, P183; GOLINELLIPIMPANEAU B, 1989, J AM CHEM SOC, V111, P3029, DOI 10.1021/ja00190a042; GOLINELLIPIMPANEAU B, 1991, EUR J BIOCHEM, V201, P175, DOI 10.1111/j.1432-1033.1991.tb16271.x; GOODAY GW, 1990, BIOCH CELL WALLS MEM, P61; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOLCENBERG JS, 1985, METHOD ENZYMOL, V113, P257; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; KENIG M, 1976, J GEN MICROBIOL, V94, P46, DOI 10.1099/00221287-94-1-46; KIKUCHI H, 1976, BIOCHIM BIOPHYS ACTA, V422, P241, DOI 10.1016/0005-2744(76)90023-1; KINGSMAN SM, 1990, METHOD ENZYMOL, V185, P329; KITZ R, 1962, J BIOL CHEM, V237, P3245; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUERMANN V, 1991, CURR GENET, V20, P1, DOI 10.1007/BF00312757; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P72; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; MEI B, 1989, J BIOL CHEM, V264, P16613; MILEWSKI S, 1993, CHITIN ENZYMOLOGY, P167; MIYAGI T, 1974, BIOCHIM BIOPHYS ACTA, V358, P144, DOI 10.1016/0005-2744(74)90266-6; MIYAGI T, 1971, BIOCHIM BIOPHYS ACTA, V250, P51, DOI 10.1016/0005-2744(71)90119-7; Niimi M, 1996, FUNGAL GENET BIOL, V20, P79, DOI 10.1006/fgbi.1996.0013; OBMOLOVA G, 1994, J MOL BIOL, V242, P703, DOI 10.1006/jmbi.1994.1619; PAVETO C, 1991, CELL BIOL INT REP, V15, P169, DOI 10.1016/0309-1651(91)90108-U; RIODAN JF, 1977, SCIENCE, V195, P884; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ G, 1976, METHOD ENZYMOL, V56, P40; Smith RJ, 1996, J BACTERIOL, V178, P2320, DOI 10.1128/jb.178.8.2320-2327.1996; SOLL DR, 1987, BIOESSAYS, V5, P5; STEIN MW, 1968, METHOD ENZYMOL, V1, P299; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2197; VESSAL U, 1972, PLANT PHYSIOL, V49, P977; Vidotto V, 1996, MYCOPATHOLOGIA, V133, P143, DOI 10.1007/BF02373021; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; ZALKIN H, 1985, METHOD ENZYMOL, V113, P278; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; Zelada A, 1998, EUR J BIOCHEM, V252, P245, DOI 10.1046/j.1432-1327.1998.2520245.x	57	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4000	4008		10.1074/jbc.274.7.4000	http://dx.doi.org/10.1074/jbc.274.7.4000			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933591	hybrid			2022-12-27	WOS:000078575500015
J	Posey, SC; Bierer, BE				Posey, SC; Bierer, BE			Actin stabilization by jasplakinolide enhances apoptosis induced by cytokine deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTERLEUKIN 1-BETA-CONVERTING ENZYME; CELL ANTIGEN-RECEPTOR; T-LYMPHOCYTES; F-ACTIN; CARCINOMA-CELLS; ZETA-CHAIN; IN-VITRO; DNASE-I; ACTIVATION	Participation of the actin cytoskeleton in the transduction of proliferative signals has been established through the use of compounds that disrupt the cytoskeleton, To address the possibility that actin also participates in the transduction of an apoptotic signal, we have studied the response of the murine interleukin 2 (IL-2)-dependent T cell line CTLL-20 to treatment with the actin-binding compound jasplakinolide upon IL-2 deprivation, Like phalloidin, jasplakinolide stabilizes F-actin and promotes actin polymerization, Treatment of CTLL-20 cells with jasplakinolide, in the presence or absence of recombinant human IL-2, altered actin morphology as assessed by confocal fluorescence microscopy. Jasplakinolide was not toxic to CTLL-20 cells, nor was apoptosis induced in the presence of exogenous recombinant human IL-2, However, actin stabilization at the time of IL-2 deprivation enhanced apoptosis by changing the time at which CTLL-20 cells committed to the apoptotic pathway. This effect of jasplakinolide correlated with its ability to stabilize polymerized actin, as treatment with a synthetic analog of jasplakinolide with a greatly reduced ability to bind actin, jasplakinolide B, did not enhance apoptosis. The enhancement occurred upstream of the induction of caspase-3-like activity and could be inhibited by the overexpression of the anti-apoptotic protein Bcl-x(L), These data suggest that the actin cytoskeleton plays an active role in modulating lymphocyte apoptosis induced by cytokine deprivation.	NHLBI, NIH, Bethesda, MD 20892 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Sci, Comm Immunol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Bierer, BE (corresponding author), NHLBI, NIH, Bldg 10,Rm 5D49,10 Ctr Dr, Bethesda, MD 20892 USA.			Bierer, Barbara/0000-0001-6448-8170	NCI NIH HHS [T32 CA09141] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, T32 GM07753-19] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6; Boise LH, 1996, J IMMUNOL METHODS, V191, P143, DOI 10.1016/0022-1759(96)00011-7; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BROCK MA, 1993, J CELL PHYSIOL, V157, P367, DOI 10.1002/jcp.1041570221; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; Chen ZH, 1996, CANCER RES, V56, P5224; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dipietrantonio A, 1996, BIOCHEM BIOPH RES CO, V224, P837, DOI 10.1006/bbrc.1996.1109; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; FABIAN I, 1995, EXP HEMATOL, V23, P583; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Gomez J, 1997, J IMMUNOL, V158, P1516; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; Guenal I, 1997, J CELL SCI, V110, P489; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Holzinger A, 1997, CELL MOTIL CYTOSKEL, V38, P365, DOI 10.1002/(SICI)1097-0169(1997)38:4<365::AID-CM6>3.0.CO;2-2; Karino A, 1996, FEBS LETT, V398, P317, DOI 10.1016/S0014-5793(96)01266-5; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lee E, 1998, CELL MOTIL CYTOSKEL, V39, P122, DOI 10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8; Levee MG, 1996, AM J PHYSIOL-CELL PH, V271, pC1981, DOI 10.1152/ajpcell.1996.271.6.C1981; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; LU Y, 1994, J IMMUNOL, V153, P1495; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SCOTT VR, 1988, ANTIMICROB AGENTS CH, V32, P1154, DOI 10.1128/AAC.32.8.1154; SENDEROWICZ AMJ, 1995, J NATL CANCER I, V87, P46, DOI 10.1093/jnci/87.1.46; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Takeuchi H, 1998, CANCER CHEMOTH PHARM, V42, P491, DOI 10.1007/s002800050850; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WALPOLE RE, 1989, PROBABILITY STAT ENG, P257; Wyllie A H, 1980, Int Rev Cytol, V68, P251	52	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4259	4265		10.1074/jbc.274.7.4259	http://dx.doi.org/10.1074/jbc.274.7.4259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933626	hybrid			2022-12-27	WOS:000078575500050
J	Rausch, O; Marshall, CJ				Rausch, O; Marshall, CJ			Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; RAS-DEPENDENT ACTIVATION; MAP KINASE; C-JUN; FACTOR-RECEPTOR; INTERLEUKIN-3 STIMULATION; TRANSDUCTION PATHWAYS; SUBSTRATE-SPECIFICITY; MAMMALIAN-CELLS; GROWTH-FACTOR	Hemopoietic cytokines such as interleukin-3 and granulocyte colony-stimulating Factor (G-CSF) are po; tent activators of hemopoietic cell growth and strongly induce activation of extracellular signal-regulated kinase (ERR), c-Jun-N-terminal kinase (JNK), and p38 mitogen-activated protein (MAP) kinases, However, the role of these kinases is unclear. Using specific chemical inhibitors for MEK and p38, we demonstrate here that both ERK and p38 pathways are critically involved in the transduction of a proliferative signal and cooperate in Gr-CSF-induced cell proliferation. We show that, like ERK and JNK activation, activation of p38 and its downstream substrate MAP kinase-activated protein kinase 2 by interleukin-3 or G-CSF requires Pas activation, We demonstrate that two distinct cytoplasmic regions of the G-CSF receptor are involved in activation of the p38 pathway: a region within the 100 membrane-proximal amino acids is sufficient to induce low levels of p38 and MAP kinase-activated protein kinase 2 activation, whereas the membrane-distal phosphorylation site Tyr(763) mediates strong activation of these kinases, The levels of p38 activation correlate closely with those of Pas activation by G-CSF, suggesting that the degree of Pas activation is a critical determinant for the extent of p38 activation by hemopoietic cytokines.	Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Rausch, O (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; deKoning JP, 1996, BLOOD, V87, P132; DEMETRI GD, 1991, BLOOD, V78, P2791; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL NH, 1995, LEUKEMIA LYMPHOMA, V16, P223, DOI 10.3109/10428199509049761; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x	65	99	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4096	4105		10.1074/jbc.274.7.4096	http://dx.doi.org/10.1074/jbc.274.7.4096			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933603	hybrid			2022-12-27	WOS:000078575500027
J	Ivaska, J; Kapyla, J; Pentikainen, O; Hoffren, AR; Hermonen, J; Huttunen, P; Johnson, MS; Heino, J				Ivaska, J; Kapyla, J; Pentikainen, O; Hoffren, AR; Hermonen, J; Huttunen, P; Johnson, MS; Heino, J			A peptide inhibiting the collagen binding function of integrin alpha I-2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; CRYSTAL-STRUCTURE; PLATELET-AGGREGATION; LIGAND-BINDING; CELL-ADHESION; A-DOMAIN; RECEPTOR; FIBRONECTIN; PROTEIN; VLA-2	Integrin alpha(2) subunit forms in the complex with the beta(1) subunit a cell surface receptor binding extracellular matrix molecules, such as collagens and laminin-1. It is a receptor for echovirus-1, as well. Ligands are recognized by the special "inserted" domain (I domain) in the integrin alpha(2) subunit, Venom from a pit viper, Bothrops jararaca, has been shown to inhibit the interaction of platelet alpha(2)beta(1) integrin with collagen because of the action of a disintegrin/metalloproteinase named jararhagin. The finding that crude B. jararaca venom could prevent the binding of human recombinant r alpha(2)I domain to type I collagen led us to study jararhagin further. Synthetic peptides representing hydrophilic and charged sequences of jararhagin, including the RSECD sequence replacing the well known RGD motif in the disintegrin-like domain, were synthesized. Although the disintegrin-like domain derived peptides failed to inhibit r alpha(2)I domain binding to collagen, a basic peptide from the metalloproteinase domain proved to be functional. In an in vitro assay, the cyclic peptide, CTRKKHDNAQC, was shown to bind strongly to human recombinant alpha(2)I domain and to prevent its binding to type I and IV collagens and to laminin-1, Mutational analysis indicated that a sequence of three amino acids, arginine-lysine-lysine (RKK), is essential for r alpha(2)I domain binding, whereas the mutation of the other amino acids in the peptide had little if any effect on its binding function. Importantly, the peptide was functional only in the cyclic conformation and its affinity was strictly dependent on the size of the cysteine-constrained loop. Furthermore, the peptide could not bind to alpha(2)I domain in the absence of Mg2+, suggesting that the conformation of the I domain was critical, as well. Cells could attach to the peptide only if they expressed alpha(2)beta(1) integrin, and the attachment was inhibited by anti-integrin antibodies.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Virol, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, Turku, Finland; Abo Akad Univ, Dept Biochem, Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland	University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University; Finland National Institute for Health & Welfare; University of Jyvaskyla	Heino, J (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.		Pentikäinen, Olli T/E-1980-2012	Pentikäinen, Olli T/0000-0001-7188-4016; Ivaska, Johanna/0000-0002-6295-6556; Kapyla, Jarmo/0000-0003-3036-713X				ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; KERN A, 1994, J BIOL CHEM, V269, P22811; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1990, J BIOL CHEM, V265, P4020; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Zhou Q, 1996, BIOCHEM BIOPH RES CO, V219, P720, DOI 10.1006/bbrc.1996.0301	39	80	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3513	3521		10.1074/jbc.274.6.3513	http://dx.doi.org/10.1074/jbc.274.6.3513			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920897	hybrid			2022-12-27	WOS:000078428200037
J	Mitchell, BA; Paulsen, IT; Brown, MH; Skurray, RA				Mitchell, BA; Paulsen, IT; Brown, MH; Skurray, RA			Bioenergetics of the staphylococcal multidrug export protein QacA - Identification of distinct binding sites for monovalent and divalent cations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; P-GLYCOPROTEIN; SUBSTRATE-SPECIFICITY; DISINFECTANT RESISTANCE; PSEUDOMONAS-AERUGINOSA; BACILLUS-SUBTILIS; PLASMA-MEMBRANE; DRUG EXTRUSION; EFFLUX PUMP; TRANSPORTER	The multidrug efflux pump QacA from Staphylococcus aureus confers resistance to an extensive range of structurally dissimilar compounds. Fluorimetric analyses demonstrated that QacA confers resistance to the divalent cation 4',6-diamidino-2-phenylindole, utilizing a proton motive force-dependent efflux mechanism previously demonstrated for QacA-mediated resistance to the monovalent cation ethidium, Both the ionophores nigericin and valinomycin inhibited QacA-mediated export of ethidium, indicating an electrogenic drug/nH(+) (n greater than or equal to 2) antiport mechanism. The kinetic parameters, K-m and V-max, were determined for QacA-mediated export of four fluorescent substrates, 4',6-diamidino-2-phenylindole, 3',3'-dipropyloxacarbocyanine, ethidium, and pyronin Y, Competition studies showed that QacA-mediated ethidium export is competitively inhibited by monovalent cations, e.g. benzalkonium, and non-competitively inhibited by divalent cations, e.g. propamidine, which suggests that monovalent and divalent cations bind at distinct sites on the QacA protein. The quaternary ammonium salt, 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene, was used as a membrane specific fluorescence probe and demonstrated that the amount of substrate entering the inner leaflet was significantly reduced in QacA-containing strains, supporting the notion that the substrate is extruded directly from the membrane.	Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	University of Sydney	Skurray, RA (corresponding author), Univ Sydney, Sch Biol Sci, Macleay Bldg A12, Sydney, NSW 2006, Australia.		Paulsen, Ian T/K-3832-2012; Brown, Melissa/V-2296-2017	Paulsen, Ian T/0000-0001-9015-9418; Brown, Melissa/0000-0001-6461-7550				AHMED M, 1993, J BIOL CHEM, V268, P11086; Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Haughland R.P., 1996, HDB FLUORESCENT PROB; Hohn B, 1979, Methods Enzymol, V68, P299; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KAPUSCINSKI J, 1979, NUCLEIC ACIDS RES, V6, P3519, DOI 10.1093/nar/6.11.3519; LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027; LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259; Liu J, 1996, J BACTERIOL, V178, P3791, DOI 10.1128/jb.178.13.3791-3795.1996; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; Ocaktan A, 1997, J BIOL CHEM, V272, P21964, DOI 10.1074/jbc.272.35.21964; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; Paulsen IT, 1998, J BACTERIOL, V180, P3477, DOI 10.1128/JB.180.13.3477-3479.1998; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; Ritchie RJ, 1996, BIOCHEM EDUC, V24, P196, DOI 10.1016/S0307-4412(96)00089-1; ROEPE PD, 1994, TRENDS PHARMACOL SCI, V15, P445, DOI 10.1016/0165-6147(94)90056-6; Schuldiner S, 1997, J EXP BIOL, V200, P335; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; WIGLER PW, 1993, BIOCHIM BIOPHYS ACTA, V1154, P173, DOI 10.1016/0304-4157(93)90010-L; Yelin R, 1995, FEBS LETT, V377, P201, DOI 10.1016/0014-5793(95)01346-6; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	41	94	98	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3541	3548		10.1074/jbc.274.6.3541	http://dx.doi.org/10.1074/jbc.274.6.3541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920900	hybrid			2022-12-27	WOS:000078428200040
J	Petit, MC; Benkirane, N; Guichard, G; Du, APC; Marraud, M; Cung, MT; Briand, JP; Muller, S				Petit, MC; Benkirane, N; Guichard, G; Du, APC; Marraud, M; Cung, MT; Briand, JP; Muller, S			Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site - Structural basis for its antigenic cross-reactivity with the parent peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SYNTHETIC PEPTIDES; PEPTIDOMIMETICS; ANTIBODIES; CONFORMATIONS; SPECTROSCOPY; IMMUNOGENICITY; RECOGNIZE; PROTEIN; PROGRAM	The antigenic activity of a 19-mer peptide corresponding to the major antigenic region of foot-and-mouth disease virus and its retro-enantiomeric analogue was found to be completely abolished when they were tested in a biosensor system in trifluoroethanol, This suggests that the folding pattern, which is alpha-helix in trifluoroethanol (confirmed by CD measurement), does not correspond to the biologically relevant conformation(s) recognized by antibodies. The NMR structures of both peptides were thus determined in aqueous solution. These studies showed that the two peptides exhibit similar folding features, particularly in their C termini, This may explain in part the cross-reactive properties of the two peptides in aqueous solution. However, the retro-inverso analogue appears to be more rigid than the parent peptide and contains five atypical beta-turns. This feature may explain why retro-inverso foot-and-mouth disease virus peptides are often better recognized than the parent peptide by anti-virion antibodies.	Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67000 Strasbourg, France; INPL, ENSIC, Lab Chim Phys Macromol, CNRS,UMR 7568, F-54000 Nancy, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Muller, S (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9021, 15 Rue Descartes, F-67000 Strasbourg, France.		Muller, Sylviane/J-5319-2014; Benkirane-Jessel, Nadia/H-6438-2016; GUICHARD, Gilles/I-3858-2016	GUICHARD, Gilles/0000-0002-2584-7502; Averlant-Petit, Marie-Christine/0000-0001-8956-1231; Benkirane-Jessel, Nadia/0000-0003-3059-3559				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ALDER AJ, 1973, METHOD ENZYMOL, V27, P675; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; Billeter M, 1995, J BIOMOL NMR, V5, P1; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545; BROWN F, 1995, SEMIN VIROL, V6, P243, DOI 10.1006/smvy.1995.0029; Carver JA, 1997, BIOPOLYMERS, V41, P569, DOI 10.1002/(SICI)1097-0282(19970415)41:5<569::AID-BIP8>3.0.CO;2-K; dePratGay G, 1997, ARCH BIOCHEM BIOPHYS, V341, P360, DOI 10.1006/abbi.1997.9982; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Higgins KA, 1997, J PEPT RES, V50, P421; HUTCHINSON GE, 1996, PROTEIN SCI, V5, P212; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANG E, 1994, J IMMUNOL METHODS, V170, P103, DOI 10.1016/0022-1759(94)90250-X; McDonnell JM, 1997, J AM CHEM SOC, V119, P5321, DOI 10.1021/ja963884o; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MULLER S, 1995, PEPTIDE RES, V8, P138; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; Pegna M, 1996, J PEPT SCI, V2, P91, DOI 10.1002/psc.50; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SILIGARDI G, 1991, EUR J BIOCHEM, V199, P545, DOI 10.1111/j.1432-1033.1991.tb16153.x; SILIGARDI G, 1991, INT J PEPT PROT RES, V38, P519; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	27	38	42	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3686	3692		10.1074/jbc.274.6.3686	http://dx.doi.org/10.1074/jbc.274.6.3686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920919	hybrid			2022-12-27	WOS:000078428200059
J	Saito, Y; Hayashi, T; Tanaka, A; Watanabe, Y; Suzuki, M; Saito, E; Takahashi, K				Saito, Y; Hayashi, T; Tanaka, A; Watanabe, Y; Suzuki, M; Saito, E; Takahashi, K			Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase - Isolation and enzymatic characterization of human selenoprotein P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; SELENIUM-DEFICIENT RATS; IODOTHYRONINE DEIODINASE; MONOCLONAL-ANTIBODIES; LIPID-PEROXIDATION; MESSENGER-RNA; PURIFICATION; CDNA; CLONING; SELENOCYSTEINE	Selenoprotein P is an extracellular protein containing presumably 10 selenocysteines that are encoded by the UGA stop codon in the open reading frame of the mRNA. The function of selenoprotein P is currently unknown, although several indirect lines of evidence suggest that selenoprotein P is a free radical scavenger. We first developed a conventional procedure to isolate selenoprotein P from human plasma. Next, we investigated the reactivities of selenoprotein P against various hydroperoxides in the presence of glutathione, Although selenoprotein P reduces neither hydrogen peroxide nor tertiary butyl hydroperoxide, it does reduce phospholipid hydroperoxide such as 1-palmitoyl-2-(13-hydroperoxy-cis-9,trans-11-octadecadienoyl)-3-phosphatidylcholine hydroperoxide. Kinetic analysis demonstrated a tert-uni ping-pong mechanism, similar to those described for classical glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase. Not only glutathione, but also dithiothreitol, mercaptoethanol, cysteine, and homocysteine, were effective as reducing substances, as in the case of phospholipid hydroperoxide glutathione peroxidase. These results show that selenoprotein P functions as a phospholipid hydroperoxide glutathione peroxidase in extracellular fluids.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Hyg Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Inst Publ Hlth, Kita Ku, Sapporo, Hokkaido 060, Japan; Nihon Univ, Sch Med, Dept Internal Med 2, Itabashi Ku, Tokyo 173, Japan	Hokkaido University; Nihon University	Takahashi, K (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Hyg Chem, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	kazu@pharm.hokudai.ac.jp	Saito, Yoshiro/H-4597-2019	Saito, Yoshiro/0000-0002-0559-5889				AKASAKA M, 1990, NUCLEIC ACIDS RES, V18, P4619, DOI 10.1093/nar/18.15.4619; AKESSON B, 1994, BBA-PROTEIN STRUCT M, V1204, P243, DOI 10.1016/0167-4838(94)90014-0; BAO YP, 1995, ANAL BIOCHEM, V224, P395, DOI 10.1006/abio.1995.1056; BAYFIELD RF, 1985, ANAL BIOCHEM, V144, P569, DOI 10.1016/0003-2697(85)90155-1; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BURK RF, 1995, LAB INVEST, V72, P723; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; BURK RF, 1995, HEPATOLOGY, V21, P561; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; EBERLE B, 1993, J TRACE ELEM ELECT H, V7, P217; Esworthy RS, 1998, BBA-GEN SUBJECTS, V1381, P213, DOI 10.1016/S0304-4165(98)00032-4; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; GIROTTI AW, 1985, ARCH BIOCHEM BIOPHYS, V236, P238, DOI 10.1016/0003-9861(85)90623-X; HATFIELD D, 1993, TRENDS GENET, V9, P69, DOI 10.1016/0168-9525(93)90215-4; HICKS M, 1979, ANAL BIOCHEM, V99, P249, DOI 10.1016/S0003-2697(79)80003-2; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MOTCHNIK PA, 1989, BIOCHIM BIOPHYS ACTA, V993, P27, DOI 10.1016/0304-4165(89)90138-4; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; READ R, 1990, J BIOL CHEM, V265, P17899; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1994, BBA-PROTEIN STRUCT M, V1208, P211, DOI 10.1016/0167-4838(94)90106-6; Sado Y, 1996, CELL BIOL INT, V20, P7, DOI 10.1006/cbir.1996.0003; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; TAKAHASHI K, 1986, BLOOD, V68, P640; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1983, J CHROMATOGR, V270, P301, DOI 10.1016/S0021-9673(01)96376-9; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; YANG JG, 1987, J BIOL CHEM, V262, P13372	42	212	219	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2866	2871		10.1074/jbc.274.5.2866	http://dx.doi.org/10.1074/jbc.274.5.2866			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915822	hybrid			2022-12-27	WOS:000078319500040
J	Suschek, CV; Krischel, V; Bruch-Gerharz, D; Berendji, D; Krutmann, J; Kroncke, KD; Kolb-Bachofen, V				Suschek, CV; Krischel, V; Bruch-Gerharz, D; Berendji, D; Krutmann, J; Kroncke, KD; Kolb-Bachofen, V			Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ULTRAVIOLET-LIGHT; CYTOCHROME-C; CYTOSKELETAL DAMAGE; INTERFERON-GAMMA; STRAND BREAKS; IN-VITRO; SYNTHASE; INHIBITION	A variety of toxic and modulating events induced by WA exposure are described to cause cell death via apoptosis, Recently, we found that UV irradiation of human skin leads to inducible nitric-oxide synthase (iNOS) expression in keratinocytes and endothelial cells (ECs). We have now searched for the role of MOS expression and nitric oxide (NO) synthesis in UVA-induced apoptosis as detected by DNA-specific fluorochrome labeling and in DNA fragmentation visualized by in situ nick translation in ECs, Activation with proinflammatory cytokines 24 h before WA exposure leading to iNOS expression and endogenous NO synthesis fully protects ECs from the onset of apoptosis. This protection was completely abolished in the presence of the iNOS inhibitor L-N-5-(1-iminoethyl)-ornithine (0.25 mM). Additionally, preincubation of cells with the NO donor (Z)-1-[N(2-aminoethyl) -N-(2-ammonioethyl)amino] diazen-1-ium-1,2-diolate at concentrations from 10 to 1000 mu M as an exogenous NO-generating source before UVA irradiation led to a dose-dependent inhibition of both DNA strand breaks and apoptosis, In search of the molecular mechanism responsible for the protective effect, we find that protection from UVA-induced apoptosis is tightly correlated with NO-mediated increases in Bcl-2 expression and a concomitant inhibition of WA-induced overexpression of Bar protein. In conclusion, we present evidence for a protective role of iNOS-derived NO in skin biology, because NO either endogenously produced or exogenously applied fully protects against WA-induced cell damage and death. me also show that the NO-mediated expression modulation of proteins of the Bcl-2 family, an event upstream of caspase activation, appears to be the molecular mechanism underlying this protection.	Univ Dusseldorf, Inst Immunobiol, Res Grp Immunobiol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Dept Dermatol, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Kolb-Bachofen, V (corresponding author), Univ Dusseldorf, Inst Immunobiol, Res Grp Immunobiol, Geb 14-80,POB 10 10 07, D-40001 Dusseldorf, Germany.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; DELICONSTANTINOS G, 1995, BRIT J PHARMACOL, V114, P1257, DOI 10.1111/j.1476-5381.1995.tb13341.x; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; FEHSEL K, 1991, AM J PATHOL, V139, P251; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FINTER NB, 1969, J GEN VIROL, V5, P419, DOI 10.1099/0022-1317-5-3-419; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GODAR DE, 1995, PHOTOCHEM PHOTOBIOL, V62, P108, DOI 10.1111/j.1751-1097.1995.tb05246.x; GODAR DE, 1993, PHOTOCHEM PHOTOBIOL, V57, P1018, DOI 10.1111/j.1751-1097.1993.tb02965.x; GODAR DE, 1992, BIOL RESPONSES ULTRA, P65; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOLB H, 1992, DIABETOLOGIA, V35, P796; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Kuhn A, 1998, J INVEST DERMATOL, V111, P149, DOI 10.1046/j.1523-1747.1998.00253.x; LAMAS S, 1992, J CLIN INVEST, V90, P879, DOI 10.1172/JCI115963; Laurent M, 1996, BIOCHEM J, V314, P109, DOI 10.1042/bj3140109; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liew FY, 1991, IMMUNOL TODAY, V12, P17; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MARAGOS CM, 1993, CANCER RES, V53, P564; MCGUIRE PG, 1987, LAB INVEST, V57, P94; MILLS CD, 1991, J IMMUNOL, V146, P2719; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; OITVAI ZN, 1993, CELL, V74, P609; PEAK JG, 1991, MUTAT RES, V246, P187, DOI 10.1016/0027-5107(91)90121-4; PROBER JS, 1990, PHYSIOL REV, V70, P427; ROBINSON AP, 1986, IMMUNOLOGY, V57, P231; ROSHCHUPKIN DI, 1975, PHOTOCHEM PHOTOBIOL, V21, P63, DOI 10.1111/j.1751-1097.1975.tb06629.x; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SIRSJO A, 1994, FEBS LETT, V338, P191, DOI 10.1016/0014-5793(94)80363-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; SUSCHEK C, 1994, AM J PATHOL, V145, P685; THOMAS DP, 1991, P 49 ANN M EL MICR S, P104; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; WOOD KS, 1990, BIOCHEM BIOPH RES CO, V170, P80, DOI 10.1016/0006-291X(90)91243-L; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMANSKY GB, 1987, J INVEST DERMATOL, V89, P603, DOI 10.1111/1523-1747.ep12461366	61	145	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6130	6137		10.1074/jbc.274.10.6130	http://dx.doi.org/10.1074/jbc.274.10.6130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037696	hybrid			2022-12-27	WOS:000078902800018
J	Shiratsuchi, A; Kawasaki, Y; Ikemoto, M; Arai, H; Nakanishi, Y				Shiratsuchi, A; Kawasaki, Y; Ikemoto, M; Arai, H; Nakanishi, Y			Role of class B scavenger receptor type I in phagocytosis of apoptotic rat spermatogenic cells by Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; MALE GERM-CELLS; SR-BI; TESTICULAR CELLS; PRIMARY CULTURE; TESTIS; PHOSPHATIDYLSERINE; RECOGNITION; SURFACE; DIFFERENTIATION	Rat Sertoli cells phagocytose apoptotic spermatogenic cells, which consist mostly of spermatocytes, in primary culture by recognizing phosphatidylserine (PS) exposed on the surface of degenerating spermatogenic cells. We compared the mode of phagocytosis using spermatogenic cells at different stages of spermatogenesis. Spermatogenic cells were separated into several groups based on their ploidy, with purities of 60-90%. When the fractionated spermatogenic cell populations were subjected to a phagocytosis assay, cells with ploidies of In, 2n, and 4n were almost equally phagocytosed by Sertoli cells, AU the cell populations exposed PS on the cell surface, and phagocytosis of all cell populations was similarly inhibited by the addition of PS-containing liposomes, Class B scavenger receptor type I (SR-BI), a candidate for the PS receptor, was detected in Sertoli cells. Overexpression of the rat SR-BI cDNA increased the PS-mediated phagocytic activity of Sertoli cell-derived cell lines. Moreover, phagocytosis of spermatogenic cells by Sertoli cells was inhibited in the presence of an anti-SR-BI antibody. Finally, the addition of high density lipoprotein, a ligand specific for SR-BI, decreased both phagocytosis of spermatogenic cells and incorporation of PS-containing liposomes by Sertoli cells. In conclusion, SR-BI functions at least partly as a PS receptor, enabling Sertoli cells to recognize and phagocytose apoptotic spermatogenic cells at all stages of differentiation.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Nakanishi, Y (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	nakanaka@kenroku.kanazawa-u.ac.jp	Eckhardt, Erik/G-1567-2010; Shiratsuchi, Akiko/D-8391-2015; Nakanishi, Yoshinobu/D-4602-2014	Shiratsuchi, Akiko/0000-0002-7811-4409; Nakanishi, Yoshinobu/0000-0002-8767-3587				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Allan D.J., 1987, P229; ALLAN DJ, 1992, CELL PROLIFERAT, V25, P241, DOI 10.1111/j.1365-2184.1992.tb01399.x; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Braun RE, 1998, NAT GENET, V18, P202, DOI 10.1038/ng0398-202; BRINKWORTH MH, 1995, J REPROD FERTIL, V105, P25, DOI 10.1530/jrf.0.1050025; Byers S., 1993, SERTOLI CELL, P461; CALLARD GV, 1995, DEV GENET, V16, P140, DOI 10.1002/dvg.1020160207; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; CHEMES H, 1986, ENDOCRINOLOGY, V119, P1673, DOI 10.1210/endo-119-4-1673; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dunkel L, 1997, CELL DEATH DIFFER, V4, P171, DOI 10.1038/sj.cdd.4400234; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fujimoto I, 1998, CELL DEATH DIFFER, V5, P426, DOI 10.1038/sj.cdd.4400362; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; Grandjean V, 1997, DEV BIOL, V184, P165, DOI 10.1006/dbio.1997.8518; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KERR JB, 1992, J REPROD FERTIL, V95, P825, DOI 10.1530/jrf.0.0950825; KIKUCHI H, 1993, BIOCHIM BIOPHYS ACTA, V1162, P171, DOI 10.1016/0167-4838(93)90144-G; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Martin Seamus J., 1996, P107; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MATHER JP, 1982, ANN NY ACAD SCI, V383, P44, DOI 10.1111/j.1749-6632.1982.tb23161.x; MIETHING A, 1992, CELL TISSUE RES, V267, P583, DOI 10.1007/BF00319381; Mizuno K, 1996, CELL DEATH DIFFER, V3, P119; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; PINEAU C, 1991, CELL TISSUE RES, V264, P589, DOI 10.1007/BF00319048; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savill J, 1997, BRIT MED BULL, V53, P491; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SHIKONE T, 1994, BIOL REPROD, V51, P865, DOI 10.1095/biolreprod51.5.865; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TAMARU M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P331, DOI 10.1016/0167-4781(90)90106-C; TOKUDA N, 1992, J UROLOGY, V147, P278, DOI 10.1016/S0022-5347(17)37213-0; UEYAMA H, 1984, MOL CELL BIOL, V4, P1073, DOI 10.1128/MCB.4.6.1073; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	62	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5901	5908		10.1074/jbc.274.9.5901	http://dx.doi.org/10.1074/jbc.274.9.5901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026214	hybrid			2022-12-27	WOS:000078804400085
J	Suttles, J; Milhorn, DM; Miller, RW; Poe, JC; Wahl, LM; Stout, RD				Suttles, J; Milhorn, DM; Miller, RW; Poe, JC; Wahl, LM; Stout, RD			CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway - A target of interleukin (IL)-4 and IL-10 anti-inflammatory action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CD40-CD40 LIGAND INTERACTIONS; COLLAGEN-INDUCED ARTHRITIS; CROSS-LINKING CD40; HYPER-IGM SYNDROME; T-CELL; B-CELLS	Ligation of CD40 on monocytes through its interaction with CD40 ligand (CD154) present on activated T helper cells, results in activation of monocyte inflammatory cytokine synthesis and rescue of monocytes from apoptosis induced through serum deprivation, Both of these consequences of CD40 stimulation have been shown to be dependent on the induction of protein tyrosine kinase activity, CD40-mediated activation of protein tyrosine kinase activity and subsequent inflammatory cytokine production are abrogated by treatment of monocytes with the T helper type 2 cytokines interleukin 4 (IL-4) and interleukin 10 (IL-10), In the current study we demonstrate that stimulation of monocytes through CD40 resulted in the phosphorylation and activation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) mitogen-activated protein kinases, whereas phosphorylation of mitogen-activated protein kinases family members p38 and c-Jun N-terminal kinase was not observed in response to this stimuli over the time course examined, PD98059, an inhibitor of the upstream activator of ERK1/2, the MAP/ERK kinase MEK1/2, suppressed IL-1 beta and tumor necrosis factor-alpha production in a dose-dependent fashion, Pretreatment of monocytes with IL-4 and IL-10 inhibited CD40-mediated activation of ERK1/2 kinase activity when used individually, and are enhanced in effectiveness when used in combination. Together, the data demonstrate that CD40-mediated induction of IL-1 beta and tumor necrosis factor-a synthesis is dependent on a MEK/ERK pathway which is obstructed by signals generated through the action of IL-4 and IL-10.	E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA; E Tennessee State Univ, Quillen Dishner Coll Med, Dept Microbiol, Johnson City, TN 37614 USA; NIDR, NIH, Immunopathol Sect, Bethesda, MD 20892 USA	East Tennessee State University; East Tennessee State University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Suttles, J (corresponding author), E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biochem & Mol Biol, Box 70581, Johnson City, TN 37614 USA.			Poe, Jonathan/0000-0002-7789-1564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034875] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; Carayanniotis G, 1997, IMMUNOLOGY, V90, P421, DOI 10.1111/j.1365-2567.1997.00421.x; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Falcone M, 1998, J IMMUNOL, V160, P4822; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hogaboam CM, 1997, J CLIN INVEST, V100, P2766, DOI 10.1172/JCI119823; Horsfall AC, 1997, J IMMUNOL, V159, P5687; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; HU HM, 1994, J BIOL CHEM, V269, P30069; IKEJIMA T, 1990, J INFECT DIS, V162, P215, DOI 10.1093/infdis/162.1.215; Karras JG, 1997, J IMMUNOL, V159, P4350; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LALMANACHGIRARD AC, 1993, J EXP MED, V177, P1215, DOI 10.1084/jem.177.4.1215; Lebeaut A, 1997, EUR CYTOKINE NETW, V8, P303; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li YY, 1996, J IMMUNOL, V157, P1440; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Narula SK, 1998, AGENT ACTION SUPPL, V49, P57; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Padmore L, 1997, CELL IMMUNOL, V177, P119, DOI 10.1006/cimm.1997.1102; Poe JC, 1997, J IMMUNOL, V159, P846; Purkerson JM, 1998, J IMMUNOL, V160, P2121; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ridley SH, 1997, J IMMUNOL, V158, P3165; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sacca R, 1997, CURR OPIN IMMUNOL, V9, P851, DOI 10.1016/S0952-7915(97)80189-6; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; STOUT RD, 1993, CURR OPIN IMMUNOL, V5, P398, DOI 10.1016/0952-7915(93)90059-2; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Stout RD, 1996, J IMMUNOL, V156, P8; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Suttles J, 1996, J LEUKOCYTE BIOL, V60, P651, DOI 10.1002/jlb.60.5.651; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tanaka Y, 1996, INFLAMM RES, V45, P283, DOI 10.1007/BF02280992; TIAN LC, 1995, EUR J IMMUNOL, V25, P306, DOI 10.1002/eji.1830250152; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YELLIN MJ, 1991, J IMMUNOL, V147, P3389; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; YELLIN MJ, 1994, J IMMUNOL, V153, P666	80	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5835	5842		10.1074/jbc.274.9.5835	http://dx.doi.org/10.1074/jbc.274.9.5835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026206	hybrid			2022-12-27	WOS:000078804400077
J	Harris, CM; Sanders, SK; Massey, V				Harris, CM; Sanders, SK; Massey, V			Role of the flavin midpoint potential and NAD binding in determining NAD versus oxygen reactivity of xanthine oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-KINETICS; MOLECULAR-OXYGEN; REDOX POTENTIALS; HALF-REACTION; DEHYDROGENASE; OXIDASE; BEHAVIOR; FLAVOPROTEINS; PURIFICATION; MOLYBDENUM	Xanthine oxidoreductase from bovine milk can be prepared in two interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH), depending on the number of protein cysteines versus cystines, Enzyme forms differ in respect to their oxidizing substrates; XDH prefers NAD to molecular oxygen, whereas XO only reacts significantly with oxygen. The preference for oxidizing substrate is partially explained by thermodynamics. Unlike XDH, the midpoint potential of the FAD, the center at which oxygen and NAD react, is too high in XO to efficiently reduce NAD (Hunt, J,, Massey, V., Dunham, W.R,, and Sands, R.H. (1993) J, Biol, Chem, 268, 18685-18691), To distinguish between changes in thermodynamics and in substrate binding, samples of both XO and XDH have been prepared in which the native FAD has been replaced with an FAD analog of different redox potential, 1-deaza-FAD or 8-CN-FAD. Reductive titrations indicate that both 1-deaza-XO and 1-deaza-XDH have a flavin midpoint potential similar to native XDH and that 8-CN-XO and 8-CN-XDH each have a flavin potential higher than XO, Both the low potential. 1-deaza-XO and the high potential 8-CN-XDH contain essentially no xanthine/NAD activity. However, 1-deaza-XDH does exhibit xanthine/NAD activity, and 8-CN-XO has normal xanthine/oxygen activity. The binding of NAD to oxidized XO and XDH was investigated by ultrafiltration and isothermal titration calorimetry. The K-d for the binding of NAD to XDH was determined to be 280 +/- 145 mu M by ultrafiltration and 160 +/- 40 mu M by isothermal titration calorimetry. No evidence for the binding of NAD to XO by either method could be obtained. A low flavin midpoint potential is necessary but not sufficient for dehydrogenase activity.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Massey, V (corresponding author), Univ Michigan, Dept Biol Chem, 3441 Med Sci 1, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA Y, 1990, J BIOL CHEM, V265, P14170; AVIS PG, 1956, J CHEM SOC, P1219, DOI 10.1039/jr9560001219; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; ENTSCH B, 1980, J BIOL CHEM, V255, P1420; Harris CM, 1997, J BIOL CHEM, V272, P28335, DOI 10.1074/jbc.272.45.28335; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; Harris CM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P723; HILLE R, 1991, J BIOL CHEM, V266, P17401; HILLE R, 1985, J BIOL CHEM, V260, P569; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1994, J BIOL CHEM, V269, P18904; HUNT J, 1993, J BIOL CHEM, V268, P18685; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; MASSEY V, 1962, J BIOL CHEM, V237, P2347; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Murthy YVSN, 1998, J BIOL CHEM, V273, P8975, DOI 10.1074/jbc.273.15.8975; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1991, ADV EXP MED BIOL, V309, P327; NISHINO T, 1989, J BIOL CHEM, V264, P6075; *PABST LAB, 1965, ULTR ABS SPECTR PYR; PALMER G, 1969, J BIOL CHEM, V244, P2614; PARKS DA, 1983, AM J PHYSIOL, V245, pG285, DOI 10.1152/ajpgi.1983.245.2.G285; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; Segel I. H., 1976, BIOCH CALCULATIONS, P414; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3586, DOI 10.1021/bi00635a014; STEVENS CR, 1991, ANN RHEUM DIS, V50, P760, DOI 10.1136/ard.50.11.760; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Tanner SJ, 1978, BIOCHEM SOC T, V6, P1328, DOI 10.1042/bst0061328; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	38	38	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4561	4569		10.1074/jbc.274.8.4561	http://dx.doi.org/10.1074/jbc.274.8.4561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988690	hybrid			2022-12-27	WOS:000078698200015
J	Hu, DD; White, CA; Panzer-Knodle, S; Page, JD; Nicholson, N; Smith, JW				Hu, DD; White, CA; Panzer-Knodle, S; Page, JD; Nicholson, N; Smith, JW			A new model of dual interacting ligand binding sites on integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; GLYCOPROTEIN-IIB/IIIA RECEPTOR; STIMULATED HUMAN-PLATELETS; IIB-IIIA COMPLEX; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; CELL-ADHESION; VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAINS; FIBRINOGEN BINDING	The platelet integrin alpha(IIIb)beta(3) mediates platelet aggregation and platelet adhesion. This integrin is the key to hemostasis and also to pathologic vascular occlusion. A key domain on alpha(IIIb)beta(3) is the ligand binding site, which can bind to plasma fibrinogen and to a number of Arg-Gly-Asp (RGD)-type ligands. However, the nature and function of the ligand binding pocket on alpha(IIIb)beta(3) remains controversial. Some studies suggest the presence of two ligand binding pockets, whereas other reports indicate a single binding pocket. Here we use surface plasmon resonance to show that alpha(IIb)beta(3) contains two distinct ligand binding pockets. One site binds to fibrinogen, and a separate site binds to RGD-type ligands, More importantly, however, the two ligand binding pockets are interactive. RGD-type ligands are capable of binding to alpha(IIb)beta(3) even when it is already occupied by fibrinogen, Once bound, RGD-type ligands induce the dissociation of fibrinogen from alpha(IIb)beta(3). This allosteric cross-talk has important implications for anti-platelet therapy because it suggests a novel approach for the dissolution of existing platelet thrombi.	La Jolla Canc Res Fdn, Canc Res Ctr, Program Cell Adhes, Burnham Inst, La Jolla, CA 92037 USA; Searle, Dept Cardiovasc Dis Res, Skokie, IL 60077 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), La Jolla Canc Res Fdn, Canc Res Ctr, Program Cell Adhes, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL58925] Funding Source: Medline; NIAMS NIH HHS [AR 45054, AR42750] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045054, R01AR042750] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BEER JH, 1992, BLOOD, V79, P117; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; Coller BS, 1997, CIRCULATION, V95, P860; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kato A, 1997, CRIT REV ONCOL HEMAT, V26, P1, DOI 10.1016/S1040-8428(97)00011-5; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Mesri M, 1998, J BIOL CHEM, V273, P744, DOI 10.1074/jbc.273.2.744; Moliterno DJ, 1997, THROMB HAEMOSTASIS, V78, P214; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PANZERKNODLE SG, 1995, PLATELETS, V6, P288, DOI 10.3109/09537109509023569; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SEGAL IH, 1975, ENZYME KINETICS; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1994, J BIOL CHEM, V269, P960; Tcheng JE, 1997, THROMB HAEMOSTASIS, V78, P205; Wagner CL, 1996, BLOOD, V88, P907; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	48	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4633	4639		10.1074/jbc.274.8.4633	http://dx.doi.org/10.1074/jbc.274.8.4633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988699	hybrid			2022-12-27	WOS:000078698200024
J	Justice, MC; Ku, T; Hsu, MJ; Carniol, K; Schmatz, D; Nielsen, J				Justice, MC; Ku, T; Hsu, MJ; Carniol, K; Schmatz, D; Nielsen, J			Mutations in ribosomal protein L10e confer resistance to the fungal-specific eukaryotic elongation factor 2 inhibitor sordarin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; EF-G; SUBUNIT; ATPASE; LIVER	The natural product sordarin, a tetracyclic diterpene glycoside, selectively inhibits fungal protein synthesis by impairing the function of eukaryotic elongation factor 2 (eEF2). Sordarin and its derivatives bind to the eEF2-ribosome-nucleotide complex in sensitive fungi, stabilizing the post-translocational GDP form. We have previously described a class of Saccharomyces cerevisiae mutants that exhibit resistance to varying levels of sordarin and have identified amino acid substitutions in yeast eEF2 that confer sordarin resistance. We now report on It second class of sordarin-resistant mutants. Biochemical and molecular genetic analysis of these mutants demonstrates that sordarin resistance is dependent on the essential large ribosomal subunit protein L10e in S. cerevisiae. Five unique L10e alleles were characterized and sequenced, and several nucleotide changes that differ from the wild-type sequence were identified. Changes that result in the resistance phenotype map to 4 amino acid substitutions and 1 amino acid deletion clustered in a conserved 10-amino acid region of L10e. Like the previously identified eEF2 mutations, the mutant ribosomes show reduced sordarin conferred stabilization of the eEF2-nucleotide-ribosome complex. To our know ledge, this report provides the first description of ribosomal protein mutations affecting translocation. These results and our previous observations with eEF2 suggest a functional linkage between L10e and eEF2.	Merck Res Labs, Dept Basic Anim Sci Res, Rahway, NJ 07065 USA; Wesleyan Univ, Middletown, CT 06459 USA	Merck & Company; Wesleyan University	Nielsen, J (corresponding author), Merck Res Labs, Dept Basic Anim Sci Res, POB 2000, Rahway, NJ 07065 USA.							ACHARYA AS, 1973, BIOCHEMISTRY-US, V12, P3108, DOI 10.1021/bi00740a026; Agafonov DE, 1997, P NATL ACAD SCI USA, V94, P12892, DOI 10.1073/pnas.94.24.12892; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; BILGIN N, 1988, BIOCHIMIE, V70, P611, DOI 10.1016/0300-9084(88)90244-1; Bocharov EV, 1998, FEBS LETT, V423, P347, DOI 10.1016/S0014-5793(98)00121-5; Capa L, 1998, ANTIMICROB AGENTS CH, V42, P2694, DOI 10.1128/AAC.42.10.2694; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2279, DOI 10.1128/AAC.42.9.2279; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2274, DOI 10.1128/AAC.42.9.2274; GUDKOV AT, 1984, FEBS LETT, V176, P32, DOI 10.1016/0014-5793(84)80906-0; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; HAUSER D, 1971, HELV CHIM ACTA, V54, P1178, DOI 10.1002/hlca.19710540427; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; Justice MC, 1998, J BIOL CHEM, V273, P3148, DOI 10.1074/jbc.273.6.3148; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; MAASSEN JA, 1974, P NATL ACAD SCI USA, V71, P1277, DOI 10.1073/pnas.71.4.1277; MITSUI K, 1989, J BIOCHEM-TOKYO, V106, P223, DOI 10.1093/oxfordjournals.jbchem.a122836; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; Skogerson L, 1979, Methods Enzymol, V60, P676; Trusca D, 1998, J BACTERIOL, V180, P3946, DOI 10.1128/JB.180.15.3946-3953.1998; Tse B, 1998, BIOORG MED CHEM LETT, V8, P2269, DOI 10.1016/S0960-894X(98)00401-6; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; URITANI M, 1988, J BIOCHEM-TOKYO, V103, P522, DOI 10.1093/oxfordjournals.jbchem.a122302; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655	30	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4869	4875		10.1074/jbc.274.8.4869	http://dx.doi.org/10.1074/jbc.274.8.4869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988728	hybrid			2022-12-27	WOS:000078698200053
J	Lee, J; Spector, D; Godon, C; Labarre, J; Toledano, MB				Lee, J; Spector, D; Godon, C; Labarre, J; Toledano, MB			A new antioxidant with alkyl hydroperoxide defense properties in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; THIOL-SPECIFIC ANTIOXIDANT; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; GLUTATHIONE-PEROXIDASE; CANDIDA-BOIDINII; TARGET GENE; THIOREDOXIN; PROTEINS; REDUCTASE	To isolate new antioxidant genes, we have searched for activities that would rescue the tert-butyl hydroperoxide (t-BOOH)-hypersensitive phenotype of a Saccharomyces cerevisiae strain deleted for the gene encoding the oxidative stress response regulator Skn7, We report the characterization of AHP1, which encodes a 19-kDa protein similar to the AhpC/TSA protein family within a small region encompassing Cys-62 of Ahp1p and the highly conserved N-terminal catalytic AhpC/TSA cysteine, Ahp1p contains a peroxisomal sorting signal, suggesting a peroxisomal localization. AHP1 exerts strong antioxidant protective functions, as demonstrated both by gene overexpression and deletion analyses, and is inducible by peroxides in an Yap1- and Skn7 dependent manner. Similar to yeast Tsa1p, Ahp1p forms a disulfide-linked homodimer upon oxidation and in, vivo requires the presence of the thioredoxin system but not of glutathione to perform its antioxidant protective function. Furthermore, in contrast to Tsa1p, which is specific for H2O2, Ahp1p is specific for organic peroxides, Therefore, with respect to substrate specificity, Ahp1p differs from Tsa1p and is similar to prokaryotic alkyl hydroperoxide reductase AhpC. These data suggest that Ahp1p is a yeast orthologue of prokaryotic AhpC and justifies its name of yeast alkyl hydroperoxide reductase.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Rutgers State Univ, Coll Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08855 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Rutgers State University New Brunswick	Toledano, MB (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.	toledano@jonas.saclay.cea.fr						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, BIOFACTORS, V4, P177; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GOODMAN JM, 1986, J BIOL CHEM, V261, P3464; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P273; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; Krems B, 1996, CURR GENET, V29, P327, DOI 10.1007/s002940050053; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LIU HP, 1992, GENETICS, V132, P665; Marinho HS, 1997, FREE RADICAL BIO MED, V22, P871, DOI 10.1016/S0891-5849(96)00468-6; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; RANDEZGIL F, 1994, FEMS MICROBIOL LETT, V122, P153, DOI 10.1111/j.1574-6968.1994.tb07158.x; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SIKORSKI RS, 1989, GENETICS, V122, P19; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	49	148	153	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4537	4544		10.1074/jbc.274.8.4537	http://dx.doi.org/10.1074/jbc.274.8.4537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988687	hybrid			2022-12-27	WOS:000078698200012
J	Johnson, GD; Stevenson, T; Ahn, KH				Johnson, GD; Stevenson, T; Ahn, KH			Hydrolysis of peptide hormones by endothelin-converting enzyme-1 - A comparison with neprilysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE 24.11 ENKEPHALINASE; MEMBRANE-BOUND METALLOPROTEASE; NEUTRAL ENDOPEPTIDASE; BIG ENDOTHELIN-1; NATRIURETIC PEPTIDE; PURIFICATION; CELLS; SPECIFICITY	Endothelins are peptide hormones with a potent vasoconstrictor activity that are also known to function as intercellular signaling molecules. The final step in the biosynthesis of endothelins is the proteolytic processing of precursor peptides by endothelin-converting enzymes (ECEs), ECE-1 is a zinc metalloendopeptidase related in amino acid sequence to neprilysin, a mammalian cell-surface peptidase involved in the metabolism of numerous biologically active peptides, Despite apparent structural similarities, ECE-1 and neprilysin have been considered to differ significantly in substrate specificity. In this study we have examined the activity of recombinant ECE-1 against a collection of biologically active peptides, ECE-1, unlike neprilysin, was found to have minimal activity against substrates smaller than hexapeptides, such as Leu-enkephalin. Larger peptides such as neurotensin, substance P, bradykinin, and the oxidized insulin B chain were hydrolyzed by ECE-1 as efficiently as big endothelin-1, a known in vivo substrate. Identification of the products of hydrolysis of six peptides indicates that ECE-1 has a substrate specificity similar to that of neprilysin, preferring to cleave substrates at the amino side of hydrophobic residues. The data indicate that ECE-1 possesses a surprisingly broad substrate specificity and is potentially involved in the metabolism of biologically active peptides distinct from the endothelins.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Biochem, Ann Arbor, MI 48105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA	Pfizer; Pfizer	Ahn, KH (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Biochem, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Kay.Ahn@aa.wl.com						Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; Ahn K, 1998, BIOCHEM BIOPH RES CO, V243, P184, DOI 10.1006/bbrc.1998.8081; AHN K, 1992, P NATL ACAD SCI USA, V89, P8606, DOI 10.1073/pnas.89.18.8606; Corder R, 1996, BIOCHEM PHARMACOL, V51, P259, DOI 10.1016/0006-2952(95)02164-7; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GAFFORD JT, 1983, BIOCHEMISTRY-US, V22, P3265, DOI 10.1021/bi00282a035; HERSH LB, 1986, J BIOL CHEM, V261, P6433; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KENNY AJ, 1993, BIOCHEM J, V291, P83, DOI 10.1042/bj2910083; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LI CW, 1995, METHOD ENZYMOL, V248, P253; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; SKIDGEL RA, 1984, PEPTIDES, V5, P769, DOI 10.1016/0196-9781(84)90020-2; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	32	117	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4053	4058		10.1074/jbc.274.7.4053	http://dx.doi.org/10.1074/jbc.274.7.4053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933597	hybrid			2022-12-27	WOS:000078575500021
J	Vilella-Bach, M; Nuzzi, P; Fang, YM; Chen, J				Vilella-Bach, M; Nuzzi, P; Fang, YM; Chen, J			The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G(1) progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; TRANSLATION INITIATION; PHAS-I; MAMMALIAN PROTEIN; MESSENGER-RNA; EARLY G1; RAPAMYCIN; YEAST; PHOSPHORYLATION; TARGET	The immunosuppressant rapamycin, in complex with its cellular receptor FKBP12, targets the cellular protein FKBP12-rapamycin-associated protein/mammalian target of rapamycin/rapamycin and FKBP12 target 1 (FRAP/mTOR/RAFT1) and inhibits/delays G(1) cell cycle progression in mammalian cells. As a member of the novel phosphatidylinositol kinase-related kinase family, FRAP's kinase activity is essential for its signaling function. The FKBP12-rapamycin binding (FIR) domain in FRAP is also speculated to play an important role in FRAP function and signaling. However, the biochemical and physiological functions of FRB, as well as the mechanism for rapamycin inhibition, have been unclear. The present study focuses on investigation of FRB's role and the functional relationship between FEB domain and kinase domain in FRAP. Microinjection of purified FRB protein into human osteosarcoma MG63 cells results in a drastic blockage of the G(1) to S cell cycle progression; such a dominant negative effect is reversed by a point mutation (Trp(2027) --> Phe). The same mutation also abolishes kinase activity of FRAP without affecting ATP binding, and truncation studies suggest that upstream sequences including FRB are required for kinase activity in vitro, Given these data, we propose a model for FRAP function, in which the FEB domain is required for activation of the kinase domain, possibly through the interaction with an upstream activator. In addition, our observations provide direct evidence linking FRAP function to G(1) cell cycle progression.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), Univ Illinois, Dept Cell & Struct Biol, 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jchen@life.uiuc.edu		Chen, Jie/0000-0002-7887-3747				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1995, J IMMUNOL, V155, P3418; Withers DJ, 1997, J BIOL CHEM, V272, P2509; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	49	111	124	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4266	4272		10.1074/jbc.274.7.4266	http://dx.doi.org/10.1074/jbc.274.7.4266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933627	hybrid			2022-12-27	WOS:000078575500051
J	Bevans, CG; Harris, AL				Bevans, CG; Harris, AL			Regulation of connexin channels by pH - Direct action of the protonated form of taurine and other aminosulfonates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GAP-JUNCTIONS; INTRACELLULAR PH; GLYCINE RECEPTOR; XENOPUS OOCYTES; CARBON-DIOXIDE; RAT-BRAIN; TRANSPORTER; EXPRESSION; SENSITIVITY; PROTEIN	Protonated aminosulfonate compounds directly inhibit connexin channel activity. This was demonstrated by pH-dependent connexin channel activity in Good's pH buffers (MES (4-morpholineethanesulfonic acid), HEPES, and TAPS (3-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]-1-propanesulfonic acid)) that have an aminosulfonate moiety in common and by the absence of pH-dependent channel activity in pH buffers without an aminosulfonate moiety (maleate, Tris, and bicarbonate). The pH-activity relation was shifted according to the pK(a) of each aminosulfonate pH buffer. At constant pH, increased aminosulfonate concentration inhibited channel activity. Taurine, a ubiquitous cytoplasmic aminosulfonic acid, had the same effect at physiological concentrations. These data raise the possibility that effects on connexin channel activity previously attributed to protonation of connexin may be mediated instead by protonation of cytoplasmic regulators, such as taurine, Modulation by aminosulfonates is specific for heteromeric connexin channels containing connexin-26; it does not occur significantly for homomeric connexin-32 channels. The identification of taurine as a cytoplasmic compound that directly interacts with and modulates connexin channel activity is likely to facilitate understanding of cellular modulation of connexin channels and lead to the development of reagents for use in structure-function studies of connexin protein.	Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University	Harris, AL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.		Bevans, Carville/C-6651-2009	Bevans, Carville/0000-0001-7389-2124; Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAGI H, 1988, NEUROSCI LETT, V95, P262, DOI 10.1016/0304-3940(88)90668-4; BENNETT MVL, 1994, SOC GEN PHY, V49, P223; Bevans C. G., 1997, Molecular Biology of the Cell, V8, p96A; Bevans C. G., 1996, Biophysical Journal, V70, pA32; Bevans C. G., 1995, Biophysical Journal, V68, pA204; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bevans CG, 1999, J BIOL CHEM, V274, P3720, DOI 10.1074/jbc.274.6.3720; CAMPOSDECARVALHO AC, 1988, BRAZ J MED BIOL RES, V21, P177; CHESLER M, 1989, J NEUROSCI, V9, P2011; CHESNEY RW, 1990, PEDIATR NEPHROL, V4, P399, DOI 10.1007/BF00862526; Christensen J.J., 1976, HDB PROTON IONIZATIO; CLEMENS M, 1993, MOL BIOL CELL, V4, pS330; CONNORS BW, 1984, J NEUROSCI, V4, P1324; DELMAR M, 1995, CARDIAC ELECTROPHYSI, P135; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; FALLON MB, 1995, AM J PHYSIOL-CELL PH, V268, pC1186, DOI 10.1152/ajpcell.1995.268.5.C1186; GOLDIN SM, 1978, J BIOL CHEM, V253, P2575; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GREEN TR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P91, DOI 10.1016/0304-4165(91)90187-L; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HARRIS AL, 1997, GAP JUNCTIONS, P60; HARRIS AL, 1994, BIOMEMBRANE ELECTROC, P197; HUXTABLE RJ, 1994, TAURINE HLTH DIS; IWATSUKI N, 1979, J PHYSIOL-LONDON, V291, P317, DOI 10.1113/jphysiol.1979.sp012815; Kumar N M, 1992, Semin Cell Biol, V3, P3; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LIU SG, 1993, BIOPHYS J, V64, P1422, DOI 10.1016/S0006-3495(93)81508-X; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Nagy JI, 1997, NEUROSCIENCE, V78, P533, DOI 10.1016/S0306-4522(96)00584-2; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; OLLIVON M, 1986, ANAL BIOCHEM, V152, P262, DOI 10.1016/0003-2697(86)90408-2; OLSON KS, 1995, J COMP PHYSIOL A, V176, P527; Peracchia C, 1996, PFLUG ARCH EUR J PHY, V431, P379, DOI 10.1007/BF02207275; Peracchia C, 1997, BRAZ J MED BIOL RES, V30, P577, DOI 10.1590/S0100-879X1997000500003; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; *RES ORG INC, 1996, 1996 7 CAT BIOCH; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; RINK TJ, 1980, NATURE, V283, P658, DOI 10.1038/283658a0; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; Schofield PR, 1996, COLD SPRING HARB SYM, V61, P333; SCHUETZE SM, 1982, J CELL BIOL, V92, P694, DOI 10.1083/jcb.92.3.694; SMITH KE, 1992, MOL PHARMACOL, V42, P563; Spray David C., 1994, P195; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; Torok K, 1997, BIOCHEM J, V326, P479; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; Vinnakota S, 1997, J NEUROCHEM, V69, P2238; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; Wang XG, 1997, BIOPHYS J, V73, P798, DOI 10.1016/S0006-3495(97)78112-8; Wang XG, 1996, PFLUG ARCH EUR J PHY, V431, P844; Wang XG, 1996, AM J PHYSIOL-CELL PH, V271, pC1743, DOI 10.1152/ajpcell.1996.271.5.C1743; WERNER R, 1991, P ROY SOC B-BIOL SCI, V243, P5, DOI 10.1098/rspb.1991.0002; YOUNG AB, 1974, MOL PHARMACOL, V10, P790	62	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3711	3719		10.1074/jbc.274.6.3711	http://dx.doi.org/10.1074/jbc.274.6.3711			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920923	hybrid			2022-12-27	WOS:000078428200063
J	Efimova, IS; Salminen, A; Pohjanjoki, P; Lapinniemi, J; Magretova, NN; Cooperman, BS; Goldman, A; Lahti, R; Baykov, AA				Efimova, IS; Salminen, A; Pohjanjoki, P; Lapinniemi, J; Magretova, NN; Cooperman, BS; Goldman, A; Lahti, R; Baykov, AA			Directed mutagenesis studies of the metal binding site at the subunit interface of Escherichia coli inorganic pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CRYSTAL-STRUCTURE; CATALYTIC PROPERTIES; ACTIVE-SITE; SUBSTITUTION; RESOLUTION; HYDROLYSIS; PHOSPHATE; ANGSTROM; CAVITIES	Recent crystallographic studies on Escherichia coli inorganic pyrophosphatase (E-PPase) have identified three Mg2+ ions/enzyme hexamer in water-filled cavities formed by Asn(24), Ala(25), and Asp(26) at the trimer-trimer interface (Kankare, J., Salminen, T., Lahti, R., Cooperman, B., Baykov, A. A., and Goldman, A. (1996) Biochemistry 35, 4670-4677). Here we show that D26S and D26N substitutions decrease the stoichiometry of tight Mg2+ binding to E-PPase by approximately 0.5 mol/mol monomer and increase hexamer stability in acidic medium. Mg2+ markedly decelerates the dissociation of enzyme hexamer into trimers at pH 5.0 and accelerates hexamer formation from trimers at pH 7.2 with wild type E-PPase and the N24D variant, in contrast to the D26S and D26N variants, when little or no effect is seen. The catalytic parameters describing the dependences of enzyme activity on substrate and Mg2+ concentrations are of the same magnitude for wild type E-PPase and the three variants. The affinity of the intertrimer site for Mg2+ at pH 7.2 is intermediate between those of two Mg2+ binding sites found in the E-PPase active site. It is concluded that the metal ion binding site found at the trimer-trimer interface of E-PPase is a high affinity site whose occupancy by Mg2+ greatly stabilizes the enzyme hexamer but has little effect on catalysis.	Moscow MV Lomonosov State Univ, An Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Univ Turku, Dept Biochem, FIN-20014 Turku, Finland; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Abo Akad Univ, FIN-20251 Turku, Finland; Turku Univ, Ctr Biotechnol, FIN-20251 Turku, Finland	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; University of Pennsylvania; Abo Akademi University; University of Turku	Lahti, R (corresponding author), Moscow MV Lomonosov State Univ, An Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander A/C-7981-2012; Salminen, Tiina A/G-7492-2019; Baykov, Alexander/AAH-5301-2021; Salminen, Tiina A./AAM-5443-2021	Salminen, Tiina A/0000-0002-4135-8020; Salminen, Tiina A./0000-0002-4135-8020; Baykov, Alexander/0000-0002-2495-8200	FOGARTY INTERNATIONAL CENTER [R03TW000407] Funding Source: NIH RePORTER; FIC NIH HHS [TW00407] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Avaeva SM, 1995, FEBS LETT, V377, P44, DOI 10.1016/0014-5793(95)01310-5; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; BORSHCHIK I B, 1986, Biokhimiya, V51, P1484; Brinen LS, 1996, BIOCHEMISTRY-US, V35, P5999, DOI 10.1021/bi9530200; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; HACHIMORI A, 1979, J BIOCHEM, V86, P121; Harutyunyan EG, 1996, KRISTALLOGRAFIYA+, V41, P84; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; HILL CP, 1991, BIOCHEMISTRY-US, V30, P917, DOI 10.1021/bi00218a006; HUBBARD SJ, 1994, PROTEIN SCI, V3, P2194, DOI 10.1002/pro.5560031205; ICHIBA T, 1990, J BIOCHEM-TOKYO, V108, P572, DOI 10.1093/oxfordjournals.jbchem.a123244; JOSSE J, 1966, J BIOL CHEM, V241, P1938; Kankare J, 1996, ACTA CRYSTALLOGR D, V52, P551, DOI 10.1107/S0907444996000376; KANKARE J, 1994, PROTEIN ENG, V7, P823, DOI 10.1093/protein/7.7.823; Kankare J, 1996, BIOCHEMISTRY-US, V35, P4670, DOI 10.1021/bi952637e; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; Kornberg A., 1962, HORIZONS BIOCH, P251; LAHTI R, 1990, BIOCHEMISTRY-US, V29, P5761, DOI 10.1021/bi00476a017; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; PARDE HE, 1993, SCIENCE, V262, P387; Petsko GA, 1996, NAT STRUCT BIOL, V3, P565, DOI 10.1038/nsb0796-565; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; SCHREIER E, 1980, FEBS LETT, V109, P67, DOI 10.1016/0014-5793(80)81313-5; SONNEWALD U, 1992, PLANT J, V2, P571; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; TEPLYAKOV A, 1994, PROTEIN SCI, V3, P1098, DOI 10.1002/pro.5560030713; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; Volk SE, 1996, BIOCHEMISTRY-US, V35, P4662, DOI 10.1021/bi952636m; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WONG SCK, 1970, J BIOL CHEM, V245, P4335	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3294	3299		10.1074/jbc.274.6.3294	http://dx.doi.org/10.1074/jbc.274.6.3294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920869	hybrid			2022-12-27	WOS:000078428200009
J	Wang, L; Xu, DZ; Dai, W; Lu, L				Wang, L; Xu, DZ; Dai, W; Lu, L			An ultraviolet-activated K+ channel mediates apoptosis of myeloblastic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CEREBELLAR GRANULE NEURONS; C-JUN; TYROSINE KINASE; PROTEIN-KINASE; DIFFERENTIAL ACTIVATION; POTASSIUM CHANNELS; HUMAN-MONOCYTES; GROWTH-FACTOR; UV RESPONSE	Exposure of mammalian cells to UV light causes initial changes in the cell membrane, induces phosphorylation and clustering of growth factor/cytokine receptors, and activates the Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway leading to programmed cell death (apoptosis). In this study, we found that an early event in the cell membrane of myeloblastic leukemia (ML-1) cells was the vigorous activation of the voltage-gated K+ channel by UV irradiation. The strong enhancement by UV irradiation of K+ channel activity in the cell membrane subsequently activated the JNK/SAPK signaling pathway and resulted in myeloblastic leukemia cell apoptosis. Suppression of UV-induced K+ channel activation with specific channel blockers prevented UV-induced apoptosis through inhibition of UV-induced activation of the proteins SEK (SPAK kinase) and JNK. However, suppression of K+ channel activity could not protect cells from etoposide-induced apoptosis, which bypasses the membrane event. Elimination of extracellular Ca2+ had no effect on the UV-induced and K+ channel-mediated JNK/SAPK activation. Thus, we have identified a novel mechanism in which activation of K+ channels by UV-irradiation upstream of SEK and SAPK/JNK mediates UV-induced myeloblastic cell apoptosis.	Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA; Univ Cincinnati, Coll Med, Dept Med, Div Hematol, Cincinnati, OH 45243 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; University of Cincinnati	Lu, L (corresponding author), Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA.	LUO.LU@WRIGHT.EDU			NCI NIH HHS [CA59985] Funding Source: Medline; NEI NIH HHS [EY11653] Funding Source: Medline; NIGMS NIH HHS [GM46834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059985] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRIGHT J, 1994, BIOSCIENCE REP, V14, P67; BUSCHER M, 1988, ONCOGENE, V3, P301; Cahill MA, 1996, ONCOGENE, V13, P2087; COFFER PJ, 1995, ONCOGENE, V11, P561; deLuca A, 1996, J NEUROSCI, V16, P4174; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holbrook N J, 1996, EXS, V77, P273; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LU L, 1993, J MEMBRANE BIOL, V132, P267; MATSUURA H, 1991, AM J PHYSIOL, V261, pH1358, DOI 10.1152/ajpheart.1991.261.5.H1358; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Rader RK, 1996, J IMMUNOL, V156, P1425; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUZAIREDUBOIS B, 1990, CELL SIGNAL, V2, P387, DOI 10.1016/0898-6568(90)90069-M; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; Schulz JB, 1996, J NEUROSCI, V16, P4696; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; SOLIVEN B, 1991, J MEMBRANE BIOL, V124, P127, DOI 10.1007/BF01870457; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; VALENZENO DP, 1991, PHOTOCHEM PHOTOBIOL, V53, P195, DOI 10.1111/j.1751-1097.1991.tb03923.x; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Wang L, 1997, AM J PHYSIOL-CELL PH, V273, pC1657, DOI 10.1152/ajpcell.1997.273.5.C1657; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; YAN MH, 1994, NATURE, V372, P798; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114	53	89	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3678	3685		10.1074/jbc.274.6.3678	http://dx.doi.org/10.1074/jbc.274.6.3678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920918	hybrid			2022-12-27	WOS:000078428200058
J	Bourne, Y; Taylor, P; Bougis, PE; Marchot, P				Bourne, Y; Taylor, P; Bougis, PE; Marchot, P			Crystal structure of mouse acetylcholinesterase - A peripheral site-occluding loop in a tetrameric assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; MOLECULAR-DYNAMICS SIMULATION; X-RAY CRYSTALLOGRAPHY; CANDIDA-RUGOSA LIPASE; INTERFACIAL ACTIVATION; ALZHEIMERS-DISEASE; ACTIVE-SITE; BRAIN ACETYLCHOLINESTERASE; PRION PROTEIN; BACK-DOOR	The crystal structure of mouse acetylcholinesterase at 2.9-? resolution reveals a tetrameric assembly of subunits with an antiparallel alignment of two canonical homodimers assembled through four-helix bundles. In the tetramer, a short Omega loop, composed of a cluster of hydrophobic residues conserved in mammalian acetylcholinesterases along with flanking alpha-helices, associates with the peripheral anionic site of the facing subunit and sterically occludes the entrance of the gorge leading to the active center. The inverse loop-peripheral site interaction occurs within the second pair of subunits, but the peripheral sites on the two loop-donor subunits remain freely accessible to the solvent. The position and complementarity of the peripheral site-occluding loop mimic the characteristics of the central loop of the peptidic inhibitor fasciculin bound to mouse acetylcholinesterase, Tetrameric forms of cholinesterases are widely distributed in nature and predominate in mammalian brain. This structure reveals a likely mode of subunit arrangement and suggests that the peripheral site, located near the rim of the gorge, is a site for association of neighboring subunits or heterologous proteins with interactive surface loops.	Univ Mediterranee, Fac Med Secteur Nord, Inst Federatif Rech Jean Roche, CNRS,UMR 6560, F-13916 Marseille 20, France; Inst Biol & Microbiol Struct, CNRS, Unite Propre Rech 9039, F-13402 Marseille 20, France; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Diego	Marchot, P (corresponding author), Univ Mediterranee, Fac Med Secteur Nord, Inst Federatif Rech Jean Roche, CNRS,UMR 6560, F-13916 Marseille 20, France.	marchot.p@jean-roche.univ-mrs.fr	MARCHOT, Pascale/AAC-4752-2022; Bourne, Yves/AAC-4635-2022; BOUGIS, Pierre E/I-2111-2013	MARCHOT, Pascale/0000-0003-0630-0541; Bourne, Yves/0000-0003-3850-0548; 	NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez A, 1998, J NEUROSCI, V18, P3213; Alvarez A, 1997, J MOL BIOL, V272, P348, DOI 10.1006/jmbi.1997.1245; ATACK JR, 1983, NEUROSCI LETT, V40, P199, DOI 10.1016/0304-3940(83)90302-6; AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAYREUTHER K, 1994, NATURE, V370, P419, DOI 10.1038/370419a0; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BRUNGER AT, 1987, SCIENCE, V235, P1118; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARSON KA, 1991, BRAIN RES, V540, P204, DOI 10.1016/0006-8993(91)90508-S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; CYGLER M, 1993, PROTEIN SCI, V2, P366; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Faerman C, 1996, FEBS LETT, V386, P65, DOI 10.1016/0014-5793(96)00374-2; FETROW JS, 1995, FASEB J, V9, P708, DOI 10.1096/fasebj.9.9.7601335; FITZGERALD MM, 1994, BIOCHEMISTRY-US, V33, P3807, DOI 10.1021/bi00179a004; Fitzgerald MM, 1996, NAT STRUCT BIOL, V3, P626, DOI 10.1038/nsb0796-626; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; Geula Changiz, 1994, P263; Giles K, 1997, PROTEIN ENG, V10, P677, DOI 10.1093/protein/10.6.677; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GREENFIELD SA, 1995, ENZYMES OF THE CHOLINESTERASE FAMILY, P415; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; LI Y, 1993, J BIOL CHEM, V268, P5790; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MORAN MA, 1993, ACTA NEUROPATHOL, V85, P362, DOI 10.1007/BF00334445; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; NICHOLLS A, 1992, GRAPS GRAPHICAL REPR; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; Reyes AE, 1997, BIOCHEM BIOPH RES CO, V232, P652, DOI 10.1006/bbrc.1997.6357; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Saxena A, 1998, MOL PHARMACOL, V53, P112, DOI 10.1124/mol.53.1.112; SCHEGG KM, 1992, NEUROBIOL AGING, V13, P697, DOI 10.1016/0197-4580(92)90092-C; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; Small DH, 1996, NEUROCHEM INT, V28, P453, DOI 10.1016/0197-0186(95)00099-2; SOTO C, 1994, J NEUROCHEM, V63, P1191; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; ULRICH J, 1990, ACTA NEUROPATHOL, V80, P624, DOI 10.1007/BF00307630; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; Velan B, 1996, FEBS LETT, V395, P22, DOI 10.1016/0014-5793(96)00995-7	70	134	138	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2963	2970		10.1074/jbc.274.5.2963	http://dx.doi.org/10.1074/jbc.274.5.2963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915834	Green Published, hybrid			2022-12-27	WOS:000078319500052
J	Choi, BH; Park, GT; Rho, HM				Choi, BH; Park, GT; Rho, HM			Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II pregenomic promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HBX PROTEIN; NF-KAPPA-B; LIVER NUCLEAR-PROTEIN; TRANSCRIPTION FACTOR; DNA-BINDING; C/EBP-ALPHA; LEUCINE-ZIPPER; TRANSACTIVATOR PROTEIN; GENE; DOMAIN	The hepatitis B viral X protein (HBx) is known to exert its transactivation activity by the interaction with several cellular transcription factors. Here we report the interaction of HBx and CCAAT/enhancer-binding protein cu (C/EBP alpha) and their effects on the enhancer/promoters of hepatitis B virus (HBV), A chloramphenicol acetyltransferase assay showed that the cotransfection of HBx and C/EBP alpha strongly activated the enhancer II/ pregenomic promoter of HBV in a synergistic manner. This effect was also observed in the heterologous expression system with promoters of SV40 and herpes simplex virus thymidine kinase genes. Serial deletion analysis of the enhancer II/pregenomic promoter identified the responsible region (nucleotides 1639-1679), in which two C/EBP-binding sites are located. An in vitro interaction assay and electrophoretic mobility shift assay showed that HBx augmented the DNA binding activity of C/EBP alpha by direct interaction with it, and its basic leucine zipper domain was responsible for the interaction with HBx, Domain analysis of HBx showed that the central region (amino acids 78-103) was necessary for direct interaction with C/EBP alpha. However, the complete form of HBx was necessary for the synergistic activation of the HBV pregenomic promoter, These results suggest that the interaction of HBx and C/EBP alpha enhances the transcription of the HBV pregenomic promoter for the effective life cycle of HBV in hepatocytes.	Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rho, HM (corresponding author), Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea.							Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; Choi CY, 1996, EUR J BIOCHEM, V239, P579, DOI 10.1111/j.1432-1033.1996.0579u.x; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FAKTOR O, 1990, ONCOGENE, V5, P861; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUO WT, 1993, MOL CELL BIOL, V13, P443, DOI 10.1128/MCB.13.1.443; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; METZGER S, 1993, J BIOL CHEM, V268, P16831; Mink S, 1996, MOL CELL BIOL, V16, P1316; NAKATAKE H, 1993, VIROLOGY, V195, P305, DOI 10.1006/viro.1993.1381; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NYE JH, 1990, P NATL ACAD SCI USA, V87, P2992; Osada S, 1996, J BIOL CHEM, V271, P3891; Park GT, 1997, DNA CELL BIOL, V16, P1459, DOI 10.1089/dna.1997.16.1459; Park GT, 1996, J GEN VIROL, V77, P2775, DOI 10.1099/0022-1317-77-11-2775; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; SHIN HJ, 1995, J BIOL CHEM, V270, P11047, DOI 10.1074/jbc.270.19.11047; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; Vietor I, 1996, J BIOL CHEM, V271, P5595, DOI 10.1074/jbc.271.10.5595; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU KJ, 1994, J BIOL CHEM, V269, P1177; WU X, 1992, VIROLOGY, V191, P490, DOI 10.1016/0042-6822(92)90217-D; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Yu XM, 1997, J VIROL, V71, P9366, DOI 10.1128/JVI.71.12.9366-9374.1997; YUH CH, 1993, J VIROL, V67, P142, DOI 10.1128/JVI.67.1.142-149.1993; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHENG YW, 1994, J BIOL CHEM, V269, P22593; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	66	77	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2858	2865		10.1074/jbc.274.5.2858	http://dx.doi.org/10.1074/jbc.274.5.2858			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915821	hybrid			2022-12-27	WOS:000078319500039
J	Minnick, DT; Bebenek, K; Osheroff, WP; Turner, RM; Astatke, M; Liu, LX; Kunkel, TA; Joyce, CM				Minnick, DT; Bebenek, K; Osheroff, WP; Turner, RM; Astatke, M; Liu, LX; Kunkel, TA; Joyce, CM			Side chains that influence fidelity at the polymerase active site of Escherichia coli DNA polymerase I (Klenow fragment)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; FRAMESHIFT FIDELITY; THUMB SUBDOMAIN; PROCESSIVITY; REPLICATION; PROTEINS; MUTANT	To investigate the interactions that determine DNA polymerase accuracy, we have measured the fidelity of 26 mutants with amino acid substitutions in the polymerase domain of a 3'-5'-exonuclease-deficient Klenow fragment. Most of these mutant polymerases synthesized DNA with an apparent fidelity similar to that of the wild-type control, suggesting that fidelity at the polymerase active site depends on highly specific enzyme-substrate interactions and is not easily perturbed. In addition to the previously studied Y766A mutator, four novel base substitution mutators were identified; they are R668A R682A, E710A, and N845A, Each of these five mutator alleles results from substitution of a highly conserved amino acid side chain located on the exposed surface of the polymerase cleft near the polymerase active site. Analysis of base substitution errors at four template positions indicated that each of the five mutator polymerases has its own characteristic error specificity, suggesting that the Arg-668, Arg-682, Glu-710, Tyr-766, and Asn-845 side chains may contribute to polymerase fidelity in a variety of different ways. We separated the contributions of the nucleotide insertion and mismatch extension steps by using a novel fidelity assay that scores base substitution errors during synthesis to fill a single nucleotide gap land hence does not require mismatch extension) and by measuring the rates of polymerase-catalyzed mismatch extension reactions. The R682A, E710A, Y766A and N845A mutations cause decreased fidelity at the nucleotide insertion step, whereas R668A results in lower fidelity in both nucleotide insertion and mismatch extension. Relative to wild type, several Klenow fragment mutants showed substantially more discrimination against extension of a TG mismatch under the conditions of the fidelity assay, providing one explanation for the anti-mutator phenotypes of mutants such as R754A and Q849A.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	catherine.joyce@yale.edu	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NIGMS NIH HHS [5-F31 GM-18508, GM-28550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550, F31GM018508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; BRUSKOV VI, 1974, DOKL AKAD NAUK SSSR+, V219, P231; BRUSKOV VI, 1979, J THEOR BIOL, V78, P29, DOI 10.1016/0022-5193(79)90323-0; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; OSHEROFF WP, 1999, IN PRESS J BIOL CHEM, V274; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2	34	111	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3067	3075		10.1074/jbc.274.5.3067	http://dx.doi.org/10.1074/jbc.274.5.3067			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915846	hybrid			2022-12-27	WOS:000078319500064
J	Visconti, PE; Galantino-Homer, H; Ning, XP; Moore, GD; Valenzuela, JP; Jorgez, CJ; Alvarez, JG; Kopf, GS				Visconti, PE; Galantino-Homer, H; Ning, XP; Moore, GD; Valenzuela, JP; Jorgez, CJ; Alvarez, JG; Kopf, GS			Cholesterol efflux-mediated signal transduction in mammalian sperm - beta-cyclodextrins initiate transmembrane signaling leading to an increase in protein tyrosine phosphorylation and capacitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SPERMATOZOA; ACROSOME REACTION; BOVINE SPERM; MECHANISM; MEMBRANE; PHOSPHOLIPIDS; FERTILIZATION; TRANSPORT; ALBUMIN; INVITRO	Sperm capacitation in vitro is highly correlated with an increase in protein tyrosine phosphorylation that is regulated by cAMP through a unique mode of signal transduction cross-talk. The activation of this signaling pathway, as well as capacitation, requires bovine serum albumin (BSA) in the incubation medium. BSA is hypothesized to modulate capacitation through its ability to remove cholesterol from the sperm plasma membrane. Here we demonstrate that the cholesterol-binding heptasaccharides, methyl-beta-cyclodextrin and OH-propyl-beta-cyclodextrin, promote the release of cholesterol from the mouse sperm plasma membrane in media devoid of BSA Both of these beta-cyclodextrins were also demonstrated to increase protein tyrosine phosphorylation in the absence of BSA in both mouse and bull sperm, and the patterns of phosphorylation were similar to those induced by media containing BSA The potency of the different beta-cyclodextrins to increase protein tyrosine phosphorylation in sperm was correlated with their cholesterol binding efficiencies, and preincubation of the beta-cyclodextrins with cholesterol-SO4- to saturate their cholesterol-binding sites blocked the ability of these compounds to stimulate protein tyrosine phosphorylation, The beta-cyclodextrin effect on protein tyrosine phosphorylation was both NaHCO3 and protein kinase A-dependent. The beta-cyclodextrins were also able to capacitate mouse sperm in the absence of BSA, as measured by the ability of the zona pellucida to induce the acrosome reaction and by successful fertilization in vitro. In summary, beta-cyclodextrins can completely replace BSA in media to support signal transduction leading to capacitation. These data further support the coupling of cholesterol efflux to the activation of membrane and transmembrane signaling events leading to the activation of a unique signaling pathway involving the cross-talk between cAMP and tyrosine kinase second messenger systems, thus defining a new mode of cellular signal transduction initiated by cholesterol release.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Kopf, GS (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Rm 313,John Morgan Bldg, Philadelphia, PA 19104 USA.	kopf@mail.med.upenn.edu	Alvarez, Juan/GSD-7155-2022		NICHD NIH HHS [HD 22732, HD 06274, HD 36146] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD036146] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aitken RJ, 1996, MOL CELL ENDOCRINOL, V117, P83, DOI 10.1016/0303-7207(95)03733-0; ALVAREZ JG, 1995, MOL REPROD DEV, V42, P334, DOI 10.1002/mrd.1080420311; AUSTIN CR, 1951, AUST J SCI RES SER B, V4, P581, DOI 10.1071/BI9510581; AUSTIN CR, 1952, NATURE, V170, P326, DOI 10.1038/170326a0; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0; CHANG MC, 1955, NATURE, V175, P1036, DOI 10.1038/1751036a0; DAVIS BK, 1976, P SOC EXP BIOL MED, V152, P257; DAVIS BK, 1979, BIOCHIM BIOPHYS ACTA, V558, P257, DOI 10.1016/0005-2736(79)90260-8; DAVIS BK, 1981, P NATL ACAD SCI-BIOL, V78, P7560, DOI 10.1073/pnas.78.12.7560; Emiliozzi C, 1997, BIOL REPROD, V56, P674, DOI 10.1095/biolreprod56.3.674; FIELDING CJ, 1995, J LIPID RES, V36, P211; GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707; GLOMSET JA, 1968, J LIPID RES, V9, P155; GO KJ, 1985, BIOL REPROD, V32, P145, DOI 10.1095/biolreprod32.1.145; Harrison RAP, 1996, REPROD FERT DEVELOP, V8, P581, DOI 10.1071/RD9960581; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALAB P, 1994, J BIOL CHEM, V269, P3810; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAIS J, 1985, GAMETE RES, V12, P183, DOI 10.1002/mrd.1120120209; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; Luconi M, 1996, BIOL REPROD, V55, P207, DOI 10.1095/biolreprod55.1.207; MOORE GD, 1993, DEV BIOL, V159, P669, DOI 10.1006/dbio.1993.1273; PARRISH JJ, 1988, BIOL REPROD, V38, P1171, DOI 10.1095/biolreprod38.5.1171; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; SHOUFFANI A, 1990, J BIOL CHEM, V265, P6002; SUZUKI F, 1989, GAMETE RES, V23, P335, DOI 10.1002/mrd.1120230310; THALER CD, 1995, BIOCHEMISTRY-US, V34, P7788, DOI 10.1021/bi00024a002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEMURI R, 1989, J BIOL CHEM, V264, P8680; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1998, J ANDROL, V19, P242; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Visconti PE, 1998, BIOL REPROD, V59, P1, DOI 10.1095/biolreprod59.1.1; WARD CR, 1984, DEV BIOL, V104, P287, DOI 10.1016/0012-1606(84)90084-8; YANAGIMACHI R, 1994, PHYSL REPROD, P183; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zar J. H., 1996, BIOSTATISTICAL ANAL	42	254	261	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3235	3242		10.1074/jbc.274.5.3235	http://dx.doi.org/10.1074/jbc.274.5.3235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915865	hybrid			2022-12-27	WOS:000078319500083
J	Tolwinski, NS; Shapiro, PS; Goueli, S; Ahn, NG				Tolwinski, NS; Shapiro, PS; Goueli, S; Ahn, NG			Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression - Requirement for phosphorylation at the activation lip and signaling downstream of MKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; CYTOPLASMIC LOCALIZATION; EXPORT; TRANSLOCATION; MITOSIS; CRM1; DIFFERENTIATION; RAF-1	Stimulation of mammalian cells results in subcellular relocalization of Ras pathway enzymes, in which extracellular signal-regulated protein kinases rapidly translocate to nuclei. In this study, we define conditions for nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) by examining effects of perturbing the nuclear export signal (NES), the regulatory phosphorylation sites Ser(218) and Ser(222), and a regulatory domain at the N terminus. After disrupting the NES (Delta 32-37), nuclear uptake of MKK was enhanced when quiescent cells were activated with serum-phorbol 12-myristate 13-acetate or BXB-Raf-1 cotransfection. Uptake was enhanced by mutation of Ser(218) and Ser(222) to Glu and Asp, respectively, and blocked by mutation of these residues to Ala, although mutation of Lys(97) to Met, which renders MKK catalytically inactive, did not interfere with uptake. Therefore, nuclear uptake of MKK requires incorporation of phosphate or negatively charged residues at the activation lip but not enzyme activity. On the other hand, uptake of an active MKK mutant with disrupted NES (Delta 32-51) was elevated in quiescent as well as stimulated cells, and pretreatment of cells with the MKK inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene blocked nuclear uptake. Thus, signaling downstream of MKK is also necessary for translocation. Finally, wild type MKK containing an intact NES translocates to nuclei during mitosis before envelope breakdown. Comparison of mutants with Ser to Glu and Asp or Ala substitutions indicates that Ser phosphorylation is also required for mitotic nuclear uptake of MKK.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Promega Corp, Madison, WI 53711 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Promega Corporation	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	ahnn@spot.colorado.edu	Tolwinski, Nicholas/Q-5782-2019; Tolwinski, Nicholas/D-1481-2014	Tolwinski, Nicholas/0000-0002-8507-2737; 	NIGMS NIH HHS [R01-GM48521, F32 GM18151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521, F32GM018151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1996, J CELL SCI, V109, P239; CHENG HN, 1992, MAKROMOL CHEM-THEOR, V1, P415; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	34	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6168	6174		10.1074/jbc.274.10.6168	http://dx.doi.org/10.1074/jbc.274.10.6168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037701	hybrid			2022-12-27	WOS:000078902800023
J	Gemel, J; Jacobsen, C; MacArthur, CA				Gemel, J; Jacobsen, C; MacArthur, CA			Fibroblast growth factor-8 expression is regulated by intronic engrailed and Pbx1-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; INT-2 GENE; GROWTH-FACTOR-4 ENHANCER; SEQUENCE HOMOLOGY; MOUSE DEVELOPMENT; BINDING PROTEINS; VERTEBRATE LIMB; MESSENGER-RNA; STEM-CELLS; FGF-8 GENE	Fibroblast growth factor-8 (FGF8) plays a critical role in vertebrate development and is expressed normally in temporally and spatially restricted regions of the vertebrate embryo. We now report on the identification of regions of Fgf8 important for its transcriptional regulation in murine ES cell-derived embryoid bodies. Stable transfection of ES cells, using a human growth hormone reporter gene, was employed to identify regions of the Fgf8 gene with promoter/enhancer activity. A 2-kilobase 5' region of Fgf8 was shown to contain promoter activity. A 0.8-kilobase fragment derived from the large intron of Fgf8 was found to enhance human growth hormone expressed from the Fgf8 promoter 3-4-fold in an orientation dependent manner. The intronic fragment contains DNA-binding sites for the AP2, Pbx1, and Engrailed transcription factors. Gel shift and Western blot experiments documented the presence of these transcription factors in nuclear extracts from ES cell embryoid bodies. In vitro mutagenesis of the Engrailed or Pbx1 site demonstrated that these sites modulate the activity of the intronic fragment. In addition, in vitro mutagenesis of both Engrailed and Pbx1 sites indicated that other unidentified sites are responsible for the transcriptional enhancement observed with the intronic fragment.	Washington Univ, Sch Med, Dept Pediat & Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	MacArthur, CA (corresponding author), Washington Univ, Sch Med, Dept Pediat & Pathol, Campus Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA070106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 70106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hogan B, 1994, MANIPULATING MOUSE E; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Lee SMK, 1997, DEVELOPMENT, V124, P959; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; LORENZI MV, 1995, ONCOGENE, V10, P2051; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MacArthur CA, 1997, GENOMICS, V42, P137, DOI 10.1006/geno.1997.4353; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAGIN TM, 1992, GENE, V122, P289, DOI 10.1016/0378-1119(92)90217-D; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Payson RA, 1996, ONCOGENE, V13, P47; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; Rohrer J, 1998, BLOOD, V91, P214, DOI 10.1182/blood.V91.1.214.214_214_221; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; TOBIAS KE, 1995, ONCOGENE, V11, P1721; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Vogel A, 1996, DEVELOPMENT, V122, P1737; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WURST W, 1994, DEVELOPMENT, V120, P2065; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	55	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					6020	6026		10.1074/jbc.274.9.6020	http://dx.doi.org/10.1074/jbc.274.9.6020			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026229	hybrid			2022-12-27	WOS:000078804400100
J	Wu, TH; Marinus, MG				Wu, TH; Marinus, MG			Deletion mutation analysis of the mutS gene in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BASE PAIRS; MISMATCH REPAIR; GENOME INSTABILITY; ATP HYDROLYSIS; PROTEIN; BINDS	The MutS protein is part of the dam-directed MutHLS mismatch repair pathway in Escherichia coli. We have constructed deletion derivatives in the mutS gene, which retain the P-loop coding region for ATP binding. The mutant proteins were assayed for ATP hydrolysis, heteroduplex DNA binding, heterodimer mutS formation, and the ability to interact with MutL. Dimerization was assayed by expressing His(6)-tagged wild-type and non-tagged deletion mutant proteins in the same cell and isolating the His(6)-tagged protein followed by MutS immunoblotting after SDS-polyacrylamide gel electrophoresis. MutS-MutL interaction was measured using the same technique except that the MutL protein carried the His, tag. Our results indicate that DNA binding ability resides in the N-terminal end of MutS, and dimerization and MutL interactions are located in the C-terminal end. Given the extensive amino acid homology in the MutS family our results with E. coli should be applicable to MutS homologues in other prokaryotes and eukaryotes.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Marinus, MG (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, 55 Lake Ave, Worcester, MA 01655 USA.	Martin.Marinus@ummed.edu			NIGMS NIH HHS [GM33233] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033233] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Eisen JA, 1998, NUCLEIC ACIDS RES, V26, P4291, DOI 10.1093/nar/26.18.4291; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Horst JP, 1999, TRENDS MICROBIOL, V7, P29, DOI 10.1016/S0966-842X(98)01424-3; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tachiki H, 1998, NUCLEIC ACIDS RES, V26, P4153, DOI 10.1093/nar/26.18.4153; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; WU TH, 1990, GENE, V87, P1, DOI 10.1016/0378-1119(90)90488-D; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	20	46	46	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5948	5952		10.1074/jbc.274.9.5948	http://dx.doi.org/10.1074/jbc.274.9.5948			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026220	hybrid			2022-12-27	WOS:000078804400091
J	Chen, JK; Wang, DW; Falck, JR; Capdevila, J; Harris, RC				Chen, JK; Wang, DW; Falck, JR; Capdevila, J; Harris, RC			Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular second messenger in response to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EPOXYEICOSATRIENOIC ACIDS; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; SMOOTH-MUSCLE; RAT-KIDNEY; CELLS; METABOLITES; CASCADE	A common feature of most isolated cell systems is low or undetectable levels of bioactive cytochrome P450. We therefore developed stable transfectants of the renal epithelial cell line, LLCPKc14, that expressed an active regio- and enantioselective arachidonic acid (AA) epoxygenase, Site-specific mutagenesis was used to convert bacterial P450 BM-3 into an active regio- and stereoselective 14S,15R-epoxygenase (F87V BM-3). In clones expressing F87V BM-3 (F87V BM-3 cells), exogenous AA induced significant 14S,15R-epoxyeicosatrienoic acid (EET) production (241.82 ng/10(8) cells, >97% of total EETs), whereas no detectable EETs were seen in cells transfected with vector alone. In F87V BM-3 cells, AA stimulated [H-3]thymidine incorporation and increased cell proliferation, which was blocked by the tyrosine kinase inhibitor, genistein, by the phosphatidylinositol 3 (PI-3) kinase inhibitors, wortmannin and LY294002, and by the mitogen-activated protein kinase kinase inhibitor, PD98059. AA also induced tyrosine phosphorylation of extracellular signal-regulated kinase (ERK) and PI-3 kinase that was inhibited by the cytochrome P450 BM-3 inhibitor, 17-ODYA. Epidermal growth factor (EGF) increased EET production in F87V BM-3 cells, which was completely abolished by pretreatment with either 17-ODYA or the phospholipase A(2) (PLA(2)) inhibitor, quinacrine, Compared with vector-transfected cells, F87 BM-3 transfected cells demonstrated marked increases in both the extent and sensitivity of DNA synthesis in response to EGF. These changes occurred in the absence of significant differences in EGF receptor expression. As seen with exogenous AA, EGF increased ERK tyrosine phosphorylation to a significantly greater extent in F87V BM-3 cells than in vector-transfected cells. Furthermore, in these control cells, neither 17-ODYA nor quinacrine inhibited EGF-induced ERK tyrosine phosphorylation. On the other hand, in F87V BM-3 cells, both inhibitors reduced ERK tyrosine phosphorylation to levels indistinguishable from that seen in cells transfected with vector alone. These studies provide the first unequivocal evidence for a role for the AA epoxygenase pathway and endogenous EET synthesis in EGF-mediated signaling and mitogenesis and provide compelling evidence for the PL2-AA-EET pathway as an important intracellular-signaling pathway in cells expressing high levels of cytochrome P450 epoxygenase.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Univ Texas SW, Dept Biochem, Dallas, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, S 3322,MCN, Nashville, TN 37232 USA.	Ray.Harris@mcmail.vanderbilt.edu		Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; BAKER RR, 1990, CLIN BIOCHEM, V23, P455; BURNS KD, 1995, AM J PHYSIOL-CELL PH, V269, pC831, DOI 10.1152/ajpcell.1995.269.4.C831; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DIMARZO V, 1995, PROSTAG LEUKOTR ESS, V53, P239, DOI 10.1016/0952-3278(95)90123-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; Li PL, 1997, CIRC RES, V80, P877; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Needleman P, 1997, J RHEUMATOL, V24, P6; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; RIBEIRO CMP, 1994, AM J PHYSIOL, V266, pF497, DOI 10.1152/ajprenal.1994.266.3.F497; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Straub SG, 1996, J BIOL CHEM, V271, P1660, DOI 10.1074/jbc.271.3.1660; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; Vane JR, 1997, SEMIN ARTHRITIS RHEU, V26, P2, DOI 10.1016/S0049-0172(97)80046-7; VANROLLINS M, 1995, BBA-LIPID LIPID MET, V1256, P263, DOI 10.1016/0005-2760(95)00029-C; WONG PYK, 1993, J LIPID MEDIATOR, V6, P199; Wong PYK, 1997, J LIPID MEDIAT CELL, V16, P155, DOI 10.1016/S0929-7855(97)00005-9	36	97	105	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4764	4769		10.1074/jbc.274.8.4764	http://dx.doi.org/10.1074/jbc.274.8.4764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988714	hybrid			2022-12-27	WOS:000078698200039
J	Choi, JY; Martin, CE				Choi, JY; Martin, CE			The Saccharomyces cerevisiae FAT1 gene encodes an acyl-CoA synthetase that is required for maintenance of very long chain fatty acid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ADRENOLEUKODYSTROPHY GENE; TRANSPORT PROTEIN; OLE1 GENE; RAT-LIVER; ACTIVATION; ELONGATION; EXPRESSION; BINDING; CLONING; IDENTIFICATION	The Saccharomyces cerevisiae FAT1 gene appears to encode an acyl-CoA synthetase that is involved in the regulation of very long chain (C-20-C-26) fatty acids. Fat1p, has homology to a rat peroxisomal very long chain fatty acyl-CoA synthetase, Very long chain acyl-CoA synthetase activity is reduced in strains containing a disrupted FAT1 gene and is increased when FAT1 is expressed in insect cells under control of a baculovirus promoter. Fat1p accounts for approximately 90% of the C-24-specific acyl-CoA synthetase activity in glucose-grown cells and approximately 66% of the total activity in cells grown under peroxisomal induction conditions. Localization of functional Fat1p:green fluorescent protein gene fusions and subcellular fractionation of C-24 acyl-CoA synthetase activities indicate that the majority of Fat1p is located in internal cellular locations. Disruption of the FAT1 gene results in the accumulation of very long chain fatty acids in the sphingolipid and phospholipid fractions. This includes a 10-fold increase in C-24 acids and a 6-fold increase in C-22 acids. These abnormal accumulations are further increased by perturbation of very long chain fatty acid synthesis. Overexpression of Elo2p, a component of the fatty acid elongation system, in fat1 Delta cells causes C-20-C-26 levels to rise to approximately 20% of the total fatty acids. These data suggest that Fat1p is involved in the maintenance of cellular very long chain fatty acid levels, apparently by facilitating beta-oxidation of excess intermediate length (C-20-C-24) species. Although fat1 Delta cells were reported to grow poorly in oleic acid-supplemented medium when fatty acid synthase activity is inactivated by cerulenin, fatty acid import is not significantly affected in cells containing disrupted alleles of FAT1 and FAS2 (a subunit of fatty acid synthase). These results suggest that the primary cause of the growth-defective phenotype is a failure to metabolize the incorporated fatty acid rather than a defect in fatty acid transport. Certain fatty acyl-CoA synthetase activities, however, do appear to be essential for bulk fatty acid transport in Saccharomyces, Simultaneous disruption of FAA1 and FAA4, which encode long chain (C-14-C-18) fatty acyl-CoA synthetases, effectively blocks the import of long chain saturated and unsaturated fatty acids.	Rutgers State Univ, Nelson Biol Labs, Bur Biol Res, Dept Cell Biol & Neurosci,Div Life Sci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Martin, CE (corresponding author), Rutgers State Univ, Nelson Biol Labs, Bur Biol Res, Dept Cell Biol & Neurosci,Div Life Sci, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi JY, 1996, J BIOL CHEM, V271, P3581; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; DOUAR AM, 1994, BIOMED PHARMACOTHER, V48, P215, DOI 10.1016/0753-3322(94)90135-X; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KALISH JE, 1995, BIOCHEM BIOPH RES CO, V206, P335, DOI 10.1006/bbrc.1995.1046; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NUNN WD, 1986, J BIOL CHEM, V261, P167; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V254, P526, DOI 10.1016/0003-9861(87)90133-0; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Swartzman EE, 1996, J CELL BIOL, V132, P549, DOI 10.1083/jcb.132.4.549; THIERINGER R, 1991, MOL CELL BIOL, V11, P510, DOI 10.1128/MCB.11.1.510; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANDERS RJA, 1987, BIOCHIM BIOPHYS ACTA, V919, P21, DOI 10.1016/0005-2760(87)90213-X	32	68	76	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4671	4683		10.1074/jbc.274.8.4671	http://dx.doi.org/10.1074/jbc.274.8.4671			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988704	hybrid			2022-12-27	WOS:000078698200029
J	Herrington, J; Rui, LY; Luo, GY; Yu-Lee, LY; Carter-Su, C				Herrington, J; Rui, LY; Luo, GY; Yu-Lee, LY; Carter-Su, C			A functional DNA binding domain is required for growth hormone-induced nuclear accumulation of Stat5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; GLUCOCORTICOID RECEPTOR; GENE ACTIVATION; MAMMARY TISSUE; SH3 DOMAINS; RAT-LIVER; FACTOR-I	The mechanisms regulating the cellular distribution of STAT family transcription factors remain poorly understood. To identify regions of Stat5B required for ligand-induced nuclear accumulation, we constructed a cDNA encoding green fluorescent protein (GFP) fused to the N terminus of Stat5B and performed site-directed mutagenesis. When co-expressed with growth hormone (GH) receptor in COS-7 cells, GFP-Stat5B is tyrosylphosphorylated, forms dimers, and binds DNA in response to GH in a manner indistinguishable from untagged Stat5B. In multiple cell types, laser scanning confocal imaging of GFP-Stat5B co-expressed with GH receptor shows that GFP-Stat5B undergoes a rapid, dramatic accumulation in the nucleus upon GH stimulation. We introduced alanine substitutions in several regions of Stat5B and assayed for GH-dependent nuclear localization. Only the mutation that prevented binding to DNA ((VVVI469)-V-466) abrogated GH-stimulated nuclear localization. This mutant fusion protein is tyrosyl-phosphorylated and dimerizes in response to GH. These results suggest that either high affinity binding to DNA contributes to nuclear accumulation of Stat5B or that this region is crucial for two functions, namely accumulation of Stat5B in the nucleus and DNA binding. Thus, we have identified a mutant Stat5 defective in nuclear localization despite its ability to be tyrosyl-phosphorylated and to dimerize.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Michigan System; University of Michigan; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 6804 Med Sci 2,1301 Catherine St, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK044625, F32DK009756] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK034171, R01-DK-34171, R01-DK-44625, F32-DK-09756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang YF, 1996, MOL CELL ENDOCRINOL, V121, P19, DOI 10.1016/0303-7207(96)03840-3; WATERS MJ, 1994, P SOC EXP BIOL MED, V206, P216; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	49	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5138	5145		10.1074/jbc.274.8.5138	http://dx.doi.org/10.1074/jbc.274.8.5138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988763	hybrid			2022-12-27	WOS:000078698200088
J	Oran, AE; Isenman, DE				Oran, AE; Isenman, DE			Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; GROWTH-HORMONE RECEPTOR; 3RD COMPONENT; BINDING-SITES; FACTOR-B; FACTOR-I; REGULATORY DOMAINS; ABOLISH BINDING; LIGAND-BINDING; CR-1	Mapping approaches employing blocking antibodies and synthetic peptides have implicated the 727-767 segment at the NH2 terminus of C3b alpha'-chain as contributing to the interactions with factor B, factor H, and CR1. Our previous mutagenesis study on the NH2-terminal acidic cluster of this segment identified residues Glu-736 and Glu-737 as contributing to the binding of C3b to factor B and CR1 but not factor H, We have now extended the charged residue mutagenic scan to cover the remainder of the segment (738-767) and have assessed the ability of the C3b-like C3(H2O) form of the mutant molecules to interact with factor H, CR1, and membrane cofactor protein (MCP) using a cofactor-dependent factor I cleavage assay as a surrogate binding assay. We have found that the negatively charged side chains of Glu-744 and Glu-747 are important for the interaction between C3(H2O) and factor H, a result in general agreement with an earlier synthetic peptide study (Fishelson, Z. (1991) Mol. Immunol. 28, 545-552) which implicated residues within the 744-754 segment in H binding. The interactions of the mutants with soluble CR1 (sCR1) revealed two classes of residues. The first are residues required for sCR1 to be an I cofactor for the first two cleavages of alpha-chain, These are all acidic residues and include the Glu-736/Glu-737 pair, Glu-747, and the Glu-754/Asp-755 pairing, The second class affects only the ability of sCR1 to be a cofactor for the third factor I cleavage and include Glu-744 and the Lys-757/Glu-758 pairing, The dominance of acidic residues in the loss-of-function mutants is striking and suggests that H and CR1 contribute basic residues to the interface. Additionally, although there is partial overlap, the contacts required for CR1 binding appear to extend over a wider portion of the 727-767 segment than is the case for factor H, Finally, none of the mutations had any effect on the interaction between soluble MCP and C3(H2O), indicating that despite its functional homology to H and CR1, MCP differs in its mode of binding to C3b/C3(H2O).	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Isenman, DE (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	d.isenman@utoronto.ca						ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1992, DEV COMP IMMUNOL, V16, P63, DOI 10.1016/0145-305X(92)90052-E; ALSENZ J, 1990, CURR TOP MICROBIOL, V153, P235; ARNAOUT MA, 1983, IMMUNOLOGY, V48, P229; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029; BECHERER JD, 1988, J BIOL CHEM, V263, P14586; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; COLE FS, 1985, J IMMUNOL, V134, P2610; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; COOPER NR, 1968, IMMUNOCHEMISTRY, V5, P155, DOI 10.1016/0019-2791(68)90100-6; COYNE KE, 1992, J IMMUNOL, V149, P2906; DIEFENBACH RJ, 1995, J IMMUNOL, V154, P2303; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; EBANKS RO, 1992, J IMMUNOL, V148, P2803; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FARRIES TC, 1990, COMPLEMENT INFLAMMAT, V7, P30, DOI 10.1159/000463124; FARRIES TC, 1996, MOL IMMUNOL S1, V33, P58; FISHELSON Z, 1991, MOL IMMUNOL, V28, P545, DOI 10.1016/0161-5890(91)90169-K; GAITHER TA, 1987, IMMUNOLOGY, V62, P405; GANU V S, 1985, Complement, V2, P27; GARRED P, 1989, COMPLEMENT INFLAMMAT, V6, P205, DOI 10.1159/000463094; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GOTZE O, 1971, J EXP MED, V134, pS90; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; KUHN S, 1995, J IMMUNOL, V155, P5663; LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lambris JD, 1996, J IMMUNOL, V156, P4821; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; MATHIAS P, 1992, P NATL ACAD SCI USA, V89, P8125, DOI 10.1073/pnas.89.17.8125; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; NAGASAWA S, 1980, J IMMUNOL, V125, P578; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; RAPP HJ, 1970, MOL BASIS COMPLEMENT, P9; ROSS GD, 1982, J IMMUNOL, V129, P2051; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; TANIGUCHISIDLE A, 1992, J BIOL CHEM, V267, P635; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; YOUNG L, 1994, PROTEIN SCI, V3, P717	57	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5120	5130		10.1074/jbc.274.8.5120	http://dx.doi.org/10.1074/jbc.274.8.5120			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988761	hybrid			2022-12-27	WOS:000078698200086
J	Van Brocklyn, JR; Tu, ZX; Edsall, LC; Schmidt, RR; Spiegel, S				Van Brocklyn, JR; Tu, ZX; Edsall, LC; Schmidt, RR; Spiegel, S			Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; SURFACE-RECEPTOR; EXTRACELLULAR ACTION; SIGNAL-TRANSDUCTION; MEMBRANE-RECEPTOR; 3T3 FIBROBLASTS; SMOOTH-MUSCLE; HIGH-AFFINITY; SPHINGOSINE-1-PHOSPHATE	Sphingosine 1-phosphate (SPP) is a lipid second messenger that also acts as a first messenger through the G protein-coupled receptor Edg-1. Here we show that SPP also binds to the related receptors H218 and Edg-3 with high affinity and specificity. SPP and sphinganine 1-phosphate bind to these receptors, whereas neither sphingosylphosphorylcholine nor lysophosphatidic acid compete with SPP for binding to either receptor. Transfection of HER293 cells with H218 or edg-3, but not edg-1, induces rounded cell morphology in the presence of serum, which contains high levels of SPP. SPP treatment of cells overexpressing H218 cultured in delipidated serum causes cell rounding. A similar but less dramatic effect was observed in cells overexpressing Edg-3 but not with Edg-1. Cell rounding was correlated with apoptotic cell death, probably as a result of loss of attachment. Nerve growth factor-induced neuritogenesis in PC12 cells was inhibited by overexpression of H218 and to a lesser extent Edg-3. SPP treatment rapidly enhanced neurite retraction in PC12 cells overexpressing Edg-1, Edg-3, or H218. Thus, H218, and possibly Edg-3, may be the cell surface receptors responsible for cell rounding and neurite retraction induced by SPP. Moreover, the identification of these two additional SPP receptors indicates that a family of highly specific receptors exists that mediate different responses to SPP.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Konstanz, Fak Chem, D-78457 Constance, Germany	Georgetown University; University of Konstanz	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 357 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.		Van Brocklyn, Jim/A-9733-2010		NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019209] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM19209-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; Edsall LC, 1997, J NEUROSCI, V17, P6952; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; Kleuser B, 1998, CANCER RES, V58, P1817; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; MacLennan AJ, 1997, NEUROSCIENCE, V79, P217, DOI 10.1016/S0306-4522(96)00601-X; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P329, DOI 10.1006/bbrc.1997.7666; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; SPIEGEL S, 1998, ANN NY ACAD SCI, V845, P1; Tarnowski A, 1997, BIOORG MED CHEM LETT, V7, P573, DOI 10.1016/S0960-894X(97)00047-4; Tas PWL, 1998, J NEUROSCI RES, V52, P427, DOI 10.1002/(SICI)1097-4547(19980515)52:4<427::AID-JNR6>3.0.CO;2-B; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; Yamamura S, 1996, FEBS LETT, V382, P193, DOI 10.1016/0014-5793(96)00175-5; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	51	165	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4626	4632		10.1074/jbc.274.8.4626	http://dx.doi.org/10.1074/jbc.274.8.4626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988698	hybrid			2022-12-27	WOS:000078698200023
J	Yamamoto, K; Takeshima, H; Hamada, K; Nakao, M; Kino, T; Nishi, T; Kochi, M; Kuratsu, J; Yoshimura, T; Ushio, Y				Yamamoto, K; Takeshima, H; Hamada, K; Nakao, M; Kino, T; Nishi, T; Kochi, M; Kuratsu, J; Yoshimura, T; Ushio, Y			Cloning and functional characterization of the 5 '-flanking region of the human monocyte chemoattractant protein-1 receptor (CCR2) gene - Essential role of 5 '-untranslated region in tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; GLIOMA; HIV-1; ORGANIZATION; INFILTRATION; SEQUENCE; CELLS	The human monocyte chemoattractant protein-1 receptor designated hCCR2 is an essential co-receptor in cell entry by the human immunodeficiency virus as well as a receptor for monocyte chemoattractant protein-1, a member of the family of C-C chemokines that mediate monocyte chemotaxis, To elucidate the molecular mechanisms underlying the transcriptional regulation of hCCR2, we cloned and sequenced the hCCR2 gene; it was approximately 8 kilobase pairs in length and consisted of three exons divided by two introns, In the 5'-flanking region, there were the typical mammalian promoter consensus elements, a CAAT box and a TATA box, resulting in a single transcription initiation site. In addition, we found clustered tissue-specific cis-regulatory elements such as GATA consensus sequences, Oct-1 binding sequences, and CAAT/enhancer-binding protein binding sequences, Luciferase assays with various promoter deletions and gel mobility shift assays indicated that three cis-regulatory elements located within the region from -89 to +118 are required for basal activity in THP-1 cells. One element is an octamer sequence 36-base pair upstream from the TATA box; it binds mainly to Oct-1 and is capable of increasing transcriptional activity. The other two elements, which are tandem recognition sites of the CAAT/enhancer-binding protein family, are located in the 5'-untranslated region and account for the transcriptional activation as well as the tissue specificity of hCCR2.	Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kagoshima Univ, Sch Med, Dept Neurosurg, Kagoshima 8908520, Japan; NCI, Immunopathol Sect, Immunol Lab, NIH, Frederick, MD 21702 USA	Kumamoto University; Kumamoto University; Kagoshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Takeshima, H (corresponding author), Kumamoto Univ, Sch Med, Dept Neurosurg, 1-1-1 Honjo, Kumamoto 8608556, Japan.	m2040@kaiju.medic.kumamoto-u.ac.jp		Yoshimura, Teizo/0000-0002-3853-2075				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; AMROLIA PJ, 1995, J BIOL CHEM, V270, P12892, DOI 10.1074/jbc.270.21.12892; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIEDERICH M, 1993, FEBS LETT, V332, P88, DOI 10.1016/0014-5793(93)80490-L; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; KASHIWAGI K, 1991, BIOCHEM BIOPH RES CO, V178, P815, DOI 10.1016/0006-291X(91)90964-9; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; KURATSU J, 1989, J NATL CANCER I, V81, P347, DOI 10.1093/jnci/81.5.347; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Meroni G, 1996, EUR J BIOCHEM, V236, P373, DOI 10.1111/j.1432-1033.1996.00373.x; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NISHI T, 1991, ONCOGENE, V6, P1555; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; TAKESHIMA H, 1994, J NEUROSURG, V80, P1056, DOI 10.3171/jns.1994.80.6.1056; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; UEDA A, 1994, J IMMUNOL, V153, P2052; WALTER S, 1991, INT J CANCER, V49, P431, DOI 10.1002/ijc.2910490321; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; YAMASHIRO S, 1994, AM J PATHOL, V145, P856; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; Yoshimura T, 1992, Cytokines, V4, P131	33	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4646	4654		10.1074/jbc.274.8.4646	http://dx.doi.org/10.1074/jbc.274.8.4646			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988701	hybrid			2022-12-27	WOS:000078698200026
J	Alemany, R; Heringdorf, DMZ; van Koppen, CJ; Jakobs, KH				Alemany, R; Heringdorf, DMZ; van Koppen, CJ; Jakobs, KH			Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; 2ND MESSENGER; CALCIUM MOBILIZATION; HUMAN NEUTROPHILS; SPHINGOSINE-1-PHOSPHATE; TRANSDUCTION; PROLIFERATION; DERIVATIVES; INHIBITION; PLATELETS	Sphingosine-1-phosphate (SPP) produced from sphingosine by sphingosine kinase has recently been reported to act as intracellular second messenger for a number of plasma membrane receptors. In the present study, we investigated whether the sphingosine kinase/SPP pathway is involved in cellular signaling of the G(i) protein-coupled formyl peptide receptor in myeloid differentiated human leukemia (HL-60) cells. Receptor activation resulted in rapid and transient production of SPP by sphingosine kinase, which was abolished after pertussis toxin treatment. Direct activation of heterotrimeric G proteins by AlF4-, also rapidly increased SPP formation in intact HL-60 cells. In cytosolic preparations of HL-60 cells, sphingosine kinase activity was stimulated by the stable GTP analog, guanosine 5'-O-(3-thiotriphosphate). Inhibition of sphingosine kinase by DL-threo-dihydrosphingosine and N,N-dimethylsphingosine did not affect phospholipase C stimulation and superoxide production but markedly inhibited receptor-stimulated Ca2+ mobilization and enzyme release. We conclude that the formyl peptide receptor stimulates through G(i)-type G proteins SPP production by sphingosine kinase, that the enzyme is also stimulated by direct G protein activation, and that the sphingosine kinase/SPP pathway apparently plays an important role in chemoattractant signaling in myeloid differentiated HL-60 cells.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	Jakobs, KH (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.	karl.jakobs@uni-essen.de	Alemany, Regina/A-2314-2011; Heringdorf, Dagmar Meyer zu/A-7705-2018	Heringdorf, Dagmar Meyer zu/0000-0003-1246-9677; Alemany, Regina/0000-0003-2180-1213				Absolom D R, 1986, Methods Enzymol, V132, P95; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Heringdorf DMZ, 1998, EUR J PHARMACOL, V354, P113, DOI 10.1016/S0014-2999(98)00436-1; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Mathias RS, 1998, AM J PHYSIOL-CELL PH, V274, pC1456, DOI 10.1152/ajpcell.1998.274.6.C1456; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NUBE O, 1997, J BIOL CHEM, V272, P28360; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Qiao LX, 1998, BIOORG MED CHEM LETT, V8, P711, DOI 10.1016/S0960-894X(98)00112-7; RIDLEY AJ, 1995, CURR BIOL, V5, P710, DOI 10.1016/S0960-9822(95)00140-0; SCHMIDT M, 1995, N-S ARCH PHARMACOL, V352, P469, DOI 10.1007/BF00169379; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P164; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; vanKoppen CJ, 1996, MOL PHARMACOL, V49, P956; WENZELSEIFERT K, 1990, IMMUNOBIOLOGY, V181, P298, DOI 10.1016/S0171-2985(11)80499-7; WIELAND T, 1995, N-S ARCH PHARMACOL, V351, P329, DOI 10.1007/BF00169072; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3	34	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3994	3999		10.1074/jbc.274.7.3994	http://dx.doi.org/10.1074/jbc.274.7.3994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933590	hybrid			2022-12-27	WOS:000078575500014
J	Jamieson, L; Carpenter, L; Biden, TJ; Fields, AP				Jamieson, L; Carpenter, L; Biden, TJ; Fields, AP			Protein kinase C iota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PHOSPHATIDYLINOSITOL 3-KINASE; PHILADELPHIA-CHROMOSOME; CELL-PROLIFERATION; K562 CELLS; DIFFERENTIATION; IDENTIFICATION; P210(BCR/ABL); INHIBITION; TRANSITION	K562 chronic myelogenous leukemia cells are highly resistant to chemotherapeutic drugs, such as taxol, that induce cell death by apoptosis. This resistance is mediated by the chimeric tyrosine kinase oncogene Bcr-Abl. However, little is known about the mechanism by which Bcr-Abl protects K562 cells from apoptosis. We recently demonstrated that expression of PKC iota is necessary for the resistance of K562 cells to taxol-induced apoptosis (Murray, N. R., and Fields, A. P. (1997) J. Biol. Chem. 272, 27521-27524). We now demonstrate that treatment of K562 cells with taxol leads to sustained activation of PKC iota. In contrast, Bcr-Abl-negative HL60 myeloid leukemia cells, which are sensitive to taxol-induced apoptosis, do not exhibit sustained PKC iota activation in response to taxol, Treatment of K562 cells with tyrphostin AG957, a selective Bcr-Abl inhibitor, blocks taxol-induced PKC iota activation and sensitizes these cells to taxol-induced apoptosis, indicating that PKC iota is a relevant downstream target of Bcr-Abl-mediated resistance. Furthermore, expression of constitutively active PKC iota by adenovirus-mediated gene transfer rescues AG957-treated K562 cells from taxol-induced apoptosis. Taken together, these results demonstrate that both Bcr-Abl and PKC iota activity are necessary for apoptotic resistance in K562 cells, Furthermore, they identify PKC iota as a critical downstream target of Bcr-Abl that is sufficient to mediate the anti-apoptotic effects of Bcr-Abl.	Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Garvan Institute of Medical Research	Jamieson, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, 301 Univ Blvd, Galveston, TX 77555 USA.		Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234	NCI NIH HHS [CA56869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ANAFI M, 1993, BLOOD, V82, P3524; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beran M, 1998, CLIN CANCER RES, V4, P1661; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Deora AB, 1997, TUMORI, V83, P756, DOI 10.1177/030089169708300409; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOTOH A, 1994, LEUKEMIA, V8, P115; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Green D R, 1994, Important Adv Oncol, P37; HIDDEMANN W, 1993, CURR OPIN ONCOL, V5, P3; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; Kaur G, 1996, ANTI-CANCER DRUG, V7, P815, DOI 10.1097/00001813-199611000-00001; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McGahon AJ, 1997, CELL DEATH DIFFER, V4, P95, DOI 10.1038/sj.cdd.4400213; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; MURRAY NR, 1997, PROTEIN KINASE C, P97; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; OKADA T, 1994, J BIOL CHEM, V269, P3563; Riordan FA, 1998, ONCOGENE, V16, P1533, DOI 10.1038/sj.onc.1201680; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sattler M, 1996, ONCOGENE, V12, P839; SPESSOT R, 1989, VIROLOGY, V168, P378, DOI 10.1016/0042-6822(89)90279-1; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	33	102	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3927	3930		10.1074/jbc.274.7.3927	http://dx.doi.org/10.1074/jbc.274.7.3927			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933579	hybrid			2022-12-27	WOS:000078575500003
J	Puglielli, L; Mandon, EC; Rancour, DM; Menon, AK; Hirschberg, CB				Puglielli, L; Mandon, EC; Rancour, DM; Menon, AK; Hirschberg, CB			Identification and purification of the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CMP-SIALIC ACID; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; GALACTOSE TRANSPORTER; HEPARAN-SULFATE; PROTEIN; RECONSTITUTION; APPARATUS; PROTEOLIPOSOMES	Glycosylation of glycoproteins, proteoglycans, and glycosphingolipids occurs mainly in the lumen of the endoplasmic reticulum and the Golgi apparatus. Nucleotide sugars, donors of all the sugars involved in Golgis glycosylation reactions, are synthesized in the cytoplasm and require specialized transporters to be translocated into the lumen of the Golgi apparatus. By controlling the supply of sugar nucleotides in the lumen of the Golgi apparatus, these transporters directly regulate the glycosylation of macromolecules transiting the Golgi. We have identified and purified the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter. The transporter was purified to apparent homogeneity by a combination of conventional and dye color chromatography. An similar to 63,000-fold purification (6% yield) was achieved starting from crude rat liver Golgi membranes and resulting in a protein with an apparent molecular mass of 43 kDa. The transporter was active when reconstituted into phosphatidylcholine vesicles and could be specifically photolabeled with P-3-(4-azidoanilido)-uridine-5'-[p(1)-P-32]triphosphate, an analog of UDP-N-acetylgalactosamine. Native functional size determination on a glycerol gradient suggested that the transporter exists as a homodimer within the Golgi membrane.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01655 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Boston University; University of Massachusetts System; University of Massachusetts Worcester; University of Wisconsin System; University of Wisconsin Madison	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St,W200, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721; Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM34396, GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CAREY DJ, 1981, J BIOL CHEM, V256, P989; Delves PJ, 1998, AUTOIMMUNITY, V27, P239, DOI 10.3109/08916939808993836; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Fredman P, 1997, NEUROCHEM RES, V22, P1071, DOI 10.1023/A:1022495430583; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; Ishida N, 1996, J BIOCHEM, V120, P1074; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KOEPSELL H, 1986, REV PHYSIOL BIOCH P, V104, P65, DOI 10.1007/BFb0031013; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MILLA ME, 1992, J BIOL CHEM, V267, P103; MINTON AP, 1989, ANAL BIOCHEM, V176, P209, DOI 10.1016/0003-2697(89)90297-2; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; Rancour DM, 1998, BIOCHEM J, V333, P661, DOI 10.1042/bj3330661; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; Toma L, 1996, J BIOL CHEM, V271, P3897; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZELLER BR, 1992, AM J PHYSIOL, V262, pC1341	33	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4474	4479		10.1074/jbc.274.7.4474	http://dx.doi.org/10.1074/jbc.274.7.4474			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933652	hybrid			2022-12-27	WOS:000078575500076
J	Samejima, K; Svingen, PA; Basi, GS; Kottke, T; Mesner, PW; Stewart, L; Durrieu, F; Poirier, GG; Alnemri, ES; Champoux, JJ; Kaufmann, SH; Earnshaw, WC				Samejima, K; Svingen, PA; Basi, GS; Kottke, T; Mesner, PW; Stewart, L; Durrieu, F; Poirier, GG; Alnemri, ES; Champoux, JJ; Kaufmann, SH; Earnshaw, WC			Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTHERAPY-INDUCED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; SCLERODERMA PATIENTS; PROTEASE ACTIVATION; CATALYTIC ACTIVITY; DRUG CAMPTOTHECIN; LEUKEMIA-CELLS; NUCLEAR EVENTS	Previous studies have demonstrated that topoisomerase I is cleaved late during apoptosis, but have not identified the proteases responsible or examined the functional consequences of this cleavage. Here, we have shown that treatment of purified topoisomerase I with caspase-3 resulted in cleavage at DDVD(146)down arrow Y and EEED(170)down arrow G, whereas treatment with caspase-6 resulted in cleavage at pEDD(123)down arrow G and EEED(170)down arrow G. After treatment of Jurkat T lymphocytic leukemia cells with anti-Fas antibody or A549 lung cancer cells with topotecan, etoposide, or paclitaxel, the topoisomerase I fragment comigrated with the product that resulted from caspase-3 cleavage at DDVD(146)down arrow Y. In contrast, two discrete topoisomerase I fragments that appeared to result from cleavage at DDVD(146)down arrow Y and EEED(170)down arrow G; were observed after treatment of MDA-MB-468 breast cancer cells with paclitaxel. Topoisomerase I cleavage did not occur in apoptotic MCF-7 cells, which lack caspase-3. Cell fractionation and band depletion studies with the topoisomerase I poison topotecan revealed that the topoisomerase I fragment remains in proximity to the chromatin and retains the ability to bind to and cleave DNA. These observations indicate that topoisomerase I is a substrate of caspase-3 and possibly caspase-6, but is cleaved at sequences that differ from those ordinarily preferred by these enzymes, thereby providing a potential explanation why topoisomerase I cleavage lags behind that of classical caspase substrates such as poly(ADP-ribose) polymerase and lamin B-1.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Athena Neurosci Inc, San Francisco, CA 94080 USA; Thomas Jefferson Univ, Jefferson Canc Inst, Philadelphia, PA 19107 USA; CHU Laval, Res Ctr, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Ste Foy, PQ G1V 4G2, Canada; Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Edinburgh; Mayo Clinic; Jefferson University; Laval University; Laval University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Michael Swann Bldg,Kings Bldgs,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	bill.earnshaw@ed.ac.uk	Alnemri, Emad S/B-4526-2010; Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621; Poirier, Guy/0000-0002-4869-1424; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA069008, CA69008] Funding Source: Medline; NIA NIH HHS [AG13487] Funding Source: Medline; NIGMS NIH HHS [GM49156] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; BOCCHIERI MH, 1991, ARTHRITIS RHEUM, V34, P599, DOI 10.1002/art.1780340512; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BONA C, 1994, CURR OPIN IMMUNOL, V6, P931, DOI 10.1016/0952-7915(94)90016-7; Buckwalter CA, 1996, CANCER RES, V56, P1674; CasciolaRosen L, 1997, LUPUS, V6, P175, DOI 10.1177/096120339700600213; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1998, CELL DEATH DIFFER, V5, P183, DOI 10.1038/sj.cdd.4400336; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Costin Dan, 1994, V29B, P51; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; DOUVAS AS, 1979, J BIOL CHEM, V254, P10514; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; FAUBION WA, 1999, IN PRESS J CLIN INVE, V103; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HSIANG YH, 1988, CANCER RES, V48, P1722; Ibrado AM, 1996, CANCER RES, V56, P4743; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; MAUL GG, 1986, P NATL ACAD SCI USA, V83, P5145, DOI 10.1073/pnas.83.14.5145; McCloskey DE, 1996, CLIN CANCER RES, V2, P847; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Sugimoto K, 1998, BLOOD, V91, P1407, DOI 10.1182/blood.V91.4.1407; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry N A, 1997, Adv Pharmacol, V41, P155, DOI 10.1016/S1054-3589(08)61058-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1997, MOL CELL BIOL, V17, P6502, DOI 10.1128/MCB.17.11.6502; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wright SC, 1998, BIOCHEM BIOPH RES CO, V245, P797, DOI 10.1006/bbrc.1998.8508; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	72	87	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4335	4340		10.1074/jbc.274.7.4335	http://dx.doi.org/10.1074/jbc.274.7.4335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933635	hybrid			2022-12-27	WOS:000078575500059
J	Wilson, KF; Fortes, P; Singh, US; Ohno, M; Mattaj, IW; Cerione, RA				Wilson, KF; Fortes, P; Singh, US; Ohno, M; Mattaj, IW; Cerione, RA			The nuclear cap-binding complex is a novel target of growth factor receptor-coupled signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IDENTIFICATION; EXPORT; CDC42; CELLS; PHOSPHORYLATION; PATHWAY; ERBB3; RAC1	In an attempt to further understand how nuclear events (such as gene expression, nuclear import/export, and cell cycle checkpoint control) might be subject to regulation by extracellular stimuli, we sought to identify nuclear activities under growth factor control. Using a sensitive photoaffinity labeling assay that measured [alpha-P-32]GTP incorporation into nuclear proteins, we identified the 20-kDa subunit of the nuclear cap-binding complex (CBC) as a protein whose binding activity is greatly enhanced by the extracellular stimulation of serum-arrested cells. The CBC represents a 20- and 80-kDa heterodimer (the subunits independently referred to as CBP20 and CBP80, respectively) that binds the 7-methylguanosine cap on RNAs transcribed by RNA polymerase II. This binding facilitates precursor messenger RNA splicing and export. We have demonstrated that the [alpha-P-32]GTP incorporation into CBP20 was correlated with an increased ability of the CBC to bind capped RNA and have used the [alpha-P-32]GTP photoaffinity assay to characterize the activation of the CBC in response to growth factors. We show that the CBC is activated by heregulin in HeLa cells and by nerve growth factor in PC12 cells as well as during the G(1)/S phase of the cell cycle and when cells are stressed with UV irradiation. Additionally, we show that cap-dependent splicing of precursor mRNA, a functional outcome of CBC activation, can be catalyzed by growth factor addition to serum-arrested cells. Taken together, these data identify the CBC as a nuclear target for growth factor-coupled signal transduction and suggest novel mechanisms by which growth factors can influence gene expression and cell growth.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Cornell University; Cornell University; European Molecular Biology Laboratory (EMBL)	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.		Fortes, Puri/J-7872-2016	Fortes, Puri/0000-0001-7571-6220; Mattaj, Iain/0000-0002-5537-8284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZEN F, 1987, NUCLEIC ACIDS RES, V15, P6489, DOI 10.1093/nar/15.16.6489; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	31	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4166	4173		10.1074/jbc.274.7.4166	http://dx.doi.org/10.1074/jbc.274.7.4166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933612	hybrid			2022-12-27	WOS:000078575500036
J	Hudak, KA; Dinman, JD; Tumer, NE				Hudak, KA; Dinman, JD; Tumer, NE			Pokeweed antiviral protein accesses ribosomes by binding to L3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; N-GLYCOSIDASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; INACTIVATING PROTEINS; RNA; INHIBITION; COMPONENTS; IDENTIFICATION; REPLICATION; MUTATIONS	Pokeweed antiviral protein (PAP), a 29-kDa ribosome-inactivating protein, catalytically removes an adenine residue from the conserved alpha-sarcin loop of the large rRNA, thereby preventing the binding of eEF-2.GTP complex during protein elongation, Because the alpha-sarcin loop has been placed near the peptidyltransferase center in Escherichia coli ribosomes, we investigated the effects of alterations at the peptidyltransferase center on the activity of PAP, We demonstrate here that a chromosomal mutant of yeast, harboring the mak8-1 allele of peptidyltransferase-linked ribosomal protein L3 (RPL3), is resistant to the cytostatic effects of PAP. Unlike wild-type yeast, ribosomes from mak8-1 cells are not depurinated when PAP expression is induced in vivo, indicating that wild-type L3 is required for ribosome depurination, Co-immunoprecipitation studies show that PAP binds directly to L3 or Mak8-1p in vitro but does not physically interact with ribosome-associated Mak8-1p. L3 is required for PAP to bind to ribosomes and depurinate the 25 S rRNA, suggesting that it is located in close proximity to the alpha-sarcin loop. These results demonstrate for the first time that a ribosomal protein provides a receptor site for an ribosome-inactivating protein and allows depurination of the target adenine.	Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Plant Pathol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Program Mol Biosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Tumer, NE (corresponding author), Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA.	tumer@aesop.rutgers.edu		Dinman, Jonathan/0000-0002-2402-9698				ALEXANDER RW, 1994, BIOCHEMISTRY-US, V33, P12109, DOI 10.1021/bi00206a014; ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032; Cui Y, 1996, EMBO J, V15, P5726, DOI 10.1002/j.1460-2075.1996.tb00956.x; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1988, J BIOL CHEM, V263, P8735; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; IPPOLITI R, 1992, FEBS LETT, V298, P145, DOI 10.1016/0014-5793(92)80042-F; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; LINDSTROM JT, 1994, PLANT PHYSIOL, V106, P7, DOI 10.1104/pp.106.1.7; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; Muralikrishna P, 1997, NUCLEIC ACIDS RES, V25, P4562, DOI 10.1093/nar/25.22.4562; MURALIKRISHNA P, 1991, BIOCHEMISTRY-US, V30, P5421, DOI 10.1021/bi00236a014; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; OTTO JJ, 1993, METHOD CELL BIOL, V37, P119, DOI 10.1016/S0091-679X(08)60247-2; Peltz SW, 1999, MOL CELL BIOL, V19, P384; STOCKLEIN W, 1980, CURR GENET, V1, P177, DOI 10.1007/BF00390941; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; TRECO DA, 1993, CURRENT PROTOCOLS MO; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; VATER CA, 1995, J BIOL CHEM, V270, P12933, DOI 10.1074/jbc.270.21.12933; WICKNER RB, 1974, GENETICS, V76, P423; WICKNER RB, 1982, P NATL ACAD SCI-BIOL, V79, P4706, DOI 10.1073/pnas.79.15.4706; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0	32	94	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3859	3864		10.1074/jbc.274.6.3859	http://dx.doi.org/10.1074/jbc.274.6.3859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920941	hybrid			2022-12-27	WOS:000078428200081
J	Wehland, M; Kiecker, C; Coplin, DL; Kelm, O; Saenger, W; Bernhard, F				Wehland, M; Kiecker, C; Coplin, DL; Kelm, O; Saenger, W; Bernhard, F			Identification of an RcsA/RcsB recognition motif in the promoters of exopolysaccharide biosynthetic operons from Erwinia amylovora and Pantoea stewartii subspecies stewartii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CAPSULAR POLYSACCHARIDE SYNTHESIS; NITROGEN REGULATOR-I; COLANIC ACID; RCSA GENE; POSITIVE REGULATOR; DNA-BINDING; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION; ACTIVATOR PROTEIN	The regulation of capsule synthesis (Rcs) regulatory network is responsible for the induction of exopolysaccharide biosynthesis in many enterobacterial species. We have previously shown that two transcriptional regulators, RcsA and RcsB, do bind as a heterodimer to the promoter of amsG, the first reading frame in the operon for amylovoran biosynthesis in the plant pathogenic bacterium Erwinia amylovora. We now identified a 23-base pair fragment from position -555 to -533 upstream of the translational start site of amsG as sufficient for the specific binding of the Res proteins. In addition, we could detect an RcsA/RcsB-binding site in a corresponding region of the promoter of cpsA, the homologous counterpart to the E. amylovora amsG gene in the operon for stewartan biosynthesis of Pantoea stewartii. The specificity and characteristic parameters of the protein-DNA interaction were analyzed by DNA retardation, protein-DNA cross-linking, and directed mutagenesis, The central core motif TRVGAAWAWTSYG of the amsG promoter was found to be most important for the specific interaction with RcsA/RcsB, as evaluated by mutational analysis and an in vitro selection approach. The wild type P. stewartii Rcs binding motif is degenerated in two positions and an up-mutation according to our consensus motif resulted in about a 5-fold increased affinity of the RcsA/RcsB proteins.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Ohio State Univ, Dept Plant Pathol, Columbus, OH 43210 USA	Free University of Berlin; University System of Ohio; Ohio State University	Bernhard, F (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	fbern@fu-berlin.chemie.de	Kiecker, Clemens/C-7170-2009	Bernhard, Frank/0000-0002-4860-1783; Wehland, Markus/0000-0002-8160-859X				AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; ALLEN P, 1987, J GEN MICROBIOL, V133, P331; Bereswill S, 1997, J BACTERIOL, V179, P1354, DOI 10.1128/jb.179.4.1354-1361.1997; BERNHARD F, 1990, MOL PLANT MICROBE IN, V3, P429, DOI 10.1094/MPMI-3-429; BEVERIDGE TJ, 1991, MICROBIOL REV, V55, P684, DOI 10.1128/MMBR.55.4.684-705.1991; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHATTERJEE A, 1990, MOL PLANT MICROBE IN, V3, P144, DOI 10.1094/MPMI-3-144; COLEMAN M, 1990, J GEN MICROBIOL, V136, P1799, DOI 10.1099/00221287-136-9-1799; COPLIN DL, 1986, J BACTERIOL, V168, P619, DOI 10.1128/jb.168.2.619-623.1986; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; GERVAIS FG, 1992, J BACTERIOL, V174, P3964, DOI 10.1128/jb.174.12.3964-3971.1992; GOTTESMAN S, 1995, REGULATION CAPSULE S, P253; Gupte G, 1997, J BACTERIOL, V179, P4328, DOI 10.1128/jb.179.13.4328-4335.1997; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; HOOPES BC, 1987, ESCHERICHIA COLI SAL, P1231; HSU ST, 1978, PHYTOPATHOLOGY, V68, P351, DOI 10.1094/Phyto-68-351; JAYARATNE P, 1993, J BACTERIOL, V175, P5384, DOI 10.1128/JB.175.17.5384-5394.1993; KEENLEYSIDE WJ, 1992, J BACTERIOL, V174, P8, DOI 10.1128/jb.174.1.8-16.1992; Kelm O, 1997, MOL GEN GENET, V256, P72, DOI 10.1007/s004380050547; LANE D, 1992, MICROBIOL REV, V3, P455; LEIGH JA, 1992, ANNU REV MICROBIOL, V46, P307, DOI 10.1146/annurev.mi.46.100192.001515; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MCCALLUM KL, 1991, INFECT IMMUN, V59, P494, DOI 10.1128/IAI.59.2.494-502.1991; MERGAERT J, 1993, INT J SYST BACTERIOL, V43, P162, DOI 10.1099/00207713-43-1-162; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POETTER K, 1991, MOL GEN GENET, V229, P155, DOI 10.1007/BF00264225; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; ROITSCH T, 1990, J BACTERIOL, V172, P6054, DOI 10.1128/jb.172.10.6054-6060.1990; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Stout V, 1996, J BACTERIOL, V178, P4273, DOI 10.1128/jb.178.14.4273-4280.1996; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; TRISLER P, 1984, J BACTERIOL, V160, P184, DOI 10.1128/JB.160.1.184-191.1984; Virlogeux I, 1996, J BACTERIOL, V178, P1691, DOI 10.1128/jb.178.6.1691-1698.1996; WACHAROTAYANKUN R, 1992, J BACTERIOL, V174, P1063, DOI 10.1128/jb.174.3.1063-1067.1992; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	44	51	53	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3300	3307		10.1074/jbc.274.6.3300	http://dx.doi.org/10.1074/jbc.274.6.3300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920870	hybrid			2022-12-27	WOS:000078428200010
J	Parente, JA; Chen, XS; Zhou, CJ; Petropoulos, AC; Chew, CS				Parente, JA; Chen, XS; Zhou, CJ; Petropoulos, AC; Chew, CS			Isolation, cloning, and characterization of a new mammalian coronin family member, coronin(se), which is regulated within the protein kinase C signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-ACID SECRETION; ACTIN-BINDING-PROTEIN; WD-REPEAT; PARIETAL-CELLS; DICTYOSTELIUM; MEMBRANE; TRANSDUCTION; COMPARTMENT	In order to understand the regulatory role of protein kinase C (PKC) in secretory epithelia, it is necessary to identify and characterize specific downstream targets. We previously identified one such protein in studies of gastric parietal cells. This protein was referred to as pp66 because it migrated with an apparent molecular mass of 66 kDa on SDS-polyacrylamide gels. The phosphorylation of pp66 is increased by the cholinergic agonist, carbachol, and by the PKC activator, phorbol-12-myristate-13-acetate, in a calcium-independent manner. In this study, we have purified pp66 to homogeneity and cloned the complete open reading frame. GenBank(Tm) searches revealed a 45% homology with the Dictyostelium actin-binding protein, coronin, and similar to 67% homology with the previously cloned human and bovine coronin-like homologue, p57. pp66 appears to be most highly expressed in the gastrointestinal mucosa and in kidney and lung. Confocal microscopic studies of an enhanced green fluorescent protein fusion construct of pp66 in cultured parietal cells and in Madin-Darby canine kidney cells indicate that pp66 preferentially localizes in F-actin-rich regions. On the basis of our findings, we propose that pp66 may play an important, PKC-dependent role in regulating membrane/cytoskeletal rearrangements in epithelial cells. We have tentatively named this protein coronin(se), because it appears to be highly expressed in secretory epithelia.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chew, CS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Sanders R&E Bldg,Rm CB 2803, Augusta, GA 30912 USA.	cchew@mailer.mcg.edu			NIDDK NIH HHS [R37 DK31900, F32 DK 09447] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009447, R37DK031900] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BROWN MR, 1989, AM J PHYSIOL, V257, pG99, DOI 10.1152/ajpgi.1989.257.1.G99; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Calhoun BC, 1997, BIOCHEM J, V325, P559, DOI 10.1042/bj3250559; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; Chew CS, 1998, AM J PHYSIOL-CELL PH, V275, pC56, DOI 10.1152/ajpcell.1998.275.1.C56; CHEW CS, 1990, METHOD ENZYMOL, V191, P640; Chew CS, 1997, AM J PHYSIOL-GASTR L, V272, pG246, DOI 10.1152/ajpgi.1997.272.2.G246; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; GLUCK SL, 1996, ANNU REV PHYSIOL, V58, P27; Grogan A, 1997, J CELL SCI, V110, P3071; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Holt MR, 1998, INT J BIOCHEM CELL B, V30, P307, DOI 10.1016/S1357-2725(97)00101-5; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Maniatis T., 1989, MOL CLONING LAB MANU, Vsecond; MORRIS AP, 1994, ANNU REV PHYSIOL, V56, P371; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Okamoto CT, 1998, AM J PHYSIOL-CELL PH, V274, pC1017, DOI 10.1152/ajpcell.1998.274.4.C1017; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; Rauchenberger R, 1997, CURR BIOL, V7, P215, DOI 10.1016/S0960-9822(97)70093-9; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	38	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3017	3025		10.1074/jbc.274.5.3017	http://dx.doi.org/10.1074/jbc.274.5.3017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915840	hybrid			2022-12-27	WOS:000078319500058
J	Zaitseva, EM; Zaitsev, EN; Kowalczykowski, SC				Zaitseva, EM; Zaitsev, EN; Kowalczykowski, SC			The DNA binding properties of Saccharomyces cerevisiae Rad51 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI RECA PROTEIN; DEPENDENT ATPASE ACTIVITY; ESCHERICHIA-COLI; SSB PROTEIN; DUPLEX DNA; IN-VITRO; GAMMA-S; EXCHANGE; RECOMBINATION	Saccharomyces cerevisiae Rad51 protein is the paradigm for eukaryotic ATP-dependent DNA strand exchange proteins. To explain some of the unique characteristics of DNA strand exchange promoted by Rad51 protein, when compared with its prokaryotic homologue the Escherichia coli RecA protein, we analyzed the DNA binding properties of the Rad51 protein. Rad51 protein binds both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in an ATP- and Mg2+-dependent manner, over a wide range of pH, with an apparent binding stoichiometry of approximately 1 protein monomer per 4 (+/-1) nucleotides or base pairs, respectively. Only dATP and adenosine 5'-gamma-(thiotriphosphate) (ATP gamma S) can substitute for ATP, but binding in the presence of ATP gamma S requires more than a 5-fold stoichiometric excess of protein. Without nucleotide co-factor, Rad51 protein binds both ssDNA and dsDNA but only at pH values lower than 6.8; in this case, the apparent binding stoichiometry covers the range of 1 protein monomer per 6-9 nucleotides or base pairs. Therefore, Rad51 protein displays two distinct modes of DNA binding. These binding modes are not inter-convertible; however, their initial selection is governed by ATP binding, On the basis of these DNA binding properties, we conclude that the main reason for the low efficiency of the DNA strand exchange promoted by Rad51 protein in vitro is its enhanced dsDNA-binding ability, which inhibits both the presynaptic and synaptic phases of the DNA strand exchange reaction as follows: during pre-synapsis, Rad51 protein interacts with and stabilizes secondary structures in ssDNA thereby inhibiting formation of a contiguous nucleoprotein filament; during synapsis, Rad51 protein inactivates the homologous dsDNA partner by directly binding to it.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Div Biol Sci, Sect Mol & Cell Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NIAID NIH HHS [AI-18987] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bianco P R, 1998, Front Biosci, V3, pD570; de Bongioanni L C, 1988, Rev Argent Microbiol, V20, P1; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAWORTH RS, 1993, MOL CELL BIOCHEM, V124, P131, DOI 10.1007/BF00929205; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN D, V1, P244; LAUDER SD, 1993, J MOL BIOL, V234, P72, DOI 10.1006/jmbi.1993.1564; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; PUGH BF, 1987, J BIOL CHEM, V262, P1326; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; TROTTA E, 1993, J BIOL CHEM, V268, P3944; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; Zaitsev EN, 1998, NUCLEIC ACIDS RES, V26, P650, DOI 10.1093/nar/26.2.650	45	103	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2907	2915		10.1074/jbc.274.5.2907	http://dx.doi.org/10.1074/jbc.274.5.2907			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915828	Green Submitted, hybrid			2022-12-27	WOS:000078319500046
J	Kida, M; Souri, M; Yamamoto, M; Saito, H; Ichinose, A				Kida, M; Souri, M; Yamamoto, M; Saito, H; Ichinose, A			Transcriptional regulation of cell type-specific expression of the TATA-less A subunit gene for human coagulation factor XIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE GENE; AMINO-ACID SEQUENCE; ZINC-FINGER GENE; BLOOD-COAGULATION; B-SUBUNIT; RESPONSE ELEMENT; HUMAN-MONOCYTES; FACTOR GATA-1; A-SUBUNIT; IIB GENE	To study the mechanism of gene regulation for coagulation factor WI A subunit (FXIIIA), we characterized its 5'-flanking region using a monocytoid (U937), a megakaryocytoid (MEG-01), and other cells. Our results confirmed that U937 and MEG-01 contained FXIIIA mRNA. A tentative transcription start site was determined to be 76 bases upstream from the first exon/intron boundary. Reporter gene assays revealed that a 5'-fragment (-2331 to +75) was sufficient to support basal expression in U937 and MEG-01 but not in the other cells. Deletion analysis confined a minimal promoter sequence from -114 to +75. DNase footprinting, electrophoretic mobility shift, and reporter gene assays demonstrated that promoter elements for a myeloid-enriched transcription factor (MZF-1-like protein) and two ubiquitous transcription factors (NF-1 and SP-1) in this region were important for the basal FXIII expression. It was also revealed that an upstream region (-806 to -290) had enhancer activity in MEG-01 but silencer activity in U937. DNA sequences for binding of myeloid-enriched factors (GATA-1 and Ets-1) were recognized in this region, and the GATA-1 element was found to be responsible for the enhancer activity. These transcription factors play a major role in the cell type-specific expression of FXIIIA, which differs from other transglutaminases.	Yamagata Univ, Sch Med, Dept Mol Pathol Biochem & Biol, Yamagata 9909585, Japan; Univ Tsukuba, Sch Med, Dept Mol Dev Biol, Tsukuba, Ibaraki 305, Japan; Nagoya Univ, Sch Med, Dept Med 1, Nagoya, Aichi 466, Japan	Yamagata University; University of Tsukuba; Nagoya University	Ichinose, A (corresponding author), Yamagata Univ, Sch Med, Dept Mol Pathol Biochem & Biol, Iida Nishi 2-2-2, Yamagata 9909585, Japan.	aichinos@med.id.yamagata-u.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				Adany R, 1996, THROMB HAEMOSTASIS, V76, P74; ADANY R, 1988, J CLIN PATHOL, V41, P49, DOI 10.1136/jcp.41.1.49; ADANY R, 1985, EUR J CELL BIOL, V38, P171; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; HO KC, 1992, J BIOL CHEM, V267, P12660; HROMAS R, 1991, J BIOL CHEM, V266, P14183; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; Ichinose A, 1998, BRIT J HAEMATOL, V101, P264, DOI 10.1046/j.1365-2141.1998.00698.x; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ICHINOSE A, 1994, HAEMOSTASIS THROMBOS, P531; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Izumi T, 1998, THROMB HAEMOSTASIS, V79, P479; KACZMAREK E, 1995, BBA-PROTEIN STRUCT M, V1247, P127, DOI 10.1016/0167-4838(94)00167-F; Kaetsu H, 1996, J BIOCHEM-TOKYO, V119, P961; KIESSELBACH TH, 1972, ANN NY ACAD SCI, V202, P318, DOI 10.1111/j.1749-6632.1972.tb16344.x; KRADIN RL, 1987, BLOOD, V69, P778; Lee JH, 1996, J BIOL CHEM, V271, P4561; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lorand L, 1980, Prog Hemost Thromb, V5, P245; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MUSZBEK L, 1985, THROMB RES, V37, P401, DOI 10.1016/0049-3848(85)90069-6; NAGY JA, 1986, BLOOD, V68, P1272; Nagy L, 1996, J BIOL CHEM, V271, P4355; PAN JL, 1993, J BIOL CHEM, V268, P22600; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P4306, DOI 10.1093/nar/19.15.4306-a; POON MC, 1989, J CLIN INVEST, V84, P787, DOI 10.1172/JCI114237; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; Takahashi N, 1998, BLOOD, V91, P2830, DOI 10.1182/blood.V91.8.2830.2830_2830_2838; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TRIMBLE CL, 1992, VIRCHOWS ARCH A, V420, P513, DOI 10.1007/BF01600256; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEISBERG LJ, 1987, BLOOD, V70, P579; WEISBERG LJ, 1987, J CLIN INVEST, V79, P649, DOI 10.1172/JCI112862	50	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6138	6147		10.1074/jbc.274.10.6138	http://dx.doi.org/10.1074/jbc.274.10.6138			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037697	hybrid			2022-12-27	WOS:000078902800019
J	Fukuhara, S; Murga, C; Zohar, M; Igishi, T; Gutkind, JS				Fukuhara, S; Murga, C; Zohar, M; Igishi, T; Gutkind, JS			A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; GTP-BINDING PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; DBL ONCOGENE PRODUCT; NIH 3T3 CELLS; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CELLULAR-TRANSFORMATION; ACTIN CYTOSKELETON	Small GTP-binding proteins of the Rho family play a critical role in signal transduction. However, there is still very limited information on how they are activated by cell surface receptors. Here, we used a consensus sequence for Dbl domains of Rho guanine nucleotide exchange factors (GEFs) to search DNA data bases, and identified a novel human GEF for Rho-related GTPases harboring structural features indicative of its possible regulatory mechanism(s). This protein contained a tandem DH/PH domain closely related to those of Rho-specific GEFs, a PDZ domain, a proline-rich domain, and an area of homology to Lsc, p115-RhoGEF, and a Drosophila RhoGEF that was termed Lsc-homology (LH) domain. This novel molecule, designated PDZ-RhoGEF, activated biological and biochemical pathways specific for Rho, and activation of these pathways required an intact DH and PH domain. However, the PDZ domain was dispensable for these functions, and mutants lacking the LH domain were more active, suggesting a negative regulatory role for the LII domain. A search for additional molecules exhibiting an LH domain revealed a limited homology with the catalytic region of a newly identified GTPase-activating protein for heterotrimeric G proteins, RGS14. This prompted us to investigate whether PDZ-RhoGEF could interact with representative members of each G protein family We found that PDZ-RhoGEF was able to form, in vivo, stable complexes with two members of the G alpha(12) family, G alpha(12) and G alpha(13) and that this interaction was mediated by the LR domain. Furthermore, we obtained evidence to suggest that PDZ-Rho-GEF mediates the activation of Rho by G alpha(12) and G alpha(13). Together, these findings suggest the existence of a novel mechanism whereby the large family of cell surface receptors that transmit signals through heterotrimeric G proteins activate Rho-dependent pathways: by stimulating the activity of members of the G alpha(12) family which, in turn, activate an exchange factor acting on Rho.	NIDCR, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, NIH, Oral & Pharyngeal Canc Branch, 30 Convent Dr,Bldg 30,Rm 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Murga, Cristina/E-1965-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077				AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABETS GGM, 1995, ONCOGENE, V10, P1371; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hotchin NA, 1996, CANCER SURV, V27, P311; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	70	327	333	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5868	5879		10.1074/jbc.274.9.5868	http://dx.doi.org/10.1074/jbc.274.9.5868			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026210	hybrid			2022-12-27	WOS:000078804400081
J	Watowich, SS; Liu, KD; Xie, XL; Lai, SY; Mikami, A; Longmore, GD; Goldsmith, MA				Watowich, SS; Liu, KD; Xie, XL; Lai, SY; Mikami, A; Longmore, GD; Goldsmith, MA			Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; TYROSINE KINASE DOMAIN; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; BETA-CHAIN; STAT5 ACTIVATION; EPO RECEPTOR; CELL-PROLIFERATION; GAMMA(C) SUBUNIT; PROTEIN HORMONE	Signal transduction by the erythropoietin receptor (EPOR) is activated by ligand-mediated receptor homodimerization. However, the relationship between extracellular and intracellular domain oligomerization remains poorly understood. To assess the requirements for dimerization of receptor cytoplasmic sequences for signaling, we overexpressed mutant EPORs in combination with wild-type (WT) EPOR to drive formation of heterodimeric (i.e. WT-mutant) receptor complexes. Dimerization of the membrane proximal portion of the EPOR cytoplasmic region was found to be critical for the initiation of mitogenic signaling. However, dimerization of the entire EPOR cytoplasmic region was not required. To examine this process more closely, we generated chimeras between the intracellular and transmembrane portions of the EPOR and the extracellular domains of the interleukin-2 receptor beta and gamma(c), chains. These chimeras allowed us to assess more precisely the signaling role of each receptor chain because only heterodimers of WT and mutant receptor chimeras form in the presence of interleukin-2. Coexpression studies demonstrated that a functional receptor complex requires the membrane-proximal region of each receptor subunit in the oligomer to permit activation of JAK2 but only one membrane-distal tail to activate STAT5 and to support cell proliferation. Thus, this study defines key relationships involved in the assembly and activation of the EPOR signal transduction complex which may be applicable to other homodimeric cytokine receptors.	Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; Washington University (WUSTL); Washington University (WUSTL)	Goldsmith, MA (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	mgoldsmith@gladstane.ucsf.edu		Lai, Stephen/0000-0001-8301-7286; Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [CA-77447, R01 CA077447-03, R01 CA077447-02] Funding Source: Medline; NHLBI NIH HHS [HL32262, P01 HL032262] Funding Source: Medline; NIGMS NIH HHS [R01 GM054351, GM-54351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gaffen Sarah L., 1998, P73; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRANTZ SB, 1991, BLOOD, V77, P419; Lai SY, 1997, J CLIN INVEST, V99, P169, DOI 10.1172/JCI119144; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; LATCHMAN DS, 1993, PRACTICAL APPROACH S, P1; Leonard WJ, 1996, ANNU REV MED, V47, P229; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tarr K, 1997, J BIOL CHEM, V272, P9099; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	57	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5415	5421		10.1074/jbc.274.9.5415	http://dx.doi.org/10.1074/jbc.274.9.5415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026152	Green Accepted, hybrid			2022-12-27	WOS:000078804400023
J	Wu, LT; Chen, P; Hwang, JJ; Barsky, LW; Weinberg, KI; Jong, A; Starnes, VA				Wu, LT; Chen, P; Hwang, JJ; Barsky, LW; Weinberg, KI; Jong, A; Starnes, VA			RNA antisense abrogation of MAT1 induces G(1) phase arrest and triggers apoptosis in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVATING KINASE; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR TFIIH; FIBROBLAST GROWTH-FACTOR; HUMAN OSTEOSARCOMA CELLS; RING FINGER PROTEIN; D-TYPE CYCLINS; DNA-REPAIR; NEOINTIMA FORMATION; CATALYTIC SUBUNIT	The human MAT1 gene (menage a trois I) is an assembly factor and a targeting subunit of cyclin-dependent kinase (CDK)-activating kinase. The novel mechanisms by which MAT1 forms an active CDH-activating kinase and determines substrate specificity of CDK7-cyclin H are involved in the cell cycle, DNA repair, and transcription. Hyperplasia of vascular smooth muscle cells (SMC) is a fundamental pathologic feature of luminal narrowing in vascular occlusive diseases, and nothing is yet known regarding the cell cycle phase specificity of the MAT1 gene in its involvement in SMC proliferation. To investigate such novel regulatory pathways, MAT1 expression was abrogated by retrovirus-mediated gene transfer of antisense MAT1 RNA in cultured rat aortic SMCs. We show that abrogation of MAT1 expression retards SMC proliferation and inhibits cell activation from a nonproliferative state. Furthermore, we have demonstrated that these effects are due to G(1) phase arrest and apoptotic cell death. Our studies indicate a link between cell cycle control and apoptosis and reveal a potential mechanism for coupling the regulation of MAT1 with G(1) exit and prevention of apoptosis.	Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Cardiothorac Surg, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Res Immunol,BMT, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California	Wu, LT (corresponding author), Univ So Calif, Sch Med, Childrens Hosp Los Angeles, Res Inst,Div Cardiothorac Surg, Smith Res Tower,MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@hsc.usc.edu						BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BILLINGHAM ME, 1994, CLIN TRANSPLANT, V8, P289; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Geary RL, 1996, ARTERIOSCL THROM VAS, V16, P34, DOI 10.1161/01.ATV.16.1.34; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORCZYCA W, 1993, CANCER RES, V53, P3186; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hwang JJ, 1996, J VIROL, V70, P8138, DOI 10.1128/JVI.70.11.8138-8141.1996; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KATO J, 1993, GENE DEV, V7, P331; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINES EW, 1993, BRIT HEART J, V69, pS30; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; REKHTER M, 1993, ARTERIOSCLER THROMB, V13, P609, DOI 10.1161/01.ATV.13.4.609; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Smith RC, 1997, CIRCULATION, V96, P1899, DOI 10.1161/01.CIR.96.6.1899; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU LT, 1994, ONCOL REP, V1, P705; WU LT, 1994, ONCOGENE, V9, P2089; WU LT, 1993, INT J ONCOL, V3, P859; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66; YAMADA T, 1995, HEART VESSELS, V10, P41, DOI 10.1007/BF01745076; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YASUDA T, 1995, J NEUROSCI RES, V40, P306, DOI 10.1002/jnr.490400304; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Yee A, 1996, J BIOL CHEM, V271, P471, DOI 10.1074/jbc.271.1.471; YEE A, 1995, CANCER RES, V55, P6058; Zhu NL, 1997, CIRCULATION, V96, P628	67	23	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5564	5572		10.1074/jbc.274.9.5564	http://dx.doi.org/10.1074/jbc.274.9.5564			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026172	hybrid			2022-12-27	WOS:000078804400043
J	Zhu, A; Haller, S; Li, H; Chaudhuri, A; Blancher, A; Suyama, K				Zhu, A; Haller, S; Li, H; Chaudhuri, A; Blancher, A; Suyama, K			Use of RhD fusion protein expressed on K562 cell surface in the study of molecular basis for D antigenic epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGEN; PLASMODIUM-VIVAX; POLYPEPTIDES; CDNA; GLYCOPROTEIN; PHENOTYPES; RECEPTOR; SUBUNITS; REGION	The human D antigens, one of the most clinically important blood groups, are presented by RhD protein with a putative 12 transmembrane topology. To understand the molecular basis for the complex antigenic profile of RhD protein, we expressed a series of RhD fusion proteins using different portions of Duffy protein as a tag in erythroleukemic K562 cells. Because the reactivity of monoclonal anti-RhD antibody, LOR15C9, depends mainly on the sequence coded by exon 7 of RhD, we altered DNA sequence corresponding to the amino acid residues 323-331(A) and 350-354(B) in the exon 7. The mutation in region B resulted in a severe reduction in LOR15C9 binding by flow cytometry analysis, suggesting that region B may play an important role in constituting antigen epitopes recognized by LOR15C9, On the other hand, a slight decrease in the antibody binding was observed for the region A mutant, suggesting that the intracellularly located region A may elicit a long distance effect on the formation of exofacial antigen epitopes, In addition, using various monoclonal. antibodies against RhD, we compared the antigenic profile of expressed RhD fusion protein with that of endogenous RhD in K562 cells as well as in erythrocytes.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Univ Toulouse 3, Hop Purpan, Immunogenet Mol Lab, F-31059 Toulouse, France	New York Blood Center; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Zhu, A (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67 St, New York, NY 10021 USA.							Apoil PA, 1997, BRIT J HAEMATOL, V98, P365, DOI 10.1046/j.1365-2141.1997.2183041.x; Avent ND, 1996, J BIOL CHEM, V271, P14233, DOI 10.1074/jbc.271.24.14233; BLANCHER A, 1997, RHESUS SYSTEM MOL BI, P147; Chang TY, 1998, BLOOD, V91, P3066, DOI 10.1182/blood.V91.8.3066.3066_3066_3078; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; Chitnis CE, 1996, J EXP MED, V184, P1531, DOI 10.1084/jem.184.4.1531; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; HERMAND P, 1993, BLOOD, V82, P669; Huang C H, 1997, Curr Opin Hematol, V4, P94; LOMAS C, 1993, TRANSFUSION MED, V3, P67, DOI 10.1111/j.1365-3148.1993.tb00106.x; MOURO I, 1994, BLOOD, V83, P1129, DOI 10.1182/blood.V83.4.1129.bloodjournal8341129; NUNOKI K, 1994, J BIOL CHEM, V269, P24138; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; Roubinet F, 1996, TRANSFUS CLIN BIOL, V3, P247, DOI 10.1016/S1246-7820(96)80004-8; ROUILLAC C, 1995, BLOOD, V85, P2937, DOI 10.1182/blood.V85.10.2937.bloodjournal85102937; Scott M, 1996, TRANSFUS CLIN BIOL, V3, P333, DOI 10.1016/S1246-7820(96)80040-1; Smythe JS, 1996, BLOOD, V87, P2968, DOI 10.1182/blood.V87.7.2968.bloodjournal8772968; SUYAMA K, 1994, BLOOD, V84, P1975, DOI 10.1182/blood.V84.6.1975.bloodjournal8461975; SUYAMA K, 1993, BLOOD, V82, P1006; Zhu A, 1996, EUR J BIOCHEM, V235, P332, DOI 10.1111/j.1432-1033.1996.00332.x	24	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5731	5737		10.1074/jbc.274.9.5731	http://dx.doi.org/10.1074/jbc.274.9.5731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026193	hybrid			2022-12-27	WOS:000078804400064
J	Atienza, JM; Susanto, D; Huang, C; McCarty, AS; Colicelli, J				Atienza, JM; Susanto, D; Huang, C; McCarty, AS; Colicelli, J			Identification of inhibitor specificity determinants in a mammalian phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CATALYTIC ACTIVITY; ROLIPRAM BINDING; AMP PHOSPHODIESTERASES; TYPE-4 INHIBITOR; MESSENGER-RNA; GUINEA-PIG; EXPRESSION; DOMAIN	Mammalian phosphodiesterase types 3 and 4 (PDE3 and PDE4) hydrolyze cAMP and are essential for the regulation of this intracellular second messenger in many cell types. Whereas these enzymes share structural and biochemical similarities, each can be distinguished by its sensitivity to isozyme-specific inhibitors. By using a series of chimeric enzymes, we have localized the region of PDE4 that confers sensitivity to selective inhibitors. This inhibitor specificity domain lies within a short sequence at the carboxyl terminus of the catalytic domain of the protein, consistent with the competitive nature of inhibition by these compounds, Surprisingly, the identified region also includes some of the most highly conserved residues among PDE isoforms, A yeast-based expression system was used for the isolation and characterization of mutations within this area that confer resistance to the PDE4-specific inhibitor rolipram. Analysis of these mutants indicated that both conserved and unique residues are required for isoform-specific inhibitor sensitivity. In some cases, combined point mutations contribute synergistically to the reduction of sensitivity (suppression of IC50). We also report that several mutations display differential sensitivity changes with respect to distinct structural classes of inhibitors.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Colicelli, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.				NINDS NIH HHS [NS31911] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031911] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atienza JM, 1998, METHODS, V14, P35, DOI 10.1006/meth.1997.0563; Barnette MS, 1996, BIOCHEM PHARMACOL, V51, P949; Bolger GB, 1997, BIOCHEM J, V328, P539; Boolell M, 1996, Int J Impot Res, V8, P47; Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X; BUSNIK T, 1996, BIOCHEM SOC T, V24, P1014; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; Cheung PP, 1996, BLOOD, V88, P1321, DOI 10.1182/blood.V88.4.1321.bloodjournal8841321; Cohan VL, 1996, J PHARMACOL EXP THER, V278, P1356; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; DAGERMAN E, 1997, J BIOL CHEM, V272, P6823; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; HALL IP, 1993, BRIT J CLIN PHARMACO, V35, P1; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; He Rui, 1998, Cell Biochemistry and Biophysics, V29, P89, DOI 10.1007/BF02737830; HENKELTIGGES J, 1990, MOL PHARMACOL, V37, P7; Holbrook M, 1996, BRIT J PHARMACOL, V118, P1192, DOI 10.1111/j.1476-5381.1996.tb15523.x; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Jacobitz S, 1996, MOL PHARMACOL, V50, P891; Jacobitz S, 1997, MOL PHARMACOL, V51, P999, DOI 10.1124/mol.51.6.999; JIN SLC, 1992, J BIOL CHEM, V267, P18929; Kleinman EF, 1998, J MED CHEM, V41, P266, DOI 10.1021/jm970685m; Leroy MJ, 1996, BIOCHEMISTRY-US, V35, P10194, DOI 10.1021/bi952711t; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; MONACO L, 1994, J BIOL CHEM, V269, P347; Omburo GA, 1997, BLOOD, V89, P1019, DOI 10.1182/blood.V89.3.1019; Owens RJ, 1997, BIOCHEM J, V326, P53, DOI 10.1042/bj3260053; PILLAI R, 1994, J BIOL CHEM, V269, P30676; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; RAEBURN D, 1994, BRIT J PHARMACOL, V113, P1423, DOI 10.1111/j.1476-5381.1994.tb17156.x; Rocque WJ, 1997, BIOCHEMISTRY-US, V36, P14250, DOI 10.1021/bi971112e; Rybalkin SD, 1996, BIOCHEM SOC T, V24, P1005, DOI 10.1042/bst0241005; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCHUDT C, 1991, BIOCHEM PHARMACOL, V42, P153, DOI 10.1016/0006-2952(91)90694-Z; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Spina D, 1998, ADV PHARMACOL, V44, P33, DOI 10.1016/S1054-3589(08)60125-8; Teixeira MM, 1997, TRENDS PHARMACOL SCI, V18, P164, DOI 10.1016/S0165-6147(97)90613-1; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; UNDERWOOD DC, 1993, J PHARMACOL EXP THER, V266, P306; Wang P, 1997, BIOCHEM BIOPH RES CO, V234, P320, DOI 10.1006/bbrc.1997.6636	47	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4839	4847		10.1074/jbc.274.8.4839	http://dx.doi.org/10.1074/jbc.274.8.4839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988724	hybrid			2022-12-27	WOS:000078698200049
J	Liu, XF; Culotta, VC				Liu, XF; Culotta, VC			Post-translation control of Nramp metal transport in yeast - Role of metal ions and the BSD2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NATURAL-RESISTANCE; IRON UPTAKE; PROTEIN; COPPER; MEMBRANE; INFECTION; HOMEOSTASIS; ENDOCYTOSIS; REPRESSION	The Saccharomyces cerevisiae SMF1 gene encodes a member of the well conserved family of Nramp metal transport proteins. Previously, we determined that heavy metal uptake by Smf1p was down-regulated by the product of the S. cerevisiae BSD2 gene. We now demonstrate that this regulation occurs at the level of protein stability. In wild type strains, the bulk of Smf1p is normally directed to the vacuole and is rapidly degraded by vacuolar proteases in a PEP4-dependent manner. In bsd2 Delta mutants, Smf1p fails to enter the vacuole, and the Nramp protein is stabilized. Metal ions themselves play an important role in the post-translational regulation of Smf1p. The depletion of heavy metals from the growth medium effects stabilization of Smf1p and additionally results in accumulation of this transporter at the cell surface. Supplementation of manganese alone is sufficient to trigger rapid degradation of Smf1p in a Bsd2p-dependent manner. Together the action of Bsd2p and metal ions provide a rapid and effective means for controlling Nramp metal transport in response to environmental changes.	Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Culotta, VC (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	vculotta@jhsph.edu			NIEHS NIH HHS [ES 07141, ES 08996] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Brachmann CB, 1998, YEAST, V14, P115; Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; GRUNHEID S, 1995, GENOMICS, V25, P514; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; JONES EW, 1991, J BIOL CHEM, V266, P7963; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEST AH, 1992, J BIOL CHEM, V267, P24625; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	37	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4863	4868		10.1074/jbc.274.8.4863	http://dx.doi.org/10.1074/jbc.274.8.4863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988727	hybrid			2022-12-27	WOS:000078698200052
J	Probst, C; Jecht, M; Gauss-Muller, V				Probst, C; Jecht, M; Gauss-Muller, V			Intrinsic signals for the assembly of hepatitis a virus particles - Role of structural proteins VP4 and 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A VIRUS; CAPSID PROTEIN; MONOCLONAL-ANTIBODIES; SUBVIRAL PARTICLES; IDENTIFICATION; CELLS; RNA; MYRISTOYLATION; CLEAVAGE; VIRIONS	Capsid assembly is the final event of virus replication, and its understanding is pivotal for the design of empty capsid-based recombinant vaccines and drug delivery systems. Although the capsid structure of several members of the picornavirus family has been elucidated, little is known about the structural elements governing the assembly process that is tightly associated with proteolytic processing of the viral polyprotein. Among the picornaviruses, hepatitis A virus (HAV) is unique in that it contains VP1-2A as a structural component and the small structural protein VP4, which argues for an assembly pathway different from that proposed for other picornaviruses. Using a recombinant system we show here that proteolytic processing of the HAV capsid proteins' precursor P1-2A is independent of the terminal domains 2A and VP4 of the substrate. However, both terminal domains play distinct roles in the assembly of viral particles. 2A as part of P1-2A is a primary signal for the assembly of pentameric structures which only further aggregate to empty viral capsids when VP4 is present as the N terminus of the precursor. Particle formation in the hepatovirus genus is thus regulated by two intrinsic signals that are distinct from those described for other picornaviruses.	Univ Lubeck, Inst Med Microbiol & Hyg, D-23538 Lubeck, Germany	University of Lubeck	Gauss-Muller, V (corresponding author), Univ Lubeck, Inst Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.							ANDERSON DA, 1990, J VIROL, V64, P5284, DOI 10.1128/JVI.64.11.5284-5289.1990; ANSARDI DC, 1992, J VIROL, V66, P4556, DOI 10.1128/JVI.66.7.4556-4563.1992; BISHOP NE, 1993, VIROLOGY, V197, P616, DOI 10.1006/viro.1993.1636; BOROVEC SV, 1993, J VIROL, V67, P3095, DOI 10.1128/JVI.67.6.3095-3102.1993; DOTZAUER A, 1995, VIROLOGY, V213, P671; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUSSMULLER V, 1986, VIROLOGY, V155, P732, DOI 10.1016/0042-6822(86)90234-5; HARMON SA, 1991, J VIROL, V65, P2757, DOI 10.1128/JVI.65.5.2757-2760.1991; HARMON SA, 1995, J VIROL, V69, P5576, DOI 10.1128/JVI.69.9.5576-5581.1995; Hellen Christopher U. T., 1995, P155; KUSOV YY, 1992, J MED VIROL, V37, P220, DOI 10.1002/jmv.1890370313; MACGREGOR A, 1983, J CLIN MICROBIOL, V18, P1237, DOI 10.1128/JCM.18.5.1237-1243.1983; MARC D, 1990, J VIROL, V64, P4099, DOI 10.1128/JVI.64.9.4099-4107.1990; MUSCUFO N, 1992, J VIROL, V67, P6849; PING LH, 1988, P NATL ACAD SCI USA, V85, P8281, DOI 10.1073/pnas.85.21.8281; PING LH, 1992, J VIROL, V66, P2208, DOI 10.1128/JVI.66.4.2208-2216.1992; Probst C, 1998, J VIROL, V72, P8013, DOI 10.1128/JVI.72.10.8013-8020.1998; Probst C, 1997, J VIROL, V71, P3288, DOI 10.1128/JVI.71.4.3288-3292.1997; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; RUCHTI F, 1991, J GEN VIROL, V72, P2159, DOI 10.1099/0022-1317-72-9-2159; Rueckert R., 1996, FIELDS VIROLOGY, P609; SCHULTHEISS T, 1994, VIROLOGY, V198, P275, DOI 10.1006/viro.1994.1030; TESAR M, 1992, VIROLOGY, V186, P609, DOI 10.1016/0042-6822(92)90027-M; TESAR M, 1993, VIROLOGY, V194, P616, DOI 10.1006/viro.1993.1301	24	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4527	4531		10.1074/jbc.274.8.4527	http://dx.doi.org/10.1074/jbc.274.8.4527			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988685	hybrid			2022-12-27	WOS:000078698200010
J	Wiersma, EJ; Ronai, D; Berru, M; Tsui, FWL; Shulman, MJ				Wiersma, EJ; Ronai, D; Berru, M; Tsui, FWL; Shulman, MJ			Role of the intronic elements in the endogenous immunoglobulin heavy chain locus - Either the matrix attachment regions or the core enhancer is sufficient to maintain expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX; GENE-EXPRESSION; SWITCH REGION; HYBRIDOMA CELLS; HIGH-LEVEL; IGH LOCUS; MU GENE; TRANSCRIPTION; DELETION; MOUSE	High level expression in mice of transgenes derived from the immunoglobulin heavy chain (IgH) locus requires both the core enhancer (E mu) and the matrix attachment regions (MARs) that flank E mu. The need for both elements implies that they each perform a different function in transcription. While it is generally assumed that expression of the endogenous IgH locus has similar requirements, it has been difficult to assess the role of these elements in expression of the endogenous heavy chain gene, because B cell development and IgH expression are strongly interdependent and also because the locus contains other redundant activating elements. We have previously described a gene-targeting approach in hybridoma cells that overcomes the redundancy problem to yield a stable cell line in which expression of the IgH locus depends strongly on elements in the MAR-E mu-MAR segment. Using this system, we have found that expression of the endogenous mu gene persists at substantially (similar to 50%) normal levels in recombinants which retain either the MARs or E mu. That is, despite the dissimilar biochemical activities of these two elements, either one is sufficient to maintain high level expression of the endogenous locus. These findings suggest new models for how the enhancer and MARs might collaborate in the initiation or maintenance of transcription.	Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Toronto Hosp, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Shulman, MJ (corresponding author), Univ Toronto, Dept Immunol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							AGUILERA RJ, 1985, EMBO J, V4, P3689, DOI 10.1002/j.1460-2075.1985.tb04136.x; BAAR J, 1995, J IMMUNOL, V155, P1911; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; Boulikas T, 1995, INT REV CYTOL, V162A, P279; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; CONNOR A, 1993, SOMAT CELL MOLEC GEN, V19, P313, DOI 10.1007/BF01232744; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GRAM H, 1992, EUR J IMMUNOL, V22, P1185, DOI 10.1002/eji.1830220512; GROSSCHEDL R, 1988, CELL, V55, P645, DOI 10.1016/0092-8674(88)90223-1; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KLEIN S, 1984, EMBO J, V3, P2473, DOI 10.1002/j.1460-2075.1984.tb02158.x; KOHLER G, 1982, EMBO J, V1, P555, DOI 10.1002/j.1460-2075.1982.tb01208.x; Lieberson R, 1995, EMBO J, V14, P6229, DOI 10.1002/j.1460-2075.1995.tb00313.x; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; OANCEA AE, 1995, J IMMUNOL, V155, P5678; OANCEA AE, 1994, INT IMMUNOL, V6, P1161, DOI 10.1093/intimm/6.8.1161; Oancea AE, 1997, MOL CELL BIOL, V17, P2658, DOI 10.1128/MCB.17.5.2658; OCHI A, 1983, P NATL ACAD SCI-BIOL, V80, P6351, DOI 10.1073/pnas.80.20.6351; PORTON B, 1990, MOL CELL BIOL, V10, P1076, DOI 10.1128/MCB.10.3.1076; Saleque S, 1997, J IMMUNOL, V158, P4780; Schubeler D, 1996, BIOCHEMISTRY-US, V35, P11160, DOI 10.1021/bi960930o; SIGURDARDOTTIR D, 1995, J IMMUNOL, V154, P2217; WABL MR, 1984, P NATL ACAD SCI-BIOL, V81, P2452, DOI 10.1073/pnas.81.8.2452; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; ZALLER DM, 1985, P NATL ACAD SCI USA, V82, P5088, DOI 10.1073/pnas.82.15.5088	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4858	4862		10.1074/jbc.274.8.4858	http://dx.doi.org/10.1074/jbc.274.8.4858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988726	hybrid			2022-12-27	WOS:000078698200051
J	Yu, LG; Fernig, DG; White, MRH; Spiller, DG; Appleton, P; Evans, RC; Grierson, I; Smith, JA; Davies, H; Gerasimenko, OV; Petersen, OH; Milton, JD; Rhodes, JM				Yu, LG; Fernig, DG; White, MRH; Spiller, DG; Appleton, P; Evans, RC; Grierson, I; Smith, JA; Davies, H; Gerasimenko, OV; Petersen, OH; Milton, JD; Rhodes, JM			Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks nuclear localization sequence-dependent nuclear protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER CELLS; HEAT-SHOCK PROTEIN-70; HUMAN-COLON-CANCER; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; CYTOSOLIC FACTORS; PEANUT LECTIN; TF ANTIGEN; IDENTIFICATION; EXPRESSION	The Gal beta 1-3GalNAc alpha (TF antigen)-binding lectin (ABL) from the common edible mushroom (Agaricus bisporus) has a potent anti-proliferative effect without any apparent cytotoxicity, This unusual combination of properties prompted investigation of its mechanism of action. In contrast to soluble lectin, agarose-immobilized, and hence noninternalizable ABL had no effect on proliferation of HT29 colon cancer cells. Electron microscopy of HT29 cells incubated with fluorescein- and gold-conjugated ABL showed internalization of the lectin into endocytotic vesicles and multivesicular bodies. Confocal microscopy showed perinuclear accumulation of fluorescein isothiocyanate-conjugated lectin, which also inhibits HT29 cell proliferation, raising the possibility that the lectin might interfere with nuclear pore function. Transport of heat shock protein 70 into the nucleus in response to heat shock was blocked by preincubation of HT29 cells for 6 h with 40 mu g/ml ABL, In digitonin-permeabilized cells, nuclear uptake of bovine albumin conjugated to a nuclear localization sequence (NLS)-containing peptide was also inhibited by a 15-min preincubation with 40-100 mu g/ml ABL, In contrast, serum-stimulated nuclear translocation of mitogen-activated protein kinase, which is NLS-independent, was not affected by pretreatment of cells with the lectin, These results suggest that the anti-proliferative effect of ABL is Likely to be a consequence of the lectin trafficking to the nuclear periphery, where it blocks NLS-dependent protein uptake into the nucleus.	Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Dept Physiol, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 3GA, Merseyside, England	University of Liverpool; University of Liverpool; University of Liverpool	Rhodes, JM (corresponding author), Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England.	rhodesjm@liv.ac.uk	Spiller, David G/I-3645-2012; Rhodes, Jonathan M/C-2496-2009; Gerasimenko, Oleg/A-6622-2010; Fernig, David G/A-3590-2008; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Fernig, David G/0000-0003-4875-4293; Spiller, David Geoffrey/0000-0003-2502-6787; White, Michael/0000-0002-3617-3232				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BADACHE A, 1995, GLYCOBIOLOGY, V5, P371, DOI 10.1093/glycob/5.4.371; BUSS F, 1994, J CELL SCI, V107, P631; CAMPBELL BJ, 1995, J CLIN INVEST, V95, P571, DOI 10.1172/JCI117700; DINWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1, DOI 10.1007/s004240050098; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HIRABAYASHI J, 1998, TRENDS GLYCOSCI GLYC, V9, P1; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWEYER DD, 1988, CELL, V51, P641; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NOVOGRODSKY A, 1977, P NATL ACAD SCI USA, V74, P676, DOI 10.1073/pnas.74.2.676; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; PRESANT CA, 1972, J BIOL CHEM, V247, P6937; PUSZTAI A, 1991, PLANT LECTINS, P78; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rhodes JM, 1996, LANCET, V347, P40, DOI 10.1016/S0140-6736(96)91563-9; RYDER SD, 1994, GASTROENTEROLOGY, V106, P85, DOI 10.1016/S0016-5085(94)94527-6; Ryder SD, 1998, GASTROENTEROLOGY, V114, P44, DOI 10.1016/S0016-5085(98)70631-6; RYDER SD, 1994, GASTROENTEROLOGY, V106, P117, DOI 10.1016/S0016-5085(94)94775-9; RYDER SD, 1992, JNCI-J NATL CANCER I, V84, P1410, DOI 10.1093/jnci/84.18.1410; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SHAMSUDDIN AM, 1995, CANCER RES, V55, P149; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SPRINGER GF, 1982, J BIOL CHEM, V257, P2744; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; YU LG, 1993, CANCER RES, V53, P4627; Yu LG, 1997, INT J CANCER, V73, P424, DOI 10.1002/(SICI)1097-0215(19971104)73:3<424::AID-IJC18>3.3.CO;2-C; ZANETTA JP, 1994, HISTOL HISTOPATHOL, V9, P385	58	104	109	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4890	4899		10.1074/jbc.274.8.4890	http://dx.doi.org/10.1074/jbc.274.8.4890			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988731	hybrid			2022-12-27	WOS:000078698200056
J	Zhang, ZH; Elly, C; Altman, A; Liu, YC				Zhang, ZH; Elly, C; Altman, A; Liu, YC			Dual regulation of T cell receptor-mediated signaling by oncogenic Cbl mutant 70Z	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-CBL; PHOSPHOTYROSINE-BINDING DOMAIN; OF-FUNCTION MUTATION; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; V-CBL; PHOSPHOINOSITIDE 3-KINASE; ADAPTER PROTEINS	We previously showed that an oncogenic Cbl mutant (70Z) is constitutively active in transcriptional activation of nuclear factor at activated T cells (NFAT), However, the mechanism underlying this effect remains unclear. Here we analyzed the effects of 70Z mutations at an amino-terminal loss of function site (Gly-306) and at carboxyl-terminal potential tyrosine or serine phosphorylation sites on association with signaling proteins and on NFAT activation. Mutation at Gly-306 of 70Z disrupted its association with Zap-70 and almost completely abolished its ability to induce NFAT activation under basal and ionomycin-stimulated conditions. However, mutations at potential tyrosine or serine phosphorylation sites had little effect. In fact, expression of 70Z with Tyr-700, Tyr-731, or Tyr-774 mutated to Phe increased NFAT activity in comparison with unmutated 70Z. These findings suggest that an amino terminus-mediated interaction of 70Z with Zap-70 plays a positive role and that a carboxyl terminus-mediated, phosphotyrosine-dependent interaction with their binding proteins plays a negative role in 70Z-mediated NFAT activation. In support of this notion are the observations that 70Z reduced T cell receptor-induced NFAT activation and that wild-type Cbl further inhibited this event, suggesting that both 70Z and wild-type Cbl employ a similar mechanism by which Cbl proteins dually regulate T cell receptor-mediated signaling.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.			LIU, YUN-CAI/0000-0002-0996-7109	NCI NIH HHS [CA35299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	48	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4883	4889		10.1074/jbc.274.8.4883	http://dx.doi.org/10.1074/jbc.274.8.4883			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988730	hybrid			2022-12-27	WOS:000078698200055
J	Kochs, G; Haller, O				Kochs, G; Haller, O			GTP-bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS; ANTIVIRAL ACTIVITY; TICK-BORNE; LEUCINE ZIPPER; RESISTANT MICE; MESSENGER-RNA; DHORI-VIRUS; MURINE MX1; INTERFERON; INHIBITION	Human MxA protein is an interferon-induced member of the dynamin superfamily of large GTPases. MxA inhibits the multiplication of several RNA viruses, including Thogoto virus, an influenza virus-like orthomyxovirus transmitted by ticks. Previous studies have indicated that GTP binding is required for antiviral activity, but the mechanism of action is still unknown. Here, we have used an in vitro cosedimentation assay to demonstrate, for the first time, a GTP-dependent interaction between MxA GTPase and a viral target structure. The assay is based on highly active MxA GTPase as effector molecules, Thogoto virus nucleocapsids as viral targets, and guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) as a stabilizing factor. We show that MxA tightly interacts with viral nucleocapsids by binding to the nucleoprotein component. This interaction requires the presence of GTP gamma S and is mediated by domains in the carboxyl-terminal moiety of MxA. We propose that GTP-bound MxA adopts an antivirally active conformation that allows interaction with viral nucleocapsids, thereby impairing their normal function.	Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, D-79008 Freiburg, Germany	University of Freiburg	Kochs, G (corresponding author), Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, Hugstetter Str 55, D-79008 Freiburg, Germany.							AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ALBANESE M, 1972, ACTA VIROL, V16, P267; ARNHEITER H, 1988, EMBO J, V7, P1315, DOI 10.1002/j.1460-2075.1988.tb02946.x; BAUDIN F, 1994, EMBO J, V13, P3158, DOI 10.1002/j.1460-2075.1994.tb06614.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPPIN PW, 1975, INFLUENZA VIRUSES IN; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; FULLER FJ, 1987, VIROLOGY, V160, P81, DOI 10.1016/0042-6822(87)90047-X; GARBER EA, 1993, VIROLOGY, V194, P715, DOI 10.1006/viro.1993.1312; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; HUANG T, 1992, J VIROL, V66, P4154, DOI 10.1128/JVI.66.7.4154-4160.1992; Johannes L, 1997, J VIROL, V71, P9792, DOI 10.1128/JVI.71.12.9792-9795.1997; JOHANNES L, 1991, J INTERFERON RES S, V11, P50; JONES LD, 1989, VIRUS RES, V14, P129, DOI 10.1016/0168-1702(89)90034-8; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; PAVLOVIC J, 1995, J VIROL, V69, P4506, DOI 10.1128/JVI.69.7.4506-4510.1995; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; PORTELA A, 1992, J GEN VIROL, V73, P2823, DOI 10.1099/0022-1317-73-11-2823; Pringle CR, 1996, ARCH VIROL, V141, P2251, DOI 10.1007/BF01718231; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; ROERS A, 1994, J INFECT DIS, V169, P807, DOI 10.1093/infdis/169.4.807; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Siebler J, 1996, ARCH VIROL, V141, P1587, DOI 10.1007/BF01718257; SIMON A, 1991, J VIROL, V65, P968, DOI 10.1128/JVI.65.2.968-971.1991; STAEHELI P, 1985, MOL CELL BIOL, V5, P2150, DOI 10.1128/MCB.5.8.2150; STAEHELI P, 1991, J VIROL, V65, P4498, DOI 10.1128/JVI.65.8.4498-4501.1991; Staeheli P, 1987, Interferon, V8, P1; STAEHELI P, 1985, J BIOL CHEM, V260, P1821; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; STRANDEN AM, 1993, VIROLOGY, V197, P642, DOI 10.1006/viro.1993.1639; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VONWUSSOW P, 1990, AIDS, V4, P119, DOI 10.1097/00002030-199002000-00004; Weber F, 1996, J VIROL, V70, P8361, DOI 10.1128/JVI.70.12.8361-8367.1996; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x; ZURCHER T, 1992, J VIROL, V66, P5059	52	86	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4370	4376		10.1074/jbc.274.7.4370	http://dx.doi.org/10.1074/jbc.274.7.4370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933640	hybrid			2022-12-27	WOS:000078575500064
J	Tanabe, K; Tucker, SJ; Matsuo, M; Proks, P; Ashcroft, FM; Seino, S; Amachi, T; Ueda, K				Tanabe, K; Tucker, SJ; Matsuo, M; Proks, P; Ashcroft, FM; Seino, S; Amachi, T; Ueda, K			Direct photoaffinity labeling of the Kir6.2 subunit of the ATP-sensitive K+ channel by 8-azido-ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; STOICHIOMETRY; CLONING	ATP-sensitive potassium channels are under complex regulation by intracellular ATP and ADP. The potentiating effect of MgADP is conferred by the sulfonylurea receptor subunit of the channel, SUR, whereas the inhibitory effect of ATP appears to be mediated via the pore-forming subunit, Kir6.2. We determined whether ATP directly interacts with a binding site on the Kir6.2 subunit to mediate channel inhibition by analyzing binding of a photoaffinity analog of ATP (8-azido-[gamma-P-32]ATP) to membranes from COS-7 cells transiently expressing Kir6.2. We demonstrate that Kir6.2 can be directly labeled by 8-azido-[gamma-P-32]ATP but that the related subunit Kir 4.1, which is not inhibited by ATP, is not labeled. Photoaffinity labeling of Kir6.2 is reduced by approximately 50% with 100 mu M ATP. In addition, mutations in the NH, terminus (R50G) and the COOH terminus (K185Q) of Kir6.2, which have both been shown to reduce the inhibitory effect of ATP upon Kir6.2 channel activity, reduced photoaffinity labeling by >50%, These results demonstrate that ATP binds directly to Kir6.2 and that both the NH2- and COOH-terminal intracellular domains may influence ATP binding.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, Chiba 2608670, Japan	Kyoto University; University of Oxford; Chiba University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan.		Tucker, Stephen J./ABE-7468-2020; Tucker, Stephen J./ABE-6741-2020	Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000; Proks, Peter/0000-0001-6097-3646; Ueda, Kazumitsu/0000-0003-2980-6078				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SEINO S, 1996, DIABETES REV, V4, P177; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983	17	86	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3931	3933		10.1074/jbc.274.7.3931	http://dx.doi.org/10.1074/jbc.274.7.3931			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933580	hybrid			2022-12-27	WOS:000078575500004
J	Das, TK; Boffi, A; Chiancone, E; Rousseau, DL				Das, TK; Boffi, A; Chiancone, E; Rousseau, DL			Hydroxide rather than histidine is coordinated to the heme in five-coordinate ferric Scapharca inaequivalvis hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; COOPERATIVE DIMERIC HEMOGLOBIN; CYTOCHROME-C PEROXIDASE; SPIN-STATE EQUILIBRIA; RAMAN-SCATTERING; STRUCTURAL CHARACTERIZATION; HOMODIMERIC HEMOGLOBIN; INOSITOL HEXAPHOSPHATE; TETRAMERIC HEMOGLOBINS; ALLOSTERIC TRANSITIONS	The ferric form of the homodimeric Scapharca hemoglobin undergoes a pH-dependent spin transition of the heme iron. The transition can also be modulated by the presence of salt. From our earlier studies it was shown that three distinct species are populated in the pH range 6-9, At acidic pH, a low-spin six-coordinate structure predominates. At neutral and at alkaline pHs, in addition to a small population of a hexacoordinate high-spin species, a pentacoordinate species is significantly populated. Isotope difference spectra clearly show that the heme group in the latter species has a hydroxide ligand and thereby is not coordinated by the proximal histidine, The stretching frequency of the Fe-OH moiety is 578 cm(-1) and shifts to 553 cm(-1) in (H2O)-O-18, as would be expected for a Fe OH unit. On the other hand, the ferrous form of the protein shows substantial stability over a wide pH range. These observations suggest that Scapharca hemoglobin has a unique heme structure that undergoes substantial redox-dependent rearrangements that stabilize the Fe-proximal histidine bond in the functional deoxy form of the protein but not in the ferric form.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ La Sapienza, Dept Biochem Sci, CNR, Ctr Biol Mol, I-00185 Rome, Italy	Yeshiva University; Albert Einstein College of Medicine; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Das, Tapan/0000-0002-3641-3988	NIGMS NIH HHS [GM54812, GM54806] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054812, R01GM054806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1984, J BIOL CHEM, V259, P6730; ANTONINI E, 1982, ADV EXP MED BIOL, V148, P67; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; ASCENZI P, 1981, J BIOL CHEM, V256, P5383; ASHER SA, 1977, BIOCHEMISTRY-US, V16, P5849, DOI 10.1021/bi00645a032; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; Boffi A, 1997, BIOCHEMISTRY-US, V36, P4505, DOI 10.1021/bi9618880; BOFFI A, 1991, J BIOL CHEM, V266, P17898; BOFFI A, 1994, J BIOL CHEM, V269, P20437; BOFFI A, 1994, BIOPHYS J, V67, P1713, DOI 10.1016/S0006-3495(94)80645-9; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CHIANCONE E, 1990, BIOPHYS CHEM, V37, P287, DOI 10.1016/0301-4622(90)88028-Q; COLETTA M, 1990, J BIOL CHEM, V265, P4828; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DESIDERI A, 1984, FEBS LETT, V166, P378, DOI 10.1016/0014-5793(84)80116-7; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Guarrera L, 1998, BIOCHEMISTRY-US, V37, P5608, DOI 10.1021/bi972380f; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HENRY ER, 1985, BIOCHEMISTRY-US, V24, P5907, DOI 10.1021/bi00342a033; INUBUSHI T, 1988, FEBS LETT, V235, P87, DOI 10.1016/0014-5793(88)81239-0; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mozzarelli A, 1996, J BIOL CHEM, V271, P3627; NAGAI K, 1980, BIOCHIM BIOPHYS ACTA, V624, P304, DOI 10.1016/0005-2795(80)90249-4; NOBLE RW, 1989, BIOCHEMISTRY-US, V28, P5293, DOI 10.1021/bi00438a056; Paoli M, 1997, J MOL BIOL, V271, P161, DOI 10.1006/jmbi.1997.1180; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2187, DOI 10.1021/bi00707a028; PERUTZ MF, 1978, BIOCHEMISTRY-US, V17, P3640, DOI 10.1021/bi00610a034; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2174, DOI 10.1021/bi00707a027; ROUSSEAU DL, 1993, J BIOL CHEM, V268, P5719; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; ROUSSEAU DL, 1980, NATURE, V285, P49, DOI 10.1038/285049a0; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPAGNUOLO C, 1983, J MOL BIOL, V164, P627, DOI 10.1016/0022-2836(83)90054-2; SPAGNUOLO C, 1994, J BIOL CHEM, V269, P20441; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Sun J, 1997, J AM CHEM SOC, V119, P2064, DOI 10.1021/ja963461m; TAKAHASHI S, 1980, BIOCHEMISTRY-US, V19, P5196, DOI 10.1021/bi00564a007; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; VERZILI D, 1982, BIOCHIM BIOPHYS ACTA, V704, P215, DOI 10.1016/0167-4838(82)90148-0; WANG J, 1996, RESONANCE RAMAN SCAT, P427; YONETANI T, 1974, J BIOL CHEM, V249, P2168	51	29	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2916	2919		10.1074/jbc.274.5.2916	http://dx.doi.org/10.1074/jbc.274.5.2916			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915829	hybrid			2022-12-27	WOS:000078319500047
J	Yamazaki, M; Zhang, Y; Watanabe, H; Yokozeki, T; Ohno, S; Kaibuchi, K; Shibata, H; Mukai, H; Ono, Y; Frohman, MA; Kanaho, Y				Yamazaki, M; Zhang, Y; Watanabe, H; Yokozeki, T; Ohno, S; Kaibuchi, K; Shibata, H; Mukai, H; Ono, Y; Frohman, MA; Kanaho, Y			Interaction of the small G protein RhoA with the C terminus of human phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; KINASE-C; RAT-BRAIN; POSTTRANSLATIONAL MODIFICATIONS; EXCHANGE PROTEINS; PHOSPHATIDIC-ACID; PUTATIVE TARGET; BINDING DOMAIN; SMALL GTPASE; D DEFINES	Mammalian phosphatidylcholine-specific phospholipase D1 (PLD1) is a signal transduction-activated enzyme thought to function in multiple cell biological settings including the regulation of membrane vesicular trafficking. PLD1 is activated by the small G proteins, ADP-ribosylation factor (ARF) and RhoA, and by protein kinase C-alpha (PKC-alpha). This stimulation has been proposed to involve direct interaction and to take place at a distinct site in PLD1 for each activator. In the present study, we employed the yeast two-hybrid system to attempt to identify these sites. Successful interaction of ARF and PKC-alpha with PLD1 was not achieved, but a C-terminal fragment of human PLD1 (denoted "D4") interacted with the active mutant of RhoA, RhoA(Val-14) Deletion of the CAAX box from RhoA(Val-14) decreased the strength of the interaction, suggesting that lipid modification of RhoA is important for efficient binding to PLD1. The specificity of the interaction was validated by showing that the PLD1 D4 fragment interacts with glutathione S-transferase-RhoA in vitro in a GTP-dependent manner and that it associates with RhoA(Val-14) in COS-7 cells, whereas the N-terminal two-thirds of PLD1 does not. Finally, we show that recombinant D4 peptide inhibits RhoA-stimulated PLD1 activation but not ARF- or PKC-alpha-stimulated PLD1 activation. These results conclusively demonstrate that the C-terminal region of PLD1 contains the RhoA-binding site and suggest that the ARF and PKC interactions occur elsewhere in the protein.	Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Yokohama, Kanagawa 2360004, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 6578501, Japan; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Program Mol & Cellular Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Tokyo Institute of Technology; Yokohama City University; Nara Institute of Science & Technology; Kobe University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanaho, Y (corresponding author), Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hiroshi/GOP-0177-2022; Ohno, Shigeo/B-1768-2010	Watanabe, Hiroshi/0000-0001-8887-5407; Ohno, Shigeo/0000-0002-1294-5269; Mukai, Hideyuki/0000-0002-0167-8695				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Aelst L, 1997, GENE DEV, V11, P2295; ANDO S, 1992, J BIOL CHEM, V267, P25709; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; FUJISE A, 1994, J BIOL CHEM, V269, P31642; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hayes F, 1997, J BIOL CHEM, V272, P28833, DOI 10.1074/jbc.272.46.28833; HORI Y, 1991, ONCOGENE, V6, P515; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Singer WD, 1996, J BIOL CHEM, V271, P4504; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	43	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6035	6038		10.1074/jbc.274.10.6035	http://dx.doi.org/10.1074/jbc.274.10.6035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037681	hybrid			2022-12-27	WOS:000078902800003
J	Ranganathan, S; Knaak, C; Morales, CR; Argraves, WS				Ranganathan, S; Knaak, C; Morales, CR; Argraves, WS			Identification of low density lipoprotein receptor-related protein-2/megalin as an endocytic receptor for seminal vesicle secretory protein II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE SPECIFIC ANTIGEN; RAT EPIDIDYMAL FLUID; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-J/CLUSTERIN; MEDIATES ENDOCYTOSIS; ORGAN DISTRIBUTION; GENE FAMILY; 2 MEMBERS; SVS-II	The low density lipoprotein receptor-related protein-2/megalin (LRP-2) is an endocytic receptor that is expressed on the apical surfaces of epithelial cells lining specific regions of the male and female reproductive tracts. In the present study, immunohistochemical staining revealed that LRP-2 is also expressed by epithelial cells lining the ductal region and the ampulla of the rat seminal vesicle. To identify LRP-2 ligands in the seminal vesicle, we probed seminal vesicle fluid with I-125-labeled LRP-2 in a gel-blot overlay assay. A 100-kDa protein (under non-reducing conditions) was found to bind the radiolabeled receptor. The protein was isolated and subjected to protease digestion, and the proteolytic fragments were subjected to mass spectroscopic sequence analysis. As a result, the 100-kDa protein was identified as the seminal vesicle secretory protein II (SVS-II), a major constituent of the seminal coagulum. Using purified preparations of SVS-II and LRP-2, solid-phase binding assays were used to show that the SVS-II bound to the receptor with high affinity (K-d = 5.6 nM). The binding of SVS-II to LRP-2 was inhibited using a known antagonist of LRP-2 function, the 39-kDa receptor-associated protein RAP. Using a series of recombinant subfragments of SVS-II, the LRP-2 binding site was mapped to a stretch of repeated 13-residue modules located in the central portion of the SVS-II polypeptide. To evaluate the ability of LRP-2 to mediate I-125-SVS-II endocytosis and lysosomal degradation, ligand clearance assays were performed using differentiated mouse F9 cells, which express high levels of LRP-2, Radiolabeled SVS-II was internalized and degraded by the cells, and both processes were inhibited by antibodies to LRP-2 or by RAP. The results indicate that LRP-2 binds SVS-II and can mediate its endocytosis leading to lysosomal degradation.	Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Medical University of South Carolina; McGill University	Argraves, WS (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, 171 Ashley Ave, Charleston, SC 29425 USA.	argraves@musc.edu	Morales, Carlos R./H-1055-2011		NIDDK NIH HHS [DK45598] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRAWAL Y, 1987, J REPROD FERTIL, V79, P409, DOI 10.1530/jrf.0.0790409; AGRAWAL Y, 1988, J ANDROL, V9, P307; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ASSMANN KJM, 1986, VIRCHOWS ARCH A, V408, P541, DOI 10.1007/BF00705307; BALASUBRAMANIAN K, 1991, INDIAN J EXP BIOL, P907; BROOKS DE, 1983, AUST J BIOL SCI, V36, P205, DOI 10.1071/BI9830205; Carballada R, 1997, J REPROD FERTIL, V109, P325, DOI 10.1530/jrf.0.1090325; CHAPMAN DA, 1984, BIOL REPROD, V31, P627, DOI 10.1095/biolreprod31.4.627; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; FORNES MW, 1991, ANDROLOGIA, V23, P347; FORNES WM, 1995, ANDROLOGIA, V27, P233; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; HERZ J, 1991, J BIOL CHEM, V266, P21232; Huang LS, 1996, P NATL ACAD SCI USA, V93, P10903, DOI 10.1073/pnas.93.20.10903; JONES R, 1981, BIOCHEM J, V200, P457, DOI 10.1042/bj2000457; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KUNSTYR I, 1982, LAB ANIM, V16, P151, DOI 10.1258/002367782781110205; Law GL, 1997, J ANDROL, V18, P32; LEE KP, 1986, LAB ANIM SCI, V36, P671; Liu K, 1996, MOL HUM REPROD, V2, P99, DOI 10.1093/molehr/2.2.99; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; Lundwall A, 1996, EUR J BIOCHEM, V235, P424, DOI 10.1111/j.1432-1033.1996.00424.x; LUNDWALL A, 1995, FEBS LETT, V374, P53, DOI 10.1016/0014-5793(95)01076-Q; Morales CR, 1996, BIOL REPROD, V55, P676, DOI 10.1095/biolreprod55.3.676; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; Renneberg H, 1995, ACTA ANAT, V153, P273; ROBERTS KP, 1995, HDB ANDROLOGY; RONQUIST G, 1978, ANDROLOGIA, V10, P261; RONQUIST G, 1978, ANDROLOGIA, V10, P427; SAYEGH RA, 1995, J SOC GYNECOL INVESD, V6, P748; SEITZ J, 1992, EUR J CELL BIOL, V57, P308; SETTY BS, 1979, ENDOKRINOLOGIE, V74, P100; SIDHU KS, 1991, INT REV CYTOL, V127, P253; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STEFANSSON S, 1995, J CELL SCI, V108, P2361; WAGNER CL, 1987, BIOL REPROD, V36, P501, DOI 10.1095/biolreprod36.2.501; WANG MC, 1979, INVEST UROL, V17, P159; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	48	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5557	5563		10.1074/jbc.274.9.5557	http://dx.doi.org/10.1074/jbc.274.9.5557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026171	hybrid			2022-12-27	WOS:000078804400042
J	Ezaki, S; Maeda, N; Kishimoto, T; Atomi, H; Imanaka, T				Ezaki, S; Maeda, N; Kishimoto, T; Atomi, H; Imanaka, T			Presence of a structurally novel type ribulose-bisphosphate carboxylase/oxygenase in the hyperthermophilic archaeon, Pyrococcus kodakaraensis KOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; CO2 FIXATION OPERON; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM; NUCLEOTIDE-SEQUENCE; STRAIN KOD1; FORM-I; EXPRESSION; GENE; PURIFICATION	We have characterized the gene encoding ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) of the hyperthermophilic archaeon, Pyrococcus kodakaraensis KOD1, The gene encoded a protein consisting of 444 amino acid residues, corresponding in size to the large subunit of previously reported Rubiscos, Rubisco of P. kodakaraensis KOD1 (Pk-Rubisco) showed only 51.4% similarity with the large subunit of type I Rubisco from spinach and 47.3% with that of type II Rubisco from Rhodospirillum rubrum, suggesting that the enzyme was not a member of either type. Active site residues identified from type I and type II Rubiscos were conserved. We expressed the gene in Escherichia coli, and we obtained a soluble protein with the expected molecular mass and N-terminal amino acid sequence. Purification of the recombinant protein revealed that Pk-Rubisco was an L-8 type homo-octamer. Pk-Rubisco showed highest specific activity of 19.8 x 10(3) nmol of CO2 fixed per min/mg, and a tau value of 310 at 90 degrees C, both higher than any previously characterized Rubisco, The optimum pH was 8.3, and the enzyme possessed extreme thermostability, with a half-life of 15 h at 80 degrees C, Northern blot analysis demonstrated that the gene was transcribed in P. kodakaraensis KOD1. Furthermore, Western blot analysis with cell-free extract of P. kodakaraensis KOD1 clearly indicated the presence of Pk-Rubisco in the native host cells.	Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.			Atomi, Haruyuki/0000-0001-9687-6426				Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN JH, 1991, J BIOL CHEM, V266, P20447; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; HARTMAN FC, 1984, ARCH BIOCHEM BIOPHYS, V232, P280, DOI 10.1016/0003-9861(84)90544-7; Hernandez JM, 1996, J BACTERIOL, V178, P347, DOI 10.1128/jb.178.2.347-356.1996; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Maniatis T., 1989, MOL CLONING LAB MANU; MORIKAWA M, 1994, APPL ENVIRON MICROB, V60, P4559, DOI 10.1128/AEM.60.12.4559-4566.1994; NARGANG F, 1984, MOL GEN GENET, V193, P220, DOI 10.1007/BF00330671; RAJAGOPALAN R, 1994, EUR J BIOCHEM, V221, P863, DOI 10.1111/j.1432-1033.1994.tb18801.x; Rashid N, 1997, J FERMENT BIOENG, V83, P412, DOI 10.1016/S0922-338X(97)82993-5; Rashid N, 1997, NUCLEIC ACIDS RES, V25, P719, DOI 10.1093/nar/25.4.719; Siddiqui MA, 1997, MOL GEN GENET, V254, P433, DOI 10.1007/s004380050436; TABITA FR, 1995, ADV PHOTOSYNTH, V2, P885; Takagi M, 1997, APPL ENVIRON MICROB, V63, P4504, DOI 10.1128/AEM.63.11.4504-4510.1997; Uemura K, 1996, PLANT CELL PHYSIOL, V37, P325, DOI 10.1093/oxfordjournals.pcp.a028949; Uemura K, 1997, BIOCHEM BIOPH RES CO, V233, P568, DOI 10.1006/bbrc.1997.6497; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Yan Z, 1997, APPL ENVIRON MICROB, V63, P785, DOI 10.1128/AEM.63.2.785-789.1997; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	22	76	78	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5078	5082		10.1074/jbc.274.8.5078	http://dx.doi.org/10.1074/jbc.274.8.5078			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988755	hybrid			2022-12-27	WOS:000078698200080
J	Wlassoff, WA; Kimura, M; Ishihama, A				Wlassoff, WA; Kimura, M; Ishihama, A			Functional organization of two large subunits of the fission yeast Schizosaccharomyces pombe RNA polymerase II - Location of the catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-BOUND P-32; ESCHERICHIA-COLI; ACTIVE-SITE; WHEAT-GERM; TRANSCRIPTION COMPLEXES; ALPHA-AMANITIN; DNA; GENE; RESIDUES; DOMAIN	The catalytically competent transcription complex of RNA polymerase II from the fission yeast Schizosaccharomyces pombe was affinity labeled with photoreactive nucleotide analogues incorporated at 3' termini of nascent RNA chains. To locate the catalytic site for RNA polymerization, the labeled subunits were separated by SDS-polyacrylamide gel electrophoresis and subjected to partial proteolysis, After microsequencing of proteolytic fragments, a complex multidomain organization was indicated for both of the two large subunits, Rpb1 and Rpb2, with the most available sites of proteolysis in junctions between the conserved sequences among RNA polymerase from both prokaryotes and eukaryotes. The cross-linking studies indicate the following: (i) the 3' termini of growing RNA chains are most extensively cross-linked to the second largest subunit Rpb2 between amino acids 825 and 994; (ii) the regions 298-535 of Rpb2 and 614-917 of Rpb1 are cross-linked to less extents, suggesting that these regions are situated in the vicinity of the catalytic site. All these regions include the conserved sequences of RNA polymerases, and the catalytic site of Rpb2 belongs to an NH2-terminal part of its conserved sequence H.	Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Ishihama, A (corresponding author), Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan.	aishiham@lab.nig.ac.jp		Kimura, Makoto/0000-0003-0868-5334				ACKER J, 1992, J MOL BIOL, V226, P1295, DOI 10.1016/0022-2836(92)91071-V; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; ASANO Y, 1995, J BIOCHEM-TOKYO, V117, P677, DOI 10.1093/oxfordjournals.jbchem.a124762; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; BARTHOLOMEW B, 1990, J BIOL CHEM, V265, P3731; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; FREUND E, 1986, BIOCHEMISTRY-US, V25, P276, DOI 10.1021/bi00349a038; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P112; Ishiguro A, 1998, J MOL BIOL, V279, P703, DOI 10.1006/jmbi.1998.1823; Ishihama A, 1981, Adv Biophys, V14, P1; JOB C, 1992, BIOCHEM J, V285, P85, DOI 10.1042/bj2850085; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAENA JFW, 1990, J ORG CHEM, V55, P3640; KawagishiKobayashi M, 1996, MOL GEN GENET, V250, P1; KELLY S, 1990, J BIOL CHEM, V265, P7787; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Miyao T, 1998, MOL GEN GENET, V259, P123, DOI 10.1007/s004380050796; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; SAFRONOV IV, 1997, RUSSIAN J BIOORGAN C, V23, P531; Sakurai H, 1998, GENE, V221, P11, DOI 10.1016/S0378-1119(98)00449-1; Sakurai H, 1997, GENE, V196, P165, DOI 10.1016/S0378-1119(97)00222-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P2248, DOI 10.1021/bi00060a017; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; WOODY AYM, 1984, BIOCHEMISTRY-US, V23, P2843, DOI 10.1021/bi00308a001; WOYCHIK NA, 1994, TRANSCRIPTION MECH R, P227; Yasui K, 1998, BIOCHEMISTRY-US, V37, P5542, DOI 10.1021/bi972939b; Yasui K, 1996, GENES CELLS, V1, P843, DOI 10.1046/j.1365-2443.1996.730274.x	43	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5104	5113		10.1074/jbc.274.8.5104	http://dx.doi.org/10.1074/jbc.274.8.5104			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988759	hybrid			2022-12-27	WOS:000078698200084
J	Auxilien, S; Keith, G; Le Grice, SFJ; Darlix, JL				Auxilien, S; Keith, G; Le Grice, SFJ; Darlix, JL			Role of post-transcriptional modifications of primer tRNA(Lys,3) in the fidelity and efficacy of plus strand DNA transfer during HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID PROTEIN; IN-VITRO; RIBONUCLEASE-H; TRANSFER-RNA; VIRAL-DNA; SPECIFICITY; DOMAIN; REPLICATION; MUTATIONS; MECHANISM	During HIV reverse transcription, (+) strand DNA synthesis is primed by an RNase H-resistant sequence, the polypurine tract, and continues as far as a 18-nt double-stranded RNA region corresponding to the 3' end of tRNA(Lys,3) hybridized to the viral primer binding site (PBS). Before (+) strand DNA transfer, reverse transcriptase (RT) needs to unwind the double-stranded tRNA-PBS RNA in order to reverse-transcribe the 3' end of primer tRNA(Lys,3). Since the detailed mechanism of (+) strand DNA transfer remains incompletely understood, we developed an in vitro system to closely examine this mechanism, composed of HIV 5' RNA, natural modified tRNA(Lys,3), synthetic unmodified tRNALys,3 Or oligonucleotides (RNA or DNA) complementary to the PBS, as well as the viral proteins RT and nucleocapsid protein (NCp7), Prior to (+) strand DNA transfer, RT stalls at the double-stranded tRNA-PBS RNA complex and is able to reverse-transcribe modified nucleosides of natural tRNA(Lys,3). Modified nucleoside m(1)A-58 of natural tRNA(Lys,3) is only partially effective as a stop signal, as RT can transcribe as far as the hyper-modified adenosine (ms(2)t(6)A-37) in the anticodon loop. m(1)A-58 is almost always transcribed into A, whereas other modified nucleosides are transcribed correctly, except for m(7)G-46, which is sometimes transcribed into T. In contrast, synthetic tRNA(Lys,3), an RNA PBS primer, and a DNA PBS primer are completely reverse-transcribed, In the presence of an acceptor template, (+) strand DNA transfer is efficient only with templates containing natural tRNA(Lys,)3 or the RNA PBS primer, Sequence analysis of transfer products revealed frequent errors at the transfer site with synthetic tRNA(Lys,3), not observed with natural tRNA(Lys,3). Thus, modified nucleoside m(1)A-58, present in all retroviral tRNA primers, appears to be important for both efficacy and fidelity of (+) strand DNA transfer. We show that other factors such as the nature of the (-) PBS of the acceptor template and the RNase PP activity of RT also influence the efficacy of (+) strand DNA transfer.	INSERM, LaboRetro ENS, U412, F-69364 Lyon 07, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9002, F-67084 Strasbourg, France; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Case Western Reserve University	Darlix, JL (corresponding author), INSERM, LaboRetro ENS, U412, 46 Allee Ditalie, F-69364 Lyon 07, France.		LUC, DARLIX JEAN/AAE-9268-2020					AGRIS PF, 1986, BIOCHEMISTRY-US, V25, P5126, DOI 10.1021/bi00366a022; Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BenArtzi H, 1996, BIOCHEMISTRY-US, V35, P10549, DOI 10.1021/bi960439x; BLAIN SW, 1995, J VIROL, V69, P4440, DOI 10.1128/JVI.69.7.4440-4452.1995; Burnett BP, 1997, P NATL ACAD SCI USA, V94, P7210, DOI 10.1073/pnas.94.14.7210; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUBER HE, 1990, J BIOL CHEM, V265, P10565; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KARAGEORGOS L, 1995, J GEN VIROL, V76, P1675, DOI 10.1099/0022-1317-76-7-1675; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KEITH G, 1983, BIOCHIMIE, V65, P661; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Liang C, 1997, J VIROL, V71, P9075, DOI 10.1128/JVI.71.12.9075-9086.1997; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SMITH JS, 1992, J BIOL CHEM, V267, P15071; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; Telesnitsky A., 1997, P121; WITTIG B, 1978, NUCLEIC ACIDS RES, V5, P1165, DOI 10.1093/nar/5.4.1165; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YU H, 1992, J BIOL CHEM, V267, P10888; Yusupova G, 1996, J MOL BIOL, V261, P315, DOI 10.1006/jmbi.1996.0463	43	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4412	4420		10.1074/jbc.274.7.4412	http://dx.doi.org/10.1074/jbc.274.7.4412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933645	hybrid			2022-12-27	WOS:000078575500069
J	Johnson, JL; Brooker, RJ				Johnson, JL; Brooker, RJ			A K319N/E325Q double mutant of the lactose permease cotransports H+ with lactose - Implications for a proposed mechanism of H+ lactose symport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR SPECIFICITY MUTATIONS; ESCHERICHIA-COLI; CARRIER PROTEIN; LAC PERMEASE; 2 HALVES; TRANSPORT; PROTON; SITE; SUPERFAMILY; SEQUENCE	In this study, we have examined the transport characteristics of the wild-type lactose permease, single mutants in which Lys-319 was changed to asparagine or alanine or Glu-325 was changed to glutamine or alanine, and the corresponding double mutant strains. The wildtype and Asn-319 mutant showed high levels of lactose uptake, with K-m values of 0.42 and 1.30 mM and V-max values of 102.6 and 48.3 nmol of lactose/min/mg of protein, respectively. The Asn-319/Gln-325 strain had a normal K-m of 0.36 mM and a moderate V-max of 18.5 nmol of lactose/min/mg of protein, By comparison, the single E325Q strain had a normal K-m of 0.27 mM but a very defective V-max of 1.3 nmol of lactose/min/mg of protein, A similar trend was observed among the alanine substitutions at these positions, although the V-max values were lower for the Ala-319 mutations. When comparing the V-max values between the single position 325 mutants with those of the double mutants, these results indicate that neutral 319 mutations substantially alleviate a defect in V-max caused by neutral 325 mutations, With regard to H+/lactose coupling, the wild-type permease is normally coupled and can transport lactose against a gradient, The position 325 single mutants showed no evidence of H+ transport with lactose or thiodigalactoside (TDG) and were unable to facilitate uphill lactose transport. The single Asn-319 mutant and double Asn-319/Gln-325 mutant were able to transport H+ upon the addition of lactose or TDG. In addition, both of these strains catalyzed a sugar-dependent Hf leak that inhibited cell growth in the presence of TDG, These two strains were also defective in uphill transport, which may be related to their sugar-dependent leak pathway. Based on these and other results in the literature, a model is presented that describes how the interactions among several ionizable residues within the lactose permease act in a concerted manner to control H+/lactose coupling. In this model, Lys-319 and Glu-325 play a central role in governing the ability of the lactose permease to couple the transport of H+ and lactose.	Univ Minnesota, Dept Genet & Cell Biol, St Paul, MN 55108 USA; Univ Minnesota, Inst Adv Studies Biol Proc Technol, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Brooker, RJ (corresponding author), Bioproc Tech Inst, Gortner Labs 240, 1479 Gortner Ave, St Paul, MN 55108 USA.				NIGMS NIH HHS [GM53259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1213; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; EELKEMA JA, 1991, J BIOL CHEM, V266, P4139; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JI, 1993, J BIOL CHEM, V268, P20007; LEE JI, 1992, J BIOL CHEM, V267, P20758; Lee JI, 1996, BBA-BIOMEMBRANES, V1278, P111, DOI 10.1016/0005-2736(95)00209-X; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mandel M, 1970, J MOL BIOL, V53, P154; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; Pazdernik NJ, 1997, J BIOL CHEM, V272, P26110, DOI 10.1074/jbc.272.42.26110; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8	38	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4074	4081		10.1074/jbc.274.7.4074	http://dx.doi.org/10.1074/jbc.274.7.4074			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933600	hybrid			2022-12-27	WOS:000078575500024
J	Rivkees, SA; Barbhaiya, H; IJzerman, AP				Rivkees, SA; Barbhaiya, H; IJzerman, AP			Identification of the adenine binding site of the human A(1) adenosine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; DIRECTED MUTAGENESIS; EXPRESSION; ANTAGONIST; DOMAINS; ARRANGEMENT; RECOGNITION; HELICES; AGONIST; SYSTEM	To provide new insights into ligand-A(1) adenosine receptor (A(1)AR) interactions, site-directed mutagenesis was used to test the role of several residues in the first four transmembrane domains of the human A(1)AR. First, we replaced eight unique A(1)AR residues with amino acids present at corresponding transmembrane (TM) positions of A(2A)ARs. We also tested the role of carboxamide amino acids in TMs 1-4, and the roles of Val-87, Leu-88, and Thr-91 in TM3, Following conversion of Gly-14 in TM1 to Thr-14, the affinity for adenosine agonists increased 100-fold, and after Pro-25 in TM1 was converted to Leu-25, the affinity for agonists fell. After conversion of TM3 sites Thr-91 to Ala-91, and Gln-92 to Ala-92, the affinity for N-6-substituted agonists was reduced, and binding of ligands without N-6 substituents was eliminated. When Leu-88 was converted to Ala-88, the binding of ligands with N-6 substituents was reduced to a greater extent than ligands without N-6 substituents. Following conversion of Pro-86 to Phe-86, the affinity for N-6-substituted agonists was lost, and the affinity for ligands without N-6 substitution was reduced. These observations strongly suggest that Thr-91 and Gln-92 in TM3 interact with the adenosine adenine moiety, and Leu-88 and Pro-86 play roles in conferring specificity for A(1)AR selective compounds. Using computer modeling based on the structure of rhodopsin, a revised model of adenosine-A,AR interactions is proposed with the N-6-adenine position oriented toward the top of TM3 and the ribose group interacting with the bottom half of TMs 3 and 7.	Yale Univ, Sch Med, Div Pediat Endocrinol, New Haven, CT 06520 USA; Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-2300 RA Leiden, Netherlands	Yale University; Leiden University; Leiden University - Excl LUMC	Rivkees, SA (corresponding author), Yale Univ, Sch Med, Div Pediat Endocrinol, POB 208081, New Haven, CT 06520 USA.		IJzerman, Ad/ABG-1353-2020	IJzerman, Ad/0000-0002-1182-2259	NINDS NIH HHS [R01 NS326224] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Barbhaiya H, 1996, MOL PHARMACOL, V50, P1635; Brundege J M, 1997, Adv Pharmacol, V39, P353, DOI 10.1016/S1054-3589(08)60076-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IJzerman A P, 1992, Drug Des Discov, V9, P49; IJZERMAN AP, 1994, EUR J PHARM-MOLEC PH, V268, P95, DOI 10.1016/0922-4106(94)90124-4; Ijzerman AP, 1996, EUR J PHARMACOL, V310, P269, DOI 10.1016/0014-2999(96)00495-5; Jiang QL, 1996, MOL PHARMACOL, V50, P512; Kennedy AP, 1996, MOL PHARMACOL, V50, P789; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; OLAH ME, 1994, J BIOL CHEM, V269, P24692; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; RIVKEES SA, 1995, ENDOCRINE, V3, P623, DOI 10.1007/BF02746338; RIVKEES SA, 1995, J BIOL CHEM, V270, P20485, DOI 10.1074/jbc.270.35.20485; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; SHRYOCK JC, 1992, J PHARMACOL EXP THER, V260, P1292; TIVEDI BK, 1990, ADENOSINE ADENOSINE, P57; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; UKENA D, 1987, FEBS LETT, V215, P203, DOI 10.1016/0014-5793(87)80146-1; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANGALEN PJM, 1994, MOL PHARMACOL, V45, P1101	25	75	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3617	3621		10.1074/jbc.274.6.3617	http://dx.doi.org/10.1074/jbc.274.6.3617			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920910	Green Published, hybrid			2022-12-27	WOS:000078428200050
J	Gross, M; Hessefort, S; Olin, A				Gross, M; Hessefort, S; Olin, A			Purification of a 38-kDa protein from rabbit reticulocyte lysate which promotes protein renaturation by heat shock protein 70 and its identification as delta-aminolevulinic acid dehydratase and as a putative DnaJ protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; CONTROLLED TRANSLATIONAL REPRESSOR; ATPASE ACTIVITY; ERYTHROID-DIFFERENTIATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; 66-KDA PROTEIN; HUMAN HOMOLOG; BOVINE LIVER; HSP70	We reported recently that a rabbit reticulocyte 66-kDa protein (termed RF-hsp 70 by our laboratory and p60 and hop by others) functions as a hsp 70 recycling protein and markedly enhances the renaturation of luciferase by hsp 70 (Gross, M., and Hessefort, S. (1996) J. Biol. Chem. 271, 16833-16841). In this report, we confirm that the ability of RF-hsp 70 to promote the conversion of hsp 70 ADP to hsp 70 ATP, thus enhancing the protein folding activity of hsp 70, is caused by the purified 66-kDa protein and not by a trace DnaJ/hsp 40 protein contaminant. To determine the relationship between RF-hsp 70 and the DnaJ/hsp 40 heat shock protein family, which also enhances protein renaturation by hsp 70, we purified a 38-kDa protein from rabbit reticulocyte lysate based upon its ability to stimulate renaturation of luciferase by hsp 70. Partial amino acid sequencing of this 38-kDa protein has indicated, unexpectedly, that it is the enzyme delta-aminolevulinic acid dehydratase (ALA-D) and that it does not contain detectable sequences corresponding to the DnaJ/hsp 40 protein family. In addition, immunoblot analysis with a polyclonal antibody made to HeLa cell hsp 40 (from Stress-Gen) confirms that our purified ALA-D contains no hsp 40, although hsp 40 is present in relatively crude rabbit reticulocyte protein fractions. Rabbit reticulocyte ALA-D is about as active in converting delta-aminolevulinic acid to porphobilinogen and as Zn2+-dependent as ALA-D purified from other sources. Rabbit reticulocyte ALA-D stimulates the renaturation of luciferase by hsp 70 up to 10-fold at concentrations that are the same as or less than that of hsp 70, and it has no renaturation activity in the absence of hsp 70. The renaturation effect of ALA-D is additive with that of RF-hsp 70 at limiting or saturating concentrations of each, and, unlike RF-hsp 70, ALA-D does not promote the dissociation of hsp 70 ADP in the presence of ATP. The renaturation-enhancing effect of ALA-D may be caused by a region near its carboxyl terminus which has sequence homology to the highly conserved domain of the DnaJ protein family, which is similar to the sequence homology between this domain and a carboxyl-terminal region in auxilin, a DnaJ-like protein that requires this region for its hsp 70-dependent function.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago	Gross, M (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mgross@midway.uchicago.edu			NHLBI NIH HHS [HL-30121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; BERU N, 1985, J BIOL CHEM, V260, P9251; BEVAN DR, 1980, J BIOL CHEM, V255, P2030; BISHOP TR, 1986, NUCLEIC ACIDS RES, V14, P10115, DOI 10.1093/nar/14.24.10115; BISHOP TR, 1989, NUCLEIC ACIDS RES, V17, P1775, DOI 10.1093/nar/17.4.1775; Blatch G. L., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P68; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHEETHAM ME, 1996, BIOCHEM J, V319, P13; CHEH A, 1973, BIOCHEM BIOPH RES CO, V55, P1060, DOI 10.1016/S0006-291X(73)80002-6; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GIBSON KD, 1955, BIOCHEM J, V61, P618, DOI 10.1042/bj0610618; GROSS M, 1987, J BIOL CHEM, V262, P6899; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; Gross M, 1996, J BIOL CHEM, V271, P16842, DOI 10.1074/jbc.271.28.16842; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1994, J BIOL CHEM, V269, P22738; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HONORE B, 1992, J BIOL CHEM, V267, P8485; ISHIDA N, 1992, J CLIN INVEST, V89, P1431, DOI 10.1172/JCI115732; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NAKAO K, 1968, ANN NY ACAD SCI, V149, P224, DOI 10.1111/j.1749-6632.1968.tb15155.x; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SASSA A, 1981, ADV HUM GENET, P121; SASSA S, 1982, ENZYME, V28, P133, DOI 10.1159/000459097; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHEMIN D, 1970, METHODS ENZYMOLOGY A, V17, P205; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; TSUKAMOTO I, 1980, INT J BIOCHEM, V12, P751; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WALL D, 1994, J BIOL CHEM, V269, P5446; WU WH, 1974, P NATL ACAD SCI USA, V71, P1767, DOI 10.1073/pnas.71.5.1767; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	49	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3125	3134		10.1074/jbc.274.5.3125	http://dx.doi.org/10.1074/jbc.274.5.3125			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915851	hybrid			2022-12-27	WOS:000078319500069
J	Hall, JA; Fann, MC; Maloney, PC				Hall, JA; Fann, MC; Maloney, PC			Altered substrate selectivity in a mutant of an intrahelical salt bridge in UhpT, the sugar phosphate carrier of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM; LACTOSE CARRIER; SALMONELLA-TYPHIMURIUM; TRANSLOCATION PATHWAY; STREPTOCOCCUS-LACTIS; MELIBIOSE CARRIER; ANION-EXCHANGE; IDENTIFICATION; PERMEASE; PROTEINS	Site-directed and second site suppressor mutagenesis identify an intrahelical salt bridge in the eleventh transmembrane segment of UhpT, the sugar phosphate carrier of Escherichia coli. Glucose 6-phosphate (G6P) transport by UhpT is inactivated if cysteine replaces either Asp(388) or Lys(391) but not if both are replaced. This suggests that Asp(388) and Lys(391) are involved in an intrahelical salt bridge and that neither is required for normal UhpT function. This interpretation is strengthened by the finding that mutations at Lys391 (K391N, K391Q, and K391T) are recovered as revertants of the inactive D388C variant. Further work shows that although the D388C variant is null for G6P transport, movement of P-32(i) by homologous P-i/P-i exchange is unaffected. This raises the possibility that this derivative may have latent function, a possibility confirmed by showing that D388C is a gain-of-function mutation in which phosphoenolpyruvate (PEP) is the preferred substrate. Added study of the P-i/P-i exchange shows that in wild type UhpT this partial reaction is readily blocked by G6P but not PEP. By contrast, in the D388C variant, Pi/Pi exchange is unaffected by G6P but is inhibited by both PEP and 3-phosphoglycerate. These latter substrates are used by PgtP, a related P-i-linked antiporter, which lacks the Asp(388)-Lys(391) Salt bridge but has instead an uncompensated arginine at position 391. For this reason, we conclude that in both UhpT and PgtP position 391 can serve as a determinant of substrate selectivity by acting as a receptor for the anionic carboxyl brought into the translocation pathway by PEP.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, F32GM019421, R01GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32GM19421, GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELVIN CM, 1985, J BACTERIOL, V161, P1054, DOI 10.1128/JB.161.3.1054-1058.1985; Fann MC, 1998, J MEMBRANE BIOL, V164, P187, DOI 10.1007/s002329900404; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P486; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; KABACK HR, 1994, J EXP BIOL, V196, P183; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1990, J BIOL CHEM, V265, P9638; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JI, 1996, BBA-BIOMEMBRANES, V1278, P111, DOI 10.1016/0005-2736(95)00209-X; Lounnas V, 1997, BIOCHEMISTRY-US, V36, P5402, DOI 10.1021/bi9622940; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1984, J BACTERIOL, V158, P238, DOI 10.1128/JB.158.1.238-245.1984; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARQUSEE S, 1994, PROTEIN SCI, V3, P2217, DOI 10.1002/pro.5560031207; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Merino G, 1997, J BACTERIOL, V179, P7687, DOI 10.1128/jb.179.24.7687-7694.1997; Miller J. H., 1972, EXPT MOL GENETICS, P431; NIIYA S, 1982, J BIOL CHEM, V257, P8902; OLSEN SG, 1993, J BACTERIOL, V175, P6269, DOI 10.1128/JB.175.19.6269-6275.1993; Panayotova-Heiermann M, 1998, BIOCHEMISTRY-US, V37, P10522, DOI 10.1021/bi9800395; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; RASHIN AA, 1984, J MOL BIOL, V173, P515, DOI 10.1016/0022-2836(84)90394-2; SAIER MH, 1975, J BIOL CHEM, V250, P5089; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SONNA LA, 1988, J BIOL CHEM, V263, P6625; STERN LJ, 1989, J BIOL CHEM, V264, P14202; Tamai E, 1997, PROTEIN EXPRES PURIF, V10, P275, DOI 10.1006/prep.1997.0754; VARADHACHARY A, 1991, J BIOL CHEM, V266, P130; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	52	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6148	6153		10.1074/jbc.274.10.6148	http://dx.doi.org/10.1074/jbc.274.10.6148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037698	hybrid			2022-12-27	WOS:000078902800020
J	Janosi, JBM; Firth, SM; Bond, JJ; Baxter, RC; Delhanty, PJD				Janosi, JBM; Firth, SM; Bond, JJ; Baxter, RC; Delhanty, PJD			N-linked glycosylation and sialylation of the acid-labile subunit - Role in complex formation with insulin-like growth factor (IGF)-binding protein-3 and the IGFs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; LEUCINE-RICH REPEATS; TERNARY COMPLEX; MOLECULAR-DISTRIBUTION; FACTOR-I; SERUM; PURIFICATION; EXPRESSION; CLONING; BINARY	Over 75% of the circulating insulin-like growth factors (IGF-I and -II) are bound in 140-kDa ternary complexes with IGF-binding protein-3 (IGFBP-3) and the 84-86-kDa acid-labile subunit (ALS), a glycoprotein containing 20 kDa of carbohydrate. The ternary complexes regulate IGF availability to the tissues. Since interactions of glycoproteins can be influenced by their glycan moieties, this study aimed to determine the role of ALS glycosylation in ternary complex formation. Complete deglycosylation abolished the ability of ALS to associate with IGFBP-3. To examine this further, seven recombinant ALS mutants each lacking one of the seven glycan attachment sites were expressed in CRO cells. All the mutants bound IGFBP-3, demonstrating that this interaction is not dependent on any single glycan chain. Enzymatic desialylation of ALS caused a shift in isoelectric point from 4.5 toward 7, demonstrating a substantial contribution of anionic charge by sialic acid. Ionic interactions are known to be involved in the association between ALS and IGFBP-3. Desialylation reduced the affinity of ALS for IGFBP-3 IGF complexes by 50-80%. Since serum protein glycosylation is often modified in disease states, the dependence of IGF ternary complex formation on the glycosylation state of ALS suggests a novel mechanism for regulation of IGF bioavailability.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Delhanty, PJD (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012; Bond, Jude j/E-5246-2017	Baxter, Robert C/0000-0001-5061-2142; Bond, Jude j/0000-0002-2913-9335				ABIDI FE, 1987, ANAL BIOCHEM, V166, P257, DOI 10.1016/0003-2697(87)90573-2; AVVAKUMOV GV, 1993, J BIOL CHEM, V268, P862; BANG P, 1994, J CLIN ENDOCR METAB, V78, P1119, DOI 10.1210/jc.78.5.1119; BAXTER RC, 1993, BIOCHEM J, V294, P847, DOI 10.1042/bj2940847; BAXTER RC, 1988, J CLIN ENDOCR METAB, V67, P265, DOI 10.1210/jcem-67-2-265; BAXTER RC, 1993, BIOCHEM BIOPH RES CO, V196, P1267, DOI 10.1006/bbrc.1993.2389; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; Baxter RC, 1997, GROWTH REGULAT, V7, P1; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; Boisclair YR, 1996, P NATL ACAD SCI USA, V93, P10028, DOI 10.1073/pnas.93.19.10028; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; DAI J, 1992, BIOCHEM BIOPH RES CO, V188, P304, DOI 10.1016/0006-291X(92)92385-B; Delhanty P, 1996, BIOCHEM BIOPH RES CO, V227, P897, DOI 10.1006/bbrc.1996.1602; Delhanty PJD, 1998, BIOCHEM BIOPH RES CO, V243, P269, DOI 10.1006/bbrc.1998.8089; DELHANTY PJD, 1998, REGULATION ACTIONS A, P135; Donaghy AJ, 1996, BAILLIERE CLIN ENDOC, V10, P421, DOI 10.1016/S0950-351X(96)80560-X; DORAI DT, 1981, ANAL BIOCHEM, V115, P130, DOI 10.1016/0003-2697(81)90535-2; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Holman SR, 1996, GROWTH REGULAT, V6, P42; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LEWITT MS, 1993, ENDOCRINOLOGY, V133, P1797, DOI 10.1210/en.133.4.1797; LIU F, 1994, J CLIN ENDOCR METAB, V79, P1883, DOI 10.1210/jc.79.6.1883; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VANDIJK W, 1995, GLYCOCONJUGATE J, V12, P227, DOI 10.1007/BF00731324; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884	36	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5292	5298		10.1074/jbc.274.9.5292	http://dx.doi.org/10.1074/jbc.274.9.5292			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026136	hybrid			2022-12-27	WOS:000078804400007
J	Satake, H; Takuwa, K; Minakata, H; Matsushima, O				Satake, H; Takuwa, K; Minakata, H; Matsushima, O			Evidence for conservation of the vasopressin/oxytocin superfamily in annelida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTOCIN-RELATED PEPTIDE; CATOSTOMUS-COMMERSONI; ARGININE VASOPRESSIN; MOLECULAR EVOLUTION; CRYSTAL-STRUCTURE; EISENIA-FOETIDA; VASOTOCIN GENE; CELL-LINE; HORMONE; RAT	Annetocin is a structurally and functionally oxytocin-related peptide isolated from the earthworm Eisenia foetida. We present the characterization of the annetocin cDNA. Sequence analyses of the deduced precursor polypeptide revealed that the annetocin precursor is composed of three segments: a signal peptide, an annetocin sequence flanked by a Gly C-terminal amidation signal and a Lys-Arg dibasic processing site, and a neurophysin domain, similar to other oxytocin family precursors. The proannetocin showed 37.4-45.8% amino acid homology to other prohormones. In the neurophysin domain, 14 cysteines and amino acid residues essential for association of a neurophysin with a vasopressin/oxytocin superfamily peptide were conserved, suggesting that the Eisenia neurophysin can bind to annetocin. Furthermore, in situ hybridization experiments demonstrated that the annetocin gene is expressed exclusively in neurons of the central nervous system predicted to be involved in regulation of reproductive behavior. These findings confirm that annetocin is a member of the vasopressin/oxytocin superfamily. This is the first identification of the cDNA encoding the precursor of an invertebrate oxytocin-related peptide and also the first report of the identification of an annelid vasopressin/oxytocin-related precursor.	Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Hiroshima Univ, Fac Sci, Dept Biol Sci, Higashihiroshima, Hiroshima 7398526, Japan	Suntory Holdings Ltd; Hiroshima University	Minakata, H (corresponding author), Suntory Inst Bioorgan Res, Wakayamadai 1-1-1, Shimamoto, Osaka 6188503, Japan.	Hiroyuki_Minakata@suntory.co.jp						Acher R., 1985, P11; Acher R, 1996, GEN COMP ENDOCR, V102, P157, DOI 10.1006/gcen.1996.0057; ACHER R, 1993, REGUL PEPTIDES, V45, P1, DOI 10.1016/0167-0115(93)90174-7; ACHER R, 1980, PROC R SOC SER B-BIO, V210, P21, DOI 10.1098/rspb.1980.0116; ADAN RAH, 1993, MOL ENDOCRINOL, V7, P47, DOI 10.1210/me.7.1.47; ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ADAN RAH, 1992, J BIOL CHEM, V267, P3771; BARNES RD, 1987, INVERTEBRATE ZOOLOGY, P312; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; BURMAN S, 1989, P NATL ACAD SCI USA, V86, P429, DOI 10.1073/pnas.86.2.429; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; CRUZ LJ, 1987, J BIOL CHEM, V262, P15821; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; FIGUEROA J, 1989, EMBO J, V8, P2873, DOI 10.1002/j.1460-2075.1989.tb08435.x; HAMANN D, 1992, J NEUROENDOCRINOL, V4, P505, DOI 10.1111/j.1365-2826.1992.tb00198.x; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; Hoyle CHV, 1998, REGUL PEPTIDES, V73, P1, DOI 10.1016/S0167-0115(97)01073-2; Hyodo S, 1997, P NATL ACAD SCI USA, V94, P13339, DOI 10.1073/pnas.94.24.13339; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAND H, 1982, NATURE, V295, P299, DOI 10.1038/295299a0; LAND H, 1983, NATURE, V302, P342, DOI 10.1038/302342a0; MCMASTER D, 1992, PEPTIDES, V13, P413, DOI 10.1016/0196-9781(92)90069-F; MOHR E, 1991, MOL BRAIN RES, V9, P293, DOI 10.1016/0169-328X(91)90075-9; MOHR E, 1990, FEBS LETT, V260, P305, DOI 10.1016/0014-5793(90)80130-B; MORLEY SD, 1990, BIOCHEMISTRY-US, V29, P2506, DOI 10.1021/bi00462a011; OEDING P, 1990, J NEUROENDOCRINOL, V2, P859, DOI 10.1111/j.1365-2826.1990.tb00652.x; OUMI T, 1994, BIOCHEM BIOPH RES CO, V198, P393, DOI 10.1006/bbrc.1994.1055; Oumi T, 1996, J EXP ZOOL, V276, P151, DOI 10.1002/(SICI)1097-010X(19961001)276:2&lt;151::AID-JEZ8&gt;3.0.CO;2-N; PARDY K, 1992, J BIOL CHEM, V267, P21746; PROUX JP, 1987, BIOCHEM BIOPH RES CO, V149, P180, DOI 10.1016/0006-291X(87)91621-4; REICH G, 1992, NEUROSCI LETT, V134, P191, DOI 10.1016/0304-3940(92)90514-8; RICHARD S, 1990, J BIOL CHEM, V265, P6098; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Takahama H, 1998, ZOOL SCI, V15, P381, DOI 10.2108/zsj.15.381; VANKESTEREN RE, 1995, J NEUROSCI, V15, P5989; VANKESTEREN RE, 1992, P NATL ACAD SCI USA, V89, P4593, DOI 10.1073/pnas.89.10.4593; VERBEECK MAE, 1991, MOL ENDOCRINOL, V5, P795, DOI 10.1210/mend-5-6-795; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440	44	69	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5605	5611		10.1074/jbc.274.9.5605	http://dx.doi.org/10.1074/jbc.274.9.5605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026177	hybrid			2022-12-27	WOS:000078804400048
J	Allgayer, H; Wang, H; Wang, Y; Heiss, MM; Bauer, R; Nyormoi, O; Boyd, D				Allgayer, H; Wang, H; Wang, Y; Heiss, MM; Bauer, R; Nyormoi, O; Boyd, D			Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2 alpha-related factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; CANCER-CELLS; POSTTRANSCRIPTIONAL REGULATION; COLON ADENOCARCINOMAS; EXPRESSION; INVASION; AP-2; PROTEIN	The urokinase receptor overexpressed in invasive cancers promotes laminin degradation. The current study was undertaken to identify cis elements and trans-acting factors activating urokinase receptor expression through a footprinted (-148/-124) region of the promoter containing putative activator protein-2- and Sp1-binding motifs, Mobility shifting experiments using nuclear extract from a high urokinase receptor-expressing cell line (RKO) indicated that Sp1, Sp3, and a factor similar to, but distinct from, activator protein-2 alpha bound to this region, Mutations preventing the binding of the activator protein 2 alpha-related factor diminished urokinase receptor promoter activity. In RKO cells, the expression of a negative regulator of activator protein-2 function diminished urokinase receptor promoter activity, protein, and laminin degradation. Conversely, urokinase receptor promoter activity in low urokinase receptor-expressing GEO cells was increased by activator protein-2 alpha A expression. Although using GEO nuclear extract, little activator protein-2 alpha-related factor bound to the footprinted region, phorbol 12-myristate 13-acetate treatment, which induces urokinase receptor expression, increased complex formation. Mutations preventing the activator protein-2 alpha-related factor and Sp1/Sp8 binding reduced urokinase receptor promoter stimulation by this agent. Thus, the constitutive and phorbol 12-myristate 13-acetate-inducible expression of the urokinase receptor is mediated partly through trans-activation of the promoter via a sequence (-152/-135) bound with an activator protein-2 alpha-related factor.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem, Houston, TX 77030 USA; Univ Sydney, Westmead Hosp, Dept Renal Med, Westmead, NSW 2145, Australia; Univ Munich, Klinikum Grosshadern, Dept Surg, D-81377 Munich, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Sydney; University of Munich	Boyd, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845, P50DE011906] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [P01 DE11906, R01 DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSSON G, 1994, CELL GROWTH DIFFER, V5, P27; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRUCKNER A, 1992, CANCER RES, V52, P3043; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; CASEY JR, 1994, BLOOD, V84, P1151; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CONESE M, 1994, J BIOL CHEM, V269, P17886; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; ELLIS V, 1991, J BIOL CHEM, V266, P12752; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KARIKO K, 1993, CANCER RES, V53, P3109; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lee BS, 1997, J BIOL CHEM, V272, P174; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Long FX, 1998, J BIOL CHEM, V273, P6542, DOI 10.1074/jbc.273.11.6542; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Min HY, 1996, CANCER RES, V56, P2428; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xing RH, 1997, CANCER RES, V57, P3585; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	58	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4702	4714		10.1074/jbc.274.8.4702	http://dx.doi.org/10.1074/jbc.274.8.4702			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988707	hybrid			2022-12-27	WOS:000078698200032
J	Bridges, EG; Jiang, ZL; Cheng, YC				Bridges, EG; Jiang, ZL; Cheng, YC			Characterization of a dCTP transport activity reconstituted from human mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BEEF-HEART MITOCHONDRIA; HUMAN LEUKEMIA-CELLS; DNA-SYNTHESIS; TRICARBOXYLATE CARRIER; PHOSPHATE-TRANSPORT; PURIFICATION; PROTEIN; ZIDOVUDINE; HYDROXYLAPATITE	A protein fraction of mitochondria from human acute lymphocytic leukemia cells, which could be reconstituted into proteoliposomes to have dCTP transport activity, has been partially purified by hydroxyapatite and blue Sepharose chromatography. The dCTP transport activity in proteoliposomes was time-dependent and could be activated by Ca2+ and to a lesser extent by Mg2+. None of the other divalent cations tested could activate the transport activity. The K-m value of dCTP in the presence of Ca2+ was shown to be 3 mu M. dCDP but not dCMP or dCyd could inhibit the transport activity. Other deoxynucleoside triphosphates could also inhibit the uptake of dCTP with the potency dGTP = dATP > TTP. Although ATP could competitively inhibit dCTP uptake with a K-i value of 8 mu M, the reconstituted dCTP uptake activity was not sensitive to the ATP/ADP carrier inhibitor atractyloside or the sulfhydryl reagent N-ethylmaleimide. This suggests that the dCTP transport system studied is not the same as the ATP/ADP carrier. In conclusion, these studies describe the first functionally reconstituted mitochondrial carrier that displays an efficient transport activity for dCTP.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, POB 802066, New Haven, CT 06520 USA.				NIAID NIH HHS [AI-38204] Funding Source: Medline; NIGMS NIH HHS [F32GM17474] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017474] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BANERJEE RK, 1983, MOL CELL BIOCHEM, V50, P3; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; Casademont J, 1996, BRAIN, V119, P1357, DOI 10.1093/brain/119.4.1357; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P143; ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861; FRILAND A, 1990, MOL PHARMACOL, V37, P665; GANDHI V, 1995, SEMIN ONCOL, V22, P61; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; Iwasaki H, 1997, BLOOD, V90, P270; JOYAL JL, 1992, J BIOL CHEM, V267, P19198; KAPLAN RS, 1985, J BIOL CHEM, V260, P293; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KLINGENBERG M, 1978, BIOCHIM BIOPHYS ACTA, V503, P193, DOI 10.1016/0005-2728(78)90182-2; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209; KRAMER R, 1994, BIOCHIM BIOPHYS ACTA, V974, P1; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; PARKER WB, 1994, J NIH RES, V6, P57; PARSONS P, 1973, J BIOL CHEM, V248, P1912; PICK U, 1981, ARCH BIOCHEM BIOPHYS, V212, P186, DOI 10.1016/0003-9861(81)90358-1; ROJO M, 1994, BBA-BIOENERGETICS, V1187, P360, DOI 10.1016/0005-2728(94)90010-8; SCHAFER JA, 1994, METHODS MEMBRANE TRA, P325; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; STIPANI I, 1983, FEBS LETT, V161, P269, DOI 10.1016/0014-5793(83)81023-0; WEHRLE JP, 1983, ARCH BIOCHEM BIOPHYS, V223, P477, DOI 10.1016/0003-9861(83)90612-4; Xie KC, 1996, CANCER RES, V56, P3030	35	60	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4620	4625		10.1074/jbc.274.8.4620	http://dx.doi.org/10.1074/jbc.274.8.4620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988697	hybrid			2022-12-27	WOS:000078698200022
J	Della Rocca, GJ; Mukhin, YV; Garnovskaya, MN; Daaka, Y; Clark, GJ; Luttrell, LM; Lefkowitz, RJ; Raymond, JR				Della Rocca, GJ; Mukhin, YV; Garnovskaya, MN; Daaka, Y; Clark, GJ; Luttrell, LM; Lefkowitz, RJ; Raymond, JR			Serotonin 5-HT1A receptor-mediated Erk activation requires calcium/calmodulin-dependent receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CALMODULIN-BINDING DOMAIN; TYROSINE-KINASE; COATED VESICLES; PHOSPHORYLATION; CELLS; DESENSITIZATION; LOCALIZATION; PP60C-SRC; IDENTIFICATION	Many receptors that couple to heterotrimeric guanine nucleotide-binding (G) proteins mediate rapid activation of the mitogen-activated protein kinases, Erk1 and Erk2. The G(i)-coupled serotonin (5-hydroxytryptamine (5-HT)) 5-HT1A receptor, heterologously expressed in Chinese hamster ovary or human embryonic kidney 293 cells, mediated rapid activation of Erk1/2 via a mechanism dependent upon both Ras activation and clathrin-mediated endocytosis. This activation was attenuated by chelation of intracellular Ca2+ and Ca2+/calmodulin (CAM) inhibitors or the CAM sequestrant protein calspermin, The CAM-dependent step in the Erk1/2 activation cascade is downstream of Ras activation, because inhibitors of CAM antagonize Erk1/2 activation induced by constitutively activated mutants of Ras and c-Src but not by constitutively activated mutants of Raf and MEK (mitogen and extracellular signal-regulated kinase). Inhibitors of the classical CAM effecters myosin light chain kinase, CAM-dependent protein kinases II and IV, PP2B, and CAM-sensitive phosphodiesterase had no effect upon 5-HT1A receptor-mediated Erk1/2 activation. Because clathrin-mediated endocytosis was required for 5-HT1A receptor-mediated Erk1/2 activation, we pos tulated a role for CAM in receptor endocytosis. Inhibition of receptor endocytosis by use of sequestration-defective mutants of beta-arrestin, and dynamin attenuated 5-HT1A receptor-stimulated Erk1/2 activation. Inhibition of CAM prevented agonist dependent endocytosis of epitope-tagged 5-HT1A receptors. We conclude that CAM-dependent activation of Erk1/2 through the 5-HT1A receptor reflects its role in endocytosis of the receptor, which is a required step in the activation of MEK and subsequently Erk1/2.	Med Univ S Carolina, Dept Med Nephrol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; NCI, NIH, Rockville, MD 20857 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Raymond, JR (corresponding author), Med Univ S Carolina, Dept Med Nephrol, 829 Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA.	raymondj@musc.edu	Della Rocca, Gregory/AAM-5281-2021; Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949; Garnovskaya, Maria/0000-0002-6216-038X	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK02352, DK52448] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002352, R56DK052448, R01DK052448] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; GEISOW MJ, 1983, NATURE, V301, P432, DOI 10.1038/301432a0; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Llorente A, 1996, EXP CELL RES, V227, P298, DOI 10.1006/excr.1996.0279; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MERISKO EM, 1985, EUR J CELL BIOL, V39, P167; Moroi K, 1998, BRAIN RES, V794, P291, DOI 10.1016/S0006-8993(98)00245-5; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEY UM, 1995, J BIOL CHEM, V270, P2395, DOI 10.1074/jbc.270.5.2395; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SALISBURY JL, 1981, NATURE, V294, P163, DOI 10.1038/294163a0; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WIDADA JS, 1990, BIOCHIMIE, V72, P19, DOI 10.1016/0300-9084(90)90168-G; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	44	127	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4749	4753		10.1074/jbc.274.8.4749	http://dx.doi.org/10.1074/jbc.274.8.4749			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988712	hybrid			2022-12-27	WOS:000078698200037
J	Freebern, WJ; Osman, A; Niles, EG; Christen, L; LoVerde, PT				Freebern, WJ; Osman, A; Niles, EG; Christen, L; LoVerde, PT			Identification of a cDNA encoding a retinoid X receptor homologue from Schistosoma mansoni - Evidence for a role in female-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACID RECEPTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; ECDYSONE RECEPTOR; DNA-BINDING; TRANSACTIVATION DOMAIN; TRANSCRIPTION FACTOR; LIGAND-BINDING; PROTEIN	Schistosoma mansoni, a multicelluar eukaryotic blood fluke, is a major cause of morbidity worldwide in humans. The study of female parasite growth, development, and gene regulation is important because the eggs produced are responsible for the pathogenesis observed in schistosomiasis, p14, an eggshell precursor gene expressed only in sexually mature females in response to a male stimulus, is a model for female-specific gene regulation. The upstream region of the p14 gene shares sequences present in insect genes known to be regulated in a sex-, temporal-, and tissue-specific manner by members of the steroid receptor superfamily, Herein, we report the identification and characterization of a cDNA that encodes the S, mansoni (Sm) RXR homologue, Sequence analysis predicts and Western blot analysis confirms the synthesis of a 74-kDa protein, the largest member of the RXR family reported to date. We show by electrophoretic mobility shift assay analysis that SmRXR binds to cis-elements of the p14 gene including a direct repeat that follows the "3-4-5" rule of binding elements recognized by members of the steroid receptor superfamily, Furthermore, we demonstrate that SmRXR can act as a transcription activator in the yeast one-hybrid system. Through quantitative reverse transcriptase-polymerase chain reaction, we show that the SmRXR gene is constitutively expressed and thus must play multiple roles throughout the schistosome life cycle.	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Ctr Microbial Pathogenesis, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	LoVerde, PT (corresponding author), SUNY Buffalo, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.	loverde@buffalo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027219, R22AI027219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27219] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BOBEK L, 1986, P NATL ACAD SCI USA, V83, P5544, DOI 10.1073/pnas.83.15.5544; BOBEK L, 1987, MOL CELL BIOL, V42, P133; BOBEK LA, 1988, MOL CELL BIOL, V8, P3008, DOI 10.1128/MCB.8.8.3008; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHEN LL, 1992, MOL BIOCHEM PARASIT, V52, P39, DOI 10.1016/0166-6851(92)90034-H; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Engers HD, 1996, DEV BIOL STAND, V87, P73; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLYNN TR, 1994, J BIOL CHEM, V269, P32713; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; Grevelding CG, 1997, PARASITOLOGY, V115, P635, DOI 10.1017/S0031182097001728; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KOSTER B, 1988, MOL BIOCHEM PARASIT, V31, P183, DOI 10.1016/0166-6851(88)90169-7; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LENG XH, 1994, J BIOL CHEM, V269, P31436; LOVERDE PT, 1991, PARASITOL TODAY, V7, P303, DOI 10.1016/0169-4758(91)90263-N; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCDONNELL DP, 1988, J STEROID BIOCHEM, V30, P41, DOI 10.1016/0022-4731(88)90074-X; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; MENRATH M, 1995, PARASITOLOGY, V111, P477, DOI 10.1017/S0031182000065987; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ORO AE, 1992, DEVELOPMENT, V115, P449; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schussler P, 1997, PARASITOLOGY, V115, P629, DOI 10.1017/S003118209700173X; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4577	4585		10.1074/jbc.274.8.4577	http://dx.doi.org/10.1074/jbc.274.8.4577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988692	hybrid			2022-12-27	WOS:000078698200017
J	Hanson, ES; Foot, LM; Leibold, EA				Hanson, ES; Foot, LM; Leibold, EA			Hypoxia post-translationally activates iron-regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYDROXYLASE MESSENGER-RNA; INDUCIBLE FACTOR 1-ALPHA; ELEMENT-BINDING PROTEIN; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; ERYTHROPOIETIN GENE; CYTOPLASMIC PROTEIN; ACONITASE ACTIVITY; OXIDATIVE STRESS	Iron-regulatory proteins 1 and 2 (IRP1 and IRP2) are RNA-binding proteins that post-transcriptionally regulate the expression of mRNAs that code for proteins involved in the maintenance of iron and energy homeostasis, Here we show that hypoxia differentially regulates the RNA binding activities of IRP1 and IRP2 in human 293 and in mouse Hepa-1 cells, In contrast to IRP1, where hypoxic exposure decreases IRP1 RNA binding activity, hypoxia increases IRP2 RNA binding activity. The hypoxic increase in IRP2 RNA binding activity results from increased IRP2 protein levels. Cobalt, which mimics hypoxia by activation of hypoxia-inducible factor 1 (HIF-1), also increases IRP2 protein levels; however, cobalt-induced IRP2 lacks RNA binding activity. Addition of a reductant to cobalt-treated extracts restored IRP2 RNA binding activity. Hypoxic activation of IRP2 is not because of an increase in transcriptional activation by HIF-1, because IRP2 accumulates in Hepa-1 cells lacking a functional HIF-1 beta subunit, nor is it because of an increase in IRP2 mRNA stability. Rather, our data indicate that hypoxia increases IRP2 levels by a post-translational mechanism involving pro tein stability. Differential regulation of IRP1 and IRP2 during hypoxia may regulate specific IRP target mRNAs whose expression is required for hypoxic adaptation. Furthermore, these data imply mechanistic parallels between the hypoxia-induced post-transcriptional regulation of IRP2 and HIF-1 alpha.	Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Div Hematol Oncol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Leibold, EA (corresponding author), Univ Utah, Eccles Program Human Mol Biol & Genet, 15 N 2030 E,Bldg 533,Rm 4220, Salt Lake City, UT 84112 USA.	betty.leibold@hci.utah.edu			NIDDK NIH HHS [T32 DK07115] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CzyzykKrzeska MF, 1997, KIDNEY INT, V51, P585, DOI 10.1038/ki.1997.84; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; ECKARDT KU, 1993, PFLUG ARCH EUR J PHY, V423, P356, DOI 10.1007/BF00374928; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Henderson ER, 1996, J BIOL CHEM, V271, P4900; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HUANG EL, 1997, J BIOL CHEM, V271, P32253; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1997, BBA-GENE STRUCT EXPR, V1352, P167, DOI 10.1016/S0167-4781(97)00052-3; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LEWIS CPL, 1992, BIOCHEM PHARMACOL, V43, P519, DOI 10.1016/0006-2952(92)90573-2; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	40	122	125	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5047	5052		10.1074/jbc.274.8.5047	http://dx.doi.org/10.1074/jbc.274.8.5047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988751	hybrid			2022-12-27	WOS:000078698200076
J	Tokitou, F; Nomura, T; Khan, MM; Kaul, SC; Wadhwa, R; Yasukawa, T; Kohno I; Ishii, S				Tokitou, F; Nomura, T; Khan, MM; Kaul, SC; Wadhwa, R; Yasukawa, T; Kohno, I; Ishii, S			Viral ski inhibits retinoblastoma protein (Rb)-mediated transcriptional repression in a dominant negative fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; CO-REPRESSOR; N-COR; ONCOGENE; COMPLEX; GENE; MAD; MYC; SEQUENCE; MSIN3A	The mechanism by which the viral oncogene ski (v-ski) transforms chicken embryo fibroblasts is currently unknown. Recently, the c-ski gene product (c-Ski) was found to bind to N-CoR (nuclear hormone receptor corepressor), an element implicated in transcriptional repression mediated by multiple transcriptional repressors including the nuclear hormone receptors and Mad. c-Ski is required for transcriptional repression mediated by Mad involved in negative regulation of cellular proliferation, v-Ski abrogates Mad-induced transcriptional repression in a dominant negative fashion. Here we report that v-Ski also inhibits transcriptional repression mediated by Rb, another tumor suppressor gene product. Rb forms a complex with c-Ski, Sin3A, and histone deacetylase (HDAC) via direct binding to c-Ski and HDAC. c-Ski is required for the transcriptional repression mediated by Rb. These results suggest that inhibition of Rb activity contributes, at least partly, to transformation by v-Ski.	RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Med Sci, Tsukuba, Ibaraki 3050006, Japan; Natl Inst Biosci & Human Technol, Agcy Ind Sci & Technol, Tsukuba, Ibaraki 3050046, Japan; Chugai Res Inst Mol Med, Niihari, Ibaraki 3004101, Japan; Iatron Labs Inc, Chiba 2892247, Japan; JST, CREST, Tokyo, Japan	RIKEN; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016; Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Ishii, Shunsuke/0000-0002-6530-2478; Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; NOMURA T, 1999, IN PRESS GENES DEV; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	28	77	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4485	4488		10.1074/jbc.274.8.4485	http://dx.doi.org/10.1074/jbc.274.8.4485			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988677	hybrid			2022-12-27	WOS:000078698200002
J	Fouts, ET; Yu, X; Egelman, EH; Botchan, MR				Fouts, ET; Yu, X; Egelman, EH; Botchan, MR			Biochemical and electron microscopic image analysis of the hexameric E1 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS TYPE-1 ORIGIN; SINGLE-STRANDED-DNA; LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; BOVINE PAPILLOMAVIRUS; ESCHERICHIA-COLI; REPLICATION PROTEIN; BRANCH MIGRATION; VIRAL ORIGIN; E2 PROTEINS	DNA replication initiator proteins bind site specifically to origin sites and in most cases participate in the early steps of unwinding the duplex. The papillomavirus preinitiation complex that assembles on the origin of replication is composed of proteins E1 and the activator protein E2, E2 is an ancillary factor that increases the affinity of E1 for the ori site through cooperative binding. Here we show that duplex DNA affects E1 (in the absence of E2) to assemble into an active hexameric structure. As a 10-base oligonucleotide can also induce this oligomerization, it seems likely that DNA binding allosterically induces a conformation that enhances hexamers, E1 assembles as a bi-lobed, presumably double hexameric structure on duplex DNA and can initiate bi-directional unwinding from an ori site. The DNA takes an apparent straight path through the double hexamers. Image analysis of E1 hexameric rings shows that the structures are heterogeneous and have either a 6- or 3-fold symmetry. The rings are about 40-50 Angstrom thick and 125 Angstrom in diameter. The density of the central cavity appears to be a variable and we speculate that a plugged center may represent a conformational flexibility of a subdomain of the monomer, to date unreported for other hexameric helicases.	Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Minnesota System; University of Minnesota Twin Cities	Botchan, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	mbotchan@uclink4.berkeley.edu	Egelman, Edward H/A-2488-2009	Egelman, Edward/0000-0003-4844-5212	NCI NIH HHS [CA42414, CA30490] Funding Source: Medline; NIGMS NIH HHS [GM35269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042414, R01CA030490, R37CA030490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISWAS EE, 1986, BIOCHEMISTRY-US, V25, P7368, DOI 10.1021/bi00371a019; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRANK J, 1988, METHOD ENZYMOL, V164, P3; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Ito K, 1996, EMBO J, V15, P5636, DOI 10.1002/j.1460-2075.1996.tb00948.x; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; MACPHERSON P, 1994, VIROLOGY, V204, P403, DOI 10.1006/viro.1994.1544; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; Martin Carmen San, 1998, Structure (London), V6, P501, DOI 10.1016/S0969-2126(98)00051-3; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MENDOZA R, 1995, J VIROL, V69, P3789, DOI 10.1128/JVI.69.6.3789-3798.1995; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MULLER F, 1994, J BIOL CHEM, V269, P17086; NILSSON M, 1991, NUCLEIC ACIDS RES, V19, P7061, DOI 10.1093/nar/19.25.7061; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SanMartin MC, 1997, J MOL BIOL, V268, P15, DOI 10.1006/jmbi.1997.0952; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SENGUPTA DJ, 1994, EMBO J, V13, P982, DOI 10.1002/j.1460-2075.1994.tb06343.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STITT BL, 1988, J BIOL CHEM, V263, P11130; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	65	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4447	4458		10.1074/jbc.274.7.4447	http://dx.doi.org/10.1074/jbc.274.7.4447			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933649	hybrid			2022-12-27	WOS:000078575500073
J	Molloy, DP; Smith, KJ; Milner, AE; Gallimore, PH; Grand, RJA				Molloy, DP; Smith, KJ; Milner, AE; Gallimore, PH; Grand, RJA			The structure of the site on adenovirus early region 1A responsible for binding to TATA-binding protein determined by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; E1A PROTEINS; CELL-GROWTH; ZINC-FINGER; FUNCTIONAL DOMAINS; PEPTIDE; GENE; ACTIVATION; TRANSFORMATION; IDENTIFICATION	Previous detailed mutational analysis has shown that the binding site on adenovirus (Ad) early region 1A (E1A) for TATA-binding protein (TBP) is located toward the N terminus of conserved region 3 (CR3), Here we demonstrate that synthetic peptides of between 15 and 22 amino acids, identical to amino acid sequences of CR3 present in the larger Ad5 E1A (13 S product) and in both the Ad12 E1A (13 and 12 S products) proteins that lie N-terminal to the zinc finger motif, can disrupt binding of E1A to TBP, These findings suggest that the peptides are biologically active in terms of interacting with TBP and must therefore comprise some, if not all, of the TBP binding site on E1A, The interaction between Ad12 E1A and TBP was confirmed by direct co precipitation experiments, In H-1 NMR studies of CR3 peptides, regular patterns of NOEs were observed from which their conformational preferences in aqueous solution were determined. Both Ad5 and Ad12 peptides were shown to contain regions of helical backbone structure in 50% trifluoroethanol. In each case, the type and intensities of NOE cross-peaks observed correlated best to alpha-helical turns. These helices are more extensive in larger peptides and extend from Glu(141) to Val(147) and from Arg(144) to Pro(152) in the full-length Ad5 and Ad12 13S E1A proteins, respectively. The structure of a 19-residue Ad5 CR3 peptide carrying the V147L mutation in the full-length protein that abolishes TBP binding was examined. No significant differences between the substituted and wild type peptides were observed, suggesting that this substitution in the intact protein may cause disruption of global rather than local structures.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	R.J.A.Grand@bham.ac.uk						BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CRISMA M, 1995, PEPTIDE RES, V8, P187; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GALLIMORE PH, 1988, CANCER RES, V45, P2670; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; LUI F, 1990, CELL, V61, P1217; LUI F, 1994, NATURE, V368, P520; MIICK SM, 1992, NATURE, V359, P653, DOI 10.1038/359653a0; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SEGAWA S, 1991, BIOPOLYMERS, V31, P497, DOI 10.1002/bip.360310505; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SHENK T, 1991, ADV CANCER RES, V57, P47; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; SMITH KJ, 1994, BIOCHEMISTRY-US, V33, P6063, DOI 10.1021/bi00186a005; SMITH LJ, 1994, STRUCTURE, V2, P703, DOI 10.1016/S0969-2126(00)00071-X; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILLIAMS J, 1994, CURR TOP MICROBIOL, V199, P149	50	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3503	3512		10.1074/jbc.274.6.3503	http://dx.doi.org/10.1074/jbc.274.6.3503			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920896	hybrid			2022-12-27	WOS:000078428200036
J	Zhu, CC; Furuichi, T; Mikoshiba, R; Wojcikiewicz, RJH				Zhu, CC; Furuichi, T; Mikoshiba, R; Wojcikiewicz, RJH			Inositol 1,4,5-trisphosphate receptor down-regulation is activated directly by inositol 1,4,5-trisphosphate binding - Studies with binding-defective mutant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH-SY5Y NEUROBLASTOMA-CELLS; TRISPHOSPHATE RECEPTOR; PHOSPHOINOSITIDASE-C; CA2+ MOBILIZATION; DESENSITIZATION; FIBROBLASTS; DEGRADATION; EXPRESSION; INVOLVEMENT; STIMULATION	Activation of certain phosphoinositidase C-linked cell surface receptors is known to cause an acceleration of the proteolysis of inositol 1,4,5-trisphosphate (InsP(3)) receptors and, thus, lead to InsP(3) receptor down-regulation. To gain insight into this process, we examined whether or not InsP(3) receptor degradation is a direct consequence of InsP(3) binding by analyzing the downregulation of exogenous wild-type and binding-defective mutant InsP(3) receptors expressed in SH-SY5Y human neuroblastoma cells. Stimulation of these cells with carbachol showed that wild-type exogenous receptors could be down-regulated but that the binding-defective mutant exogenous receptors were not. Thus, InsP(3) binding appears to mediate down-regulation. To validate this conclusion, a comprehensive analysis of the effects of the exogenous receptors was undertaken. This showed that exogenous receptors (i) are localized appropriately within the cell, (ii) enhance InsP(3)-induced Ca2+ release in permeabilized cells, presumably by increasing the number of InsP(3)-sensitive Ca2+ channels, (iii) have minimal effects on Ca2+ mobilization and InsP(3) formation in intact cells, (iv) form heteromers with endogenous receptors, and (v) do not alter the down-regulation of endogenous receptors, In total, these data show that the introduction of exogenous receptors into SH-SY5Y cells does not compromise intracellular signaling or the down-regulatory process. We can thus conclude that InsP(3) binding directly activates InsP(3) receptor degradation. Because InsP(3) binding induces a conformational change in the InsP(3) receptor, these data suggest that this change provides the signal for accelerated proteolysis.	SUNY Hlth Sci Ctr, Coll Med, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 108, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Tokyo	Wojcikiewicz, RJH (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@vax.cs.hscsyr.edu	Furuichi, Teiichi/B-5086-2014	Furuichi, Teiichi/0000-0002-9676-1888	NIDDK NIH HHS [DK49194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194, R29DK049194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1994, J BIOL CHEM, V269, P27167; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DeSmedt H, 1997, BIOCHEM J, V322, P575; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lievremont JP, 1996, BIOCHEM J, V317, P755, DOI 10.1042/bj3170755; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; WATRAS J, 1991, J NEUROSCI, V11, P3239; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, MOL PHARMACOL, V53, P656, DOI 10.1124/mol.53.4.656; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; Yoshida Y, 1997, JPN J PHARMACOL, V74, P125, DOI 10.1254/jjp.74.125	43	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3476	3484		10.1074/jbc.274.6.3476	http://dx.doi.org/10.1074/jbc.274.6.3476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920893	hybrid			2022-12-27	WOS:000078428200033
J	Liu, N; Cigola, E; Tinti, C; Jin, BK; Conti, B; Volpe, BT; Baker, H				Liu, N; Cigola, E; Tinti, C; Jin, BK; Conti, B; Volpe, BT; Baker, H			Unique regulation of immediate early gene and tyrosine hydroxylase expression in the odor-deprived mouse olfactory bulb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASE; ELEMENT-BINDING PROTEIN; CENTRAL-NERVOUS-SYSTEM; CAMP RESPONSE ELEMENT; CYCLIC-AMP; MESSENGER-RNA; C-FOS; TRANSCRIPTION FACTORS; ADRENAL-MEDULLA; TRANSGENIC MICE	Tyrosine hydroxylase (TH), expressed in a population of periglomerular neurons intrinsic to the olfactory bulb, displays dramatic down-regulation in response to odor deprivation. To begin to elucidate the importance of immediate early genes (IEG) in TH gene regulation, the present study examined expression of IEGs in the olfactory bulb in response to odor deprivation. In addition, the composition of TH AP-1 and CRE binding complexes was investigated in control and odor-deprived mice. Immunocytochemical studies showed that c-Fos, Fos-B, Jun-D, CRE-binding protein (CREB), and phosphorylated CREB (pCREB) are colocalized with TH in the dopaminergic periglomerular neurons. Unilateral naris closure resulted in down-regulation of c-Fos and Fos-B, but not Jun-D, CREB, or pCREB, in the glomerular layer of the ipsilateral olfactory bulb. Gel shift assays demonstrated a significant decrease (32%) in TH AP-I, but not CRE, binding activity in the odor-deprived bulb. Fos-B was found to be the exclusive member of the Fos family present in the TH BP-l complex. CREB, CRE modulator protein (CREM), Fos-B, and Jun-D, but not c-Fos, all contributed to the CRE: DNA-protein complex. These results indicated that Fos-B, acting through both AP-1 and CRE motifs, may be implicated in the regulation of TH expression in the olfactory bulb dopaminergic neurons.	Cornell Univ, Coll Med, Burke Med Res Inst, Mol Neurobiol Lab, White Plains, NY 10605 USA	Cornell University	Baker, H (corresponding author), Cornell Univ, Coll Med, Burke Med Res Inst, Mol Neurobiol Lab, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	habaker@med.cornell.edu	volpe, b/U-8409-2019	Conti, Bruno/0000-0002-9185-5201; Volpe, Bruce/0000-0002-1098-1848	PHS HHS [NIA09686] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER H, 1984, NEUROSCIENCE, V11, P605, DOI 10.1016/0306-4522(84)90047-2; BAKER H, 1983, J NEUROSCI, V3, P69; BAKER H, 1990, NEUROSCIENCE, V36, P761, DOI 10.1016/0306-4522(90)90018-Y; BAKER H, 1993, NEUROSCIENCE, V52, P115, DOI 10.1016/0306-4522(93)90187-K; BAKER H, 1993, BRAIN RES, V614, P109, DOI 10.1016/0006-8993(93)91023-L; BRUNJES PC, 1985, DEV BRAIN RES, V22, P1, DOI 10.1016/0165-3806(85)90063-X; CHEN JS, 1995, MOL PHARMACOL, V48, P880; Cho JY, 1996, J COMP NEUROL, V369, P264; CUBELLS JF, 1995, J NEUROCHEM, V65, P502; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS BJ, 1983, J COMP NEUROL, V214, P427, DOI 10.1002/cne.902140407; DEMMER J, 1993, MOL BRAIN RES, V17, P279, DOI 10.1016/0169-328X(93)90012-E; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Ghee M, 1998, MOL BRAIN RES, V55, P101, DOI 10.1016/S0169-328X(97)00370-7; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN R, 1980, J CELL BIOL, V84, P495, DOI 10.1083/jcb.84.3.495; GUTHRIE KM, 1990, J NEUROSCI, V10, P3402; GUTHRIE KM, 1995, NEUROREPORT, V6, P2145, DOI 10.1097/00001756-199511000-00012; HABENER JF, 1990, METABOLISM, V39, P13, DOI 10.1016/0026-0495(90)90199-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; HUGHES P, 1995, PHARMACOL REV, V47, P133; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Jin BK, 1996, INT J DEV NEUROSCI, V14, P971, DOI 10.1016/S0736-5748(96)00044-5; JOH TH, 1973, J NEUROCHEM, V39, P342; KIM KS, 1993, J BIOL CHEM, V268, P15689; Kumer SC, 1996, J NEUROCHEM, V67, P443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MCLEAN JH, 1988, J NEUROSCI, V8, P3658; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PENNYPACKER KR, 1995, DEV BRAIN RES, V86, P242, DOI 10.1016/0165-3806(95)00033-A; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabban EL, 1997, SEMIN CELL DEV BIOL, V8, P101, DOI 10.1006/scdb.1996.0129; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, V3rd Edn, P133; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; STONE DM, 1991, J COMP NEUROL, V311, P223, DOI 10.1002/cne.903110205; STONE DM, 1990, MOL BRAIN RES, V8, P291, DOI 10.1016/0169-328X(90)90042-C; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trocme C, 1997, J NEUROSCI RES, V48, P489, DOI 10.1002/(SICI)1097-4547(19970615)48:6<489::AID-JNR1>3.0.CO;2-6; WEISER M, 1993, MOL BRAIN RES, V17, P319, DOI 10.1016/0169-328X(93)90017-J; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	60	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3042	3047		10.1074/jbc.274.5.3042	http://dx.doi.org/10.1074/jbc.274.5.3042			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915843	Green Published, hybrid			2022-12-27	WOS:000078319500061
J	Lin, PJ; Luby-Phelps, K; Stull, JT				Lin, PJ; Luby-Phelps, K; Stull, JT			Properties of filament-bound myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; RHO-ASSOCIATED KINASE; ENDOTHELIAL-CELL RETRACTION; PROTEIN-KINASE; OKADAIC ACID; PHOSPHORYLATION; CONTRACTION; ACTIN; BINDING; CALMODULIN	Myosin light chain kinase binds to actin-containing filaments from cells with a greater affinity than to F-actin, However, it is not known if this binding in cells is regulated by Ca2+/calmodulin as it is with F-actin. Therefore, the binding properties of the kinase to stress fibers were examined in smooth muscle-derived A7r5 cells, Full-length myosin light chain kinase or a truncation mutant lacking residues 2-142 was expressed as chimeras containing green fluorescent protein at the C terminus. In intact cells, the full-length kinase bound to stress fibers, whereas the truncated kinase showed diffuse fluorescence in the cytoplasm. After permeabilization with saponin, the fluorescence from the truncated kinase disappeared, whereas the fluorescence of the full-length kinase was retained on stress fibers. Measurements of fluorescence intensities and fluorescence recovery after photobleaching of the full-length myosin light chain kinase in saponin-permeable cells showed that Ca2+/calmodulin did not dissociate the kinase from these filaments. However, the filament-bound kinase was sufficient for Ca2+ dependent phosphorylation of myosin regulatory light chain and contraction of stress fibers. Thus, dissociation of myosin light chain kinase from actin-containing thin filaments is not necessary for phosphorylation of myosin light chain in thick filaments. We note that the distance between the N terminus and the catalytic core of the kinase is sufficient to span the distance between thin and thick filaments.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Luby-Phelps, Katherine/0000-0002-8378-1409	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; COHEN DM, 1978, J GEN PHYSIOL, V72, P369, DOI 10.1085/jgp.72.3.369; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; Hartshorne D J, 1989, Adv Exp Med Biol, V255, P269; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Jian XY, 1996, J NEUROBIOL, V31, P379, DOI 10.1002/(SICI)1097-4695(199611)31:3<379::AID-NEU10>3.0.CO;2-B; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; Mabuchi Y, 1998, BIOPHYS J, V74, pA38; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OBARA K, 1989, PFLUG ARCH EUR J PHY, V414, P134, DOI 10.1007/BF00580954; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; POWIS G, 1994, CANCER RES, V54, P2419; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SOMLYO AP, 1973, PHILOS T ROY SOC B, V265, P223, DOI 10.1098/rstb.1973.0027; Stull JT, 1997, ADV SEC MESS PHOSPH, V31, P141; Stull JT, 1998, ACTA PHYSIOL SCAND, V164, P471, DOI 10.1111/j.1365-201X.1998.tb10699.x; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; Walsh MP, 1996, BIOCHEM CELL BIOL, V74, P485, DOI 10.1139/o96-053; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	53	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5987	5994		10.1074/jbc.274.9.5987	http://dx.doi.org/10.1074/jbc.274.9.5987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026225	hybrid			2022-12-27	WOS:000078804400096
J	Nishimura, JS; Narayanasami, R; Miller, RT; Roman, LJ; Panda, S; Masters, BSS				Nishimura, JS; Narayanasami, R; Miller, RT; Roman, LJ; Panda, S; Masters, BSS			The stimulatory effects of Hofmeister ions on the activities of neuronal nitric-oxide synthase - Apparent substrate inhibition by L-arginine is overcome in the presence of protein-destabilizing agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME; BINDING; TETRAHYDROBIOPTERIN; CALMODULIN; OXIDATION; MECHANISM; EXPRESSION; REDUCTASE; COMPLEX	A variety of monovalent anions and cations were effective in stimulating both calcium ion/calmodulin (Ca2+/CaM)-independent NADPH-cytochrome c reductase activity of, and Ca2+/CaM-dependent nitric oxide (NO.) synthesis by, neuronal nitric oxide synthase (nNOS), The efficacy of the ions in stimulating both activities could be correlated, in general, with their efficacy in precipitating or stabilizing certain proteins, an order referred to as the Hofmeister ion series. In the hemoglobin capture assay, used for measurement of NO. production, apparent substrate inhibition by L-arginine was almost completely reversed by the addition of sodium perchlorate (NaClO4), one of the more effective protein-destabilizing agents tested. Examination of this phenomenon by the assay of L-arginine conversion to L-citrulline revealed that the stimulatory effect of NaClO4 on the reaction was observed only in the presence of oxyhemoglobin or superoxide anion (generated by xanthine and xanthine oxidase), both scavengers of NO.. Spectrophotometric examination of nNOS revealed that the addition of NaClO4 and a superoxide-generating system, but neither alone, prevented the increase of heme absorption at 436 nm, which has been attributed to the nitrosyl complex, The data are consistent with the release of autoinhibitory NO. coordinated to the prosthetic group of nNOS, which, in conjunction with an NO. scavenger, causes stimulation of the reaction.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Nishimura, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030050, R01HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30050] Funding Source: Medline; NIGMS NIH HHS [GM 52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; GREGOR HP, 1955, J AM CHEM SOC, V77, P2713, DOI 10.1021/ja01615a011; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HAMABATA A, 1973, BIOCHEMISTRY-US, V12, P1264, DOI 10.1021/bi00731a004; Hofmeister F., 1888, N-S ARCH EXP PATH PH, V24, P247; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1992, J BIOL CHEM, V267, P11374; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters B, 1967, METHOD ENZYMOL, V10, P565; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MELANDER W, 1977, ARCH BIOCHEM BIOPHYS, V183, P200, DOI 10.1016/0003-9861(77)90434-9; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Schrammel A, 1998, BBA-PROTEIN STRUCT M, V1387, P257, DOI 10.1016/S0167-4838(98)00138-1; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Sorrentino R, 1997, LIFE SCI, V61, P1283, DOI 10.1016/S0024-3205(97)00673-5; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; VONHIPPE.PH, 1969, ACCOUNTS CHEM RES, V2, P257, DOI 10.1021/ar50021a001; VONHIPPEL PH, 1964, SCIENCE, V145, P577, DOI 10.1126/science.145.3632.577; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512	46	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5399	5406		10.1074/jbc.274.9.5399	http://dx.doi.org/10.1074/jbc.274.9.5399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026150	hybrid			2022-12-27	WOS:000078804400021
J	Denny, MF; Kaufman, HC; Chan, AC; Straus, DB				Denny, MF; Kaufman, HC; Chan, AC; Straus, DB			The Lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PROTOONCOGENE C-CBL; TYROSINE KINASE; SRC-FAMILY; CROSS-LINKING; ZETA-CHAIN; NEGATIVE SELECTION; BINDING PROTEIN; ZAP-70 KINASE; TRANSDUCTION	Initiation of T-cell antigen receptor (TCR) signaling is dependent upon the activity of protein tyrosine kinases, The Src family kinase Lck is required for the initial events in TCR signaling, such as the phosphorylation of the TCR complex and the activation of ZAP-70, but little is known of its role in downstream signaling. Expression of a mutated form of Lck lacking SH3 domain function (LckW97A) in the Lck-deficient T-cell line JCaM1 revealed a requirement for Lck beyond the initiation of TCR signaling. In cells expressing LckW97A, stimulation of the TCR failed to activate the mitogen-activated protein kinase (MAPK) pathway, despite normal TCR zeta chain phosphorylation, ZAP-70 recruitment, and ZAP-70 activation. Activation of extracellular signal-regulated kinase (ERK) and MAPK kinase (MEK), as well as the induction of CD69 expression, was greatly impaired in JCaM1/LckW97A cells. In contrast, the phosphorylation of phospholipase C gamma 1 (PLC gamma 1) and corresponding elevations in intracellular calcium concentration ([Ca2+](i)) were intact. Thus, cells expressing LckW97A exhibit selective defect in the activation of the MAPK pathway. These results demonstrate that Lck has a role in the activation of signaling pathways beyond the initiation of TCR signaling and suggest that the MAPK pathway may be selectively controlled by regulating the function of Lck.	Univ Chicago, Dept Med & Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	University of Chicago; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Straus, DB (corresponding author), Univ Chicago, Dept Med MC6084, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dstraus@midway.uchicago.edu		Denny, Michael/0000-0002-7874-1744	NCI NIH HHS [CA71516-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; August A, 1996, J BIOL CHEM, V271, P10054; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; LeeFruman KK, 1996, J BIOL CHEM, V271, P25003, DOI 10.1074/jbc.271.40.25003; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Popik W, 1996, MOL CELL BIOL, V16, P6532; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; TESTI R, 1989, J IMMUNOL, V142, P1854; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wong J, 1998, MOL CELL BIOL, V18, P2855, DOI 10.1128/MCB.18.5.2855; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	58	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5146	5152		10.1074/jbc.274.8.5146	http://dx.doi.org/10.1074/jbc.274.8.5146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988764	hybrid			2022-12-27	WOS:000078698200089
J	Xiao, H; Tao, Y; Roeder, RG				Xiao, H; Tao, Y; Roeder, RG			The human homologue of Drosophila TRF-proximal protein is associated with an RNA polymerase II SRB complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; REPEAT DOMAIN; HOLOENZYME; MEDIATOR; COMPONENTS; INITIATION; YEAST; CTD	Mammalian RNA polymerase II holoenzymes are large complexes that have been reported to contain, in addition to RNA polymerase II, homologues of several yeast SRBs, various general transcription factors, and other polypeptides. On the basis of its copurification with an SRB-containing RNA polymerase II complex by conventional chromatography procedures, we have identified a human homologue of Drosophila TRF-proximal protein, designated hTRFP, and isolated its cognate cDNA Antibody specific for SRB7 can immunoprecipitate hTRFP and RNA polymerase II and, reciprocally, antibody specific for hTRFP can immunoprecipitate RNA polymerase II and SRB7. These data indicate that hTRFP is an integral component of an RNA polymerase II-SRB complex. Whereas the precise function of hTRFP remains to be determined, the hTRFP-containing RNA polymerase II-SRB complex supports basal level transcription and, relative to RNA polymerase II alone, enhances transcriptional activation by Ga14-VP16 in the presence of cofactor PC4. Thus, hTRFP may regulate transcription of class II genes through association with the RNA polymerase II-SRB complex.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA.	roeder@rockvax.rockefeller.edu			NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037327] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI37327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GU W, 1998, IN PRESS MOL CELL; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LEE YC, 1997, MOL CELL BIOL, V9, P5364; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NONET ML, 1989, GENETICS, V123, P715; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146	33	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3937	3940		10.1074/jbc.274.7.3937	http://dx.doi.org/10.1074/jbc.274.7.3937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933582	hybrid			2022-12-27	WOS:000078575500006
J	Szak, ST; Pietenpol, JA				Szak, ST; Pietenpol, JA			High affinity insertion/deletion lesion binding by p53 - Evidence for a role of the p53 central domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SEQUENCE-SPECIFIC DNA; DAMAGE-RECOGNITION; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; CRYSTAL-STRUCTURE; UV IRRADIATION; STRAND BREAKS; IN-VIVO	In addition to binding DNA in a sequence-specific manner, p53 can interact with nucleic acids in a sequence-independent manner. p53 can bind short single-stranded DNA and double-stranded DNA containing nucleotide loops; these diverse associations may be critical for p53 signal transduction, In this study, we analyzed p53 binding to DNA fragments containing insertion/deletion mismatches (IDLs). p53 required an intact central domain and dimerization domain for high affinity complex formation with IDLs. In fact, the C terminus of p53 (amino acids 293-393) was functionally replaceable with a foreign dimerization domain in IDL binding assays. From saturation binding studies we determined that the K-D of p53 binding to IDLs was 45 pM as compared with a K-D of 31 pM for p53 binding to DNA fragments containing a consensus binding site. Consistent with these dissociation constants, p53-IDL complexes were dissociated with relatively low concentrations of competitor consensus site-containing DNA. Although p53 has a higher affinity for DNA with a consensus site as compared with IDLs, the relative number and availability of each form of DNA in a cell immediately after DNA damage may promote p53 interaction with DNA lesions. Understanding how the sequence-specific and nonspecific DNA binding activities of p53 are integrated will contribute to our knowledge of how signaling cascades are initiated after DNA damage.	Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, 652 Med Res Bldg 2, Nashville, TN 37232 USA.	pietenpol@toxicology.mc.vanderbilt.edu			NCI NIH HHS [CA68485, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070856, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1997, BIOCHEM J, V328, P1, DOI 10.1042/bj3280001; COATES PJ, 1995, J PATHOL, V176, P19, DOI 10.1002/path.1711760105; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P806; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Ji C, 1998, CARCINOGENESIS, V19, P1275, DOI 10.1093/carcin/19.7.1275; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Sutherland BM, 1996, ANAL BIOCHEM, V239, P53, DOI 10.1006/abio.1996.0290; WAKAGUCHI K, 1998, GENE DEV, V12, P2831; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	56	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3904	3909		10.1074/jbc.274.6.3904	http://dx.doi.org/10.1074/jbc.274.6.3904			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920946	hybrid			2022-12-27	WOS:000078428200086
J	Gao, JH; Li, Y; Yan, HG				Gao, JH; Li, Y; Yan, HG			NMR solution structure of domain 1 of human annexin I shows an autonomous folding unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CORRELATION SPECTROSCOPY; IMPROVED SENSITIVITY; LARGER PROTEINS; H-1-NMR SPECTRA; CAPPING BOX; PROTON; H-1; IDENTIFICATION; ASSOCIATION	Annexins are excellent models for studying the folding mechanisms of multidomain proteins because they have four-eight homologous helical domains with low identity in sequence but high similarity in folding. The structure of an isolated domain 1 of human annexin I has been determined by NMR spectroscopy, The sequential assignments of the H-1, C-13, and N-15 resonances of the isolated domain 1 were established by multinuclear, multidimensional NMR spectroscopy. The solution structure of the isolated domain 1 was derived from 1,099 experimental NMR restraints using a hybrid distance geometry-simulated annealing protocol. The root mean square deviation of the ensemble of 20 refined conformers that represent the structure from the mean coordinate set derived from them was 0.57 +/- 0.14 Angstrom and 1.11 +/- 0.19 ? for the backbone atoms and all heavy atoms, respectively. The NMR structure of the isolated domain 1 could be superimposed with a root mean square deviation of 1.36 Angstrom for all backbone atoms with the corresponding part of the crystal structure of a truncated human annexin I containing all four domains, indicating that the structure of the isolated domain 1 is highly similar to that when it folded together with the other three domains. The result suggests that in contrast to isolated domain 2, which is largely unfolded in solution, isolated domain 1 constitutes an autonomous folding unit and interdomain interactions may play critical roles in the folding of annexin I.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Yan, HG (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	yanh@pilot.msu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08299] Funding Source: Medline; NIGMS NIH HHS [GM51901] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cordier-Ochsenbein F, 1998, J MOL BIOL, V279, P1177, DOI 10.1006/jmbi.1998.1828; Cordier-Ochsenbein F, 1998, J MOL BIOL, V279, P1163, DOI 10.1006/jmbi.1998.1829; CordierOchsenbein F, 1996, BIOCHEMISTRY-US, V35, P10347, DOI 10.1021/bi960747v; CREIGHTON TE, 1992, PROTEIN FOLDING; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Jaenicke R, 1996, CURR TOP CELL REGUL, V34, P209, DOI 10.1016/S0070-2137(96)80008-2; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; MACQUAIRE F, 1993, BIOCHEMISTRY-US, V32, P7244, DOI 10.1021/bi00079a022; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MORGAN RO, 1995, MOL BIOL EVOL, V12, P967; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ODAERT B, 1995, BIOCHEMISTRY-US, V34, P12820, DOI 10.1021/bi00039a043; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SRERE PA, 1984, TRENDS BIOCHEM SCI, V9, P387, DOI 10.1016/0968-0004(84)90221-4; Voges D, 1995, ADV ENZYMOL RAMB, V71, P209; WENG XW, 1993, PROTEIN SCI, V2, P448; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; ZHU G, 1992, J MAGN RESON, V100, P202, DOI 10.1016/0022-2364(92)90379-L	48	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2971	2977		10.1074/jbc.274.5.2971	http://dx.doi.org/10.1074/jbc.274.5.2971			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915835	hybrid			2022-12-27	WOS:000078319500053
J	Nakashima, N; Rose, DW; Xiao, S; Egawa, K; Martin, SS; Haruta, T; Saltiel, AR; Olefsky, JM				Nakashima, N; Rose, DW; Xiao, S; Egawa, K; Martin, SS; Haruta, T; Saltiel, AR; Olefsky, JM			The functional role of CrkII in actin cytoskeleton organization and mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; PHOSPHORYLATION-DEPENDENT MANNER; COMPLEXES IN-VIVO; TYROSINE PHOSPHORYLATION; C-CRK; V-CRK; SIGNALING PATHWAYS; INSULIN-RECEPTOR; BINDING PROTEIN	Crk is a member of a family of adapter proteins predominantly composed of Src homology 2 and 3 domains, whose role in signaling pathways is presently unclear. Using an in situ electroporation system which permits the introduction of glutathione S-transferase (GST) fusion proteins into cells, we found that c-CrkII bound to p130(cas), but not to paxillin in serum-starved rat-1 fibro-blasts overexpressing the human insulin receptor (HIRc cells) in vivo, 17 nM insulin stimulation dissociated the binding of c-CrkII to p130(cas), whereas 13 nM insulin-like growth factor-I, 16 nM epidermal growth factor (EGF), and 10% serum each showed little or no effect. We found that stress fiber formation is consistent with a change in the p130(cas.)c-CrkII interactions before and after growth factor stimulation. Microinjection of either GST-Crk-SH2 or -Crk-(N)SH3 domains, or anti-Crk antibody each inhibited stress fiber formation before and after insulin-like growth factor-I, EGF, and serum stimulation. Insulin stimulation by itself caused stress fiber breakdown and there was no additive effect of microinjection. Microinjection of anti-p130(cas) antibody also blocked stress fiber formation in quiescent cells. Microinjection of the Crk-inhibitory reagents also inhibited DNA synthesis after insulin-like growth factor-I, EGF, and serum stimulation, but not after insulin. These data suggest that the complex containing p130(cas) .c-CrkII may play a crucial role in actin cytoskeleton organization and in anchorage-dependent DNA synthesis.	Univ Calif San Diego, Dept Med 9111-G, Div Endocrinol & Metab, Whittier Diabetes Program, La Jolla, CA 92093 USA; Vet Adm Med Ctr, Med Res Serv, La Jolla, CA 92161 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Signal Transduct, Ann Arbor, MI 48105 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 9111-G, Div Endocrinol & Metab, Whittier Diabetes Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [R01 DK36651] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Flinn HM, 1996, J CELL SCI, V109, P1133; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ishiki M, 1997, ENDOCRINOLOGY, V138, P4950, DOI 10.1210/en.138.11.4950; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nievers MG, 1997, J CELL SCI, V110, P389; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tobe K, 1996, MOL CELL BIOL, V16, P4765; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3001	3008		10.1074/jbc.274.5.3001	http://dx.doi.org/10.1074/jbc.274.5.3001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915838	hybrid			2022-12-27	WOS:000078319500056
J	Pugazhenthi, S; Boras, T; O'Connor, D; Meintzer, MK; Heidenreich, KA; Reusch, JEB				Pugazhenthi, S; Boras, T; O'Connor, D; Meintzer, MK; Heidenreich, KA; Reusch, JEB			Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells - Involvement of p38 mitogen-activated protein kinase-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; PHOSPHORYLATED CREB; APOPTOSIS; DIFFERENTIATION; RECEPTOR; MEMORY; CONSOLIDATION; REQUIREMENT	IGF-I is known to support growth and to prevent apoptosis in neuronal cells. Activation of the nuclear transcription factor cAMP response element-binding protein (CREB) has emerged as a central determinant in neuronal functions. In the present investigation, we examined the IGF-I-mediated phosphorylation and transcriptional activation of CREB in rat pheochromocytoma (PC12) cells, a cellular model for neuronal differentiation, and defined three distinct postreceptor signaling pathways important for this effect including the p38 mitogen-activated protein kinase (MAPK) pathway. CREB phosphorylation at serine 133 and its transcriptional activation as measured by a CREB-specific Gal4-CREB reporter and the neuroendocrine-specific gene chromogranin A was induced 2-3.3-fold by insulinlike growth factor (IGF)-I. This activation was significantly blocked (p < 0.001) by the dominant negative K-CREB or by mutation of the CRE site. IGF-I stimulated chromogranin A gene expression by Northern blot analysis 3.7-fold. Inhibition of MAPK kinase with PD98059, PI 3-kinase with wortmannin, and p38 MAPK with SB203580 blocked IGF-I-mediated phosphorylation and transcriptional activation of CREB by 30-50% (p < 0.001), Constitutively active and dominant negative regulators of the Ras and PI 3-kinase pathways confirmed the contribution of these pathways for CREB regulation by IGF-I, Cotransfection of PC12 cells with p38 beta and constitutively active MAPK kinase 6 resulted in enhanced basal as well. as IGF-I-stimulated chromogranin A promoter. IGF-I activated p38 MAPK, which was blocked by the inhibitor SB203580, This is the first description of a p38 MAPK-mediated nuclear signaling pathway for IGF-I leading to CREB-dependent neuronal specific gene expression.	Vet Affairs Med Ctr, Sect Endocrinol 111H, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Dept Vet Affairs Med Ctr, San Diego, CA 92161 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego; University of California System; University of California San Diego	Pugazhenthi, S (corresponding author), Vet Affairs Med Ctr, Sect Endocrinol 111H, 1055 Clermont St, Denver, CO 80220 USA.	jreusch@sembilan.uchsc.edu		Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [KO8 DK02351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevilaqua L, 1997, BRAZ J MED BIOL RES, V30, P967, DOI 10.1590/S0100-879X1997000800009; Canaff L, 1998, ENDOCRINOLOGY, V139, P1184, DOI 10.1210/en.139.3.1184; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Das S, 1997, SYNAPSE, V25, P227; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; ISHII DN, 1994, PHARMACOL THERAPEUT, V62, P125, DOI 10.1016/0163-7258(94)90007-8; ISHII DN, 1995, BRAIN RES REV, V20, P47, DOI 10.1016/0165-0173(94)00005-A; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONNIER D, 1994, MOL CELL ENDOCRINOL, V104, P139, DOI 10.1016/0303-7207(94)90116-3; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parrizas M, 1997, J BIOL CHEM, V272, P154; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shimomura A, 1998, J NEUROCHEM, V70, P1029; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; VINIK AI, 1995, DIABETES REV, V3, P139; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1	53	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2829	2837		10.1074/jbc.274.5.2829	http://dx.doi.org/10.1074/jbc.274.5.2829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915817	hybrid			2022-12-27	WOS:000078319500035
J	Chen, RW; Chuang, DM				Chen, RW; Chuang, DM			Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression - A prominent role in neuroprotection against excitotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CYTOCHROME-C; APOPTOSIS; INHIBITION; RELEASE; MITOCHONDRIA; PROTEASE; NEURONS; AP-1	This study was undertaken to investigate the molecular mechanisms underlying the neuroprotective actions of lithium against glutamate excitotoxicity with a focus on the role of proapoptotic and antiapoptotic genes. Long term, but not acute, treatment of cultured cerebellar granule cells with LiCl induces a concentration-dependent decrease in mRNA and protein levels of proapoptotic p53 and Bax; conversely, mRNA and protein levels of cytoprotective Bcl-2 are remarkably increased. The ratios of Bcl-2/Bax protein levels increase by approximately 5-fold after lithium treatment for 5-7 days. Exposure of cerebellar granule cells to glutamate induces a rapid increase in p53 and Bax mRNA and protein levels with no apparent effect on Bcl-2 expression. Pretreatment with LiCl for 7 days prevents glutamate-induced increase in p53 and Bax expression and maintains Bcl-2 in an elevated state. Glutamate exposure also triggers the release of cytochrome c from the mitochondria into the cytosol. Lithium pretreatment blocks glutamate-induced cytochrome c release and cleavage of lamin B1, a nuclear substrate for caspase-3. These results strongly suggest that lithium-induced Bcl-2 up-regulation and p53 and Bax down-regulation play a prominent role in neuroprotection against excitotoxicity. Our results further suggest that lithium, in addition to its use in the treatment of bipolar depressive illness, may have an expanded use in the intervention of neurodegeneration.	NIMH, Mol Neurobiol Sect, BPB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, BPB, NIH, Bldg 10,Rm 3N212,10 Ctr Dr,MSC 1272, Bethesda, MD 20892 USA.	chuang@helix.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002468, Z01MH002468] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; FUKAMAUCHI F, 1993, MOL PHARMACOL, V44, P940; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUDSON CJ, 1993, SYNAPSE, V13, P278, DOI 10.1002/syn.890130311; Jope RS, 1997, MOL BRAIN RES, V50, P171, DOI 10.1016/S0169-328X(97)00183-6; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LENOX RH, 1998, J CLIN PSYCHIAT, V570, P333; MANJI HK, 1992, AM J PSYCHIAT, V149, P746; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Nonaka S, 1998, J PHARMACOL EXP THER, V286, P539; Ozaki N, 1997, J NEUROCHEM, V69, P2336; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VARNEY MA, 1992, MOL PHARMACOL, V42, P671; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yuan PX, 1998, MOL BRAIN RES, V58, P225, DOI 10.1016/S0169-328X(98)00114-4	30	301	331	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6039	6042		10.1074/jbc.274.10.6039	http://dx.doi.org/10.1074/jbc.274.10.6039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037682	hybrid			2022-12-27	WOS:000078902800004
J	Torigoe, H; Ferdous, A; Watanabe, H; Akaike, T; Maruyama, A				Torigoe, H; Ferdous, A; Watanabe, H; Akaike, T; Maruyama, A			Poly(L-lysine)-graft-dextran copolymer promotes pyrimidine motif triplex DNA formation at physiological pH - Thermodynamic and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRIUM ASSOCIATION CONSTANTS; HELIX FORMATION; OPTICAL BIOSENSOR; NUCLEIC-ACIDS; NEUTRAL PH; BINDING; SEQUENCE; OLIGODEOXYNUCLEOTIDES; 5-METHYLCYTOSINE; OLIGONUCLEOTIDES	Extreme instability of pyrimidine motif tripler DNA at physiological pH severely limits its use for artificial control of gene expression in vivo. Stabilization of the pyrimidine motif tripler at physiological pH is therefore of great importance in improving its therapeutic potential. To this end, isothermal titration calorimetry interaction analysis system and electrophoretic mobility shift assay have been used to explore the thermodynamic and kinetic effects of our previously reported tripler stabilizer, poly (L-lysine)-graft-dextran (PLL-g-Dex) copolymer, on pyrimidine motif tripler formation at physiological pH. Both the thermodynamic and kinetic analyses have clearly indicated that in the presence of the PLL-g-Dex copolymer, the binding constant of the pyrimidine motif tripler formation at physiological pH was about 100 times higher than that observed without any tripler stabilizer. Of importance, the tripler-promoting efficiency of the copolymer was more than 20 times higher than that of physiological concentrations of spermine, a putative intracellular tripler stabilizer. Kinetic data have also demonstrated that the observed copolymer-mediated promotion of the tripler formation at physiological pH resulted from the considerable increase in the association rate constant rather than the decrease in the dissociation rate constant. Our results certainly support the idea that the PLL g-Dex copolymer could be a key material and may eventually lead to progress in therapeutic applications of the antigene strategy in vivo.	Inst Phys & Chem Res, RIKEN, Tsukuba Life Sci Ctr, Gene Bank, Tsukuba, Ibaraki 3050074, Japan; Tokyo Inst Technol, Dept Biomol Engn, Yokohama, Kanagawa 2268501, Japan	RIKEN; Tokyo Institute of Technology	Maruyama, A (corresponding author), Inst Phys & Chem Res, RIKEN, Tsukuba Life Sci Ctr, Gene Bank, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Maruyama, Atsushi/C-9186-2015	Maruyama, Atsushi/0000-0002-7495-2974				BATES PJ, 1995, NUCLEIC ACIDS RES, V23, P3627, DOI 10.1093/nar/23.18.3627; BOND JP, 1994, BIOPHYS J, V67, P825, DOI 10.1016/S0006-3495(94)80542-9; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; Ferdous A, 1998, J PHARM SCI-US, V87, P1400, DOI 10.1021/js980066g; Ferdous A, 1998, NUCLEIC ACIDS RES, V26, P3949, DOI 10.1093/nar/26.17.3949; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRANKKAMENETSKII MD, 1992, METHOD ENZYMOL, V211, P180; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; HAYNES M, 1970, BIOCHEMISTRY-US, V9, P4410, DOI 10.1021/bi00824a600; JETTER MC, 1993, BIOCHEMISTRY-US, V32, P3249, DOI 10.1021/bi00064a006; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; KRAWCZYK SH, 1992, P NATL ACAD SCI USA, V89, P3761, DOI 10.1073/pnas.89.9.3761; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; Maruyama A, 1997, BIOCONJUGATE CHEM, V8, P3, DOI 10.1021/bc960071g; Maruyama A, 1998, BIOCONJUGATE CHEM, V9, P292, DOI 10.1021/bc9701510; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5; ONO A, 1991, J AM CHEM SOC, V113, P4032, DOI 10.1021/ja00010a077; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SHINDO H, 1993, BIOCHEMISTRY-US, V32, P8963, DOI 10.1021/bi00085a030; SINGLETON SF, 1993, BIOCHEMISTRY-US, V32, P13171, DOI 10.1021/bi00211a028; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; SOYFER VN, 1996, TROPLE HELICAL NUCL; SUN JS, 1991, P NATL ACAD SCI USA, V88, P6023, DOI 10.1073/pnas.88.14.6023; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; THOMAS T, 1993, BIOCHEMISTRY-US, V32, P14068, DOI 10.1021/bi00213a041; TSUBOI M, 1967, CONFORM BIOPOLYM, V2, P689; Ueno Y, 1998, BIOCONJUGATE CHEM, V9, P33, DOI 10.1021/bc9701508; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625	43	57	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6161	6167		10.1074/jbc.274.10.6161	http://dx.doi.org/10.1074/jbc.274.10.6161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037700	hybrid			2022-12-27	WOS:000078902800022
J	He, XH; Rezaie, AR				He, XH; Rezaie, AR			Identification and characterization of the sodium-binding site of activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; FACTOR-LIKE DOMAIN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; BIOLOGICAL-ACTIVITY; ENZYME COMPLEXES; MOLECULAR-BASIS; FACTOR-V; FACTOR-X; SPECIFICITY	Activated protein C (APC) requires both Ca2+ and Na+ for its optimal catalytic function. In contrast to the Ca2+-binding sites, the Na+-binding site(s) of APC has not been identified. Based on a recent study with thrombin, the 221-225 loop is predicted to be a potential Na+-binding site in APC. The sequence of this loop is not conserved in trypsin. We engineered a Gla domainless form of protein C (GDPC) in which the 221-225 loop was replaced with the corresponding loop of trypsin. We found that activated GDPC (aGDPC) required Na+ (or other alkali cations) for its amidolytic activity with dissociation constant (K-d(app)) = 44.1 +/- 8.6 mM. In the presence of Ca2+, however, the requirement for Na+ by aGDPC was eliminated, and Na+ stimulated the cleavage rate 5-6-fold with K-d(app) = 2.3 +/- 0.3 mm. Both cations were required for efficient factor Va inactivation by aGDPC. In the presence of Ca2+, the catalytic function of the mutant was independent of Na+. Unlike aGDPC, the mutant did not discriminate among monovalent cations. We conclude that the 221-225 loop is a Na+-binding site in APC and that an allosteric link, between the Na+ and Ca2+ binding loops modulates the structure and function of this anticoagulant enzyme.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Rezaie, AR (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	alireza-rezaie@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, BIOCHEMISTRY-US, V20, P2156, DOI 10.1021/bi00511a013; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREENQUIST AC, 1975, BLOOD, V45, P769; GRINNELL BW, 1991, ADV APPL BIOTECHNOL, V11, P29; GUINTO ER, 1982, J BIOL CHEM, V257, P38; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL KAW, 1986, J BIOL CHEM, V261, P4991; HILL KAW, 1987, J BIOL CHEM, V262, P7105; HILL KAW, 1987, J BIOL CHEM, V262, P9581; HILL KAW, 1987, J BIOL CHEM, V262, P7098; HILL KAW, 1987, ARCH BIOCHEM BIOPHYS, V254, P196, DOI 10.1016/0003-9861(87)90095-6; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P8701, DOI 10.1021/bi00027a020; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; OWEN WG, 1974, J BIOL CHEM, V249, P594; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; REZAIE AR, 1995, BIOCHEMISTRY-US, V34, P12221, DOI 10.1021/bi00038a016; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STEINER SA, 1982, BIOCHEMISTRY-US, V21, P4609, DOI 10.1021/bi00262a015; STEINER SA, 1998, BIOCHEMISTRY-US, V24, P609; STENFLO J, 1991, BLOOD, V78, P1637; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	52	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4970	4976		10.1074/jbc.274.8.4970	http://dx.doi.org/10.1074/jbc.274.8.4970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988741	hybrid			2022-12-27	WOS:000078698200066
J	Ishida, H; Makino, A; Mae, T				Ishida, H; Makino, A; Mae, T			Fragmentation of the large subunit of ribulose-1,5-bisphosphate carboxylase by reactive oxygen species occurs near Gly-329	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; OXIDATIVE STRESS; RICE LEAVES; PROTEOLYTIC ACTIVITY; HYDROXYL RADICALS; OAT CHLOROPLASTS; WHEAT SEEDLINGS; DEGRADATION; LIGHT; SENESCENCE	The large subunit (LSU) of ribulose-1,5-bisphosphate carboxylase/oxygenase (rubisco) in the illuminated lysates of wheat (Triticum aestivum L.) chloroplasts is broken down by reactive oxygen radicals into 37- and 16-kDa polypeptides, Analysis of the terminal amino acid residues of both fragments revealed that the C terminus of the 37-kDa fragment was Ser-328 and the N terminus of the 16-kDa fragment was Thr-330. Gly-329, which links the two fragments, was missing, suggesting that the fragmentation of the LSU in the lysates driven by oxygen-free radicals occurs at Gly-329. Purified rubisco, exposed to a hydroxyl radical-generating system, was also cleaved at the same site of the LSU, The cleavage site was positioned at the N-terminal end of the flexible loop (loop 6) within the beta/alpha-barrel domain, constituting the catalytic site of rubisco. The binding of a reaction intermediate analogue, 2-carboxyarabinitol 1,5-bisphosphate, to the active form of rubisco completely protected the enzyme from the fragmentation. The fragmentation was differentially affected by CO2, Mg2+, ribulose 1,5-bisphosphate, or 2-carboxyarabinitol 1,5-bisphosphate, All these results indicate that the conformation of the catalytic site of the enzyme is involved as an important factor determining the breakdown of rubisco by reactive oxygen species. Reactive oxygen species generated at its catalytic site by a Fenton-type reaction may trigger the site-specific degradation of the LSU in the lysates of chloroplasts in the light.	Tohoku Univ, Fac Agr, Dept Appl Biol Chem, Aoba Ku, Sendai, Miyagi 9818555, Japan	Tohoku University	Mae, T (corresponding author), Tohoku Univ, Fac Agr, Dept Appl Biol Chem, Aoba Ku, 1-1 Tsutsumidori Amamiyamachi, Sendai, Miyagi 9818555, Japan.			Ishida, Hiroyuki/0000-0002-8682-4566				Asada K., 1987, PHOTOINHIBITION, P227; BADGER MR, 1980, J BIOL CHEM, V255, P7870; Barlow JN, 1997, BIOCHEMISTRY-US, V36, P3563, DOI 10.1021/bi962521y; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BHALLA PL, 1986, J PLANT PHYSIOL, V122, P289, DOI 10.1016/S0176-1617(86)80162-6; CASANO LM, 1990, PLANT CELL PHYSIOL, V31, P377; CASANO LM, 1994, PLANT CELL PHYSIOL, V35, P145; CHRISTELLER JT, 1981, BIOCHEM J, V193, P839, DOI 10.1042/bj1930839; Desimone M, 1996, PLANT PHYSIOL, V111, P789, DOI 10.1104/pp.111.3.789; Desimone M, 1998, PLANTA, V205, P459, DOI 10.1007/s004250050344; Evans J.R., 1989, PHOTOSYNTHESIS, P183; HOUTZ RL, 1989, P NATL ACAD SCI USA, V86, P1855, DOI 10.1073/pnas.86.6.1855; HUFFAKER RC, 1990, NEW PHYTOL, V116, P199, DOI 10.1111/j.1469-8137.1990.tb04710.x; Ishida H, 1997, PLANT CELL PHYSIOL, V38, P471, DOI 10.1093/oxfordjournals.pcp.a029191; Ishida H, 1998, PLANTA, V204, P305, DOI 10.1007/s004250050260; Jakob B, 1996, PLANT CELL PHYSIOL, V37, P629, DOI 10.1093/oxfordjournals.pcp.a028991; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY LG, 1993, PLANT PHYSIOL, V101, P1355, DOI 10.1104/pp.101.4.1355; MAKINO A, 1985, PLANTA, V166, P414, DOI 10.1007/BF00401181; MAKINO A, 1984, PLANT CELL PHYSIOL, V25, P429; MAKINO A, 1985, PLANT PHYSIOL, V79, P57, DOI 10.1104/pp.79.1.57; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; MITSUHASHI W, 1992, J PLANT PHYSIOL, V139, P653, DOI 10.1016/S0176-1617(11)81706-2; MIZIORKO HM, 1979, J BIOL CHEM, V254, P270; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PERCHOROWICZ JT, 1981, P NATL ACAD SCI-BIOL, V78, P2985, DOI 10.1073/pnas.78.5.2985; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; SCHNEIDER G, 1992, ANNU REV BIOPH BIOM, V21, P119, DOI 10.1146/annurev.bb.21.060192.001003; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; SUGIYAMA T, 1967, J BIOCHEM, V62, P474; Taylor TC, 1997, BIOCHEMISTRY-US, V36, P4041, DOI 10.1021/bi962818w; TERACHI T, 1987, JPN J GENET, V62, P375, DOI 10.1266/jjg.62.375; TERRY N, 1982, J PLANT NUTR, V5, P301, DOI 10.1080/01904168209362959; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; YOKOTA S, 1990, SOIL SCI PLANT NUTR, V36, P91, DOI 10.1080/00380768.1990.10415713	38	92	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5222	5226		10.1074/jbc.274.8.5222	http://dx.doi.org/10.1074/jbc.274.8.5222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988772	hybrid			2022-12-27	WOS:000078698200097
J	Zachos, G; Clements, B; Conner, J				Zachos, G; Clements, B; Conner, J			Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE LARGE SUBUNIT; RNA-POLYMERASE-II; C-JUN; GENE-EXPRESSION; CELLS; MUTANT; GROWTH; STRESS; DOMAIN; RAS	Cells respond to environmental stress and proinflammatory cytokines by stimulating the Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and the p38 mitogen-activated protein kinase cascades. Infection of eukaryotic cells with herpes simplex virus type 1 (HSV-1) resulted in stimulation of both JNK/SAPK and p38 mitogen-activated protein kinase after 3 h of infection, and activation reached a maximum of 4-fold by 9 h post-infection. By using a series of mutant viruses, we showed that the virion transactivator protein VP16 stimulates p38/JNK, whereas no immediate-early, early, or late viral expressed gene is involved. We identified the stress-activated protein kinase kinase 1 as an upstream activator of p38/JNK, and we demonstrated that activation of AP-1 binding proceeded p38/JNK stimulation. During infection, the activated AP-1 consisted mainly of JunB and JunD with a simultaneous decrease in the cellular levels of Jun protein. We suggest that activation of the stress pathways by HSV-1 infection either represents a cascade triggered by the virus to facilitate the lytic cycle or a defense mechanism of the host cell against virus invasion.	Glasgow Caledonian Univ, Sch Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Inst Virol, Glasgow G11 5JR, Lanark, Scotland	Glasgow Caledonian University; University of Glasgow	Conner, J (corresponding author), Glasgow Caledonian Univ, Sch Biol & Biomed Sci, Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.	J.Conner@gcal.ac.uk	Li, Chia Cheng/D-9906-2015					ACE CI, 1989, J VIROL, V63, P2260, DOI 10.1128/JVI.63.5.2260-2269.1989; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CONNER J, 1992, J VIROL, V66, P7511, DOI 10.1128/JVI.66.12.7511-7516.1992; CONNER J, 1995, VIROLOGY, V213, P615, DOI 10.1006/viro.1995.0033; CONNER J, 1993, BIOCHEMISTRY-US, V32, P13673, DOI 10.1021/bi00212a036; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERETT R, 1993, J GEN VIROL, V74, P1955, DOI 10.1099/0022-1317-74-9-1955; EVERETT RD, 1993, VIROLOGY, V197, P751, DOI 10.1006/viro.1993.1651; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Ingram A, 1996, J GEN VIROL, V77, P1847, DOI 10.1099/0022-1317-77-8-1847; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; MARTI A, 1994, ONCOGENE, V9, P1213; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; PATERSON T, 1988, VIROLOGY, V166, P186, DOI 10.1016/0042-6822(88)90160-2; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; RICE SA, 1995, J VIROL, V69, P5550, DOI 10.1128/JVI.69.9.5550-5559.1995; ROIZMAN B, 1996, FIELDS VIROLOGY, P2281; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shackelford DA, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P466; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	51	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5097	5103		10.1074/jbc.274.8.5097	http://dx.doi.org/10.1074/jbc.274.8.5097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988758	hybrid			2022-12-27	WOS:000078698200083
J	Hippler, M; Drepper, F; Rochaix, JD; Muhlenhoff, U				Hippler, M; Drepper, F; Rochaix, JD; Muhlenhoff, U			Insertion of the N-terminal part of PsaF from Chlamydomonas reinhardtii into photosystem I from Synechococcus elongatus enables efficient binding of algal plastocyanin and cytochrome c(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER COMPLEXES; FAST-ELECTRON TRANSFER; GREEN-ALGA; NUCLEOTIDE-SEQUENCE; FLASH-PHOTOLYSIS; SUBUNIT; COPPER; GENE; MUTAGENESIS; EXPRESSION	A strain of the cyanobacterium Synechococcus elongatus was generated that expresses a hybrid version of the photosystem I subunit PsaF consisting of the first 83 amino acids of PsaF from the green alga Chlamydomonas reinhardtii fused to the C-terminal portion of PsaF from S, elongatus, The corresponding modified gene was introduced into the genome of the psaF-deletion strain FK2 by cointegration with an antibiotic resistance gene. The transformants express a new PsaF subunit similar in size to PsaF from C, reinhardtii that is assembled into photosystem I (PSI). Hybrid PSI complexes isolated from these strains show an increase by 2 or 3 orders of magnitude in the rate of P700(+) reduction by C, reinhardtii cytochrome c(6) or plastocyanin in 30% of the complexes as compared with wild type cyanobacterial PSI. The corresponding optimum second-order rate constants (k(2) = 4.0 and 1.7 x 10(7) M-1 S-1 for cytochrome c(6) and plastocyanin) are similar to those of PSI from C, reinhardtii. The remaining complexes are reduced at a slow rate similar to that observed with wild type PSI from S. elongatus and the algal donors, At high concentrations of C, reinhardtii cytochrome c(6), a fast first-order kinetic component (t(1/2) = 4 mu s) is revealed, indicative of intramolecular electron transfer within a complex between the hybrid PSI and cytochrome c(6). This first-order phase is characteristic for P700(+) reduction by cytochrome c(6) or plastocyanin in algae and higher plants. However, a similar fast phase is not detected for plastocyanin, Crosslinking studies show that, in contrast to PSI from wild type S, elongatus, the chimeric PsaF of PSI from the transformed strain cross-links to cytochrome c(6) or plastocyanin with a similar efficiency as PsaF from C. reinhardtii PSI. Our data indicate that development of a eukaryotic type of reaction mechanism for binding and electron transfer between PSI and its electron donors required structural changes in both PSI and cytochrome c(6) or plastocyanin.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Geneva, Dept Mol Biol & Plant Biol, CH-1211 Geneva, Switzerland	University of Freiburg; University of Geneva	Muhlenhoff, U (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.		Rochaix, Jean-David/ABC-5243-2020	Michael, Hippler/0000-0001-9670-6101; Drepper, Friedel/0000-0002-2043-5795				BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; DELOSME R, 1991, PHOTOSYNTH RES, V29, P45, DOI 10.1007/BF00035205; DIAZ A, 1994, EUR J BIOCHEM, V222, P1001, DOI 10.1111/j.1432-1033.1994.tb18951.x; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FRANZEN LG, 1989, PLANT MOL BIOL, V12, P463, DOI 10.1007/BF00017585; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HAEHNEL W, 1989, J CELL BIOL, V108, P1397, DOI 10.1083/jcb.108.4.1397; Harlow E., 1988, ANTIBODIES LAB MANUA; HATANAKA H, 1993, BIOCHIM BIOPHYS ACTA, V1141, P45, DOI 10.1016/0005-2728(93)90187-K; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; KOIKE H, 1979, PLANT CELL PHYSIOL, V20, P1157; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LEE BH, 1995, J BIOCHEM, V117, P1209; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Morand L.Z., 1994, MOL BIOL CYANOBACTER, P381; Muhlenhoff U, 1996, MOL GEN GENET, V252, P93, DOI 10.1007/s004389670011; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; NAKAMURA M, 1992, J BIOCHEM, V111, P219, DOI 10.1093/oxfordjournals.jbchem.a123740; NECHUSHTAI R, 1996, ADV PHOTOSYNTHESIS O, P289; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; Reith M, 1996, OXYGENIC PHOTOSYNTHE, P643; ROGNER M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P415, DOI 10.1016/0005-2728(90)90074-E; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; XU QA, 1994, J BIOL CHEM, V269, P3205	43	53	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4180	4188		10.1074/jbc.274.7.4180	http://dx.doi.org/10.1074/jbc.274.7.4180			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933614	Green Published, hybrid			2022-12-27	WOS:000078575500038
J	Kriegler, S; Sudweeks, S; Yakel, JL				Kriegler, S; Sudweeks, S; Yakel, JL			The nicotinic alpha 4 receptor subunit contributes to the lining of the ion channel pore when expressed with the 5-HT3 receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SUBSTITUTION; M2 SEGMENT; RESIDUES; IDENTIFICATION; MUTANTS	To understand the wide variation of calcium permeability seen in native and recombinant 5-HT3, receptor (5-HT3R) channels, we reported previously the novel hypothesis that the serotonin 5-HT3R subunit can co-assemble with the alpha 4 subunit of the nicotinic acetylcholine receptor (van Hooft, J. A., Spier, A. D., Yakel, J. L., Lummis, S. C. R. & Vijverberg, H. P. M. (1998) Proc. Natl. Acad, Sci. U. S. A. 95, 11456-11461), To test the hypothesis that the alpha 4 subunit contributes to the lining of the pore of the resulting 5-HT3R channel, a mutant nicotinic alpha 4 subunit with a reactive cysteine residue engineered into the putative pore region was constructed by substituting the leucine at position 285 (alpha 4-L285C), The sulfhydryl-modifying reagent [2-(trimethylammonium) ethyl]methanethiosulfonate (MTSET) reduced the acetylcholine-induced current in oocytes expressing this mutant nicotinic (alpha 4-L285C subunit along with the nicotinic beta 2 subunit by similar to 60%. When the alpha 4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current, No reduction was seen when the 5-HT3R was expressed alone or with the wild-type alpha 4 subunit, These data provide direct molecular evidence that the nicotinic alpha 4 subunit co-assembles with the 5-HT3R subunit and forms an integral part of the ion channel pore.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yakel, JL (corresponding author), NIEHS, Lab Signal Transduct, NIH, F2-08,POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	yakel@niehs.nih.gov		Yakel, Jerrel/0000-0001-5463-674X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090089, Z01ES090089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Egan TM, 1998, J NEUROSCI, V18, P2350; Fletcher S, 1998, NEUROPHARMACOLOGY, V37, P397, DOI 10.1016/S0028-3908(98)00052-5; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Nayak S. V., 1998, Society for Neuroscience Abstracts, V24, P1819; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; Ronde P, 1997, CELL CALCIUM, V22, P357, DOI 10.1016/S0143-4160(97)90020-8; Ronde P, 1998, J NEUROCHEM, V70, P1094; van Hooft JA, 1998, P NATL ACAD SCI USA, V95, P11456, DOI 10.1073/pnas.95.19.11456; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177	17	21	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3934	3936		10.1074/jbc.274.7.3934	http://dx.doi.org/10.1074/jbc.274.7.3934			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933581	hybrid			2022-12-27	WOS:000078575500005
J	Ward, C; Chilvers, ER; Lawson, MF; Pryde, JG; Fujihara, S; Farrow, SN; Haslett, C; Rossi, AG				Ward, C; Chilvers, ER; Lawson, MF; Pryde, JG; Fujihara, S; Farrow, SN; Haslett, C; Rossi, AG			NF-kappa B activation is a critical regulator of human granulocyte apoptosis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ZINC-FINGER PROTEIN; NECROSIS-FACTOR-ALPHA; IN-VITRO; NEUTROPHIL APOPTOSIS; BACTERIAL LIPOPOLYSACCHARIDE; MACROPHAGE PHAGOCYTOSIS; SYNTHESIS INHIBITORS; DNA FRAGMENTATION; AGING NEUTROPHILS	During beneficial inflammation, potentially tissue-damaging granulocytes undergo apoptosis before being cleared by phagocytes in a non-phlogistic manner. Here we show that the rate of constitutive apoptosis in human neutrophils and eosinophils is greatly accelerated in both a rapid and concentration-dependent manner by the fungal metabolite gliotoxin, but not by its inactive analog methylthiogliotoxin, This induction of apoptosis was abolished by the caspase inhibitor zVAD-fmk, correlated with the inhibition of nuclear factor-kappa B (NF-kappa B), and was mimicked by a cell permeable inhibitory peptide of NF-kappa B, SN-50; other NF-kappa B inhibitors, curcumin and pyrrolidine dithiocarbamate; and the proteasome inhibitor, MG-132, Gliotoxin also augmented dramatically the early (2-6 h) pro-apoptotic effects of tumor necrosis factor-alpha (TNF-alpha) in neutrophils and unmasked the ability of TNF-alpha to induce eosinophil apoptosis, In neutrophils, TNF-alpha caused a gliotoxin-inhibitable activation of an inducible form of NF-kappa B, a response that may underlie the ability of TNF-alpha to delay apoptosis at later times (12-24 h) and limit its early killing effect. Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappa B may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha, These data shed light on the biochemical and molecular mechanisms regulating human granulocyte apoptosis and, in particular, indicate that the transcription factor NF-kappa B plays a crucial role in regulating the physiological cell death pathway in granulocytes.	Univ Edinburgh, Sch Med, Rayne Lab, Dept Med,Resp Med Unit, Edinburgh EH8 9AG, Midlothian, Scotland; Glaxo Wellcome Res & Dev Ltd, Cell Biol Unit, Stevenage SG1 2NY, Herts, England	University of Edinburgh; GlaxoSmithKline	Rossi, AG (corresponding author), Univ Edinburgh, Sch Med, Rayne Lab, Dept Med,Resp Med Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	a.g.rossi@ed.ac.uk		Chilvers, Edwin/0000-0002-4230-9677; Lawson, Mark/0000-0001-5361-2842				Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; BAEUERLE PA, 1994, ADV IMMUNOL, V62, P1192; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BRAITHWAITE AW, 1987, MOL IMMUNOL, V24, P47, DOI 10.1016/0161-5890(87)90110-6; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; COLOTTA F, 1992, BLOOD, V80, P2012; Cousin JM, 1997, BIOCHEM SOC T, V25, pS243, DOI 10.1042/bst025243s; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; Faggioli L, 1997, BIOCHEM BIOPH RES CO, V233, P507, DOI 10.1006/bbrc.1997.6489; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HACHIYA O, 1995, MICROBIOL IMMUNOL, V39, P715, DOI 10.1111/j.1348-0421.1995.tb03247.x; Hallsworth MP, 1996, BRIT J PHARMACOL, V117, P79, DOI 10.1111/j.1476-5381.1996.tb15157.x; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; HASLETT C, 1985, AM J PATHOL, V119, P101; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LUI ZG, 1996, CELL, V87, P565; MACDONALD PP, 1997, FEBS LETT, V412, P583; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Meagher LC, 1996, J IMMUNOL, V156, P4422; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozaki K, 1997, FEBS LETT, V410, P297, DOI 10.1016/S0014-5793(97)00653-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stern M, 1996, AM J PATHOL, V149, P911; STERN M, 1992, J IMMUNOL, V148, P3543; Sutton P, 1995, BIOCHEM PHARMACOL, V50, P2009, DOI 10.1016/0006-2952(95)02101-9; SUTTON P, 1994, INFECT IMMUN, V62, P1192, DOI 10.1128/IAI.62.4.1192-1198.1994; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vollebregt M, 1998, FEBS LETT, V432, P40, DOI 10.1016/S0014-5793(98)00821-7; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Ward C, 1997, BIOCHEM SOC T, V25, pS245, DOI 10.1042/bst025245s; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WARING P, 1988, J BIOL CHEM, V263, P18493; WARING P, 1990, J BIOL CHEM, V265, P14476; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Whyte MKB, 1997, J LEUKOCYTE BIOL, V62, P195, DOI 10.1002/jlb.62.2.195; WONG T, 1997, J CLIN SCI, V92, P7; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	59	308	331	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4309	4318		10.1074/jbc.274.7.4309	http://dx.doi.org/10.1074/jbc.274.7.4309			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933632	hybrid			2022-12-27	WOS:000078575500056
J	Zhao, H; Wiederkehr, MR; Fan, LZ; Collazo, RL; Crowder, LA; Moe, OW				Zhao, H; Wiederkehr, MR; Fan, LZ; Collazo, RL; Crowder, LA; Moe, OW			Acute inhibition of Na/H exchanger NHE-3 by cAMP - Role of protein kinase A and NHE-3 phosphoserines 552 and 605	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; RENAL EPITHELIAL-CELLS; PARATHYROID-HORMONE; MEDIATED INHIBITION; MEMBRANE; ISOFORM; ANTIPORTER; COFACTOR; ACID; IDENTIFICATION	Regulation of the renal Na/H exchanger NHE-3 by protein kinase A (PKA) is a key intermediate step in the hormonal regulation of acid-base and salt balance. We studied the role of NHE-3 phosphorylation in this process in NHE-deficient AP-1 cells transfected with NHE-3 and in OKP cells expressing native NHE-8. A dominant-negative PRA-regulatory subunit completely abolished the effect of cAMP on NHE-5 activity demonstrating a role of PEA in the functional regulation of NHE-3 by cAMP, NHE-3 isolated from cAMP-treated cells showed lower phosphorylation by purified PKA in vitro suggesting that NHE-5 is a PKA substrate in vivo. Although changes in NHE-3 whole protein phosphorylation is difficult to detect in response to cAMP addition, the tryptic phosphopeptide map of in vivo phosphorylated NHE-3 showed a complex pattern of constitutive and cAMP-induced phosphopeptides. To test the causal relationship between phosphorylation and activity, we mutated eight serines in the cytoplasmic domain to glycine or alanine, Single or multiple mutants harboring S552A or S605G showed no PEA activation or reduced regulation by PKA activation. Ser-552 and Ser-605 were phosphorylated in vivo. However, multiple mutations of serines other than Ser-552 or Ser-605 also reduced the functional PKA regulation. We conclude that regulation of NHE-3 by PKA in vivo involves complex mechanisms, which include phosphorylation of Ser-552 and Ser-605.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Vet Affairs Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	omoe@mednet.swmed.edu			NIDDK NIH HHS [DK48482, T32 DK07257-17] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048482, R01DK048482, T32DK007257] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CANO A, 1993, J CLIN INVEST, V92, P1632, DOI 10.1172/JCI116748; CASAVOLA V, 1989, BIOCHEM BIOPH RES CO, V165, P833, DOI 10.1016/S0006-291X(89)80041-5; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAUPP UB, 1995, CURR OPIN NEUROBIOL, V5, P434, DOI 10.1016/0959-4388(95)80002-6; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MOE OW, 1998, STRUCTURE FUNCTION M; MORELL G, 1990, AM J PHYSIOL, V259, pF867, DOI 10.1152/ajprenal.1990.259.6.F867; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; TSE CM, 1992, J BIOL CHEM, V267, P9340; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1998, AM J PHYSIOL, V258, pF1254; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; ZHANG J, STRUCTURE, V3, P299	33	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3978	3987		10.1074/jbc.274.7.3978	http://dx.doi.org/10.1074/jbc.274.7.3978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933588	hybrid			2022-12-27	WOS:000078575500012
J	Daniele, N; Rajas, F; Payrastre, B; Mauco, G; Zitoun, C; Mithieux, G				Daniele, N; Rajas, F; Payrastre, B; Mauco, G; Zitoun, C; Mithieux, G			Phosphatidylinositol 3-kinase translocates onto liver endoplasmic reticulum and may account for the inhibition glucose-6-phosphatase during refeeding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; PHOSPHATASE-ACTIVITY; INSULIN-RESISTANT; PROTEIN-KINASE; MESSENGER-RNA; IN-VITRO; RATS; MUSCLE; CELLS; GENE	By using a rapid procedure of isolation of microsomes, we have shown that the liver glucose-6-phosphatase activity was lowered by about 30% (p < 0.001) after refeeding for 360 min rats previously unfed for 48 h, whereas the amount of glucose-6-phosphatase protein was not lowered during the same time. The amount of the regulatory subunit (p85) and the catalytic activity of phosphatidylinositol 3-kinase (PI3K) were higher by a factor of 2.6 and 2.4, respectively (p < 0.01), in microsomes from refed as compared with fasted rats. This resulted from a translocation process because the total amount of p85 was the same in the whole liver homogenates from fasted and refed rats. The amount of insulin receptor substrate 1 (IRS1) was also higher by a factor of 2.6 in microsomes from refed rats (p < 0.01). Microsome-bound IRS1 was only detected in p85 immunoprecipitates. These results strongly suggest that an insulin-triggered mechanism of translocation of PI3K onto microsomes occurs in the liver of rats during refeeding. This process, via the lipid products of PI3K, which are potent inhibitors of glucose-6-phosphatase (Mithieux, G., Daniele, N., Payrastre, B., and Zitoun, C. (1998) J. Biol. Chem. 273, 17-19), may account for the inhibition of the enzyme and participate to the inhibition of hepatic glucose production occurring in this situation.	Fac Med RTH Laennec, INSERM, F-69372 Lyon 08, France; Fac Med RTH Laennec, U449, F-69372 Lyon, France; Hop Purpan, U326, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Mithieux, G (corresponding author), Fac Med RTH Laennec, INSERM, Rue G Paradin, F-69372 Lyon 08, France.		Danièle, Nathalie/J-7432-2013; Mauco, Gerard/A-3164-2016; RAJAS, Fabienne/P-4091-2016	Mauco, Gerard/0000-0003-2998-2397; RAJAS, Fabienne/0000-0002-9233-7633; , Bernard/0000-0002-8693-0190; Gilles, Mithieux/0000-0003-3579-8529; Daniele, Nathalie/0000-0002-7985-2788				AJZANNAY A, 1994, J BIOCHEM-TOKYO, V116, P1336, DOI 10.1093/oxfordjournals.jbchem.a124684; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BODE AM, 1992, J BIOL CHEM, V267, P2860; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG PY, 1995, J BIOL CHEM, V270, P29928; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; GUIGNOT L, 1994, DIABETOLOGIA S1, V39, P13; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Harlow E., 1988, ANTIBODIES LAB MANUA; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KELLY KL, 1992, J BIOL CHEM, V267, P3423; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITRA SR, 1994, BIOCHEM BIOPH RES CO, V204, P716, DOI 10.1006/bbrc.1994.2518; MASSILLON D, 1996, DIABETES S2, V45, P35; Mevorach M, 1998, J CLIN INVEST, V102, P744, DOI 10.1172/JCI2720; Minassian C, 1996, MOL CELL BIOCHEM, V155, P37, DOI 10.1007/BF00714331; Minassian C, 1998, BIOCHEM PHARMACOL, V55, P1213, DOI 10.1016/S0006-2952(97)00576-5; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; MINASSIAN C, 1995, J NUTR, V125, P2727; Mithieux G, 1998, J BIOL CHEM, V273, P17, DOI 10.1074/jbc.273.1.17; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P53; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SCHULTZ RM, 1995, ANTICANCER RES, V15, P1135; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Thomson FJ, 1996, BIOCHEM J, V316, P161, DOI 10.1042/bj3160161; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	39	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3597	3601		10.1074/jbc.274.6.3597	http://dx.doi.org/10.1074/jbc.274.6.3597			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920907	hybrid			2022-12-27	WOS:000078428200047
J	Lupold, DS; Caoile, AGFS; Stern, DB				Lupold, DS; Caoile, AGFS; Stern, DB			The maize mitochondrial cox2 gene has five promoters in two genomic regions, including a complex promoter consisting of seven overlapping units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; PERENNIAL TEOSINTES; CYTOCHROME-OXIDASE; IN-VITRO; RNA; SEQUENCE; CONTAINS; CHLOROPLASTS; ARABIDOPSIS; EXPRESSION	Plant mitochondrial genes are often transcribed into complex sets of RNAs, resulting from multiple initiation sites and processing steps. To elucidate the role of initiation in generating the more than 10 cox2 transcripts found in maize mitochondria, we surveyed sequences upstream of cox2 for active promoters. Because the cox2 coding region is immediately downstream of a 0.7-kb recombination repeat, cox2 is under the control of two different sets of potential expression signals. Using an in vitro transcription assay, we localized four promoters upstream of the coding region in the so-called master chromosome, and two promoters upstream of the coding region in the recombinant subgenome, Ribonuclease protection analysis of labeled primary transcripts confirmed that all but one of these promoters is active in vivo. Primer extension was used to identify the promoter sequences and initiation sites, which agree with the consensus established earlier for maize mitochondria. This study identified two unusual promoters, the core sequences of which were composed entirely of adenines and thymines, and one of which was a complex promoter consisting of seven overlapping units. Deletion mutagenesis of the complex promoter suggested that each of its units was recognized independently by RNA polymerase, While each active promoter fit the maize core consensus sequence YRTAT, not all such sequences surveyed supported initiation. We conclude that in vitro transcription is a powerful tool for locating mitochondrial promoters and that, in the case of cox2, promoter multiplicity contributes strongly to transcript complexity.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Genet & Dev Sect, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research; Cornell University	Stern, DB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.		Stern, David B/H-7852-2012		NIGMS NIH HHS [R01GM52560] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052560] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bendich AJ, 1996, J MOL BIOL, V255, P564, DOI 10.1006/jmbi.1996.0048; BINDER S, 1995, J BIOL CHEM, V270, P22182, DOI 10.1074/jbc.270.38.22182; Biswas TK, 1998, GENE, V212, P305, DOI 10.1016/S0378-1119(98)00133-4; Caoile AGFS, 1997, NUCLEIC ACIDS RES, V25, P4055, DOI 10.1093/nar/25.20.4055; Chang TL, 1996, CURR GENET, V30, P522, DOI 10.1007/s002940050165; COOPER P, 1990, GENETICS, V126, P461; Dombrowski S, 1997, EMBO J, V16, P5069, DOI 10.1093/emboj/16.16.5069; FANGMAN WL, 1984, P NATL ACAD SCI-BIOL, V81, P7156, DOI 10.1073/pnas.81.22.7156; FAURON C, 1995, TRENDS GENET, V11, P228, DOI 10.1016/S0168-9525(00)89056-3; FINNEGAN PM, 1990, PLANT CELL, V2, P71, DOI 10.1105/tpc.2.1.71; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; Giese A, 1996, MOL GEN GENET, V252, P429, DOI 10.1007/BF02173008; HANICJOYCE PJ, 1991, MOL CELL BIOL, V11, P2035, DOI 10.1128/MCB.11.4.2035; HECK JD, 1988, J BIOL CHEM, V263, P857; IRATNI R, 1994, GENE DEV, V8, P2928, DOI 10.1101/gad.8.23.2928; Li XQ, 1996, PLANT CELL, V8, P1961, DOI 10.1105/tpc.8.11.1961; LONSDALE DM, 1984, NUCLEIC ACIDS RES, V12, P9249, DOI 10.1093/nar/12.24.9249; MULLIGAN RM, 1988, MOL GEN GENET, V211, P373, DOI 10.1007/BF00425688; MULLIGAN RM, 1991, MOL CELL BIOL, V11, P533, DOI 10.1128/MCB.11.1.533; MULLIGAN RM, 1988, P NATL ACAD SCI USA, V85, P7998, DOI 10.1073/pnas.85.21.7998; NEWTON KJ, 1985, P NATL ACAD SCI USA, V82, P6879, DOI 10.1073/pnas.82.20.6879; NEWTON KJ, 1995, EMBO J, V14, P585, DOI 10.1002/j.1460-2075.1995.tb07034.x; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; RAPP WD, 1993, MOL CELL BIOL, V13, P7232, DOI 10.1128/MCB.13.12.7232; RAPP WD, 1992, EMBO J, V11, P1065, DOI 10.1002/j.1460-2075.1992.tb05145.x; SCHINKEL AH, 1988, NUCLEIC ACIDS RES, V16, P9147, DOI 10.1093/nar/16.19.9147; STOHL LL, 1992, MOL CELL BIOL, V12, P2561, DOI 10.1128/MCB.12.6.2561; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; TRACY RL, 1995, CURR GENET, V28, P205, DOI 10.1007/BF00309779; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57	31	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3897	3903		10.1074/jbc.274.6.3897	http://dx.doi.org/10.1074/jbc.274.6.3897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920945	hybrid			2022-12-27	WOS:000078428200085
J	Matsunaga, J; Sinha, D; Pannell, L; Santis, C; Solano, F; Wistow, GJ; Hearing, VJ				Matsunaga, J; Sinha, D; Pannell, L; Santis, C; Solano, F; Wistow, GJ; Hearing, VJ			Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE INDUCES APOPTOSIS; FACTOR MIF; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DOPACHROME TAUTOMERASE; MOLECULAR-CLONING; SUBSTANTIA-NIGRA; BOVINE BRAIN; CELL-DEATH; NEUROMELANIN	Macrophage migration inhibitory factor (MIF) is a relatively small, 12.5-kDa protein that is structurally related to some isomerases and for which multiple immune and catalytic roles have been proposed. MIF is widely expressed in tissues with particularly high levels in neural tissues. Here we show that MIF is able to catalyze the conversion of 3,4-dihydroxyphenylaminechrome and norepinephrinechrome, toxic quinone products of the neurotransmitter catecholamines 3,4-dihydroxyphenylamine and norepinephrine, to indoledihydroxy derivatives that may serve as precursors to neuromelanin. This raises the possibility that MIF participates in a detoxification pathway for catecholamine products and could therefore have a protective role in neural tissues, which as in Parkinson's disease, may be subject to catecholamine-related cell death.	NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NEI, Sect Mol Struct & Funct, NIH, Bethesda, MD 20892 USA; Univ Murcia, Dept Biochem, E-30100 Murcia, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Murcia	Hearing, VJ (corresponding author), NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Solano, Francisco/G-5001-2013	Solano, Francisco/0000-0001-9612-761X	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [Z01EY000320, ZIAEY000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032102] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apte RS, 1998, J IMMUNOL, V160, P5693; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; dIschia M, 1997, PIGM CELL RES, V10, P370, DOI 10.1111/j.1600-0749.1997.tb00694.x; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; ENOCHS WS, 1993, J NEUROCHEM, V61, P68, DOI 10.1111/j.1471-4159.1993.tb03538.x; Esumi N, 1998, MAMM GENOME, V9, P753, DOI 10.1007/s003359900858; GALAT A, 1994, EUR J BIOCHEM, V224, P417, DOI 10.1111/j.1432-1033.1994.00417.x; GALAT A, 1993, FEBS LETT, V319, P233, DOI 10.1016/0014-5793(93)80553-7; Hastings TG, 1997, J NEURAL TRANSM-SUPP, P103; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LINDQUIST NG, 1987, PIGM CELL RES, V1, P133, DOI 10.1111/j.1600-0749.1987.tb00403.x; Magi B, 1998, ELECTROPHORESIS, V19, P2010, DOI 10.1002/elps.1150191120; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; MIKAYAMA T, 1993, P NATL ACAD SCI USA, V90, P10056, DOI 10.1073/pnas.90.21.10056; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Mischke R, 1998, FEBS LETT, V427, P85, DOI 10.1016/S0014-5793(98)00400-1; MozeticFrancky B, 1997, PROTEIN EXPRES PURIF, V9, P115, DOI 10.1006/prep.1996.0641; Nishibori M, 1996, NEUROSCI LETT, V213, P193; Nishibori M, 1997, BRAIN RES, V758, P259, DOI 10.1016/S0006-8993(97)00342-9; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Offen D, 1997, NEUROCHEM INT, V31, P207, DOI 10.1016/S0197-0186(96)00150-7; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PARALKAR V, 1994, GENOMICS, V19, P48, DOI 10.1006/geno.1994.1011; PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0; PAWELEK JM, 1978, NATURE, V276, P627, DOI 10.1038/276627a0; PROTA G, 1993, PIGM CELL RES, V6, P333, DOI 10.1111/j.1600-0749.1993.tb00610.x; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SeguraAguilar J, 1997, J BIOL CHEM, V272, P5727, DOI 10.1074/jbc.272.9.5727; Shinkai T, 1997, J NEUROSCI RES, V47, P393; Smythies J, 1996, P ROY SOC B-BIOL SCI, V263, P487, DOI 10.1098/rspb.1996.0073; STEEL KP, 1992, DEVELOPMENT, V115, P1111; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Sun HW, 1996, PROTEIN ENG, V9, P631, DOI 10.1093/protein/9.8.631; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Suzuki M, 1997, J BIOCHEM-TOKYO, V122, P1040; Temlett JA, 1996, CURR OPIN NEUROL, V9, P303, DOI 10.1097/00019052-199608000-00011; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wilhelmsen K, 1997, ANN NEUROL, V41, P813, DOI 10.1002/ana.410410619; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; WISTOW GJ, 1998, ENCY IMMUNOLOGY, P1658; ZECCA L, 1992, BIOCHIM BIOPHYS ACTA, V1138, P6, DOI 10.1016/0925-4439(92)90144-C; ZHANG M, 1995, FEBS LETT, V373, P203, DOI 10.1016/0014-5793(95)01041-C; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	53	73	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3268	3271		10.1074/jbc.274.6.3268	http://dx.doi.org/10.1074/jbc.274.6.3268			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920865	hybrid			2022-12-27	WOS:000078428200005
J	Pham, PT; Olson, MW; McHenry, CS; Schaaper, RM				Pham, PT; Olson, MW; McHenry, CS; Schaaper, RM			Mismatch extension by Escherichia coli DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE MISINCORPORATION; FIDELITY; REPLICATION; BACTERIOPHAGE-T4; EXONUCLEASE; FREQUENCIES; MUTATIONS; COMPLEX; ERRORS; GENE	The in vitro fidelity of Escherichia coli DNA polymerase III holoenzyme (HE) is characterized by an unusual propensity for generating (-1)-frameshift mutations, Here we have examined the capability of HE isolated from both a wild-type and a proofreading-impaired mutD5 strain to polymerize from M13mp2 DNA primer-templates containing a terminal T(template).C mismatch, These substrates contained either an A or a G as the next (5') template base. The assay allows distinction between: (i) direct extension of the terminal C (producing a base substitution), (ii) exonucleolytic removal of the C, or (iii), for the G-containing template, extension after misalignment of the C on the next template G (producing a (-1)-frameshift), On the A-containing substrate, both HEs did not extend the terminal C (<1%); instead, they exonucleolytically removed it (>99%), In contrast, on the G-containing substrate, the MutD5 HE yielded 61% (-1)-frameshifts and 6% base substitutions, The wild-type HE mostly excised the mispaired C from this substrate before extension (98%), but among the 2% mutants, (-1)-frameshifts exceeded base substitutions by 20 to 1, The preference of polymerase III HE for misalignment extension over direct mismatch extension provides a basis for explaining the in vitro (-1)-frameshift specificity of polymerase III HE.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Schaaper, RM (corresponding author), NIEHS, Mol Genet Lab, NIH, E3-01,POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	schaaper@niehs.nih.gov	Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196				BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FARABAUGH PJ, 1978, J MOL BIOL, V126, P847, DOI 10.1016/0022-2836(78)90023-2; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kornberg A., 1992, DNA REPLICATION, P165; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; RIPLEY LS, 1986, J MOL BIOL, V191, P601, DOI 10.1016/0022-2836(86)90448-1; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	24	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3705	3710		10.1074/jbc.274.6.3705	http://dx.doi.org/10.1074/jbc.274.6.3705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920922	hybrid			2022-12-27	WOS:000078428200062
J	Prince, LS; Peter, K; Hatton, SR; Zaliauskiene, L; Cotlin, LF; Clancy, JP; Marchase, RB; Collawn, JF				Prince, LS; Peter, K; Hatton, SR; Zaliauskiene, L; Cotlin, LF; Clancy, JP; Marchase, RB; Collawn, JF			Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR INTERNALIZATION; CFTR CHLORIDE CHANNELS; CYTOPLASMIC DOMAIN; SORTING SIGNALS; SEQUENCE; MOTIF; DNA; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION	We previously demonstrated that the cystic fibrosis transmembrane conductance regulator (CFTR) is rapidly endocytosed in epithelial cells (Prince, L. S., Workman, R. B., Jr., and Marchase, R. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5192-5196), To determine the structural features of CFTR required for endocytosis, we prepared chimeric molecules consisting of the amino-terminal (residues 2-78) and carboxyl-terminal tail regions (residues 1391-1476) of CFTR, each fused to the transmembrane and extracellular domains of the transferrin receptor. Functional analysis of the CFTR-(2-78) and CFTR-(1391-1476) indicated that both chimeras were rapidly internalized. Deletion of residues 1440-1476 had no effect on chimera internalization. Mutations of potential internalization signals in both cytoplasmic domains reveal that only one mutation inhibits internalization, Y1424A. Using a surface biotinylation reaction, we also examined internalization rates of wild type and mutant CFTRs expressed in COS-7 cells, We found that both wild type and A1440X CFTR were rapidly internalized, whereas the Y1424A CFTR mutant, like the chimeric protein, had similar to 40% reduced internalization activity. Deletions in the amino-terminal tail region of CFTR resulted in defective trafficking of CFTR out of the endoplasmic reticulum to the cell surface, suggesting that an intact amino terminus is critical for biosynthesis, In summary, our results suggest that both tail regions of CFTR are sufficient to promote rapid internalization of a reporter molecule and that tyrosine 1424 is required for efficient CFTR endocytosis.	Univ Alabama Birmingham, Dept Cell Biol, UAB Stn, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, UAB Stn, Gregory Fleming James Cyst Fibrosis Res Ctr, BHSB 392, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Collawn, James/0000-0002-2528-2759	NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; George AL, 1998, P NATL ACAD SCI USA, V95, P7843, DOI 10.1073/pnas.95.14.7843; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HUGHES SH, 1990, J REPROD FERTIL, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOGAN JJ, 1995, GENE THER, V2, P38; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILEY HS, 1982, J BIOL CHEM, V257, P4222	45	79	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3602	3609		10.1074/jbc.274.6.3602	http://dx.doi.org/10.1074/jbc.274.6.3602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920908	hybrid			2022-12-27	WOS:000078428200048
J	Schierau, A; Dietz, F; Lange, H; Schestag, F; Parastar, A; Gieselmann, V				Schierau, A; Dietz, F; Lange, H; Schestag, F; Parastar, A; Gieselmann, V			Interaction of arylsulfatase A with UDP-N-acetylglucosamine : lysosomal enzyme-N-acetylglucosamine-1-phosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN RECOGNITION DETERMINANTS; ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PROCATHEPSIN-D; TARGETING SIGNAL; ACTIVE-SITE; PHOSPHORYLATION; OLIGOSACCHARIDES; PHOSPHOTRANSFERASE; GLYCOSYLATION; MUTAGENESIS	The critical step in lysosomal targeting of soluble lysosomal enzymes is the recognition by an UDP-N-acetyl-glucosamine:lysosomal enzyme-N-acetylglucosamine-1-phosphotransferase. The structure of the determinant common to all lysosomal enzymes for proper recognition by the phosphotransferase is not completely understood. Our current knowledge is largely based on the introduction of targeted amino acid substitutions into lysosomal enzymes and analysis of their effects on phosphotransferase recognition. We have investigated the effect of eight anti-arylsulfatase A monoclonal antibodies on the interaction of arylsulfatase A with the lysosomal enzyme phosphotransferase in vitro, We also show that a lysine-rich surface area of arylsulfatases A and B is essential for proper recognition by the phosphotransferase, Monoclonal antibodies bind to at least six different epitopes at different locations on the surface of arylsulfatase A. All antibodies bind outside the lysine-rich recognition area, but nevertheless Fab fragments of these antibodies prevent interaction of arylsulfatase A with the phosphotransferase, Our data support a model in which binding of arylsulfatase A to the phosphotransferase is not restricted to a limited surface area but involves the simultaneous recognition of large parts of arylsulfatase A.	Univ Kiel, Inst Biochem, D-24098 Kiel, Germany	University of Kiel	Gieselmann, V (corresponding author), Univ Kiel, Inst Biochem, Olshausenstr 40, D-24098 Kiel, Germany.							AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KAARTINEN M, 1983, J IMMUNOL, V130, P937; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LANG L, 1984, J BIOL CHEM, V259, P4663; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Peters J, 1992, MONOCLONAL ANTIBODIE; SCHULZEGARG C, 1993, J CELL BIOL, V122, P541, DOI 10.1083/jcb.122.3.541; SOMMERLADE HJ, 1994, J BIOL CHEM, V269, P20977; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; STEIN C, 1989, J BIOL CHEM, V264, P1252; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; VONFIGURA K, 1990, NATURWISSENSCHAFTEN, V77, P116, DOI 10.1007/BF01134471	27	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3651	3658		10.1074/jbc.274.6.3651	http://dx.doi.org/10.1074/jbc.274.6.3651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920914	hybrid			2022-12-27	WOS:000078428200054
J	Xia, M; Dempski, R; Hille, R				Xia, M; Dempski, R; Hille, R			The reductive half-reaction of xanthine oxidase - Reaction with aldehyde substrates and identification of the catalytically labile oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOM TRANSFER-REACTIONS; ANALOG REACTION SYSTEM; MOLYBDENUM OXOTRANSFERASES; ACTIVE-SITES; COMPLEXES; KINETICS; O-17; MOLYBDOENZYMES; MECHANISM; DEHYDROGENASE	The kinetics of xanthine oxidase has been investigated with the aim of addressing several outstanding questions concerning the reaction mechanism of the enzyme. Steady-state and rapid kinetic studies with the substrate 2,5-dihydroxybenzaldehyde demonstrated that (k(cat)/K-m)(app) and k(red)/K-d exhibit comparable bell-shaped pH dependence with pK(a) values of 6.4 +/- 0.2 and 8.4 +/- 0.2, with the lower pK(a) assigned to an active-site residue of xanthine oxidase (possibly Glu-1261, by analogy to Glu-869 in the crystallographically known aldehyde oxidase from Desulfovibrio gigas) and the higher pK(a) to substrate. Early steps in the catalytic sequence have been investigated by following the reaction of the oxidized enzyme with a second aldehyde substrate, 2-aminopteridine-6-aldehyde. The absence of a well defined acid limb in this pH profile and other data indicate that this complex represents an E-ox.S rather than E-red.P complex (i.e. no chemistry requiring the active-site base has taken place in forming the long wavelength-absorbing complex seen with this substrate). It appears that xanthine oxidase (and by inference, the closely related aldehyde oxidases) hydroxylates both aromatic heterocycles and aldehydes by a mechanism involving base-assisted catalysis, Single-turnover experiments following incorporation of O-17 into the molybdenum center of the enzyme demonstrated that a single oxygen atom is incorporated at a site that gives rise to strong hyperfine coupling to the unpaired electron spin of the metal in the Mo-V oxidation state. By analogy to the hyperfine interactions seen in a homologous series of molybdenum model compounds, we conclude that this strongly coupled, catalytically labile site represents a metal-coordinated hydroxide rather than the Mo=O group and that this Mo-OH represents the oxygen that is incorporated into product in the course of catalysis.	Ohio State Univ, Dept Biochem Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Hille, R (corresponding author), Ohio State Univ, Dept Biochem Med, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	Hille.1@osu.edu			NIAMS NIH HHS [AR38917] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038917] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1993, ADV INORGANIC CHEM, DOI DOI 10.1016/S0898-8838(08)60181-6; BERG JM, 1985, J AM CHEM SOC, V107, P917, DOI 10.1021/ja00290a029; BERG JM, 1984, J AM CHEM SOC, V106, P3035, DOI 10.1021/ja00322a050; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; GEORGE GN, 1988, BIOCHEMISTRY-US, V27, P3603, DOI 10.1021/bi00410a011; GHELLER SF, 1992, J AM CHEM SOC, V114, P6934, DOI 10.1021/ja00043a059; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTTERIDGE S, 1980, BIOCHEM J, V189, P615, DOI 10.1042/bj1890615; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1981, PHARMACOL THERAPEUT, V14, P249, DOI 10.1016/0163-7258(81)90063-2; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM RH, 1987, CHEM REV, V87, P1401, DOI 10.1021/cr00082a005; HOLM RH, 1993, POLYHEDRON, V12, P571, DOI 10.1016/S0277-5387(00)84972-4; Howes BD, 1996, BIOCHEMISTRY-US, V35, P1432, DOI 10.1021/bi9520500; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUNT J, 1994, J BIOL CHEM, V269, P18904; JOHNSON KA, 1992, ENZYMES, V20, P2; KIM JH, 1993, J BIOL CHEM, V268, P44; Kim JH, 1996, J BIOL CHEM, V271, P6771, DOI 10.1074/jbc.271.12.6771; KOMAI H, 1969, J BIOL CHEM, V244, P1692; LISTER JH, 1971, CHEM HETEROCYCLIC 2, P203; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MORPETH FF, 1983, BIOCHIM BIOPHYS ACTA, V744, P328, DOI 10.1016/0167-4838(83)90207-8; OLSON JS, 1974, J BIOL CHEM, V249, P4350; PARSONS SM, 1972, BIOCHEMISTRY-US, V11, P1633, DOI 10.1021/bi00759a015; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; ROBERTS SA, 1990, INORG CHEM, V29, P3650, DOI 10.1021/ic00344a007; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; Schindelin H, 1997, J BIOL INORG CHEM, V2, P773, DOI 10.1007/s007750050194; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; SCHULTZ BE, 1993, INORG CHEM, V32, P4244, DOI 10.1021/ic00072a016; SCHULTZ BE, 1993, J AM CHEM SOC, V115, P2714, DOI 10.1021/ja00060a021; SKIBO EB, 1987, BIOCHEMISTRY-US, V26, P3032, DOI 10.1021/bi00385a013; Stiefel E.I, 1977, PROG INORG CHEM, P1, DOI 10.1002/9780470166239.ch1; Voityuk AA, 1997, J AM CHEM SOC, V119, P3159, DOI 10.1021/ja963901+; XIAO ZG, 1992, J AM CHEM SOC, V114, P9194, DOI 10.1021/ja00049a065	41	84	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3323	3330		10.1074/jbc.274.6.3323	http://dx.doi.org/10.1074/jbc.274.6.3323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920873	hybrid			2022-12-27	WOS:000078428200013
J	Mittelstadt, PR; Ashwell, JD				Mittelstadt, PR; Ashwell, JD			Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; TRANSCRIPTION FACTORS; CYCLOSPORINE-A; LYMPHOPROLIFERATIVE DISORDERS; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; GENE-MUTATIONS; LPR/LPR MICE; FAMILY GENE; NGFI-A	We previously identified a Fas ligand regulatory element (FLRE) in the Fas ligand (fasL) promoter that binds Egr family proteins and demonstrated that Egr-3 (PILOT) but not Egr-1 (NGFI-A, Krox-24, Tis-8, and Zif-268) induces transcription of fast. The aberrant CD4(-)CD8(-) T cells from lpr/lpr and gld/gld mice, which have mutations in the genes encoding Fas and Fast, respectively, have an activated phenotype and constitutively express high levels of fasL mRNA, prompting us to ask what role if any the FLRE and Egr family proteins have in this aberrant expression of fast. Unstimulated MRL-lpr/lpr and C3H-gld/gld CD4(-)CD8(-) T cells constitutively contained high levels of two proteins that bound to the FLRE, Supershift analysis revealed these proteins to be Egr-1 and Egr-2 (Krox-20); Egr-3 was not detected. Activation of normal lymph node cells resulted in increased expression of Egr-1, -2, and -3, As with egr-3, expression of egr-2 was blocked by cyclosporin A. Although overexpressed Egr-1 was ineffective, overexpressed Egr-2 was as potent as Egr-3 in inducing fast promoter-dependent reporter constructs in T cell hybridomas and HeLa cells, and both up-regulated endogenous fast mRNA in HeLa cells. FasL- dependent reporter constructs in MRL-lpr/lpr and C3H-gld/gld CD4(-)CD8(-) T cells were constitutively active, and this activity was largely prevented by mutation of the critical Egr family binding element. Thus, Egr-2, in addition to Egr-3, regulates Fast expression in activated normal T cells, and Egr-2 is likely to play a direct role in aberrant fast up-regulation in lpr/lpr and gld/gld CD4(-)CD8(-) T cells.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.	jda@Box-j.nih.gov						AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V9; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHU JL, 1995, J EXP MED, V181, P393, DOI 10.1084/jem.181.1.393; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMENTS JL, 1995, J IMMUNOL, V154, P6372; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DAVIGNON JL, 1985, J IMMUNOL, V135, P2423; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIESE T, 1993, J IMMUNOL, V151, P597; GIESE T, 1992, J IMMUNOL, V149, P3097; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; IWATA M, 1992, J IMMUNOL, V149, P3302; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; Matsui K, 1997, EUR J IMMUNOL, V27, P2269, DOI 10.1002/eji.1830270922; Mimura T, 1997, J IMMUNOL, V158, P2977; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; Nittenberg R, 1997, DEVELOPMENT, V124, P2297; Nonchev S, 1996, DEVELOPMENT, V122, P543; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; Skerka C, 1997, IMMUNOBIOLOGY, V198, P179, DOI 10.1016/S0171-2985(97)80039-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Theil T, 1998, DEVELOPMENT, V125, P443; TOMITAYAMAGUCHI M, 1990, J IMMUNOL, V144, P3946; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Williams MS, 1996, J IMMUNOL, V157, P2395; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	59	72	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3222	3227		10.1074/jbc.274.5.3222	http://dx.doi.org/10.1074/jbc.274.5.3222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915863	hybrid			2022-12-27	WOS:000078319500081
J	Nakamura, E; Sato, M; Yang, HL; Miyagawa, F; Harasaki, M; Tomita, K; Matsuoka, S; Noma, A; Iwai, K; Minato, N				Nakamura, E; Sato, M; Yang, HL; Miyagawa, F; Harasaki, M; Tomita, K; Matsuoka, S; Noma, A; Iwai, K; Minato, N			4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE ANTIGEN; EXPRESSION CLONING; SYSTEM; ACTIVATION; CYSTINURIA; INHIBITION; OOCYTES; SUBUNIT; FUSION; CDNA	4F2, also termed CD98, is an integral membrane protein consisting of a heavy chain linked to a light chain by disulfide bond. We have generated a monoclonal antibody to the mouse 4F2 light chain and cloned the cDNA It encodes a mouse counterpart of rat L-type amino acid transporter-1, and induces system L amino acid transport in Xenopus oocytes in the presence of 4F2 heavy chain. Transfection studies in mammalian cells have indicated that the 4F2 heavy chain is expressed on the plasma membrane on its own, whereas the 4F2 light chain can be transported to the surface only in the presence of 4F2 heavy chain. 4F2 heavy chain is expressed diffusely on the surface of fibroblastic L cells, whereas it is localized selectively to the cell-cell adhesion sites in L cells expressing cadherins, These results indicate that the 4F2 heavy chain is associated covalently with an amino acid transporter and controls the cell surface expression as well as the membrane topology of the 4F2 heterodimer. Although 4F2 heavy and light chains are expressed coordinately in most tissues, the light chain is barely detected by the antibody in kidney and intestine, despite the presence of heavy chain in a complex form. The results predict the presence of multiple 4F2 light chains.	Kyoto Univ, Fac Med, Dept Immunol & Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Physiol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Minato, N (corresponding author), Kyoto Univ, Fac Med, Dept Immunol & Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	minato@med.kyoto-u.ac.jp	IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer A, 1998, BIOCHEM J, V333, P549, DOI 10.1042/bj3330549; Chillaron J, 1997, J BIOL CHEM, V272, P9543; CHOW DC, 1995, J EXP BIOL, V198, P1; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; HAYNES BF, 1981, J IMMUNOL, V127, P347; HEMLER ME, 1982, J IMMUNOL, V129, P623; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KUBOTA H, 1994, INT IMMUNOL, V6, P1323, DOI 10.1093/intimm/6.9.1323; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LUMADUE JA, 1987, P NATL ACAD SCI USA, V84, P9204, DOI 10.1073/pnas.84.24.9204; MICHALAK M, 1986, J BIOL CHEM, V261, P92; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAGITA H, 1986, CANCER RES, V46, P1478	29	232	241	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3009	3016		10.1074/jbc.274.5.3009	http://dx.doi.org/10.1074/jbc.274.5.3009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915839	hybrid			2022-12-27	WOS:000078319500057
J	Ghafourifar, P; Klein, SD; Schucht, O; Schenk, U; Pruschy, M; Rocha, S; Richter, C				Ghafourifar, P; Klein, SD; Schucht, O; Schenk, U; Pruschy, M; Rocha, S; Richter, C			Ceramide induces cytochrome c release from isolated mitochondria - Importance of mitochondrial redox state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CELL-PERMEABLE CERAMIDE; INDUCED APOPTOSIS; TNF-ALPHA; KAPPA-B; MECHANISM; DEATH; REQUIREMENT; GENERATION; INHIBITION	In the present study we show that N-acetylsphingosine (C-2-ceramide), N-hexanoylsphingosine (C-6-ceramide), and, to a much lesser extent, C-2-dihydroceramide induce cytochrome c (cyto c) release from isolated rat liver mitochondria. Ceramide-induced cyto c release is prevented by preincubation of mitochondria with a low concentration (40 nM) of Bcl-2. The release takes place when cyto c is oxidized but not when it is reduced. Upon cyto c loss, mitochondrial oxygen consumption, mitochondrial transmembrane potential (Delta Psi), and Ca2+ retention are diminished. Incubation with Bcl-2 prevents, and addition of cyto c reverses the alteration of these mitochondrial functions. In ATP-energized mitochondria, ceramides do not alter Delta Psi, neither when cyto c is oxidized nor when it is reduced, ruling out a nonspecific disturbance by ceramides of mitochondrial membrane integrity. Furthermore, ceramides decrease the reducibility of cyto c. We conclude that the apoptogenic properties of ceramides are in part mediated via their interaction with mitochondrial cyto c followed by its release and that the redox state of cyto c influences its detachment by ceramide from the inner mitochondrial membrane.	Swiss Fed Inst Technol, Biochem Lab 1, CH-8092 Zurich, Switzerland; Univ Zurich Hosp, Dept Radiat Oncol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital	Richter, C (corresponding author), Swiss Fed Inst Technol, Biochem Lab 1, Univ Str 16, CH-8092 Zurich, Switzerland.	richter@bc.biol.ethz.ch	Klein, Sabine D./T-2854-2019	Klein, Sabine D./0000-0001-6843-1454; Pruschy, Martin/0000-0002-3124-9015; Rocha, Sonia/0000-0002-2413-4981				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DUTTON PL, 1975, BIOCHIM BIOPHYS ACTA, V387, P536, DOI 10.1016/0005-2728(75)90092-4; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; FREI B, 1985, J BIOL CHEM, V260, P7394; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hampton MB, 1998, BIOCHEM J, V329, P95; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENNET T, 1993, CANCER RES, V53, P1456; HERMANN S, 1995, SCIENCE, V267, P1445; Higuchi M, 1996, J IMMUNOL, V157, P297; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kuroki J, 1996, LEUKEMIA, V10, P1950; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Shidoji Y, 1997, BIOCHEM BIOPH RES CO, V230, P58, DOI 10.1006/bbrc.1996.5883; Subramanian M, 1998, BIOCHEMISTRY-US, V37, P1394, DOI 10.1021/bi9716581; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wadia JS, 1998, J NEUROSCI, V18, P932; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	43	224	232	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6080	6084		10.1074/jbc.274.10.6080	http://dx.doi.org/10.1074/jbc.274.10.6080			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037689	hybrid			2022-12-27	WOS:000078902800011
J	Hedlund, H; Hedbom, E; Heinegard, D; Mengarelli-Widholm, S; Reinholt, FP; Svensson, O				Hedlund, H; Hedbom, E; Heinegard, D; Mengarelli-Widholm, S; Reinholt, FP; Svensson, O			Association of the aggrecan keratan sulfate-rich region with collagen in bovine articular cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; PROTEOGLYCAN; DECORIN; PROTEIN; FIBRILS; FIBROMODULIN; MATRIX; IX	Aggrecan, the predominant large proteoglycan of cartilage, is a multidomain macromolecule with each domain contributing specific functional properties. One of the domains contains the majority of the keratan sulfate (KS) chain substituents and a protein segment with a proline-rich hexapeptide repeat sequence. The function of this domain is unknown but the primary structure suggests a potential for binding to collagen fibrils. We have examined binding of aggrecan fragments encompassing the KS-rich region in a solid-phase assay, A moderate affinity (apparent K-d = 1.1 mu M) for isolated collagen II, as well as collagen I, was demonstrated. Enzymatic digestion of the RS chains did not alter the capacity of the peptide to bind to collagen, whereas cleavage of the protein core abolished the interaction. The distribution of the aggrecan KS-rich region in bovine tarsometatarsal joint cartilage was investigated using immunoelectron microscopy. Immunoreactivity was relatively low in the superficial zone and higher in the intermediate and deep zones of the uncalcified cartilage. Within the pericellular and territorial matrix compartments the epitopes representing the aggrecan KS-rich region were detected preferentially near or at collagen fibrils. Along the fibrils, epitope reactivity was non-randomly distributed, showing preference for the gap region within the D-period. Our data suggest that collagen fibrils interact with the KS-rich regions of several aggrecan monomers aligned within a proteoglycan aggregate. The fibril could therefore serve as a backbone in at least some of the aggrecan complexes.	Huddinge Univ Hosp, Karolinska Inst, Dept Orthoped, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Pathol, SE-14186 Huddinge, Sweden; Univ Oslo, Natl Hosp, Dept Pathol, NO-0027 Oslo, Norway; Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland; Univ Lund, Dept Cell & Mol Biol, SE-22100 Lund, Sweden	Karolinska Institutet; Karolinska Institutet; University of Oslo; National Hospital Norway; University of Zurich; University Zurich Hospital; Lund University	Hedlund, H (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Orthoped, SE-14186 Huddinge, Sweden.	Hakan.Hedlund@karo.ki.se						ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; AYAD S, 1991, BIOCHEM J, V278, P441, DOI 10.1042/bj2780441; CATERSON B, 1983, J BIOL CHEM, V258, P8848; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FRANZEN A, 1981, BIOCHEM J, V195, P535, DOI 10.1042/bj1950535; Griffiths G., 1993, FINE STRUCTURE IMMUN, P237; HAGG R, 1998, IN PRESS J CELL BIOL; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1993, APMIS, V101, P133, DOI 10.1111/j.1699-0463.1993.tb00092.x; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P305; HEINEGARD D, 1978, BIOCHEM J, V175, P913, DOI 10.1042/bj1750913; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; Heinegard Dick, 1993, P189; HUKINS DWL, 1985, TRENDS BIOCHEM SCI, V10, P260, DOI 10.1016/0968-0004(85)90077-5; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; LEMPERG R, 1974, CALC TISS RES, V15, P237, DOI 10.1007/BF02059060; MAROUDAS A, 1976, NATURE, V260, P808, DOI 10.1038/260808a0; OEGEMA TR, 1975, ARCH BIOCHEM BIOPHYS, V170, P698, DOI 10.1016/0003-9861(75)90167-8; ORFORD CR, 1984, CONNECT TISSUE RES, V12, P345, DOI 10.3109/03008208409013696; POOLE AR, 1982, J CELL BIOL, V93, P921, DOI 10.1083/jcb.93.3.921; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; STOCKWELL RA, 1967, NATURE, V215, P1376, DOI 10.1038/2151376a0; TOOLE BP, 1976, J BIOL CHEM, V251, P895; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WIEDEMANN H, 1984, BIOCHEM J, V224, P331, DOI 10.1042/bj2240331; WIESLANDER J, 1979, BIOCHEM J, V179, P35, DOI 10.1042/bj1790035	31	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5777	5781		10.1074/jbc.274.9.5777	http://dx.doi.org/10.1074/jbc.274.9.5777			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026199	hybrid			2022-12-27	WOS:000078804400070
J	Murphy, M; Godson, C; Cannon, S; Kato, S; Mackenzie, HS; Martin, F; Brady, HR				Murphy, M; Godson, C; Cannon, S; Kato, S; Mackenzie, HS; Martin, F; Brady, HR			Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; FACTOR-BETA; DIABETIC GLOMERULOPATHY; DIFFERENTIAL DISPLAY; CDNA; HYPERGLYCEMIA; PATHOGENESIS; ADHESION	Accumulation of mesangial matrix is a pivotal event in the pathophysiology of diabetic nephropathy. The molecular triggers for matrix production are still being defined. Here, suppression subtractive hybridization identified 15 genes differentially induced when primary human mesangial cells are exposed to high glucose (30 mM versus 5 mM) in vitro. These genes included (a) known regulators of mesangial cell activation in diabetic nephropathy (fibronectin, caldesmon, thrombospondin, and plasminogen activator inhibitor-1), (b) novel genes, and (c) known genes whose induction by high glucose has not been reported. Prominent among the latter were genes encoding cytoskeleton-associated proteins and connective tissue growth factor (CTGF), a modulator of fibroblast matrix production. In parallel experiments, elevated CTGF mRNA levels were demonstrated in glomeruli of rats with streptozotocin-induced diabetic nephropathy. Mannitol provoked less mesangial cell CTGF expression in vitro than high glucose, excluding hyperosmolality as the key stimulus. The addition of recombinant CTGF to cultured mesangial cells enhanced expression of extracellular matrix proteins. High glucose stimulated expression of transforming growth factor beta 1 (TGF-beta 1), and addition of TGF-beta 1 to mesangial cells triggered CTGF expression. CTGF expression induced by high glucose was partially suppressed by anti-TGF-pl antibody and by the protein kinase C inhibitor GF 109203X. Together, these data suggest that 1) high glucose stimulates mesangial CTGF expression by TGF beta 1-dependent and protein kinase C dependent pathways, and 2) CTGF may be a mediator of TGF beta 1-driven matrix production within a diabetic milieu.	Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Natl Univ Ireland Univ Coll Dublin, Dept Pharmacol, Dublin 4, Ireland	Mater Misericordiae University Hospital; University College Dublin; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University College Dublin	Brady, HR (corresponding author), Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland.	hrbrady@mater.ie		Godson, Catherine/0000-0003-0655-1041				AYO SH, 1991, AM J PHYSIOL, V260, pF185, DOI 10.1152/ajprenal.1991.260.2.F185; AYO SH, 1990, AM J PATHOL, V136, P1339; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; DENTON MD, 1991, AM J PHYSIOL, V261, pF1071, DOI 10.1152/ajprenal.1991.261.6.F1071; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; FUMO P, 1994, AM J PHYSIOL-RENAL, V267, pF632, DOI 10.1152/ajprenal.1994.267.4.F632; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gurskaya NG, 1996, ANAL BIOCHEM, V240, P90, DOI 10.1006/abio.1996.0334; Holmes DIR, 1997, BIOCHEM BIOPH RES CO, V238, P179, DOI 10.1006/bbrc.1997.7265; Hong CY, 1998, J DIABETES COMPLICAT, V12, P43, DOI 10.1016/S1056-8727(97)00045-7; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Makino H, 1996, DIABETES, V45, P488, DOI 10.2337/diabetes.45.4.488; Murphy M, 1998, CURR OPIN NEPHROL HY, V7, P563, DOI 10.1097/00041552-199809000-00013; Park IS, 1997, DIABETES, V46, P473, DOI 10.2337/diabetes.46.3.473; PARRING HH, 1996, BRENNER RECTORS KIDN, P1864; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Tada H, 1998, NEPHRON, V79, P38, DOI 10.1159/000044989; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wahab NA, 1996, BIOCHEM J, V316, P985, DOI 10.1042/bj3160985; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; ZHOU XP, 1995, LAB INVEST, V73, P372; Zhou XP, 1997, KIDNEY INT, V51, P1797, DOI 10.1038/ki.1997.247	38	325	388	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5830	5834		10.1074/jbc.274.9.5830	http://dx.doi.org/10.1074/jbc.274.9.5830			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026205	hybrid			2022-12-27	WOS:000078804400076
J	Petersen, C				Petersen, C			Inhibition of cellular growth by increased guanine nucleotide pools - Characterization of an Escherichia coli mutant with a guanosine kinase that is insensitive to feedback inhibition by GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; SALMONELLA-TYPHIMURIUM; PHOSPHORIBOSYLTRANSFERASE; HYPOXANTHINE; OPERON; GSK	In Escherichia coli the enzyme guanosine kinase phosphorylates guanosine to GMP, which is further phosphorylated to GDP and GTP by other enzymes. Here I report that guanosine kinase is subject to efficient feedback inhibition by the end product of the pathway, GTP, and that this regulation is abolished by a previously described mutation, gsk-3, in the structural gene for guanosine kinase (Hove-Jensen, B., and Nygaard, P. (1989) J. Gen. Microbiol. 135, 1263-1273). Consequently, the gsk-3 mutant strain was extremely sensitive to guanosine, which caused the guanine nucleotide pools to increase dramatically, thereby initiating a cascade of metabolic changes that eventually led to growth arrest. By isolation and characterization of guanosine-resistant derivatives of the gsk-3 mutant, some of the crucial steps in this deleterious cascade of events were found to include the following: first, conversion of GMP to adenine nucleotides via GMP reductase, encoded by the guaC gene; second, inhibition of phosphoribosylpyrophosphate synthetase by an adenine nucleotide, presumably ADP, causing starvation for histidine, tryptophan, and pyrimidines, all of which require PRPP for their synthesis; third, accumulation of the regulatory nucleotide guanosine 5',3'-bispyrophosphate (ppGpp), a general transcriptional inhibitor synthesized by the relA gene product in response to amino acid starvation.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen K, Denmark	University of Copenhagen	Petersen, C (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, Solvgade 83H, DK-1307 Copenhagen K, Denmark.							ANDREWS SC, 1988, BIOCHEM J, V255, P35, DOI 10.1042/bj2550035; BOUVIER J, 1984, P NATL ACAD SCI-BIOL, V81, P4139, DOI 10.1073/pnas.81.13.4139; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; DEHAAN PG, 1969, MUTAT RES, V8, P505, DOI 10.1016/0027-5107(69)90067-0; DEO SS, 1985, BIOCHIM BIOPHYS ACTA, V839, P233, DOI 10.1016/0304-4165(85)90003-0; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; EDLIN G, 1966, J MOL BIOL, V15, P428, DOI 10.1016/S0022-2836(66)80118-3; GIBSON KJ, 1982, J BIOL CHEM, V257, P2391; HARLOW KW, 1995, J BACTERIOL, V177, P2236, DOI 10.1128/jb.177.8.2236-2240.1995; Hochstadt J, 1978, Methods Enzymol, V51, P558; Hochstadt J, 1978, Methods Enzymol, V51, P549; HOULBERG U, 1983, J BACTERIOL, V153, P837, DOI 10.1128/JB.153.2.837-845.1983; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1989, J GEN MICROBIOL, V135, P1263; HOVEJENSEN B, 1982, EUR J BIOCHEM, V126, P327; Jensen KF, 1996, EUR J BIOCHEM, V240, P637, DOI 10.1111/j.1432-1033.1996.0637h.x; JENSEN KF, 1979, ANAL BIOCHEM, V98, P254, DOI 10.1016/0003-2697(79)90138-6; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; Miller J.H., 1972, EXPT MOL GENETICS; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; NEUHARD J, 1996, ESCHERICHIA COLI SAL, V1, P580; SADLER WC, 1977, J BIOL CHEM, V252, P8504; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TURNBOUGH CL, 1983, J BACTERIOL, V153, P998, DOI 10.1128/JB.153.2.998-1007.1983; XIAO H, 1991, J BIOL CHEM, V266, P5980; ZALKIN H, 1996, ESCHERICHIA COLI SAL, V1, P561	30	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5348	5356		10.1074/jbc.274.9.5348	http://dx.doi.org/10.1074/jbc.274.9.5348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026143	hybrid			2022-12-27	WOS:000078804400014
J	Burden, DA; Osheroff, N				Burden, DA; Osheroff, N			In vitro evolution of preferred topoisomerase II DNA cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP ATTACHMENT SITES; EUKARYOTIC TOPOISOMERASE; DROSOPHILA-MELANOGASTER; RELIGATION REACTION; SEQUENCE; BINDING; ENZYMES; MECHANISM; REGIONS; PROTEIN	Topoisomerase II is an essential enzyme that is the target for several clinically important anticancer drugs. Although this enzyme must create transient double-stranded breaks in the genetic material in order to carry out its indispensable DNA strand passage reaction, the factors that underlie its nucleotide cleavage specificity remain an enigma. Therefore, to address the critical issue of enzyme specificity, a modified systematic evolution of ligands by exponential enrichment (SELEX) protocol was employed to select/evolve DNA sequences that were preferentially cleaved by Drosophila melanogaster topoisomerase II. Levels of DNA scission rose substantially (from 3 to 20%) over 20 rounds of SELEX, In vitro selection/evolution converged on an alternating purine/pyrmidine sequence that was highly AT-rich (TATATATACATATATATA). The preference for this sequence was more pronounced for Drosophila topoisomerase II over other species and was increased in the presence of DNA cleavage-enhancing anticancer drugs. Enhanced cleavage appeared to be based on higher rates of DNA scission rather than increased binding affinity or decreased religation rates. The preferred sequence for topoisomerase II-mediated DNA cleavage is dramatically overrepresented (similar to 10,000-fold) in the euchromatic genome of D. melanogaster, implying that it may be a site for the physiological action of this enzyme.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANDERSON HJ, 1992, CELL BIOL INT REP, V16, P717, DOI 10.1016/S0309-1651(05)80016-5; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BLASQUEZ VC, 1989, GENOME, V31, P503, DOI 10.1139/g89-098; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Capranico G, 1996, Cancer Chemother Biol Response Modif, V16, P68; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cornarotti M, 1996, MOL PHARMACOL, V50, P1463; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEE MP, 1989, J BIOL CHEM, V264, P21779; LINDSLEY JE, 1995, FASEB J, V9, pA1392; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1983, J BIOL CHEM, V258, P5365; LUND K, 1990, J BIOL CHEM, V265, P13856; Malonne H, 1997, ANTI-CANCER DRUG, V8, P811, DOI 10.1097/00001813-199710000-00001; Miassod R, 1997, NUCLEIC ACIDS RES, V25, P2041, DOI 10.1093/nar/25.11.2041; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; RAZIN SV, 1991, BIOCHEM BIOPH RES CO, V177, P265, DOI 10.1016/0006-291X(91)91977-K; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SPITZNER JR, 1990, NUCLEIC ACIDS RES, V18, P1, DOI 10.1093/nar/18.1.1; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Yarovaya OV, 1998, MOL BIOL+, V32, P36; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	58	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5227	5235		10.1074/jbc.274.8.5227	http://dx.doi.org/10.1074/jbc.274.8.5227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988773	hybrid			2022-12-27	WOS:000078698200098
J	Campos-Caro, A; Carrasco-Serrano, C; Valor, LM; Viniegra, S; Ballesta, JJ; Criado, M				Campos-Caro, A; Carrasco-Serrano, C; Valor, LM; Viniegra, S; Ballesta, JJ; Criado, M			Multiple functional Sp1 domains in the minimal promoter region of the neuronal nicotinic receptor alpha 5 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; BOVINE CHROMAFFIN CELLS; ACETYLCHOLINE-RECEPTOR; TRANSCRIPTIONAL REGULATION; REPRESSES TRANSCRIPTION; POU DOMAIN; EXPRESSION; BETA-4; DNA; ACTIVATION	The alpha 5 subunit is a component of the neuronal nicotinic acetylcholine receptors, which are probably involved in the activation step of the catecholamine secretion process in bovine adrenomedullary chromaffin cells. The promoter of the gene coding for this subunit was isolated, and its proximal region was characterized, revealing several GC boxes located close to the site of transcription initiation (from -111 to -40). Deletion analysis and transient transfections showed that a 266-base pair region (-111 to +155) gave rise to similar to 77 and 100% of the maximal transcriptional activity observed in chromaffin and SHSY-5Y neuroblastoma cells, respectively. Site-directed mutagenesis of five different GC motifs indicated that all of them contribute to the activity of the alpha 5 gene, but in a different way, depending on the type of transfected cell. Thus, in SHSY-5Y cells, alteration of the most promoter-proximal of the GC boxes decreased alpha 5 promoter activity by similar to 50%, whereas single mutations of the other GC boxes had no effect. In chromaffin cells, by contrast, modification of any of the GC boxes produced a similar decrease in promoter activity (50-69%). In both cell types, however, activity was almost abolished when four GC boxes were suppressed simultaneously. Electrophoretic mobility shift assays using nuclear extracts from either chromaffin or SHSY-5Y cells showed the specific binding of Sp1 protein to fragment -111 to -27, Binding of Sp1 to the GC boxes was also demonstrated by DNase I footprint analysis. This study suggests that the general transcription factor Sp1 plays a dominant role in alpha 5 subunit expression, as has also been demonstrated previously for alpha 3 and beta 4 subunits, Since these three subunits have their genes tightly clustered and are expressed in chromaffin cells, probably as components of the same receptor subtype, we propose that Sp1 constitutes the key factor of a regulatory mechanism common to the three subunits.	Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain; Univ Miguel Hernandez, Dept Pharmacol, Alicante 03550, Spain; Univ Miguel Hernandez, Inst Neurosci, Alicante 03550, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche	Criado, M (corresponding author), Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain.	Manuel.Criado@umh.es	Criado, Manuel/K-5109-2014; Viniegra, Salvador/K-5063-2014; Campos-Caro, Antonio/T-2807-2019; Valor, Luis/ABG-1754-2020	Criado, Manuel/0000-0002-3953-0346; Viniegra, Salvador/0000-0002-3892-8563; Campos-Caro, Antonio/0000-0001-8532-2153; Valor, Luis M./0000-0002-1229-0565				BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOULTER J, 1990, J BIOL CHEM, V265, P4472; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Carrasco-Serrano C, 1998, J BIOL CHEM, V273, P20021, DOI 10.1074/jbc.273.32.20021; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; GANDIA L, 1991, BRIT J PHARMACOL, V103, P1073, DOI 10.1111/j.1476-5381.1991.tb12302.x; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOWARD MJ, 1995, DEV BIOL, V170, P479, DOI 10.1006/dbio.1995.1231; IKEDA K, 1993, GENE, V136, P341; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; McDonough J, 1997, J NEUROSCI, V17, P2273; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SIF S, 1993, ONCOGENE, V8, P2501; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A	48	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4693	4701		10.1074/jbc.274.8.4693	http://dx.doi.org/10.1074/jbc.274.8.4693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988706	hybrid			2022-12-27	WOS:000078698200031
J	Haas, H; Zadra, I; Stoffler, G; Angermayr, K				Haas, H; Zadra, I; Stoffler, G; Angermayr, K			The Aspergillus nidulans GATA factor SREA is involved in regulation of siderophore biosynthesis and control of iron uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ENCODING GENE; USTILAGO-MAYDIS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ZINC-FINGER; PENICILLIUM-CHRYSOGENUM; EXPRESSION SIGNALS; MOLECULAR ANALYSIS; DNA-BINDING; URBS1	A gene encoding a new GATA factor from Aspergillus nidulans, sreA, was isolated and characterized. SREA displays homology to two fungal regulators of siderophore biosynthesis: about 30% overall identity to SRE from Neurospora crassa and about 50% identity to URBS1 from Ustilago maydis over a stretch of 200 amino acid residues containing two GATA-type zinc finger motifs and a cysteine-rich region. This putative DNA binding domain, expressed as a fusion protein in Escherichia coli, specifically binds to GATA sequence motifs, Deletion of sreA results in derepression of L-ornithine-N(5)-oxygenase activity and consequently in derepression of the biosynthesis of the hydroxamate siderophore N,N',N "-triacetyl fusarinine under sufficient iron supply in A. nidulans, Transcription of sreA is confined to high iron conditions, underscoring the function of SREA as a repressor of siderophore biosynthesis under sufficient iron supply. Nevertheless, overexpression of sreA does not result in repression of siderophore synthesis under low iron conditions, suggesting additional mechanisms involved in this regulatory circuit. Consistent with increased sensitivity to the iron-activated antibiotics phleomycin and streptonigrin, the sreA deletion mutant displays increased accumulation of (59)Fe. These results demonstrate that SREA plays a central role in iron uptake in addition to siderophore biosynthesis.	Univ Innsbruck, Sch Med, Dept Microbiol, A-6020 Innsbruck, Austria	University of Innsbruck	Haas, H (corresponding author), Univ Innsbruck, Sch Med, Dept Microbiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	hubertus.haas@uibk.ac.at						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; CHARLANG G, 1982, J BACTERIOL, V150, P785, DOI 10.1128/JB.150.2.785-787.1982; de Souza CC, 1998, CURR GENET, V33, P60, DOI 10.1007/s002940050309; Feng B, 1998, MOL CELL BIOL, V18, P3983, DOI 10.1128/MCB.18.7.3983; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; Haas H, 1997, J BIOL CHEM, V272, P22576, DOI 10.1074/jbc.272.36.22576; Hoe KL, 1996, BIOCHEM MOL BIOL INT, V39, P127; Huschka H G, 1989, Biol Met, V2, P108, DOI 10.1007/BF01129209; Konetschny-Rapp S, 1988, Biol Met, V1, P9, DOI 10.1007/BF01128012; Leong SA, 1998, MET IONS BIOL SYST, V35, P147; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MOORE CW, 1994, ANTIMICROB AGENTS CH, V38, P1615, DOI 10.1128/AAC.38.7.1615; MOORE CW, 1989, CANCER RES, V49, P6935; NILIUS AM, 1997, FUNGAL DIS, P401; PAYNE SM, 1994, METHOD ENZYMOL, V235, P329; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PUNT PJ, 1991, J BIOTECHNOL, V17, P19, DOI 10.1016/0168-1656(91)90024-P; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sambrook J., 2002, MOL CLONING LAB MANU; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; UPSHALL A, 1986, MOL GEN GENET, V204, P349, DOI 10.1007/BF00425521; VANGORCOM RFM, 1986, GENE, V48, P211, DOI 10.1016/0378-1119(86)90079-X; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; WHITE JR, 1982, BIOCHEM BIOPH RES CO, V106, P407, DOI 10.1016/0006-291X(82)91125-1; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470; ZHOU L, 1997, MOL GEN GENET, V259, P532	39	133	141	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4613	4619		10.1074/jbc.274.8.4613	http://dx.doi.org/10.1074/jbc.274.8.4613			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988696	hybrid			2022-12-27	WOS:000078698200021
J	Iozzo, RV; Moscatello, DK; McQuillan, DJ; Eichstetter, I				Iozzo, RV; Moscatello, DK; McQuillan, DJ; Eichstetter, I			Decorin is a biological ligand for the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; SQUAMOUS CARCINOMA-CELLS; MONOCLONAL-ANTIBODIES; COLLAGEN FIBRILLOGENESIS; GENE-EXPRESSION; PURIFICATION; INHIBITION; P21; SUPPRESSION; ACTIVATION	Ectopic expression of decorin induces profound cytostatic effects in transformed cells with diverse histogenetic backgrounds. The mechanism of action has only recently begun to be elucidated. Exogenous decorin activates the epidermal growth factor (EGF) receptor, thereby triggering a signaling cascade that leads to phosphorylation of mitogen-activated protein (MAP) kinase, induction of p21, and growth suppression. In this study we demonstrate a direct interaction of decorin with the EGF receptor. Binding of decorin induces dimerization of the EGF receptor and rapid and sustained phosphorylation of MAP kinase in squamous carcinoma cells. In a cell-free system, decorin induces autophosphorylation of purified EGF receptor by activating the receptor tyrosine kinase and can also act as a substrate for the EGF receptor kinase itself. Using radioligand binding assays we show that both immobilized and soluble decorin bind to the EGF receptor ectodomain or to purified EGF receptor. The binding is mediated by the protein core and has relatively low affinity (K-d similar to 87 nM). Thus, decorin should be considered as a novel biological ligand for the EGF receptor, an interaction that could regulate cell growth during remodeling and cancer growth.	Thomas Jefferson Univ, JAH, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Jefferson University; Jefferson University; Texas A&M University System	Iozzo, RV (corresponding author), Thomas Jefferson Univ, JAH, Dept Pathol Anat & Cell Biol, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NIAMS NIH HHS [R01 AR42826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; FAN Z, 1993, J BIOL CHEM, V268, P21073; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jakus J, 1996, ONCOGENE, V12, P2369; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; YARDEN Y, 1985, J BIOL CHEM, V260, P315	30	308	318	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4489	4492		10.1074/jbc.274.8.4489	http://dx.doi.org/10.1074/jbc.274.8.4489			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988678	hybrid			2022-12-27	WOS:000078698200003
J	Krieger, J; Schmitt, A; Lobell, D; Gudermann, T; Schultz, G; Breer, H; Boekhoff, I				Krieger, J; Schmitt, A; Lobell, D; Gudermann, T; Schultz, G; Breer, H; Boekhoff, I			Selective activation of G protein subtypes in the vomeronasal organ upon stimulation with urine-derived compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; ADENYLYL-CYCLASE; GLUTAMATE RECEPTORS; MULTIGENE FAMILY; BINDING-PROTEINS; FEMALE MICE; RAT; MAMMALS; SYSTEM; ORGANIZATION	Chemosensory neurons in the vomeronasal organ (VNO) detect pheromones related to social and reproductive behavior in most terrestrial vertebrates. Current evidence indicate that the chemoelectrical transduction process is mediated by G protein-coupled second messenger cascades. In the present study, attempts were made to identify the G protein subtypes which are activated upon stimulation with urinary pheromonal components. G protein-specific antibodies were employed to interfere specifically with inositol 1,3,4-trisphosphate formation induced by urinary stimuli and to immunoprecipitate G alpha-subunits, activation dependently labeled with [alpha-P-32]GTP azidoanilide. The results of both experimental approaches indicate that stimulation of female VNO membrane preparations with male urine samples induces activation of G(i) as well as G(o) subtypes, Experiments using different fractions of urine revealed that upon stimulation with lipophilic volatile odorants, only G(i) proteins were activated, whereas G(o) activation was elicited by alpha(2u)-globulin, a major urinary protein, which is a member of the lipocalin superfamily, Since each G protein subtype is stereotypically coexpressed with one of the two structurally different candidate pheromone receptors (V1R and V2R), the results provide the first experimental evidence that V1Rs coexpressed with G(i) may be activated by lipophilic probably volatile odorants, whereas V2Rs coexpressed with G(o) seem to be specialized to interact with pheromonal components of proteinaceous nature.	Univ Stuttgart Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	University Hohenheim; Free University of Berlin	Boekhoff, I (corresponding author), Univ Stuttgart Hohenheim, Inst Physiol, Garbenstr 30, D-70593 Stuttgart, Germany.	boekhoff@uni-hohenheim.de						BACCHINI A, 1992, EXPERIENTIA, V48, P419, DOI 10.1007/BF01923448; Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CLARK AJ, 1985, EMBO J, V4, P3159, DOI 10.1002/j.1460-2075.1985.tb04059.x; CLISSOLD PM, 1984, BIOCHEM GENET, V22, P379, DOI 10.1007/BF00484236; DIHN BL, 1965, J IMMUNOL, V95, P774; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Flower DR, 1996, BIOCHEM J, V318, P1; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOLMQUIST L, 1990, J BIOCHEM BIOPH METH, V20, P303, DOI 10.1016/0165-022X(90)90092-Q; Inamura K, 1997, CHEM SENSES, V22, P93, DOI 10.1093/chemse/22.1.93; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kroner C, 1996, NEUROREPORT, V7, P2989, DOI 10.1097/00001756-199611250-00038; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Lobel D, 1998, EUR J BIOCHEM, V254, P318, DOI 10.1046/j.1432-1327.1998.2540318.x; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; MENZIES RA, 1992, PHYSIOL BEHAV, V52, P741, DOI 10.1016/0031-9384(92)90408-T; MUCIGNATCARETTA C, 1995, J PHYSIOL-LONDON, V486, P517, DOI 10.1113/jphysiol.1995.sp020830; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOVOTNY M, 1985, P NATL ACAD SCI USA, V82, P2059, DOI 10.1073/pnas.82.7.2059; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P268; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PELOSI P, 1994, CRIT REV BIOCHEM MOL, V29, P199, DOI 10.3109/10409239409086801; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schandar M, 1998, J BIOL CHEM, V273, P16669, DOI 10.1074/jbc.273.27.16669; SHOJI T, 1991, J GEN PHYSIOL, V98, P909, DOI 10.1085/jgp.98.5.909; SINGER AG, 1990, CHEM SENSES, V15, P199, DOI 10.1093/chemse/15.2.199; VANDENBERGH JG, 1975, J REPROD FERTIL, V43, P515, DOI 10.1530/jrf.0.0430515; Wekesa KS, 1997, ENDOCRINOLOGY, V138, P3497, DOI 10.1210/en.138.8.3497; WYSOCKI CJ, 1991, NEUROBIOLOGY TASTE S, P125; Zhou AW, 1997, NEUROREPORT, V8, P2173, DOI 10.1097/00001756-199707070-00017	45	134	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4655	4662		10.1074/jbc.274.8.4655	http://dx.doi.org/10.1074/jbc.274.8.4655			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988702	hybrid			2022-12-27	WOS:000078698200027
J	Wagstaff, MJD; Collaco-Moraes, Y; Smith, J; de Belleroche, JS; Coffin, RS; Latchman, DS				Wagstaff, MJD; Collaco-Moraes, Y; Smith, J; de Belleroche, JS; Coffin, RS; Latchman, DS			Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SYSTEMIC LUPUS-ERYTHEMATOSUS; THERMAL-STRESS; CULTURED NEURONS; HYPERTHERMIA PROTECTS; ACTIN POLYMERIZATION; GANGLION NEURONS; MAMMALIAN-CELLS; MESSENGER-RNAS; EXPRESSION	Overexpression of the gene encoding the 70-kDa heat shock protein (hsp70) has previously been shown to protect neuronal cells against subsequent thermal or ischemic stress. It has no protective effect, however, against stimuli that induce apoptosis, although a mild heat shock (sufficient to induce hsp synthesis) does have a protective effect against apoptosis. We have prepared disabled herpes simplex virus-based vectors that are able to produce high level expression of individual hsps in infected neuronal cells without damaging effects. We have used these vectors to show that hsp27 and hsp56 (which have never previously been overexpressed in neuronal cells) as well as hsp70 can protect dorsal root ganglion neurons from thermal or ischemic stress. In contrast, only hsp27 can protect dorsal root ganglion neurons from apoptosis induced by nerve growth factor withdrawal, and hsp27 also protects the ND7 neuronal cell line from retinoic acid-induced apoptosis. However, hsp70 showed no protective effect against apoptosis in contrast to its anti-apoptotic effect in non-neuronal cell types. These results thus identify hsp27 as a novel neuroprotective factor and show that it can mediate this effect when delivered via a high efficiency viral vector.	UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Neuromuscular Dis, London W6 8RF, England	University of London; University College London; UCL Medical School; Imperial College London	Latchman, DS (corresponding author), UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,Cleveland St, London W1P 6DB, England.	d.latchman@ucl.ac.uk						Amin V, 1996, NEUROSCI LETT, V206, P45, DOI 10.1016/0304-3940(96)12421-6; AMIN V, 1995, NEUROSCI LETT, V200, P85, DOI 10.1016/0304-3940(95)12074-E; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; BANSAL GS, 1991, EXP CELL RES, V195, P303, DOI 10.1016/0014-4827(91)90377-7; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Coffin RS, 1996, GENE THER, V3, P886; COFFIN RS, 1995, GENETIC MANIPULATION, P99; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; FERRINI U, 1984, INT J CANCER, V34, P651, DOI 10.1002/ijc.2910340511; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fink SL, 1997, J NEUROCHEM, V68, P961; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; GAMSTROP I, 1984, PROGR SPINAL MUSCULA; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; HEADS RJ, 1994, J MOL CELL CARDIOL, V26, P695, DOI 10.1006/jmcc.1994.1084; Howard MK, 1998, GENE THER, V5, P1137, DOI 10.1038/sj.gt.3300700; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; Howard MK, 1997, J MOL NEUROSCI, V9, P65; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LATCHMAN DS, 1991, J ROY COLL PHYS LOND, V25, P295; LAVOIE J, 1990, NUCLEIC ACIDS RES, V18, P1637, DOI 10.1093/nar/18.6.1637; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MILLER EK, 1991, J NEUROCHEM, V56, P2060, DOI 10.1111/j.1471-4159.1991.tb03467.x; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; SACKS WR, 1985, J VIROL, V55, P796, DOI 10.1128/JVI.55.3.796-805.1985; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; TWOMEY BM, 1993, J AUTOIMMUN, V6, P495, DOI 10.1006/jaut.1993.1041; UNEY JB, 1993, FEBS LETT, V334, P313, DOI 10.1016/0014-5793(93)80701-U; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; WATSON K, 1984, FEBS LETT, V169, P267; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; WIEDLITZ RB, 1986, MOL CELL BIOL, V6, P1088; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wyatt S, 1996, MOL BRAIN RES, V39, P52, DOI 10.1016/0169-328X(95)00352-S	54	189	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5061	5069		10.1074/jbc.274.8.5061	http://dx.doi.org/10.1074/jbc.274.8.5061			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988753	hybrid			2022-12-27	WOS:000078698200078
J	Chen, YG; Massague, J				Chen, YG; Massague, J			Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; I RECEPTORS; MAD PROTEINS; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; MEDIATOR SMAD1; ACTIVIN; KINASE; DROSOPHILA; IDENTIFICATION	Two structural elements, the L45 loop on the kinase domain of the transforming growth factor-beta (TGF-beta) family type I receptors and the L3 loop on the MH2 domain of Smad proteins, determine the specificity of the interactions between these receptors and Smad proteins. The L45 sequence of the TGF-beta type I receptor (T beta R-I) specifies Smad2 interaction, whereas the related L45 sequence of the bone morphogenetic protein (BMP) type I receptor (BMPR-I) specifies Smad1 interactions. Here we report that members of a third receptor group, which includes ALK1 and ALK2 from vertebrates and Saxophone from Drosophila, specifically phosphorylate and activate Smad1 even though the L45 sequence of this group is very divergent from that of BMPR-I. We investigated the structural elements that determine the specific recognition of Smad1 by ALK1 and ALK2, In addition to the receptor L45 loop and the Smad1 L3 loop, the specificity of this recognition requires the alpha-helix 1 of Smad1, The alpha-helix 1 is a conserved structural element located in the vicinity of the L3 loop on the surface of the Smad MH2 domain. Thus, Smad1 recognizes two distinct groups of receptors, the BMPR-I group and the ALK1 group, through different L45 sequences on the receptor kinase domain and a differential use of two surface structures on the Smad1 MH2 domain.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, 1275 York Ave,Box 116, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armes NA, 1997, DEVELOPMENT, V124, P3797; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Candia AF, 1997, DEVELOPMENT, V124, P4467; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Das P, 1998, DEVELOPMENT, V125, P1519; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hudson JB, 1998, DEVELOPMENT, V125, P1407; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	163	180	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3672	3677		10.1074/jbc.274.6.3672	http://dx.doi.org/10.1074/jbc.274.6.3672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920917	hybrid			2022-12-27	WOS:000078428200057
J	Hsu, W; Zeng, L; Costantini, F				Hsu, W; Zeng, L; Costantini, F			Identification of a domain of axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE FUSED LOCUS; BETA-CATENIN; XENOPUS EMBRYOS; SIGNAL-TRANSDUCTION; CELL-GROWTH; MAP KINASE; PATHWAY; ACTIVATION; DROSOPHILA; GENE	Axin is a negative regulator of embryonic axis formation in vertebrates, which acts through a Wnt signal transduction pathway involving the serine/threonine kinase GSK-3 and beta-catenin. Axin has been shown to have distinct binding sites for GSK-3 and beta-catenin and to promote the phosphorylation of beta-catenin and its consequent degradation. This provides an explanation for the ability of Axin to inhibit signaling through beta-catenin, In addition, a more N-terminal region of Axin binds to adenomatous polyposis coli (APC), a tumor suppressor protein that also regulates levels of beta-catenin. Here, we report the results of a yeast two-hybrid screen for proteins that interact with the C-terminal third of Axin, a region in which no binding sites for other proteins have previously been identified, We found that Axin can bind to the catalytic subunit of the serine/threonine protein phosphatase 2A through a domain between amino acids 632 and 836. This interaction was confirmed by in vitro binding studies as well as by co-immunoprecipitation of epitope-tagged proteins expressed in cultured cells. Our results suggest that protein phosphatase 2A might interact with the Axin.APC.GSK-3.beta-catenin complex, where it could modulate the effect of GSK-3 on beta-catenin or other proteins in the complex. We also identified a region of Axin that may allow it to form dimers or multimers, Through two-hybrid and co-immunoprecipitation studies, we demonstrated that the C-terminal 100 amino acids of Axin could bind to the same region as other Axin molecules.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Costantini, F (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.	fdc3@columbia.edu	Hsu, Wei/ABG-6856-2021	Hsu, Wei/0000-0001-6738-6030				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carnac G, 1996, DEVELOPMENT, V122, P3055; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fagotto F, 1997, DEVELOPMENT, V124, P453; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; GREENSPAN RJ, 1986, P NATL ACAD SCI USA, V83, P4413, DOI 10.1073/pnas.83.12.4413; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; James P, 1996, GENETICS, V144, P1425; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; MAYERJAEKEL RE, 1995, SEMIN CANCER BIOL, V6, P249, DOI 10.1006/scbi.1995.0032; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; PERRY WL, 1995, GENETICS, V141, P321; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Reed SC, 1937, GENETICS, V22, P1; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tilghman SM, 1996, GENOME RES, V6, P773, DOI 10.1101/gr.6.9.773; Vasicek TJ, 1997, GENETICS, V147, P777; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	61	209	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3439	3445		10.1074/jbc.274.6.3439	http://dx.doi.org/10.1074/jbc.274.6.3439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920888	hybrid			2022-12-27	WOS:000078428200028
J	Hughes, JMX; Ptushkina, M; Karim, MM; Koloteva, N; von der Haar, T; McCarthy, JEG				Hughes, JMX; Ptushkina, M; Karim, MM; Koloteva, N; von der Haar, T; McCarthy, JEG			Translational repression by human 4E-BP1 in yeast specifically requires human eIF4E as target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4E; CAP-DEPENDENT TRANSLATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; BINDING; SYSTEM; CELL; PHOSPHORYLATION; RIBOSOMES; PROTEINS	4E-binding proteins (4E-BPs) are believed to have important regulatory functions in controlling the rate of translation initiation in mammalian cells. They do so by binding to the mRNA cap-binding protein, eIF4E, thereby inhibiting formation of the cap-binding complex, a process essential for cap-dependent translation initiation. We have reproduced the translation-repressive function of human 4E-BP1 in yeast and find its activity to be dependent on substitution of human eIF4E for its yeast counterpart. Translation initiation and growth are inhibited when human 4E-BP1 is expressed in a strain with the human eIF4E substitution, but not in an unmodified strain. We have compared the relative affinities of human 4E-BP1 for human and yeast eIF4E, both in vitro using an m(7)GTP cap-binding assay and in vivo using a yeast two-hybrid assay, and find that the affinity of human 4E-BP1 for human eIF4E is markedly greater than for yeast eIF4E. Thus yeast eIF4E lacks structural features required for binding to human 4E-BP1. These results therefore demonstrate that the features of eIF4E required for binding to 4E-BP1 are distinct from those required for cap-complex assembly.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, Manchester M60 1QD, Lancs, England	University of Manchester	Hughes, JMX (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.		Karim, Muhammad Manjurul/ABC-6229-2020	Karim, Muhammad Manjurul/0000-0003-0476-8239				Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; EDERY I, 1987, TRANSLATIONAL REGULA, P335; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; LANG V, 1994, J BIOL CHEM, V269, P6117; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SCHNEPPE B, 1994, GENE, V143, P201, DOI 10.1016/0378-1119(94)90097-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	27	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3261	3264		10.1074/jbc.274.6.3261	http://dx.doi.org/10.1074/jbc.274.6.3261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920863	hybrid			2022-12-27	WOS:000078428200003
J	Kisselev, AF; Akopian, TN; Woo, KM; Goldberg, AL				Kisselev, AF; Akopian, TN; Woo, KM; Goldberg, AL			The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes - Implications for understanding the degradative mechanism and antigen presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR-HISTOCOMPATIBILITY-COMPLEX; ACTIVE-SITE FORMATION; THERMOPLASMA-ACIDOPHILUM; PROCESSIVE DEGRADATION; ESCHERICHIA-COLI; ENCODED SUBUNITS; ATP HYDROLYSIS; UBIQUITIN; REQUIREMENT; RESOLUTION	Knowledge about the sizes of peptides generated by proteasomes during protein degradation is essential to fully understand their degradative mechanisms and the subsequent steps in protein turnover and generation of major histocompatibility complex class I antigenic peptides. We demonstrate here that 26 S and activated 20 S proteasomes from rabbit muscle degrade denatured, nonubiquitinated proteins in a highly processive fashion but generate different patterns of peptides (despite their containing identical proteolytic sites). With both enzymes, products range in length from 3 to 22 residues, and their abundance decreases with increasing length according to a log-normal distribution. Less than 15% of the products are the length of class I presented peptides (8 or 9 residues), and two-thirds are too short to function in antigen presentation, Surprisingly, these mammalian proteasomes, which contain two "chymotryptic," two "tryptic," and two "post-acidic" active sites, generate peptides with a similar size distribution as do archaeal 20 S proteasomes, which have 14 identical sites. Furthermore, inactivation of the "tryptic" sites altered the peptides produced without significantly affecting their size distribution. Therefore, this distribution is not determined by the number, specificity, or arrangement of the active sites (as proposed by the "molecular ruler" model); instead, we propose that proteolysis continues until products are small enough to diffuse out of the proteasomes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	agoldber@bcmp.med.harvard.edu						Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EDMUNDS T, 1986, J CELL BIOCHEM, V32, P187, DOI 10.1002/jcb.240320304; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG HC, 1997, THESIS HARVARD U; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LEIBOVITZ D, 1995, J BIOL CHEM, V270, P11029, DOI 10.1074/jbc.270.19.11029; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; McCormack TA, 1998, BIOCHEMISTRY-US, V37, P7792, DOI 10.1021/bi980097q; Michalek MT, 1996, J IMMUNOL, V157, P617; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Stock D, 1995, COLD SPRING HARB SYM, V60, P525, DOI 10.1101/SQB.1995.060.01.056; Stuart DI, 1997, NATURE, V386, P437, DOI 10.1038/386437a0; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	55	420	431	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3363	3371		10.1074/jbc.274.6.3363	http://dx.doi.org/10.1074/jbc.274.6.3363			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920878	hybrid			2022-12-27	WOS:000078428200018
J	Pallaoro, M; Fejzo, MS; Shayesteh, L; Blount, JL; Caughey, GH				Pallaoro, M; Fejzo, MS; Shayesteh, L; Blount, JL; Caughey, GH			Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG TRYPTASE; COMPLEMENTARY-DNA; PHYSICAL MAP; CLONING; TRANSCRIPTION; EXPRESSION; PROTEASES; AIRWAY; AMPLIFICATION; PURIFICATION	Tryptases are serine proteases implicated in asthma and are very highly expressed in human mast cells. They fall into two groups, alpha and beta. Although several related tryptase mRNAs are known, it is unclear which if any are transcripts of separate haploid genes. The studies described here investigated the nature and number of human tryptases and sought possibly novel members of the family. To this end, two human bacterial artificial chromosome (BAC) clones containing tryptase genes were identified and mapped to chromosome 16p13.3, of which similar to 2.2 megabases are syntenic with the part of mouse chromosome 17 containing tryptase genes mouse mast cell protease (mMCP)-6 and -7, Sequencing and restriction mapping suggest that the BACs may partially overlap. Sequenced BAC genes correspond to three known beta-tryptases (beta I, beta II, and beta III), an alpha-like gene, and a pair of novel hybrid genes related partly to alpha/beta-tryptases and partly to orthologs of mMCP-7. beta II and beta III, beta I and alpha II, as well as the two mMCP-7-like genes, may be alleles at single loci; in total, there are at least three nonallelic tryptase genes in the isolated BAC clones. DNA blotting and restriction analysis suggest that the BACs include most members of the immediate tryptase family. Thus, chromosome 16p13.3 harbors a cluster of known and previously undescribed members of the tryptase gene family.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.		Pallaoro, Michele/AAU-7429-2020	Fejzo, Marlena/0000-0001-6800-687X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL054774] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136, HL-54774] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLOM T, 1993, SCAND J IMMUNOL, V37, P203, DOI 10.1111/j.1365-3083.1993.tb01757.x; Caughey GH, 1997, AM J RESP CELL MOL, V16, P621, DOI 10.1165/ajrcmb.16.6.9191463; Caughey GH, 1995, MAST CELL PROTEASES, P305; CHAN H, 1995, FASEB J, V9, pA1343; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DOGGETT NA, 1995, NATURE, V377, P335; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; HARVIMA IT, 1989, ARCH DERMATOL RES, V281, P231, DOI 10.1007/BF00431056; HUANG R, 1993, SCAND J IMMUNOL, V38, P359, DOI 10.1111/j.1365-3083.1993.tb01738.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KOURILSKY P, 1986, TRENDS GENET, V2, P60, DOI 10.1016/0168-9525(86)90179-4; KRISHNA MT, 1998, AM J RESP CRIT CARE, V157, P456; LITTLE SS, 1995, BIOCHEM J, V307, P341, DOI 10.1042/bj3070341; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SANCTIS GTD, 1995, NAT GENET, V11, P150; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1985, BIOCHEM BIOPH RES CO, V129, P76, DOI 10.1016/0006-291X(85)91405-6; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; STACK MS, 1994, J BIOL CHEM, V269, P9416; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; XIA HZ, 1995, J IMMUNOL, V154, P5472; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747	40	112	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3355	3362		10.1074/jbc.274.6.3355	http://dx.doi.org/10.1074/jbc.274.6.3355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920877	hybrid			2022-12-27	WOS:000078428200017
J	Roghani, M; Becherer, JD; Moss, ML; Atherton, RE; Erdjument-Bromage, H; Arribas, J; Blackburn, RK; Weskamp, G; Tempst, P; Blobel, CP				Roghani, M; Becherer, JD; Moss, ML; Atherton, RE; Erdjument-Bromage, H; Arribas, J; Blackburn, RK; Weskamp, G; Tempst, P; Blobel, CP			Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SPERM-EGG FUSION; ANGIOTENSIN-CONVERTING ENZYME; FACTOR-ALPHA; TNF RECEPTOR; SURFACE PROTEIN; CYSTEINE SWITCH; POTENTIAL ROLE; CELL-ADHESION; IL-6 RECEPTOR	Metalloprotease disintegrins are a family of membrane-anchored glycoproteins that are known to function in fertilization, myoblast fusion, neurogenesis, and ectodomain shedding of tumor necrosis factor (TNF)-alpha. Here we report the analysis of the intracellular maturation and catalytic activity of the widely expressed metalloprotease disintegrin MDC9, Our results suggest that the pro-domain of MDC9 is removed by a furin-type pro-protein convertase in the secretory pathway before the protein emerges on the cell surface. The soluble metalloprotease domain of MDC9 cleaves the insulin B-chain, a generic protease substrate, providing the first evidence that MDC9 is catalytically active. Soluble MDC9 appears to have distinct specificities for cleaving candidate substrate peptides compared with the TNF-cu convertase (TACE/ADAM17). The catalytic activity of MDC9 can be inhibited by hydroxamic acid-type metalloprotease inhibitors in the low nanomolar range, in one case with up to 50-fold selectivity for MDC9 versus TACE, Peptides mimicking the predicted cysteine-switch region of MDC9 or TACE inhibit both enzymes in the low micromolar range, providing experimental evidence for regulation of metalloprotease disintegrins via a cysteine-switch mechanism. Finally, MDC9 is shown to become phosphorylated when cells are treated with the phorbol ester phorbol la-myristate 13-acetate, a known inducer of protein ectodomain shedding. This work implies that removal of the inhibitory pro-domain of MDC9 by a fur-in-type pro-protein convertase in the secretory pathway is a prerequisite for protease activity, After pro-domain removal, additional steps, such as protein kinase C-dependent phosphorylation, may be involved in regulating the catalytic activity of MDC9, which is likely to target different substrates than the related TNF-alpha-convertase.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ Med Coll, Grad Sch, Program Mol Biol, New York, NY 10021 USA; Glaxo Wellcome Res & Dev Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Inc, Dept Analyt Chem, Res Triangle Pk, NC 27709 USA; Hosp Gen Psg Vall Hebron, Lab Rec Oncol, Barcelona 08035, Spain	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; GlaxoSmithKline; GlaxoSmithKline; Hospital Universitari Vall d'Hebron	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051988] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [R55GM51988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BECHERER JD, 1991, J CELL BIOCH G S, V15, P139; BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P76; BICKETT DM, 1993, ANAL BIOCHEM, V212, P58, DOI 10.1006/abio.1993.1291; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FOX JW, 1995, METHOD ENZYMOL, V248, P368; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MCGEEHAN GM, 1995, METHOD ENZYMOL, V248, P35; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Williams J W, 1979, Methods Enzymol, V63, P437; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	66	267	278	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3531	3540		10.1074/jbc.274.6.3531	http://dx.doi.org/10.1074/jbc.274.6.3531			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920899	hybrid			2022-12-27	WOS:000078428200039
J	Tang, XB; Kovacs, R; Sterling, D; Casey, JR				Tang, XB; Kovacs, R; Sterling, D; Casey, JR			Identification of residues lining the translocation pore of human AE1, plasma membrane anion exchange protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTEINE-SCANNING MUTAGENESIS; SITE-DIRECTED MUTAGENESIS; CELL BAND-3 PROTEIN; LACTOSE PERMEASE; ESCHERICHIA-COLI; CHLORIDE CHANNEL; INTRACELLULAR PH; SUBSTITUTION; LOCALIZATION	AE1 is the chloride/bicarbonate anion exchanger of the erythrocyte plasma membrane. We have used scanning cysteine mutagenesis and sulfhydryl-specific chemistry to identify pore-lining residues in the Ser(643)-Ser(690) region of the protein. The Ser(643)-Ser(690) region spans transmembrane segment 8 of AE1 and surrounds Glu(681), which may reside at the transmembrane permeability barrier. Glu(681) also directly interacts with some anions during anion transport. The introduced cysteine mutants were expressed by transient transfection of HEK293 cells. Anion exchange activity was assessed by measurement of changes of intracellular pH, which follow transmembrane bicarbonate movement mediated by AE1, To identify residues that might form part of an aqueous transmembrane pore, we measured anion exchange activity of each introduced cysteine mutant before and after incubation with the sulfhydryl reagents para-chloromercuribenzene sulfonate and 2-(aminoethyl)methanethiosulfonate hydrobromide, Our data identified transmembrane mutants A666C, S667C, L669C, L673C, L677C, and L680C and intracellular mutants I684C and I688C that could be inhibited by sulfhydryl reagents and may therefore form a part of a transmembrane pore. These residues map to one face of a helical wheel plot. The ability to inhibit two intracellular mutants suggests that transmembrane helix 8 extends at least two helical turns beyond the intracellular membrane surface. The identified hydrophobic pore-lining residues (leucine, isoleucine, and alanine) may limit interactions with substrate anions.	Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; JENNINGS ML, 1992, J BIOL CHEM, V267, P13964; JENNINGS ML, 1989, ANION TRANSPORT PROT, P59; JONS T, 1994, HISTOCHEMISTRY, V102, P255, DOI 10.1007/BF00269161; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LINN SC, 1992, J BIOL CHEM, V267, P7927; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; MULLERBERGER S, 1995, BIOCHEMISTRY-US, V34, P9315; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEKLER I, 1995, J BIOL CHEM, V270, P28751, DOI 10.1074/jbc.270.48.28751; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; ZHANG ZH, 1992, BIOCHIM BIOPHYS ACTA, V1106, P31, DOI 10.1016/0005-2736(92)90218-B	47	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3557	3564		10.1074/jbc.274.6.3557	http://dx.doi.org/10.1074/jbc.274.6.3557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920902	hybrid			2022-12-27	WOS:000078428200042
J	Tait, JF; Smith, C				Tait, JF; Smith, C			Phosphatidylserine receptors: Role of CD36 in binding of anionic phospholipid vesicles to monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MEMBRANE PHOSPHATIDYLSERINE; PHAGOCYTE RECOGNITION; APOPTOTIC CELLS; HUMAN CD68; SR-BI; EXPOSURE; MACROPHAGES; PROTEIN; IDENTIFICATION	Exposure of phosphatidylserine (PtdSer) has been implicated in the recognition and phagocytosis of senescent and apoptotic cells, and CD36 has been proposed as one receptor protein that recognizes PtdSer and other anionic phospholipids. We investigated the binding of phospholipid vesicles to the monocytic leukemia cell lines THP-1 and J774A.1 with a flow cytometric assay; vesicles contained 50 mol% PtdSer, phosphatidylinositol (PtdIns), or phosphatidylglycerol (PtdGro), with the balance being phosphatidylcholine. Specific, high affinity binding was observed for vesicles containing PtdSer, PtdIns, or PtdGro, Specificity of the assay was confirmed by control experiments with erythrocytes, which showed minimal vesicle binding, and with annexin V, which blocked the binding of PtdSer, PtdGro, and PtdIns vesicles to the THP-1 cells. However, O-phospho-L-serine (to 1 mM) had no effect on the binding of PtdSer vesicles, indicating that high affinity binding requires a surface containing multiple phosphoserine groups rather than a single molecule. A monoclonal antibody to CD36 blocked up to 60% of the specific binding of PtdSer vesicles but had minimal to no effect on the binding of PtdGro or PtdIns vesicles. This antibody also selectively inhibited the phagocytosis of PtdSer-containing vesicles as measured by fluorescence microscopy, indicating that CD36 is functionally significant for phagocytosis of this vesicle type. In addition, collagen and thrombospondin, two other putative ligands of CD36, were unable to inhibit the binding of PtdSer vesicles. We conclude that CD36 is the primary protein responsible for the high affinity binding of PtdSer vesicles to these monocyte like cells. In addition, CD36 appears to be specific for PtdSer among anionic phospholipids, and non-phospholipid ligands of CD36 do not share binding sites with PtdSer on CD36.	Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tait, JF (corresponding author), Univ Washington, Dept Lab Med, Room NW-120,Box 357110, Seattle, WA 98195 USA.	tait@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASTION ML, 1993, LAB MED, V24, P341, DOI 10.1093/labmed/24.6.341; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1993, J IMMUNOL, V151, P4274; FADOK VA, 1992, J IMMUNOL, V148, P2207; GABRIEL NE, 1984, BIOCHEMISTRY-US, V23, P4011, DOI 10.1021/bi00313a001; LEE KD, 1993, BIOCHEMISTRY-US, V32, P889, DOI 10.1021/bi00054a021; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; RALPH P, 1975, J IMMUNOL, V114, P898; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wood BL, 1996, BLOOD, V88, P1873; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	32	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3048	3054		10.1074/jbc.274.5.3048	http://dx.doi.org/10.1074/jbc.274.5.3048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915844	hybrid			2022-12-27	WOS:000078319500062
J	Berjukow, S; Gapp, F; Aczel, S; Sinnegger, J; Mitterdorfer, J; Glossmann, H; Hering, S				Berjukow, S; Gapp, F; Aczel, S; Sinnegger, J; Mitterdorfer, J; Glossmann, H; Hering, S			Sequence differences between alpha(1C) and alpha(1S) Ca2+ channel subunits reveal structural determinants of a guarded and modulated benzothiazepine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI CALCIUM CHANNELS; AMINO-ACID-RESIDUES; MOLECULAR DETERMINANTS; 1,4-DIHYDROPYRIDINE SENSITIVITY; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; IVS6 SEGMENT; PHENYLALKYLAMINES; BINDING; BLOCK	The molecular basis of the Ca2+ channel block by (+)cis-diltiazem was studied in class A/L-type chimeras and mutant ore. Ca2+ channels. Chimeras consisted of either rabbit heart (alpha(1C-a)) or carp skeletal muscle (alpha(1S)) sequence in transmembrane segments IILS6, IVS6, and adjacent S5-S6 linkers. Only chimeras containing sequences from alpha(1C-a) were efficiently blocked by (+)-cis-diltiazem, whereas the phenylalkylamine (-)-gallopamil efficiently blocked both constructs. Carp skeletal muscle and rabbit heart Ca2+ channel alpha(1) subunits differ with respect to two nonconserved amino acids in segments IVS6. Transfer of a single leucine (Leu(1383), located at the extracellular mouth of the pore) from IVS6 alpha(1C-a) to IVS6 of alpha(1S) Significantly increased the (+)-cis-diltiazem sensitivity of the corresponding mutant L1383I. An analysis of the role of the two heterologous amino acids in a L-type alpha(1) subunit revealed that corresponding amino acids in position 1487 (outer channel mouth) determine recovery of resting Ca2+ channels from block by (+)-cis-diltiazem. The second heterologous amino acid in position 1504 of segment IVS6 (inner channel mouth) was identified as crucial inactivation determinant of L-type Ca2+ channels. This residue simultaneously modulates drug binding during membrane depolarization. Our study provides the first evidence for a guarded and modulated benzothiazepine receptor on L-type channels.	Inst Biochem Pharmacol, A-6020 Innsbruck, Austria		Hering, S (corresponding author), Inst Biochem Pharmacol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.	Steffen.Hering@uibk.ac.at	Glossmann, Hartmut/AAL-9790-2020	Brauns, Martina/0000-0002-0547-2731; glossmann, hartmut h./0000-0002-7392-3266				Barrish J C, 1993, Bioorg Med Chem, V1, P309, DOI 10.1016/S0968-0896(00)82135-5; Berjukov S, 1996, BRIT J PHARMACOL, V119, P1197, DOI 10.1111/j.1476-5381.1996.tb16022.x; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Bodi I, 1997, J BIOL CHEM, V272, P24952, DOI 10.1074/jbc.272.40.24952; Cai DM, 1997, MOL PHARMACOL, V51, P872, DOI 10.1124/mol.51.5.872; Degtiar VE, 1997, BIOPHYS J, V73, P157, DOI 10.1016/S0006-3495(97)78056-1; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; Ito H, 1997, MOL PHARMACOL, V52, P735, DOI 10.1124/mol.52.4.735; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; Kraus RL, 1998, BIOPHYS J, V74, pA107; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; STARMER CF, 1985, MOL PHARMACOL, V28, P348; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0	32	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6154	6160		10.1074/jbc.274.10.6154	http://dx.doi.org/10.1074/jbc.274.10.6154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037699	hybrid			2022-12-27	WOS:000078902800021
J	Kwon, BS; Yu, KY; Ni, J; Yu, GL; Jang, IK; Kim, YJ; Xing, L; Liu, D; Wang, SX; Kwon, BS				Kwon, BS; Yu, KY; Ni, J; Yu, GL; Jang, IK; Kim, YJ; Xing, L; Liu, D; Wang, SX; Kwon, BS			Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; FACTOR-KAPPA-B; APOPTOSIS-MEDIATING RECEPTOR; CELL-SURFACE ANTIGEN; DEATH-DOMAIN; MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; MEMBER; FAMILY; TRAIL	Among members of the tumor necrosis factor receptor (TNFR) superfamily, 4-1BB, CD27, and glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) share a striking homology in the cytoplasmic domain. Here we report the identification of a new member, activation-inducible TNFR family member (AITR), which belongs to this subfamily, and its ligand. The receptor is expressed in lymph node and peripheral blood leukocytes, and its expression is up-regulated in human peripheral mononuclear cells mainly after stimulation with anti-CD3/CD28 monoclonal antibodies or phorbol 12-myristate 13-acetate/ionomycin. AITR associates with TRAF1 (TNF receptor-associated factor 1), TRAF2, and TRAF3, and induces nuclear factor (NF)-kappa B activation via TRAF2. The ligand for AITR (AITRL) was found to be an undescribed member of the TNF family, which is expressed in endothelial cells. Thus, AITR and AITRL seem to be important for interactions between activated T lymphocytes and endothelial cells.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Human Genome Sci, Rockville, MD 20850 USA; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Univ Ulsan, Dept Sci Biol, Ulsan 680749, South Korea	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; GlaxoSmithKline; Human Genome Sciences Inc; University of Ulsan; University of Ulsan	Kwon, BS (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	kkwon@sunflower.bio.indiana.edu			NIAID NIH HHS [AI28125] Funding Source: Medline; NIDCR NIH HHS [DE12156] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI028125, R44AI028125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012156] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; HU HM, 1994, J BIOL CHEM, V269, P30069; Jang IK, 1998, BIOCHEM BIOPH RES CO, V242, P613, DOI 10.1006/bbrc.1997.8016; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; OEHM A, 1992, J BIOL CHEM, V267, P10709; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POLLOK KE, 1993, J IMMUNOL, V150, P771; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; ROTHE M, 1995, SCIENCE, V269, P1421; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	41	159	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6056	6061		10.1074/jbc.274.10.6056	http://dx.doi.org/10.1074/jbc.274.10.6056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037686	hybrid			2022-12-27	WOS:000078902800008
J	Sueyoshi, T; Kawamoto, T; Zelko, I; Honkakoski, P; Negishi, M				Sueyoshi, T; Kawamoto, T; Zelko, I; Honkakoski, P; Negishi, M			The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; DEXAMETHASONE; EXPRESSION; ELEMENTS; BINDING; P450	The endogenous CYP2B6 gene becomes phenobarbital (PB) inducible in androstenol-treated HepG2 cells either transiently or stably transfected with a nuclear receptor CAR expression vector. The PB induction mediated by CAR is regulated by a conserved 51-base pair element called PR-responsive enhancer module (PBREM) that has now been located between -1733 and -1683 bp in the gene's 5'-flanking region. An in vitro translated CAR acting as a retinoid X receptor alpha heterodimer binds directly to the two nuclear receptor sites NR1 and NR2 within PBREM, In a stably transfected HepG2 cell line, both PBREM and NR1 are activated by PB and PR-type compounds such as chlorinated pesticides, polychlorinated biphenyls and chlorpromazine, In addition to PBREM, CAR also transactivates the steroid/rifampicin-response element of the human CYP3A4 gene in HepG2 cells. Thus, activation of the repressed nuclear receptor CAR appears to be a versatile mediator that regulates PB induction of the CYP2B and other genes.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Eastern Finland	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		, 河本健/D-7938-2015; Negishi, Masahiko/F-7805-2019; Zelko, Igor N/L-2673-2013; Honkakoski, Paavo/AAJ-1278-2020	, 河本健/0000-0003-3337-1775; Negishi, Masahiko/0000-0002-2076-8928; Zelko, Igor N/0000-0003-3976-3884; Honkakoski, Paavo/0000-0002-4332-3577				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BULGER WH, 1985, MOL PHARMACOL, V27, P115; CONNEY AH, 1982, CANCER RES, V42, P4875; DEWAZIERS I, 1992, PHARMACOGENETICS, V2, P12, DOI 10.1097/00008571-199202000-00003; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GOWER DB, 1993, J ENDOCRINOL, V137, P167, DOI 10.1677/joe.0.1370167; Hoffman SMG, 1995, J MOL EVOL, V41, P894; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Huss JM, 1996, P NATL ACAD SCI USA, V93, P4666, DOI 10.1073/pnas.93.10.4666; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KENDE AS, 1985, MOL PHARMACOL, V28, P445; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; REMMER H, 1963, SCIENCE, V142, P1657, DOI 10.1126/science.142.3600.1657; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577	24	579	601	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6043	6046		10.1074/jbc.274.10.6043	http://dx.doi.org/10.1074/jbc.274.10.6043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037683	hybrid			2022-12-27	WOS:000078902800005
J	Froy, O; Zilberberg, N; Gordon, D; Turkov, M; Gilles, N; Stankiewicz, N; Pelhate, M; Loret, E; Oren, DA; Shaanan, B; Gurevitz, M				Froy, O; Zilberberg, N; Gordon, D; Turkov, M; Gilles, N; Stankiewicz, N; Pelhate, M; Loret, E; Oren, DA; Shaanan, B; Gurevitz, M			The putative bioactive surface of insect-selective scorpion excitatory neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS HECTOR; IMPROVED BACULOVIRUS INSECTICIDE; SITE-DIRECTED ANTIBODIES; SODIUM-CHANNELS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; BUTHOTUS-JUDAICUS; TOXIN-II; VENOM; EXPRESSION	Scorpion neurotoxins of the excitatory group show total specificity for insects and serve as invaluable probes for insect sodium channels. However, despite their significance and potential for application in insect-pest control, the structural basis for their bioactivity is still unknown. We isolated, characterized, and expressed an atypically long excitatory toxin, Bj-xtrIT, whose bioactive features resembled those of classical excitatory toxins, despite only 49% sequence identity. With the objective of clarifying the toxic site of this unique pharmacological group, Bj-xtrIT was employed in a genetic approach using point mutagenesis and biological and structural assays of the mutant products. A primary target for modification was the structurally unique C-terminal region, Sequential deletions of C-terminal residues suggested an inevitable significance of Ile(73) and Ile(74) for toxicity. Based on the bioactive role of the C-terminal region and a comparison of Bj-xtrIT with a Bj-xtrIT-based model of a classical excitatory toxin, AaHIT, a conserved surface comprising the C terminus is suggested to form the site of recognition with the sodium channel receptor.	Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; CE Saclay, Dept Ingn & Etudes Proteines, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Univ Angers, Fac Med, Neurophysiol Lab, F-49045 Angers, France; CNRS, LIDSM, IBSM, UPR 9027, F-13402 Marseille, France; Hebrew Univ Jerusalem, Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Tel Aviv University; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); Hebrew University of Jerusalem; Hebrew University of Jerusalem	Shaanan, B (corresponding author), Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.	boazsh@vms.huji.ac.il; mamgur@ccsg.tau.ac.il	Stankiewicz, Maria/H-6780-2014; Froy, Oren/C-3550-2009; Shaanan, Boaz/F-1202-2012; Zilberberg, Noam/F-2005-2012	Shaanan, Boaz/0000-0001-8925-4362; Zilberberg, Noam/0000-0002-7848-2391; Maria, Stankiewicz/0000-0001-7038-0959				ALMASSY RJ, 1983, J MOL BIOL, V170, P497, DOI 10.1016/S0022-2836(83)80159-4; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; CORY JS, 1994, NATURE, V370, P138, DOI 10.1038/370138a0; DARBON H, 1991, BIOCHEMISTRY-US, V30, P1836, DOI 10.1021/bi00221a016; DARBON H, 1982, INT J PEPT PROT RES, V20, P320; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1989, J MOL EVOL, V29, P63, DOI 10.1007/BF02106182; FROY O, 1999, IN PRESS J MOL EVOL; Gershburg E, 1998, FEBS LETT, V422, P132, DOI 10.1016/S0014-5793(97)01614-1; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; GORDON D, 1990, BIOCHIM BIOPHYS ACTA, V1026, P80, DOI 10.1016/0005-2736(90)90335-L; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; HERRMANN R, 1995, TOXICON, V33, P1099, DOI 10.1016/0041-0101(95)98053-X; Jarvis DL, 1996, BIOL CONTROL, V7, P228, DOI 10.1006/bcon.1996.0088; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOPEYAN C, 1990, FEBS LETT, V261, P423, DOI 10.1016/0014-5793(90)80607-K; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESTER D, 1982, BIOCHIM BIOPHYS ACTA, V701, P370, DOI 10.1016/0167-4838(82)90240-0; LORET EP, 1990, BIOCHEMISTRY-US, V29, P1492, DOI 10.1021/bi00458a021; MAEDA S, 1991, VIROLOGY, V184, P777, DOI 10.1016/0042-6822(91)90451-G; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTINEAUCLAIRE MF, 1994, EUR J BIOCHEM, V223, P637, DOI 10.1111/j.1432-1033.1994.tb19036.x; MCCUTCHEN BF, 1991, BIO-TECHNOL, V9, P848, DOI 10.1038/nbt0991-848; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; PANG SZ, 1992, GENE, V116, P165, DOI 10.1016/0378-1119(92)90512-N; PELHATE M, 1982, J INSECT PHYSIOL, V28, P889, DOI 10.1016/0022-1910(82)90104-4; PELHATE M, 1982, J EXP BIOL, V97, P67; PICHON Y, 1967, J EXP BIOL, V47, P343; REED L. J., 1938, AMER JOUR HYG, V27, P493; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; STEWART LMD, 1991, NATURE, V352, P85, DOI 10.1038/352085a0; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; ZILBERBERG N, 1991, TOXICON, V29, P1155, DOI 10.1016/0041-0101(91)90213-B; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1971, BIOCHIMIE, V53, P1073, DOI 10.1016/S0300-9084(71)80195-5; ZLOTKIN E, 1987, ENDEAVOUR, V11, P168, DOI 10.1016/0160-9327(87)90280-8; ZLOTKIN E, 1979, INSECT BIOCHEM, V9, P347, DOI 10.1016/0020-1790(79)90081-7; Zlotkin E., 1985, P243	46	90	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5769	5776		10.1074/jbc.274.9.5769	http://dx.doi.org/10.1074/jbc.274.9.5769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026198	hybrid			2022-12-27	WOS:000078804400069
J	Wells, RG; Gilboa, L; Sun, Y; Liu, XD; Henis, YI; Lodish, HF				Wells, RG; Gilboa, L; Sun, Y; Liu, XD; Henis, YI; Lodish, HF			Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I type II receptor complex in live cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; HETEROOLIGOMERIC COMPLEXES; SIGNAL-TRANSDUCTION; PROTEINS; FORM; TRANSPHOSPHORYLATION; COMPLEMENTATION; PHOSPHORYLATION; EXPRESSION	Transforming growth factor-beta (TGF-beta) binds to and signals via two serine-threonine kinase receptors, the type I (T beta RI) and type II (T beta RII) receptors. We ha ve used different and complementary techniques to study the physical nature and Ligand dependence of the complex formed by T beta RI and T beta RII. Velocity centrifugation of endogenous receptors suggests that ligand-bound T beta RI and T beta RII form a heteromeric complex that is most likely a heterotetramer. Antibody-mediated immunofluorescence co-patching of epitope-tagged receptors provides the first evidence in live cells that T beta RI.T beta RII complex formation occurs at a low but measurable degree in the absence of ligand, increasing significantly after TGF-beta binding. In addition, we demonstrate that pretreatment of cells with dithiothreitol, which inhibits the binding of TGF-beta to T beta RI, does not prevent formation of the T beta RI.T beta RII complex, but increases its sensitivity to detergent and prevents TGF-beta-activated T beta RI from phosphorylating Smad3 in vitro. This indicates that either a specific conformation of the T beta RI.T beta RII complex, disrupted by dithiothreitol, or direct binding of TGF-beta to T beta RI is required for signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Henis, Yoav/0000-0002-1408-3877; LIU, XUEDONG/0000-0001-7209-4964	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002290] Funding Source: NIH RePORTER; NCI NIH HHS [CA63260] Funding Source: Medline; NIDDK NIH HHS [DK02290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; JOKIRANTA TS, 1995, FEBS LETT, V376, P31, DOI 10.1016/0014-5793(95)01239-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KURKELA R, 1988, J IMMUNOL METHODS, V110, P229, DOI 10.1016/0022-1759(88)90108-1; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1996, CANCER SURV, V27, P41; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; OKADOME T, 1994, J BIOL CHEM, V269, P30753; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; Wells RG, 1997, J BIOL CHEM, V272, P11444; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	38	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5716	5722		10.1074/jbc.274.9.5716	http://dx.doi.org/10.1074/jbc.274.9.5716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026191	hybrid			2022-12-27	WOS:000078804400062
J	Behre, G; Whitmarsh, AJ; Coghlan, MP; Hoang, T; Carpenter, CL; Zhang, DE; Davis, RJ; Tenen, DG				Behre, G; Whitmarsh, AJ; Coghlan, MP; Hoang, T; Carpenter, CL; Zhang, DE; Davis, RJ; Tenen, DG			c-Jun is a JNK-independent coactivator of the PU.1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASE; FACTOR-I RECEPTOR; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; HA-RAS; MACROPHAGE DIFFERENTIATION; MONOCYTIC DIFFERENTIATION; REGULATES EXPRESSION; TARGETED DISRUPTION	The ETS domain transcription factor PU.1 is necessary for the development of monocytes and regulates, in particular, the expression of the monocyte-specific macrophage colony-stimulating factor (M-CSF) receptor, which is critical for monocytic cell survival, proliferation, and differentiation. The bZIP transcription factor c-Jun, which is part of the AP-1 transcription factor complex, is also important for monocytic differentiation, but the monocyte-specific M-CSF receptor promoter has no AP-1 consensus binding sites. We asked the question of whether c-Jun could promote the induction of the M-CSF receptor by collaborating with PU.1. We demonstrate that c-Jun enhances the ability of PU.1 to transactivate the M-CSF receptor promoter as well as a minimal thymidine kinase promoter containing only PU.1 DNA binding sites. c-Jun does not directly bind to the M-CSF receptor promoter but associates via its basic domain with the ETS domain of PU.1, Consistent with our observation that AP-1 binding does not contribute to c-Jun coactivation is the observation that the activation of PU.1 by c-Jun is blocked by overexpression of c-Fos. Phosphorylation of c-Jun by c-Jun NH2-terminal kinase on Ser-63 and -73 does not alter the ability of c-Jun to enhance PU.1 transactivation. Activated Ras enhances the transcriptional activity of PU.1 by up-regulating c-Jun expression without changing the phosphorylation pattern of PU.1. The activation of PU.1 by Ras is blocked by a mutant c-Jun protein lacking the basic domain. The expression of this mutant form of c-Jun also completely blocks 12-O-tetradecanoylphorbol-13-acetate-induced M-CSF receptor promoter activity during monocytic differentiation. We propose therefore that c-Jun acts as a c-Jun NH2-terminal kinase-independent coactivator of PU.1, resulting in M-CSF receptor expression and development of the monocytic lineage.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Tenen, DG (corresponding author), Harvard Inst Med, Room 954,77 Ave Louis Pasteur, Boston, MA 02115 USA.	dtenen@bidmc.harvard.edu		Whitmarsh, Alan/0000-0003-1184-6610; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456, P01CA072009] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA72009, CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; GAYNOR R, 1991, BLOOD, V77, P2618; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hass R, 1997, LEUKEMIA RES, V21, P589, DOI 10.1016/S0145-2126(97)00010-6; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; HIBI S, 1993, BLOOD, V81, P1841; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Hume DA, 1997, MOL REPROD DEV, V46, P46; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JIN DI, 1995, MOL CELL BIOL, V15, P693; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lodie TA, 1997, J IMMUNOL, V158, P1848; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Maher J, 1996, LEUKEMIA, V10, P83; Mao C, 1996, ONCOGENE, V12, P863; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Olweus J, 1996, BLOOD, V88, P3741, DOI 10.1182/blood.V88.10.3741.bloodjournal88103741; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHERR CJ, 1990, BLOOD, V75, P1; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WASYLYK C, 1994, ONCOGENE, V9, P3665; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAN MH, 1994, NATURE, V372, P798; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	68	151	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4939	4946		10.1074/jbc.274.8.4939	http://dx.doi.org/10.1074/jbc.274.8.4939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988737	hybrid			2022-12-27	WOS:000078698200062
J	Perez-Juste, G; Aranda, A				Perez-Juste, G; Aranda, A			The cyclin-dependent kinase inhibitor p27(Kip1) is involved in thyroid hormone-mediated neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST CELL-CYCLE; RETINOBLASTOMA PROTEIN; NEUROBLASTOMA-CELLS; RESTRICTION POINT; NEURO-2A CELLS; MESSENGER-RNA; RECEPTOR; GROWTH; ARREST; PHASE	The thyroid hormone (triiodothyronine, T3) is essential for normal brain maturation. To determine the mechanisms by which T3 controls neuronal proliferation and differentiation, we have analyzed the effect of this hormone on the expression and activity of cell cycle-regulating molecules in neuroblastoma N2a-beta cells that overexpress the beta 1 isoform of the T3 receptor. Our results show that incubation of N2a-beta cells with T3 leads to a rapid down-regulation of the c-myc gene and to a decrease of cyclin D1 levels. T3 also causes a strong and sustained increase of the levels of the cyclin kinase inhibitor p27(Kip1). This increase is secondary, to the augmented levels of p27(Kip1) transcripts as well as to stabilization of the p27(Kip1) protein. The increased levels of p27(Kip1) lead to a significant increase in the amount of p27(Kip1) associated with cyclin-dependent kinase 2 (CDK2), and to a marked inhibition of the kinase activity of the cyclin . CDK2 complexes. As a consequence, the retinoblastoma protein (pRb) and the retinoblastoma protein-related protein p130 are hypophosphorylated in T3-treated N2a-beta cells. This study shows for the first time that T3-mediated growth arrest and neuronal differentiation are associated with an increase in the levels of a cyclin kinase inhibitor, which does not allow the inactivation of retinoblastoma proteins required for progression through the restriction point in the cell cycle.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LAZAR MA, 1993, ENDOCR REV, V14, P194; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLIAK K, 1994, CELL, V78, P59; POLIAK K, 1994, GENE DEV, V8, P9; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Puymirat J, 1995, J BIOL CHEM, V270, P30651, DOI 10.1074/jbc.270.51.30651; PUYMIRAT J, 1992, PROG NEUROBIOL, V39, P281, DOI 10.1016/0301-0082(92)90019-B; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QM, 1997, CANCER RES, V57, P2851; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUSTA B, 1990, J NEUROSCI RES, V27, P1, DOI 10.1002/jnr.490270102	39	78	79	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5026	5031		10.1074/jbc.274.8.5026	http://dx.doi.org/10.1074/jbc.274.8.5026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988748	Green Published, hybrid			2022-12-27	WOS:000078698200073
J	Angerer, ND; Du, Y; Nalbant, D; Williams, SC				Angerer, ND; Du, Y; Nalbant, D; Williams, SC			A short conserved motif is required for repressor domain function in the myeloid-specific transcription factor CCAAT enhancer-binding protein epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C/EBP-BETA; ACTIVATION DOMAINS; EXPRESSION NF-IL6; INHIBITOR DOMAIN; LEUCINE-ZIPPER; DEFICIENT MICE; NUCLEAR FACTOR; DIFFERENTIATION; CELLS	CCAAT/enhancer-binding protein epsilon (C/EBP epsilon) is expressed almost exclusively in the myeloid lineage of the hematopoietic system and functions during terminal differentiation of neutrophils and macrophages, and in the regulation of cytokine gene expression in macrophages and T cells. We have undertaken a series of structure/function studies on the murine C/EBP epsilon polypeptide to investigate the mechanism by which C/EBP epsilon activates transcription. Studies with deletion mutants and fusion proteins consisting of C/EBP epsilon sequences joined to the Gal4 DNA-binding protein identified two transcriptional activation domains in C/EBP epsilon, Removal of sequences between the two activation domains or sequences between the second activation domain and the C-terminal DNA binding domain significantly increased the activity of C/EBP epsilon, suggesting the presence of two separate regulatory domains (designated RD-1 epsilon and RD-2 epsilon), RD-1 epsilon behaved as a classic active repressor domain being capable of inhibiting adjacent activation domains irrespective of their origin and when linked to a heterologous DNA binding domain. Mutagenesis studies revealed a short motif in RD-1 epsilon that appears to be a target site for protein-protein interactions and is conserved in repressor domains from C/EBP beta, Sp3, c-Fos, and FosB, The juxtaposition of activation and repressor domains may permit C/EBP epsilon to function as a transcriptional activator or repressor at different stages of myeloid differentiation or as an inducible transcriptional activator of cytokine genes.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; Texas Tech Univ, Med Ctr, SW Canc Ctr, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St, Lubbock, TX 79430 USA.	cbbscw@ttuhsc.edu						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hu HM, 1998, J IMMUNOL, V160, P2334; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; POLI V, 1994, LIVER GENE EXPRESSIO, P131; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Williams SC, 1997, GENE EXPRESSION, V6, P371; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4147	4154		10.1074/jbc.274.7.4147	http://dx.doi.org/10.1074/jbc.274.7.4147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933609	hybrid			2022-12-27	WOS:000078575500033
J	Harth, G; Horwitz, MA				Harth, G; Horwitz, MA			Export of recombinant Mycobacterium tuberculosis superoxide dismutase is dependent upon both information in the protein and mycobacterial export machinery - A model for studying export of leaderless proteins by pathogenic mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLUTAMINE-SYNTHETASE; EXPRESSION; GENE; IDENTIFICATION; PHAGOCYTOSIS; RECEPTORS; SEQUENCE; ANTIGEN; RELEASE	We have investigated the expression and extracellular release of enzymatically active superoxide dismutase, one of the 10 major extracellular proteins of Mycobacterium tuberculosis, both in its native host and in the heterologous host Mycobacterium smegmatis, We found that the M, tuberculosis superoxide dismutase gene, encoding a leaderless polypeptide of M-r similar to 23,000 representing one of the four identical subunits of the enzyme, is expressed constitutively under normal growth conditions and at a B-fold increased level under conditions of hydrogen peroxide stress. The highly pathogenic mycobacterium M. tuberculosis expresses 93-fold more superoxide dismutase than the nonpathogenic mycobacterium M. smegmatis, and it exports a much higher proportion of expressed enzyme (76 versus 21%); taking both expression and export into consideration, IM, tuberculosis exports similar to 350-fold more enzyme than M, smegmatis, In M. smegmatis, recombinant M. tuberculosis superoxide dismutase is expressed at 8.4 times the level of the endogenous enzyme and the proportion exported (66%) approaches that in the homologous host; hence M. smegmatis exports up to 26-fold more of the recombinant than endogenous enzyme. Interestingly, subunits of the M. tuberculosis and M. smegmatis enzymes readily and stoichiometrically exchange with each other, forming five different complexes of four subunits, both when the enzymes are expressed in the recombinant host and when the purified enzymes are incubated together; however, each subunit retains its characteristic metal ion, iron for IM. tuberculosis and manganese for M.. smegmatis, Compared with the cell-associated enzyme, the supernatant enzyme of recombinant IM, smegmatis is enriched for M, tuberculosis enzyme subunits, consistent with preferential export of the M. tuberculosis enzyme. Recombinant M. tuberculosis superoxide dismutase transcomplements a superoxide dismutase-deficient Escherichia coli, resulting in a reduction of sensitivity of the strain to oxidative stress, but the enzyme is not exported from this nonmycobacterial host. Our findings indicate that the information for export of the M, tuberculosis superoxide dismutase is contained within the protein but that export additionally requires export machinery specific to mycobacteria.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Horwitz, MA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042925, R01AI031338] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR05554] Funding Source: Medline; NIAID NIH HHS [AI 31338, AI 42925] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BULL TJ, 1995, J CLIN PATHOL-CL MOL, V48, pM124; Bunting K, 1998, EUR J BIOCHEM, V251, P795, DOI 10.1046/j.1432-1327.1998.2510795.x; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; EIDUS I, 1964, AM REV RESPIR DIS, V90, P258; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harth G, 1997, INFECT IMMUN, V65, P2321, DOI 10.1128/IAI.65.6.2321-2328.1997; Harth G, 1997, J BIOL CHEM, V272, P22728, DOI 10.1074/jbc.272.36.22728; HARTH G, 1994, P NATL ACAD SCI USA, V91, P9342, DOI 10.1073/pnas.91.20.9342; Horwitz LD, 1998, P NATL ACAD SCI USA, V95, P5263, DOI 10.1073/pnas.95.9.5263; HOWARD NS, 1995, GENE, V166, P181, DOI 10.1016/0378-1119(95)00597-X; KEELE BB, 1970, J BIOL CHEM, V245, P6176; MAYER BK, 1986, INFECT IMMUN, V53, P631, DOI 10.1128/IAI.53.3.631-635.1986; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; MUNO D, 1981, BIOCHEM INT, V2, P33; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; STEINMAN HM, 1973, P NATL ACAD SCI USA, V70, P3725, DOI 10.1073/pnas.70.12.3725; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; ZHANG Y, 1991, MOL MICROBIOL, V5, P381, DOI 10.1111/j.1365-2958.1991.tb02120.x; ZOLG JW, 1994, J CLIN MICROBIOL, V32, P2801, DOI 10.1128/JCM.32.11.2801-2812.1994	28	68	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4281	4292		10.1074/jbc.274.7.4281	http://dx.doi.org/10.1074/jbc.274.7.4281			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933629	hybrid			2022-12-27	WOS:000078575500053
J	Kose, S; Imamoto, N; Tachibana, T; Yoshida, M; Yoneda, Y				Kose, S; Imamoto, N; Tachibana, T; Yoshida, M; Yoneda, Y			beta-subunit of nuclear pore-targeting complex (importin-beta) can be exported from the nucleus in a Ran-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; PROTEIN IMPORT; BINDING PROTEIN; GTPASE ACTIVITY; MESSENGER-RNA; LEPTOMYCIN-B; LIVING CELLS; RCC1; TRANSPORT; SIGNAL	The nuclear export of importin-alpha is mediated by GAS, which is related to importin-beta, whereas the mechanism for the export of importin-beta remains unclear. In this study, we demonstrate that the nuclear export of importin-beta is mediated by the nuclear pore complex-binding domain of this molecule, Insensitivity to leptomycin B indicates that its export is not mediated by a leucine-rich nuclear export signal-specific receptor, CRM1. Furthermore, the nuclear export of importin-a was not inhibited by co-injection with a GTPase-deficient Ran mutant (G19V), The cell line tsBN2 contains a temperature-sensitive point mutation in the RCC1 gene, which encodes a guanine nucleotide exchange factor of Ran. At the nonpermissive temperature, importin-beta was exported from the nucleus of these cells, even when Ran-GAP1, a GTPase-activating protein for Ran, was co-injected. These results not only provide support for the view that Ran-dependent GTP hydrolysis is not required for the nuclear export of importin-beta but also indicate that nuclear RanGTP is not essential for its export. As a result, we propose: that importin-beta can be recycled from the nucleus alone in a Ran-independent manner.	Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; University of Tokyo	Yoneda, Y (corresponding author), Osaka Univ, Sch Med, Dept Anat & Cell Biol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	yyoneda@anat3.med.osaka-u.ac.jp	Yoshida, Minoru/C-8049-2014; Imamoto, Naoko/A-7458-2015	Yoshida, Minoru/0000-0002-4376-5674; Imamoto, Naoko/0000-0002-2886-3022				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NISHI K, 1994, J BIOL CHEM, V269, P6320; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	46	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3946	3952		10.1074/jbc.274.7.3946	http://dx.doi.org/10.1074/jbc.274.7.3946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933584	hybrid			2022-12-27	WOS:000078575500008
J	Shibata, N; Inoue, T; Nagano, C; Nishio, N; Kohzuma, T; Onodera, K; Yoshizaki, F; Sugimura, Y; Kai, Y				Shibata, N; Inoue, T; Nagano, C; Nishio, N; Kohzuma, T; Onodera, K; Yoshizaki, F; Sugimura, Y; Kai, Y			Novel insight into the copper-ligand geometry in the crystal structure of Ulva pertusa plastocyanin at 1.6-angstrom resolution - Structural basis for regulation of the copper site by residue 88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; DATA-COLLECTION SYSTEM; GREEN-ALGA; POPLAR PLASTOCYANIN; ELECTRON-TRANSFER; IMAGING PLATE; CHLAMYDOMONAS-REINHARDTII; ENTEROMORPHA-PROLIFERA; SYNCHROTRON-RADIATION; PARSLEY PLASTOCYANIN	The crystal structure of plastocyanin from a green alga, Ulva pertusa, has been determined at 1.6-Angstrom resolution. At its copper site, U. pertusa plastocyanin has a distorted tetrahedral coordination geometry similar to other plastocyanins. In comparison with structures of plastocyanins reported formerly, a Cu(II)-S-delta(Met(92)) bond distance (2.69 Angstrom) is shorter by about 0.2 Angstrom and a Cu(II)-S-gamma(Cys(84)) distance is longer by less than 0.1 Angstrom in U. pertusa plastocyanin. These subtle but significant differences are caused by the structural change at a His-Met loop (His(87)- Met(92)) due to an absence of a O(Asp(85))-O-gamma(Ser(88)) hydrogen bond which is found in Enteromorpha prolifera plastocyanin. In addition, poplar and Chlamydomonas reinhardtii plastocyanins with a glutamine at residue 88 have a weak cation-rr interaction with Tyr(83). This interaction lengthens the Cu(II)-S-delta(Met(92)) bond of poplar and C, reinhardtii plastocyanins by 0.14 and 0.20 Angstrom respectively. As a result of structural differences, U. pertusa plastocyanin has a less distorted geometry than the other plastocyanins. Thus, the cupric geometry is finely tuned by the interactions between residues 85 and 88 and between residues 83 and 88, This result implies that the copper site is more flexible than reported formerly and that the rack mechanism would be preferable to the entatic theory. The His-Met loop may regulate the electron transfer rate within the complex between plastocyanin and cytochrome f.	Osaka Univ, Fac Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; Ibaraki Univ, Dept Chem, Mito, Ibaraki 3108512, Japan; Toho Univ, Fac Sci, Dept Biol, Funabashi, Chiba 2748510, Japan	Osaka University; Ibaraki University; Toho University	Kai, Y (corresponding author), Osaka Univ, Fac Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.		Shibata, Naoki/AFK-9971-2022; Kohzuma, Takamitsu/U-2966-2019	Shibata, Naoki/0000-0002-5096-1104; 				ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; AITKEN A, 1975, BIOCHEM J, V149, P675, DOI 10.1042/bj1490675; ARUDCHANDRAN A, 1994, BBA-BIOENERGETICS, V1188, P447, DOI 10.1016/0005-2728(94)90069-8; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P6611, DOI 10.1021/bi00187a031; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CHURCH WB, 1986, J BIOL CHEM, V261, P234; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; DETLEFSEN DJ, 1989, NUCLEIC ACIDS RES, V17, P6414, DOI 10.1093/nar/17.15.6414; DIMITROV MI, 1993, BIOCHIM BIOPHYS ACTA, V1203, P184, DOI 10.1016/0167-4838(93)90081-2; DIMITROV MI, 1990, FEBS LETT, V265, P141, DOI 10.1016/0014-5793(90)80904-W; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRASER ED, 1995, ACTA CRYSTALLOGR D, V51, P1052; Gray H. B., 1983, COMMENTS INORG CHEM, V2, P203; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; GUSS JM, 1983, J MOL BIOL, V169, P521; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HAGLER AT, 1976, J AM CHEM SOC, V98, P4600, DOI 10.1021/ja00431a045; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; INOUE T, 1994, ACTA CRYSTALLOGR D, V50, P317, DOI 10.1107/S0907444994000260; INOUE T, 1994, J BIOCHEM-TOKYO, V116, P1193, DOI 10.1093/oxfordjournals.jbchem.a124661; KELLY J, 1974, BIOCHEM J, V143, P681, DOI 10.1042/bj1430681; LaCroix LB, 1996, J AM CHEM SOC, V118, P7755, DOI 10.1021/ja961217p; LAST DI, 1989, PLANT MOL BIOL, V12, P655, DOI 10.1007/BF00044156; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MALMSTROM BG, 1994, EUR J BIOCHEM, V223, P711, DOI 10.1111/j.1432-1033.1994.tb19044.x; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MILNE PR, 1974, BIOCHEM J, V143, P691, DOI 10.1042/bj1430691; MOORE JM, 1991, J MOL BIOL, V221, P533, DOI 10.1016/0022-2836(91)80071-2; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; MOORE JM, 1988, SCIENCE, V240, P314, DOI 10.1126/science.3353725; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P46; QUINN J, 1993, J BIOL CHEM, V268, P7832; RAMACHANDRAN GN, 1974, BIOCHIM BIOPHYS ACTA, V359, P298, DOI 10.1016/0005-2795(74)90228-1; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODHAM DA, 1993, NATURE, V362, P735, DOI 10.1038/362735a0; ROTHER C, 1986, CURR GENET, V11, P171, DOI 10.1007/BF00420603; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Ryde U, 1996, J MOL BIOL, V261, P586, DOI 10.1006/jmbi.1996.0484; Sakabe K, 1997, J SYNCHROTRON RADIAT, V4, P136, DOI 10.1107/S0909049597003683; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sasakawa Y, 1998, INORG CHIM ACTA, V283, P184, DOI 10.1016/S0020-1693(98)00228-X; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SCAWEN MD, 1974, BIOCHEM J, V143, P257, DOI 10.1042/bj1430257; SIMPSON RJ, 1986, EUR J BIOCHEM, V157, P497, DOI 10.1111/j.1432-1033.1986.tb09694.x; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; VALLEE BL, 1968, P NATL ACAD SCI USA, V59, P498, DOI 10.1073/pnas.59.2.498; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WILLIAMS RJP, 1995, EUR J BIOCHEM, V234, P363, DOI 10.1111/j.1432-1033.1995.363_b.x; YOSHIZAKI F, 1989, J BIOCHEM-TOKYO, V106, P282, DOI 10.1093/oxfordjournals.jbchem.a122845; 1994, ACTA CRYSTALLOG D, V50, P760	67	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4225	4230		10.1074/jbc.274.7.4225	http://dx.doi.org/10.1074/jbc.274.7.4225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933621	hybrid			2022-12-27	WOS:000078575500045
J	Melville, MW; Tan, SL; Wambach, M; Song, J; Morimoto, RI; Katze, MG				Melville, MW; Tan, SL; Wambach, M; Song, J; Morimoto, RI; Katze, MG			The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; MOLECULAR CHAPERONE; STRESS-RESPONSE; J-DOMAIN; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION; SUBSTRATE-BINDING; ESCHERICHIA-COLI; T ANTIGENS; DNAJ	p58(IPK), a member of the tetratricopeptide repeat and J-domain protein families, was first recognized for its ability to inhibit the double-stranded RNA-activated protein kinase, PKR. PKR is part of the interferon-induced host defense against viral infection, and down-regulates translation initiation via phosphorylation of eukaryotic initiation factor 2 on the alpha-subunit. P58(IPK) is activated in response to infection by influenza virus, and inhibits PKR through direct protein-protein interaction. Previously, we demonstrated that the molecular chaperone heat shock protein 40 (hsp40) was a negative regulator of p58(IPK). We could now report that influenza virus activates the p58(IPK) pathway by promoting the dissociation of hsp40 from p58(IPK) during infection. We also found that the P58(IPK)-hsp40 association was disrupted during recovery from heat shock, which suggested a regulatory role for P58(IPK) in the absence of virus infection. The PKR pathway is even more complex as we show in this report that the molecular chaperone, hsp/Hsc70, was a component of a trimeric complex with hsp40 and p58(IPK). Moreover, like other J-domain proteins, p58(IPK) stimulated the ATPase activity of Hsc70, Taken together, our data suggest that p58(IPK) is a co-chaperone, possibly directing hsp/Hsc70 to refold, and thus inhibit kinase function.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98185 USA	University of Washington; University of Washington Seattle; Northwestern University; University of Washington; University of Washington Seattle	Katze, MG (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	honey@u.washington.edu	Tan, Seang Lin/I-7710-2012	Song, Jaewhan/0000-0001-8152-9210	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041629, R01AI022646] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline; NIAID NIH HHS [AI-41629, AI-22646] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Gale M, 1996, MOL CELL BIOL, V16, P4172; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; JINDAL S, 1992, J VIROL, V66, P5357, DOI 10.1128/JVI.66.9.5357-5362.1992; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; King C, 1997, BIOCHEMISTRY-US, V36, P4067, DOI 10.1021/bi9625307; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MACEJAK DG, 1991, VIROLOGY, V180, P120, DOI 10.1016/0042-6822(91)90015-4; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Mayer MP, 1998, BIOL CHEM, V379, P261; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; SAGARA J, 1992, VIROLOGY, V190, P845, DOI 10.1016/0042-6822(92)90923-D; SAITO S, 1990, MICROBIOL IMMUNOL, V34, P859, DOI 10.1111/j.1348-0421.1990.tb01064.x; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Smith DF, 1998, BIOL CHEM, V379, P283; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tang NM, 1996, J BIOL CHEM, V271, P28660, DOI 10.1074/jbc.271.45.28660; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trgovcich J, 1997, VIROLOGY, V227, P234, DOI 10.1006/viro.1996.8289; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	62	110	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3797	3803		10.1074/jbc.274.6.3797	http://dx.doi.org/10.1074/jbc.274.6.3797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920933	hybrid			2022-12-27	WOS:000078428200073
J	Stockand, JD; Al-Baldawi, NF; Al-Khalili, OK; Worrell, RT; Eaton, DC				Stockand, JD; Al-Baldawi, NF; Al-Khalili, OK; Worrell, RT; Eaton, DC			S-adenosyl-L-homocysteine hydrolase regulates aldosterone-induced Na+ transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLHOMOCYSTEINE-HYDROLASE; SODIUM-TRANSPORT; APICAL MEMBRANE; METHYLATION; CHANNELS; PURIFICATION; METABOLISM; EXPRESSION; EPITHELIA	Aldosterone-induced Na+ reabsorption, in part, is regulated by a critical methyl esterification; however, the signal transduction pathway regulating this methylation remains unclear. The A6 cell line was used as a model epithelia to investigate regulation of aldosterone-induced Na+ transport by S-adenosyl-L-homocysteine hydrolase (SAHHase), the only enzyme in vertebrates known to catabolize S-adenosyl-L-homocysteine (SAH), an end product inhibitor of methyl esterification, Sodium reabsorption was decreased within 2 h by 3-deazaadenosine, a competitive inhibitor of SAHHase, with a half inhibitory concentration between 40 and 50 mu M. Aldosterone increased SAH catabolism by activating SAHHase. Increased SAH catabolism was associated with a concomitant increase in S-adenosylmethionine catabolism, Moreover, SAH decreased substrate methylation. Antisense oligonucleotide complementary to SAHHase mRNA decreased SAHHase activity and Na+ current by approximately 50%. Overexpression of SAHHase increased SAHHase activity and dependent substrate methyl esterification, Whereas basal Na+ current was not affected by overexpression of SAHHase, aldosterone-induced current in SAHHase-overexpressing cells was significantly potentiated. These results demonstrate that aldosterone induction of SAHHase activity is necessary for a concomitant relief of the methylation reaction from end product inhibition by SAH and the subsequent increase in Na+ reabsorption. Thus, regulation of SAHHase activity is a control point for aldosterone signal transduction, but SAHHase is not an aldosterone-induced protein.	Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	Emory University	Stockand, JD (corresponding author), Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signaling, 1648 Pierce Dr, Atlanta, GA 30322 USA.	jstocka@emory.edu		Stockand, James/0000-0002-3817-4319; Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963, R37DK037963, F32DK009729] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37963, DK09729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBALDAWI NF, 1998, FASEB J, V21, P2447; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC1928, DOI 10.1152/ajpcell.1997.272.6.C1928; CHEN S, 1998, J AM SOC NEPHROL, V9, P398; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; FINKELSTEIN JD, 1973, ARCH BIOCHEM BIOPHYS, V159, P160, DOI 10.1016/0003-9861(73)90440-2; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; KIM IK, 1983, ARCH BIOCHEM BIOPHYS, V226, P65, DOI 10.1016/0003-9861(83)90271-0; Kloor D, 1996, KIDNEY BLOOD PRESS R, V19, P100, DOI 10.1159/000174051; Ling BN, 1997, J BIOL CHEM, V272, P594; PALMER JL, 1979, J BIOL CHEM, V254, P1217; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SCHRADER J, 1981, BIOCHEM J, V196, P65, DOI 10.1042/bj1960065; SEERY LT, 1994, BIOCHEM BIOPH RES CO, V205, P1539, DOI 10.1006/bbrc.1994.2842; TREWYN RW, 1981, J BIOCHEM BIOPH METH, V4, P299, DOI 10.1016/0165-022X(81)90070-1; UELAND PM, 1982, PHARMACOL REV, V34, P223; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43	23	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3842	3850		10.1074/jbc.274.6.3842	http://dx.doi.org/10.1074/jbc.274.6.3842			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920939	hybrid			2022-12-27	WOS:000078428200079
J	Yeh, JC; Ong, E; Fukuda, M				Yeh, JC; Ong, E; Fukuda, M			Molecular cloning and expression of a novel beta-1,6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; HAMSTER OVARY CELLS; BLOOD GROUP-I; L-SELECTIN; CARBOHYDRATE STRUCTURE; GLYCAN BIOSYNTHESIS; GASTRIC-MUCOSA; GENE FAMILY; ANTIGEN; MUCIN	Mucin-type O-glycans are classified according to their core structures. Among them, cores 2 and 4 are important for having N-acetyllactosamine side chains, which can be further modified to express various functional oligosaccharides. Previously, we discovered by cloning cDNAs that the core 2 branching enzyme, termed core 2 beta-1,6-N-acetylglucosaminyltransferase-leukocyte type (C2GnT-L), is highly homologous to the I branching beta-1,6-N-acetylglucosaminyltransferase (IGnT) (Bierhuizen, M. F. A., Mattei, M.-G., and Fukuda, M. (1993) Genes Dev. 7, 468-478). Using these homologous sequences as probes, we identified an expressed sequence tag in dbEST, which has significant homology to C2GnT-L and IGnT, This approach, together with 5' and 3' rapid amplification of cDNA ends, yielded a human cDNA that encompasses a whole coding region of an enzyme, termed C2GnT-mucin type (C2GnT-M), C2GnT-M has 48.2 and 33.8% identity with C2GnT-L and IGnT at the amino acid levels. The expression of C2GnT-M cDNA directed the expression of core 2 branched oligosaccharides and I antigen on the cell surface. Moreover, a soluble chimeric C2GnT-M had core 4 branching activity in addition to core 2 and I branching activities. A soluble chimeric C2GnT-L, in contrast, almost exclusively contains core 2 branching activity. Northern blot analysis demonstrated that the C2GnT-M transcripts are heavily expressed in colon, small intestine, trachea, and stomach, where mucin is produced. In contrast, the transcripts of C2GnT-L were more widely detected, including the lymph node and bone marrow. These results indicate that the newly cloned C2GnT-M plays a critical role in O-glycan synthesis in mucins and might have distinctly different roles in oligosaccharide ligand formation compared with C2GnT-L.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org			NATIONAL CANCER INSTITUTE [R37CA033000, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R37 CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Edge ASB, 1997, ARCH BIOCHEM BIOPHYS, V343, P73, DOI 10.1006/abbi.1997.0143; ELLIES LG, 1998, IN PRESS IMMUNITY; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; Gebe JA, 1997, J BIOL CHEM, V272, P6151, DOI 10.1074/jbc.272.10.6151; GU J, 1992, J BIOL CHEM, V267, P2994; HANISCH FG, 1989, J BIOL CHEM, V264, P261; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOUNSELL EF, 1980, BIOCHEM BIOPH RES CO, V92, P1143, DOI 10.1016/0006-291X(80)90406-4; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Mattila P, 1998, J BIOL CHEM, V273, P27633, DOI 10.1074/jbc.273.42.27633; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PILLER F, 1984, J BIOL CHEM, V259, P3385; PILLER F, 1988, J BIOL CHEM, V263, P15146; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Shimodaira K, 1997, CANCER RES, V57, P5201; SMITH DF, 1990, J BIOL CHEM, V265, P6225; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; VAVASSEUR F, 1995, GLYCOBIOLOGY, V5, P351, DOI 10.1093/glycob/5.3.351; WEN DX, 1992, J BIOL CHEM, V267, P21011; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	41	169	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3215	3221		10.1074/jbc.274.5.3215	http://dx.doi.org/10.1074/jbc.274.5.3215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915862	hybrid			2022-12-27	WOS:000078319500080
J	Nixon, AB; O'Flaherty, JT; Salyer, JK; Wykle, RL				Nixon, AB; O'Flaherty, JT; Salyer, JK; Wykle, RL			Acetyl-CoA : 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase is directly activated by p38 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CYTOSOLIC PHOSPHOLIPASE A(2); DEPENDENT PROTEIN-KINASE; HUMAN-NEUTROPHILS; FACTOR PAF; ARACHIDONIC-ACID; CALCIUM IONOPHORE; BIOSYNTHESIS; PHOSPHORYLATION; INHIBITOR	Acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase, along with phospholipase A(2), is a key regulator of platelet-activating factor biosynthesis via the remodeling pathway. We have now obtained evidence in human neutrophils indicating that this enzyme is regulated by a specific member of the mitogen-activated protein kinases, namely the p38 kinase, We earlier demonstrated that tumor necrosis factor-alpha (TNF-alpha) as well as N-formyl-methionyl-leucyl-phenylalanine treatment leads to increased phosphorylation and activation of p38 kinase in human neutrophils, Strikingly, in the present study these stimuli increased the catalytic activity of acetyltransferase up to S-fold, whereas 4-phorbol 12-myristate 13-acetate, which activates the extracellular-regulated kinases (ERKs) but not p38 kinase, had no effect. Furthermore, a selective inhibitor of p38 kinase, SE 203580, was able to abolish the TNF-alpha- and N-formyl-methionyl-leucyl-phenylalanine-induced activation of acetyltransferase. The same effect was not observed in the presence of an inhibitor that blocked ERK activation (PD 98059), Complementing the findings in intact cells, we have shown that recombinant, activated p38 kinase added to microsomes in the presence of Mg2+ and ATP increased acetyltransferase activity to the same degree as in microsomes obtained from TNF-alpha-stimulated cells. No activation of acetyltransferase occurred upon treatment of microsomes with either recombinant, activated ERK-1 or ERK-2, Finally, the increases in acetyltransferase activity induced by TNF-alpha could be ablated by treating the microsomes with alkaline phosphatase. Thus acetyltransferase appears to be a downstream target for p38 kinase but not ERKs, These data from whole cells as well as cell-free systems fit a model wherein stimulus-induced acetyltransferase activation is mediated by a phosphorylation event catalyzed directly by p38 kinase.	Wake Forest Univ, Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Med Ctr, Dept Med Infect Dis, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	Wykle, RL (corresponding author), Wake Forest Univ, Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA.		Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964	NHLBI NIH HHS [HL-50395, HL-56710] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056710, P01HL050395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT DH, 1983, J BIOL CHEM, V258, P97; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALONSO F, 1982, J BIOL CHEM, V257, P3376; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELLER R, 1991, J BIOL CHEM, V266, P21358; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LEYRAVAUD S, 1989, J IMMUNOL, V143, P245; MOLLINEDO F, 1988, BIOCHEM BIOPH RES CO, V154, P1232, DOI 10.1016/0006-291X(88)90271-9; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; NIETO ML, 1988, J BIOL CHEM, V263, P2217; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OFLAHERTY JT, 1983, BIOCHEM BIOPH RES CO, V111, P1, DOI 10.1016/S0006-291X(83)80108-9; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEPLOW PV, 1990, PROSTAG LEUKOTR ESS, V41, P71, DOI 10.1016/0952-3278(90)90057-R; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RECORD M, 1989, J CELL BIOCHEM, V40, P353, DOI 10.1002/jcb.240400311; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1989, P SOC EXP BIOL MED, V190, P125; SWENDSEN CL, 1983, BIOCHEM BIOPH RES CO, V113, P72, DOI 10.1016/0006-291X(83)90433-3; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; WYKLE RL, 1988, METHOD ENZYMOL, V163, P44; WYKLE RL, 1980, J BIOL CHEM, V255, P256; WYKLE RL, 1987, PLATELET ACTIVATING, P273; WYKLE RL, 1983, INSERM S, V23, P277; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5469	5473		10.1074/jbc.274.9.5469	http://dx.doi.org/10.1074/jbc.274.9.5469			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026159	hybrid			2022-12-27	WOS:000078804400030
J	Rao, GN; Katki, KA; Madamanchi, NR; Wu, YX; Birrer, MJ				Rao, GN; Katki, KA; Madamanchi, NR; Wu, YX; Birrer, MJ			JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; C-FOS EXPRESSION; RAT MESANGIAL CELLS; HYDROGEN-PEROXIDE; REACTIVE-OXYGEN; ANGIOTENSIN-II; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; OXIDATION-REDUCTION; ARACHIDONIC-ACID	To understand the role of redox-sensitive mechanisms in vascular smooth muscle cell (VSMC) growth, we have studied the effect of N-acetylcysteine (NAC), a thiol antioxidant, and diphenyleneiodonium (DPI), a potent NADH/NADPH oxidase inhibitor, on serum-, platelet-derived growth factor BB-, and thrombin-induced ERK2, JNK1, and p38 mitogen-activated protein (MAP) kinase activation; c-Fos, c-Jun, and JunB expression; and DNA synthesis. Both NAC and DPI completely inhibited agonist-induced AP-1 activity and DNA synthesis in VSMC. On the contrary, these compounds had differential effects on agonist-induced ERK2, JNK1, and p38 MAP kinase activation and c-Fos, c-Jun, and JunB expression. NAC inhibited agonist-induced ERK2, JNK1, and p38 MAP kinase activation and c-Fos, c-Jun, and JunB expression except for platelet-derived growth factor BB-induced ERK2 activation. In contrast, DPI only inhibited agonist-induced p38 MAP kinase activation and c-Fos and JunB expression. Antibody supershift assays indicated the presence of c-Fos and JunB in the AP-1 complex formed in response to all three agonists. In addition, cotransfection of VSMC with expression plasmids for c-Fos and members of the Jun family along with the AP-l-dependent reporter gene revealed that AP-1 with c-Fos and JunB composition exhibited a higher transactivating activity than AP-I with other compositions tested. All three agonists significantly stimulated reactive oxygen species production, and this effect was inhibited by both NAC and DPI. Together, these results strongly suggest a role for redox-sensitive mechanisms in agonist-induced ERK2, JNK1, and p38 MAP kinase activation; c-Fos, c-Jun, and JunB expression; AP-1 activity; and DNA synthesis in VSMC. These results also suggest a role for NADH/NADPH oxidase activity in some subset of early signaling events such as p38 MAP kinase activation and c-Fos and JunB induction, which appear to be important in agonist-induced AP-I activity and DNA synthesis in VSMC.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; NCI, NIH, Div Canc Prevent & Control, Rockville, MD 20850 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rao, GN (corresponding author), Univ Texas, Med Branch, Old John Sealy Hosp 4 124B, 301 Univ Blvd,Route 0567, Galveston, TX 77555 USA.	grao@utmb.edu		Madamanchi, Nageswara/0000-0003-0590-0908				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CRAVEN PA, 1986, J CLIN INVEST, V77, P850, DOI 10.1172/JCI112382; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUQUE I, 1993, J PHARMACOL EXP THER, V267, P612; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONDO T, 1992, J BIOL CHEM, V267, P23609; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, ONCOGENE, V13, P713; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; WARNER GL, 1986, CELL IMMUNOL, V101, P425, DOI 10.1016/0008-8749(86)90155-3; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	68	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					6003	6010		10.1074/jbc.274.9.6003	http://dx.doi.org/10.1074/jbc.274.9.6003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026227	hybrid			2022-12-27	WOS:000078804400098
J	Wong, V; Ching, DX; McCrea, PD; Firestone, GL				Wong, V; Ching, DX; McCrea, PD; Firestone, GL			Glucocorticoid down-regulation of fascin protein expression is required for the steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-ALPHA; ADHESION MOLECULE UVOMORULIN; TYROSINE KINASE SUBSTRATE; ACTIN-BUNDLING PROTEINS; BETA-CATENIN COMPLEX; E-CADHERIN; ADHERENS JUNCTIONS; SUPPRESSOR PROTEIN; HORMONE RECEPTORS; MEMBRANE-PROTEIN	Glucocorticoid hormones, which are physiological regulators of mammary epithelium development, induce the formation of tight junctions in rat Con8 mammary epithelial tumor cells. We have discovered that, as part of this process, the synthetic glucocorticoid dexamethasone strongly and reversibly down-regulated the expression of fascin, an actin-bundling protein that also interacts with the adherens junction component beta-catenin, Ectopic constitutive expression of full-length mouse fascin containing a Myc epitope tag (Myc-fascin) in Con8 cells inhibited the dexamethasone stimulation of transepithelial electrical resistance, disrupted the induced localization of the tight junction protein occludin and the adherens junction protein beta-catenin to the cell periphery, and prevented the rearrangement of the actin cytoskeleton, Ectopic expression of either the carboxyl-terminal 213 amino acids of fascin, which includes the actin and beta-catenin-binding sites, or the amino-terminal 313 amino acids of fascin failed to disrupt the glucocorticoid induction of tight junction formation. Mammary tumor cells expressing the full-length Myc-fascin remained generally glucocorticoid responsive and displayed no changes in the levels or protein-protein interactions of junctional proteins or the amount of cytoskeletal associated actin filaments, However, a cell aggregation assay demonstrated that the expression of Myc-fascin abrogated the dexamethasone induction of cell-cell adhesion. Our results implicate the down-regulation of fascin as a key intermediate step that directly links glucocorticoid receptor signaling to the coordinate control of junctional complex formation and cell-cell interactions in mammary tumor epithelial cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Texas System; UTMD Anderson Cancer Center	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; CITI S, 1989, J CELL SCI, V93, P107; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DRENCKHAHN D, 1986, J CELL BIOL, V102, P1843, DOI 10.1083/jcb.102.5.1843; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner B, 1990, CURR OPIN CELL BIOL, V2, P881, DOI 10.1016/0955-0674(90)90087-U; GUMBINER B, 1987, AM J PHYSIOL, V253, P749; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; MADARA JL, 1992, ANN NY ACAD SCI, V664, P47, DOI 10.1111/j.1749-6632.1992.tb39748.x; MADARA JL, 1987, AM J PHYSIOL, V253, P171; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; McCarthy KM, 1996, J CELL SCI, V109, P2287; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; OWARIBE K, 1981, J CELL BIOL, V90, P507, DOI 10.1083/jcb.90.2.507; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P719; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SINGER KL, 1994, J BIOL CHEM, V269, P16108; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; Stevenson BR, 1989, CURR OPIN CELL BIOL, V1, P884, DOI 10.1016/0955-0674(89)90054-9; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHONG Y, 1994, EXP CELL RES, V214, P614, DOI 10.1006/excr.1994.1299; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	86	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5443	5453		10.1074/jbc.274.9.5443	http://dx.doi.org/10.1074/jbc.274.9.5443			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026156	hybrid			2022-12-27	WOS:000078804400027
J	Yamada, K; Duong, DT; Scott, DK; Wang, JC; Granner, DK				Yamada, K; Duong, DT; Scott, DK; Wang, JC; Granner, DK			CCAAT/enhancer-binding protein beta is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SYNERGISTICALLY ACTIVATE TRANSCRIPTION; C/EBP-BETA; DNA-BINDING; GTP GENE; REGULATORY ELEMENT; HEPATOMA-CELLS; NUCLEAR FACTOR; COUP-TF; EXPRESSION	The cyclic AMP response element (CRE) of the rat phosphoenolpyruvate carboxykinase (PEPCK) gene promoter is required for a complete glucocorticoid response. Proteins known to bind the PEPCK CRE include the CRE-binding protein (CREB) and members of the CCAAT/enhancer-binding protein (C/EBP) family We took two different approaches to determine which of these proteins provides the accessory factor activity for the glucocorticoid response from the PEPCK CRE. The first strategy involved replacing the CRE of the PEPCK promoter/chloramphenicol acetyltransferase reporter plasmid (pPL32) with a consensus C/EBP-binding sequence. This construct, termed p Delta CREC/EBP, binds C/EBP alpha and beta but not CREB, yet it confers a nearly complete glucocorticoid response when transiently transfected into H4IIE rat hepatoma cells. These results suggest that one of the C/EBP family members may be the accessory factor. The second strategy involved cotransfecting H4IIE cells with a pPL32 mutant, in which the CRE was replaced with a GAL4-binding sequence (p Delta CREGAL4), and various GAL4 DNA-binding domain (DBD) fusion protein expression vectors. Although chimeric proteins consisting of the GAL4 DBD fused to either CREB or C/EBPa: are able to confer an increase in basal transcription, they do not facilitate the glucocorticoid response. In contrast, a fusion protein consisting of the GAIA DBD and amino acids 1-118 of C/EBP beta provides a significant glucocorticoid response. Additional GAIA fusion studies were done to map the minimal domain of C/EBP beta needed for accessory factor activity to the glucocorticoid response. Chimeric proteins containing amino acid regions 1-84, 52-118, or 85-118 of C/EBP beta fused to the GAL4 DBD do not mediate a glucocorticoid response. We conclude that the amino terminus of C/EBP beta contains a multicomponent domain necessary to confer accessory factor activity to the glucocorticoid response from the CRE of the PEPCK gene promoter.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.		Wang, Jen-Chywan/AAX-4445-2020	Wang, Jen-Chywan/0000-0001-6030-6886	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, P60DK020593, R37DK035107, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM T, 1992, J BIOL CHEM, V267, P5021; ANGRAND PO, 1994, CELL GROWTH DIFFER, V5, P957; BARIK S, 1993, PCR PROTOCOLS CURREN; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crosson SM, 1997, DIABETOLOGIA, V40, P1117, DOI 10.1007/s001250050796; DAY RN, 1989, J BIOL CHEM, V264, P431; FRIEDMAN JE, 1994, AM J PHYSIOL, V266, pE560, DOI 10.1152/ajpendo.1994.266.4.E560; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Osada S, 1996, J BIOL CHEM, V271, P3891; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; TEBBEY PW, 1995, BIOCHEM BIOPH RES CO, V215, P1006, DOI 10.1006/bbrc.1995.2564; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x	51	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5880	5887		10.1074/jbc.274.9.5880	http://dx.doi.org/10.1074/jbc.274.9.5880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026211	hybrid			2022-12-27	WOS:000078804400082
J	Griner, RD; Qin, F; Jung, EM; Sue-Ling, CK; Crawford, KB; Mann-Blakeney, R; Bollag, RJ; Bollag, WB				Griner, RD; Qin, F; Jung, EM; Sue-Ling, CK; Crawford, KB; Mann-Blakeney, R; Bollag, RJ; Bollag, WB			1,25-dihydroxyvitamin D-3 induces phospholipase D-1 expression in primary mouse epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; RAT-BRAIN; VITAMIN-D; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PHOSPHOINOSITIDE TURNOVER; TERMINAL DIFFERENTIATION; CELLS; CALCIUM; CLONING	The hormone 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) elicits the programmed pattern of differentiation in epidermal keratinocytes. Based on data indicating a potential role of phospholipase D (PLD) in mediating keratinocyte differentiation, we investigated the effect of 1,25(OH),D, on PLD expression, A 24-h exposure to 1,25(OH)(2)D-3 stimulated PLD-1, but not PLD-2, mRNA expression. This 1,25(OH)(2)D-3-enhanced expression was accompanied by increased total PLD and PLD-1 activity. Time course studies indicated that 1,25(OH)(2)D-3 induced PLD-1 expression by 8 h, with a maximal increase at 20-24 h. Exposure to 1,25(OH)(2)D-3 inhibited proliferation over the same time period with similar kinetics. Expression of the early (spinous) differentiation marker keratin 1 decreased in response to 1,25(OH)(2)D-3 over 12-24 h, Treatment with 1,25(OH)(2)D-3 enhanced the activity of transglutaminase, a late (granular) differentiation marker, by 12 h with a maximal increase after 24 h. In situ hybridization studies demonstrated that the highest levels of PLD-1 expression are in the more differentiated (spinous and granular) layers of the epidermis, with little expression in basal keratinocytes. Our results suggest a role for PLD expression/activity during keratinocyte differentiation.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med Dermatol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Bollag, WB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med & Cellular Biol & Anat, 1120 15th St, Augusta, GA 30912 USA.			Bollag, Wendy/0000-0003-3146-162X	NIAMS NIH HHS [AR45212] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR045212, R01AR045212] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERTHJONES J, 1992, BRIT J DERMATOL, V127, P71, DOI 10.1111/j.1365-2133.1992.tb08035.x; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BIKLE DD, 1995, J NUTR, V125, pS1709; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; Bollag W B, 1998, Methods Mol Biol, V105, P151; BOLLAG WB, 1991, ENDOCRINOLOGY, V128, P231, DOI 10.1210/endo-128-1-231; BOLLAG WB, 1995, J CELL PHYSIOL, V163, P248, DOI 10.1002/jcp.1041630205; CHANG PL, 1994, ENDOCRINOLOGY, V135, P863, DOI 10.1210/en.135.3.863; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; Geilen GC, 1997, J BIOL CHEM, V272, P8997, DOI 10.1074/jbc.272.14.8997; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HANAFIN NM, 1995, J CELL BIOCHEM, V57, P362, DOI 10.1002/jcb.240570220; Inohara S, 1992, Exp Dermatol, V1, P207, DOI 10.1111/j.1600-0625.1992.tb00079.x; Iwasaki-Bessho Y, 1998, J INVEST DERMATOL, V110, P376; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; JOHNSON RM, 1992, SEC MESS PHOSPHOPROT, V14, P21; Jung EM, 1998, J INVEST DERMATOL, V110, P318, DOI 10.1046/j.1523-1747.1998.00137.x; KIM HJ, 1992, J CELL PHYSIOL, V151, P579, DOI 10.1002/jcp.1041510318; Kodaki T, 1997, J BIOL CHEM, V272, P11408; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LU B, 1994, J BIOL CHEM, V269, P7443; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohguchi K, 1997, J BIOL CHEM, V272, P1990, DOI 10.1074/jbc.272.3.1990; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; SEISHIMA M, 1995, J INVEST DERMATOL, V104, P835, DOI 10.1111/1523-1747.ep12607015; SREEKUMAR P, 1995, J CLIN INVEST, V96, P602, DOI 10.1172/JCI118075; SU MJ, 1994, J BIOL CHEM, V269, P14723; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TALWAR HS, 1990, J INVEST DERMATOL, V95, P705, DOI 10.1111/1523-1747.ep12514507; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2; YADA Y, 1991, BIOCHEM J, V279, P665, DOI 10.1042/bj2790665; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201; YUSPA SH, 1990, UCLA SYM BI, V124, P211; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	46	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4663	4670		10.1074/jbc.274.8.4663	http://dx.doi.org/10.1074/jbc.274.8.4663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988703	hybrid			2022-12-27	WOS:000078698200028
J	Hirabayashi, T; Kume, K; Hirose, K; Yokomizo, T; Iino, M; Itoh, H; Shimizu, T				Hirabayashi, T; Kume, K; Hirose, K; Yokomizo, T; Iino, M; Itoh, H; Shimizu, T			Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; NUCLEAR-ENVELOPE; FACTOR RECEPTOR; SUBCELLULAR-LOCALIZATION; PROTEIN-KINASE; MAP KINASE; CALCIUM; PHOSPHORYLATION; CELLS; EXPRESSION	When cells are exposed to certain external stimuli, arachidonic acid (AA) is released from the membrane and serves as a precursor of various types of eicosanoids. A Ca2+-regulated cytosolic phospholipase A(2) (cPLA(2)) plays a dominant role in the release of AA. To closely examine the relation between Ca2+ response and AA release by stimulation of G protein-coupled receptors, we established several lines of Chinese hamster ovary cells expressing platelet-activating factor receptor or leukotriene B-4 receptor. Measurement of intracellular Ca2+ concentration ([Ca2+](i)) demonstrated that cell lines capable of releasing AA. elicited a sustained [Ca2+](i) increase when stimulated by agonists. The prolonged [Ca2+](i) elevation is the result of Ca2+ entry, because this elevation was blocked by EGTA treatment or in the presence of Ca2+ channel blockers (SKF 96365 and methoxyverapamil). cPLA(2) fused with a green fluorescent protein (cPLA(2)-GFP) translocated from the cytosol to the perinuclear region in response to increases in [Ca2+](i). When EGTA was added shortly after [Ca2+](i) increase, the cPLA(2)-GFP returned to the cytosol, without liberating AA. After a prolonged [Ca2+](i) increase, even by EGTA treatment, the enzyme was not readily redistributed to the cytosol. Thus, we propose that a critical time length of [Ca2+](i) elevation is required for continuous membrane localization and full activation of cPLA(2).	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	University of Tokyo; University of Tokyo; Tokyo Institute of Technology	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		; Yokomizo, Takehiko/P-5673-2016	Hirabayashi, Tetsuya/0000-0001-8099-5367; Kume, Kazuhiko/0000-0003-4232-1657; Yokomizo, Takehiko/0000-0002-5219-1553				Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KLEY N, 1987, J BIOL CHEM, V262, P4083; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Miyakawa T, 1998, BIOCHEM J, V329, P107, DOI 10.1042/bj3290107; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; TAKANO T, 1994, J BIOL CHEM, V269, P22453; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VIAL D, 1995, J NEUROCHEM, V64, P2765; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; XU XX, 1994, J BIOL CHEM, V269, P31693; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	44	147	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5163	5169		10.1074/jbc.274.8.5163	http://dx.doi.org/10.1074/jbc.274.8.5163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988766	hybrid			2022-12-27	WOS:000078698200091
J	Picard, V; Marque, PE; Paolucci, F; Aiach, M; Le Bonniec, BF				Picard, V; Marque, PE; Paolucci, F; Aiach, M; Le Bonniec, BF			Topology of the stable serpin-protease complexes revealed by an autoantibody that fails to react with the monomeric conformers of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CENTER LOOP; CRYSTAL-STRUCTURE; BETA-SHEET; BOND LOOP; CONFORMATIONAL-CHANGES; HEPARIN-BINDING; C1 INHIBITOR; SITE LOOP; ALPHA-1-PROTEINASE INHIBITOR	Solving the structure of the stable complex between a serine protease inhibitor (serpin) and its target has been a long standing goal. We describe herein the characterization of a monoclonal antibody that selectively recognizes antithrombin in complex with either thrombin, factor Xa, or a synthetic peptide corresponding to residues P-14 to P-9 of the serpin's reactive center loop (RCL, ultimately cleaved between the P-1 and P'(1) residues), Accordingly, this antibody reacts with none of the monomeric conformers of antithrombin (native, latent, and RCL-cleaved) and does not recognize heparin-activated antithrombin or antithrombin bound to a non-catalytic mutant of thrombin (S195A, in which the serine of the charge stabilizing system has been swapped for alanine). The neoepitope encompasses the motif DAFHX, located in native antithrombin on strand 4 of beta-sheet A, which becomes strand 5 of beta-sheet A in the RCL-cleaved and latent conformers. The inferences on the structure of the antithrombin-protease stable complex are that either a major remodeling of antithrombin accompanies the final elaboration of the complex or that, within the complex, at the most residues P-14 to P-9 of the RCL are inserted into beta-sheet A. These conclusions limit drastically the possible locations of the defeated protease within the complex.	Univ Paris 05, Fac Pharm, INSERM, U428, F-75270 Paris 06, France; Sanofi Res, F-34000 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis	Le Bonniec, BF (corresponding author), Univ Paris 05, Fac Pharm, INSERM, U428, 4 Av Observ, F-75270 Paris 06, France.		Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363				ASAKURA S, 1990, J BIOL CHEM, V265, P5135; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1992, J BIOL CHEM, V267, P19047; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Fitton HL, 1997, BIOL CHEM, V378, P1059; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kjoller L, 1996, EUR J BIOCHEM, V241, P38, DOI 10.1111/j.1432-1033.1996.0038t.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; Nordling K, 1996, BIOCHEMISTRY-US, V35, P10436, DOI 10.1021/bi9603579; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Song HK, 1995, FEBS LETT, V377, P150; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Zahedi R, 1996, J BIOL CHEM, V271, P24307, DOI 10.1074/jbc.271.39.24307	63	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4586	4593		10.1074/jbc.274.8.4586	http://dx.doi.org/10.1074/jbc.274.8.4586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988693	hybrid			2022-12-27	WOS:000078698200018
J	Sun, XM; MacFarlane, M; Zhuang, JG; Wolf, BB; Green, DR; Cohen, GM				Sun, XM; MacFarlane, M; Zhuang, JG; Wolf, BB; Green, DR; Cohen, GM			Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-LIKE PROTEASES; INDUCED CELL-DEATH; CYTOCHROME-C; SIGNALING COMPLEX; BCL-2; MITOCHONDRIA; INVOLVEMENT; ACTIVATION; PATHWAY; RELEASE	Release of cytochrome c is important in many forms of apoptosis. Recent studies of CD95 (Fas/APO-1)-induced apoptosis have implicated caspase-8 cleavage of Bid, a BH3 domain-containing proapoptotic member of the Bcl-2 family, in this release. We now demonstrate that both receptor-induced (CD95 and tumor necrosis factor) and chemical-induced apoptosis result in a similar time-dependent activation of caspases-3, -7, -8, and -9 in Jurkat T cells and human leukemic U937 cells. In receptor-mediated apoptosis, the caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone (Z-VAD.FMK), inhibits apoptosis prior to commitment to cell, death by inhibiting the upstream activator caspase-8, cleavage of Bid, release of mitochondrial cytochrome c, processing of effector caspases, loss of mitochondrial membrane potential, and externalization of phosphatidylserine, However, Z-VAD.FMK inhibits chemical-induced apoptosis at a stage after commitment to cell death by inhibiting the initiator caspase-9 and the resultant postmitochondrial activation of effector caspases. Cleavage of Bid but not release of cytochrome c is blocked by Z-VAD.FMK demonstrating that in chemical-induced apoptosis cytochrome c release is caspase-independent and is not mediated by activation of Bid. We propose that caspases form an integral part of the cell death-inducing mechanism in receptor-mediated apoptosis, whereas in chemical-induced apoptosis they act solely as executioners of apoptosis.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	University of Leicester; La Jolla Institute for Immunology	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Green, Douglas R/N-8083-2018; Cohen, Gerald M/A-1687-2008	Green, Douglas R/0000-0002-7332-1417; Zhuang, Jianguo/0000-0003-3245-0789				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	770	787	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5053	5060		10.1074/jbc.274.8.5053	http://dx.doi.org/10.1074/jbc.274.8.5053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988752	hybrid			2022-12-27	WOS:000078698200077
J	Benov, L; Fridovich, I				Benov, L; Fridovich, I			Why superoxide imposes an aromatic amino acid auxotrophy on Escherichia coli - The transketolase connection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDRATASE; ENZYME; INACTIVATION; DISMUTASE; MUTANTS; 7-PHOSPHATE; CLUSTER; STRESS	The lack of superoxide dismutase and the consequent elevation of [O-2(-)] imposes, on Escherichia coli, auxotrophies far branched chain, sulfur-containing, and aromatic amino acids. The former two classes of auxotrophies have already been explained, whereas the third is explained herein. Thus O-2(-) is shown to interfere with the production of erythrose-4-phosphate, which is essential for the first step of the aromatic biosynthetic pathway. It does so by oxidizing the 1,2-dihydroxyethyl thiamine pyrophosphate; intermediate of transketolase and inactivating this enzyme.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				ASAMI S, 1977, BIOCHEMISTRY-US, V16, P2202, DOI 10.1021/bi00629a025; Benov L, 1998, J BIOL CHEM, V273, P25741, DOI 10.1074/jbc.273.40.25741; Benov L, 1998, J BIOL CHEM, V273, P10313, DOI 10.1074/jbc.273.17.10313; Benov L, 1996, J BIOL CHEM, V271, P21037, DOI 10.1074/jbc.271.35.21037; Benov L, 1997, ARCH BIOCHEM BIOPHYS, V347, P271, DOI 10.1006/abbi.1997.0343; BLACKMORE PF, 1976, FEBS LETT, V64, P222, DOI 10.1016/0014-5793(76)80288-8; BROWN OR, 1995, ARCH BIOCHEM BIOPHYS, V319, P10, DOI 10.1006/abbi.1995.1262; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P315; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P320; CREWE R, 1966, BIOCH PREP, V11, P21; DATTA AG, 1961, J BIOL CHEM, V236, P617; DRATHS KM, 1992, J AM CHEM SOC, V114, P3956, DOI 10.1021/ja00036a050; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; FROST JW, 1984, BIOCHEMISTRY-US, V23, P4465, DOI 10.1021/bi00314a035; HASLAN E, 1987, METHOD ENZYMOL, V142, P498; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; JOSEPHSON BL, 1974, J BACTERIOL, V118, P1082, DOI 10.1128/JB.118.3.1082-1089.1974; KUO CF, 1987, J BIOL CHEM, V262, P4724; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; Maniatis T, 1982, MOL CLONING LABORATO, P68; MEHDI S, 1987, METHOD ENZYMOL, V142, P306; PAOLETTI F, 1979, ANAL BIOCHEM, V95, P250, DOI 10.1016/0003-2697(79)90213-6; SCHONER R, 1976, J BIOL CHEM, V251, P5440; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; TAKABE T, 1980, BIOCHEMISTRY-US, V19, P3985, DOI 10.1021/bi00558a015; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; TRIBE DE, 1976, J BACTERIOL, V127, P1085, DOI 10.1128/JB.127.3.1085-1097.1976; WILLIAMS JF, 1980, INT J BIOCHEM, V12, P339, DOI 10.1016/0020-711X(80)90112-3	31	55	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4202	4206		10.1074/jbc.274.7.4202	http://dx.doi.org/10.1074/jbc.274.7.4202			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933617	hybrid			2022-12-27	WOS:000078575500041
J	Bozue, JA; Tullius, MV; Wang, J; Gibson, BW; Munson, RS				Bozue, JA; Tullius, MV; Wang, J; Gibson, BW; Munson, RS			Haemophilus ducreyi produces a novel sialyltransferase - Identification of the sialyltransferase gene and construction of mutants deficient in the production of the sialic acid-containing glycoform of the lipooligosaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FORESKIN FIBROBLASTS; GENITAL ULCER DISEASE; NEISSERIA-GONORRHOEAE; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE BIOSYNTHESIS; MONOCLONAL-ANTIBODIES; HEMOPHILUS-INFLUENZAE; MUCOSAL PATHOGENS; MASS-SPECTROMETRY; HUMAN NEUTROPHILS	Haemophilus ducreyi, the cause of the sexually transmitted disease chancroid produces a lipooligosaccharide (LOS) containing a terminal sialyl N-acetyllactosamine trisaccharide, Previously, we reported the identification and characterization of the N-acetylneuraminic acid cytidylsynthetase gene (neuA), Forty-nine base pairs downstream of the synthetase gene is an open reading frame (ORF) encoding a protein with a predicted molecular weight of 34,646, This protein has weak homology to the polysialyltransferase of Escherichia colt K92, Downstream of this ORF is the gene encoding the H, ducreyi homologue of the Salmonella typhimurium rmlB gene. Mutations were constructed in the neuA gene and the gene encoding the second ORF by insertion of an Omega kanamycin cassette, and isogenic strains were constructed. LOS was isolated from each strain and characterized by SDS-polyacrylamide gel electrophoresis, carbohydrate, and mass spectrometric analysis, LOS isolated from strains containing a mutation in neuA or in the second ORF, designated Ist, lacked the sialic acid-containing glycoform, Complementation studies were performed, The neuA gene and the ist gene were each cloned into the shuttle vector pLS88 after polymerase chain reaction amplification. Complementation of the mutation in the ist gene was observed, but we were unable to complement the neuA mutation, Since it is possible that transcription of the neuA gene and the Ist gene were coupled, we constructed a nonpolar mutation in the neuA gene, in this construct, the neuA mutation was complemented, suggesting transcriptional coupling of the neuA gene and the ist gene, Sialyltransferase activity was detected by incorporation of C-14-labeled NeuAc from CMP-NeuAc into trichloroacetic acid-precipitable material when the Ist gene was overexpressed in the nonpolar neuA mutant. We conclude that the Ist gene encodes the H, ducreyi sialyltransferase, Since the Ist gene product has little, if any, structural relationship to other sialyltransferases, this protein represents a new class of sialyltransferase.	Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; Ohio State Univ, Dept Med Microbiol, Columbus, OH 43205 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California San Francisco	Munson, RS (corresponding author), Childrens Hosp Res Fdn, 700 Childrens Dr,Room W402, Columbus, OH 43205 USA.	munsonr@pediatrics.ohio-state.edu	Bozue, Joel/AAE-4363-2022; Munson, Jr, Robert/E-3710-2011; Bozue, Joel/AAE-4357-2022	Bozue, Joel/0000-0001-6959-8176; Munson, Jr, Robert/0000-0002-3204-3019; Bozue, Joel/0000-0001-6959-8176	NIAID NIH HHS [AI31254, AI34967, AI38444] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038444, R01AI031254, R01AI034967] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABECK D, 1992, INT J STD AIDS, V3, P319, DOI 10.1177/095646249200300503; Ahmed HJ, 1997, INFECT IMMUN, V65, P3151, DOI 10.1128/IAI.65.8.3151-3158.1997; Alfa MJ, 1997, MICROB PATHOGENESIS, V22, P39, DOI 10.1006/mpat.1996.0089; Alfa MJ, 1996, INFECT IMMUN, V64, P2349, DOI 10.1128/IAI.64.6.2349-2352.1996; APICELLA MA, 1994, METHOD ENZYMOL, V235, P242; APICELLA MA, 1990, J INFECT DIS, V162, P506, DOI 10.1093/infdis/162.2.506; BARCAK GJ, 1991, METHOD ENZYMOL, V204, P321; BITTERSUERMANN D, 1993, POLYSIALIC ACID MICR, P11; Bozue JA, 1998, FEMS MICROBIOL LETT, V164, P269, DOI 10.1111/j.1574-6968.1998.tb13097.x; CAMPAGNARI AA, 1994, INFECT IMMUN, V62, P2379, DOI 10.1128/IAI.62.6.2379-2386.1994; CAMPAGNARI AA, 1990, MICROB PATHOGENESIS, V8, P353, DOI 10.1016/0882-4010(90)90094-7; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; Cope LD, 1997, P NATL ACAD SCI USA, V94, P4056, DOI 10.1073/pnas.94.8.4056; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON LG, 1994, PLASMID, V32, P228, DOI 10.1006/plas.1994.1060; FLOOD JM, 1993, J INFECT DIS, V167, P1106, DOI 10.1093/infdis/167.5.1106; FOX AJ, 1989, MICROB PATHOGENESIS, V7, P317, DOI 10.1016/0882-4010(89)90050-8; Gibson BW, 1997, J BACTERIOL, V179, P5062, DOI 10.1128/jb.179.16.5062-5071.1997; Gibson BW, 1997, J AM SOC MASS SPECTR, V8, P645, DOI 10.1016/S1044-0305(97)00042-1; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; HAMMERSCHMIDT S, 1994, MOL MICROBIOL, V11, P885, DOI 10.1111/j.1365-2958.1994.tb00367.x; HAMMOND GW, 1978, ANTIMICROB AGENTS CH, V13, P608, DOI 10.1128/AAC.13.4.608; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; INZANA TJ, 1983, J INFECT DIS, V148, P492, DOI 10.1093/infdis/148.3.492; Jann K., 1985, The virulence of Escherichia coli, P157; JENNINGS HJ, 1984, PURE APPL CHEM, V56, P893, DOI 10.1351/pac198456070893; JESSAMINE PG, 1990, MED CLIN N AM, V74, P1417, DOI 10.1016/S0025-7125(16)30488-6; JOHNSON KG, 1976, CAN J MICROBIOL, V22, P29, DOI 10.1139/m76-004; KIM JJ, 1992, INFECT IMMUN, V60, P4439, DOI 10.1128/IAI.60.10.4439-4442.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGERGARD T, 1992, MICROB PATHOGENESIS, V13, P203, DOI 10.1016/0882-4010(92)90021-F; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; Maniatis T., 1982, MOL CLONING; McGee DJ, 1996, INFECT IMMUN, V64, P4129, DOI 10.1128/IAI.64.10.4129-4136.1996; Melaugh W, 1996, J BACTERIOL, V178, P564, DOI 10.1128/jb.178.2.564-570.1996; MELAUGH W, 1994, BIOCHEMISTRY-US, V33, P13070, DOI 10.1021/bi00248a016; MENARD R, 1993, J BACTERIOL, V175, P5899; MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137, DOI 10.1128/CMR.2.2.137-157.1989; Munoz P, 1997, ARCH INTERN MED, V157, P213, DOI 10.1001/archinte.157.2.213; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; REST RF, 1992, INFECT IMMUN, V60, P989, DOI 10.1128/IAI.60.3.989-997.1992; REUTER G, 1994, METHOD ENZYMOL, V230, P168; RICE PA, 1987, A VAN LEEUW J MICROB, V53, P565, DOI 10.1007/BF00415518; RICE PA, 1977, J CLIN INVEST, V60, P1149, DOI 10.1172/JCI108867; ROBERTSON BD, 1994, J BACTERIOL, V176, P6915, DOI 10.1128/JB.176.22.6915-6920.1994; ROMANA LK, 1991, BIOCHEM BIOPH RES CO, V174, P846, DOI 10.1016/0006-291X(91)91495-X; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; SCHOOLNIK GK, 1976, J CLIN INVEST, V58, P1163, DOI 10.1172/JCI108569; SCHULTE J M, 1992, Morbidity and Mortality Weekly Report, V41, P57; SCHWEDA EKH, 1995, J BACTERIOL, V177, P5316, DOI 10.1128/jb.177.18.5316-5321.1995; SCHWEDA EKH, 1994, J BIOL CHEM, V269, P12040; SHAW DJ, 1982, J BACTERIOL, V152, P1132; SMITH H, 1992, FEMS MICROBIOL LETT, V100, P287, DOI 10.1016/0378-1097(92)90223-B; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; Spinola SM, 1996, J INFECT DIS, V173, P394, DOI 10.1093/infdis/173.2.394; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; SWANSON J, 1991, NEISSERIAE 1990, P391; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; TIMMIS KN, 1985, CURR TOP MICROBIOL, V118, P197; TREES DL, 1995, CLIN MICROBIOL REV, V8, P357, DOI 10.1128/CMR.8.3.357; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TUFFREY M, 1990, J EXP PATHOL, V71, P233; Tullius MV, 1996, J BIOL CHEM, V271, P15373, DOI 10.1074/jbc.271.26.15373; VANPUTTEN JPM, 1995, MOL MICROBIOL, V16, P847; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; Vogel U, 1997, MED MICROBIOL IMMUN, V186, P159, DOI 10.1007/s004300050059; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	76	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4106	4114		10.1074/jbc.274.7.4106	http://dx.doi.org/10.1074/jbc.274.7.4106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933604	hybrid			2022-12-27	WOS:000078575500028
J	Chrisman, TD; Garbers, DL				Chrisman, TD; Garbers, DL			Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; NITRIC-OXIDE; CLEARANCE RECEPTOR; MESANGIAL CELLS; CYCLIC-GMP; INHIBITION; MECHANISM; CYCLASE	The fibroblast, a cell central to effective wound remodeling, not only contains various growth factor receptors but also high activities of a guanylyl cyclase receptor (GC-B), Here we demonstrate that marked elevations of cyclic GMP induced by C-type natriuretic peptide (CNP), the ligand of GC-B, blocks activation of the mitogen-activated protein kinase cascade in fibroblasts. We also show that platelet-derived growth factor, fibroblast growth factor, serum, or Na3VO4 rapidly (within 5 min) and extensively (up to 85% inhibition) disrupt CNP-dependent elevations of cyclic GMP. In addition, the mitogens also lower cyclic GMP concentrations (50% decrease) in cells not treated with CNP. Cytoplasmic forms of guanylyl cyclase, in contrast to the CNP-stimulated pathway, are not antagonized by the various mitogens, The effects of the mitogens on cellular cyclic GMP are fully explained by a direct and stable inactivation of GC-B. Homogenates obtained from fibroblasts treated with or without the various mitogens contain equivalent amounts of GC-B protein, but both ligand-dependent and ligand-independent activity are markedly (up to 90% inhibition of CNP-dependent activity) decreased after mitogen addition. The stable inactivation is correlated with the dephosphorylation of phosphoserine and phosphothreonine residues of the cyclase receptor. These results not only establish a specific and reciprocal antagonistic relationship between mitogen-activated and GC-B-regulated signaling pathways in the fibroblast but also suggest that one of the earliest events following mitogen activation of a fibroblast is an interruption of cyclic GMP production from this receptor.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75325 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chrisman, TD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75325 USA.	Ted.Chrisman@email.swmed.edu						APPEL RG, 1990, AM J PHYSIOL, V259, pE312, DOI 10.1152/ajpendo.1990.259.3.E312; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; Diegelmann RF, 1997, J UROLOGY, V157, P298, DOI 10.1016/S0022-5347(01)65364-3; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; GARG UC, 1991, J BIOL CHEM, V266, P9; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; GRAINGER DJ, 1995, CLIN CHIM ACTA, V235, P11, DOI 10.1016/0009-8981(94)05995-4; Haneda M, 1996, KIDNEY INT, V50, P384, DOI 10.1038/ki.1996.327; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hutchinson HG, 1997, CARDIOVASC RES, V35, P158, DOI 10.1016/S0008-6363(97)00086-2; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; Kohno M, 1997, CIRC RES, V81, P585, DOI 10.1161/01.RES.81.4.585; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MEYERINGOLD W, 1995, CELL BIOL INT, V19, P389, DOI 10.1006/cbir.1995.1084; NESBITT JA, 1976, J BIOL CHEM, V251, P2344; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; SUGIMOTO T, 1993, BIOCHEM BIOPH RES CO, V195, P72, DOI 10.1006/bbrc.1993.2011; SUZUKI R, 1992, J ENDOCRINOL, V135, P317, DOI 10.1677/joe.0.1350317; Takizawa T, 1997, HYPERTENSION, V30, P1035, DOI 10.1161/01.HYP.30.5.1035; TAWARAGI Y, 1991, BIOCHEM BIOPH RES CO, V175, P645, DOI 10.1016/0006-291X(91)91614-I; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; YU SM, 1997, CIRCULATION, V95, P1296; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	39	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4293	4299		10.1074/jbc.274.7.4293	http://dx.doi.org/10.1074/jbc.274.7.4293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933630	hybrid			2022-12-27	WOS:000078575500054
J	Shriver, Z; Liu, DF; Hu, Y; Sasisekharan, R				Shriver, Z; Liu, DF; Hu, Y; Sasisekharan, R			Biochemical investigations and mapping of the calcium-binding sites of heparinase I from Flavobacterium heparinum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOODWARDS-REAGENT-K; CHEMICAL MODIFICATION; DIRECTED MUTAGENESIS; HISTIDINE RESIDUE; ESCHERICHIA-COLI; GLYCOSAMINOGLYCANS; PROTEINS; PURIFICATION; LANTHANIDES; CATALYSIS	The heparinases from Flavobacterium heparinum are lyases that specifically cleave heparin-like glycosaminoglycans, Previously, amino acids located in the active site of heparinase I have been identified and mapped. In an effort to further understand the mechanism by which heparinase I cleaves its polymer substrate, we sought to understand the role of calcium, as a necessary cofactor, in the enzymatic activity of heparinase I, Specifically, we undertook a series of biochemical and biophysical experiments to answer the question of whether heparinase I binds to calcium and, if so, which regions of the protein are involved in calcium binding. Using the fluorescent calcium analog terbium, we found that heparinase I tightly bound divalent and trivalent cations, Furthermore, we established that this interaction was specific for ions that closely approximate the ionic radius of calcium. Through the use of the modification reagents N-ethyl-5-phenylisoxazolium-3'-sulfonate (Woodward's reagent K) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, we showed that the interaction between heparinase I and calcium was essential for proper functioning of the enzyme. Preincubation with either calcium alone or calcium in the presence of heparin was able to protect the enzyme from inactivation by these modifying reagents. In addition, through mapping studies of Woodward's reagent K-modified heparinase I, we identified two putative calcium-binding sites, CB-1 (Glu(207)-Ala(219)) and CB-2 (Thr(373)-Arg(384)), in heparinase I that not only are specifically modified by Woodward's reagent K, leading to loss of enzymatic activity, but also conform to the calcium-coordinating consensus motif.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 16-561,77 Massachusetts Ave, Cambridge, MA 02139 USA.	ramnat@mit.edu			NIGMS NIH HHS [GM 57073] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073, R37GM057073] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRAUD C, 1988, INT J BIOL MACROMOL, V10, P2, DOI 10.1016/0141-8130(88)90059-1; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; Bustos P, 1996, J PROTEIN CHEM, V15, P467, DOI 10.1007/BF01886854; CHAUTHAIWALE J, 1994, BBA-PROTEIN STRUCT M, V1204, P164, DOI 10.1016/0167-4838(94)90004-3; DEJERSEY J, 1980, ARCH BIOCHEM BIOPHYS, V205, P536, DOI 10.1016/0003-9861(80)90136-8; EPSTEIN M, 1974, BIOCHEMISTRY-US, V13, P1777, DOI 10.1021/bi00705a034; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Evans C.H, 2013, BIOCH LANTHANIDES, V8; GABRIEL DA, 1989, AM J MED SCI, V298, P8, DOI 10.1097/00000441-198907000-00002; Godavarti R, 1998, J BIOL CHEM, V273, P248, DOI 10.1074/jbc.273.1.248; Godavarti R, 1996, BIOCHEMISTRY-US, V35, P6846, DOI 10.1021/bi960356g; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KERESZTESSY Z, 1994, ARCH BIOCHEM BIOPHYS, V314, P142, DOI 10.1006/abbi.1994.1422; KOMISSAROV AA, 1995, J BIOL CHEM, V270, P10050, DOI 10.1074/jbc.270.17.10050; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KUIMOV AN, 1988, ANAL BIOCHEM, V172, P56, DOI 10.1016/0003-2697(88)90411-3; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Liu DF, 1999, J BIOL CHEM, V274, P4089, DOI 10.1074/jbc.274.7.4089; LLAMAS K, 1986, J AM CHEM SOC, V108, P5543, DOI 10.1021/ja00278a030; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Lyle S.J., 1963, TALANTA, V10, P1177, DOI [DOI 10.1016/0039-9140(63)80170-8, 10.1016/0039-9140(63)80170-8]; MARALIHALLI GB, 1993, J PROTEIN CHEM, V12, P451, DOI 10.1007/BF01025045; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Raser KJ, 1996, BBA-PROTEIN STRUCT M, V1292, P9, DOI 10.1016/0167-4838(95)00170-0; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; SASISEKHARAN R, 1995, BIOCHEMISTRY-US, V34, P14441, DOI 10.1021/bi00044a022; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; YANG VC, 1985, J BIOL CHEM, V260, P1849	33	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4082	4088		10.1074/jbc.274.7.4082	http://dx.doi.org/10.1074/jbc.274.7.4082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933601	hybrid			2022-12-27	WOS:000078575500025
J	Faure, S; Vigneron, S; Galas, S; Brassac, T; Delsert, C; Morin, N				Faure, S; Vigneron, S; Galas, S; Brassac, T; Delsert, C; Morin, N			Control of G(2)/M transition in Xenopus by a member of the p21-activated kinase (PAK) family: A link between protein kinase a and PAK signaling pathways?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; OOCYTE MATURATION; MAP KINASE; MEIOTIC MATURATION; CYCLIN-B; ONCOGENE PRODUCT; EGG EXTRACTS; ACTIVATION; MOS; INITIATION	X-PAKs are involved in negative control of the process of oocyte maturation in Xenopus (1), In the present study, we define more precisely the events targetted by the kinase in the inhibition of the G(2)/M transition. We show that microinjection of recombinant X-PAK1-Cter active kinase into progesterone-treated oocytes prevents c-Mos accumulation and activation of both MAPK and maturation-promoting factor (MPF), In conditions permissive for MAPK activation, MPF activation still fails. We demonstrate that a constitutive truncated version of X-PAK1 (X-PAK1-Cter) does not prevent the association of cyclin B with p34(cdc2) but rather prevents the activation of the inactive complexes present in the oocyte. Proteins participating in the MPF amplification loop, including the Cdc25-activating Polo-like kinase are all blocked. Indeed, using active MPF, the amplification loop is not turned on in the presence of X-PAK1. Our results indicate that X-PAK and protein kinase A targets in the control of oocyte maturation are similar and furthermore that this negative regulation is not restricted to meiosis, because we demonstrate that G(2)/M progression is also prevented in Xenopus cycling extracts in the presence of active X-PAK1.	Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; IFREMER, F-17390 La Tremblade, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Ifremer	Morin, N (corresponding author), Ctr Rech Biochim Macromol, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	morin@crbm.cnrs-mop.fr	Galas, Simon/X-1312-2019; FAURE, Sandrine/N-6506-2018	Galas, Simon/0000-0002-1717-1266; FAURE, Sandrine/0000-0002-8902-8274; Morin, Nathalie/0000-0001-8677-1401				Abrieu A, 1998, J CELL SCI, V111, P1751; Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Faure S, 1998, ONCOGENE, V17, P1215, DOI 10.1038/sj.onc.1202056; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; Keryer G, 1998, J BIOL CHEM, V273, P34594, DOI 10.1074/jbc.273.51.34594; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V201, P291; LEBERER E, 1997, CURR OPIN GENE DEV, V7, P162; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MACKNIGHT GS, 1991, CURR OPIN CELL BIOL, V3, P213; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALLER JL, 1977, J BIOL CHEM, V252, P1712; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murakami MS, 1998, DEVELOPMENT, V125, P237; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	49	31	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3573	3579		10.1074/jbc.274.6.3573	http://dx.doi.org/10.1074/jbc.274.6.3573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920904	hybrid			2022-12-27	WOS:000078428200044
J	Hu, WM; Bellone, CJ; Baldassare, JJ				Hu, WM; Bellone, CJ; Baldassare, JJ			RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; FIBROBLAST CELL-CYCLE; CDK INHIBITOR; RAS TRANSFORMATION; GROWTH-FACTOR; GENE-PRODUCT; G(1) PHASE; 3T3 CELLS; TGF-BETA; PROTEIN	RhoA has been identified as an important regulator of cell proliferation. We recently showed that the Ras/RhoA pathway regulates the degradation of p27(Kip) and the progression of Chinese hamster embryo fibroblasts (IIC9 cells) through G(1) into S phase (Weber, J. D., Hu, W., Jefcoat, S. C., Raben, D. M., and Baldassare, J. J. (1997) J. Biol. Chem, 272, 32966-32971). In this report, we have demonstrated that, in IIC9 cells, RhoA regulates cyclin E/CDK2 activity, which is required for p27(Kip) degradation. As previously shown in several fibroblasts cell lines, expression of dominant-negative CDK2 in IIC9 cells blocked serum-induced cyclin E/CDK2 activity and p27(Kip) degradation. In the absence of serum, expression of constitutively active RhoA(63) resulted in significant stimulation of cyclin E/CDK2 activity and degradation of p27(Kip). Cotransfection of dominant-negative CDK2 and RhoA(63) inhibited RhoA(63)-induced cyclin E/CDK2 activity and p27(Kip) degradation. In addition, expression of dominant-negative RhoA blocked serum-induced cyclin E/CDK2 activity and p27(Kip) degradation. Finally, expression of catalytically active cyclin E/CDK2 rescued the effect of expression of dominant-negative RhoA, Taken together, these data show that RhoA regulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63110 USA.				NIDDK NIH HHS [R01 DK46814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Geng Y, 1996, ONCOGENE, V12, P1173; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirai A, 1997, J BIOL CHEM, V272, P13; KATO J, 1993, GENE DEV, V7, P331; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	36	105	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3396	3401		10.1074/jbc.274.6.3396	http://dx.doi.org/10.1074/jbc.274.6.3396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920882	hybrid			2022-12-27	WOS:000078428200022
J	Moilanen, AM; Karvonen, U; Poukka, H; Yan, W; Toppari, J; Janne, OA; Palvimo, JJ				Moilanen, AM; Karvonen, U; Poukka, H; Yan, W; Toppari, J; Janne, OA; Palvimo, JJ			A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; COACTIVATORS; BINDING; SEARCH; DNA	We have characterized a novel partner for androgen receptor (AR), termed ARIP3, that interacts with the DNA-binding domain/zinc finger region of AR and is predominantly expressed in the testis. Rat ARIP3 is a nuclear protein comprising 572 amino acids, It modulates AR-dependent but not basal transcription, suggesting that ARIP3 acts as an AR transcriptional coregulator. Except for the C-terminal AR-interacting domain, ARIP3 contains distinct regions that are also present in two recently described proteins, a protein inhibitor of activated Stat3 and an RNA helicase II-interacting protein (Gu/RH-II binding protein). Conserved structural features of these proteins indicate the existence of a gene family involved in the regulation of various transcription factors. Collectively, ARIP3 belongs to a novel nuclear protein family and is perhaps the first tissue-specific coregulator of androgen receptor.	Univ Helsinki, Inst Biomed, Dept Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland; Univ Turku, Dept Physiol & Pediat, FIN-20520 Turku, Finland	University of Helsinki; University of Helsinki; University of Turku	Palvimo, JJ (corresponding author), Univ Helsinki, Inst Biomed, Dept Physiol, POB 9,Siltavuorenpenger 20J, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinki.fi	Yan, Wei/G-1618-2011	Palvimo, Jorma/0000-0003-2373-0578				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; ZHANG FP, 1995, ENDOCRINOLOGY, V136, P2904, DOI 10.1210/en.136.7.2904	27	128	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3700	3704		10.1074/jbc.274.6.3700	http://dx.doi.org/10.1074/jbc.274.6.3700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920921	hybrid			2022-12-27	WOS:000078428200061
J	Schmidt, PH; Dransfield, DT; Claudio, JO; Hawley, RG; Trotter, KW; Milgram, SL; Goldenring, JR				Schmidt, PH; Dransfield, DT; Claudio, JO; Hawley, RG; Trotter, KW; Milgram, SL; Goldenring, JR			AKAP350, a multiply spliced protein kinase A-anchoring protein associated with centrosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC PARIETAL-CELLS; REGULATORY SUBUNIT; GOLGI-COMPLEX; GAMMA-TUBULIN; IDENTIFICATION; SYSTEM; SCAFFOLD; CLONING; NEURONS; LOCALIZATION	Protein kinase A-anchoring proteins (AKAPs) localize the second messenger response to particular subcellular domains by sequestration of the type II protein kinase A. Previously, AKAP120 was identified from a rabbit gastric parietal cell cDNA library; however, a monoclonal antibody raised against AKAP120 labeled a 350-kDa band in Western blots of parietal cell cytosol, Recloning has now revealed that AKAP120 is a segment of a larger protein, AKAP350, We have now obtained a complete sequence of human gastric AKAP350 as well as partial cDNA sequences from human lung and rabbit parietal cells. The genomic region containing AKAP350 is found on chromosome 7q21 and is multiply spliced, producing at least three distinct AKAP350 isoforms as well as yotiao, a protein associated with the N-methyl-D-aspartate receptor, Rabbit parietal cell AKAP350 is missing a sequence corresponding to a single exon in the middle of the molecule located just after the yotiao homology region. Two carboxyl-terminal splice variants were also identified. Both of the major splice variants showed tissue- and cell-specific expression patterns. Immunofluorescence microscopy demonstrated that AKAP350 was associated with centrosomes in many cell types. In polarized Madin-Darby canine kidney cells, AKAP350 localized asymmetrically to one pole of the centrosome, and nocodazole did not alter its localization. During the cell cycle, AKAP350 was associated with the centrosomes as well as with the cleavage furrow during anaphase and telophase, Several epithelial cell types also demonstrated noncentrosomal pools of AKAP350, especially parietal cells, which contained multiple cytosolic immunoreactive foci throughout the cells. The localization of AKAP350 suggests that it may regulate centrosomal and noncentrosomal cytoskeletal systems in many different cell types.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat & Cellular Biol, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ Toronto, Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Goldenring, JR (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med, 1120 15th St, Augusta, GA 30912 USA.	jgolden@mail.mcg.edu		Hawley, Robert/0000-0003-3512-5818	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370, R29DK050744, R01DK043405, R29DK043405] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48370, DK50744, DK43405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BERGLINDH T, 1979, ACTA PHYSL SCAND, V96, P150; Breer H, 1996, BEHAV GENET, V26, P209, DOI 10.1007/BF02359381; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; GOSTITESTU F, 1986, EMBO J, V5, P2545, DOI 10.1002/j.1460-2075.1986.tb04533.x; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLOTZ C, 1990, J CELL BIOL, V110, P405, DOI 10.1083/jcb.110.2.405; KOMESLI S, 1989, J CELL BIOL, V109, P2869, DOI 10.1083/jcb.109.6.2869; LEWIS JJ, 1990, AM J PHYSIOL, V258, pG476, DOI 10.1152/ajpgi.1990.258.3.G476; Lin JW, 1998, J NEUROSCI, V18, P2017; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MILLER P, 1982, P NATL ACAD SCI-BIOL, V79, P5562, DOI 10.1073/pnas.79.18.5562; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SOROKA CJ, 1993, EUR J CELL BIOL, V60, P76; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SZOLLOSI D, 1964, J CELL BIOL, V21, P465, DOI 10.1083/jcb.21.3.465; TANG LH, 1992, BIOCHEM J, V285, P715, DOI 10.1042/bj2850715; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104	40	114	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3055	3066		10.1074/jbc.274.5.3055	http://dx.doi.org/10.1074/jbc.274.5.3055			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915845	hybrid, Green Published			2022-12-27	WOS:000078319500063
J	Thottassery, JV; Sun, DX; Zambetti, GP; Troutman, A; Sukhatme, VP; Schuetz, EG; Schuetz, JD				Thottassery, JV; Sun, DX; Zambetti, GP; Troutman, A; Sukhatme, VP; Schuetz, EG; Schuetz, JD			Sp1 and Egr-1 have opposing effects on the regulation of the rat pgp2/mdr1b gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; MDR1 PROMOTER; MESSENGER-RNA; EXPRESSION; CELLS; LIVER; ACTIVATION; HEPATOCYTES	The promoter of the rat pgp2/mdr1b gene has a GC-rich region (pgp2GC) that is highly conserved in mdr genes and contains an consensus Sp1 site. Sp1's role in transactivation of the pgp2/mdr1b promoter was tested in Drosophila Schneider cells. The pgp2/mdr1b promoter was strongly activated by co-transfected wild type Sp1 but not mutant Sp1 and mutation of the Sp1 site abrogated Sp1-dependent transactivation, In gel shift assays, the same mutations abolished Sp1-DNA complex formation. Moreover, basal activity of the pgp2/mdr1b Sp1 mutant promoter was dramatically lower. Enforced ectopic overexpression of Sp1 in H35 rat hepatoma cells revealed that cell lines overexpressing Sp1 had increased endogenous pgp2/mdr1b mRNA, demonstrating that Spl activates the endogenous pgp2/mdr1b gene. Pgp2GC oligonucleotide also bound Egr-1 in gel shift assays and Egr-1 competitively displaced bound Sp1. In transient transfections of H35 cells land human LS180 and HepG2 cells) Egr-1 potently and specifically suppressed pgp2/mdr1b promoter activity and mutations in the Egr-1 site decreased Egr-1 binding and correlated with pgp2/mdr1b up-regulation. Ectopic overexpression of Egr-1 in H35 cells decreased Pgp expression and selectively increased vinblastine sensitivity. In conclusion, Sp1 positively regulates while Egr-1 negatively regulates the rat pgp2/mdr1b gene, Moreover, competitive interactions between Sp1 and Egr-1 in all likelihood determine the constitutive expression of the pgp2/mdr1b gene in H35 cells.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Beth Israel Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Schuetz, Erin/N-8087-2018; Zambetti, Gerard/N-8093-2018; Schuetz, John D/N-2692-2018; Sukhatme, Vikas/W-2776-2019	Zambetti, Gerard/0000-0002-0929-5007; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R01ES008658, R29ES005851] Funding Source: NIH RePORTER; NCI NIH HHS [CA63203] Funding Source: Medline; NIEHS NIH HHS [ES05851, ES08658] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; BHUSHAN A, 1992, MOL PHARMACOL, V42, P69; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; COHEN D, 1991, J BIOL CHEM, V266, P2239; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DENT CL, 1994, TRANSCRIPTION FACTOR, P1; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; Furuya KN, 1997, J BIOL CHEM, V272, P11518; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HUS JM, 1996, P NATL ACAD SCI USA, V93, P4666; Ince TA, 1996, CANCER RES, V56, P2021; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MOHN KL, 1990, J BIOL CHEM, V265, P21914; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; SCHUETZ EG, 1995, MOL CARCINOGEN, V12, P61, DOI 10.1002/mc.2940120202; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P31; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SCHUETZ JD, 1995, CELL GROWTH DIFFER, V6, P1321; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, DNA CELL BIOL, V10, P433, DOI 10.1089/dna.1991.10.433; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; YANG CPH, 1990, J BIOL CHEM, V265, P10282; YU LJ, 1993, J BIOL CHEM, V268, P7520	38	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3199	3206		10.1074/jbc.274.5.3199	http://dx.doi.org/10.1074/jbc.274.5.3199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915860	hybrid			2022-12-27	WOS:000078319500078
J	Gehring, NH; Hentze, MW; Pantopoulos, K				Gehring, NH; Hentze, MW; Pantopoulos, K			Inactivation of both RNA binding and aconitase activities of iron regulatory protein-1 by quinone-induced oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; SULFUR CLUSTERS; MESSENGER-RNA; NITRIC-OXIDE; ESCHERICHIA-COLI; CELLS; MODULATION; METABOLISM; INDUCTION; OXYGEN	Iron regulatory protein-1 (IRP-1) controls the expression of several mRNAs by binding to iron-responsive elements (IREs) in their untranslated regions, In iron-replete cells, a 4Fe-4S cluster converts IRP-1 to cytoplasmic aconitase, IRE binding activity is restored by cluster loss in response to iron starvation, NO, or extracellular H2O2. Here, we study the effects of intracellular quinone-induced oxidative stress on IRP-1. Treatment of murine Be fibroblasts with menadione sodium bisulfite (MSB), a redox cycling drug, causes a modest activation of IRP-1 to bind to IREs within 15-30 min. However, IRE binding drops to basal levels within 60 min. Surprisingly, a remarkable loss of both IRE binding and aconitase activities of IRP-1 follows treatment with MSB for 1-2 h, These effects do not result from alterations in IRP-1 half-life, can be antagonized by the antioxidant N-acetylcysteine, and regulate IRE-containing mRNAs; the capacity of iron-starved MSB-treated cells to increase transferrin receptor mRNA levels is inhibited, and MSB increases the translation of a human growth hormone indicator mRNA bearing an IRE in its 5'-untranslated region, Nonetheless, MSB inhibits ferritin synthesis. Thus, menadione-induced oxidative stress leads to post-translational inactivation of both genetic and enzymatic functions of IRP-1 by a mechanism that lies beyond the "classical" Fe-S cluster switch and exerts multiple effects on cellular iron metabolism.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Pantopoulos, K (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Chemin Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mbgl@musica.mcgill.ca	Pantopoulos, Kostas/A-9668-2008; Hentze, Matthias W/V-3980-2017	Pantopoulos, Kostas/0000-0002-2305-0057; Hentze, Matthias W/0000-0002-4023-7876				Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; DASILVA JJR, 1991, BIOL CHEM ELEMENTS I, V21, P319; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hentze MW, 1996, TRENDS BIOCHEM SCI, V21, P282, DOI 10.1016/S0968-0004(96)20019-2; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; Liu HD, 1996, GENE DEV, V10, P592; MALORNI W, 1993, J CELL SCI, V106, P309; MALORNI W, 1993, EXP CELL RES, V206, P195, DOI 10.1006/excr.1993.1138; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; PANTOPOULOS K, 1995, RNA, V1, P155; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; SHI MM, 1994, J BIOL CHEM, V269, P26512; Shi MM, 1996, J BIOL CHEM, V271, P5878, DOI 10.1074/jbc.271.10.5878; SHI MM, 1994, AM J PHYSIOL, V11, pL414; TANG CK, 1992, J BIOL CHEM, V267, P24466	39	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6219	6225		10.1074/jbc.274.10.6219	http://dx.doi.org/10.1074/jbc.274.10.6219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037708	hybrid			2022-12-27	WOS:000078902800030
J	Luchin, S; Putzer, H; Hershey, JWB; Cenatiempo, Y; Grunberg-Manago, M; Laalami, S				Luchin, S; Putzer, H; Hershey, JWB; Cenatiempo, Y; Grunberg-Manago, M; Laalami, S			In vitro study of two dominant inhibitory GTPase mutants of Escherichia coli translation initiation factor IF2 - Direct evidence that GTP hydrolysis is necessary for factor recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; AMINOACYL-TRANSFER RNA; PROTEIN-SYNTHESIS; EF-TU; BINDING DOMAIN; RIBOSOMAL-RNA; SUBSTITUTION; HISTIDINE-84; MECHANISM; GROWTH	We have recently shown that the Escherichia coli initiation factor 2 (IF2) G-domain mutants V400G and H448E do not support cell survival and have a strong negative effect on growth even in the presence of wildtype IF2. We have isolated both mutant proteins and performed an in vitro study of their main functions. The affinity of both mutant proteins for GTP is almost unchanged compared with wild-type IF2. However, the uncoupled GTPase activity of the V400G and H448E mutants is severely impaired, the V-max values being 11- and 40-fold lower, respectively. Both mutant forms promoted fMet-tRNA(f)(Met) binding to 70 S ribosomes with similar efficiencies and were as sensitive to competitive inhibition by GDP as wild-type IF2. Formation of the first peptide bond, as measured by the puromycin reaction, was completely inhibited in the presence of the H448E mutant but still significant in the case of the V400G mutant. Sucrose density gradient centrifugation revealed that, in contrast to wild-type IF2, both mutant proteins stay blocked on the ribosome after formation of the 70 S initiation complex. This probably explains their dominant negative effect in vivo. Our results underline the importance of GTP hydrolysis for the recycling of IF2.	Univ Poitiers, Inst Biol Mol & Ingn Genet, CNRS, ESA 6031, F-86022 Poitiers, France; Inst Biol Physicochim, CNRS, UPR 9073, F-75005 Paris, France; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Davis	Laalami, S (corresponding author), Univ Poitiers, Inst Biol Mol & Ingn Genet, CNRS, ESA 6031, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	Soumaya.Laalami@cri.univ-poitiers.fr	Putzer, Harald/GRY-6203-2022					BEAUDRY P, 1979, BIOCHEMISTRY-US, V18, P202, DOI 10.1021/bi00568a031; BENNE R, 1972, FEBS LETT, V20, P347, DOI 10.1016/0014-5793(72)80104-2; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; CENATIEMPO Y, 1987, BIOCHEMISTRY-US, V26, P5070, DOI 10.1021/bi00390a028; COOL RH, 1991, BIOCHEMISTRY-US, V30, P362, DOI 10.1021/bi00216a008; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DONDON J, 1985, BIOCHIMIE, V67, P643, DOI 10.1016/S0300-9084(85)80206-6; DUBNOFF JS, 1972, J BIOL CHEM, V247, P2884; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; FAKUNDING JL, 1973, J BIOL CHEM, V248, P4206; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GODEFROYCOLBURN T, 1975, J MOL BIOL, V94, P461, DOI 10.1016/0022-2836(75)90215-6; Grunberg-Manago M., 1996, ESCHERICHIA COLI SAL, V1, P1432; GUALERZI CO, 1991, J BIOL CHEM, V266, P16356; HEIMARK RL, 1976, J BIOL CHEM, V251, P779; HERSHEY JWB, 1987, ESCHERICHIA COLI SAL, V1, P613; JACQUET E, 1989, EUR J BIOCHEM, V185, P341, DOI 10.1111/j.1432-1033.1989.tb15121.x; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAY A, 1973, BIOCHEM BIOPH RES CO, V51, P979, DOI 10.1016/0006-291X(73)90023-5; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KOLAKOFSKY D, 1968, P NATL ACAD SCI USA, V61, P1066, DOI 10.1073/pnas.61.3.1066; KOLAKOFSKY D, 1969, NATURE, V223, P694, DOI 10.1038/223694a0; Laalami S, 1996, BIOCHIMIE, V78, P577, DOI 10.1016/S0300-9084(96)80004-6; LAALAMI S, 1994, MOL MICROBIOL, V11, P293, DOI 10.1111/j.1365-2958.1994.tb00309.x; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; LELONG JC, 1970, NATURE, V226, P505, DOI 10.1038/226505a0; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LOCKWOOD AH, 1972, P NATL ACAD SCI USA, V69, P3602, DOI 10.1073/pnas.69.12.3602; MAZUMDER R, 1972, P NATL ACAD SCI USA, V69, P2770, DOI 10.1073/pnas.69.10.2770; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; PON CL, 1985, J BIOL CHEM, V260, P8918; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SACERDOT C, 1992, J MOL BIOL, V225, P67, DOI 10.1016/0022-2836(92)91026-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARANO G, 1995, FEBS LETT, V365, P214, DOI 10.1016/0014-5793(95)00469-P; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; THACH SS, 1971, NATURE-NEW BIOL, V229, P219, DOI 10.1038/newbio229219a0; WEIEL J, 1981, BIOCHEMISTRY-US, V20, P5859, DOI 10.1021/bi00523a032	46	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6074	6079		10.1074/jbc.274.10.6074	http://dx.doi.org/10.1074/jbc.274.10.6074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037688	hybrid			2022-12-27	WOS:000078902800010
J	Braverman, LE; Quilliam, LA				Braverman, LE; Quilliam, LA			Identification of Grb4/Nck beta, a Src homology 2 and 3 domain-containing adapter protein having similar binding and biological properties to Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ALDRICH SYNDROME PROTEIN; C-CBL PROTOONCOGENE; EXCHANGE FACTOR SOS; SH2 DOMAIN; RAS TRANSFORMATION; SIGNALING PATHWAYS; TYROSINE KINASE; FACTOR RECEPTOR; K-RAS	Adapter proteins made up of Src homology (SH) domains mediate multiple cellular signaling events initiated by receptor protein tyrosine kinases. Here we report that Grb4 is an adapter protein closely related to but distinct from Nck that is made up of three SH3 domains and one SH2 domain. Northern analysis indicated that both genes are expressed in multiple tissues. Both Nck and Grb4 proteins could associate with receptor tyrosine kinases and the SH3-binding proteins PAH, Sos1, and PRK2, and they synergized with v-Abl and Sos to induce gene expression via the transcription factor Elk-1. Although neither protein was transforming on its own, both Nck and Grb4 cooperated with v-Abl to transform NIR 3T3 cells and influenced the morphology and anchorage-dependent growth of wild type Ras-transformed cells. Nck and Grb4 therefore appear to be functionally redundant.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Braverman, Lewis/0000-0003-1263-1099	NCI NIH HHS [CA63139] Funding Source: Medline; NIDDK NIH HHS [P60 DK20542-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Byrne JL, 1996, ONCOGENE, V13, P2055; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUEBNER K, 1994, GENOMICS, V22, P281, DOI 10.1006/geno.1994.1385; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SCHLAEFER M, 1993, SPRACHWISSENSCHAFT, V18, P213; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367	59	65	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5542	5549		10.1074/jbc.274.9.5542	http://dx.doi.org/10.1074/jbc.274.9.5542			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026169	hybrid			2022-12-27	WOS:000078804400040
J	Murthy, HMK; Clum, S; Padmanabhan, R				Murthy, HMK; Clum, S; Padmanabhan, R			RETRACTED: Dengue virus NS3 serine protease - Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects (Retracted Article. See vol 284, pg 34468, 2009)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							HEPATITIS-C VIRUS; YELLOW-FEVER VIRUS; PUTATIVE NONSTRUCTURAL PROTEINS; POLYPROTEIN PRECURSOR; VIRAL POLYPROTEIN; NS2B-NS3 COMPLEX; CATALYTIC TRIAD; TYPE-2; CLEAVAGE; DOMAIN	The mosquito-borne dengue viruses are widespread human pathogens causing dengue fever, dengue hemorrhagic fever, and dengue shock syndrome, placing 40% of the world's population at risk with no effective treatment. The viral genome is a positive strand RNA that encodes a single polyprotein precursor. Processing of the polyprotein precursor into mature proteins is carried out by the host signal peptidase and by NS3 serine protease, which requires NS2B as a cofactor. We report here the crystal structure of the NS3 serine protease domain at 2.1 Angstrom resolution. This structure of the protease combined with modeling of peptide substrates into the active site suggests identities of residues involved in substrate recognition as well as providing a structural basis for several mutational effects on enzyme activity. This structure will be useful for development of specific inhibitors as therapeutics against dengue and other flaviviral proteases.	Temple Univ, Fels Inst, Philadelphia, PA 19140 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Kansas; University of Kansas Medical Center	Murthy, HMK (corresponding author), Univ Alabama Birmingham, CMC, 79-THT,MCLM-248,1918 Univ Blvd, Birmingham, AL 35294 USA.	murthy@onyx.cmc.uab.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGELIDES KJ, 1979, BIOCHEMISTRY-US, V18, P2363, DOI 10.1021/bi00578a035; [Anonymous], ACTA CRYSTALLOGR D, V50, P760; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BAZAN JF, 1989, FEBS LETT, V249, P5, DOI 10.1016/0014-5793(89)80003-1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, XPLOR MANUAL VERSION; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HUANG QC, 1993, J MOL BIOL, V229, P1022, DOI 10.1006/jmbi.1993.1102; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JAN LR, 1995, J GEN VIROL, V76, P573, DOI 10.1099/0022-1317-76-3-573; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Kautner I, 1997, J PEDIATR-US, V131, P516, DOI 10.1016/S0022-3476(97)70054-4; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Neurath H, 1989, PROTEOLYTIC ENZYMES; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P101; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PERONA JJ, 1993, SCIENCE, V261, P620, DOI 10.1126/science.8342029; Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; READ RJ, 1986, INTRO PROTEIN INHIBI, P301; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Steinkuhler C, 1996, J VIROL, V70, P6694; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Valle RPC, 1998, J VIROL, V72, P624, DOI 10.1128/JVI.72.1.624-632.1998; WESTAWAY EG, 1987, ADV VIRUS RES, V33, P45, DOI 10.1016/S0065-3527(08)60316-4; Yan YW, 1998, PROTEIN SCI, V7, P837; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992	73	101	107	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5573	5580		10.1074/jbc.274.9.5573	http://dx.doi.org/10.1074/jbc.274.9.5573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026173	hybrid			2022-12-27	WOS:000078804400044
J	Liu, JA; Shworak, NW; Sinay, P; Schwartz, JJ; Zhang, LJ; Fritze, LMS; Rosenberg, RD				Liu, JA; Shworak, NW; Sinay, P; Schwartz, JJ; Zhang, LJ; Fritze, LMS; Rosenberg, RD			Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE N-SULFOTRANSFERASE; GLOMERULAR-BASEMENT-MEMBRANE; MOLECULAR-CLONING; ANTITHROMBIN-III; HIGH-AFFINITY; BIOSYNTHESIS; MOUSE; PURIFICATION; PROTEOGLYCAN; CELLS	The 3-O-sulfation of glucosamine residues is an important modification during the biosynthesis of heparan sulfate (HS), Our previous studies have led us to purify and molecularly clone the heparan sulfate D-glucosaminyl 5-O-sulfotransferase (5-OST-1), which is the key enzyme converting nonanticoagulant heparan sulfate (HSinact) to anticoagulant heparan sulfate (HSact). In this study, we expressed and characterized the full-length cDNAs of 3-OST-1 homologous genes, designated as 3-OST-2, 3-OST-3(A), and 3-OST-3(B) as described in the accompanying paper (Shworak, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, N. A., and Rosenberg, R. D. (1999) J. Biol. Chem, 274, 5170-5184), All these cDNAs were successfully expressed in COS-7 cells, and heparan sulfate sulfotransferase activities were found in the cell extracts, We demonstrated that 3-OST-2, 3-OST-3(A), and 3-OST-3(B) are heparan sulfate D-glucosaminyl 3-O-sulfotransferases because the enzymes transfer sulfate from adenosine 3'-phosphophate 5'-phospho-[S-35]sulfate ([S-35]PAPS) to the 5-OH position of glucosamine, 3-OST-3(A) and 3-OST-3(B) sulfate an identical disaccharide. HSact conversion activity in the cell extract transfected by 3-OST-1 was shown to be 300-fold greater than that in the cell extracts transfected by 5-OST-2 and 3-OST-3(A), suggesting that 3-OST-2 and 3-OST-3(A) do not make HSact. The results of the disaccharide analysis of the nitrous acid-degraded [35S]HS suggested that 3-OST-2 transfers sulfate to GlcA2S-GlcNS and IdoA2S-GlcNS; 3-OST-3(A) transfers sulfate to IdoA2S-GlcNS. Our results demonstrate that the 3-O-sulfation of glucosamine is generated by different isoforms depending on the saccharide structures around the modified glucosamine residue. This discovery has provided evidence for a new cellular mechanism for generating a defined saccharide sequence in structurally complex HS polysaccharide.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Hosp, Sch Med, Dept Med, Boston, MA 02215 USA; Ecole Normale Super, Dept Chim, F-75231 Paris, France	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [5-P01-HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAME KJ, 1991, J BIOL CHEM, V266, P10287; BIELICKI J, 1990, BIOCHEM J, V271, P75, DOI 10.1042/bj2710075; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DELANEY SR, 1980, ANAL BIOCHEM, V100, P253; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHEN GQ, 1995, ARCH BIOCHEM BIOPHYS, V321, P83, DOI 10.1006/abbi.1995.1371; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VERNIER RL, 1992, KIDNEY INT, V41, P1070, DOI 10.1038/ki.1992.163; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	40	143	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5185	5192		10.1074/jbc.274.8.5185	http://dx.doi.org/10.1074/jbc.274.8.5185			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988768	hybrid			2022-12-27	WOS:000078698200093
J	Reddy, GB; Srinivas, VR; Ahmad, N; Surolia, A				Reddy, GB; Srinivas, VR; Ahmad, N; Surolia, A			Molten globule-like state of peanut lectin monomer retains its carbohydrate specificity - Implications in protein folding and legume lectin oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LACTALBUMIN; CONCANAVALIN-A; 3-STATE DENATURATION; CRYSTAL-STRUCTURE; BINDING; APOMYOGLOBIN; AGGLUTININ; INTERMEDIATE; RESOLUTION; STABILITY	A central question in biological chemistry is the minimal structural requirement of a protein that would determine its specificity and activity, the underlying basis being the importance of the entire structural element of a protein with regards to its activity vis a vis the overall integrity and stability of the protein. Although there are many reports on the characterization of protein folding/ unfolding intermediates, with considerable secondary structural elements but substantial loss of tertiary structure, none of them have been reported to show any activity toward their respective ligands. This may be a result of the conditions under which such intermediates have been isolated or due to the importance of specific structural elements for the activity. In this paper we report such an intermediate in the unfolding of peanut agglutinin that seems to retain, to a considerable degree, its carbohydrate binding specificity and activity. This result has significant implications on the molten globule state during the folding pathway(s) of proteins in general and the quaternary association in legume lectins in particular, where precise subunit topology is required for their biologic activities.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		Reddy, G Bhanuprakash/AAJ-3494-2020; SUROLIA, AVADESHA/C-5442-2009	Reddy, G Bhanuprakash/0000-0003-4787-3944; 				Ahmad N, 1998, BIOCHEMISTRY-US, V37, P16765, DOI 10.1021/bi9811720; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; Banerjee R, 1996, J MOL BIOL, V259, P281, DOI 10.1006/jmbi.1996.0319; BARRICK D, 1994, J MOL BIOL, V237, P588, DOI 10.1006/jmbi.1994.1257; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BREWER CF, 1996, CHEMTRACTS BIOCH MOL, V6, P165; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; FISH WW, 1978, ARCH BIOCHEM BIOPHYS, V190, P693, DOI 10.1016/0003-9861(78)90328-4; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; KIEFHABER T, 1995, J MOL BIOL, V252, P122, DOI 10.1006/jmbi.1995.0479; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1976, J MOL BIOL, V106, P359, DOI 10.1016/0022-2836(76)90091-7; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; Lis H, 1991, CURR OPIN STRUC BIOL, V1, P741, DOI 10.1016/0959-440X(91)90173-Q; LOTAN R, 1975, J BIOL CHEM, V250, P8518; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; NEUROHR KJ, 1980, J BIOL CHEM, V255, P9205; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; Nozaki Y, 1972, Methods Enzymol, V26, P43; Prabu MM, 1998, J MOL BIOL, V276, P787, DOI 10.1006/jmbi.1997.1568; SAANAN B, 1991, SCIENCE, V234, P862; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SUROLIA A, 1996, J BIOL CHEM, V271, P17696; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YOUNG NM, 1991, EUR J BIOCHEM, V196, P693	30	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4500	4503		10.1074/jbc.274.8.4500	http://dx.doi.org/10.1074/jbc.274.8.4500			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988681	hybrid			2022-12-27	WOS:000078698200006
J	Ziady, AG; Ferkol, T; Dawson, DV; Perlmutter, DH; Davis, PB				Ziady, AG; Ferkol, T; Dawson, DV; Perlmutter, DH; Davis, PB			Chain length of the polylysine in receptor-targeted gene transfer complexes affects duration of reporter gene expression both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SEC RECEPTOR; HEPATOMA-CELLS; DNA COMPLEXES; DELIVERY; IDENTIFICATION; ENDOCYTOSIS; EFFICIENCY; PROTEIN; ALPHA	Complexes composed of peptide ligand for the serpin enzyme complex receptor covalently coupled to poly-L-lysine condensed by charge interaction with plasmid DNA direct gene transfer into receptor bearing cells, We compared intensity and duration of reporter gene expression in vitro and in vivo from serpin-enzyme receptor-directed gene transfer complexes prepared with poly-L-lysine of different chain lengths. When substituted with linker and ligand to comparable extents, DNA complexes containing short chain poly-L-lysine were larger and gave higher peak expression but significantly shorter duration of expression than those containing long chain poly-L-lysine. Both peak expression and duration of expression exceeded that observed with Lipofectin, Neither naked DNA nor DNA complexed with unsubstituted polylysine was effective in gene transfer. For in vivo experiments, complexes containing optimal ligand and degree of substitution (based on in vitro data, peptide C105Y, 11 ligands/plasmid DNA molecule) were prepared with either short chain or long chain polylysine and a beta-galactosidase expression plasmid. Following injection into the tail veins of mice, longer chain complexes gave significantly higher expression of reporter gene in lung and spleen that lasted for a significantly longer period of time than the shorter chain complexes. The short chain poly-L-lysine-DNA complexes were larger in diameter, as assessed by electron microscopy or atomic force microscopy, and gave less protection against DNase digestion in, vitro than longer chain complexes. Thus, for gene transfer complexes directed at the serpin enzyme complex receptor, longer chain poly-L-lysine gave a much longer duration of expression both in vitro and in vivo, We speculate that this may be due to protection against degradation afforded the plasmid DNA by the tighter compaction produced by long chain poly-L-lysine.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Washington Univ, Sch Med, Dept Pediat Cell Biol & Physiol, St Louis, MO 63110 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Washington University (WUSTL)	Davis, PB (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	pbd@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043999, P30DK027651, R01DK049138] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43999, P30 DK27651, DK 49138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Brubaker JO, 1996, J IMMUNOL, V157, P1598; BU GJ, 1992, J BIOL CHEM, V267, P15595; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; ERBACHER P, 1995, BIOCONJUGATE CHEM, V6, P401, DOI 10.1021/bc00034a010; FERKOL T, 1993, J CLIN INVEST, V92, P2394, DOI 10.1172/JCI116845; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; Ferkol T, 1996, P NATL ACAD SCI USA, V93, P101, DOI 10.1073/pnas.93.1.101; GLANTZ SA, 1987, BIOSTATISTICS, P287; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JUNG G, 1981, BIOCHEM BIOPH RES CO, V101, P599, DOI 10.1016/0006-291X(81)91301-2; Kleinbaum D, 1988, APPL REGRESSION ANAL; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LIN WC, 1991, BIOTECHNIQUES, V11, P344; Maniatis T., 1989, MOL CLONING LAB MANU; MAURER PH, 1962, J IMMUNOL, V88, P330; MICHAEL SI, 1994, GENE THER, V1, P223; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1994, PEDIATR RES, V36, P271, DOI 10.1203/00006450-199409000-00001; Scidmore MA, 1996, J CELL BIOL, V134, P363, DOI 10.1083/jcb.134.2.363; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILSON DL, 1995, LANGMUIR, V11, P265, DOI 10.1021/la00001a045; Wolfert MA, 1996, GENE THER, V3, P269; WU GY, 1987, J BIOL CHEM, V262, P4299; Ziady AG, 1997, AM J PHYSIOL-GASTR L, V273, pG545, DOI 10.1152/ajpgi.1997.273.2.G545	31	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4908	4916		10.1074/jbc.274.8.4908	http://dx.doi.org/10.1074/jbc.274.8.4908			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988733	hybrid			2022-12-27	WOS:000078698200058
J	Das, TK; Lee, HC; Duff, SMG; Hill, RD; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB				Das, TK; Lee, HC; Duff, SMG; Hill, RD; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB			The heme environment in barley hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; RESONANCE RAMAN; DISTAL HISTIDINE; CARBON-MONOXIDE; HORSERADISH-PEROXIDASE; FECO UNIT; MYOGLOBIN; PROTEINS; PLANTS; GENE	To elucidate the environment and ligand structure of the heme in barley hemoglobin (Hb), resonance Raman and electron paramagnetic resonance spectroscopic studies have been carried out. The heme is shown to have bis-imidazole coordination, and neither of the histidines has imidazolate character. Barley Hb has a unique heme environment as judged from the Fe-CO and C-O stretching frequencies in the CO complex. Two Fe-CO stretching modes are observed with frequencies at 534 and 493 cm(-1), with relative intensities that are pH sensitive. The 534 cm(-1) conformer shows a deuterium shift, indicating that the iron-bound CO is hydrogen-bonded, presumably to the distal histidine, A C-O stretching mode at 1924 cm(-1) is assigned as being associated with the 534 cm(-1) conformer. Evidence is presented that the high Fe-CO and low C-O stretching frequencies (534 and 1924 cm(-1), respectively) arise from a short hydrogen bond between the distal histidine and the CO. The 493 cm(-1) conformer arises from an open conformation of the heme pocket and becomes the dominant population under acidic conditions when the distal histidine moves away from the CO. Strong hydrogen bonding between the bound ligand and the distal histidine in the CO complex of barley Hb implies that a similar structure may occur in the oxy derivative, imparting a high stability to the bound oxygen. This stabilization is confirmed by the dramatic decrease in the oxygen dissociation rate compared with sperm whale myoglobin.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada	Yeshiva University; Albert Einstein College of Medicine; University of Manitoba	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.			Das, Tapan/0000-0002-3641-3988	NIGMS NIH HHS [GM40168, GM54806, GM54812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812, R37GM040168, R01GM040168] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; APPLEBY CA, 1992, SCI PROG, V76, P365; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BELL RL, 1994, J CHEM PHYS, V101, P10442, DOI 10.1063/1.467862; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOGUSZ D, 1988, NATURE, V331, P178, DOI 10.1038/331178a0; BOGUSZ D, 1990, PLANT CELL, V2, P633, DOI 10.1105/tpc.2.7.633; BOISPOLTORATSKY R, 1967, EUR J BIOCHEM, V2, P361, DOI 10.1111/j.1432-1033.1967.tb00146.x; CAUGHEY WS, 1978, BIOCH CLIN ASPECTS H, P29; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DEROPP JS, 1985, J AM CHEM SOC, V107, P8268, DOI 10.1021/ja00312a080; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; DURLEY RCE, 1994, PROTEIN DATA BANK BR; EVANGELISTAKIRKUP R, 1986, BIOCHEMISTRY-US, V25, P4420, DOI 10.1021/bi00363a037; Hill RD, 1998, CAN J BOT, V76, P707, DOI 10.1139/cjb-76-5-707; HIROTA S, 1995, J AM CHEM SOC, V117, P821, DOI 10.1021/ja00107a028; HORI H, 1971, BIOCHIM BIOPHYS ACTA, V251, P227, DOI 10.1016/0005-2795(71)90106-1; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LING JH, 1994, BBA-BIOENERGETICS, V1188, P417, DOI 10.1016/0005-2728(94)90063-9; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241; MYLRAJAN M, 1990, BIOCHEMISTRY-US, V29, P9617, DOI 10.1021/bi00493a016; Nie XZ, 1997, PLANT PHYSIOL, V114, P835, DOI 10.1104/pp.114.3.835; NIE XZ, 1997, REGULATION FUNCTION; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; PEISACH J, 1968, J BIOL CHEM, V243, P1871; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; Scheiner S, 1996, J AM CHEM SOC, V118, P1511, DOI 10.1021/ja9530376; SMULEVICH G, 1986, BIOCHEMISTRY-US, V25, P4426, DOI 10.1021/bi00363a038; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; SPRINGER BA, 1989, J BIOL CHEM, V264, P3087; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Unno M, 1998, J AM CHEM SOC, V120, P2670, DOI 10.1021/ja973293d; UNO T, 1987, J BIOL CHEM, V262, P4549; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	51	56	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4207	4212		10.1074/jbc.274.7.4207	http://dx.doi.org/10.1074/jbc.274.7.4207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933618	hybrid			2022-12-27	WOS:000078575500042
J	Liu, DF; Shriver, Z; Godavarti, R; Venkataraman, G; Sasisekharan, R				Liu, DF; Shriver, Z; Godavarti, R; Venkataraman, G; Sasisekharan, R			The calcium-binding sites of heparinase I from Flavobacterium heparinum are essential for enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL MODIFICATION; DIRECTED MUTAGENESIS; GLYCOSAMINOGLYCANS; EXPRESSION; CATALYSIS; RESIDUE; CLONING	In the accompanying paper (Shriver, Z,, Liu, D., Hu, Y., and Sasisekharan, R, (1999) J. Biol. Chem. 274, 4082-4088), we have shown that calcium binds specifically to heparinase I and have identified two major calcium-binding sites (CB-1 and CB-2) that partly conform to the EF-hand calcium-binding motif. In this study, through systematic site-directed mutagenesis, we have confirmed the accompanying biochemical studies and have shown that both CB-1 and CB-2 are involved in calcium binding and enzymatic activity. More specifically, we identified critical residues (viz, Asp(210), Asp(212), Gly(213), and Thr(216) in CB-1 and Asn(375), Tyr(379), and Glu(381) in CB-2) that are important for calcium binding and heparinase I enzymatic activity. Mutations in CB-1 resulted in a lower k(cat), but did not change the product profile of heparinase I action on heparin; conversely, mutations in CB-2 not only altered the k(cat) for heparinase I, but also resulted in incomplete degradation, leading to longer saccharides. Fluorescence competition experiments along with heparin affinity chromatography suggested that mutations in CB-1 alter heparinase I activity primarily through decreasing the enzyme's affinity for its calcium cofactor without altering heparin binding to heparinase I. Compared with CB-1 mutations, mutations in CB-2 affected calcium binding to a lesser extent, but they had a more pronounced effect on heparinase I activity, suggesting a different role for CB-2 in the enzymatic action of heparinase I. These results, taken together with our accompanying study, led us to propose a model for calcium binding to heparinase I that includes both CB-1 and CB-2 providing critical interactions, albeit via a different mechanism. Through binding to CB-1 and/or CB-2, we propose that calcium may play a role in the catalytic mechanism and/or in the exolytic processive mechanism of heparin-like glycosaminoglycan depolymerization by heparinase I.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; Genet Inst, Andover, MA 01810 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 16-561,77 Massachusetts Ave, Cambridge, MA 02139 USA.	ramnat@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073, R37GM057073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1996, BIOCHEM J, V315, P589, DOI 10.1042/bj3150589; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; Godavarti R, 1998, J BIOL CHEM, V273, P248, DOI 10.1074/jbc.273.1.248; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V225, P751, DOI 10.1006/bbrc.1996.1246; Godavarti R, 1996, BIOCHEMISTRY-US, V35, P6846, DOI 10.1021/bi960356g; Higuchi R., 1990, PCR PROTOCOLS GUIDE; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; SASISEKHARAN R, 1995, BIOCHEMISTRY-US, V34, P14441, DOI 10.1021/bi00044a022; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; Shriver Z, 1999, J BIOL CHEM, V274, P4082, DOI 10.1074/jbc.274.7.4082; TEJIDOR L, 1993, THROMB HAEMOSTASIS, V69, P866	19	27	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4089	4095		10.1074/jbc.274.7.4089	http://dx.doi.org/10.1074/jbc.274.7.4089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933602	hybrid			2022-12-27	WOS:000078575500026
J	Kessler, B; Michielin, O; Blanchard, CL; Apostolou, I; Delarbre, C; Gachelin, G; Gregoire, C; Malissen, B; Cerottini, JC; Wurm, F; Karplus, M; Luescher, IF				Kessler, B; Michielin, O; Blanchard, CL; Apostolou, I; Delarbre, C; Gachelin, G; Gregoire, C; Malissen, B; Cerottini, JC; Wurm, F; Karplus, M; Luescher, IF			T cell recognition of hapten - Anatomy of T cell receptor binding of a H-2K(d)-associated photoreactive peptide derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LIGAND INTERACTIONS; ANTIGEN RECEPTOR; MHC RESTRICTION; ALPHA; COMPLEX; CHAIN; SITE; DETERMINANTS; SPECIFICITY	To elucidate the structural basis of T cell recognition of hapten-modified antigenic peptides, we studied the interaction of the T1 T cell antigen receptor (TCR) with its ligand, the H-2K(d)-bound Plasmodium berghei circumsporozoite peptide 252-260 (SYIPSAEKI) containing photoreactive 4-azidobenzoic acid (ABA) on P. berghei circumsporozoite Lys(259). The photoaffinity-labeled TCR residue(s) were mapped as Tyr(48) and/or Tyr(50) of complementary determining region 2 beta (CDR2 beta). Other TCR-ligand contacts were identified by mutational analysis. Molecular modeling, based on crystallographic coordinates of closely related TCR and major histocompatibility complex I molecules, indicated that ABA binds strongly and specifically in a cavity between CDR3 alpha and CDR2 beta. We conclude that TCR expressing selective V beta and CDR3 alpha sequences form a binding domain between CDR3 alpha and CDR2 beta that can accommodate nonpeptidic moieties conjugated at the C-terminal portion of peptides binding to major histocompatibility complex (MHC) encoded proteins.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Inst Pasteur, INSERM, Dept Immunol, U277, F-75015 Paris, France; CNRS, INSERM, Ctr Immunol, F-13288 Marseille, France; Univ Strasbourg 1, Inst Le Bel, F-67404 Strasbourg, France; Ecole Polytech Fed Lausanne, Dept Chem, Ctr Biotechnol, CH-1015 Lausanne, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Luescher, IF (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.		Kessler, Benedikt/AAY-8614-2021; Michielin, Olivier/ABE-7924-2020; Wurm, Florian M./D-7224-2013; Blanchard, Christopher L/P-5124-2016; Malissen, Bernard/AAK-4659-2020	Kessler, Benedikt/0000-0002-8160-2446; Blanchard, Christopher L/0000-0001-5800-4678; Malissen, Bernard/0000-0003-1340-9342				Anjuere F, 1997, J BIOL CHEM, V272, P8505, DOI 10.1074/jbc.272.13.8505; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bjorkman PJ, 1997, CELL, V89, P167, DOI 10.1016/S0092-8674(00)80195-6; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GANJU RK, 1992, P NATL ACAD SCI USA, V89, P11552, DOI 10.1073/pnas.89.23.11552; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GODEAU F, 1991, RES IMMUNOL, V142, P409, DOI 10.1016/0923-2494(91)90039-L; Gregoire C, 1996, P NATL ACAD SCI USA, V93, P7184, DOI 10.1073/pnas.93.14.7184; HARDING CV, 1993, J IMMUNOL, V151, P2419; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Jensen T, 1997, J IMMUNOL, V158, P3769; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KEESEY J, 1987, BIOCH PROTEIN RES, P87; Kohler J, 1997, J IMMUNOL, V158, P591; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN S, 1993, J IMMUNOL, V151, P678; MARTIN S, 1992, J IMMUNOL, V149, P2569; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; NALEFSKI EA, 1992, J EXP MED, V175, P1553, DOI 10.1084/jem.175.6.1553; NALEFSKI EA, 1993, J IMMUNOL, V150, P3806; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; ROMERO P, 1993, J EXP MED, V177, P1245; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHRAGGER H, 1987, ANAL BIOCHEM, V166, P368; SILICIANO RF, 1986, CELL, V47, P161, DOI 10.1016/0092-8674(86)90439-3; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5	40	18	18	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3622	3631		10.1074/jbc.274.6.3622	http://dx.doi.org/10.1074/jbc.274.6.3622			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920911	hybrid			2022-12-27	WOS:000078428200051
J	Krishnamoorthy, RR; Crawford, MJ; Chaturvedi, MM; Jain, SK; Aggarwal, BB; Al-Ubaidi, MR; Agarwal, N				Krishnamoorthy, RR; Crawford, MJ; Chaturvedi, MM; Jain, SK; Aggarwal, BB; Al-Ubaidi, MR; Agarwal, N			Photo-oxidative stress down-modulates the activity of nuclear factor-kappa B via involvement of caspase-1, leading to apoptosis of photoreceptor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; LIPID-PEROXIDATION; T-ANTIGEN; ACTIVATION; ALPHA; DEATH; DEGENERATION; EXPRESSION; PROTEINS	The mechanisms of photoreceptor cell death via apoptosis, in retinal dystrophies, are largely not understood. In the present report we show that visible light exposure of mouse cultured 661W photoreceptor cells at 4.5 milliwatt/cm(2) caused a significant increase in oxidative damage of 661W cells, leading to apoptosis of these cells. These cells show constitutive expression of nuclear factor-kappa B (NF-kappa B), and light exposure of photoreceptor cells results in lowering of NF-kappa B levels in both the nuclear and cytosolic fractions in a time-dependent manner. Immunoblot analysis of I kappa B alpha and p50, and p65 (RelA) subunits of NF-kappa B, suggested that photo-oxidative stress results in their depletion. Immunocytochemical studies using antibody to RelA subunit of NF-kappa B further revealed the presence of this subunit constitutively both in the nucleus and cytoplasm of the 661W cells. Upon exposure to photo-oxidative stress, a depletion of the cytoplasmic and nuclear RelA subunit was observed. The depletion of NF-kappa B appears to be mediated through involvement of caspase-1, Furthermore, transfection of these cells with a dominant negative mutant I kappa B alpha greatly enhanced the kinetics of down modulation of NF-kappa B, resulting in a faster photo-oxidative stress-induced apoptosis. Taken together, these studies show that the presence of NF-kappa B RelA subunit in the nucleus is essential for protection of photoreceptor cells against apoptosis mediated by an oxidative pathway.	Univ N Texas, Hlth Sci Ctr, Dept Anat & Cell Biol, N Texas Eye Res Inst, Ft Worth, TX 76107 USA; Louisiana State Univ, Med Ctr, Dept Pediat, Shreveport, LA 71130 USA; Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Mol Oncol, Houston, TX 77030 USA; Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA	University of North Texas System; University of North Texas Health Science Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Texas System; UTMD Anderson Cancer Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Agarwal, N (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Anat & Cell Biol, N Texas Eye Res Inst, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	nagarwal@hsc.unt.edu	Aggarwal, Bharat B/G-3388-2013	Jain, Sushil/0000-0002-9574-0436				ABLER AS, 1994, INVEST OPHTH VIS SCI, V35, P1517; AGARWAL N, 1990, J NEUROSCI, V10, P3275; Agarwal N, 1996, BIOCHEM BIOPH RES CO, V225, P84, DOI 10.1006/bbrc.1996.1134; AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; ANDERSON RE, 1994, ADV EXP MED BIOL, V366, P73; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HALL MO, 1975, BIOCHEM BIOPH RES CO, V67, P1199, DOI 10.1016/0006-291X(75)90800-1; HEATH H, 1962, VISION RES, V2, P333, DOI 10.1016/0042-6989(62)90001-9; Hecker M, 1996, FEBS LETT, V380, P224, DOI 10.1016/0014-5793(96)00046-4; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JAIN SK, 1989, J BIOL CHEM, V264, P21340; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KAGAN VE, 1973, BIOCHIM BIOPHYS ACTA, V330, P76, DOI 10.1016/0005-2736(73)90285-X; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Li SH, 1995, DEGENERATIVE DISEASES OF THE RETINA, P27; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MEYER M, 1994, MCBU, P217; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775; Noell W K, 1966, Invest Ophthalmol, V5, P450; Organisciak DT, 1995, DEGENERATIVE DISEASES OF THE RETINA, P9; ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; PAPERMASTER DS, 1995, INVEST OPHTH VIS SCI, V36, P977; Penn J.S., 1985, RETINAL DEGENERATION, P439; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Rapp L, 1985, RETINAL DEGENERATION, P421; RAPP LM, 1990, INVEST OPHTH VIS SCI, V31, P1186; Ravi R, 1998, CANCER RES, V58, P882; Reme CE, 1995, DEGENERATIVE DISEASES OF THE RETINA, P19; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SEN J, 1995, J IMMUNOL, V154, P3213; Shen YM, 1996, AM J PHYSIOL-HEART C, V270, pH1624, DOI 10.1152/ajpheart.1996.270.5.H1624; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO MOM, 1994, INVEST OPHTH VIS SCI, V35, P2693; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	68	131	143	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3734	3743		10.1074/jbc.274.6.3734	http://dx.doi.org/10.1074/jbc.274.6.3734			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920926	hybrid			2022-12-27	WOS:000078428200066
J	Liu, XD; Prabhu, A; Van Ness, B				Liu, XD; Prabhu, A; Van Ness, B			Developmental regulation of the kappa locus involves both positive and negative sequence elements in the 3 ' enhancer that affect synergy with the intron enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE-TRANSCRIPTION; LIGHT-CHAIN ENHANCERS; PRE-B CELLS; IG-KAPPA; 3'-ENHANCER REGION; NUCLEAR FACTOR; EXPRESSION; ACTIVATION; BINDING; SITE	Expression of the mouse immunoglobulin kappa locus is regulated by the intron and 3' enhancers. Previously, we have reported that these enhancers can synergize at mature B cell stages. Here we present our recent studies on the identification and characterization of the 3' enhancer sequences that play important roles in this synergy. By performing mutational analyses with novel reporter constructs, we find that the 5' region of the cAMP response element (CRE), the PU.1/PIP, and the E2A motifs of the 3' enhancer are critical for the synergy. These motifs are known to contribute to the enhancer activity. However, we also show that mutating other functionally important sequences has no significant effect on the synergy. Those sequences include the 3' region of the CRE motif, the BSAP motif, and the region 3' of the E2A motif. We have further demonstrated that either the 5'-CRE, the PU.1/PIP, or the E2A motif alone is sufficient to synergize with the intron enhancer. Moreover, the PU.1 motif appears to act as a negative element at pre-B cell stages but as a positive element at mature B cell stages. We have also identified a novel negative regulatory sequence within the 3' enhancer that contributes to the regulation of synergy, as well as developmental stage and tissue specificity of expression. While the levels of many of the 3' enhancer binding factors change very little in cell lines representing different B cell stages, the intron enhancer binding factors significantly increase at more mature B cell stages.	Univ Minnesota, Inst Human Genet, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Univ Minnesota, Inst Human Genet, Dept Biochem, Canc Ctr Res Bldg,Box 806 UMHC,425 E River Rd SE, Minneapolis, MN 55455 USA.							BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EMORINE L, 1983, NATURE, V304, P447, DOI 10.1038/304447a0; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; FULTON R, 1994, NUCLEIC ACIDS RES, V22, P4216, DOI 10.1093/nar/22.20.4216; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Hayashi R, 1997, J IMMUNOL, V159, P4145; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hiramatsu R, 1995, CELL, V83, P1113, DOI 10.1016/0092-8674(95)90138-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Meyer KB, 1996, INT IMMUNOL, V8, P1561, DOI 10.1093/intimm/8.10.1561; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MEYER KB, 1994, NUCLEIC ACIDS RES, V22, P1576, DOI 10.1093/nar/22.9.1576; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NELMS K, 1990, NUCLEIC ACIDS RES, V18, P1037; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARSLOW TG, 1982, NATURE, V299, P449, DOI 10.1038/299449a0; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Sambrook J., 2002, MOL CLONING LAB MANU; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4	37	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3285	3293		10.1074/jbc.274.6.3285	http://dx.doi.org/10.1074/jbc.274.6.3285			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920868	hybrid			2022-12-27	WOS:000078428200008
J	Ruiz, A; Winston, A; Lim, YH; Gilbert, BA; Rando, RR; Bok, D				Ruiz, A; Winston, A; Lim, YH; Gilbert, BA; Rando, RR; Bok, D			Molecular and biochemical characterization of lecithin retinol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL ACYLTRANSFERASE; PIGMENT-EPITHELIUM; VITAMIN-A; BINDING-PROTEIN; ENERGY-SOURCE; RAT-LIVER; 11-CIS-RETINOIDS; DEHYDROGENASE; BIOSYNTHESIS; EXPRESSION	The enzyme responsible for conversion of all-trans-retinol into retinyl esters, the lecithin retinol acyltransferase (LRAT) has been characterized at the molecular level, The cDNA coding for this protein was cloned and its amino acid sequence deduced. LRAT is composed of a polypeptide of 230 amino acid residues with a calculated mass of 25.3 kDa. Tissue distribution analysis by Northern blot showed expression of a 5.0-kilobase transcript in the human retinal pigment epithelium as well as in other tissues that are known for their high LRAT activity and vitamin A processing. Affinity labeling experiments using specific compounds with high affinity for LRAT and monospecific polyclonal antibodies raised in rabbits against two peptide sequences for LRAT confirmed the molecular mass of LRAT as a 25-kDa protein. High performance liquid chromatography analysis of the reaction product formed by HEK-293 cells transfected with LRAT cDNA confirmed the ability of the transfected cells to convert [H-3]all-trans-retinol into authentic [H-3]all-trans-retinyl palmitate as chemically determined.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rando, RR (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	rando@warren.med.harvard.edu			NEI NIH HHS [EY00331, EY00444, EY04096] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000444, R37EY000444, P30EY000331, R01EY004096, R37EY004096] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARON L, 1978, J BIOL CHEM, V253, P7220; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BOK D, 1993, J CELL SCI, P189; BOK D, 1992, EXP EYE RES, V55, P853, DOI 10.1016/0014-4835(92)90011-G; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P7938, DOI 10.1021/bi00398a059; Goodman DS, 1984, RETINOIDS, V2, P2; Goodman DS, 1984, RETINOIDS, V2, P42; HELLER J, 1976, AM J OPHTHALMOL, V81, P93, DOI 10.1016/0002-9394(76)90198-7; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JANIN J, 1985, METHOD ENZYMOL, V115, P420; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEAN J, 1986, P NATL ACAD SCI USA, V83, P2335; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; Ross A. Catharine, 1994, P521; ROSS AC, 1993, J LIPID RES, V34, P1201; SAARI JC, 1989, J BIOL CHEM, V264, P8636; Saari John C., 1994, P351; SCHMITT MC, 1993, BIOL REPROD, V49, P972, DOI 10.1095/biolreprod49.5.972; SGOUTAS DS, 1972, BIOCHEMISTRY-US, V11, P293, DOI 10.1021/bi00752a022; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P1257, DOI 10.1021/bi00056a009; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P3077, DOI 10.1021/bi00063a019; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	35	211	220	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3834	3841		10.1074/jbc.274.6.3834	http://dx.doi.org/10.1074/jbc.274.6.3834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920938	hybrid			2022-12-27	WOS:000078428200078
J	Corbett, EF; Oikawa, K; Francois, P; Tessier, DC; Kay, C; Bergeron, JJM; Thomas, DY; Krause, KH; Michalak, M				Corbett, EF; Oikawa, K; Francois, P; Tessier, DC; Kay, C; Bergeron, JJM; Thomas, DY; Krause, KH; Michalak, M			Ca2+ regulation of interactions between endoplasmic reticulum chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; TRIGLYCERIDE-TRANSFER PROTEIN; GENE-EXPRESSION; CALRETICULIN INCREASES; STRUCTURAL-PROPERTIES; INTRACELLULAR STORES; BINDING-PROTEIN; CALCIUM; INHIBITION	Casade Blue (CB), a fluorescent dye, was used to investigate the dynamics of interactions between endoplasmic reticulum (ER) lumenal chaperones including calreticulin, protein disulfide isomerase (PDI), and ERp57. PDI and ERp57 were labeled with CB, and subsequently, we show that the fluorescence intensity of the CB-conjugated proteins changes upon exposure to microenvironments of a different polarity. CD analysis of the purified proteins revealed that changes in the fluorescence intensity of CB-ERp57 and CB-PDI correspond to conformational changes in the proteins. Using this technique we demonstrate that PDI interacts with calreticulin at low Ca2+ concentration (below 100 mu M), whereas the protein complex dissociates at >400 mu M Ca2+. These are the Ca2+ concentrations reminiscent of Ca2+ levels found in empty or full ER Ca2+ stores. The N-domain of calreticulin interacts with PDI, but Ca2+ binding to the C-domain of the protein is responsible for Ca2+ sensitivity of the interaction. ERp57 also interacts with calreticulin through the N-domain of the protein. Initial interaction between these proteins is Ca2+-independent, but it is modulated by Ca2+ binding to the C-domain of calreticulin. We conclude that changes in ER lumenal Ca2+ concentration may be responsible for the regulation of protein-protein interactions. Calreticulin may play a role of Ca2+ "sensor" for ER chaperones via regulation of Ca2+-dependent formation and maintenance of structural and functional complexes between different proteins involved in a variety of steps during protein synthesis, folding, and post-translational modification.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, MRC Canada, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, MRC Canada, Grp Prot Struct & Funct, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2H7, Canada; Univ Hosp Geneva, Div Infect Dis, CH-1216 Geneva, Switzerland; Natl Res Council Canada, Biotechnol Res Inst, Genet Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Geneva; National Research Council Canada; McGill University	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	marek.michalak@ualberta.ca	Bergeron, John/AAW-1893-2021; francois, patrice/AAL-5583-2020; Krause, Karl-Heinz/E-8030-2011; Thomas, David/M-7661-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Thomas, David/0000-0002-8854-762X; francois, patrice/0000-0002-0540-750X				Ausubel FM, 1988, MOL REPROD DEV; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BAKSH S, 1995, BIOCHEM BIOPH RES CO, V209, P310, DOI 10.1006/bbrc.1995.1504; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Favre CJ, 1996, J BIOL CHEM, V271, P14925, DOI 10.1074/jbc.271.25.14925; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LI WWF, 1993, J BIOL CHEM, V268, P12003; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; Lucero HA, 1998, J BIOL CHEM, V273, P9857, DOI 10.1074/jbc.273.16.9857; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MICHALAK M, 1995, CALRETICULIN; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MORI K, 1993, CELL, V74, P743; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RACCHETTI G, 1994, BIOCHEM BIOPH RES CO, V203, P828, DOI 10.1006/bbrc.1994.2257; Reilly BA, 1998, J BIOL CHEM, V273, P3747, DOI 10.1074/jbc.273.6.3747; SONTHEIMER RD, 1995, J INVEST MED, V43, P362; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WHITAKER JE, 1991, ANAL BIOCHEM, V198, P119, DOI 10.1016/0003-2697(91)90515-U; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	55	163	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6203	6211		10.1074/jbc.274.10.6203	http://dx.doi.org/10.1074/jbc.274.10.6203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037706	hybrid			2022-12-27	WOS:000078902800028
J	Chang, DK; Cheng, SF; Trivedi, VD				Chang, DK; Cheng, SF; Trivedi, VD			Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1 - Implications on viral fusion mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CELL FUSION; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; ATOMIC-STRUCTURE; LEUCINE ZIPPER; PEPTIDE; DOMAIN; INFECTIVITY	A peptide of 51 amino acids corresponding to the NH2-terminal region (5-55) of the glycoprotein gp41 of human immunodeficiency virus type 1 was synthesized to study its conformation and assembly. Nuclear magnetic resonance experiments indicated the sequence NH2-terminal to the leucine zipper-like domain of gp41 was induced into helix in the micellar solution, in agreement with circular dichroism data. Light scattering experiment showed that the peptide molecules self-assembled in water into trimeric structure on average. That the peptide molecules oligomerize in aqueous solution was supported by gel filtration and diffusion coefficient experiments. Molecular dynamics simulation based on the NMR data revealed a flexible region adjacent to the hydrophobic NH2, terminus of gp41. The biological significance of the present findings on the conformational flexibility and the propensity of oligomerization of the peptide may be envisioned by a proposed model for the interaction of gp41 with membranes during fusion process.	Acad Sinica, Inst Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chang, DK (corresponding author), Acad Sinica, Inst Chem, Taipei 11529, Taiwan.	dkc@chem.sinica.edu.tw	Cheng, Shu-Fang/ABE-1287-2020; Chang, Ding-Kwo/E-7079-2015	Cheng, Shu-Fang/0000-0003-0536-4404; 				AROETI B, 1991, J BIOL CHEM, V266, P15845; BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CARR CI, 1950, J CHEM PHYS, V18, P1616, DOI 10.1063/1.1747550; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chang DK, 1997, EUR J BIOCHEM, V247, P896, DOI 10.1111/j.1432-1033.1997.00896.x; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; Myers GK, 1995, HUMAN RETROVIRUSES A; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAND RP, 1981, ANNU REV BIOPHYS BIO, V10, P277, DOI 10.1146/annurev.bb.10.060181.001425; SATTENTAU QJ, 1990, J EXP BIOL, V174, P407; SCHAAL H, 1995, J VIROL, V69, P3308, DOI 10.1128/JVI.69.6.3308-3314.1995; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; SLEPUSHKIN VA, 1992, AIDS RES HUM RETROV, V8, P9, DOI 10.1089/aid.1992.8.9; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEFFY KR, 1992, J VIROL, V66, P4532, DOI 10.1128/JVI.66.7.4532-4535.1992; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	41	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5299	5309		10.1074/jbc.274.9.5299	http://dx.doi.org/10.1074/jbc.274.9.5299			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026137	hybrid			2022-12-27	WOS:000078804400008
J	Dowd, CJ; Cooney, CL; Nugent, MA				Dowd, CJ; Cooney, CL; Nugent, MA			Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; BOVINE DESCEMETS MEMBRANE; PLASMINOGEN-ACTIVATOR PRODUCTION; ENDOTHELIAL-CELLS; PROTEOLYTIC DEGRADATION; CORNEAL ENDOTHELIUM; MAGNETIC-RESONANCE; ANGIOGENIC PROTEIN; BALB/C3T3 CELLS	Basic fibroblast growth factor (bFGF) is a pluripotent cytokine with a wide range of target cells. Heparan sulfate binds bFGF, and this interaction has been demonstrated to protect bFGF against physical denaturation and protease degradation. The high concentrations of heparan sulfate in basement membranes have implicated these matrices as storage sites for bFGF in vivo. However, the mechanisms by which basement membranes modulate bFGF storage and release is unknown. To gain insight into these mechanisms, we have developed experimental and mathematical models of extracellular growth factor transport through basement membrane. Intact Descemet's membranes isolated from bovine corneas were mounted within customized diffusion cells and growth factor transport was measured under a variety of conditions that decoupled the diffusion process from the heparan sulfate binding phenomenon. Transport experiments were conducted with bFGF and interleukin 1 beta. In addition, bFGF-heparan sulfate binding was disrupted in diffusion studies with high ionic strength buffer and buffers containing protamine sulfate. Transport of bFGF was enhanced dramatically when heparan sulfate binding was inhibited. This process was modeled as a problem of diffusion with fast reversible binding. Experimental parameters were incorporated into a mathematical model and independent simulations were run that showed that the experimental data were accurately predicted by the mathematical model. Thus, this study indicated that basement membranes function as dynamic regulators of growth factor transport, allowing for rapid response to changing environmental conditions. The fundamental principles controlling bFGF transport through basement membrane that have been identified here might have applications in understanding how growth factor distribution is regulated throughout an organism during development and in the adult state.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Boston University; Boston University; Massachusetts Institute of Technology (MIT)	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			Nugent, Matthew/0000-0002-8630-4712	NATIONAL EYE INSTITUTE [R01EY011004] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902] Funding Source: NIH RePORTER; NEI NIH HHS [EY11004] Funding Source: Medline; NHLBI NIH HHS [HL46902] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BENNETT NT, 1993, AM J SURG, V166, P74, DOI 10.1016/S0002-9610(05)80589-6; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; CLORE GM, 1991, J MOL BIOL, V221, P47, DOI 10.1016/0022-2836(91)90802-D; COOKE J, 1995, BIOESSAYS, V17, P93, DOI 10.1002/bies.950170202; DABIN I, 1991, J CELL PHYSIOL, V147, P396, DOI 10.1002/jcp.1041470303; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; Hata R, 1996, CELL BIOL INT, V20, P59, DOI 10.1006/cbir.1996.0009; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; Johnston TP, 1998, PHARMACEUT RES, V15, P246, DOI 10.1023/A:1011966602179; KAPOOR R, 1986, BIOCHEMISTRY-US, V25, P3930, DOI 10.1021/bi00361a029; KIM JH, 1971, EXP EYE RES, V12, P231, DOI 10.1016/0014-4835(71)90143-6; LABERMEIER U, 1983, EXP EYE RES, V37, P225, DOI 10.1016/0014-4835(83)90157-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUBIMOV AV, 1995, LAB INVEST, V72, P461; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MCMANUS JFA, 1946, NATURE, V158, P202, DOI 10.1038/158202a0; Miao HQ, 1996, J BIOL CHEM, V271, P4879; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moy FJ, 1996, BIOCHEMISTRY-US, V35, P13552, DOI 10.1021/bi961260p; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Papageorgiou S, 1996, DEV DYNAM, V207, P461; PHILLIPS RJ, 1989, AICHE J, V35, P1761, DOI 10.1002/aic.690351102; Press W., 1986, NUMERICAL RECIPES; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; REGNIER FE, 1976, J CHROMATOGR SCI, V14, P316, DOI 10.1093/chromsci/14.7.316; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SAWADA H, 1982, CELL TISSUE RES, V226, P241, DOI 10.1007/BF00218356; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SYMES K, 1994, DEVELOPMENT, V120, P2339; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Trinkaus-Randall V, 1998, J CONTROL RELEASE, V53, P205, DOI 10.1016/S0168-3659(97)00254-X; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	53	133	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5236	5244		10.1074/jbc.274.8.5236	http://dx.doi.org/10.1074/jbc.274.8.5236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988774	hybrid			2022-12-27	WOS:000078698200099
J	Klussmann, E; Maric, K; Wiesner, B; Beyermann, M; Rosenthal, W				Klussmann, E; Maric, K; Wiesner, B; Beyermann, M; Rosenthal, W			Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED WATER CHANNEL; ANTIDIURETIC-HORMONE; PHOSPHORYLATION; EXPRESSION; VESICLES; CLONING; IDENTIFICATION; PERMEABILITY; TRAFFICKING; SCAFFOLD	The antidiuretic hormone arginine-vasopressin (AVP) regulates water reabsorption in renal collecting duct principal cells by inducing a cAMP-dependent translocation of water channels (aquaporin-2, AQP-2) from intracellular vesicles into the apical cell membranes. In subcellular fractions from primary cultured rat inner medullary collecting duct (IMCD) cells, enriched for intracellular AQP-2-bearing vesicles, catalytic protein kinase A (PKA) subunits and several protein kinase A anchoring proteins (AKAPs) were detected. In nonstimulated IMCD cells the majority of AQP-2 staining was detected intracellularly but became mainly localized within the cell membrane after stimulation with AVP or forskolin, Quantitative analysis revealed that preincubation of the cells with the synthetic peptide S-Ht31, which prevents the binding between AKAPs and regulatory subunits of PKA, strongly inhibited AQP-2 translocation in response to forskolin, Preincubation of the cells with the PRA inhibitor H89 prior to forskolin stimulation abolished AQP-2 translocation. In contrast to H89, S-Ht31 did not affect the catalytic activity of PKA. These data demonstrate that not only the activity of PRA, but also its tethering to subcellular compartments, are prerequisites for cAMP-dependent AQP-2 translocation.	Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Klussmann, E (corresponding author), Forschungsinst Mol Pharmakol, Alfred Kowalke Str 4, D-10315 Berlin, Germany.							AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Bretscher A, 1997, J CELL SCI, V110, P3011; CARR DW, 1992, J BIOL CHEM, V267, P13376; Deen PMT, 1998, CURR OPIN NEPHROL HY, V7, P37; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; Klussmann E., 1998, Journal of Molecular Medicine (Berlin), V76, pB58; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LIEBENHOFF U, 1995, FEBS LETT, V365, P209, DOI 10.1016/0014-5793(95)00476-P; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; ROSENTHAL W, 1998, ADV MOL CELL ENDOCR, V2, P143; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; SCHWOCH G, 1980, BIOCHEM J, V192, P223, DOI 10.1042/bj1920223; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747	37	134	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4934	4938		10.1074/jbc.274.8.4934	http://dx.doi.org/10.1074/jbc.274.8.4934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988736	hybrid			2022-12-27	WOS:000078698200061
J	Kodym, R; Calkins, P; Story, M				Kodym, R; Calkins, P; Story, M			The cloning and characterization of a new stress response protein a mammalian member of - A family of theta class glutathione S-transferase-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RADIATION-INDUCED APOPTOSIS; INDUCED CELL-DEATH; ESCHERICHIA-COLI; TRYPANOSOMA-CRUZI; HUMAN HSP27; RESISTANCE; GENE; EXPRESSION; STARVATION	Using differential display, a cDNA fragment was identified as being overexpressed in a mouse lymphoma cell line that had gained resistance to cell death after exposure to a variety of agents used in cancer therapy. The fall-length cDNA of 1.1 kb that was cloned contained an open reading frame coding for a previously unidentified 28-kDa mammalian protein, p28, p28 showed significant homologies to a large family of stress response proteins that contain a glutathione S-transferase (GST) domain. In correspondence with the sequence homology, p28 was found to bind glutathione; however, GST or glutathione peroxidase activity could not be demonstrated. Northern analysis of the mRNA of this protein showed abundant expression in mouse heart and liver tissues, whereas anti-p28 antibody binding identified p28 expression in mouse 3T3 cells and early passage mouse embryo fibroblasts. Subcellular protein fractionation revealed p28 localization in the cytoplasm, but with thermal stress p28 relocated to the nuclear fraction of cellular proteins. Based on sequence homology and protein activity we conclude that p28 acts as a small stress response protein, likely involved in cellular redox homeostasis, and belongs to a family of GST-like proteins related to class theta GSTs.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Story, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	mstory@odin.mdacc.tmc.edu	Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NCI NIH HHS [CA62209, CA77050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA077050, R29CA062209] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Ban N, 1996, CANCER RES, V56, P3577; BOMPART GJ, 1990, CLIN BIOCHEM, V23, P501, DOI 10.1016/0009-9120(90)80039-L; BUREL C, 1992, EXPERIENTIA, V48, P629, DOI 10.1007/BF02118307; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; CZARNECKA E, 1984, PLANT MOL BIOL, V3, P45, DOI 10.1007/BF00023415; DREWINKO B, 1972, P SOC EXP BIOL MED, V140, P339; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Elliott MJ, 1998, CANCER CHEMOTH PHARM, V41, P457, DOI 10.1007/s002800050767; Habig W H, 1981, Methods Enzymol, V77, P398; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HUOT J, 1991, CANCER RES, V51, P5245; JAKOBY WB, 1985, METHOD ENZYMOL, V113, P495; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppa S, 1997, ANN MED, V29, P73, DOI 10.3109/07853899708998745; Lock RB, 1996, CANCER RES, V56, P4006; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; MOUTIEZ M, 1995, BIOCHEM J, V310, P433, DOI 10.1042/bj3100433; NOEL F, 1994, P NATL ACAD SCI USA, V91, P4150, DOI 10.1073/pnas.91.10.4150; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; REEH S, 1976, MOL GEN GENET, V149, P279, DOI 10.1007/BF00268529; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; SCHONECK R, 1994, BIOL CELL, V80, P1, DOI 10.1016/0248-4900(94)90011-6; SERIZAWA H, 1987, NUCLEIC ACIDS RES, V15, P1153, DOI 10.1093/nar/15.3.1153; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; TAYLOR JL, 1990, MOL PLANT MICROBE IN, V3, P72; Trautinger F, 1996, J PHOTOCH PHOTOBIO B, V35, P141, DOI 10.1016/S1011-1344(96)07344-7; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; vanderKop DAM, 1996, PLANT MOL BIOL, V30, P839, DOI 10.1007/BF00019016; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; WILLIAMS MD, 1994, MOL MICROBIOL, V11, P1029, DOI 10.1111/j.1365-2958.1994.tb00381.x	41	88	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5131	5137		10.1074/jbc.274.8.5131	http://dx.doi.org/10.1074/jbc.274.8.5131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988762	hybrid			2022-12-27	WOS:000078698200087
J	Rahman, I; Antonicelli, F; MacNee, W				Rahman, I; Antonicelli, F; MacNee, W			Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HEAVY SUBUNIT GENE; CIGARETTE-SMOKE; TRANSCRIPTIONAL REGULATION; SUPEROXIDE-DISMUTASE; ENDOTHELIAL-CELLS; LINING FLUID; LUNG-CANCER; IN-VITRO	Glutathione (GSH) is an important physiological antioxidant in lung epithelial cells and lung lining fluid. We studied the regulation of GSH synthesis in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the anti-inflammatory agent dexamethasone in human alveolar epithelial cells (A549). TNF-alpha (10 ng/ml) exposure increased GSH levels, concomitant with a significant increase in gamma-glutamylcysteine synthetase (gamma-GCS) activity and the expression of gamma-GCS heavy subunit (gamma-GCS-HS) mRNA at 24 h, Treatment with TNF-alpha also increased chloramphenicol acetyltransferase (CAT) activity of a gamma-GCS-HS 5'-flanking region reporter construct, transfected into alveolar epithelial cells. Mutation of the putative proximal AP-1-binding site (-269 to -263 base pairs), abolished TNF-alpha-mediated activation of the promoter. Gel shift and supershift analysis showed that TNF-alpha increased AP-1 DNA binding which was predominantly formed by dimers of c-Jun. Dexamethasone (3 mu M) produced a significant decrease in the levels of GSH, decreased gamma-GCS activity and gamma-GCS-HS mRNA expression at 24 h. The increase in GSH levels, gamma-GCS-HS mRNA, gamma-GCS-HS promoter activity, and AP-1 DNA binding produced by TNF-alpha were abrogated by co-treating the cells with dexamethasone. Thus these data demonstrate that TNF-alpha and dexamethasone modulate GSH levels and gamma-GCS-HS mRNA expression by their effects on AP-1 (c-Jun homodimer). These data have implications for the oxidant/antioxidant balance in inflammatory lung diseases.	Univ Edinburgh, Sch Med, Resp Med Unit, Rayne Lab, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Rahman, I (corresponding author), Univ Edinburgh, Sch Med, Resp Med Unit, Rayne Lab, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	IR@srv1.med.ed.ac.uk		MacNee, William/0000-0002-3692-1448				AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Imanishi H, 1997, BIOCHEM BIOPH RES CO, V230, P120, DOI 10.1006/bbrc.1996.5901; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KONDO T, 1993, J BIOL CHEM, V268, P20366; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; LI XY, 1994, AM J RESP CRIT CARE, V149, P1518, DOI 10.1164/ajrccm.149.6.8004308; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; MADHU C, 1992, TOXICOL APPL PHARM, V115, P191, DOI 10.1016/0041-008X(92)90323-K; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; McIntosh LJ, 1998, BRAIN RES, V791, P209, DOI 10.1016/S0006-8993(98)00115-2; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Melloni B, 1996, AM J RESP CRIT CARE, V154, P1706, DOI 10.1164/ajrccm.154.6.8970359; Morales A, 1998, FEBS LETT, V427, P15, DOI 10.1016/S0014-5793(98)00381-0; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MORRIS PE, 1994, AM J MED SCI, V307, P119, DOI 10.1097/00000441-199402000-00010; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80, DOI 10.1152/ajplung.1998.275.1.L80; Rahman I, 1998, FEBS LETT, V427, P129, DOI 10.1016/S0014-5793(98)00410-4; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285, DOI 10.1152/ajplung.1995.269.3.L285; Rahman I, 1997, FEBS LETT, V411, P393; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEKHAR KR, 1997, BIOCHEM BIOPH RES CO, V234, P488; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHI MM, 1994, J BIOL CHEM, V269, P26512; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tomonari A, 1997, BIOCHEM BIOPH RES CO, V236, P616, DOI 10.1006/bbrc.1997.7020; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Tu ZH, 1998, BIOCHEM BIOPH RES CO, V244, P801, DOI 10.1006/bbrc.1998.8345; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YAO KS, 1995, CANCER RES, V55, P4367; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	53	113	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5088	5096		10.1074/jbc.274.8.5088	http://dx.doi.org/10.1074/jbc.274.8.5088			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988757	hybrid			2022-12-27	WOS:000078698200082
J	Yan, Q; Prestwich, GD; Lennarz, WJ				Yan, Q; Prestwich, GD; Lennarz, WJ			The Ost1p subunit of yeast oligosaccharyl transferase recognizes the peptide glycosylation site sequence, -Asn-X-Ser/Thr-	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; ASPARAGINE-LINKED GLYCOSYLATION; PROTEIN DISULFIDE-ISOMERASE; ACTIVE-SITE; N-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; SUBSTRATE RECOGNITION; ENZYMATIC CONVERSION; BINDING	Other laboratories have established that oligosaccharyl transferase (OST) from Saccharomyces cerevisiae can be purified as a protein complex containing eight different subunits. To identify the OST subunit that recognizes the peptide sites that can be glycosylated, we developed photoaffinity probes containing a photoreactive benzophenone derivative, p-benzoylphenylalanine (Bpa), as part of an I-125-labeled peptide that could be expected to be glycosylated. We found that Asn-Bpa-Thr peptides served as substrates for OST and that photoactivation of these probes in the presence of microsomes abolished the OST activity. Photoactivation of 125I-labeled Asn-Epa-Thr in the presence of microsomes resulted in specific covalent labeling of a protein doublet of molecular mass 62 and 64 kDa. By carrying out the photoactivation of the probe using microsomes containing epitope-tagged Ost1p, we demonstrated that the I-125-labeled protein was Ost1p. Radiolabeling of this protein was dependent on irradiation at 350 nm. No labeling was detected using a probe containing Ala instead of Thr as the third amino acid residue. We conclude that Ost1p is the subunit of the OST complex that recognizes the peptide sites in the nascent chains that are destined to be glycosylated.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Utah System of Higher Education; University of Utah	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Bause E, 1997, BIOCHEM J, V322, P95, DOI 10.1042/bj3220095; BAUSE E, 1983, BIOCHEM J, V209, P323, DOI 10.1042/bj2090323; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HART GW, 1979, J BIOL CHEM, V254, P9747; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HORTIN G, 1983, J BIOL CHEM, V258, P4047; HORTIN G, 1980, J BIOL CHEM, V255, P8007; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRONQUIST KE, 1978, J SUPRAMOL STR CELL, V8, P51, DOI 10.1002/jss.400080105; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAU JTY, 1983, J BIOL CHEM, V258, P5255; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NOIVA R, 1993, J BIOL CHEM, V268, P19210; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; RONIN C, 1981, EUR J BIOCHEM, V118, P159, DOI 10.1111/j.1432-1033.1981.tb05499.x; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; Xu T, 1998, BIOORGAN MED CHEM, V6, P1821, DOI 10.1016/S0968-0896(98)00135-7	32	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5021	5025		10.1074/jbc.274.8.5021	http://dx.doi.org/10.1074/jbc.274.8.5021			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988747	hybrid			2022-12-27	WOS:000078698200072
J	McCawley, LJ; Li, SN; Wattenberg, EV; Hudson, LG				McCawley, LJ; Li, SN; Wattenberg, EV; Hudson, LG			Sustained activation of the mitogen-activated protein kinase pathway - A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAP KINASE; INFLAMMATORY CYTOKINES; MAMMALIAN-CELLS; EGF RECEPTOR; PC12 CELLS; EXPRESSION; COLLAGENASE; SIGNAL; RAS	Activation of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway is required for ligand-dependent regulation of numerous cellular functions by receptor tyrosine kinases. We have shown previously that although many receptor tyrosine kinase ligands are mitogens for keratinocytes, cell migration and induction of the 92-kilodalton gelatinase/matrix metalloproteinase (MMP)-9 are selectively regulated by the epidermal growth factor and scatter factor/hepatocyte growth factor receptors. In this report we present evidence of an underlying mechanism to account for these observed differences in receptor tyrosine kinase-mediated response. Ligands that are mitogenic, but do not induce MMP-9 or colony dispersion, transiently activate the p42/p44 ERK/MAP kinases. In contrast, ligands that stimulate MMP-9 induction and colony dispersion induced sustained activation of these kinases. The functional significance of sustained MAPK activation was demonstrated by inhibition of the MAP kinase kinase MEK1. Disruption of the prolonged signal by addition of the MEK1 inhibitor PD 98059 up to 4 h after growth factor stimulation substantially impaired ligand-dependent colony dispersion and MMP-9 induction. These findings support the conclusion that duration of MAPK activation is an important determinant for certain growth factor-mediated functions in keratinocytes.	Univ New Mexico, Ctr Hearing Sci, Program Pharmacol & Toxicol, Coll Pharm, Albuquerque, NM 87131 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Environm & Occupat Hlth, Minneapolis, MN 55455 USA	University of New Mexico; Northwestern University; University of Minnesota System; University of Minnesota Twin Cities	Hudson, LG (corresponding author), Univ New Mexico, Ctr Hearing Sci, Program Pharmacol & Toxicol, Coll Pharm, 2502 Marble NE, Albuquerque, NM 87131 USA.	lghudson@unm.edu			NCI NIH HHS [CA72498] Funding Source: Medline; NIAMS NIH HHS [R01AR42989] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Boyd D, 1996, CANCER METAST REV, V15, P77, DOI 10.1007/BF00049488; Chen RH, 1996, ONCOGENE, V12, P1493; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Heldin CH, 1996, CANCER SURV, V27, P7; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; JENSEN PJ, 1993, J CELL PHYSIOL, V155, P333, DOI 10.1002/jcp.1041550214; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kuroki DW, 1996, CANCER RES, V56, P637; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SALO T, 1994, LAB INVEST, V70, P176; SATO H, 1993, J BIOL CHEM, V268, P23460; Simon C, 1998, CANCER RES, V58, P1135; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; Vu TH, 1998, BIOL EXTRAC, P115	37	189	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4347	4353		10.1074/jbc.274.7.4347	http://dx.doi.org/10.1074/jbc.274.7.4347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933637	hybrid			2022-12-27	WOS:000078575500061
J	Proost, P; Struyf, S; Schols, D; Opdenakker, G; Sozzani, S; Allavena, P; Mantovani, A; Augustyns, K; Bal, G; Haemers, A; Lambeir, AM; Scharpe, S; Van Damme, J; De Meester, I				Proost, P; Struyf, S; Schols, D; Opdenakker, G; Sozzani, S; Allavena, P; Mantovani, A; Augustyns, K; Bal, G; Haemers, A; Lambeir, AM; Scharpe, S; Van Damme, J; De Meester, I			Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; IN-VIVO; INHIBITION; CD26; MDC	The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) and chemokines are known key players in immunological processes; Surprisingly, CD26/DPP IV not only removed the expected Gly(1)-Pro(2) dipeptide from the NH(2) terminus of macrophage-derived chemokine (MDC) but subsequently also the Tyr(3)-Gly(4) dipeptide, generating MDC(5-69). This second cleavage after a Gly residue demonstrated that the substrate specificity of this protease is less restricted than anticipated. The unusual processing of MDC by CD26/DPP TV was confirmed on the synthetic peptides GPYGANMED (MDC(1-9)) and YGANMED (MDC(3-9)). Compared with intact MDC(1-69), CD26/DPP IV-processed MDC(5-69) had reduced chemotactic activity on lymphocytes and monocyte-derived dendritic cells, showed impaired mobilization of intracellular Ca(2+) through CC chemokine receptor 4 (CCR4), and was unable to desensitize for MDC-induced Ca(2+)-responses in CCR4 transfectants. However, MDC(5-69) remained equally chemotactic as intact MDC(1-69) on monocytes. In contrast to the reduced binding to lymphocytes and CCR4 transfectants, MDC(5-69) retained its binding properties to monocytes and its anti-HIV-l activity. Thus, NH(2)-terminal truncation of MDC by CD26/DPP TV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Expt Chemotherapy, B-3000 Louvain, Belgium; Mario Negri Inst Pharmacol Res, Immunol Lab, I-20157 Milan, Italy; Univ Instelling Antwerp, Lab Clin Biochem, B-2610 Antwerp, Belgium	KU Leuven; KU Leuven; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Antwerp	Proost, P (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	Paul.Proost@rega.kuleuven.ac.be	Proost, Paul/V-3052-2017; Opdenakker, Ghislain/Q-3130-2017; Augustyns, Koen/C-1102-2008; Augustyns, Koen/ABG-2306-2020; Schols, Dominique/S-9057-2017; Opdenakker, Ghislain/V-8562-2019; De Meester, Ingrid/A-6881-2017; Lambeir, Anne-Marie/B-2477-2017; Sozzani, Silvano/C-1447-2009; Mantovani, Alberto/HCI-7449-2022; Schols, Dominique/AAC-1309-2021; Struyf, Sofie/U-2455-2017; Allavena, Paola/HHM-5218-2022	Proost, Paul/0000-0002-0133-5545; Opdenakker, Ghislain/0000-0003-1714-2294; Augustyns, Koen/0000-0002-5203-4339; Augustyns, Koen/0000-0002-5203-4339; Schols, Dominique/0000-0003-3256-5850; Opdenakker, Ghislain/0000-0003-1714-2294; De Meester, Ingrid/0000-0002-3421-0124; Lambeir, Anne-Marie/0000-0001-9386-3777; Sozzani, Silvano/0000-0002-3144-8743; Mantovani, Alberto/0000-0001-5578-236X; Schols, Dominique/0000-0003-3256-5850; Struyf, Sofie/0000-0003-4558-0769; Allavena, Paola/0000-0002-6697-6028				Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; Chang MS, 1997, J BIOL CHEM, V272, P25229, DOI 10.1074/jbc.272.40.25229; Chantry D, 1998, J LEUKOCYTE BIOL, V64, P49, DOI 10.1002/jlb.64.1.49; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DeMeester I, 1997, BIOCHEM PHARMACOL, V54, P173, DOI 10.1016/S0006-2952(97)00149-4; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOFFMANN T, 1993, FEBS LETT, V336, P61, DOI 10.1016/0014-5793(93)81609-4; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; KEIL B, 1992, SPECIFICITY PROTEOLY, P19; Korom S, 1997, TRANSPLANTATION, V63, P1495, DOI 10.1097/00007890-199705270-00021; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Schmitz T, 1996, J CLIN INVEST, V97, P1545, DOI 10.1172/JCI118577; Schols D, 1998, ANTIVIR RES, V39, P175, DOI 10.1016/S0166-3542(98)00039-4; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3082, DOI 10.1073/pnas.91.8.3082; Van Coillie E, 1998, BIOCHEMISTRY-US, V37, P12672, DOI 10.1021/bi980497d; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; von Bonin A, 1998, IMMUNOL REV, V161, P43; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	32	127	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3988	3993		10.1074/jbc.274.7.3988	http://dx.doi.org/10.1074/jbc.274.7.3988			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933589	hybrid			2022-12-27	WOS:000078575500013
J	Feng, JH; Ito, M; Kureishi, Y; Ichikawa, K; Amano, M; Isaka, N; Okawa, K; Iwamatsu, A; Kaibuchi, K; Hartshorne, DJ; Nakano, T				Feng, JH; Ito, M; Kureishi, Y; Ichikawa, K; Amano, M; Isaka, N; Okawa, K; Iwamatsu, A; Kaibuchi, K; Hartshorne, DJ; Nakano, T			Rho-associated kinase of chicken gizzard smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; SERINE-THREONINE KINASE; LIGHT-CHAIN PHOSPHATASE; ACTIN STRESS FIBERS; MYOSIN PHOSPHATASE; SERINE/THREONINE KINASE; ARACHIDONIC-ACID; PUTATIVE TARGET; CA2+ SENSITIZATION; FOCAL ADHESIONS	Rho-associated kinase (Rho-kinase) from chicken gizzard smooth muscle was purified to apparent homogeneity (160 kDa on SDS-polyacrylamide gel electrophoresis) and identified as the ROK alpha isoform, Several substrates were phosphorylated. Rates with myosin phosphatase target subunit 1 (MYPT1), myosin, and the 20-kDa myosin light chain were higher than other substrates, Thiophosphorylation of MYPT1 inhibited myosin phosphatase activity. Phosphorylation of myosin at serine 19 increased actin-activated Mg+-ATPase activity, i.e, similar to myosin light chain kinase. Myosin phosphorylation was increased at higher ionic strengths, possibly by formation of 6 S myosin, Phosphorylation of the isolated light chain and myosin phosphatase was decreased by increasing ionic strength. Rhokinase was stimulated 1.5-2-fold by guanosine 5'-O-3-(thio)triphosphate.RhoA whereas limited tryptic hydrolysis caused a 5-6-fold activation, independent of RhoA. Several kinase inhibitors were screened and most effective were Y-27632, staurosporine, and H-89, Several lipids caused slight activation of Rho-kinase, but arachidonic acid (30-50 mu M) induced a 5-6-fold activation, independent of RhoA. These results suggest that Rho-kinase of smooth muscle may be involved in the contractile process via phosphorylation of MYPT1 and myosin, Activation by arachidonic acid presents a possible regulatory mechanism for Rho-kinase.	Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 236, Japan; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Mie University; Nara Institute of Science & Technology; Kirin Brewery Company Limited; University of Arizona	Ito, M (corresponding author), Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan.	m-ito@clin.medic.mie-u.ac.jp	Bando, Yasuko K./M-4831-2014; Amano, Mutsuki/M-4820-2014	Bando, Yasuko K./0000-0003-4166-6784; Amano, Mutsuki/0000-0002-0662-1524	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984, R01HL023615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23615, HL20984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; GONG MC, 1992, J BIOL CHEM, V267, P21492; Gong MC, 1997, J BIOL CHEM, V272, P10704; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1984, BIOCHEMISTRY-US, V23, P5062, DOI 10.1021/bi00316a036; IKEBE M, 1986, J BIOL CHEM, V261, P36; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MERKEL L, 1989, BIOCHEMISTRY-US, V28, P2215, DOI 10.1021/bi00431a037; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	54	214	220	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3744	3752		10.1074/jbc.274.6.3744	http://dx.doi.org/10.1074/jbc.274.6.3744			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920927	hybrid			2022-12-27	WOS:000078428200067
J	Igarashi, K; Verhagen, MFJM; Samejima, M; Schulein, M; Eriksson, KEL; Nishino, T				Igarashi, K; Verhagen, MFJM; Samejima, M; Schulein, M; Eriksson, KEL; Nishino, T			Cellobiose dehydrogenase from the fungi Phanerochaete chrysosporium and Humicola insolens - A flavohemoprotein from Humicola insolens contains 6-hydroxy-FAD as the dominant active cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPOROTRICHUM-PULVERULENTUM; QUINONE OXIDOREDUCTASE; OXIDIZING ENZYMES; OXIDASE; CELLULOSE; PURIFICATION; DEGRADATION; OXIDATION; BREAKDOWN; CULTURES	Cellobiose dehydrogenases (CDH) were purified from cellulose-grown cultures of the fungi Phanerochaete chrysosporium and Humicola insolens, The pH optimum of the cellobiose cytochrome c oxidoreductase activity of P, chrysosporium CDH was acidic, whereas that of H, insolens CDH was neutral. The absorption spectra of the two CDHs showed them to be typical hemoproteins, but there was a small. difference in the visible region. Limited proteolysis between the heme and flavin domains was performed to investigate the cofactors, There was no difference in absorption spectrum between the heme domains of P, chrysosporium and H, insolens CDHs. The midpoint potentials of heme at pH 7.0 were almost identical, and no difference in pH dependence was observed over the range of pH 3-9, The pH dependence of cellobiose oxidation by the flavin domains was similar to that of the native CDHs, indicating that the difference in the pH dependence of the catalytic activity between the two CDHs is because of the flavin domains. The absorption spectrum of the flavin domain from H, insolens CDH has absorbance maxima at 343 and 426 and a broad absorption peak at 660 nm, whereas that of P, chrysosporium CDH showed a normal flavoprotein spectrum. Flavin cofactors were extracted from the flavin domains and analyzed by high-performance liquid chromatography. The flavin cofactor from H. insolens was found to be a mixture of 60% 6-hydroxy-FAD and 40% FAD, whereas that from P, chrysosporium CDH was normal FAD, After reconstitution of the deflavo-proteins it was found that flavin domains containing B-hydroxy-FAD were clearly active but their cellobiose oxidation rates were lower than those of flavin domains containing normal FAD, Reconstitution of flavin cofactor had no effect on the optimum pH, From these results, it is concluded that the pH dependence is not because of the flavin cofactor but is because of the protein molecule.	Univ Tokyo, Sch Agr & Life Sci, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan	University of Tokyo; University System of Georgia; University of Georgia; Novo Nordisk; Nippon Medical School	Samejima, M (corresponding author), Univ Tokyo, Sch Agr & Life Sci, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138657, Japan.	amsam@hongo.ecc.u-tokyo.ac.jp	Igarashi, Kiyohiko/E-6799-2016	Igarashi, Kiyohiko/0000-0001-5152-7177				ANDER P, 1994, FEMS MICROBIOL REV, V13, P297, DOI 10.1016/0168-6445(94)90087-6; AYERS AR, 1978, EUR J BIOCHEM, V90, P171, DOI 10.1111/j.1432-1033.1978.tb12588.x; BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; ERIKSSON KE, 1975, EUR J BIOCHEM, V51, P213, DOI 10.1111/j.1432-1033.1975.tb03921.x; ERIKSSON KE, 1974, FEBS LETT, V49, P282, DOI 10.1016/0014-5793(74)80531-4; ERIKSSON KEL, 1993, ENZYME MICROB TECH, V15, P1002, DOI 10.1016/0141-0229(93)90046-5; HABU N, 1993, FEBS LETT, V327, P161, DOI 10.1016/0014-5793(93)80162-N; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; HENRIKSSON G, 1991, EUR J BIOCHEM, V196, P101, DOI 10.1111/j.1432-1033.1991.tb15791.x; HENRIKSSON G, 1995, COMPREHENSIVE SUMMAR, V112, P35; Igarashi K, 1997, FUNGAL GENET BIOL, V21, P214, DOI 10.1006/fgbi.1996.0954; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KREMER SM, 1992, FEMS MICROBIOL LETT, V92, P187, DOI 10.1111/j.1574-6968.1992.tb05257.x; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE HJ, 1956, J BIOL CHEM, V221, P983; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MORPETH FF, 1986, BIOCHEM J, V236, P221, DOI 10.1042/bj2360221; Radola BJ, 1980, ELECTROPHORESIS, V1, P43, DOI DOI 10.1002/ELPS.1150010109; RENGANATHAN V, 1990, APPL MICROBIOL BIOT, V32, P609, DOI 10.1007/BF00173735; SAMEJIMA M, 1992, EUR J BIOCHEM, V207, P103, DOI 10.1111/j.1432-1033.1992.tb17026.x; Samejima M, 1997, BIOTECHNOL APPL BIOC, V25, P135; SAMEJIMA M, 1992, FEBS LETT, V306, P165, DOI 10.1016/0014-5793(92)80991-O; Schou C, 1998, BIOCHEM J, V330, P565, DOI 10.1042/bj3300565; Schulein M, 1993, FDN BIOTECH IND FERM, V8, P109; WESTERMARK U, 1974, ACTA CHEM SCAND B, VB 28, P209, DOI 10.3891/acta.chem.scand.28b-0209; WESTERMARK U, 1975, ACTA CHEM SCAND B, V29, P419, DOI 10.3891/acta.chem.scand.29b-0419; WOOD JD, 1992, BIOCHIM BIOPHYS ACTA, V1119, P90, DOI 10.1016/0167-4838(92)90239-A; WOOD TM, 1972, BIOCHEM J, V128, P1183, DOI 10.1042/bj1281183	30	66	66	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3338	3344		10.1074/jbc.274.6.3338	http://dx.doi.org/10.1074/jbc.274.6.3338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920875	hybrid			2022-12-27	WOS:000078428200015
J	Kosa, JL; Sweasy, JB				Kosa, JL; Sweasy, JB			3 '-azido-3 '-deoxythymidine-resistant mutants of DNA polymerase beta identified by in vivo selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HIV-1 REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MECHANISM; ALPHA; MUTAGENESIS; RESOLUTION; RESISTANCE; FRAGMENT	We developed an in vivo selection to identify 3-'azido-3'-deoxythymidine (AZT)-resistant mutants of rat DNA polymerase beta (pol beta). The selection utilizes pol beta's ability to substitute for Escherichia coli DNA polymerase I (pol I) in the SC18-12 strain, which lacks active pol I. pol beta allows SC18-12 cells to grow, but they depend on pol beta activity, so inhibition of pol beta by AZT kills them. We screened a library of randomly mutated pol beta cDNA for complementation of the pol I defect in the presence of AZT, and identified AZT-resistant mutants. We purified two enzymes with nonconservative mutations in the palm domain of the polymerase, The substitutions D246V and R253M result in reductions in the steady-state catalytic efficiency (K-cat/K-m) of AZT-TP incorporation. The efficiency of dTTP incorporation was unchanged for the D246V enzyme, indicating that the substantial decrease in AZT-TP incorporation is responsible for its drug resistance, The R253M enzyme exhibits significantly higher K-m(dTTP) and K-cat(dTTP) values, implying that the incorporation reaction is altered. These are the first pol beta mutants demonstrated to exhibit AZT resistance in vitro. The locations of the Asp-246 and Arg-253 side chains indicate that substrate specificity is influenced by residues distant from the nucleotide-binding pocket.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA.	joann.sweasy@yale.edu						Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bouayadi K, 1997, CANCER RES, V57, P110; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P10272, DOI 10.1021/bi00157a014; Clairmont CA, 1996, J BACTERIOL, V178, P656, DOI 10.1128/jb.178.3.656-661.1996; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; Falcieri E, 1996, CELL STRUCT FUNCT, V21, P213, DOI 10.1247/csf.21.213; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LACEY SF, 1992, J BIOL CHEM, V267, P15789; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Miscia S, 1997, CELL PROLIFERAT, V30, P325; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Reichenberger S, 1998, EUR J BIOCHEM, V251, P81, DOI 10.1046/j.1432-1327.1998.2510081.x; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STEIN CA, 1994, J MED VIROL, V44, P115, DOI 10.1002/jmv.1890440203; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; WITKIN EM, 1982, MOL GEN GENET, V185, P43, DOI 10.1007/BF00333788; WITKIN EM, 1992, J BACTERIOL, V174, P4166, DOI 10.1128/jb.174.12.4166-4168.1992; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	32	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3851	3858		10.1074/jbc.274.6.3851	http://dx.doi.org/10.1074/jbc.274.6.3851			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920940	hybrid			2022-12-27	WOS:000078428200080
J	Minard, KI; McAlister-Henn, L				Minard, KI; McAlister-Henn, L			Dependence of peroxisomal beta-oxidation on cytosolic sources of NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; SACCHAROMYCES-CEREVISIAE; ISOCITRATE DEHYDROGENASE; HYDROGEN-PEROXIDE; FATTY-ACIDS; YEAST; GENE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; EXPRESSION; DISRUPTION	Growth of Saccharomyces cerevisiae with a fatty acid as carbon source was shown previously to require function of either glucose-6-phosphate dehydrogenase (ZWF1) or cytosolic NADP(+)-specific isocitrate dehydrogenase (IDP2), suggesting dependence of beta-oxidation on a cytosolic source of NADPH. In this study, we find that Delta IDP2 Delta ZWF1 strains containing disruptions in genes encoding both enzymes exhibit a rapid loss of viability when transferred to medium containing oleate as the carbon source. This loss of viability is not observed following transfer of a Delta IDP3 strain lacking peroxisomal isocitrate dehydrogenase to medium with docosahexaenoate, a nonpermissive carbon source that requires function of IDP3 for beta-oxidation. This suggests that the fatty acid(-) phenotype of Delta IDP2 Delta ZWF1 strains is not a simple defect in utilization. Instead, we propose that the common function shared by IDP2 and ZWF1 is maintenance of significant levels of NADPH for enzymatic removal of the hydrogen peroxide generated in the first step of peroxisomal beta-oxidation in yeast and that inadequate levels of the reduced form of the cofactor can produce lethality. This proposal is supported by the finding that the sensitivity to exogenous hydrogen peroxide previously reported for Delta ZWF1 mutant strains is less pronounced when analyses are conducted with a nonfermentable carbon source, a condition associated with elevated expression of IDP2. Under those conditions, similar slow growth phenotypes are observed for Delta ZWF1 and hIDP2 strains, and co-disruption of both genes dramatically exacerbates the H2O2s phenotype, Collectively, these results suggest that IDP2, when expressed, and ZWF1 have critical overlapping functions in provision of reducing equivalents for defense against endogenous or exogenous sources of H2O2.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	henn@uthscsa.edu						BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HALLIWELL B, 1994, NUTR REV, V52, P253; HARDER W, 1989, YEASTS, V3, P261; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAZAROW PB, 1997, MOL CELLULAR BIOL YE, V3, P547; Lee SM, 1998, BBA-PROTEIN STRUCT M, V1382, P167, DOI 10.1016/S0167-4838(97)00172-6; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; STRYER L, 1988, BIOCHEMISTRY-US, P431; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149	28	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3402	3406		10.1074/jbc.274.6.3402	http://dx.doi.org/10.1074/jbc.274.6.3402			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920883	hybrid			2022-12-27	WOS:000078428200023
J	Wright, RM; Clayton, DK; Riley, MG; McManaman, JL; Repine, JE				Wright, RM; Clayton, DK; Riley, MG; McManaman, JL; Repine, JE			cDNA cloning, sequencing, and characterization of male and female rat liver aldehyde oxidase (rAOX1) - Differences in redox status may distinguish male and female forms of hepatic AOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHINE DEHYDROGENASE; MOLYBDENUM-COFACTOR; MOLECULAR CHARACTERIZATION; DROSOPHILA-PSEUDOOBSCURA; SUBSTRATE-SPECIFICITY; ALS2 GENE; PURIFICATION; CONVERSION; CANDIDATE; ENZYMES	Molecular characterization of male and female rat liver aldehyde oxidase is reported. As described for the mouse liver, male and female rat liver expressed kinetically distinct forms of aldehyde oxidase, Our data suggest that the two forms arise as a result of differences in redox state and are most simply explained by expression of a single gene encoding aldehyde oxidase in rats, In support of this argument we have sequenced cDNAs from male and female rat liver, We examined mRNA expression by Northern blot analysis with RNA from males and females, from several tissues, and following androgen induction. Purified rat liver enzyme from males or females revealed a single 150-kDa species consistent with cDNA sequence analysis. Both male and female forms were reactive to the same carboxyl-terminal directed antisera. K-m(app) values obtained in crude extracts of male or female rat liver and post-benzamidine-purified aldehyde oxidase differed substantially from each other but could be interconverted by chemical reduction with dithiothreitol or oxidation with 4,4'-dithiodipyridine, Our data indicate that a single gene is most likely expressed in male or female rat liver and that the kinetic differences between male and female rat liver aldehyde oxidases are sensitive to redox manipulation.	Univ Colorado, Hlth Sci Ctr, Webb Waring Antioxidant Res Inst, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wright, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Webb Waring Antioxidant Res Inst, 4200 E 9th Ave, Denver, CO 80262 USA.				NHLBI NIH HHS [HL45582, HL52509] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052509, R01HL045582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEEDHAM C, 1987, EUR J DRUG METAB PH, V12, P307, DOI 10.1007/BF03189919; BEEDHAM C, 1995, ARCH BIOCHEM BIOPHYS, V319, P481, DOI 10.1006/abbi.1995.1320; Bendotti C, 1997, NEUROREPORT, V8, P2343, DOI 10.1097/00001756-199707070-00048; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cai S, 1997, J MEMBRANE BIOL, V158, P147, DOI 10.1007/s002329900252; Comeron JM, 1996, GENETICS, V144, P1053; DICKINSON WJ, 1970, GENETICS, V66, P487; Eager KR, 1998, J MEMBRANE BIOL, V163, P9, DOI 10.1007/s002329900365; FELSTED RL, 1967, J BIOL CHEM, V242, P1274; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; GLUECKSO.S, 1967, J BIOL CHEM, V242, P1271; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Hille R., 1985, Metal Ions in Biology, V7, P443; Hoff T, 1998, BBA-GENE STRUCT EXPR, V1398, P397, DOI 10.1016/S0167-4781(98)00085-2; HOLMES RS, 1979, BIOCHEM GENET, V17, P517, DOI 10.1007/BF00498887; HUFF SD, 1967, J BIOL CHEM, V242, P1265; KEITH TP, 1985, MOL BIOL EVOL, V2, P206; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; Li Calzi Marco, 1995, Journal of Biological Chemistry, V270, P31037; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; NISHINO T, 1994, J BIOCHEM, V116, P1; OHKUBO M, 1982, BIOCHEM INT, V4, P353; OHKUBO M, 1983, ARCH BIOCHEM BIOPHYS, V221, P534, DOI 10.1016/0003-9861(83)90172-8; Ori N, 1997, J BIOL CHEM, V272, P1019, DOI 10.1074/jbc.272.2.1019; RILEY MA, 1992, MOL BIOL EVOL, V9, P56; SAITO T, 1989, J BIOL CHEM, V264, P10015; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Sekimoto H, 1997, J BIOL CHEM, V272, P15280, DOI 10.1074/jbc.272.24.15280; Sugihara K, 1995, BIOCHEM MOL BIOL INT, V37, P861; TAYLOR SM, 1984, BIOCHEM J, V220, P67, DOI 10.1042/bj2200067; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TYNES RE, 1985, ARCH BIOCHEM BIOPHYS, V240, P77, DOI 10.1016/0003-9861(85)90010-4; WARNER CK, 1981, MOL GEN GENET, V184, P92, DOI 10.1007/BF00271201; WARNER CK, 1980, MOL GEN GENET, V180, P449, DOI 10.1007/BF00425861; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; Wright RM, 1997, REDOX REP, V3, P135, DOI 10.1080/13510002.1997.11747101; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; Wright RM, 1995, REDOX REP, V1, P313, DOI 10.1080/13510002.1995.11747005; Yoshihara S, 1997, ARCH BIOCHEM BIOPHYS, V338, P29, DOI 10.1006/abbi.1996.9774; Yoshihara S, 1997, BIOCHEM PHARMACOL, V53, P1099, DOI 10.1016/S0006-2952(97)00088-9; Zheng SY, 1997, INT J BIOL MACROMOL, V20, P307, DOI 10.1016/S0141-8130(97)00030-5; ZIEGLER DM, 1980, CIBA FDN S, V72, P191	47	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3878	3886		10.1074/jbc.274.6.3878	http://dx.doi.org/10.1074/jbc.274.6.3878			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920943	hybrid			2022-12-27	WOS:000078428200083
J	Dooley, KA; Bennett, MK; Osborne, TF				Dooley, KA; Bennett, MK; Osborne, TF			A critical role for cAMP response element-binding protein (CREB) as a co-activator in sterol-regulated transcription of 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CYCLIC-AMP; SOMATOSTATIN GENE; REDUCTASE GENE; RECEPTOR GENE; A SYNTHASE; NF-Y; IDENTIFICATION; FAMILY; EXPRESSION	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, a key regulatory enzyme in the pathway for endogenous cholesterol synthesis, is a target for negative feedback regulation by cholesterol, When cellular sterol levels are low, the sterol regulatory element-binding proteins (SREBPs) are released from the endoplasmic reticulum membrane, allowing them to translocate to the nucleus and activate SREBP target genes. However, in all SREBP-regulated promoters studied to date, additional co-regulatory transcription factors are required for sterol-regulated activation of transcription. We have previously shown that, in addition to SREBPs, NF-Y/CBF is required for sterol-regulated transcription of HMG-CoA synthase, This heterotrimeric transcription factor has recently been shown to function as a co-regulator in several other SREBP-regulated promoters, as well. In addition to cis-acting sites for both SREBP and NF-Y/CBF, the sterol regulatory region of the synthase promoter also contains a consensus cAMP response element (CRE), an element that binds members of the CREB/ATF family of transcription factors. Here, we show that this consensus CRE is essential for sterol-regulated transcription of the synthase promoter. Using in vitro binding assays, we also demonstrate that CREB binds to this CRE, and mutations within the CRE that result in a loss of CREB binding also result in a loss of sterol-regulated transcription. We further show that efficient activation of the synthase promoter in Drosophila SL2 cells requires the simultaneous expression of all three factors: SREBPs, NF-Y/CBF, and CREB. To date this is the first promoter shown to require CREB for efficient sterol-regulated transcription, and to require two different co-regulatory factors in addition to SREBPs for maximal activation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 19172 Jamboree Rd, Irvine, CA 92697 USA.	tfosborn@uci.edu			NHLBI NIH HHS [HL48044] Funding Source: Medline; NIGMS NIH HHS [GM07311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENBROOK D, 1990, ONCOGENE, V5, P293; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guan GM, 1997, J BIOL CHEM, V272, P10295; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLETT SM, 1994, NUCLEIC ACIDS RES, V22, P5184, DOI 10.1093/nar/22.24.5184; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	41	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5285	5291		10.1074/jbc.274.9.5285	http://dx.doi.org/10.1074/jbc.274.9.5285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026135	hybrid			2022-12-27	WOS:000078804400006
J	Miseta, A; Fu, LW; Kellermayer, R; Buckley, J; Bedwell, DM				Miseta, A; Fu, LW; Kellermayer, R; Buckley, J; Bedwell, DM			The Golgi apparatus plays a significant role in the maintenance of Ca2+ homeostasis in the vps33 Delta vacuolar biogenesis mutant of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; PLASMA-MEMBRANE; YEAST MUTANTS; CALCINEURIN; CALCIUM; TRANSPORT; PMR1; HOMOLOG; CELLS; CYCLOSPORINE	The vacuole is the major site of intracellular Ca2+ storage in yeast and functions to maintain cytosolic Ca2+ levels within a narrow physiological range, In this study, we examined how cellular Ca2+ homeostasis is maintained in a vps33 Delta vacuolar biogenesis mutant. We found that growth of the vps33 Delta strain was sensitive to high or low extracellular Ca2+ This strain could not properly regulate cytosolic Ca2+ levels and was able to retain only a small fraction of its total cellular Ca2+ in a nonexchangeable intracellular pool. Surprisingly, the vps33 Delta strain contained more total cellular Ca2+ than the wild type strain. Because most cellular Ca2+ is normally found within the vacuole, this suggested that other intracellular compartments compensated for the reduced capacity to store Ca2+ within the vacuole of this strain. To test this hypothesis, we examined the contribution of the Golgi-localized Ca2+ ATPase Pmr1p in the maintenance of cellular Ca2+ homeostasis, We found that a vps33 Delta/pmr1 Delta strain was hypersensitive to high extracellular Ca2+. In addition, certain combinations of mutations effecting both vacuolar and Golgi Ca2+ transport resulted in synthetic lethality. These results indicate that the Golgi apparatus plays a significant role in maintaining Ca2+ homeostasis when vacuolar biogenesis is compromised.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Bedwell, DM (corresponding author), Univ Alabama, Dept Microbiol, Bevill Biomed Res Bldg,Rm 432, Birmingham, AL 35294 USA.	dbedwell@uab.edu		Miseta, Attila/0000-0002-7984-3347; Fu, Karl/0000-0001-5386-9429; Bedwell, David/0000-0002-6605-818X				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Catty P, 1996, BIOSCIENCE REP, V16, P75, DOI 10.1007/BF01206198; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; FOOR F, 1992, NATURE, V360, P682; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; HEMENWAY CS, 1995, GENETICS, V141, P833; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; OHYA Y, 1991, J BIOL CHEM, V266, P13971; OKOROKOV LA, 1980, J BACTERIOL, V144, P661, DOI 10.1128/JB.144.2.661-665.1980; OKOROKOV LA, 1978, IZV AKAD NAUK BIOL+, V5, P638; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sorin A, 1997, J BIOL CHEM, V272, P9895; STANTON MG, 1968, ANAL BIOCHEM, V22, P27, DOI 10.1016/0003-2697(68)90255-8; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263	40	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5939	5947		10.1074/jbc.274.9.5939	http://dx.doi.org/10.1074/jbc.274.9.5939			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026219	hybrid			2022-12-27	WOS:000078804400090
J	Piossek, C; Schneider-Mergener, J; Schirner, M; Vakalopoulou, E; Germeroth, L; Thierauch, KH				Piossek, C; Schneider-Mergener, J; Schirner, M; Vakalopoulou, E; Germeroth, L; Thierauch, KH			Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; PERMEABILITY FACTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; FLT-1 RECEPTOR; FACTOR FAMILY; IN-VIVO; ANGIOGENESIS; MITOGEN; CELLS	Vascular endothelial growth factor (VEGF) directly stimulates endothelial cell proliferation and migration via tyrosine kinase receptors of the split kinase domain family. It mediates vascular growth and angiogenesis in the embryo but also in the adult in a variety of physiological and pathological conditions. The potential binding site of VEGF with its receptor was identified using cellulose-bound overlapping peptides of the extracytosolic part of the human vascular endothelial growth factor receptor II (VEGFR II). Thus, a peptide originating from the third globular domain of the VEGFR II comprising residues (247)RTELNVGIDFNWEYP(261) was revealed as contiguous sequence stretch, which bound I-125-VEGF(165). A systematic replacement with L-amino acids within the peptide representing the putative VEGF-binding site on VEGFR II indicates Asp(255) as the hydrophilic key residue for binding. The dimerized peptide (RTELNVGIDFNWEYPAS)(2)K inhibits VEGF(165) binding with an IC50 of 0.5 mu M on extracellular VEGFR II fragments and 30 mu M on human umbilical vein cells. VEGF(165)-stimulated autophosphorylation of VEGFR II as well as proliferation and migration of microvascular endothelial cells was inhibited by the monomeric peptide RTELNVGIDFNWEYPASK at a half-maximal concentration of 3-10, 0.1, and 0.1 mu M, respectively, We conclude that transduction of the VEGF(165) signal can be interrupted with a peptide derived from the third Ig-like domain of VEGFR LI by blockade of VEGF(165) binding to its receptor.	JERINI BIO TOOLS GMBH, D-12489 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany; Schering AG, Res Labs, D-13342 Berlin, Germany	Shire Pharmaceuticals Limited; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG	Germeroth, L (corresponding author), JERINI BIO TOOLS GMBH, Rudower Chaussee 5, D-12489 Berlin, Germany.							AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Barleon B, 1997, J BIOL CHEM, V272, P10382; Birkenhager R, 1996, BIOCHEM J, V316, P703, DOI 10.1042/bj3160703; BRAY AM, 1991, TETRAHEDRON LETT, V32, P6163, DOI 10.1016/0040-4039(91)80779-6; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JACKSON CJ, 1990, J CELL SCI, V96, P257; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; Joukov V, 1996, EMBO J, V15, P290; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Reineke U, 1998, PROTEIN SCI, V7, P951; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; YEO TK, 1991, BIOCHEM BIOPH RES CO, V179, P1568, DOI 10.1016/0006-291X(91)91752-X	49	40	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5612	5619		10.1074/jbc.274.9.5612	http://dx.doi.org/10.1074/jbc.274.9.5612			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026178	hybrid			2022-12-27	WOS:000078804400049
J	Tsunoda, SP; Muneyuki, E; Amano, T; Yoshida, M; Noji, H				Tsunoda, SP; Muneyuki, E; Amano, T; Yoshida, M; Noji, H			Cross-linking of two beta subunits in the closed conformation in F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; APPARENT NEGATIVE COOPERATIVITY; THERMOPHILIC BACILLUS PS3; DISULFIDE BOND FORMATION; NUCLEOTIDE-BINDING SITE; CATALYTIC SITES; ATP HYDROLYSIS; ALPHA(3)BETA(3)GAMMA COMPLEX; NONCATALYTIC SITES	In the crystal structure of mitochondrial F-1-ATPase, two beta subunits with a bound Mg-nucleotide are in "closed" conformations, whereas the third beta subunit without bound nucleotide is in an "open" conformation. In this "CCO" (beta-closed beta-closed beta-open) conformational state, Ile-390s of the two closed beta subunits, even though they are separated by an intervening alpha subunit, have a direct contact. We replaced the equivalent Ile of the alpha(3)beta(3)gamma subcomplex of thermophilic F-1-ATPase with Cys and observed the formation of the beta-beta cross-link through a disulfide bond. The analysis of conditions required for the cross-link formation indicates that: (i) F-1-ATPase takes the CCO conformation when two catalytic sites are filled with Mg-nucleotide, (ii) intermediate(s) with the CCO conformation are generated during catalytic cycle, (iii) the Mg-ADP inhibited form is in the CCO conformation, and (iv) F-1-ATPase dwells in conformational state(s) other than CCO when only one (or none) of catalytic sites is filled by Mg-nucleotide or when catalytic sites are filled by Mg2+-free nucleotide, The alpha(3)beta(3)gamma subcomplex containing the beta-beta cross-link retained the activity of uni-site catalysis but lost that of multiple catalytic turnover, suggesting that open-closed transition of beta subunits is required for the rotation of gamma subunit but not for hydrolysis of a single ATP.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 226, Japan.	myoshida@res.titech.ac.jp	Tsunoda, Satoshi/AAN-7023-2021	Tsunoda, Satoshi/0000-0003-3636-1521				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; EBEL RE, 1975, J BIOL CHEM, V250, P191; Garcia JJ, 1998, J BIOL CHEM, V273, P15940, DOI 10.1074/jbc.273.26.15940; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Grodsky NB, 1998, BIOCHEMISTRY-US, V37, P1007, DOI 10.1021/bi972349d; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KAGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P295, DOI 10.1093/oxfordjournals.jbchem.a134599; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; Milgrom YM, 1997, J BIOL CHEM, V272, P32211, DOI 10.1074/jbc.272.51.32211; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1997, FEBS LETT, V413, P55, DOI 10.1016/S0014-5793(97)00878-8; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stiggall D L, 1979, Methods Enzymol, V55, P308; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1994, J BIOL CHEM, V269, P11261; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407	47	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5701	5706		10.1074/jbc.274.9.5701	http://dx.doi.org/10.1074/jbc.274.9.5701			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026189	hybrid			2022-12-27	WOS:000078804400060
J	Houston, M; Estevez, A; Chumley, P; Aslan, M; Marklund, S; Parks, DA; Freeman, BA				Houston, M; Estevez, A; Chumley, P; Aslan, M; Marklund, S; Parks, DA; Freeman, BA			Binding of xanthine oxidase to vascular endothelium - Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-SUPEROXIDE DISMUTASE; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; OXYGEN METABOLITES; LIPOPROTEIN-LIPASE; RABBIT MYOCARDIUM; GENE-EXPRESSION; CELL-SURFACE; LUNG INJURY; DEHYDROGENASE	Concentrations of up to 1.5 milliunits/ml xanthine oxidase (XO) (1.1 mu g/ml) are found circulating in plasma during diverse inflammatory events. The saturable, high affinity binding of extracellular XO to vascular endothelium and the effects of cell binding on both XO catalytic activity and differentiated vascular cell function are reported herein. Xanthine oxidase purified from bovine cream bound specifically and with high affinity (K-d = 6 nM) at 4 degrees C to bovine aortic endothelial cells, increasing cell XO specific activity up to 10-fold, Xanthine oxidase-cell binding was not inhibited by serum or albumin and was partially inhibited by the addition of heparin. Pretreatment of endothelial cells with chondroitinase, but not heparinase or heparitinase, diminished endothelial binding by similar to 50%, suggesting association with chondroitin sulfate proteoglycans. Analysis of rates of superoxide production by soluble and cell-bound XO revealed that endothelial binding did not alter the percentage of univalent reduction of oxygen to superoxide. Com parison of the extent of CuZn-SOD inhibition of native and succinoylated cytochrome c reduction by cell-bound XO indicated that XO-dependent superoxide production was occurring in a cell compartment inaccessible to CuZn-SOD, This was further supported by the observation of a shift of exogenously added XO from extracellular binding sites to intracellular compartments, as indicated by both protease-reversible cell. binding and immunocytochemical localization studies. Endothelium-bound XO also inhibited nitric oxide-dependent cGMP production by smooth muscle cell co-cultures in an SOD-resistant manner. This data supports the concept that circulating XO can bind to vascular cells, impairing cell function via oxidative mechanisms, and explains how vascular XO activity diminishes vasodilatory responses to acetylcholine in hypercholesterolemic rabbits and atherosclerotic humans, The ubiquity of cell-XO binding and endocytosis as a fundamental mechanism of oxidative tissue injury is also affirmed by the significant extent of XO binding to human vascular endothelial cells, rat lung type 2 alveolar epthelial cells, and fibroblasts.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Umea Univ Hosp, Dept Clin Chem, S-90185 Umea, Sweden	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Umea University	Freeman, BA (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 946 Tinsley Harrison Tower,619 S 19th St, Birmingham, AL 35233 USA.	bruce.freeman@ccc.uab.edu	Freeman, Bruce A/H-9342-2012; Aslan, Mutay/C-7566-2016	Aslan, Mutay/0000-0002-0660-971X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051245, R01HL058115] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL51245, P01 HL40456, R01 HL58115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1993, BIOCHEM J, V289, P523, DOI 10.1042/bj2890523; BARLOW GH, 1966, J BIOL CHEM, V241, P1473; BECKMAN JS, 1989, FREE RADICAL BIO MED, V6, P607, DOI 10.1016/0891-5849(89)90068-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Benboubetra M, 1997, EUR J CLIN INVEST, V27, P611, DOI 10.1046/j.1365-2362.1997.1550704.x; BOISSINOT M, 1993, BIOCHEM BIOPH RES CO, V190, P250, DOI 10.1006/bbrc.1993.1038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Cardillo C, 1997, HYPERTENSION, V30, P57, DOI 10.1161/01.HYP.30.1.57; CLARE DA, 1991, ARCH BIOCHEM BIOPHYS, V286, P233, DOI 10.1016/0003-9861(91)90034-G; CRUZ FS, 1983, J PARASITOL, V69, P237, DOI 10.2307/3281307; DUPONT GP, 1992, J CLIN INVEST, V89, P197, DOI 10.1172/JCI115563; FUKUSHIMA T, 1995, BIOL PHARM BULL, V18, P156; GARDNER TJ, 1983, SURGERY, V94, P423; GILER S, 1975, CLIN CHIM ACTA, V63, P37, DOI 10.1016/0009-8981(75)90375-7; GRACE PA, 1994, BRIT J SURG, V81, P637, DOI 10.1002/bjs.1800810504; Grum C.M., 1987, J CRIT CARE, V2, P22; GRUM CM, 1986, BIOCHEM BIOPH RES CO, V141, P1104, DOI 10.1016/S0006-291X(86)80157-7; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; Hassoun PM, 1998, AM J RESP CRIT CARE, V158, P299, DOI 10.1164/ajrccm.158.1.9709116; HIEBERT LM, 1990, ATHEROSCLEROSIS, V83, P47, DOI 10.1016/0021-9150(90)90129-7; INOUE M, 1991, J BIOL CHEM, V266, P16409; JEROUDI MO, 1994, AM J CARDIOL, V73, pB2, DOI 10.1016/0002-9149(94)90257-7; KARLSSON K, 1989, LAB INVEST, V60, P659; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOIKE K, 1993, J SURG RES, V54, P469, DOI 10.1006/jsre.1993.1072; KOOIJ A, 1994, HEPATOLOGY, V19, P1488, DOI 10.1002/hep.1840190626; KOPACZ M, 1993, J MOL CELL CARDIOL, V25, P859, DOI 10.1006/jmcc.1993.1095; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; LAPENNA D, 1992, BIOCHEM PHARMACOL, V44, P188, DOI 10.1016/0006-2952(92)90057-P; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; MARZI I, 1989, TRANSPLANT P, V21, P1319; MIYAMOTO Y, 1995, SOC EXP BIOL MED, V211, P366; Mohacsi A, 1996, BBA-MOL BASIS DIS, V1316, P210, DOI 10.1016/0925-4439(96)00027-0; MUGGE A, 1991, AM J PHYSIOL, V260, pC219, DOI 10.1152/ajpcell.1991.260.2.C219; Murad F, 1996, JAMA-J AM MED ASSOC, V276, P1189, DOI 10.1001/jama.276.14.1189; NIELSEN VG, 1994, J THORAC CARDIOV SUR, V107, P1222, DOI 10.1016/S0022-5223(94)70041-9; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OHTA H, 1994, FREE RADICAL BIO MED, V16, P501, DOI 10.1016/0891-5849(94)90128-7; PALERMARTINEZ A, 1994, ARCH BIOCHEM BIOPHYS, V311, P79, DOI 10.1006/abbi.1994.1211; PANUS PC, 1992, ARCH BIOCHEM BIOPHYS, V294, P695, DOI 10.1016/0003-9861(92)90743-G; PARKS D, 1998, REACTIVE OXYGEN SPEC, P397; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PARTRIDGE CA, 1992, ARCH BIOCHEM BIOPHYS, V294, P184, DOI 10.1016/0003-9861(92)90155-P; Pasquet JPEE, 1996, BIOCHIMIE, V78, P785, DOI 10.1016/S0300-9084(97)82537-0; Patetsios P, 1996, ANN NY ACAD SCI, V800, P243, DOI 10.1111/j.1749-6632.1996.tb33318.x; PFEFFER KD, 1994, J IMMUNOL, V153, P1789; Poss WB, 1996, AM J PHYSIOL-LUNG C, V270, pL941, DOI 10.1152/ajplung.1996.270.6.L941; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 1997, ARCH BIOCHEM BIOPHYS, V339, P125, DOI 10.1006/abbi.1996.9844; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROSS R, 1992, INFLAMMATION BASIC P, P1057; RYAN US, 1986, J TISSUE CULT METHOD, V10, P7; Sanders SA, 1997, EUR J BIOCHEM, V245, P541, DOI 10.1111/j.1432-1033.1997.00541.x; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Sarnesto A, 1996, LAB INVEST, V74, P48; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SCHWARTZ CJ, 1993, AM J CARDIOL, V71, pB9, DOI 10.1016/0002-9149(93)90139-4; SELLAK H, 1994, BLOOD, V83, P2669; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; Suzuki H, 1998, P NATL ACAD SCI USA, V95, P4754, DOI 10.1073/pnas.95.8.4754; TAN S, 1995, SOUTHERN MED J, V88, P479, DOI 10.1097/00007611-199504000-00021; TAN S, 1993, FREE RADICAL BIO MED, V15, P407, DOI 10.1016/0891-5849(93)90040-2; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; TERADA LS, 1992, P NATL ACAD SCI USA, V89, P3362, DOI 10.1073/pnas.89.8.3362; TERADA LS, 1991, AM J PHYSIOL, V260, pH805, DOI 10.1152/ajpheart.1991.260.3.H805; TERADA LS, 1992, AM J PHYSIOL, V263, pL394, DOI 10.1152/ajplung.1992.263.3.L394; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; WEINBROUM A, 1995, AM J PHYSIOL-GASTR L, V268, pG988, DOI 10.1152/ajpgi.1995.268.6.G988; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; YAMANAKA H, 1992, METABOLISM, V41, P364, DOI 10.1016/0026-0495(92)90069-M; ZIMMERMAN BJ, 1988, AM J PHYSIOL, V255, pH202, DOI 10.1152/ajpheart.1988.255.1.H202	76	198	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4985	4994		10.1074/jbc.274.8.4985	http://dx.doi.org/10.1074/jbc.274.8.4985			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988743	hybrid			2022-12-27	WOS:000078698200068
J	Kim, E; Arnould, T; Sellin, LK; Benzing, T; Fan, MJ; Gruning, W; Sokol, SY; Drummond, I; Walz, G				Kim, E; Arnould, T; Sellin, LK; Benzing, T; Fan, MJ; Gruning, W; Sokol, SY; Drummond, I; Walz, G			The polycystic kidney disease 1 gene product modulates Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; BETA-CATENIN; C-JUN; MOLECULAR MECHANISM; XENOPUS EMBRYOS; AXIS INDUCTION; PROTEIN; EXPRESSION; PATHWAY; LITHIUM	Two distinct signaling pathways, involving Wnt signaling and polycystin, have been found to be critical for normal kidney development. Renal tubulogenesis requires the presence of certain Wnt proteins, whereas mutations in polycystin impede the terminal differentiation of renal tubular epithelial cells, causing the development of large cystic kidneys that characterize autosomal dominant polycystic kidney disease. Polycystin is an integral membrane protein, consisting of several extracellular motifs indicative of cell-cell and cell-matrix interactions, coupled through multiple transmembrane domains to a functionally active cytoplasmic domain. We report here that expression of the C-terminal cytoplasmic domain of polycystin stabilizes soluble endogenous beta-catenin and stimulates TCF-dependent gene transcription in human embryonic kidney cells. Microinjection of the polycystin C-terminal cytoplasmic do main induces dorsalization in zebrafish, Our findings suggest that polycystin has the capacity to modulate Wnt signaling during renal development.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Mol & Dev Neurosci, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Renal Unit, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Walz, G (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA.	gwalz@bidmc.harvard.edu	Benzing, Thomas/X-5476-2019	Sokol, Sergei/0000-0002-3963-9202	NIMH NIH HHS [MH-01147] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001147] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BURROW CR, 1997, J AM SOC NEPHROL, V8, P370; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, pS498; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Griffin MD, 1997, KIDNEY INT, V52, P1196, DOI 10.1038/ki.1997.444; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hatta K, 1996, DEV DYNAM, V205, P183, DOI 10.1002/(SICI)1097-0177(199602)205:2<183::AID-AJA9>3.0.CO;2-E; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KELLY GM, 1995, MECH DEVELOP, V53, P261, DOI 10.1016/0925-4773(95)00442-4; Kispert A, 1996, DEVELOPMENT, V122, P3627; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Peters DJM, 1996, LAB INVEST, V75, P221; Pierce SB, 1996, DEV BIOL, V175, P256, DOI 10.1006/dbio.1996.0113; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602	46	227	236	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4947	4953		10.1074/jbc.274.8.4947	http://dx.doi.org/10.1074/jbc.274.8.4947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988738	hybrid			2022-12-27	WOS:000078698200063
J	Law, BK; Norgaard, P; Gnudi, L; Kahn, BB; Poulson, HS; Moses, HL				Law, BK; Norgaard, P; Gnudi, L; Kahn, BB; Poulson, HS; Moses, HL			Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; IN-VIVO; GROWTH; RECEPTOR; INSULIN; PHOSPHORYLATION	Previously, the protein farnesyltransferase inhibitor (FTI), L-744,832, has been shown to inhibit the proliferation of a number of tumor cell lines in vitro in a manner that correlated with the inhibition of the mitogen-activated protein kinase cascade. Here we show that FTI inhibits p70(s6k) phosphorylation in mammary tumors in vivo in transgenic mice. Furthermore, in a mouse keratinocyte cell line, FTI inhibits p70(s6k) phosphorylation and activity and inhibits PHAS-1 phosphorylation in vitro in both rapidly growing cells and in growth factor-stimulated quiescent cells, Dominant-negative Ras expression inhibits p70(s6k) stimulation by epidermal growth factor, demonstrating a requirement for Pas activity during p70(s6k) activation. FTI does not inhibit protein kinase B phosphorylation on Ser(473), indicating that FTI does not act by inhibiting phosphatidylinositol 3-kinase, FTI also inhibits DNA synthesis in keratinocytes, and inhibition of DNA synthesis correlates closely with p70(S6k) inhibition. Rapamycin, an inhibitor of p70(s6k) and PHAS-1 phosphorylation, causes a 30-45% reduction in DNA synthesis in keratinocytes, while FTI induces an 80-90% reduction in DNA synthesis. These observations suggest that alteration of p70(s6k) and PHAS-1 function by FTI are responsible for a substantial portion of the growth-inhibitory properties of FTI. Together, these data demonstrate that p70S6k and PHAS-1 are novel downstream targets of FTI and suggest that the antitumor properties of FTI are probably due to the inhibition of multiple mitogenic pathways.	Vanderbilt Univ, Ctr Canc, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Rigshosp, Finsen Ctr, Sect Radiat Biol, DK-2100 Copenhagen, Denmark; Beth Israel Deaconess Med Ctr, Dept Med, Diabet Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Vanderbilt University; Vanderbilt University; Rigshospitalet; University of Copenhagen; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Moses, HL (corresponding author), Vanderbilt Univ, Ctr Canc, 649 Med Res Bldg II, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Law, Brian/L-6043-2019	gnudi, luigi/0000-0002-6353-630X	NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043051, R01DK043051] Funding Source: NIH RePORTER; NCI NIH HHS [CA09582] Funding Source: Medline; NIDDK NIH HHS [R01 DK043051, DK43051] Funding Source: Medline; PHS HHS [A42572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; MANGUES R, 1998, CANCER RES, V58, P153; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SUN JZ, 1995, CANCER RES, V55, P4243; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	50	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4743	4748		10.1074/jbc.274.8.4743	http://dx.doi.org/10.1074/jbc.274.8.4743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988711	hybrid			2022-12-27	WOS:000078698200036
J	Chiorini, JA; Miyamoto, S; Harkin, SJ; Safer, B				Chiorini, JA; Miyamoto, S; Harkin, SJ; Safer, B			Genomic cloning and characterization of the human eukaryotic initiation factor-2 beta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; GENE; FACTOR-EIF-2; EXPRESSION	The translation initiation factor eIF2 consists of three subunits that are present in equal molar amounts. The genomic DNA containing the gene for eIF2 beta and its promoter were cloned and sequenced to characterize further the mechanism of their regulated synthesis. Whereas Southern blot analysis indicated that a number of copies of the gene may exist, only one full-length intron-containing copy was identified. Similar to the eIF2 alpha promoter, the eIF2 beta promoter is TATA-less, CAAT-less, and CC-rich and contains an alpha-Pal binding motif, Mutation of the alpha-Pal binding sequence resulted in an 8-fold decrease in activity when assayed by the luciferase reporter gene constructs. The data suggest a common mechanism of transcriptional control for the two cloned subunits of eIF2.	NHLBI, DIR, Mol Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Safer, B (corresponding author), NHLBI, DIR, Mol Hematol Branch, NIH, Bldg 10,Rm 7D18,MSC 1654, Bethesda, MD 20892 USA.							CHIORINI JA, 1993, J BIOL CHEM, V268, P13748; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; SELDEN RF, 1987, CURRENT PROTOCOLS MO	14	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4195	4201		10.1074/jbc.274.7.4195	http://dx.doi.org/10.1074/jbc.274.7.4195			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933616	hybrid			2022-12-27	WOS:000078575500040
J	Nadeau, OW; Domanski, P; Usacheva, A; Uddin, S; Platanias, LC; Pitha, P; Raz, R; Levy, D; Majchrzak, B; Fish, E; Colamonici, OR				Nadeau, OW; Domanski, P; Usacheva, A; Uddin, S; Platanias, LC; Pitha, P; Raz, R; Levy, D; Majchrzak, B; Fish, E; Colamonici, OR			The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation - Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINE RECEPTORS; ANTIVIRAL STATE; IFN-ALPHA; SUBUNIT; KINASE; PATHWAY; EXPRESSION; PROTEIN	The precise role of the different subunits (alpha/IFNAR1 and beta(L)/IFNAR2) of the type I interferon receptor (IFN-R) in the activation of signal transducer and activator of transcription (Stat) 1, Stat2, and Stat3 has not yet been established. In this report we demonstrate that there are functionally redundant phosphotyrosine-dependent and -independent binding sites for Stat2 in the alpha and beta subunits of the type I IFN-R, Expression of a type I IFN-R containing only the constitutive Stat2 site or the proximal tyrosines of beta(L), but not the docking site on the a chain (Tyr(466) and Tyr(481)), supported low levels of Stat2 activation. However, the presence of only one intact Stat2 site did not lead to induction of interferon-stimulated gene factor 3 (ISGF3) or an antiviral state. Normal levels of Stat2 tyrosine phosphorylation, induction of ISGF3, and an antiviral effect always required the proximal tyrosines of beta(L) and at least one of the other Stat2 sites (Tyr(alpha 466,481) or beta(L404-462)). These data suggest that a threshold of Stat2 tyrosine phosphorylation is required for complete activation of ISGF3. Interestingly, a receptor in which all tyrosines were mutated to phenylalanine shows normal Stat3 phosphorylation and low levels of activation of Stat1.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Moscow Region, Russia; Univ Illinois, Hematol Oncol Sect, Chicago, IL 60606 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	University of Tennessee System; University of Tennessee Health Science Center; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; New York University; Johns Hopkins University; Johns Hopkins Medicine	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott,Rm E403 M-C 868, Chicago, IL 60612 USA.	ocolamon@uic.edu	Usacheva, Anna/J-7543-2018	Usacheva, Anna/0000-0001-7508-6513; Levy, David/0000-0002-7320-7788; Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; GHISLAIN J, 1995, J BIOL CHEM, V270, P21785, DOI 10.1074/jbc.270.37.21785; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4045	4052		10.1074/jbc.274.7.4045	http://dx.doi.org/10.1074/jbc.274.7.4045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933596	hybrid			2022-12-27	WOS:000078575500020
J	Overall, CM; King, AE; Sam, DK; Ong, AD; Lau, TTY; Wallon, UM; DeClerck, YA; Atherstone, J				Overall, CM; King, AE; Sam, DK; Ong, AD; Lau, TTY; Wallon, UM; DeClerck, YA; Atherstone, J			Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase a by site-directed mutagenesis - The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HUMAN 72-KDA GELATINASE; HIGH-AFFINITY BINDING; MATRIX METALLOPROTEINASE; PROGELATINASE-A; CRYSTAL-STRUCTURE; AUTOPROTEOLYTIC ACTIVATION; EXTRACELLULAR-MATRIX; HUMAN-FIBROBLASTS; KINETIC-ANALYSIS	Cell surface activation of progelatinase A occurs in a quaternary complex with the tissue inhibitor of metalloproteinases-2 (TIMP-2) and two membrane-type matrix metalloproteinases. We have mutated the unique cationic clusters found in hemopexin modules III and TV of the carboxyl domain (C domain) of human gelatinase A to determine their role in binding TIMP-2. Twelve single, double, and triple site-directed mutations were produced that exhibited different TIMP-2 binding properties. Notably, single alanine substitutions at Lys(547) and Lys(617) reduced TIMP-2 binding by an order of magnitude from that of the recombinant wild-type C domain. Mutations that completely disrupted the C domain TIMP-2 interaction were K558A/R561A, K610T/K617A, and K566A/K568A/K617A. A triple mutation, K566A/K568A/K575A, having TIMP-2 binding indistinguishable from the wild-type C domain (K-d 3.0 X 10-2 M), showed that simple reduction of net positive charge does not reduce TIMP-2 affinity. Because the double mutation R566A/K568A also did not alter TIMP-2 binding, these data do not confirm previously reported chimera studies that indicated the importance of the triple lysine cluster at positions 566/567/568 in TIMP-2 binding. Nonetheless, a subtle role in TIMP-2 interaction for the 566/567/568-lysine triad is indicated from the enhanced reduction in TIMP-2 binding that occurs when mutations here were combined with K617A. Thus, these analyses indicate that the TIMP-2 binding surface lies at the junction of hemopexin modules III and IV on the peripheral rim of the gelatinase A C domain. This location implies that considerable molecular movement of the TIMP-2 C domain complex would be needed for the bound TIMP-2 to inhibit in cis the gelatinase A active site.	Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Los Angeles, CA 90027 USA	University of British Columbia; University of British Columbia; Children's Hospital Los Angeles; University of Southern California	Overall, CM (corresponding author), Univ British Columbia, Fac Dent, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	overall@interchange.ubc.ca		Lau, Tim/0000-0001-6447-7797; DeClerck, Yves/0000-0002-3688-0113				Assmann V, 1998, J CELL SCI, V111, P1685; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; CUNNINGHAM BG, SCIENCE, V244, P1081; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIEDMAN R, 1992, J BIOL CHEM, V267, P15398; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hewitt RE, 1996, TRENDS GLYCOSCI GLYC, V8, P23, DOI 10.4052/tigg.8.23; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Maurus R, 1997, BBA-PROTEIN STRUCT M, V1341, P1, DOI 10.1016/S0167-4838(97)00064-2; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; OVERALL CM, 1999, IN PRESS ANN NY ACAD; OVERALL CM, 1991, TRENDS GLYCOSCI GLYC, V3, P384; OVERALL CM, 1999, IN PRESS INHIBITORS; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	48	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4421	4429		10.1074/jbc.274.7.4421	http://dx.doi.org/10.1074/jbc.274.7.4421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933646	hybrid			2022-12-27	WOS:000078575500070
J	Tian, XQ; Holick, MF				Tian, XQ; Holick, MF			A liposomal model that mimics the cutaneous production of vitamin D-3 - Studies of the mechanism of the membrane-enhanced thermal isomerization of previtamin D-3 to vitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTROPIC PHASE-BEHAVIOR; CHOLESTEROL SIDE-CHAIN; HUMAN-SKIN; LIPID-PEROXIDATION; PHOTOSYNTHESIS; ORGANIZATION; ERGOSTEROL; TAMOXIFEN; BILAYERS; NMR	We reported previously that the rate of previtamin D-3 (preD(3)) half right arrow over half left arrow vitamin D-3 isomerization was enhanced by about 10 times in the skin compared with that in organic solvents, To elucidate the mechanism by which the rate of this reaction is enhanced in the skin, we developed a liposomal model that mimicked the enhanced isomerization of preD(3) to vitamin D-3 that was described in human skin. Using this model we studied the effect of changing the polarity of preD(3) as well as changing the chain length and the degree of saturation of liposomal phospholipids on the kinetics of preD(3) half right arrow over half left arrow vitamin D-3 isomerization, We found that a decrease in the hydrophilic interaction of the preD(3) with liposomal phospholipids by an esterification of the 3 beta-hydroxy of preD(3) (previtamin D-3-3 beta-acetate) reduced the rate of the isomerization by 67%. The addition of a hydroxyl on C-25 of the hydrophobic side chain (25-hydroxyprevitamin D-3), which decreased the hydrophobic interaction of preD(3) with the phospholipids, reduced the rate by 87%, In contrast, in an isotropic n-hexane solution, there was little difference among the rates of the conversion of preD(3), its BP-acetate, and 25-hydroxy derivatives to their corresponding vitamin D-3 compounds, We also determined rate constants (k) of preD(3) half right arrow over half left arrow vitamin D-3 isomerization in liposomes containing phosphatidylcholines with different carbon chain lengths, The rates of the reaction were found to be enhanced as the number of carbons (C-n) in the hydrocarbon chain of the phospholipids increased from 10 to 18, In conclusion, these results support our hypothesis that amphipathic interactions between preD(3) and membrane phospholipids stabilize preD(3) in its "cholesterol like" cZc-conformer, the only conformer of preD(3) that can convert to vitamin D-3. The stronger these interactions were, the more preD(3) was likely in its cZc conformation at any moment and the faster was the rate of its conversion to vitamin D-3.	Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Physiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Vitamin D Skin & Bone Res Lab, Endocrinol Nutr & Diabet Sect, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Holick, MF (corresponding author), Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA.	mfholick@bu.edu		Holick, Michael/0000-0001-6023-9062	NIAMS NIH HHS [R0-AR-36963] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bittman R, 1997, Subcell Biochem, V28, P145; CASSIS EG, 1982, PHOTOCHEM PHOTOBIOL, V35, P439; DAUBEN WG, 1988, J ORG CHEM, V53, P5376, DOI 10.1021/jo00257a039; DAUBEN WG, 1987, J ORG CHEM, V53, P5070; HAVINGA E, 1973, EXPERIENTIA, V29, P1181, DOI 10.1007/BF01935064; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; HOLICK MF, 1995, P NATL ACAD SCI USA, V92, P3124, DOI 10.1073/pnas.92.8.3124; HOLICK MF, 1994, AM J CLIN NUTR, V60, P619, DOI 10.1093/ajcn/60.4.619; HOLICK MF, 1989, VERTEBRATE ENDOCRINO, V3, P7; LANCEEHERMKENS AMW, 1977, BIOCHIM BIOPHYS ACTA, V470, P141, DOI 10.1016/0005-2736(77)90095-5; MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884; MCMULLEN TPW, 1994, BIOPHYS J, V66, P741, DOI 10.1016/S0006-3495(94)80850-1; MCMULLEN TPW, 1993, BIOCHEMISTRY-US, V32, P516, DOI 10.1021/bi00053a016; MORIARTY RM, 1980, J AM CHEM SOC, V102, P4257, DOI 10.1021/ja00532a047; OKAMURA WH, 1995, J STEROID BIOCHEM, V53, P603, DOI 10.1016/0960-0760(95)00107-B; SCHLATMANN JLM, 1964, RECL TRAV CHIM PAY B, V83, P1173; THEUNISSEN JJH, 1986, BIOCHIM BIOPHYS ACTA, V860, P66, DOI 10.1016/0005-2736(86)90499-2; TIAN XQ, 1993, J BIOL CHEM, V268, P14888; TIAN XQ, 1995, J BIOL CHEM, V270, P8706, DOI 10.1074/jbc.270.15.8706; TIAN XQ, 1994, ENDOCRINOLOGY, V135, P655, DOI 10.1210/en.135.2.655; Tian XQ, 1995, BIOL EFFECTS LIGHT 1, P39; VERMA SP, 1983, BIOCHEMISTRY-US, V22, P4587, DOI 10.1021/bi00288a037; Villalain J, 1996, EUR J BIOCHEM, V241, P586, DOI 10.1111/j.1432-1033.1996.00586.x; WISEMAN H, 1993, FEBS LETT, V326, P285, DOI 10.1016/0014-5793(93)81809-E; WISEMAN H, 1990, FEBS LETT, V274, P107, DOI 10.1016/0014-5793(90)81341-K; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; WOODWARD RB, 1965, J AM CHEM SOC, V87, P2511, DOI 10.1021/ja01089a050; WU WG, 1991, J AM CHEM SOC, V113, P4683, DOI 10.1021/ja00012a049	28	39	41	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4174	4179		10.1074/jbc.274.7.4174	http://dx.doi.org/10.1074/jbc.274.7.4174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933613	hybrid			2022-12-27	WOS:000078575500037
J	Beltman, J; Erickson, JR; Martin, GA; Lyons, JF; Cook, SJ				Beltman, J; Erickson, JR; Martin, GA; Lyons, JF; Cook, SJ			C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PROTEIN-TYROSINE PHOSPHORYLATION; MULTIPLE SEQUENCE ELEMENTS; N-TERMINAL KINASE; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION	Lysophosphatidic acid (LPA) stimulates the c-Fos serum response element (SRE) by activating two distinct signal pathways regulated by the small GTPases, Pas and RhoA. has activates the ERK cascade leading to phosphorylation of the transcription factors Elk-1 and Sap1a at the Ets/TCF site, RhoA regulates an undefined pathway required for the activation of the SRF/CArG site. Here we have examined the role of the Ras and RhoA pathways in activation of the SRF: and c-Fos expression in Rat-1 cells. Pertussis toxin and PD98059 strongly inhibited LPA-stimulated c-Fos expression and activation of a SRE:Luc reporter. C3 toxin completely inhibited RhoA function, partially inhibited SRE:Luc activity, but had no effect on LPA-stimulated c-Fos expression, Thus, in a physiological context the Ras-Raf-MEK-ERK pathway, but not RhoA, is required for LPA-stimulated c-Fos expression in Rat-1 cells. C3 toxin stimulated the stress-activated protein kinases JNK and p38 and potentiated c-Jun expression and phosphorylation; these properties were shared by another cellular stress agonist the protein kinase C inhibitor Ro-31-8220, However, C3 toxin alone or in combination with growth factors did not stimulate AP-1:Luc activity and actually antagonized the synergistic activation of AP-1:Luc observed in response to co-stimulation with growth factors and Ro-31-8220, These data indicate that C3 toxin is a cellular stress which antagonizes activation of AP-1 at a point downstream of stress-activated kinase activation or immediate-early gene induction.	Onyx Pharmaceut, Richmond, CA 94806 USA		Cook, SJ (corresponding author), Babraham Inst, Dept Signaling, Babraham Hall, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk			NIGMS NIH HHS [GM 16575] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL S, 1995, ONCOGENE, V11, P427; AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen RH, 1996, ONCOGENE, V12, P1493; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; DECESARE D, 1995, ONCOGENE, V11, P365; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnson CM, 1997, J NEUROSCI, V17, P6189; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORII N, 1995, METHOD ENZYMOL, V256, P196; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SASSONECORSI P, 1988, NATURE, V334, P310; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	61	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3772	3780		10.1074/jbc.274.6.3772	http://dx.doi.org/10.1074/jbc.274.6.3772			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920930	hybrid			2022-12-27	WOS:000078428200070
J	Dzantiev, L; Romano, LJ				Dzantiev, L; Romano, LJ			Interaction of Escherichia coli DNA polymerase I (Klenow fragment) with primer-templates containing N-acetyl-2-aminofluorene or N-2-aminofluorene adducts in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; FIDELITY; AMINOFLUORENE; IDENTIFICATION; TRIPHOSPHATE; JUNCTION	DNA adducts formed by aromatic amines such as N-acetyl-2-aminofluorene (AAF) and N-2-aminofluorene (AF) are known to cause mutations by interfering with the process of DNA replication. To understand this phenomenon better, a gel retardation assay was used to measure the equilibrium dissociation constants for the binding of an exonuclease-deficient Escherichia coli DNA polymerase I (Klenow fragment) to DNA primer-templates modified with an AAF or AF adduct. The results indicate that the nature of the adduct as well as the presence and nature of an added dNTP have a significant influence on the strength of the binding of the polymerase to the DNA. More specifically, it was found that the binding is 5-10-fold stronger when an AAF adduct, but not an AF adduct, is positioned in the enzyme active site. In addition, the polymerase was found to bind the unmodified primer-template less strongly in the presence of a noncomplementary dNTP than in the presence of the correct nucleotide. The same trend holds true for the primer-template having an AF adduct, although the magnitude of this difference was lower. In the case of the AAF adduct, the interaction of the polymerase with the primer-template was stronger and almost independent of the nucleotide present.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Romano, LJ (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.				NATIONAL CANCER INSTITUTE [R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA40605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BELGUISEVALLADIER P, 1995, J MOL BIOL, V249, P903, DOI 10.1006/jmbi.1995.0347; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Burnouf DY, 1998, MUTAT RES-DNA REPAIR, V407, P35, DOI 10.1016/S0921-8777(97)00058-X; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DOISY R, 1995, BIOCHEMISTRY-US, V34, P4358, DOI 10.1021/bi00013a027; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; Hoffmann GR, 1997, CHEM RES TOXICOL, V10, P347, DOI 10.1021/tx960128n; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8470; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; Liu DY, 1997, CHEM BIOL, V4, P919, DOI 10.1016/S1074-5521(97)90300-8; Mao B, 1997, BIOCHEMISTRY-US, V36, P14491, DOI 10.1021/bi972206r; Mao B, 1998, BIOCHEMISTRY-US, V37, P95, DOI 10.1021/bi972258g; MICHAELS ML, 1991, CARCINOGENESIS, V12, P1641, DOI 10.1093/carcin/12.9.1641; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; Patel DJ, 1998, CHEM RES TOXICOL, V11, P391, DOI 10.1021/tx9702143; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; Singh SB, 1998, BIOCHEMISTRY-US, V37, P878, DOI 10.1021/bi9720639; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118; ZHOU YZ, 1993, BIOCHEMISTRY-US, V32, P14043, DOI 10.1021/bi00213a038	37	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3279	3284		10.1074/jbc.274.6.3279	http://dx.doi.org/10.1074/jbc.274.6.3279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920867	hybrid			2022-12-27	WOS:000078428200007
J	Jiang, YQ; Roberts, SC; Jardim, A; Carter, NS; Shih, S; Ariyanayagam, M; Fairlamb, AH; Ullman, B				Jiang, YQ; Roberts, SC; Jardim, A; Carter, NS; Shih, S; Ariyanayagam, M; Fairlamb, AH; Ullman, B			Ornithine decarboxylase gene deletion mutants of Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DL-ALPHA-DIFLUOROMETHYLORNITHINE; TRYPANOSOMA-BRUCEI; CRITHIDIA-FASCICULATA; MOLECULAR-CLONING; CRUZI; TRYPANOTHIONE; BIOSYNTHESIS; REPLACEMENT; INHIBITORS; SPERMIDINE	A knockout strain of Leishmania donovani lacking both ornithine decarboxylase (ODC) alleles has been created by targeted gene replacement. Growth of Delta odc cells in polyamine-deficient medium resulted in a rapid and profound depletion of cellular putrescine pools, although levels of spermidine were relatively unaffected. Concentrations of trypanothione, a spermidine conjugate, were also reduced, whereas glutathione concentrations were augmented. The Delta odc L, donovani exhibited an auxotrophy for polyamines that could be circumvented by the addition of the naturally occurring polyamines, putrescine or spermidine, to the culture medium. Whereas putrescine supplementation restored intracellular pools of both putrescine and spermidine, exogenous spermidine was not converted back to putrescine, indicating that spermidine alone is sufficient to meet the polyamine requirement, and that L, donovani does not express the enzymatic machinery for polyamine degradation. The lack of a polyamine catabolic pathway in intact parasites was confirmed radiometrically, In addition, the Delta odc strain could grow in medium supplemented with either 1,3-diaminopropane or 1,5-diaminopentane (cadaverine), but polyamine auxotrophy could not be overcome by other aliphatic diamines or spermine. These data establish genetically that ODC is an essential gene in L, donovani, define the polyamine requirements of the parasite, and reveal the absence of a polyamine-degradative pathway.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	Oregon Health & Science University; University of Dundee	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	ullmanb@ohsu.edu	Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041622, R56AI041622] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41622] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; Ariyanayagam MR, 1997, MOL BIOCHEM PARASIT, V84, P111, DOI 10.1016/S0166-6851(96)02788-0; Bacchi C.J., 1987, P317; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COHN MS, 1980, J BACTERIOL, V142, P791, DOI 10.1128/JB.142.3.791-799.1980; COWARD JK, 1987, ADV ENZYME REGUL, V26, P107, DOI 10.1016/0065-2571(87)90008-2; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; GIFFIN BF, 1986, J PROTOZOOL, V33, P238, DOI 10.1111/j.1550-7408.1986.tb05599.x; GILLIN FD, 1984, J PROTOZOOL, V31, P161, DOI 10.1111/j.1550-7408.1984.tb04308.x; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HANSON S, 1992, J BIOL CHEM, V267, P2350; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; KIERSZENBAUM F, 1987, P NATL ACAD SCI USA, V84, P4278, DOI 10.1073/pnas.84.12.4278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Li F, 1996, MOL BIOCHEM PARASIT, V78, P227, DOI 10.1016/S0166-6851(96)02630-8; MAJUMDER S, 1992, J PARASITOL, V78, P371, DOI 10.2307/3283493; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; PAULUS TJ, 1982, J BACTERIOL, V152, P291; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; RojasChaves M, 1996, MOL BIOCHEM PARASIT, V75, P261, DOI 10.1016/0166-6851(95)02520-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIM H, 1988, J GEN MICROBIOL, V134, P807; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; TABOR CW, 1968, BIOCHEM BIOPH RES CO, V30, P339, DOI 10.1016/0006-291X(68)90747-X; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; WILSON K, 1991, J BIOL CHEM, V266, P1665; WITTICH RM, 1990, MOL BIOCHEM PARASIT, V38, P13, DOI 10.1016/0166-6851(90)90199-V; Zappia V, 1988, PROGR POLYAMINE RES, V250	41	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3781	3788		10.1074/jbc.274.6.3781	http://dx.doi.org/10.1074/jbc.274.6.3781			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920931	hybrid			2022-12-27	WOS:000078428200071
J	Marks, DS; Gregory, CA; Wallis, GA; Brass, A; Kadler, RE; Boot-Handford, RP				Marks, DS; Gregory, CA; Wallis, GA; Brass, A; Kadler, RE; Boot-Handford, RP			Metaphyseal chondrodysplasia type Schmid mutations are predicted to occur in two distinct three-dimensional clusters within type X collagen NC1 domains that retain the ability to trimerize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBULAR DOMAIN; SEQUENCE; PROTEIN; CHAIN; GENE; CARTILAGE; MICE; C1Q; PRECEREBELLIN; LOCALIZATION	Metaphyseal chondrodysplasia type Schmid (MCDS) is caused by mutations in COL10A1 that are clustered in the carboxyl-terminal non-collagenous (NC1) encoding domain. This domain is responsible for initiating trimerization of type X collagen during biosynthesis, We have built a molecular model of the NC1 domain trimer based on the crystal structure coordinates of the highly homologous trimeric domain of ACRP30 (adipocyte complement-related protein of 30 kDa or AdipoQ), Mapping of the MCDS mutations onto the structure reveals two specific clusters of residues as follows: one on the surface of the monomer which forms a tunnel through the center of the assembled trimer and the other on a patch exposed to solvent on the exterior surface of each monomeric unit within the assembled trimer. Biochemical studies on recombinant trimeric NC1 domain show that the trimer has an unusually high stability not exhibited by the closely related ACRP30, The high thermal stability of the trimeric NC1 domain, in comparison with ACRP30, appears to be the result of a number of factors including the 17% greater total buried solvent-accessible surface and the increased numbers of hydrophobic contacts formed upon trimerization. The 27 amino acid sequence present at the amino terminus of the NC1 domain, which has no counterpart in ACRP30, also contributes to the stability of the trimer. We have also shown that NC1 domains containing the MCDS mutations Y598D and S600P retain the ability to homotrimerize and heterotrimerize with wild type NC1 domain, although the trimeric complexes formed are less stable than those of the wild type molecule. These studies suggest strongly that the predominant mechanism causing MCDS involves a dominant interference of mutant chains on wild type chain assembly.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Boot-Handford, RP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ray.boot-handford@man.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Gregory, Carl/0000-0001-6444-5541; Brass, Andrew/0000-0002-0389-7058; Boot-Handford, Raymond/0000-0002-6167-8419				BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; GRANT WT, 1987, J BIOL CHEM, V262, P9844; GREGORY CA, 1998, THESIS U MANCHESTER; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETRY F, 1992, EUR J BIOCHEM, V209, P129, DOI 10.1111/j.1432-1033.1992.tb17269.x; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; THOMAS JT, 1991, BIOCHEM SOC T, V19, P804, DOI 10.1042/bst0190804; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; WADA C, 1991, MOL BRAIN RES, V9, P71, DOI 10.1016/0169-328X(91)90131-G; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	34	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3632	3641		10.1074/jbc.274.6.3632	http://dx.doi.org/10.1074/jbc.274.6.3632			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920912	hybrid			2022-12-27	WOS:000078428200052
J	Toraya, T; Mori, K				Toraya, T; Mori, K			A reactivating factor for coenzyme B-12-dependent diol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; GLYCEROL; ENTEROBACTERIACEAE; 1,2-PROPANEDIOL; FERMENTATION; EXPRESSION; OXYTOCA; ENZYME; GENERA	Adenosylcobalamin-dependent diol dehydratase of Klebsiella oxytoca undergoes suicide inactivation by glycerol, a physiological substrate. The coenzyme is modified through irreversible cleavage of its cobalt-carbon bond, resulting in inactivation of the enzyme by tight binding of the modified coenzyme to the active site. Recombinant DdrA and DdrB proteins of K. oxytoca were co-purified to homogeneity from cell-free extracts of Escherichia coli overexpressing the ddrAB genes. They existed as a tight complex, i.e. a putative reactivating factor, with an apparent molecular weight of 150,000, The factor consists of equimolar amounts of the two subunits with M-r of 64,000 (A) and 14,000 (B), encoded by the ddrA and ddrB genes, respectively. Therefore, its subunit structure is most likely A(2)B(2). The factor not only reactivated glycerol-inactivated and O-2-inactivated holoenzymes but also activated enzyme-cyanocobalamin complex in the presence of free adenosylcobalamin, ATP, and Mg2+. The reactivating factor mediated ATP-dependent exchange of the enzyme-bound cyanocobalamin for free 5-adeninylpentylcobalamin in the presence of ATP and Mg2+, but the reverse was not the case. Thus, it can be concluded that the inactivated holoenzyme becomes reactivated by exchange of the enzyme-bound, adenine-lacking cobalamins for free adenosylcobalamin, an adenine-containing cobalamin.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Tsushima Naka, Okayama 7008530, Japan.		Mori, Koichi/ABC-7268-2021; MORI, Koichi/B-2567-2011	Mori, Koichi/0000-0001-8865-2107; 				Babior B. M., 1982, B12, V2, P263; BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V16, P1082, DOI 10.1021/bi00625a009; BACHOVCHIN WW, 1978, BIOCHEMISTRY-US, V17, P2218, DOI 10.1021/bi00604a031; Blakley R.L., 1982, B12, V2, P381; Buckel W, 1996, CHEM SOC REV, V25, P329, DOI 10.1039/cs9962500329; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; FORAGE RG, 1982, J BACTERIOL, V149, P413, DOI 10.1128/JB.149.2.413-419.1982; FORAGE RG, 1979, BIOCHIM BIOPHYS ACTA, V569, P249, DOI 10.1016/0005-2744(79)90060-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HONDA S, 1980, J BACTERIOL, V143, P1458, DOI 10.1128/JB.143.3.1458-1465.1980; HOSOI N, 1978, J FERMENT TECHNOL, V56, P566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mori K, 1997, BIOSCI BIOTECH BIOCH, V61, P1729, DOI 10.1271/bbb.61.1729; Mori K, 1997, J BIOL CHEM, V272, P32034, DOI 10.1074/jbc.272.51.32034; POZNANSKAYA AA, 1977, BIOCHIM BIOPHYS ACTA, V484, P236, DOI 10.1016/0005-2744(77)90128-0; Retey J., 1982, B12, VII, P357; Sambrook J., 1989, MOL CLONING, pA1; SANDO GN, 1976, BIOCHIM BIOPHYS ACTA, V428, P228; SCHNEIDER Z, 1966, ACTA BIOCHIM POL, V13, P311; SWITZER RL, 1982, B12, V2, P289; Tobimatsu T, 1997, ARCH BIOCHEM BIOPHYS, V347, P132, DOI 10.1006/abbi.1997.0325; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; TORAYA T, 1978, J BACTERIOL, V135, P726, DOI 10.1128/JB.135.2.726-729.1978; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; Toraya T., 1982, B12, P233; USHIO K, 1982, J NUTR SCI VITAMINOL, V28, P225; WAGNER OW, 1966, J BIOL CHEM, V241, P1751	36	67	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3372	3377		10.1074/jbc.274.6.3372	http://dx.doi.org/10.1074/jbc.274.6.3372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920879	hybrid			2022-12-27	WOS:000078428200019
J	Galiegue, S; Jbilo, O; Combes, T; Bribes, E; Carayon, P; Le Fur, G; Casellas, P				Galiegue, S; Jbilo, O; Combes, T; Bribes, E; Carayon, P; Le Fur, G; Casellas, P			Cloning and characterization of PRAX-1 - A new protein that specifically interacts with the peripheral benzodiazepine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; MOLECULAR-CLONING; SH3 DOMAINS; LOCALIZATION; CELLS; BINDING; STEROIDOGENESIS; EXPRESSION; MEMBRANE; INVITRO	Using a cytoplasmic domain of the peripheral benzodiazepine receptor (PBR) as a bait in the yeast two-hybrid system, we have isolated a cDNA encoding a new protein that specifically interacts with PER. We named it PRAX-1, for peripheral benzodiazepine receptor-associated protein 1. PRAX-1 is a 1857-amino acid protein, the sequence of which was structurally unrelated to any known proteins. The gene encoding PRAX-1 is located in the q22-q23 region of the long arm of the human chromosome 17. The PRAX-1 mRNA is 7.5 kilobase pairs, predominantly expressed in the central nervous system, pituitary gland, and thymus, At the protein level, we found the PRAX-1 as a single 220-250-kDa protein in the brain and in many different human cell lines tested using specific antibody raised against PRAX-1, Parallel analysis of the PRAX-1 mRNA and protein expression performed in mouse and rat gave similar results. Immunocytochemistry analysis carried out to define the distribution of the PRAX-1 protein in the rat brain showed that PRAX-1 was prevalent in the mesolimbic system, specially abundant in the CA1 subfield of the hippocampus. Exhibiting several domains involved in protein-protein interaction (three proline-rich domains, three leucine-zipper motifs, and an Src homology region 3-like domain), the PRAX-1 may be looked upon as a new adaptator protein. We show that both the Src homology region 3-like domain and a proline-rich domain in PRAX-1 are required for the interaction with PER, PRAX-1 is a cytoplasmic protein that also partially colocalizes with PER in the mitochondria, as determined by confocal microscopy and Western blotting. Altogether our observations support a model of interaction implicating PER and this newly described protein, PRAX-1, As being the first cytoplasmic protein associated with PER, PRAX-1 is a new tool that opens new fields for exploring PER biological roles.	Sanofi Rech, Dept Immunol, F-34184 Montpellier 04, France; Sanofi Rech, F-75013 Paris, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Rech, Dept Immunol, 371 Rue Prof Joseph Blayac, F-34184 Montpellier 04, France.	pierre.casellas@sanofi.com						ANHOLT RRH, 1984, J NEUROSCI, V4, P593; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BAKER ME, 1991, CELL, V65, P721, DOI 10.1016/0092-8674(91)90379-D; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; Bessler H, 1997, INT J IMMUNOPHARMACO, V19, P249, DOI 10.1016/S0192-0561(97)00013-1; Bird TD, 1997, NEUROLOGY, V48, P949, DOI 10.1212/WNL.48.4.949; BRAESTRUP C, 1977, P NATL ACAD SCI USA, V74, P3805, DOI 10.1073/pnas.74.9.3805; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAHARD D, 1994, LAB INVEST, V70, P23; CANAT X, 1993, LIFE SCI, V52, P107, DOI 10.1016/0024-3205(93)90293-C; Carayon P, 1996, BLOOD, V87, P3170, DOI 10.1182/blood.V87.8.3170.bloodjournal8783170; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dussossoy D, 1996, CYTOMETRY, V24, P39; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEW E, 1981, P NATL ACAD SCI-BIOL, V78, P3935, DOI 10.1073/pnas.78.6.3935; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1994, MOL CELL ENDOCRINOL, V104, pR5, DOI 10.1016/0303-7207(94)90061-2; PAROLA AL, 1993, LIFE SCI, V52, P1329, DOI 10.1016/0024-3205(93)90168-3; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RUFF MR, 1985, SCIENCE, V229, P1281, DOI 10.1126/science.2994216; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P3770, DOI 10.1073/pnas.81.12.3770; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101	45	79	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2938	2952		10.1074/jbc.274.5.2938	http://dx.doi.org/10.1074/jbc.274.5.2938			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915832	hybrid			2022-12-27	WOS:000078319500050
J	Murakami, M; Kambe, T; Shimbara, S; Kudo, I				Murakami, M; Kambe, T; Shimbara, S; Kudo, I			Functional coupling between various phospholipase A(2)s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; ARACHIDONIC-ACID MOBILIZATION; MAST-CELLS; II PHOSPHOLIPASE-A(2); H SYNTHASE-1; P388D(1) MACROPHAGES; GENE DISRUPTION; GENERATION; MOUSE; INHIBITION	Several distinct phospholipase A(2)s (PLA(2)s) and two cyclooxygenases (COXs) were transfected, alone or in combination, into human embryonic kidney 293 cells, and their functional coupling during immediate and delayed prostaglandin (PG)-biosynthetic responses was reconstituted, Signaling PLA(2)s, i.e. cytosolic PLA(2) (cPLA(2)) (type IV) and two secretory PLA(2)s (sPLA(2)), types IIA (sPLA(2)-IIA) and V (sPLA(2)-V), promoted arachidonic acid (AA) release from their respective transfectants after stimulation with calcium ionophore or, when bradykinin receptor was cotransfected, with bradykinin, which evoked the immediate response, and interleukin-l plus serum, which induced the delayed response. Experiments on cells transfected with either COX alone revealed subtle differences between the PG-biosynthetic properties of the two isozymes in that COX-1 and COX-2 were favored over the other in the presence of high and low exogenous AA concentrations, respectively. Moreover, COX-2, but not COX-1, could turn on endogenous AA release, which was inhibited by a cPLA(2) inhibitor. When PLA(2) and COX were coexpressed, AA released by cPLA(2), sPLA(2)-IIA and sPLA(2)-V was converted to PGE(2) by both COX-1 and COX-2 during the immediate response and predominantly by COX-2 during the delayed response. Ca2+-independent PLA(2) (iPLA(2)) (type VI), which plays a crucial role in phospholipid remodeling, failed to couple with COX-2 during the delayed response, whereas it was linked to ionophore-induced immediate PGE(2) generation via COX-1 in marked preference to COX-2. Finally, coculture of PLA(2) and COX transfectants revealed that extracellular sPLA(2)s-IIA and -V, but neither intracellular cPLA(2) nor iPLA(2), augmented PGE, generation by neighboring COX-expressing cells, implying that the heparin-binding sPLA(2)s play a particular role as paracrine amplifiers of the PG-biosynthetic response signal from one cell to another.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.	kudo@pharm.showa-u.ac.jp						ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CAPDEVILA JH, 1996, J BIOL CHEM, V271, P22263; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; KIRIKARA K, 1998, J EXP MED, V187, P517; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1043, P34; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Naraba H, 1998, J IMMUNOL, V160, P2974; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Polgar J, 1997, BIOCHEM J, V327, P259, DOI 10.1042/bj3270259; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; SUGA H, 1995, J BIOCHEM-TOKYO, V118, P939, DOI 10.1093/jb/118.5.939; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; Tada K, 1998, J IMMUNOL, V161, P5008; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522	62	319	325	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3103	3115		10.1074/jbc.274.5.3103	http://dx.doi.org/10.1074/jbc.274.5.3103			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915849	hybrid			2022-12-27	WOS:000078319500067
J	Bertoldi, M; Frigeri, P; Paci, M; Voltattorni, CB				Bertoldi, M; Frigeri, P; Paci, M; Voltattorni, CB			Reaction specificity of native and nicked 3,4-dihydroxyphenylalanine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASES; DOPA DECARBOXYLASE; PIG-KIDNEY; ASPARTATE-AMINOTRANSFERASE; SERINE HYDROXYMETHYLTRANSFERASE; FORM; ORIGIN; ASSAY; PROBE; SITE	3,4-Dihydroxyphenylalanine (Dopa) decarboxylase is a stereospecific pyridoxal 5'-phosphate (PLP)-dependent cu-decarboxylase that converts L-aromatic amino acids into their corresponding amines, We now report that reaction of the enzyme with D-5-hydroxytryptophan or D-Dopa results in a time-dependent inactivation and conversion of the PLP coenzyme to pyridoxamine 5'-phosphate and PLP-D-amino acid Pictet-Spengler adducts, which have been identified by high performance liquid chromatography. We also show that the reaction specificity of Dopa decarboxylase toward aromatic amines depends on the experimental conditions. Whereas oxidative deamination occurs under aerobic conditions (Bertoldi, M., Moore, P. S., Maras, B., Dominici, P., and Borri Voltattorni, C, (1996) J. Biol. Chem. 271, 23954-23959; Bertoldi, M,, Dominici, P., Moore, P, S,, Maras, B., and Borri Voltattorni, C. (1998) Biochemistry 37, 6552-6561), half-transamination and Pictet-Spengler reactions take place under anaerobic conditions. Moreover, we examined the reaction specificity of nicked Dopa decarboxylase, obtained by selective tryptic cleavage of the native enzyme between Lys(334) and His(335). Although this enzymatic species does not exhibit either decarboxylase or oxidative deamination activities, it retains a large percentage of the native transaminase activity toward D-aromatic amino acids and displays a slow transaminase activity toward aromatic amines, These transamination reactions occur concomitantly with the formation of cyclic coenzyme-substrate adducts. Together with additional data, we thus suggest that native Dopa decarboxylase can exist as an equilibrium among "open," "half-open," and "closed" forms.	Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; Univ Roma Tor Vergata, Dipartimento Sci & Tecnol Chim, I-00173 Rome, Italy	University of Verona; University of Rome Tor Vergata	Voltattorni, CB (corresponding author), Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, St Grazie 8, I-37134 Verona, Italy.	cborri@borgoroma.univr.it		BERTOLDI, Mariarita/0000-0002-2337-9928				BARBONI E, 1981, BIOCHEM BIOPH RES CO, V99, P576, DOI 10.1016/0006-291X(81)91784-8; Bertoldi M, 1996, J BIOL CHEM, V271, P23954, DOI 10.1074/jbc.271.39.23954; Bertoldi M, 1998, BIOCHEMISTRY-US, V37, P6552, DOI 10.1021/bi9718898; CHARTERIS A, 1975, ANAL BIOCHEM, V66, P365, DOI 10.1016/0003-2697(75)90604-1; CHRISTENSON JG, 1970, ARCH BIOCHEM BIOPHYS, V141, P356, DOI 10.1016/0003-9861(70)90144-X; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; DOMINICI P, 1984, EXPERIENTIA, V40, P834, DOI 10.1007/BF01951979; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Ishii S, 1998, PROTEIN SCI, V7, P1802, DOI 10.1002/pro.5560070816; Ishii S, 1996, J BIOCHEM, V120, P369; KOCHHAR S, 1992, EUR J BIOCHEM, V203, P563, DOI 10.1111/j.1432-1033.1992.tb16584.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MARAS B, 1991, EUR J BIOCHEM, V201, P385, DOI 10.1111/j.1432-1033.1991.tb16295.x; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; Moore PS, 1997, FEBS LETT, V412, P245, DOI 10.1016/S0014-5793(97)00788-6; Moore PS, 1996, BIOCHEM J, V315, P249, DOI 10.1042/bj3150249; NAGATA H, 1994, J CHEM SOC P1, V2, P983; OLEARY MH, 1977, J BIOL CHEM, V252, P7168; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; RUDD EA, 1979, J MED CHEM, V22, P233, DOI 10.1021/jm00189a003; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SHERALD AF, 1973, ANAL BIOCHEM, V56, P300, DOI 10.1016/0003-2697(73)90194-2; STOVER P, 1992, J BIOL CHEM, V267, P17679; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; TANCINI B, 1988, ARCH BIOCHEM BIOPHYS, V260, P569, DOI 10.1016/0003-9861(88)90483-3; VOLTATTO.CB, 1971, FEBS LETT, V17, P231, DOI 10.1016/0014-5793(71)80153-9; VOLTATTORNI CB, 1983, BIOCHEMISTRY-US, V22, P2249, DOI 10.1021/bi00278a030	32	37	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5514	5521		10.1074/jbc.274.9.5514	http://dx.doi.org/10.1074/jbc.274.9.5514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026165	hybrid			2022-12-27	WOS:000078804400036
J	Grant, GA; Kim, SJ; Xu, XL; Hu, ZQ				Grant, GA; Kim, SJ; Xu, XL; Hu, ZQ			The contribution of adjacent subunits to the active sites of D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLYCERATE DEHYDROGENASE; BINDING; ENZYME	D-3-Phosphoglycerate dehydrogenase (PGDH) from Escherichia coli is allosterically inhibited by L-serine, the end product of its metabolic pathway. Previous results have shown that inhibition by serine has a large effect on V-max and only a small or negligible effect on K-m. PGDH is thus classified as a V-type allosteric enzyme. In this study, the active site of PGDH has been studied by site directed mutagenesis to assess the role of-certain residues in substrate binding and catalysis. These consist of a group of cationic residues (Arg-240, Arg-60, Arg-62, Lys-39, and Lys-141') that potentially form an electrostatic environment for the binding of the negatively charged substrate, as well as the only tryptophan residue found in PG;DH and which fits into a hydrophobic pocket immediately adjacent to the active site histidine residue. Interestingly Trp-139' and Lys-141' are part of the polypeptide chain of the subunit that is adjacent to the active site. The results of mutating these residues show that Arg-240, Arg-60, Arg-62, and Lys-141' play distinct roles in the binding of the substrate to the active site. Mutants of Trp-139' show that this residue may play a role in stabilizing the catalytic center of the enzyme. Furthermore, these mutants appear to have a significant effect on the cooperativity of serine inhibition and suggest a possible role for Trp-139' in the cooperative interactions between subunits.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid Ave,Box 8103, St Louis, MO 63110 USA.			Kim, Sung Joon/0000-0002-2007-6606	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORMACK B, 1991, CURRENT PROTOCOLS MO; CREIGHTON TE, 1984, PROTEINS, P7; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	13	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5357	5361		10.1074/jbc.274.9.5357	http://dx.doi.org/10.1074/jbc.274.9.5357			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026144	hybrid			2022-12-27	WOS:000078804400015
J	Heiskanen, KM; Bhat, MB; Wang, HW; Ma, JJ; Nieminen, AL				Heiskanen, KM; Bhat, MB; Wang, HW; Ma, JJ; Nieminen, AL			Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION; BCL-2; ACTIVATION; MEMBRANE	Cytochrome c is released from mitochondria into the cytosol in cells undergoing apoptosis. The temporal relationship between cytochrome c release and loss of mitochondrial membrane potential was monitored by laser-scanning confocal microscopy in single living pheochromocytoma-6 cells undergoing apoptosis induced by staurosporine. Mitochondrial membrane potential monitored by tetramethylrhodamine methyl ester decreased abruptly in individual cells from 2 to 7 h after treatment with staurosporine. Depolarization was accompanied by cytochrome c release documented by release of transfected green fluorescent protein-tagged cytochrome c in these cells. The results show that mitochondrial depolarization accompanies cytochrome c release in pheochromocytoma-6 cells undergoing apoptosis.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, W520,10900 Euclid Ave, Cleveland, OH 44106 USA.	axn25@po.cwru.edu			NIA NIH HHS [AG 13318] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG013318] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Messam CA, 1998, EXP CELL RES, V238, P389, DOI 10.1006/excr.1997.3845; Mills JC, 1998, J CELL SCI, V111, P625; NIEMINEN AL, 1990, J BIOL CHEM, V265, P2399; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rottenberg H, 1997, BIOCHEM BIOPH RES CO, V240, P68, DOI 10.1006/bbrc.1997.7605; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	296	301	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5654	5658		10.1074/jbc.274.9.5654	http://dx.doi.org/10.1074/jbc.274.9.5654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026183	hybrid			2022-12-27	WOS:000078804400054
J	Hiraiwa, H; Pan, CJ; Lin, BC; Moses, SW; Chou, JY				Hiraiwa, H; Pan, CJ; Lin, BC; Moses, SW; Chou, JY			Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL GLUCOSE-6-PHOSPHATASE SYSTEM; MUTATIONS; DEFECT; GENE; IB; 1A; ACID	Glycogen storage disease type 1b (GSD-1b) is proposed to be caused by a deficiency in microsomal glucose 6-phosphate (G6P) transport, causing a loss of glucose-6-phosphatase activity and glucose homeostasis, However, for decades, this disorder has defied molecular characterization. In this study, we characterize the structural organization of the G6P transporter gene and identify mutations in the gene that segregate with the GSD-1b disorder. We report the functional characterization of the recombinant G6P transporter and demonstrate that mutations uncovered in GSD-1b patients disrupt G6P transport. Our results, for the first time, define a molecular basis for functional deficiency in GSD-1b and raise the possibility that the defective G6P transporter contributes to neutropenia and neutrophil/monocyte dysfunctions characteristic of GSD-1b patients.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Ben Gurion Univ Negev, Div Pediat, IL-84101 Beer Sheva, Israel	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Ben Gurion University	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Rm 9S241,Bldg 10, Bethesda, MD 20892 USA.		Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785				Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; ARION WJ, 1980, J BIOL CHEM, V255, P396; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FULCERI R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P129, DOI 10.1016/0005-2736(90)90409-H; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33; IGARASHI Y, 1984, BIOCHEM BIOPH RES CO, V119, P593, DOI 10.1016/S0006-291X(84)80290-9; KILPATRICK L, 1990, J CLIN INVEST, V86, P196, DOI 10.1172/JCI114684; Kure S, 1998, BIOCHEM BIOPH RES CO, V248, P426, DOI 10.1006/bbrc.1998.8985; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Middleditch C, 1998, FEBS LETT, V433, P33, DOI 10.1016/S0014-5793(98)00878-3; MOSES SW, 1990, J PEDIAT GASTROENTER, V11, P156; NARISAWA K, 1978, BIOCHEM BIOPH RES CO, V83, P1360, DOI 10.1016/0006-291X(78)91371-2; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068	27	123	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5532	5536		10.1074/jbc.274.9.5532	http://dx.doi.org/10.1074/jbc.274.9.5532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026167	hybrid			2022-12-27	WOS:000078804400038
J	Burns, CM; Nowatzke, WL; Richardson, JP				Burns, CM; Nowatzke, WL; Richardson, JP			Activation of rho dependent transcription termination by NusG - Dependence on terminator location and acceleration of RNA release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MICROCOCCUS-LUTEUS; PROTEIN; POLYMERASE; ELONGATION; SEQUENCE; ANTITERMINATION; EFFICIENCY; LAMBDA; GENE	There is a kinetic limitation to Rho function at the first intragenic terminator in the lacZ gene (tiZ1) which can be overcome by NusG:Rho can terminate transcription with slowly moving, but not rapidly moving, RNA polymerase unless NusG is also present. Here we report further studies with two other Rho dependent terminators that are not kinetically limited (tiZ2 and lambda tR1) which show that the requirement for NusG depends on the properties of the terminator and its location in the transcription unit. NusG is also shown to increase the rate of Rho-mediated dissociation of transcription complexes arrested at a specific termination stop point in the tiZ1 region and the rates of dissociation with three different Rho factors and two different terminators correlated with their sensitivity to RNA polymerase elongation kinetics. These results suggest a model of NusG function which involves an alteration in the susceptibility of the transcription complex to Rho action which allows termination to occur within the short kinetic window when RNA polymerase is traversing the termination region.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	jrichard@bio.indiana.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI010142, R01AI010142] Funding Source: NIH RePORTER; NIAID NIH HHS [AI10142] Funding Source: Medline; NIGMS NIH HHS [GM07227] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burns CM, 1998, J MOL BIOL, V278, P307, DOI 10.1006/jmbi.1998.1691; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; BURNS CM, 1996, THESIS INDIANA U, P109; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; LI J, 1992, J BIOL CHEM, V267, P6012; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Nehrke Keith W., 1993, Gene Expression, V3, P119; NEHRKE KW, 1994, J MOL BIOL, V243, P830, DOI 10.1006/jmbi.1994.1685; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1997, J BIOL CHEM, V272, P2207; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; OLINS PO, 1983, GENE, V26, P11, DOI 10.1016/0378-1119(83)90031-8; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; RUTESHOUSER EC, 1989, J MOL BIOL, V208, P23, DOI 10.1016/0022-2836(89)90085-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGESADA K, 1980, NUCLEIC ACIDS RES, V8, P3355, DOI 10.1093/nar/8.15.3355; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; Washburn RS, 1996, J MOL BIOL, V260, P347, DOI 10.1006/jmbi.1996.0405; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	35	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5245	5251		10.1074/jbc.274.8.5245	http://dx.doi.org/10.1074/jbc.274.8.5245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988775	hybrid			2022-12-27	WOS:000078698200100
J	Aridor, M; Bannykh, SI; Rowe, T; Balch, WE				Aridor, M; Bannykh, SI; Rowe, T; Balch, WE			Cargo can modulate COPII vesicle formation from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; MANNOSE 6-PHOSPHATE RECEPTORS; VIRAL MEMBRANE GLYCOPROTEIN; CLATHRIN-COATED VESICLES; PROTEIN-TRANSPORT; SECRETORY PATHWAY; GOLGI-COMPLEX; QUALITY-CONTROL; SELECTIVE TRANSPORT; CYTOPLASMIC DOMAIN	The COPII coat complex found on endoplasmic reticulum (ER)-derived vesicles plays a critical role in cargo selection. We now address the potential role of biosynthetic cargo in modulating COPII coat assembly and vesicle budding. The ER accumulation of vesicular stomatitis glycoprotein (VSV-G), a transmembrane protein, or the soluble PiZ variant of alpha 1-antitrypsin, reduced levels of general COPII vesicle formation in vivo. Consistent with this result, conditions that prevent the export of VSV-G; from the ER led to a significant inhibition of general COPII vesicle budding from ER microsomes and the export of an endogenous recycling protein p58 in vitro. In contrast, synchronized export of VSV-G stimulated COPII vesicle budding both in vivo and in vitro. Under conditions where VSV-G is retained in the ER, we find that it can to be recovered in pre-budding complexes containing COPII components. These results suggest that the export of biosynthetic cargo is integrated with ER functions involved in protein folding and oligomerization. The ability of biosynthetic cargo to prevent or enhance ER export suggests that interactions of cargo with the COPII machinery contribute to the formation of vesicles budding from the ER.	Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell & Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNIGAN DD, 1983, J VIROL, V45, P618, DOI 10.1128/JVI.45.2.618-626.1983; FABBRI M, 1994, J BIOL CHEM, V269, P26848; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KELLER GA, 1986, J HISTOCHEM CYTOCHEM, V34, P12223; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Melancon P, 1989, Soc Gen Physiol Ser, V44, P175; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Pryde JG, 1998, MOL CELL BIOL, V18, P1125, DOI 10.1128/MCB.18.2.1125; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JE, 1996, SCIENCE, V272, P272; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SIFERS RN, 1989, J BIOL CHEM, V264, P15696; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SIFERS RN, 1992, SEMIN LIVER DIS, V12, P301, DOI 10.1055/s-2008-1040399; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; STORRIE B, 1994, J CELL SCI, V107, P1309; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU Y, 1994, P NATL ACAD SCI USA, V267, P1072; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; ZAGOURAS P, 1991, J VIROL, V65, P1976, DOI 10.1128/JVI.65.4.1976-1984.1991	84	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4389	4399		10.1074/jbc.274.7.4389	http://dx.doi.org/10.1074/jbc.274.7.4389			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933643	hybrid			2022-12-27	WOS:000078575500067
J	Laird, AD; Morrison, DK; Shalloway, D				Laird, AD; Morrison, DK; Shalloway, D			Characterization of Raf-1 activation in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-CYCLE; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; INDEPENDENT MANNER; RAS BINDING; REQUIREMENT; PATHWAY; DOMAIN	We have used site-directed mutagenesis to explore the mechanisms underlying Raf-1 activation in mitosis, and we have excluded most previously characterized activating interactions. Our results indicate that the primary locus of activation lies in the carboxyl-half of the molecule, although the extent of activation can be influenced by the amino-proximal region, particularly by the Raf-1 zinc finger, We also found that Raf-1 is hyperphosphorylated in mitosis at multiple sites within residues 283-302 and that these hyperphosphorylations are not required for activation, In addition, neither Mek1 nor Mek2 are stably activated in coordination with Raf-1 in nocodazole-arrested cells. Overall, the data suggest that the mechanism(s) responsible for activating Raf-1 during mitosis, and the subsequent downstream effects, are distinct from those involved in growth factor stimulation.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA; NCI, Frederick Canc Res & Dev Ctr, ABL, Mol Basis Carcinogenesis Lab,Basic Res Program, Frederick, MD 21702 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shalloway, D (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA.	dis2@cornell.edu			NCI NIH HHS [CA 68743, CA32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068743, R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HAGAG N, 1990, ONCOGENE, V5, P1481; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huby RDJ, 1998, J BIOL CHEM, V273, P12024, DOI 10.1074/jbc.273.20.12024; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lovric J, 1996, ONCOGENE, V12, P1109; Lovric J, 1998, J BIOL CHEM, V273, P22848; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MCGREW BR, 1992, ONCOGENE, V7, P33; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; Popik W, 1996, MOL CELL BIOL, V16, P6532; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TAYLOR SJ, 1993, CURR OPIN CELL BIOL, V3, P36; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Torres K, 1998, CANCER RES, V58, P3620; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	82	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4430	4439		10.1074/jbc.274.7.4430	http://dx.doi.org/10.1074/jbc.274.7.4430			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933647	hybrid			2022-12-27	WOS:000078575500071
J	Li, J; Foitzik, K; Calautti, E; Baden, H; Doetschman, T; Dotto, GP				Li, J; Foitzik, K; Calautti, E; Baden, H; Doetschman, T; Dotto, GP			TGF-beta 3, but not TGF-beta 1, protects keratinocytes against 12-O-tetradecanoylphorbol-13-acetate-induced cell death in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; MOUSE EPIDERMIS; APOPTOSIS; DIFFERENTIATION; MICE; IDENTIFICATION; EXPRESSION; DISRUPTION; RECEPTORS	We have examined the role that individual TGF-beta isoforms, and in particular TGF-beta 3, play in control of epidermal homeostasis, Mice with a knockout mutation of the TGF-beta 3 gene die a few hours after birth. A full-thickness skin grafting approach was used to investigate the postnatal development and homeostatic control of the skin of these mice. Grafted skin of mice with a disruption of the TGF-beta 3 gene developed similarly to grafts of wild type and TGF-beta 1 knockout animals. However, a strikingly different response was observed after acute treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), When exposed to TPA, the grafted skin of wild type and TGF-beta 1 knockout mice underwent a hyperplastic response similar to that of normal mouse skin. In marked contrast, TPA treatment of TGF-beta 3 knockout grafts induced widespread areas of keratinocyte cell death. Analysis of cultured keratinocytes treated with purified TGF-beta isoforms revealed that TGF-beta 3 plays a direct and specific function in protecting keratinocytes against TPA-induced cell death. The protective function of TGF-beta 3 on TPA-induced cell death was not because of general suppression of the signaling pathways triggered by this agent, as ERK1/2 activation occurred to a similar if not greater extent in TGF-beta 3-treated versus control keratinocytes. Instead, TGF-beta 3 treatment led to a significant reduction in TPA-induced c-Jun N-terminal kinase activity, which was associated and possibly explained by specific counteracting effects of TGF-beta 3 on TPA-induced disruption of keratinocyte focal adhesions.	MGH E, CBRC, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Harvard University; University System of Ohio; University of Cincinnati	Dotto, GP (corresponding author), MGH E, CBRC, 13th St, Charlestown, MA 02129 USA.	Paolo.Dotto@cbrc2.mgh.harvard.edu	Calautti, Enzo/M-8283-2018	Calautti, Enzo/0000-0002-4439-9709	NCI NIH HHS [CA73796, CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; Benassi L, 1997, J INVEST DERMATOL, V109, P276, DOI 10.1111/1523-1747.ep12335756; Brissette JL, 1996, GENE DEV, V10, P2212, DOI 10.1101/gad.10.17.2212; Budunova IV, 1996, MOL CARCINOGEN, V15, P202; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Escherick J S, 1993, Cancer Res, V53, P5517; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MASSAGUE J, 1992, CANCER SURV, V12, P81; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SHAH M, 1995, J CELL SCI, V108, P985; Shimizu S, 1996, ONCOGENE, V12, P2045; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu JS, 1996, CANCER RES, V56, P5423	40	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4213	4219		10.1074/jbc.274.7.4213	http://dx.doi.org/10.1074/jbc.274.7.4213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933619	hybrid			2022-12-27	WOS:000078575500043
J	Tandai-Hiruma, M; Endo, T; Kobata, A				Tandai-Hiruma, M; Endo, T; Kobata, A			Detection of novel carbohydrate binding activity of interleukin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; HUMAN-PREGNANCY URINE; SUGAR CHAINS; N-ACETYLGALACTOSAMINE; MONOCLONAL-ANTIBODY; STRUCTURAL-ANALYSIS; UROMODULIN; LECTIN; PROTEIN	Tamm-Horsfall glycoprotein (THGP) and the oligosaccharide fraction liberated from THGP by hydrazinolysis inhibited tetanus toroid-induced T cell proliferation. Intact THGP showed approximately 100-fold more inhibitory activity than the free oligosaccharides. After fractionating the oligosaccharides by anion-exchange column chromatography, the inhibitory activity could be detected in a sialidase-resistant acidic oligosaccharide fraction (fraction AR). The inhibitory activity of fraction AR was not observed when the fraction was added to the T cell culture medium 24 h after the addition of tetanus toroid. Increased concentration of interleukin (IL) 1 beta and decreased concentration of IL-2 were observed in the T cell culture medium after the addition of fraction AR. The oligosaccharides in fraction AR also inhibited the growth of an IL-1-dependent cell line, D10-G4. These results strongly suggested that the oligosaccharides in fraction AR bind to IL-1 beta and suppress its cytokine activity. IL-1 beta actually bound to the fraction AR immobilized on an amino-bonded thin layer plate. Fractionation of the oligosaccharides indicated that only oligosaccharides containing an N-acetylgalactosamine residue and a sulfate residue bound specifically to IL-1 beta. Removal of either the sulfate residue or the N-acetylgalactosamine residue from the oligosaccharides abolished both the proliferation-inhibition and IL-1 beta binding activities. Since IL-1 beta did not bind to thyroid-stimulating hormone, which has the sulfate group at C-4 of the N-acetylgalactosamine residue in its N-linked sugar chains, the binding of IL-1 beta toward oligosaccharides in fraction AR was considered to be highly specific.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1080071, Japan	University of Tokyo	Endo, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Glycobiol, Itabashi Ku, Tokyo 1730015, Japan.	endo@tmig.or.jp						ABBONDANZA A, 1980, BIOCHEM J, V187, P525, DOI 10.1042/bj1870525; ADLER W H, 1970, Journal of Experimental Medicine, V131, P1049, DOI 10.1084/jem.131.6.1049; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN KM, 1986, P NATL ACAD SCI USA, V83, P9119, DOI 10.1073/pnas.83.23.9119; DALLOLIO F, 1988, CARBOHYD RES, V178, P327, DOI 10.1016/0008-6215(88)80123-X; DALLOLIO F, 1991, CELL IMMUNOL, V137, P303, DOI 10.1016/0008-8749(91)90081-L; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Fukushima K, 1997, J BIOL CHEM, V272, P10579; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; KAYE J, 1984, J IMMUNOL, V133, P1339; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MAKITA A, 1963, JPN J EXP MED, V33, P361; MOONEN P, 1988, FEBS LETT, V226, P314, DOI 10.1016/0014-5793(88)81446-7; MUCHMORE AV, 1987, J IMMUNOL, V138, P2547; MUCHMORE AV, 1985, SCIENCE, V229, P479, DOI 10.1126/science.2409603; MUCHMORE AV, 1990, J LEUKOCYTE BIOL, V48, P457, DOI 10.1002/jlb.48.5.457; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; MUCHMORE AV, 1986, J BIOL CHEM, V261, P3404; OHBAYASHI H, 1989, ANAL BIOCHEM, V182, P200, DOI 10.1016/0003-2697(89)90579-4; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SERAFINICESSI F, 1979, BIOCHEM J, V183, P381, DOI 10.1042/bj1830381; SMAGULA RM, 1990, GLYCOCONJUGATE J, V7, P609, DOI 10.1007/BF01189081; TADANO K, 1982, J BIOL CHEM, V257, P1482; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; YAMAKAWA T, 1962, J BIOCHEM-TOKYO, V52, P226, DOI 10.1093/oxfordjournals.jbchem.a127602; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144	36	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4459	4466		10.1074/jbc.274.7.4459	http://dx.doi.org/10.1074/jbc.274.7.4459			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933650	hybrid			2022-12-27	WOS:000078575500074
J	Watababe, A; Kurokawa, Y; Yoshimura, T; Kurihara, T; Soda, K; Esaki, N				Watababe, A; Kurokawa, Y; Yoshimura, T; Kurihara, T; Soda, K; Esaki, N			Role of lysine 39 of alanine racemase from Bacillus stearothermophilus that binds pyridoxal 5 '-phosphate - Chemical rescue studies of Lys(39)-> Ala mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; PROTEIN-SEQUENCE DETERMINATION; SITE-DIRECTED MUTANT; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; ENZYME-PURIFICATION; BRONSTED ANALYSIS; EXOGENOUS AMINES; LYSYL RESIDUE; DNA	The lysine residue binding with the cofactor pyridoxal 5'-phosphate (PLP) plays an important role in catalysis, such as in the transaldimination and abstraction of alpha-hydrogen from a substrate amino acid in PLP-dependent enzymes. We studied the role of Lys(39) Of alanine racemase (EC 5.1.1.1) from Bacillus stearothermophilus, the PLP-binding residue of the enzyme, by replacing it site-specifically with alanine and characterizing the resultant K39A mutant enzyme. The mutant enzyme turned out to be inherently inactive, but gained an activity as high as about 0.1% of that of the wild-type enzyme upon addition of 0.2 M methylamine. The amine-assisted activity of the mutant enzyme depended on the pK(a), values and molecular volumes of the alkylamines used. A strong kinetic isotope effect was observed when alpha-deuterated D-alanine was used as a substrate in the methylamine-assisted reaction, but little effect was observed using its antipode, In marked contrast, only L-enantiomer of alanine showed a solvent isotope effect in deuterium oxide in the methylamine-assisted reaction. These results suggest that methylamine serves as a base not only to abstract the alpha-hydrogen from D-alanine but also to transfer a proton from water to the alpha-position of the deprotonated (achiral) intermediate to form D-alanine. Therefore, the exogenous amine can be regarded as a functional group fully representing Lys(39) of the wild-type enzyme. Lys(39) Of the wild-type enzyme probably acts as the base catalyst specific to the D-enantiomer of alanine. Another residue specific to the L-enantiomer in the wild-type enzyme is kept intact in the K39A mutant.	Kyoto Univ, Inst Chem Res, Lab Biofunct Mol, Uji, Kyoto 6110011, Japan; Kansai Univ, Fac Engn, Dept Biotechnol, Suita, Osaka 5648680, Japan	Kyoto University; Kansai University	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Lab Biofunct Mol, Uji, Kyoto 6110011, Japan.	esaki@scl.kyoto-u.ac.jp						BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; Boehlein SK, 1997, J BIOL CHEM, V272, P12384, DOI 10.1074/jbc.272.19.12384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS B, 1992, BIOCHEM BIOPH RES CO, V184, P1386, DOI 10.1016/S0006-291X(05)80036-1; ESAKI N, 1985, BIOCHEMISTRY-US, V24, P3857, DOI 10.1021/bi00336a007; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; Fersht A., 1985, ENZYME STRUCTURE MEC; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P13363, DOI 10.1021/bi961453c; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; HARPEL MR, 1994, BIOCHEMISTRY-US, V33, P5553, DOI 10.1021/bi00184a026; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; INAGAKI K, 1986, BIOCHEMISTRY-US, V25, P3268, DOI 10.1021/bi00359a028; KIRSCH JF, 1990, ANN NY ACAD SCI, V585, P48, DOI 10.1111/j.1749-6632.1990.tb28040.x; Kurokawa Y, 1998, J BIOCHEM-TOKYO, V124, P1163, DOI 10.1093/oxfordjournals.jbchem.a022234; LU ZC, 1993, J BIOL CHEM, V268, P8727; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; Nishino J, 1997, J BIOCHEM-TOKYO, V121, P604; Rynkiewicz MJ, 1996, BIOCHEMISTRY-US, V35, P16174, DOI 10.1021/bi961311i; SAWADA S, 1994, BIOSCI BIOTECH BIOCH, V58, P807, DOI 10.1271/bbb.58.807; SEKIMOTO T, 1993, J BIOL CHEM, V268, P27039; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; TANIZAWA K, 1989, J BIOL CHEM, V264, P2445; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TOYAMA H, 1991, J BIOL CHEM, V266, P13634; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; YOSHIMURA T, 1992, BIOCHEMISTRY-US, V31, P11748, DOI 10.1021/bi00162a011	31	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4189	4194		10.1074/jbc.274.7.4189	http://dx.doi.org/10.1074/jbc.274.7.4189			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933615	hybrid			2022-12-27	WOS:000078575500039
J	Bascom, RA; Srinivasan, S; Nussbaum, RL				Bascom, RA; Srinivasan, S; Nussbaum, RL			Identification and characterization of Golgin-84, a novel Golgi integral membrane protein with a cytoplasmic coiled-coil domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET-II ONCOGENE; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAINS; VESICLE DOCKING; SEQUENCES; COMPLEX; RECOGNITION; APPARATUS; RECEPTORS; RETENTION	The cytoplasmic face of the Golgi contains a variety of proteins with coiled-coil domains. We identified one such protein in a yeast two hybrid screen, using as bait the peripheral Golgi phosphatidylinositol(4,5)P-2 8-phosphatase OCRL1 that is implicated in a human disease, the oculocerebrorenal syndrome. The similar to 2.8-kilobase mRNA is ubiquitously expressed and abundant in testis; it encodes a 731-amino acid protein with a predicted mass of 83 kDa. Antibodies against the sequence detect a novel similar to 84-kDa Golgi protein we termed golgin-84. Golgin-84 is an integral membrane protein with a single transmembrane domain close to its C terminus. In vitro, the protein inserts post-translationally into microsomal membranes with an N-cytoplasmic and C-lumen orientation. Cross-linking indicates that golgin-84 forms dimers, consistent with the prediction of an similar to 400-residue dimerizing coiled coil domain in its N terminus. The dimerization potential is supported by a data base search that showed that the N-terminal 497 residues of golgin-84 contain a coiled-coil domain that when fused to the RET tyrosine kinase domain had the ability to activate it, forming the RET-II oncogene. Data base searching also indicates golgin-84 is similar in structure and sequence to giantin, a membrane protein that tethers coatamer complex I vesicles to the Golgi.	NHGRI, GDRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nussbaum, RL (corresponding author), NHGRI, GDRB, NIH, 49 Convent Dr, Bethesda, MD 20892 USA.	rlnuss@nhgri.nih.gov		Bascom, Roger/0000-0002-9106-8224				ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Desjardins C, 1993, CELL MOL BIOL TESTIS; DOHLMAN JG, 1993, BIOCHEM BIOPH RES CO, V195, P686, DOI 10.1006/bbrc.1993.2100; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; Riezman H, 1997, SCIENCE, V278, P1728, DOI 10.1126/science.278.5344.1728; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Tong Q, 1997, J BIOL CHEM, V272, P9043; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	46	84	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2953	2962		10.1074/jbc.274.5.2953	http://dx.doi.org/10.1074/jbc.274.5.2953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915833	hybrid			2022-12-27	WOS:000078319500051
J	Makino, Y; Yoshikawa, N; Okamoto, K; Hirota, K; Yodoi, J; Makino, I; Tanaka, H				Makino, Y; Yoshikawa, N; Okamoto, K; Hirota, K; Yodoi, J; Makino, I; Tanaka, H			Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; STEROID-HORMONE RECEPTORS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CONFORMATIONAL-CHANGES; NUCLEAR TRANSLOCATION; ACTIVATING FACTOR; ACTIVITY INVITRO; PROTEIN-KINASE	The glucocorticoid receptor (GR) is considered to belong to a class of transcription factors, the functions of which are exposed to redox regulation. We have recently demonstrated that thioredoxin (TRX), a cellular reducing catalyst, plays an important role in restoration of GR function in vivo under oxidative conditions. Although both the ligand binding domain and other domains of the GR have been suggested to be modulated by TRX, the molecular mechanism of the interaction is largely unknown. In the present study, we hypothesized that the DNA binding domain (DBD) of the GR, which is highly conserved among the nuclear receptors, is also responsible for communication with TRX in vivo, Mammalian two-hybrid assay and glutathione S-transferase pull-down assay revealed the direct association between TRX and the GR DBD. Moreover, analysis of subcellular localization of TRX and the chimeric protein harboring herpes simplex viral protein 16 transactivation domain and the GR DBD indicated that the interaction might take place in the nucleus under oxidative conditions. Together these observations indicate that TRX, via a direct association with the conserved DBD motif, may represent a key mediator operating in interplay between cellular redox signaling and nuclear receptor-mediated signal transduction.	Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Kyoto 6068507, Japan	Asahikawa Medical College; Kyoto University; Kyoto University	Tanaka, H (corresponding author), Asahikawa Med Coll, Dept Internal Med 2, 4-5-3 Nishikagura, Asahikawa, Hokkaido 0788510, Japan.	hirotnk@asahikawa-med.ac.jp	Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BODWELL JE, 1984, BIOCHEMISTRY-US, V23, P1392, DOI 10.1021/bi00302a009; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GRIPPO JF, 1983, J BIOL CHEM, V258, P3658; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JEWELL CM, 1995, J STEROID BIOCHEM, V55, P135, DOI 10.1016/0960-0760(95)00174-X; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Makino Y, 1996, MOL PHARMACOL, V49, P612; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanchez Edwin R., 1996, Methods (Orlando), V9, P188, DOI 10.1006/meth.1996.0025; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; TAGAYA Y, 1990, MOL IMMUNOL, V27, P1279; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TANAKA H, 1995, MOL PHARMACOL, V48, P938; Tanaka H, 1996, J IMMUNOL, V156, P1601; Tanaka T, 1997, LAB INVEST, V77, P145; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; Wu XS, 1996, MOL CELL BIOL, V16, P1035; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YOKOMIZO A, 1995, CANCER RES, V55, P4293	64	161	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3182	3188		10.1074/jbc.274.5.3182	http://dx.doi.org/10.1074/jbc.274.5.3182			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915858	hybrid			2022-12-27	WOS:000078319500076
J	Matroule, JY; Bonizzi, G; Morliere, P; Paillous, N; Santus, R; Bours, V; Piette, J				Matroule, JY; Bonizzi, G; Morliere, P; Paillous, N; Santus, R; Bours, V; Piette, J			Pyropheophorbide-a methyl ester-mediated photosensitization activates transcription factor NF-kappa B through the interleukin-1 receptor-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTODYNAMIC THERAPY; SINGLET OXYGEN; CERAMIDE GENERATION; INDUCED EXPRESSION; IN-VIVO; CELLS; TUMOR; PROTEINS; KINASE; ALPHA	Pyropheophorbide-a methyl ester (PPME) is a second generation of photosensitizers used in photodynamic therapy. We demonstrated that PPME photosensitization activated NF-kappa B transcription Factor in colon cancer cells. Unexpectedly, this activation occurred in two separate waves, i.e. a rapid and transient one and a second slower but sustained phase. The former was due to photosensitization by PPME localized in the cytoplasmic membrane which triggered interleukin-l receptor internalization and the transduction pathways controlled by the interleukin-l type I receptor. Indeed, TRAF6 dominant negative mutant abolished NF-kappa B activation by PPME photosensitization, and TRAF2 dominant negative mutant was without any effect, and overexpression of I kappa B kinases increased gene transcription controlled by NF-kappa B, Oxidative stress was not likely involved in the activation. On the other hand, the slower and sustained wave could be the product of the release of ceramide through activation of the acidic sphingomyelinase, PPME localization within the lysosomal membrane could explain why ceramide acted as second messenger in NF-kappa B activation by PPME photosensitization. These data will allow a better understanding of the molecular basis of tumor eradication by photodynamic therapy, in particular the importance of the host cell response in the treatment.	Univ Liege, Inst Pathol B23, Virol Lab, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Med Chem Lab, B-4000 Liege, Belgium; Museum Natl Hist Nat, F-75231 Paris 05, France; Univ Toulouse, IMRCP Lab, CNRS URA 470, F-31062 Toulouse, France	University of Liege; University of Liege; Museum National d'Histoire Naturelle (MNHN); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Virol Lab, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Bonizzi, Giuseppina/AAD-9042-2022					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATHAR M, 1988, J INVEST DERMATOL, V90, P652, DOI 10.1111/1523-1747.ep12560814; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bonizzi G, 1997, J IMMUNOL, V159, P5264; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Daziano JP, 1996, PHOTOCHEM PHOTOBIOL, V64, P712, DOI 10.1111/j.1751-1097.1996.tb03129.x; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY TJ, 1993, PHOTOCHEM PHOTOBIOL, V58, P895, DOI 10.1111/j.1751-1097.1993.tb04990.x; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FISHER AMR, 1995, LASER SURG MED, V17, P2, DOI 10.1002/lsm.1900170103; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAULLIER JM, 1995, PHOTOCHEM PHOTOBIOL, V62, P114, DOI 10.1111/j.1751-1097.1995.tb05247.x; GEZE M, 1993, J PHOTOCH PHOTOBIO B, V20, P23, DOI 10.1016/1011-1344(93)80128-V; GLINSKI JA, 1995, PHOTOCHEM PHOTOBIOL, V62, P144, DOI 10.1111/j.1751-1097.1995.tb05250.x; Gollnick SO, 1997, CANCER RES, V57, P3904; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Henderson BW, 1997, CANCER RES, V57, P4000; ITO T, 1978, PHOTOCHEM PHOTOBIOL, V28, P493, DOI 10.1111/j.1751-1097.1978.tb06957.x; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KESSEL D, 1984, BIOCHEM PHARMACOL, V33, P1389, DOI 10.1016/0006-2952(84)90403-9; KIK G, 1996, BRIT J CANCER, V74, P30; Kim MJ, 1998, BLOOD, V91, P4106, DOI 10.1182/blood.V91.11.4106.411k40_4106_4117; Korbelik M, 1997, BRIT J CANCER, V75, P202, DOI 10.1038/bjc.1997.34; KRUTMANN J, 1989, J BIOL CHEM, V264, P11407; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Morliere P, 1998, CANCER RES, V58, P3571; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pandey RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P194, DOI 10.1111/j.1751-1097.1996.tb02442.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; PIETTE J, 1986, PHOTOCHEM PHOTOBIOL, V44, P793, DOI 10.1111/j.1751-1097.1986.tb05539.x; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIEMAN DJ, 1992, ONCOL RES, V4, P193; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Separovic D, 1997, CANCER RES, V57, P1717; SERET A, 1990, PHOTOCHEM PHOTOBIOL, V52, P601, DOI 10.1111/j.1751-1097.1990.tb01805.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLARI R, 1994, BIOCHEM PHARMACOL, V47, P93, DOI 10.1016/0006-2952(94)90441-3; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sousa C, 1996, PHOTOCHEM PHOTOBIOL, V63, P601, DOI 10.1111/j.1751-1097.1996.tb05662.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; VILE GF, 1995, FREE RADICAL BIO MED, V18, P721, DOI 10.1016/0891-5849(94)00192-M; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	71	74	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2988	3000		10.1074/jbc.274.5.2988	http://dx.doi.org/10.1074/jbc.274.5.2988			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915837	hybrid			2022-12-27	WOS:000078319500055
J	McCormack, FX; Damodarasamy, M; Elhalwagi, BM				McCormack, FX; Damodarasamy, M; Elhalwagi, BM			Deletion mapping of N-terminal domains of surfactant protein A - The N-terminal segment is required for phospholipid aggregation and specific inhibition of surfactant secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; MANNOSE-BINDING PROTEIN; PULMONARY SURFACTANT; II CELLS; HIGH-AFFINITY; HELIX FORMATION; LUNG; APOPROTEIN; LIPIDS; GENE	The objective of the current study was to examine the functional importance of the N-terminal domains of surfactant protein A (SP-A) including the N-terminal segment from Asn(1) to Ala(7) (denoted domain 1), the N-terminal portion of the collagen domain from Gly(8) to Gly(44) (domain 2), and the C-terminal portion of the collagenlike domain from Gly(45) to Pro(80) (domain 3), Wild type recombinant SP-A (Sp-A(hyp); where hyp indicates hydroxyproline-deficient) and truncated mutant (TM) SP-As containing deletions of domain(s) 1 (TM1), 2 (TM2), 1 and 2 (TM1-2), and 1, 2, and 3 (TM1-2-3) were synthesized in insect cells and purified by mannose-Sepharose affinity chromatography, N-terminal disulfide-dependent dimerization was preserved at near wild type levels in the TM1-2 (at Cys(-1)) and TM2 proteins (at Cys(-1) and Cys(6)), and to a lesser extent in TM1 (at Cys(-1)), but not in TM1-2-3, Cross-linking analyses demonstrated that the neck + CRD was sufficient for assembly of monomers into noncovalent trimers and that the N-terminal segment was required for the association of trimers to form higher oligomers, All TM proteins except TM1-2-3 bound to phospholipid, but only the N-terminal segment containing TM proteins aggregated phospholipid vesicles. The TM1, TM1-2, and TM2 but not the TM1-2-3 inhibited the secretion of surfactant from type II cells as effectively as Sp-A(hyp), but the inhibitory activity of each mutant was blocked by excess alpha-methylmannoside and therefore nonspecific, TM1 and TM1-2-3 did not enhance the uptake of phospholipids by isolated type II cells, but the TM1-2 and TM2 had activities that were 72 and 83% of Sp-A(hyp), respectively. We conclude the following for SP-A: 1) trimerization does not require the collagen-like region or interchain disulfide linkage; 2) the N-terminal portion of the collagen-like domain is required for specific inhibition of surfactant secretion but not for binding to liposomes or for enhanced uptake of phospholipids into type II cells; 3) N-terminal interchain disulfide linkage can functionally replace the N-terminal segment for lipid binding, receptor binding, and enhancement of lipid uptake; 4) the N-terminal segment is required for the association of trimeric subunits into higher oligomers, for phospholipid aggregation, and for specific inhibition of surfactant secretion and cannot be functionally replaced by disulfide linkage alone for these activities.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA	University of Cincinnati	McCormack, FX (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NIEHS NIH HHS [P30ES-0609606] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL42; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LeVine AM, 1997, J IMMUNOL, V158, P4336; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MCCORMACK FX, 1996, COLLECTINS INNATE IM, P9; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; Zhang M, 1998, BIOCHEMISTRY-US, V37, P16481, DOI 10.1021/bi9817966	44	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3173	3181		10.1074/jbc.274.5.3173	http://dx.doi.org/10.1074/jbc.274.5.3173			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915857	hybrid			2022-12-27	WOS:000078319500075
J	Sugiura, T; Kodaka, T; Nakane, S; Miyashita, T; Kondo, S; Suhara, Y; Takayama, H; Waku, K; Seki, C; Baba, N; Ishima, Y				Sugiura, T; Kodaka, T; Nakane, S; Miyashita, T; Kondo, S; Suhara, Y; Takayama, H; Waku, K; Seki, C; Baba, N; Ishima, Y			Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor - Structure-activity relationship of 2-arachidonoylglycerol ether-linked analogues, and related compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYBRID NG108-15 CELLS; ENZYMATIC-SYNTHESIS; ENDOGENOUS LIGAND; RAT-BRAIN; ARACHIDONIC-ACID; ANANDAMIDE; BIOSYNTHESIS; TRANSACYLASE; HYDROLYSIS; TRANSIENT	An endogenous cannabimimetic molecule, 2-arachidonoylglycerol, induces a rapid, transient increase in intracellular free Ca2+ concentrations in NG108-15 cells through a cannabinoid CB1 receptor-dependent mechanism. We examined the activities of 24 relevant compounds (2-arachidonoylglycerol, its structural analogues, and several synthetic cannabinoids). We found that 2-arachidonoylglycerol is the most potent compound examined so far: its activity was detectable from as low as 0.3 nM, and the maximal response induced by 2-arachidonoylglycerol exceeded the responses by others. Activities of HU-210 and CP55940, potent cannabinoid receptor agonists, were also detectable from as low as 0.3 nM, whereas the maximal responses induced by these compounds were low compared with 2-arachidonoylglycerol, Anandamide was also found to act as a partial agonist in this assay system. We confirmed that free arachidonic acid failed to elicit a response. Furthermore, we found that a metabolically stable ether-linked analogue of 2-arachidonoylglycerol possesses appreciable agonistic activity, although its activity was apparently lower than that of 2-arachidonoylglycerol. We also confirmed that pretreating cells with various cannabinoid receptor agonists nullified the response induced by 2-arachidonoylglycerol, whereas pretreating cells with other neurotransmitters or neuromodulators did not affect the response. These results strongly suggested that the cannabinoid CB1 receptor is originally a 2-arachidonoylglycerol receptor, and 2-arachidonoylglycerol is the intrinsic physiological ligand for the cannabinoid CB1 receptor.	Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan; Okayama Univ, Fac Agr, Tsushima, Okayama 7008530, Japan; Ishima Inst Neurosci, Tokyo 1860002, Japan	Teikyo University; Okayama University	Sugiura, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan.			Suhara, Yoshitomo/0000-0002-4770-2910				Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; Cadas H, 1997, J NEUROSCI, V17, P1226; DEADWYLER SA, 1995, CANNABINOID RECEPTOR, P205; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; Di Marzo V, 1998, BIOCHEMISTRY-MOSCOW+, V63, P13; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Di Marzo V, 1998, BIOCHEM J, V331, P15; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; GAMMON CM, 1989, J NEUROCHEM, V53, P95, DOI 10.1111/j.1471-4159.1989.tb07299.x; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; HANSEN HS, BIOCH BIOPHYS ACTA, V1258, P303; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HERKENHAM M, 1995, CANNABINOID RECEPTOR, P145; HOWLETT AC, 1995, CANNABINOID RECEPTOR, P167; Kempe K, 1996, J BIOL CHEM, V271, P17287, DOI 10.1074/jbc.271.29.17287; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; MARTIN JB, 1953, J AM CHEM SOC, V75, P5482, DOI 10.1021/ja01118a004; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MECHOULAM R, 1995, CANNABINOID RECEPTOR, P233; Murphy L, 1992, MARIJUANA CANNABINOI; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; SCHMID PC, 1996, FEBS LETT, V385, P124; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 1997, BIOCHEM BIOPH RES CO, V233, P207, DOI 10.1006/bbrc.1997.6425; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V229, P58, DOI 10.1006/bbrc.1996.1757; Sugiura T, 1997, J BIOCHEM-TOKYO, V122, P890; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; SUGIURA T, 1994, P JPN C BIOCH LIPIDS, V36, P71; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	43	250	258	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2794	2801		10.1074/jbc.274.5.2794	http://dx.doi.org/10.1074/jbc.274.5.2794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915812	hybrid			2022-12-27	WOS:000078319500030
J	Wu, YX; Patterson, C				Wu, YX; Patterson, C			The human KDR/flk-1 gene contains a functional initiator element that is bound and transactivated by TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; RNA-POLYMERASE-II; TATA-LESS PROMOTER; MAMMALIAN-CELLS; BINDING PROTEIN; DNA-SEQUENCE; TRANSCRIPTION; EXPRESSION; ANGIOGENESIS	KDR/flk-1, the receptor for vascular endothelial growth factor, is required for normal vascular development. KDR/flk-1 is a TATA-less gene, containing four upstream Spl sites and a single transcription start site, although analysis of the start site sequence discloses only weak similarities with the consensus initiator element (Inr) sequence. In vitro transcription assays, however, demonstrate that the region from -10 to +10 relative to the start site contains Inr activity that is orientation- and position-dependent, and mutagenesis of the KDR/flk-1 Inr reduces promoter activity to 28% of the wild-type promoter in transient transfection assays. Gel shift assays confirm that nuclear proteins specifically bind the Inr, and competition experiments demonstrate that TFII-I, a multifunctional Inr-binding nuclear protein, is a component of these DNA-protein complexes. TFII-I transactivates the wild-type KDR/flk-1 promoter, but not a promoter containing a mutated Inr, in transient transfection assays. Immunodepletion of TFII-I from nuclear extracts prior to in vitro transcription assays abolishes transcription from the KDR/flk-1 Inr, an effect that can be rescued by adding back purified TFII-I, reflecting the importance of TFII-I in KDR/flk-1 Inr activity. These experiments demonstrate that the KDR/flk-1 gene contains a functional Inr that is bound by TFII-I and that both the functional Inr and TFII-I activity are essential for transcription.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Cardiol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Patterson, C (corresponding author), Univ Texas, Med Branch, Div Cardiol, 9-138 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	cpatters@utmb.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003658, R01HL061656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61656, HL03658] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Goetz TL, 1996, J BIOL CHEM, V271, P33317, DOI 10.1074/jbc.271.52.33317; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEWIS BA, 1995, J BIOL CHEM, V270, P28139; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yin LY, 1998, MAMM GENOME, V9, P408, DOI 10.1007/s003359900783; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	47	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3207	3214		10.1074/jbc.274.5.3207	http://dx.doi.org/10.1074/jbc.274.5.3207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915861	hybrid			2022-12-27	WOS:000078319500079
J	Farooq, A; Plotnikova, O; Zeng, L; Zhou, MM				Farooq, A; Plotnikova, O; Zeng, L; Zhou, MM			Phosphotyrosine binding domains of Shc and insulin receptor substrate 1 recognize the NPXpY motif in a thermodynamically distinct manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRS-1 PTB DOMAIN; SIGNAL-TRANSDUCTION; PROTEIN; REGION; PHOSPHORYLATION; PHOSPHOPEPTIDE; ASSOCIATION; ACTIVATION; PEPTIDES; KINASES	Phosphotyrosine binding (PTB) domains of the adaptor protein Shc and insulin receptor substrate (IRS-1) interact with a distinct set of activated and tyrosine-phosphorylated cytokine and growth factor receptors and play important roles in mediating mitogenic signal transduction. By using the technique of isothermal titration calorimetry, we have studied the thermodynamics of binding of the Shc and IRS-1 PTB domains to tyrosine-phosphorylated NPXY-containing peptides derived from known receptor binding sites. The results showed that relative contributions of enthalpy and entropy to the free energy of binding are dependent on specific phosphopeptides. Binding of the Shc PTB domain to tyrosine-phosphorylated peptides from TrkA, epidermal growth factor, ErbB3, and insulin receptors is achieved via an overall entropy-driven reaction. On the other hand, recognition of the phosphopeptides of insulin and interleukin-4 receptors by the IRS-1 PTB domain is predominantly an enthalpy-driven process. Mutagenesis and amino acid substitution experiments showed that in addition to the tyrosine-phosphorylated NPXY motif, the PTB domains of Shc and IRS-1 prefer a large hydrophobic residue at pY-5 and a small hydrophobic residue at pY-1, respectively (where pY is phosphotyrosine). These results agree with the calculated solvent accessibility of these two key peptide residues in the PTB domain/peptide structures and support the notion that the PTB domains of Shc and IRS-1 employ functionally distinct mechanisms to recognize tyrosine-phosphorylated receptors.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zhou, MM (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, 1 Gustave L Levy Pl,Box 1677, New York, NY 10029 USA.		Farooq, Amjad/B-5084-2012					BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GEER P, 1995, CURR BIOL, V5, P404; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARIAN JE, 1995, NATURE, V371, P167; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Livingstone JR, 1996, NATURE, V384, P491, DOI 10.1038/384491a0; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Olejniczak ET, 1997, BIOCHEMISTRY-US, V36, P4118, DOI 10.1021/bi963050i; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; TRUB T, 1995, J BIOL CHEM, V270, P18205; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zhou MM, 1995, PROG BIOPHYS MOL BIO, V64, P221, DOI 10.1016/S0079-6107(96)00005-3; ZHOU S, 1995, J BIOL CHEM, V270, P14863	43	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6114	6121		10.1074/jbc.274.10.6114	http://dx.doi.org/10.1074/jbc.274.10.6114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037694	hybrid			2022-12-27	WOS:000078902800016
J	Gallagher, PG; Sabatino, DE; Romana, M; Cline, AP; Garrett, LJ; Bodine, DM; Forget, BG				Gallagher, PG; Sabatino, DE; Romana, M; Cline, AP; Garrett, LJ; Bodine, DM; Forget, BG			A human beta-spectrin gene promoter directs high level expression in erythroid but not muscle or neural cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; PORPHOBILINOGEN DEAMINASE GENE; HUMAN SKELETAL-MUSCLE; KRUPPEL-LIKE FACTOR; PRE-MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; MAMMALIAN-CELLS; CACCC ELEMENT; GLYCOPHORIN-B; PROTEINS	beta-Spectrin is an erythrocyte membrane protein that is defective in many patients with abnormalities of red blood cell shape including hereditary spherocytosis and elliptocytosis. It is expressed not only in erythroid tissues but also in muscle and brain. We wished to determine the regulatory elements that determine the tissue-specific expression of the beta-spectrin gene. We mapped the 5'-end of the beta-spectrin erythroid cDNA and cloned the 5'-flanking genomic DNA containing the putative beta-spectrin gene promoter. Using transfection of promoter/reporter plasmids in human tissue culture cell lines, in vitro DNase I footprinting analyses, and gel mobility shift assays, a beta-spectrin gene erythroid promoter with two binding sites for GATA-1 and one site for CACCC-related proteins was identified. All three binding sites were required for full promoter activity; one of the GATA-1 motifs and the CACCC-binding motif were essential for activity. The beta-spectrin gene promoter was able to be transactivated in heterologous cells by forced expression of GATA-1. In transgenic mice, a reporter gene directed by the beta-spectrin promoter was expressed in erythroid tissues at all stages of development. Only weak expression of the reporter gene was detected in muscle and brain tissue, suggesting that additional regulatory elements are required for high level expression of the beta-spectrin gene in these tissues.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Natl Human Genome Res Inst, Hematopoiesis Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	Yale University; Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.		Romana, Marc/K-6442-2017	Romana, Marc/0000-0002-8715-9836				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMIN KM, 1993, GENOMICS, V18, P118, DOI 10.1006/geno.1993.1434; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; Bewick GS, 1996, J NEUROCYTOL, V25, P367; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; CHANG JG, 1993, GENOMICS, V17, P287, DOI 10.1006/geno.1993.1323; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ZL, 1994, BLOOD, V84, P1992; COLIN Y, 1990, J BIOL CHEM, V265, P16729; COX KH, 1995, J BIOL CHEM, V270, P19752, DOI 10.1074/jbc.270.34.19752; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DANIELS MP, 1990, J CELL SCI, V97, P615; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Ehmer S, 1997, ACTA NEUROPATHOL, V94, P240, DOI 10.1007/s004010050699; ELEOUET JF, 1993, EUR J BIOCHEM, V212, P763, DOI 10.1111/j.1432-1033.1993.tb17716.x; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUSHIMA Y, 1990, CYTOGENET CELL GENET, V53, P232, DOI 10.1159/000132939; GALLAGHER P, 1994, BLOOD, V84, P361; Gallagher PG, 1998, J BIOL CHEM, V273, P1339, DOI 10.1074/jbc.273.3.1339; *GEN COMP GROUP, 1994, GCG SEQ AN SOFTW PAC; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HOGAN B, 1986, MANIPULATING MOUSE E; HU RJ, 1992, J BIOL CHEM, V267, P18715; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KUDRYCKI KE, 1993, AM J PHYSIOL, V264, pF540, DOI 10.1152/ajprenal.1993.264.3.F540; LAMBERT S, 1993, J NEUROSCI, V13, P3725; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MASON P, 1993, GENE TRANSCRIPTION P, P47; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Mora M, 1996, DEV BRAIN RES, V91, P70, DOI 10.1016/0165-3806(95)00169-7; MORROW JS, 1997, HDB PHYSIOL 14, P485; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; PRCHAL JT, 1990, J CELL PHYSIOL, V144, P287, DOI 10.1002/jcp.1041440215; PRCHAL JT, 1987, P NATL ACAD SCI USA, V84, P7468, DOI 10.1073/pnas.84.21.7468; PUMPLIN DW, 1995, J CELL SCI, V108, P3145; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Sahr KE, 1996, BLOOD, V88, P4500, DOI 10.1182/blood.V88.12.4500.bloodjournal88124500; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Surinya KH, 1997, J BIOL CHEM, V272, P26585, DOI 10.1074/jbc.272.42.26585; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VYBIRAL T, 1992, CELL MOTIL CYTOSKEL, V21, P293, DOI 10.1002/cm.970210405; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINKELMANN JC, 1988, BLOOD, V72, P328; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZIMMER WE, 1992, BRAIN RES, V594, P75, DOI 10.1016/0006-8993(92)91030-I	73	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6062	6073		10.1074/jbc.274.10.6062	http://dx.doi.org/10.1074/jbc.274.10.6062			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037687	hybrid			2022-12-27	WOS:000078902800009
J	Chariot, A; Princen, F; Gielen, J; Merville, MP; Franzoso, G; Brown, K; Siebenlist, U; Bours, V				Chariot, A; Princen, F; Gielen, J; Merville, MP; Franzoso, G; Brown, K; Siebenlist, U; Bours, V			I kappa B-alpha enhances transactivation by the HOXB7 homeodomain-containing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING; HOMEOBOX GENE; EXPRESSION; ACTIVATION; DROSOPHILA; FAMILY; TRANSCRIPTION; VERTEBRATES; HOMODIMERS	Combinatorial interactions between distinct transcription factors generate specificity in the controlled expression of target genes. In this report, we demonstrated that the HOXB7 homeodomain-containing protein, which plays a key role in development and differentiation, physically interacted in vitro with I kappa B-alpha, an inhibitor of NF-kappa B activity. This interaction was mediated by the I kappa B-alpha ankyrin repeats and C-terminal domain as well as by the HOXB7 N-terminal domain. In transient transfection experiments, I kappa B-alpha markedly increased HOXB7-dependent transcription from a reporter plasmid containing a homeodomain consensus-binding sequence. This report therefore showed a novel function for I kappa B-alpha, namely a positive regulation of transcriptional activation by homeodomain-containing proteins.	Univ Liege, Lab Med Chem & Med Oncol, B-4000 Sart, Belgium; NIAID, Natl Inst Hlth, Immunoregulat Lab, Bethesda, MD 20892 USA	University of Liege; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Bours, V (corresponding author), Univ Liege, Lab Med Chem & Med Oncol, CHU B35, B-4000 Sart, Belgium.		Franzoso, Guido/GRR-8628-2022	Chariot, Alain/0000-0002-1691-4347; Franzoso, Guido/0000-0002-0778-988X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000723] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAIER LJ, 1991, BLOOD, V78, P1047; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chariot A, 1998, J CELL BIOCHEM, V71, P46; Chariot A, 1996, BIOCHEM J, V319, P91, DOI 10.1042/bj3190091; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DEGUCHI Y, 1991, BLOOD, V78, P445; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; LEVINE M, 1984, CELL, V38, P667, DOI 10.1016/0092-8674(84)90261-7; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2452; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P118, DOI 10.1073/pnas.91.1.118; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	48	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5318	5325		10.1074/jbc.274.9.5318	http://dx.doi.org/10.1074/jbc.274.9.5318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026139	Green Submitted, hybrid			2022-12-27	WOS:000078804400010
J	Chu, WA; Moehlenkamp, JD; Bittel, D; Andrews, GK; Johnson, JA				Chu, WA; Moehlenkamp, JD; Bittel, D; Andrews, GK; Johnson, JA			Cadmium-mediated activation of the metal response element in human neuroblastoma cells lacking functional metal response element-binding transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-EXPRESSION; III MESSENGER-RNA; FACTOR MTF-1; ASTROCYTE CULTURES; OXIDATIVE STRESS; TRANSGENIC MICE; MOUSE-BRAIN; I GENE; INDUCTION; PROTEIN	Metal response element-binding transcription factor-1 (MTF-1) binds specifically to metal response elements (MREs) and transactivates metallothionein (MT) gene expression in response to zinc and cadmium. This investigation contrasts the mechanism of mouse MT gene (mMT I) promoter activation by cadmium and zinc in IMR-32 human neuroblastoma cells to determine whether MTF-1 binding to the MRE is necessary for activation by these metals. Cadmium activated a mMT-1 promoter (-150 base pairs) luciferase reporter 20-25-fold through a MRE-dependent mechanism. In contrast, zinc had little effect on the mMT-1 luciferase reporter, IMR-32 cells lacked MRE binding activity, and treatment with zinc in vitro or in vivo did not generate a MTF-1 MRE complex, suggesting that IMR-32 cells lack functional MTF-1 Overexpression of mMTF-1 regenerated a zinc-mediated induction of the MRE without affecting cadmium activation. Because no other transition metals tested activated the MRE, this effect appeared to be cadmium-specific. These data demonstrate that in IMR-32 human neuroblastoma cells, zinc and cadmium can use independent mechanisms for activation of the mMT-I promoter and cadmium-mediated MRE activation is independent of TTF-l and zinc.	Univ Kansas, Med Ctr, Dept Pharmacol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Toxicol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Therapeut, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Biochem, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Johnson, JA (corresponding author), Univ Kansas, Med Ctr, Dept Pharmacol, G017B Breidenthal,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	jjohnso2@kumc.edu			NATIONAL CANCER INSTITUTE [R01CA061262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007079, R01ES005704] Funding Source: NIH RePORTER; NCI NIH HHS [CA61262] Funding Source: Medline; NIEHS NIH HHS [T32 ES07079, ES05704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMORUSO MA, 1982, TOXICOL LETT, V10, P133, DOI 10.1016/0378-4274(82)90064-9; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; Aschner M, 1996, NEUROTOXICOLOGY, V17, P663; Belloso E, 1996, NEUROENDOCRINOLOGY, V64, P430, DOI 10.1159/000127149; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CHAO SH, 1995, ARCH TOXICOL, V69, P197, DOI 10.1007/s002040050158; CHOUDHURI S, 1993, TOXICOL APPL PHARM, V119, P1, DOI 10.1006/taap.1993.1037; CHOUDHURI S, 1995, TOXICOL APPL PHARM, V131, P144, DOI 10.1006/taap.1995.1056; Cigliano S, 1996, EXP CELL RES, V228, P173, DOI 10.1006/excr.1996.0314; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kramer KK, 1996, TOXICOL APPL PHARM, V141, P1; Kramer KK, 1996, TOXICOL APPL PHARM, V136, P94, DOI 10.1006/taap.1996.0011; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Remondelli P, 1997, FEBS LETT, V416, P254, DOI 10.1016/S0014-5793(97)01212-X; RISING L, 1995, BRAIN RES, V678, P91, DOI 10.1016/0006-8993(95)00170-U; Rojas P, 1997, NEUROCHEM RES, V22, P17, DOI 10.1023/A:1027312901477; SINGH PK, 1989, TOXICOL APPL PHARM, V97, P572, DOI 10.1016/0041-008X(89)90262-7; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TAKEDA K, 1995, BIOCHEM BIOPH RES CO, V207, P160, DOI 10.1006/bbrc.1995.1167; VIG PJ, 1991, BIOCH INT, V239, P27; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0; ZHENG H, 1995, NEUROCHEM INT, V27, P43, DOI 10.1016/0197-0186(94)00167-S; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	39	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5279	5284		10.1074/jbc.274.9.5279	http://dx.doi.org/10.1074/jbc.274.9.5279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026134	hybrid			2022-12-27	WOS:000078804400005
J	Constantinou, A; Gunz, D; Evans, E; Lalle, P; Bates, PA; Wood, RD; Clarkson, SG				Constantinou, A; Gunz, D; Evans, E; Lalle, P; Bates, PA; Wood, RD; Clarkson, SG			Conserved residues of human XPG protein important for nuclease activity and function in nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; DNA-POLYMERASE-I; TRANSCRIPTION-COUPLED REPAIR; COCKAYNE-SYNDROME PATIENTS; BACTERIOPHAGE-T4 RNASE-H; COMPLEMENTATION GROUP-G; WILD-TYPE P53; ESCHERICHIA-COLI; RESTRICTION-ENDONUCLEASE; 5'-NUCLEASE DOMAIN	The human XPG endonuclease cuts on the 3' side of a DNA lesion during nucleotide excision repair. Mutations in XPG can lead to the disorders xeroderma pigmentosum (XP) and Cockayne syndrome. XPG shares sequence similarities in two regions with a family of structure-specific nucleases and exonucleases. To begin defining its catalytic mechanism, we changed highly conserved residues and determined the effects on the endonuclease activity of isolated XPG, its function in open complex formation and dual incision reconstituted with purified proteins, and its ability to restore cellular resistance to UV light. The substitution A792V present in two XP complementation group G (XP-G) individuals reduced but did not abolish endonuclease activity, explaining their mild clinical phenotype. Isolated XPG proteins with Asp-77 or Glu-791 substitutions did not cleave DNA. In the reconstituted repair system, alanine substitutions at these positions permitted open complex formation but were inactive for 3' cleavage, whereas D77E and E791D proteins retained considerable activity. The function of each mutant protein in the reconstituted system was mirrored by its ability to restore UV resistance to XP-G cell lines. Hydrodynamic measurements indicated that XPG exists as a monomer in high salt conditions, but immunoprecipitation of intact and truncated XPG proteins showed that XPG polypeptides can interact with each other, suggesting dimerization as an element of XPG function. The mutation results define critical residues in the catalytic center of XPG and strongly suggest that key features of the strand cleavage mechanism and active site structure are shared by members of the nuclease family.	Univ Geneva, Med Ctr, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Imperial Canc Res Fund, Biomol Modelling Lab, London WC2A 3PX, England	University of Geneva; Cancer Research UK	Clarkson, SG (corresponding author), Univ Geneva, Med Ctr, Dept Genet & Microbiol, 9 Ave Champel, CH-1211 Geneva 4, Switzerland.	Stuart.Clarkson@medecine.unige.ch	Bates, Paul A/AAF-8561-2020; LALLE, Philippe/G-7734-2018; Constantinou, Angelos/E-5337-2013; Wood, Richard D/M-6319-2018; Bates, Paul/A-1651-2011	Bates, Paul A/0000-0003-0621-0925; Wood, Richard D/0000-0002-9495-6892; Constantinou, Angelos/0000-0002-2994-8140				ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; Bates PA, 1997, PROTEINS, P59; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; BIGGERSTAFF M, 1999, DNA REPAIR PROTOCOLS; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; DUTHU A, 1992, ONCOGENE, V7, P2161; Ellison AR, 1998, EXP CELL RES, V243, P22, DOI 10.1006/excr.1998.4147; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gerlt J. A., 1993, NUCLEASES, P1; GERSTEIN M, 1996, 4 INT C INT SYST MOL, V4, P59; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11086, DOI 10.1021/bi963125i; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LALLE P, 1995, ONCOGENE, V10, P2447; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Moriwaki SI, 1996, J INVEST DERMATOL, V107, P647, DOI 10.1111/1523-1747.ep12584287; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; NOUSPIKEL T, 1996, THESIS U GENEVA; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Okinaka RT, 1997, MUTAT RES-DNA REPAIR, V385, P107, DOI 10.1016/S0921-8777(97)00031-1; PAGE B, 1993, INT J ONCOL, V3, P473; Park MS, 1997, J BIOL CHEM, V272, P27823, DOI 10.1074/jbc.272.44.27823; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SPICKOFSKY N, 1990, DNA PROT ENG TECH, V2, P14; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XU SY, 1991, J BACTERIOL, V173, P5030, DOI 10.1128/jb.173.16.5030-5035.1991; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967	71	90	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5637	5648		10.1074/jbc.274.9.5637	http://dx.doi.org/10.1074/jbc.274.9.5637			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026181	hybrid			2022-12-27	WOS:000078804400052
J	Gandhi, CS; Shuck, K; Lear, JD; Dieckmann, GR; DeGrado, WF; Lamb, RA; Pinto, LH				Gandhi, CS; Shuck, K; Lear, JD; Dieckmann, GR; DeGrado, WF; Lamb, RA; Pinto, LH			Cu(II) inhibition of the proton translocation machinery of the influenza A virus M-2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M(2) ION-CHANNEL; INTEGRAL MEMBRANE-PROTEIN; CARBONIC ANHYDRASE-II; A VIRUS; M2 PROTEIN; CATALYTIC MECHANISM; AMANTADINE; SAXITOXIN; RESIDUE; MODEL	The homotetrameric M-2 integral membrane protein of influenza virus forms a proton-selective ion channel. An essential histidine residue (His-37) in the M-2 transmembrane domain is believed to play an important role in the conduction mechanism of this channel. Also, this residue is believed to form hydrogen-bonded interactions with the ammonium group of the anti-viral compound, amantadine, A molecular model of this channel suggests that the imidazole side chains of His-37 from symmetry-related monomers of the homotetrameric pore converge to form a coordination site for transition metals, Thus, membrane currents of oocytes of Xenopus laevis expressing the M-2 protein were recorded when the solution bathing the oocytes contained various transition metals. Membrane currents were strongly and reversibly inhibited by Cu2+ with biphasic reaction kinetics. The biphasic inhibition curves may be explained by a two-site model involving a fast-binding peripheral site with low specificity for divalent metal ions, as well as a high affinity site (K-diss similar to 2 mu M) that lies deep within the pore and shows rather slow-binding kinetics (k(on) = 18.6 +/- 0.9 M-1 s(-1)). The pH dependence of the interaction with the high affinity Cu2+-binding site parallels the pH dependence of inhibition by amantadine, which has previously been ascribed to protonation of His-37. The voltage dependence of the inhibition at the high affinity site indicates that the binding site Lies within the transmembrane region of the pore. Furthermore, the inhibition by Cu2+ could be prevented by prior application of the reversible blocker of M-2 channel activity, BL-1743, providing further support for the location of the site within the pore region of M-2. Finally, substitutions of His-37 by alanine or glycine eliminated the high affinity site and resulted in membrane currents that were only partially inhibited at millimolar concentrations of Cu2+. Binding of Cu2+ the high affinity site resulted in an approximately equal inhibition of both inward and outward currents. The wild-type protein showed very high specificity for Cu2+ as only partially inhibited by 1 mM Ni2+, Pt2+, and Zn2+. These data are discussed in terms of the functional role of His-37 in the mechanism of proton translocation through the channel.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Fdn, Philadelphia, PA 19104 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University; Northwestern University; University of Pennsylvania	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.	larry-pinto@nwu.edu			NIAID NIH HHS [AI-20201, AI-31882] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI020201, R01AI031882, R01AI020201, R37AI020201] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DOYLE DD, 1993, J GEN PHYSIOL, V101, P153, DOI 10.1085/jgp.101.2.153; DUFF KC, 1992, FEBS LETT, V311, P256, DOI 10.1016/0014-5793(92)81114-2; DUFF KC, 1993, BIOCHIM BIOPHYS ACTA, V1145, P149, DOI 10.1016/0005-2736(93)90392-D; FAVRE I, 1995, J GEN PHYSIOL, V106, P203, DOI 10.1085/jgp.106.2.203; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; Kovacs FA, 1997, BIOPHYS J, V73, P2511, DOI 10.1016/S0006-3495(97)78279-1; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sansom MSP, 1997, VIROLOGY, V233, P163, DOI 10.1006/viro.1997.8578; Shimbo K, 1996, BIOPHYS J, V70, P1335, DOI 10.1016/S0006-3495(96)79690-X; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993	33	108	110	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5474	5482		10.1074/jbc.274.9.5474	http://dx.doi.org/10.1074/jbc.274.9.5474			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026160	hybrid			2022-12-27	WOS:000078804400031
J	Jarrousse, AS; Petit, F; Kreutzer-Schmid, C; Gaedigk, R; Schmid, HP				Jarrousse, AS; Petit, F; Kreutzer-Schmid, C; Gaedigk, R; Schmid, HP			Possible involvement of proteasomes (prosomes) in AUUUA-mediated mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; HELA-CELLS; DEGRADATION; PROTEINS; IDENTIFICATION; STABILITY; SEQUENCES; PURIFICATION; EXPRESSION	We have identified a cellular target for proteasomal endonuclease activity. Thus, 20 S proteasomes interact with the 3'-untranslated region of certain cytoplasmic mRNAs in vivo, and 20 S proteasomes isolated from Friend leukemia virus-infected mouse spleen cells were found to be associated with a mRNA fragment showing great homology to the 3'-untranslated region of tumor necrosis factor-beta mRNA that contains AUUUA sequences. We furthermore demonstrate that 20 S proteasomes destabilize oligoribonucleotides corresponding to the 3'-untranslated region of tumor necrosis factor-alpha, creating a specific cleavage pattern. The cleavage reaction is accelerated with increasing number of AUUUA motifs, and major cleavage sites are localized at the 5' side of the A residues. These results strongly suggest that 20 S proteasomes could be involved in the destabilization of cytokine mRNAs such as tumor necrosis factor mRNAs and other short-lived mRNAs containing AUUUA sequences.	Univ Clermont Ferrand 2, UA 987, Equipe Proteasome & Atuosurveill Cellulaire, OVGV,INRA, F-63177 Clermont Ferrand, France; Univ Stuttgart, Inst Biol, D-70569 Stuttgart 80, Germany	INRAE; Universite Clermont Auvergne (UCA); University of Stuttgart	Schmid, HP (corresponding author), Univ Clermont Ferrand 2, UA 987, Equipe Proteasome & Atuosurveill Cellulaire, OVGV,INRA, 24 Ave Landais, F-63177 Clermont Ferrand, France.	hpschmid@cicsun.univ-bpclermont.fr		Gaedigk, Roger/0000-0001-5942-1609				ARRIGO AP, 1985, EMBO J, V4, P399, DOI 10.1002/j.1460-2075.1985.tb03642.x; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CIVELLI OC, 1980, EUR J BIOCHEM, V108, P577; FRANSEN L, 1985, NUCLEIC ACIDS RES, V13, P4417, DOI 10.1093/nar/13.12.4417; GAEDIGK R, 1988, THESIS U STUTTGART S; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HORSCH A, 1989, FEBS LETT, V246, P131, DOI 10.1016/0014-5793(89)80268-6; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GTY, 1979, J MOL BIOL, V129, P221, DOI 10.1016/0022-2836(79)90278-X; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTINS DC, 1986, J MOL BIOL, V187, P479; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NOTHWANG HG, 1992, NUCLEIC ACIDS RES, V20, P1959, DOI 10.1093/nar/20.8.1959; PAMNANI V, 1994, EUR J BIOCHEM, V225, P511, DOI 10.1111/j.1432-1033.1994.00511.x; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PERRY RP, 1972, BIOCHIM BIOPHYS ACTA, V262, P220, DOI 10.1016/0005-2787(72)90236-5; Petit F, 1997, MOL BIOL REP, V24, P113, DOI 10.1023/A:1006886911852; Petit F, 1997, BIOCHEM J, V326, P93, DOI 10.1042/bj3260093; POUCH MN, 1995, J BIOL CHEM, V270, P22023, DOI 10.1074/jbc.270.37.22023; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHMID HP, 1984, EMBO J, V3, P29, DOI 10.1002/j.1460-2075.1984.tb01757.x; SCHMID HP, 1982, J CELL BIOL, V93, P893, DOI 10.1083/jcb.93.3.893; SCHONFELDER M, 1985, P NATL ACAD SCI USA, V82, P6884, DOI 10.1073/pnas.82.20.6884; SHAM G, 1986, CELL, V46, P659; SIPPEL AE, 1973, EUR J BIOCHEM, V37, P31, DOI 10.1111/j.1432-1033.1973.tb02953.x; TOMEK W, 1990, J CHROMATOGR, V521, P221, DOI 10.1016/0021-9673(90)85046-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	38	45	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5925	5930		10.1074/jbc.274.9.5925	http://dx.doi.org/10.1074/jbc.274.9.5925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026217	hybrid			2022-12-27	WOS:000078804400088
J	Meza, JE; Brzovic, PS; King, MC; Klevit, RE				Meza, JE; Brzovic, PS; King, MC; Klevit, RE			Mapping the functional domains of BRCA1 - Interaction of the ring finger domains of BRCA1 and BARD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER; OVARIAN-CANCER; SEQUENCE; IDENTIFICATION; MUTATIONS; BREAST; MOTIF; GENE; FAMILIES	Breast cancer I (BRCA1) and BRCA1-associated RING domain 1 (BARD1) are multidomain proteins that interact in vivo via their N-terminal RING finger motif regions. To characterize functional aspects of the BRCA1/BARD1 interaction, we have defined the structural domains required for the interaction, as well as their oligomerization state, relative stability, and possible nucleic acid binding activity. We have found that the RING finger motifs do not themselves constitute stable structural domains but are instead part of larger domains comprising residues 1-109 of BRCA1 and residues 26-119 of BARD1, These domains exist as homodimers and preferentially form a stable heterodimer. Shorter BRCA1 RING finger constructs do not interact with BARD1 or with longer BRCA1 constructs, indicating that the heterodimeric and homodimer interactions are mediated by regions outside the canonical RING finger motif, Nucleic acid binding is a generally proposed function of RING finger domains. We show that neither the homodimers nor the heterodimer displays affinity for nucleic acids, indicating that the proposed roles of BRCA1 and BARD1 in DNA repair and/or transcriptional activation must be mediated either by other regions of the proteins or by additional cofactors.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Klevit, RE (corresponding author), Univ Washington, Dept Biochem, Box 357742, Seattle, WA 98195 USA.	klevit@u.washington.edu	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [R01 CA79953, R01 CA27632] Funding Source: Medline; NIGMS NIH HHS [R01 GM46701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079953, R01CA027632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Roehm PC, 1997, BIOCHEMISTRY-US, V36, P10240, DOI 10.1021/bi970863d; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SHUSTER J, 1986, MOL CELL BIOL, V6, P1894, DOI 10.1128/MCB.6.6.1894; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	23	118	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5659	5665		10.1074/jbc.274.9.5659	http://dx.doi.org/10.1074/jbc.274.9.5659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026184	hybrid			2022-12-27	WOS:000078804400055
J	Sanders, WJ; Gordon, EJ; Dwir, O; Beck, PJ; Alon, R; Kiessling, LL				Sanders, WJ; Gordon, EJ; Dwir, O; Beck, PJ; Alon, R; Kiessling, LL			Inhibition of L-selectin-mediated leukocyte rolling by synthetic glycoprotein mimics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; OPENING METATHESIS POLYMERIZATION; CARBOHYDRATE-PROTEIN INTERACTIONS; ENDOTHELIAL-DERIVED LIGAND; EPIDERMAL GROWTH-FACTOR; MAJOR CAPPING GROUP; P-SELECTIN; BINDING-SPECIFICITY; LYMPHOCYTE ADHESION; SULFATED OLIGOSACCHARIDES	Synthetic carbohydrate and glycoprotein mimics displaying sulfated saccharide residues have been assayed for their L-selectin inhibitory properties under static and flow conditions. Polymers displaying the L-selectin recognition epitopes 3',6-disulfo Lewis x(Glc) (3-O-SO3-Gal beta 1 alpha 4(Fuc alpha 1 alpha 3)-6-O-SO3-Glc beta-OR) and 3',6'-disulfo Lewis x(Glc) (3,6-di-O-SO3-Gal beta 1 alpha 4(Fuc alpha 1 alpha 3)Glc beta-OR) both inhibit L-selectin binding to heparin under static, cell-free binding conditions with similar efficacies. Under conditions of shear flow, however, only the polymer displaying 3',6-disulfo Lewis x(Glc) inhibits the rolling of L-selectin-transfected cells on the glycoprotein ligand GlyCAM-1, Although it has been shown to more effective than sialyl Lewis x at blocking the L-selectin-GlyCAM-1 interaction in static binding studies, the corresponding monomer had no effect in the dynamic assay. These data indicate that multivalent ligands are far more effective inhibitors of L-selectin-mediated rolling than their monovalent counterparts and that the inhibitory activities are dependent on the specific sulfation pattern of the recognition epitope, Importantly, our results indicate the L-selectin specificity for one ligand over another found in static, cell-free binding assays is not necessarily retained under the conditions of shear flow. The results suggest that monovalent or polyvalent carbohydrate or glycoprotein mimetics that inhibit selectin binding in static assays may not block the more physiologically relevant process of selectin-mediated rolling.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; Weizmann Institute of Science	Kiessling, LL (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.		Kiessling, Laura L/A-4074-2008; ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369; Kiessling, Laura/0000-0001-6829-1500				Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; ALON R, 1995, J IMMUNOL, V154, P5356; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bertozzi CR, 1997, J IMMUNOL METHODS, V203, P157, DOI 10.1016/S0022-1759(97)00026-4; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Choi SK, 1996, CHEM BIOL, V3, P97, DOI 10.1016/S1074-5521(96)90285-9; Crocker PR, 1996, CURR OPIN STRUC BIOL, V6, P679, DOI 10.1016/S0959-440X(96)80036-4; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; Crottet P, 1996, GLYCOBIOLOGY, V6, P191, DOI 10.1093/glycob/6.2.191; Dias EL, 1997, J AM CHEM SOC, V119, P3887, DOI 10.1021/ja963136z; Dwir O, 1998, CELL ADHES COMMUN, V6, P349, DOI 10.3109/15419069809010793; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; FRASER C, 1995, MACROMOLECULES, V28, P7248, DOI 10.1021/ma00125a030; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Galustian C, 1997, BIOCHEMISTRY-US, V36, P5260, DOI 10.1021/bi962887a; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Gordon EJ, 1998, BIOORGAN MED CHEM, V6, P1293, DOI 10.1016/S0968-0896(98)00122-9; Gordon EJ, 1998, NATURE, V392, P30, DOI 10.1038/32073; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HWANG ST, 1996, J EXP MED, V184, P1; IMAI Y, 1993, NATURE, V361, P555; Ivin K. J., 1997, OLEFIN METATHESIS ME; Kanai M, 1997, J AM CHEM SOC, V119, P9931, DOI 10.1021/ja972089n; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; Kogan TP, 1998, J MED CHEM, V41, P1099, DOI 10.1021/jm9704917; Kogan TP, 1995, J MED CHEM, V38, P4976, DOI 10.1021/jm00026a004; Kolb HC, 1997, PURE APPL CHEM, V69, P1879, DOI 10.1351/pac199769091879; Konstantopoulos K, 1996, J CLIN INVEST, V98, P2661, DOI 10.1172/JCI119088; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027; Liang R, 1997, P NATL ACAD SCI USA, V94, P10554, DOI 10.1073/pnas.94.20.10554; Lowe JB, 1997, J CLIN INVEST, V99, P822, DOI 10.1172/JCI119244; Lynn DM, 1998, J AM CHEM SOC, V120, P1627, DOI 10.1021/ja9736323; Lynn DM, 1996, J AM CHEM SOC, V118, P784, DOI 10.1021/ja950327d; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; Mann DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/ja9818506; MANNING DD, 1995, J ORG CHEM, V60, P6254, DOI 10.1021/jo00125a005; Manning DD, 1997, J AM CHEM SOC, V119, P3161, DOI 10.1021/ja964046x; Manning DD, 1997, TETRAHEDRON, V53, P11937, DOI 10.1016/S0040-4020(97)00707-2; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MORTELL KH, 1994, J AM CHEM SOC, V116, P12053, DOI 10.1021/ja00105a056; Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q; NELSON RM, 1993, BLOOD, V82, P3253; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Norman KE, 1998, BLOOD, V91, P475, DOI 10.1182/blood.V91.2.475.475_475_483; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Record M T Jr, 1985, Adv Biophys, V20, P109; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; Revelle BM, 1996, J BIOL CHEM, V271, P16160, DOI 10.1074/jbc.271.27.16160; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Roy R, 1996, BIOORG MED CHEM LETT, V6, P1399, DOI 10.1016/0960-894X(96)00240-5; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; Sanders WJ, 1997, TETRAHEDRON, V53, P16391, DOI 10.1016/S0040-4020(97)01024-7; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; Shailubhai K, 1997, GLYCOBIOLOGY, V7, P305; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; Spevak W, 1996, J MED CHEM, V39, P1018, DOI 10.1021/jm950914+; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Tu LL, 1996, J IMMUNOL, V157, P3995; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yarema KJ, 1998, CURR OPIN CHEM BIOL, V2, P49, DOI 10.1016/S1367-5931(98)80035-5	93	82	85	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5271	5278		10.1074/jbc.274.9.5271	http://dx.doi.org/10.1074/jbc.274.9.5271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026133	hybrid			2022-12-27	WOS:000078804400004
J	Schonherr, R; Hehl, S; Terlau, H; Baumann, A; Heinemann, SH				Schonherr, R; Hehl, S; Terlau, H; Baumann, A; Heinemann, SH			Individual subunits contribute independently to slow gating of bovine EAG potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; XENOPUS-OOCYTES; RAT EAG; DROSOPHILA; STOICHIOMETRY; ETHER; ACTIVATION; MUTATION; FAMILY; CDNAS	The bovine ether a go-go gene encodes a delayed rectifier potassium channel. In contrast to other delayed rectifiers, its activation kinetics is largely determined by the holding potential and the concentration of extracellular Mg2+, giving rise to slowly activating currents with a characteristic sigmoidal rising phase. Replacement of a single amino acid in the extracellular linker between transmembrane segments S3 and S4 (L322H) strongly reduced the prepulse dependence and accelerated activation by 1 order of magnitude. In addition, compared with the wild type, the half-activation voltage of this mutant was shifted by more than 30 mV to more negative potentials. We used dimeric and tetrameric constructs of the bovine eag1 gene to analyze channels with defined stoichiometry of mutated and wild-type subunits within the tetrameric channel complexes. With increasing numbers of mutated subunits, the channel activation was progressively accelerated, and the sig moidicity of the current traces was reduced, Based on a quantitative analysis, we show that the slow gating, typical for EAG channels, is mediated by independent conformational transitions of individual subunits, which gain their voltage dependence from the S4 segment. At a given voltage, external Mg2+ increases the probability of a channel subunit to be in the slowly activating conformation, whereas mutation L322H strongly reduces this probability.	Max Planck Gesell, Arbeitsgrp Mol & Zellulare Biophys, D-07747 Jena, Germany; Max Planck Inst Expt Med, Abt Mol Biol Neuronaler Signale, D-37075 Gottingen, Germany; Forschungzentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Max Planck Society; Max Planck Society	Heinemann, SH (corresponding author), Max Planck Gesell, Arbeitsgrp Mol & Zellulare Biophys, Drackendorfer Str 1, D-07747 Jena, Germany.		Schönherr, Roland/K-8713-2013; Baumann, Arnd/I-7941-2013	Schönherr, Roland/0000-0003-0633-0775; Baumann, Arnd/0000-0001-9456-7275; Heinemann, Stefan H./0000-0002-4144-0251				CACECI MS, 1984, BYTE, V9, P340; COLE KS, 1960, BIOPHYS J, V1, P1, DOI 10.1016/S0006-3495(60)86871-3; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Frings S, 1998, J GEN PHYSIOL, V111, P583, DOI 10.1085/jgp.111.4.583; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; Hurst RS, 1995, RECEPTOR CHANNEL, V3, P263; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; London B, 1997, CIRC RES, V81, P870; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; Meyer R, 1998, J PHYSIOL-LONDON, V508, P49, DOI 10.1111/j.1469-7793.1998.049br.x; Occhiodoro T, 1998, FEBS LETT, V434, P177, DOI 10.1016/S0014-5793(98)00973-9; Ogielska EM, 1995, BIOPHYS J, V69, P2449, DOI 10.1016/S0006-3495(95)80114-1; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Shi WM, 1998, J PHYSIOL-LONDON, V511, P675, DOI 10.1111/j.1469-7793.1998.675bg.x; Shi WM, 1997, J NEUROSCI, V17, P9423; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P399, DOI 10.1085/jgp.111.3.399; Stuhmer W, 1992, PRACTICAL ELECTROPHY, P121; Tang CY, 1997, J GEN PHYSIOL, V109, P301, DOI 10.1085/jgp.109.3.301; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; Terlau H, 1996, PFLUG ARCH EUR J PHY, V432, P301, DOI 10.1007/s004240050137; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Yang YS, 1997, J GEN PHYSIOL, V109, P779, DOI 10.1085/jgp.109.6.779	28	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5362	5369		10.1074/jbc.274.9.5362	http://dx.doi.org/10.1074/jbc.274.9.5362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026145	hybrid			2022-12-27	WOS:000078804400016
J	Weidemann, A; Paliga, K; Durrwang, U; Reinhard, FBM; Schuckert, O; Evin, G; Masters, CL				Weidemann, A; Paliga, K; Durrwang, U; Reinhard, FBM; Schuckert, O; Evin, G; Masters, CL			Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENILIN-2 MUTATION N141I; BETA-PROTEIN; PC12 CELLS; IN-VIVO; MISSENSE MUTATIONS; TRANSFECTED CELLS; APOPTOSIS; GENE; EXPRESSION; CLEAVAGE	Alzheimer's disease is characterized by neurodegeneration and deposition of beta A4, a peptide that is proteolytically released from the amyloid precursor protein (APP), Missense mutations in the genes coding for APP and for the polytopic membrane proteins presenilin (PS) 1 and PS2 have been linked to familial forms of early-onset Alzheimer's disease. Overexpression of presenilins, especially that of PS2, induces increased susceptibility for apoptosis that is even more pronounced in cells expressing presenilin mutants. Additionally, presenilins themselves are, targets for activated caspases in apoptotic cells, When we analyzed APP in COS-7 cells overexpressing PS2, we observed proteolytic processing close to the APP carboxyl terminus. Proteolytic conversion was increased in the presence of PS2-I, which encodes one of the known PS2 pathogenic mutations. The same proteolytic processing occurred in cells treated with chemical inducers of apoptosis, suggesting a participation of activated caspases in the carboxyl-terminal truncation of APP, This was confirmed by showing that specific caspase inhibitors blocked the apoptotic conversion of APP, Sequence analysis of the APP cytosolic domain revealed a consensus motif for group LII caspases ((IVL)ExD), Mutation of the corresponding Asp(664) residue abolished cleavage, thereby identifying APP as a target molecule for caspase-like proteases in the pathways of programmed cellular death.	Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Ruprecht Karls University Heidelberg; University of Melbourne	Weidemann, A (corresponding author), Zentrum Mol Biol Heidelberg, Im Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	weidemanna@sun0.urz.uni-heidelberg.de	Evin, Genevieve M/E-5891-2013					Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann H, 1997, J BIOL CHEM, V272, P14505, DOI 10.1074/jbc.272.23.14505; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; WASCO W, 1998, PRESENILINS ALZHEIME, P59; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Zhao B, 1997, J NEUROSCI RES, V47, P253	50	149	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5823	5829		10.1074/jbc.274.9.5823	http://dx.doi.org/10.1074/jbc.274.9.5823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026204	hybrid			2022-12-27	WOS:000078804400075
J	Arai, M; Imai, H; Koumura, T; Yoshida, M; Emoto, K; Umeda, M; Chiba, N; Nakagawa, Y				Arai, M; Imai, H; Koumura, T; Yoshida, M; Emoto, K; Umeda, M; Chiba, N; Nakagawa, Y			Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; HEART-MITOCHONDRIA; KAPPA-B; ACTIVATION; STRESS; BCL-2	Phospholipid hydroperoxide glutathione peroxidase (PHGPx) is synthesized as a long form (L-form; 23 kDa) and a short form (S-form; 20 kDa). The L-form contains a leader sequence that is required for transport to mitochondria, whereas the S-form lacks the leader sequence. A construct encoding the leader sequence of PHGPx tagged with green fluorescent protein was used to transfect RBL-2H3 cells, and the fusion protein was transported to mitochondria. The L-form of PHGPx was identified as the mitochondrial form of PHGPx and the S-form as the non-mitochondrial form of PHGPx since preferential enrichment of mitochondria for PHGPx was detected in M15 cells that overexpressed the L-form of PHGPx, whereas no similar enrichment was detected in L9 cells that overexpressed the S-form. Cell death caused by mitochondrial injury due to potassium cyanide (KCN) or rotenone (chemical hypoxia) was considerably suppressed in the M15 cells, whereas the L9 cells and control RBL-2H3 cells (S1 cells, transfected with the vector alone) succumbed to the cytotoxic effects of KCN, Flow cytometric analysis showed that mitochondrial PHGPx suppressed the generation of hydroperoxide, the loss of mitochondrial membrane potential, and the loss of plasma membrane integrity that are induced by KCN. Mitochondrial PHGPx might prevent changes in mitochondrial functions and cell death by reducing intracellular hydroperoxides. Mitochondrial PHGPx failed to protect M15 cells from mitochondrial injury by carbonyl cyanide m-chlorophenylhydrazone, which directly reduces membrane potential without the generation of hydroperoxides. M15 cells were more resistant than L9 cells to cell death caused by direct damage to mitochondria and to extracellular oxidative stress. L9 cells were more resistant to tert-butylhydroperoxide than S1 cells, whereas resistance to t-butylhydroperoxide was even more pronounced in M15 cells than in L9 cells. These results suggest that mitochondria might be a target for intracellular and extracellular oxidative stress and that mitochondrial PHGPx, as distinct form non-mitochondrial PHGPx, might play a primary role in protecting cells from oxidative stress.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflamat Res, Bunkyo Ku, Tokyo 113, Japan; Japan Energy Corp, Toda, Saitama 335, Japan	Kitasato University; Tokyo Metropolitan Institute of Medical Science; Japan Energy Corporation	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 108, Japan.	nakagaway@pharm.kitasato-u.ac.jp	EMOTO, KAZUO/G-4992-2014					Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRIGELIUSFLOHE R, 1997, BIOCHEM J, V15, P199; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHU FF, 1994, CYTOGENET CELL GENET, V66, P96, DOI 10.1159/000133675; Crapo J D, 1978, Methods Enzymol, V53, P382; de Duve C, 1995, BIOCHEM J, V60, P604; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; EDWARD MM, 1996, J NEUROCHEM, V67, P1039; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GODEAS C, 1994, BBA-BIOMEMBRANES, V1191, P147, DOI 10.1016/0005-2736(94)90242-9; GUARNIERI C, 1992, FREE RADICALS AGING, P73; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; IMAI K, 1983, ANAL BIOCHEM, V128, P471, DOI 10.1016/0003-2697(83)90404-9; Imanaka T, 1996, J BIOL CHEM, V271, P3706; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LAWRENCE JJ, 1976, BIOCHEMISTRY-US, V15, P3301, DOI 10.1021/bi00660a021; LESTIENNE P, 1994, BIOMED PHARMACOTHER, V48, P199, DOI 10.1016/0753-3322(94)90134-1; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McGuire SO, 1997, LIPIDS, V32, P219, DOI 10.1007/s11745-997-0028-x; MYERS KM, 1995, J NEUROCHEM, V65, P2432; NADERI S, 1990, ANAL BIOCHEM, V190, P304, DOI 10.1016/0003-2697(90)90198-I; NOHL H, 1987, FEBS LETT, V214, P269, DOI 10.1016/0014-5793(87)80068-6; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Piette J, 1997, BIOL CHEM, V378, P1237; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; RODERICK AC, 1995, METHOD ENZYMOL, V260, P117; SCHONHEIT K, 1995, BBA-MOL BASIS DIS, V1271, P335, DOI 10.1016/0925-4439(95)00052-6; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS JP, 1990, J BIOL CHEM, V265, P454; TRITSCHLER HJ, 1994, BIOCHEM MOL BIOL INT, V34, P169; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	53	235	248	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4924	4933		10.1074/jbc.274.8.4924	http://dx.doi.org/10.1074/jbc.274.8.4924			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988735	hybrid			2022-12-27	WOS:000078698200060
J	Faure, V; Hecquet, C; Courtois, Y; Goureau, O				Faure, V; Hecquet, C; Courtois, Y; Goureau, O			Role of interferon regulatory factor-1 and mitogen-activated protein kinase pathways in the induction of nitric oxide synthase-2 in retinal pigmented epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; GLIAL-CELLS; EXPRESSION; GAMMA; IRF-1; GENE; PROLIFERATION; MACROPHAGES; CYTOKINES; ENDOTOXIN	Bovine retinal pigmented epithelial cells express an inducible nitric oxide synthase (NOS-2) after activation with interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS). Experiments were performed to investigate the involvement of interferon regulatory factor-1 (IRF-1) on NOS-2 induction and its regulation by NOS-2 inhibitors such as pyrrolidine dithiocarbamate (PDTC), an antioxidant, or protein kinase inhibitors. Analysis by transitory transfections showed that LPS, alone or with IFN-gamma, stimulated activity of the murine NOS-2 promoter fragment linked upstream of luciferase and its suppression by PDTC and by the different protein kinase inhibitors, genistein (tyrosine kinase inhibitor), PD98059 (mitogen-actived protein (MAP) kinase kinase inhibitor), and SE 203580 (p38 MAP inhibitor). Using specific antibodies, we have confirmed that extracellular signal-regulated kinases and p38 MAP kinase were activated by LPS and IFN-gamma in retinal pigmented epithelial cells. Analysis by reverse transcriptase-polymerase chain reaction, Western blot, and electrophoretic mobility shift assay demonstrated that IFN-gamma alone or combined with LPS induced an accumulation of IRF-1 mRNA and protein and IRF-1 DNA binding. Transfections assays with the IRF-1 promoter showed an induction of this promoter with IFN-gamma, potentiated by LPS. The decrease of LPS/IFN-gamma-induced IRF-1 promoter activity, IRF-1 synthesis, and IRF-1 activation, by PDTC, genistein, PD98059, and SE 203580, could explained in part the inhibition of the NOS-2 induction by these compounds. Our results demonstrate that IRF-1 is necessary for NOS-2 induction by LPS and IFN-gamma and that its synthesis requires the involvement of a redox-sensitive step, the activation of tyrosine kinases, and extracellular signal-regulated kinases 1/2 and p38 MAP kinases.	INSERM, U450, Dev Vieillissement & Pathol Reinte, F-75016 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Goureau, O (corresponding author), INSERM, U450, Dev Vieillissement & Pathol Reinte, 29 Rue Wilhelm, F-75016 Paris, France.	ogoureau@infobiogen.fr	GOUREAU, Olivier/F-2752-2017; GOUREAU, Olivier/ABH-9547-2020	GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU, Olivier/0000-0001-7730-9143				BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157; Bhat NR, 1998, J NEUROSCI, V18, P1633; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Faure V, 1997, J BIOL CHEM, V272, P32169, DOI 10.1074/jbc.272.51.32169; Faure V, 1998, AM J PHYSIOL-CELL PH, V275, pC208, DOI 10.1152/ajpcell.1998.275.1.C208; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Fujimura M, 1997, BRAIN RES, V759, P247, DOI 10.1016/S0006-8993(97)00264-3; GOUREAU O, 1995, J IMMUNOL, V154, P6518; GOUREAU O, 1994, BIOCHEM BIOPH RES CO, V198, P120, DOI 10.1006/bbrc.1994.1017; Goureau O, 1995, DEGENERATIVE DISEASES OF THE RETINA, P61; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GOUREAU O, 1994, J NEUROCHEM, V63, P310; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hecker M, 1996, BRIT J PHARMACOL, V118, P2178, DOI 10.1111/j.1476-5381.1996.tb15660.x; HICKS D, 1990, EXP EYE RES, V51, P119, DOI 10.1016/0014-4835(90)90063-Z; Hinton DR, 1998, EXP CELL RES, V239, P11, DOI 10.1006/excr.1997.3873; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LIVERSIDGE J, 1994, IMMUNOLOGY, V83, P404; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; SPARROW JR, 1994, EXP EYE RES, V59, P129, DOI 10.1006/exer.1994.1091; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; XIE QW, 1994, J BIOL CHEM, V269, P4705	39	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4794	4800		10.1074/jbc.274.8.4794	http://dx.doi.org/10.1074/jbc.274.8.4794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988718	hybrid			2022-12-27	WOS:000078698200043
J	Lakkakorpi, PT; Nakamura, I; Nagy, RM; Parsons, JT; Rodan, GA; Duong, LT				Lakkakorpi, PT; Nakamura, I; Nagy, RM; Parsons, JT; Rodan, GA; Duong, LT			Stable association of PYK2 and p(130)Cas in their co-localization in the sealing zone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; MEDIATED CELL-ADHESION; EXPRESS HIGH-LEVELS; BONE-RESORPTION; VITRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; BETA-3 INTEGRIN; V-SRC; P130(CAS)	Bone resorption is initiated by osteoclast attachment to the mineralized matrix, cytoskeletal reorganization, cellular polarization, and the formation of the sealing zone. The present study examines the interaction between PYK2 and p130(Cas) ((C) under bar rk-(a) under bar ssociated (s) under bar ubstrate), suggested to be part of the signaling pathway initiated by osteoclast adhesion. Using murine osteoclast-like cells (OCLs) and their mononuclear precursors (pOCs), generated in a co-culture of bone marrow and osteoblastic MB1.8 cells, we show that: 1) p130(Cas) is tyrosine-phosphorylated upon adhesion of pOCs to vitronectin or ligation of beta(3) integrins; 2) p130(Cas) colocalizes with PYK2 and the cytoskeletal proteins F-actin, vinculin, and paxillin in the podosomal-rich ring-like structures of OCLs plated on glass and in the sealing zone in actively resorbing OCLs on bone; 3) p130(Cas) and PYK2 form a stable complex in pOCs, independent of tyrosine phosphorylation of either molecule, and this complex is present in Src (-/-) OCLs, in which neither protein is phosphorylated or associated with the osteoclast adhesion structure; 4) the association of p130(Cas) and PYK2 is mediated by the SH3 domain of p130(Cas) and the C-terminal domain of PYK2. These findings suggest that p130(Cas) and its association with PYK2 may play an important role in the adhesion-dependent signaling that leads to cytoskeletal reorganization and formation of the sealing zone during osteoclast activation.	Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA; Univ Turku, Inst Biomed, Dept Anat, FIN-20014 Turku, Finland; Univ Turku, Med Res Labs, FIN-20014 Turku, Finland; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	Merck & Company; University of Turku; University of Turku; University of Virginia; University of Virginia	Duong, LT (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis Res, WP26A-1000, West Point, PA 19486 USA.	le_duong@merck.com						Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756-3282(96)00223-2; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1996, CELL TISSUE RES, V286, P507, DOI 10.1007/s004410050720; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Raja S, 1997, J BIOL CHEM, V272, P10941; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	45	95	97	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4900	4907		10.1074/jbc.274.8.4900	http://dx.doi.org/10.1074/jbc.274.8.4900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988732	hybrid			2022-12-27	WOS:000078698200057
J	Zhao, WC; Schorey, JS; Groger, R; Allen, PM; Brown, EJ; Ratliff, TL				Zhao, WC; Schorey, JS; Groger, R; Allen, PM; Brown, EJ; Ratliff, TL			Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; BLADDER-TUMOR CELLS; BOVIS BCG; INTERNALIZATION; TUBERCULOSIS; ANTIGEN; LEPRAE	Studies were performed to define the fibronectin binding motif of the previously identified Mycobacterium avium fibronectin attachment protein (FAP-A). Using synthetic peptides of a previously identified fibronectin binding region (amino acids 269-292), the minimal binding sequence was determined to be 12 amino acids, 269-280 (FAP-A-(269-280)), Synthetic peptides were prepared in which each amino acid in the 269-280 sequence was substituted with Ala, Assessment of the effect of Ala substitution on fibronectin binding showed that the presence of Ala at amino acids 273-276 (RWFV) completely abrogated fibronectin binding activity. Furthermore, the ability to inhibit the attachment of viable Mycobacterium bovis BCG to fibronectin was abrogated by Ala substitution at the RWFV sites. To validate the function of RWFV, further studies were performed with recombinant FAP-A in which single Ala mutations were generated for the RWFV sites and as controls at amino acids 269 and 280. Mutant FAP-A containing single Ala substitutions at the RWFV sites (amino acids 273, 274, 275, or 276) showed significant abrogation of fibronectin binding function. Recombinant FAP-A with Ala substitutions at either 269 or 280 showed wild type activity. When the four essential amino acids (RWFV) were either substituted en bloc with Ala or were all deleted, complete loss of fibronectin binding function was observed. Control recombinant proteins with en bloc Ala substitutions or deletions at four positions outside the fibronectin binding region (amino acids 255-257) retained functional activity. These data show that the RWFV sequence is necessary for fibronectin binding function of FAP-A, Furthermore, the data suggest that mycobacterial FAP proteins, all of which share the RWFV binding motif, constitute a family of highly homologous proteins that bind fibronectin in a unique manner.	Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Iowa; Washington University (WUSTL); Washington University (WUSTL)	Ratliff, TL (corresponding author), Univ Iowa, Dept Urol, 200 Hawkins Dr,3 RCP, Iowa City, IA 52242 USA.	tim-ratliff@uiowa.edu			NATIONAL CANCER INSTITUTE [R55CA044426, R01CA044426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033348] Funding Source: NIH RePORTER; NCI NIH HHS [CA44426] Funding Source: Medline; NIAID NIH HHS [AI33348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; BECICH MJ, 1991, J UROLOGY, V145, P1316, DOI 10.1016/S0022-5347(17)38622-6; GOLDSTEIN DS, 1993, J ENDOUROL, V7, P237, DOI 10.1089/end.1993.7.237; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; KAVOUSSI LR, 1989, J UROLOGY, V142, P875, DOI 10.1016/S0022-5347(17)38934-6; KURODA K, 1993, J CLIN INVEST, V91, P69, DOI 10.1172/JCI116202; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; Naito M, 1998, J BIOL CHEM, V273, P2905, DOI 10.1074/jbc.273.5.2905; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; RATLIFF TL, 1987, CANCER RES, V47, P1762; RATLIFF TL, 1988, J GEN MICROBIOL, V134, P1307; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOREY JS, 1995, INFECT IMMUN, V63, P2652, DOI 10.1128/IAI.63.7.2652-2657.1995; Schorey JS, 1996, MOL MICROBIOL, V21, P321, DOI 10.1046/j.1365-2958.1996.6381353.x; THOLE JER, 1992, MOL MICROBIOL, V6, P153, DOI 10.1111/j.1365-2958.1992.tb01996.x; WIKER HG, 1990, AM REV RESPIR DIS, V141, P830, DOI 10.1164/ajrccm/141.4_Pt_1.830	17	49	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4521	4526		10.1074/jbc.274.8.4521	http://dx.doi.org/10.1074/jbc.274.8.4521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988684	hybrid			2022-12-27	WOS:000078698200009
J	Attaphitaya, S; Park, K; Melvin, JE				Attaphitaya, S; Park, K; Melvin, JE			Molecular cloning and functional expression of a rat Na+/H+ exchanger (NHE5) highly expressed in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA/H EXCHANGER; INTRACELLULAR PH; MAMMALIAN-CELLS; ANTIPORTER; GROWTH; ISOFORMS; SEQUENCE; PROTEIN	We report here the cloning, primary structure, heterologous expression, tissue distribution, and localization of a cDNA encoding rat NHE5, a fifth member of the mammalian plasma membrane Na+/H+ exchanger (NHE) gene family. The full-length open reading frame as well as 34 nucleotides of 5'-untranslated and 1443 nucleotides of 3'-untranslated sequences were obtained using a polymerase chain reaction strategy involving reverse transcription-polymerase chain reaction and 5'/3'-rapid amplification of cDNA ends. The NHE5 cDNA encodes a protein of 898 amino acids with a calculated M-r of 99,044 and is predicted to contain 11-13 transmembrane domains. An amino acid comparison of the coding region of rat NHE5 reveals 95% identity with human NHE5. Northern hybridization analysis showed that high level expression of NHE5 mRNA is restricted to brain. Transfection of the coding region of rat NHE5 into NHE-deficient PS120 cells resulted in Na+/H+ exchange activity that was relatively insensitive to the amiloride analogue, 5-(N-ethyl-N-isopropyl) amiloride, with a half-maximal inhibitory concentration (IC50) of 1.53 +/- 0.25 mu M. In situ hybridization of rat brain sections revealed significant NHE5 mRNA levels in the dentate gyrus with lower levels observed in the hippocampus and cerebral cortex. These results suggest a specialized role for this fifth NHE isoform in neuronal tissues.	Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Melvin, JE (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.	james_melvin@nrmc.rochester.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE00159, DE08921] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; BASSNETT S, 1990, AM J PHYSIOL, V258, pC171, DOI 10.1152/ajpcell.1990.258.1.C171; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V272, pC90, DOI 10.1152/ajpcell.1997.272.1.C90; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin CW, 1996, BRAIN RES, V731, P108, DOI 10.1016/S0006-8993(96)00512-4; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SAUVAIGO S, 1984, BRAIN RES, V301, P371, DOI 10.1016/0006-8993(84)91106-5; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG Z, 1993, J BIOL CHEM, V268, P11925; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHANG GH, 1992, J MEMBRANE BIOL, V129, P311	28	111	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4383	4388		10.1074/jbc.274.7.4383	http://dx.doi.org/10.1074/jbc.274.7.4383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933642	hybrid			2022-12-27	WOS:000078575500066
J	Hall, KU; Collins, SP; Gamm, DM; Massa, E; DePaoli-Roach, AA; Uhler, MD				Hall, KU; Collins, SP; Gamm, DM; Massa, E; DePaoli-Roach, AA; Uhler, MD			Phosphorylation-dependent inhibition of protein phosphatase-1 by G-substrate - A Purkinje cell substrate of the cyclic GMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; 3'-5'-MONOPHOSPHATE-REGULATED NEURONAL PHOSPHOPROTEIN; CAMP-REGULATED PHOSPHOPROTEIN; SYNTHETIC PEPTIDE ANALOGS; CATALYTIC SUBUNIT; MAMMALIAN BRAIN; 2 ISOFORMS; DIFFERENTIAL EXPRESSION; GLYCOGEN-METABOLISM; MESSENGER-RNA	G-substrate, a specific substrate of the cGMP-dependent protein kinase, has previously been localized to the Purkinje cells of the cerebellum. We report here the isolation from mouse brain of a cDNA encoding G-substrate. This cDNA was used to localize G-substrate mRNA expression, as well as to produce recombinant protein for the characterization of G-substrate phosphatase inhibitory activity. Brain and eye were the only tissues in which a G-substrate transcript was detected. Within the brain, G-substrate transcripts were restricted almost entirely to the Purkinje cells of the cerebellum, although transcripts were also detected at low levels in the paraventricular region of the hypothalamus and the pons/medulla, Like the native protein, the recombinant protein was preferentially phosphorylated by cGMP-dependent protein kinase (K-m = 0.2 mu M) over cAMP-dependent protein kinase (K-m = 2.0 mu M). Phospho-G-substrate inhibited the catalytic subunit of native protein phosphatase-1 with an IC50 of 131 +/- 27 nM. Dephospho-G-substrate was not found to be inhibitory. Both dephospho and phospho-G-substrate were weak inhibitors of native protein phosphatase-2A(1), which dephosphorylated G-substrate 20 times faster than the catalytic subunit of protein phosphatase-1. G-substrate potentiated the action of cAMP-dependent protein kinase on a cAMP-regulated luciferase reporter construct, consistent with an inhibition of cellular phosphatases in vivo. These results provide the first demonstration that G-substrate inhibits protein phosphatase-1 and suggest a novel mechanism by which cGMP-dependent protein kinase I can regulate the activity of the type 1 protein phosphatases.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis	Uhler, MD (corresponding author), Univ Michigan, Mental Hlth Res Inst, Neurosci Lab Bldg,1103 E Huron St, Ann Arbor, MI 48109 USA.	muhler@umich.edu			NIDDK NIH HHS [DK36569] Funding Source: Medline; NIGMS NIH HHS [GM50791] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050791] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; AITKEN A, 1981, J BIOL CHEM, V256, P3501; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASWAD DW, 1981, J BIOL CHEM, V256, P3494; ASWAD DW, 1981, J BIOL CHEM, V256, P3487; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1977, FEBS LETT, V76, P182, DOI 10.1016/0014-5793(77)80147-6; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DETRE JA, 1984, J NEUROSCI, V4, P2843; Eadie GS, 1942, J BIOL CHEM, V146, P85; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Ferrendelli J A, 1978, Adv Cyclic Nucleotide Res, V9, P453; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; FOULKES JG, 1983, J BIOL CHEM, V258, P431; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1990, PEPTIDES PROTEIN PHO; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; KING MM, 1984, J BIOL CHEM, V259, P8080; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; NIMMO GA, 1978, EUR J BIOCHEM, V87, P353, DOI 10.1111/j.1432-1033.1978.tb12384.x; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SAITOH Y, 1989, BRAIN RES, V489, P291, DOI 10.1016/0006-8993(89)90862-7; SCHLICHTER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P5537, DOI 10.1073/pnas.77.9.5537; SCHLICHTER DJ, 1978, NATURE, V273, P61, DOI 10.1038/273061a0; SEASHOLTZ AF, 1995, P NATL ACAD SCI USA, V92, P1734, DOI 10.1073/pnas.92.5.1734; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAKAISHI T, 1991, BIOCHEM BIOPH RES CO, V174, P393, DOI 10.1016/0006-291X(91)90533-D; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Wang X, 1997, J NEUROCHEM, V68, P443; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890	54	62	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3485	3495		10.1074/jbc.274.6.3485	http://dx.doi.org/10.1074/jbc.274.6.3485			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920894	hybrid			2022-12-27	WOS:000078428200034
J	Kil, SJ; Hobert, M; Carlin, C				Kil, SJ; Hobert, M; Carlin, C			A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED PIT ADAPTINS; POSTENDOCYTIC TRAFFICKING; INDUCED INTERNALIZATION; ENHANCED DEGRADATION; PROTEIN-DEGRADATION; MEMBRANE-TRANSPORT; ENDOCYTIC PATHWAY; EGF RECEPTORS; CELLS; MOTIF	Ligand binding causes the epidermal growth factor (EGF) receptor to undergo accelerated internalization with eventual degradation in lysosomes. The goal of this study was to investigate the molecular basis of endocytic sorting, focussing on post-internalization events. We have identified a sequence located between amino acid residues 675 and 697, encompassing a dileucine motif at residues 679 and 680, that enhances endosome-to-lysosome transport when conformational restraints in the EGF receptor carboxyl terminus are removed by truncation. The same dileucine motif is also necessary for efficient lysosomal transport of ligand-occupied full-length EGF receptors, A L679A,L680A substitution diminished the degradation of occupied full-length EGF receptors without affecting internalization but had a significant effect on recycling. Rapid recycling of mutant receptors resulted in reduced intracellular retention of occupied EGF receptors and delayed down-regulation of cell surface receptors, We propose that the L679A,L680A substitution acts primarily to impair transport of ligand-receptor complexes through an early endosomal compartment, diverting occupied receptors to a recycling compartment at the expense of incorporation into lysosome transport vesicles. We also found that mutant receptors with truncations at the distal half of tyrosine kinase domain (residues 809-957) were not efficiently delivered to the cell surface but were destroyed in an endoplasmic reticulum-associated degradative pathway.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 1900 Euclid Ave, Cleveland, OH 44106 USA.	cxc39@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA049540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045669] Funding Source: NIH RePORTER; NCI NIH HHS [CA49540] Funding Source: Medline; NHLBI NIH HHS [T 32-HL07717] Funding Source: Medline; NIDDK NIH HHS [DK45669] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HOFFMAN P, 1994, MOL CELL BIOL, V14, P3695, DOI 10.1128/MCB.14.6.3695; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; MATSUI H, 1991, CANCER RES, V22, P6170; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083	52	63	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3141	3150		10.1074/jbc.274.5.3141	http://dx.doi.org/10.1074/jbc.274.5.3141			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915853	hybrid			2022-12-27	WOS:000078319500071
J	Smith, JA; Poteet-Smith, CE; Malarkey, K; Sturgill, TW				Smith, JA; Poteet-Smith, CE; Malarkey, K; Sturgill, TW			Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; IN-VIVO; C-FOS; PHOSPHORYLATION; DOMAIN; CELLS; CASCADE; INSULIN; PATHWAY	Glutathione S-transferase (GST)-fusion proteins containing the carboxyl-terminal tails of three p90 ribosomal S6 kinase (RSK) isozymes (RSK1, RSK2, and RSK3) interacted with extracellular signal-regulated kinase (ERK) but not c-Jun-NH2-kinase (JNK) or p38 mitogen-activated protein kinase (MAPK). Within the carboxyl-terminal residues of the RSK isozymes is a region of high conservation corresponding to residues (722)LAQRRVRKLPSTTL(735) in RSK1, Truncation of the carboxyl-terminal 9 residues, (VRKLPSTTL735)-V-727, completely eliminated the interaction of the GST-RSK1 fusion protein with purified recombinant ERK2, whereas the truncation of residues (PSTTL735)-P-731 had no effect on the interaction with purified ERK2. ERK1 and ERK2 co-immunoprecipitated with hemagglutinin-tagged wild type RSK2 (HA-RSK2) in BHK cell cytosol, However, ERK did not coimmunoprecipitate with HA-RSK2((1-729)), a mutant missing the carboxyl-terminal 11 amino acids, similar to the minimal truncation that eliminated in vitro interaction of ERK with the GST-RSK1 fusion protein. Kinase activity of HA-RSK2 increased B-fold in response to insulin. HA-RSK2((1-729)) had similar basal kinase activity to that of HA-RSK2 but was not affected by insulin treatment. Immunoprecipitated HA-RSK2 and HA-RSK2((1-729)) could be activated to the same extent in vitro by active ERK2, demonstrating that HA-RSK2((1-729)) was properly folded. These data suggest that the conserved region of the RSK isozymes ((722)LAQRRVRKL(730) Of RSK1) provides for a specific ERK docking site approximately 150 amino acids carboxyl-terminal to the nearest identified ERK phosphorylation site (Thr(573)). Complex formation between RSK and ERK is essential for the activation of RSK by ERK in vivo, Comparison of the docking site of RSK with the carboxyl-terminal tails of other MAPK-activated kinases reveals putative docking sites within each of these MAPK-targeted kinases, The number and placement of lysine and arginine residues within the conserved region correlate with specificity for activation by ERK and p38 MAPKs in vivo.	Univ Virginia, Ctr Hlth Sci, Howard Hughes Med Inst, Charlottesville, VA 22908 USA; Univ Virginia, Markey Ctr Cell Signaling, Dept Med & Pharmacol, Charlottesville, VA 22908 USA	Howard Hughes Medical Institute; University of Virginia; University of Virginia	Sturgill, TW (corresponding author), Univ Virginia, Ctr Hlth Sci, Howard Hughes Med Inst, Box 577, Charlottesville, VA 22908 USA.				NIDDK NIH HHS [DK41077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; DAI TN, 1995, ONCOGENE, V10, P849; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Pende M, 1997, J NEUROSCI, V17, P1291; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	35	235	239	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2893	2898		10.1074/jbc.274.5.2893	http://dx.doi.org/10.1074/jbc.274.5.2893			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915826	hybrid			2022-12-27	WOS:000078319500044
J	Zhang, Y; Neo, SY; Han, JH; Yaw, LP; Lin, SC				Zhang, Y; Neo, SY; Han, JH; Yaw, LP; Lin, SC			RGS16 attenuates G alpha(q)-dependent p38 mitogen-activated protein kinase activation by platelet-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; MAP KINASE; COUPLED RECEPTORS; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; FAMILY; NEUTROPHILS	The large gene family encoding the regulators of G protein signaling (RGS) proteins has been implicated in the fine tuning of a variety of cellular events in response to G protein-coupled receptor activation. Several studies have shown that the RGS proteins can attenuate Gr protein-activated extracellular signal-regulated kinase (ERK) group of mitogen-activated protein kinases. We demonstrate herein that the production of inositol trisphosphate and the activation of the p38 group of mitogen-activated protein kinases by the G; protein-coupled platelet-activating factor (PAF) receptor was attenuated by RGS16 in both CHO cells transiently and stably expressing RGS16. The inhibition was not observed with RGS2, RGS5, and a functionally defective form of RGS16, RGS16(R169S/F170C). The PAF-induced p38 and ERK pathways appeared to be preferentially regulated by RGS16 and RGS1, respectively. Overexpression of a constitutively active form of G alpha(11) (G alpha(11)Q209L) prevented the RGS16-mediated attenuation of p38 activity, suggesting that G alpha(q/11) is involved in PAF activation of p38. The G(alpha q/11) involvement is further supported by the observation that p38 activation by PAF was pertussis toxin-insensitive. These results demonstrate for the first time that apart from ERK, p38 activation by a G protein-coupled receptor can be attenuated by an RGS protein and provide further evidence for the specificity of RGS function in G protein signaling pathways.	Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, Singapore 117609, Singapore; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Scripps Research Institute	Lin, SC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		Han, J/G-4671-2010; Lin, SC/G-4666-2010	Zhang, Yi/0000-0003-2785-1780	NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Coso OA, 1996, J BIOL CHEM, V271, P3963; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONG JX, 1993, J IMMUNOL, V150, P3895; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOIKE H, 1994, EUR J PHARM-MOLEC PH, V269, P299, DOI 10.1016/0922-4106(94)90037-X; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lazou A, 1998, BIOCHEM J, V332, P459, DOI 10.1042/bj3320459; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AY, 1994, BBA-MOL CELL RES, V1224, P323, DOI 10.1016/0167-4889(94)90206-2; LIN SC, 1991, J BIOL CHEM, V266, P23347; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Reiser COA, 1998, BIOCHEM J, V330, P1107; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	53	38	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2851	2857		10.1074/jbc.274.5.2851	http://dx.doi.org/10.1074/jbc.274.5.2851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915820	hybrid			2022-12-27	WOS:000078319500038
J	Arbet-Engels, C; Tartare-Deckert, S; Eckhart, W				Arbet-Engels, C; Tartare-Deckert, S; Eckhart, W			C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 2-HYBRID SYSTEM; TYROSINE KINASES; PROTEIN-KINASE; PHOSPHORYLATION; CELLS; SUBSTRATE-1; PP60C-SRC; CSK; BINDING; SITES	Increased expression of the insulin-like growth factor-I receptor (IGF-IR) protein-tyrosine kinase occurs in several kinds of cancer and induces neoplastic transformation in fibroblast cell lines. The transformed phenotype can be reversed by interfering with the function of the IGF-IR. The IGF-IR is required for transformation by a number of viral and cellular oncoproteins, including SV40 large T antigen, Ras, Raf, and Src. The IGF-IR is a substrate for Src in vitro and is phosphorylated in v-Src-transformed cells. Ne observed that the IGF-IR and IR associated with the C-terminal Src kinase (CSK) following ligand stimulation. We found that the SH2 domain of CSK binds to the tyrosine-phosphorylated form of IGF-IR and IR We determined the tyrosine residues in the IGF-IR and in the IR responsible for this interaction. We also observed that fibroblasts stimulated with IGF-I or insulin showed a rapid and transient decrease in c-Src tyrosine kinase activity. The results suggest that c-Src and CSK are involved in IGF-IR and IR signaling and that the interaction of CSK with the IGF-IR may play a role in the decrease in c-Src activity following IGF-I stimulation.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Arbet-Engels, C (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	arbet@axp1.salk.edu	TARTARE-DECKERT, Sophie/P-6057-2015	TARTARE-DECKERT, Sophie/0000-0001-8680-5720	NATIONAL CANCER INSTITUTE [P30CA014195, R37CA013884, R01CA013884] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 13884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MSUTELIN T, 1994, SRC FAMILY TRYOSINE; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OKADA M, 1989, J BIOL CHEM, V264, P20886; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TOBE K, 1993, J BIOL CHEM, V268, P11167; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	50	54	55	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5422	5428		10.1074/jbc.274.9.5422	http://dx.doi.org/10.1074/jbc.274.9.5422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026153	hybrid			2022-12-27	WOS:000078804400024
J	Wakabayashi, H; Natsuka, S; Mega, T; Otsuki, N; Isaji, M; Naotsuka, M; Koyama, S; Kanamori, T; Sakai, K; Hase, S				Wakabayashi, H; Natsuka, S; Mega, T; Otsuki, N; Isaji, M; Naotsuka, M; Koyama, S; Kanamori, T; Sakai, K; Hase, S			Novel proteoglycan linkage tetrasaccharides of human urinary soluble thrombomodulin, SO4-3GlcA beta 1-3Gal beta 1-3(+/- Sia alpha 2-6)Gal beta 1-4Xyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RECOMBINANT HUMAN THROMBOMODULIN; FALCIPARUM-INFECTED ERYTHROCYTES; HNK-1 CARBOHYDRATE EPITOPE; SUGAR CHAINS; CHONDROITIN SULFATE; PROTEIN-C; OLIGOSACCHARIDES; GLYCOSAMINOGLYCAN; GLYCOPROTEINS	O-linked sugar chains with xylose as a reducing end linked to human urinary soluble thrombomodulin were studied. Sugar chains were Liberated by hydrazinolysis followed by N-acetylation and tagged with 2-aminopyridine. Two fractions containing pyridylaminated Xyl as a reducing end were collected. Their structures were determined by partial acid hydrolysis, two-dimensional sugar mapping combined with exoglycosidase digestions, methylation analysis, mass spectrometry, and NMR as SO4-3GlcA beta 1-3Gal beta 1-3(+/-Sia alpha 2-6)Gal beta 1-4Xyl. These sugar chains could bind to an HNK-1 monoclonal antibody. This is believed to be the first example of a proteoglycan linkage tetrasaccharide with glucuronic acid 3-sulfate and sialic acid.	Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; Mochida Pharmaceut Co Ltd, Pharmaceut Lab, Fujieda, Shizuoka 4268640, Japan; Mochida Pharmaceut Co Ltd, Biosci Res Lab, Kita Ku, Tokyo 1158515, Japan	Osaka University; Mochida Pharmaceutical Co Ltd; Mochida Pharmaceutical Co Ltd	Hase, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan.		Natsuka, Shunji/L-9330-2018	Natsuka, Shunji/0000-0003-1726-8946				Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Dudek AZ, 1997, J BIOL CHEM, V272, P31785, DOI 10.1074/jbc.272.50.31785; Edano T, 1998, INT J BIOCHEM CELL B, V30, P77, DOI 10.1016/S1357-2725(97)00078-2; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Florea D, 1997, CARBOHYD RES, V302, P179, DOI 10.1016/S0008-6215(97)00129-8; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HASE S, 1994, METHOD ENZYMOL, V230, P225; HASE S, 1992, BIOSCI BIOTECH BIOCH, V56, P1676, DOI 10.1271/bbb.56.1676; HASE S, 1978, BIOCHEM BIOPH RES CO, V85, P257, DOI 10.1016/S0006-291X(78)80037-0; JACKSON DE, 1994, EUR J BIOCHEM, V221, P1079, DOI 10.1111/j.1432-1033.1994.tb18827.x; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; KURAYA N, 1992, J BIOCHEM, V112, P122, DOI 10.1093/oxfordjournals.jbchem.a123850; LIN JH, 1994, J BIOL CHEM, V269, P25021; Makino Y, 1996, ANAL BIOCHEM, V238, P54, DOI 10.1006/abio.1996.0250; MEGA T, 1991, J BIOCHEM-TOKYO, V109, P600, DOI 10.1093/oxfordjournals.jbchem.a123426; MEGA T, 1992, J BIOCHEM-TOKYO, V111, P396, DOI 10.1093/oxfordjournals.jbchem.a123768; Nakano M, 1998, THROMB HAEMOSTASIS, V79, P331; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; SLOMIANY A, 1981, BIOCHEM BIOPH RES CO, V100, P778, DOI 10.1016/S0006-291X(81)80242-2; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1989, P 10 INT S GLYC SEPT, P322; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; Takagaki K, 1997, J BIOCHEM-TOKYO, V122, P1129; Takahashi Y, 1997, THROMB HAEMOSTASIS, V77, P789; TAKAHASHI Y, 1995, THROMB HAEMOSTASIS, V73, P805; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; YAMAMOTO S, 1993, J BIOCHEM-TOKYO, V113, P433, DOI 10.1093/oxfordjournals.jbchem.a124063	33	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5436	5442		10.1074/jbc.274.9.5436	http://dx.doi.org/10.1074/jbc.274.9.5436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026155	hybrid			2022-12-27	WOS:000078804400026
J	Aragay, AM; Quick, MW				Aragay, AM; Quick, MW			Functional regulation of G alpha(16) by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTOR KINASES; GTP-BINDING-PROTEIN; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; XENOPUS-OOCYTES; INOSITOL TRISPHOSPHATE; TRANSMEMBRANE SIGNALS; ACTIVATION	Recent evidence demonstrates that the a subunits of some heterotrimeric GTP-binding proteins (G proteins) are subject to modification by protein kinase C (PKC). For the family of G proteins that activate the phospholipase C/inositol trisphosphate/calcium/PKC pathway, such modification could result in G protein autoregulation. To examine the potential regulation of members of the G alpha(q) family by PKC phosphorylation, we expressed the thyrotropin-releasing hormone (TRH) receptor in combination with G alpha(q), G alpha(11), G alpha(14), G alpha(15), or G alpha(16) in Xenopus oocytes and examined the regulation of signaling by PKC activators and inhibitors, For G alpha(16) and G alpha(15), the two family members of hematopoietic lineage, PKC activators reduce both the magnitude and the time course of TRH-mediated responses; PKC inhibitors have the opposite effect. The PKC-mediated effects are evident in measurements of GTPase activity, suggesting that the regulation is occurring early in the signaling pathway. In vivo phosphorylation experiments demonstrate that G alpha(16) is a substrate for PHC modification. By comparison, G alpha(q) is not phosphorylated by PHC in vivo and oocytes expressing G alpha(q) are not functionally modulated by PKC. Repeated TRH stimulation of oocytes expressing G alpha(16) mimics the effects of PKC activators, and this functional regulation is correlated with an increase in G alpha(16) phosphorylation. A mutant G alpha(16) with four consensus PKC phosphorylation sites removed is not phosphorylated in vivo, and TRH responses mediated through the mutant are not regulated by PKC. These results demonstrate that signaling involving hematopoietic G proteins is subject to PKC-mediated autoregulation, at least in part, by phosphorylation of the G protein a subunit.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol, E-28049 Madrid, Spain	University of Alabama System; University of Alabama Birmingham; Autonomous University of Madrid	Quick, MW (corresponding author), Univ Alabama, Dept Neurobiol, CIRC 446,1719 6th Ave S, Birmingham, AL 35294 USA.	quick@nrc.uab.edu	Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bohm SK, 1997, BIOCHEM J, V322, P1; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COREY JL, 1994, J BIOL CHEM, V269, P14759; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DenisHenriot D, 1996, BIOCHEM BIOPH RES CO, V220, P443, DOI 10.1006/bbrc.1996.0392; Fenster CP, 1997, J NEUROSCI, V17, P5747; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GIERSCHIK P, 1992, HDB EXPT PHARM, V102, P807; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HO BY, 1992, FEBS LETT, V301, P303, DOI 10.1016/0014-5793(92)80262-F; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KESSELRING F, 1994, BLOOD, V84, P4088, DOI 10.1182/blood.V84.12.4088.bloodjournal84124088; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOSAZA T, 1996, J BIOL CHEM, V271, P12562; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MAPARA MY, 1995, BLOOD, V85, P1836, DOI 10.1182/blood.V85.7.1836.bloodjournal8571836; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; NEER EJ, 1994, PROTEIN SCI, V3, P3; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PARK DG, 1993, J BIOL CHEM, V268, P4573; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Quick Michael W., 1994, V19, P261; QUICK MW, 1994, J BIOL CHEM, V269, P30164; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UI M, 1990, ADP RIBOSYLATING TOX, P45; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4807	4815		10.1074/jbc.274.8.4807	http://dx.doi.org/10.1074/jbc.274.8.4807			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988720	hybrid			2022-12-27	WOS:000078698200045
J	Machaca, K; Hartzell, HC				Machaca, K; Hartzell, HC			Adenophostin A and inositol 1,4,5-trisphosphate differentially activate Cl- currents in Xenopus oocytes because of disparate Ca2+ release kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; PANCREATIC ACINAR-CELLS; BETA-GAMMA-SUBUNITS; LAEVIS OOCYTES; PENICILLIUM-BREVICOMPACTUM; INTRACELLULAR CALCIUM; POTENT AGONISTS; RECEPTOR; INFLUX; STORES	Depletion of endoplasmic reticulum Ca2+ stores induces Ca2+ entry from the extracellular space by a process termed "store-operated Ca2+ entry" (SOCE), It has been suggested that the novel fungal metabolite adenophostin-A may be able to stimulate Ca2+ entry without stimulating Ca2+ release from stores. To test this idea further, we compared Ca2+ release, SOCE, and the stimulation of Ca2+-activated Cl- currents in Xenopus oocytes in response to inositol 1,4,5-trisphosphate (IP3) and adenophostin-A injection. IP3 stimulated an outward Cl- current, ICIl-S, in response to Ca2+ release from stores followed by an inward current, I-Cl2, in response to SOCE. In contrast, low concentrations of adenophostins (AdAs) activated I-Cl2 without activating ICl1-S, consistent with the suggestion that AdA can activate Ca2+ entry without stimulating Ca2+ release. However, when Ca2+ entry has been stimulated by AdA, Ca2+ stores are largely depleted of Ca2+, as assessed by the inability of ionomycin to release additional Ca2+. The Ca2+ release stimulated by AdA, however, was 7 times slower than the release stimulated by IP3, which could explain the minimal activation of ICl1-S; when Ca2+ is released slowly, the threshold level required for ICl1-S, activation is not attained.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Hartzell, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.	Criss@cellbio.emory.edu	Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021195, R37HL021195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055276] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21195] Funding Source: Medline; NIGMS NIH HHS [GM55276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARISH ME, 1984, J PHYSIOL-LONDON, V352, P243, DOI 10.1113/jphysiol.1984.sp015289; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DeLisle S, 1997, J BIOL CHEM, V272, P9956; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; Grygorczyk R, 1996, J NEUROSCI METH, V67, P19; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kobrinsky E, 1995, DEV BIOL, V172, P531, DOI 10.1006/dbio.1995.8058; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Kuruma A, 1999, AM J PHYSIOL-CELL PH, V276, pC161, DOI 10.1152/ajpcell.1999.276.1.C161; Machaca K, 1998, BIOPHYS J, V74, P1286, DOI 10.1016/S0006-3495(98)77842-7; MACHACA K, 1999, IN PRESS J GEN PHYSL; Marchant JS, 1998, BIOCHEM J, V334, P505, DOI 10.1042/bj3340505; Marchant JS, 1997, BIOCHEMISTRY-US, V36, P12780, DOI 10.1021/bi971397v; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAKAHASHI M, 1993, J ANTIBIOT, V46, P1643, DOI 10.7164/antibiotics.46.1643; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684	36	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4824	4831		10.1074/jbc.274.8.4824	http://dx.doi.org/10.1074/jbc.274.8.4824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988722	hybrid			2022-12-27	WOS:000078698200047
J	Radisky, D; Kaplan, J				Radisky, D; Kaplan, J			Regulation of transition metal transport across the yeast plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; COPPER UPTAKE; GENE ENCODES; MOLECULAR CHARACTERIZATION; ZINC TRANSPORTER; PROTEIN; EXPRESSION; COMPLEMENTATION; METABOLISM		Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, Salt Lake City, UT 84132 USA.		Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784				Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BODE HP, 1995, EUR J BIOCHEM, V228, P337; Chua ACG, 1997, J COMP PHYSIOL B, V167, P361, DOI 10.1007/s003600050085; CULOTTA VC, 1998, METALS GENETICS; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P232; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	42	120	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4481	4484		10.1074/jbc.274.8.4481	http://dx.doi.org/10.1074/jbc.274.8.4481			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988676	hybrid			2022-12-27	WOS:000078698200001
J	Reuter, M; Schneider-Mergener, D; Kupper, D; Meisel, A; Mackeldanz, P; Kruger, DH; Schroeder, C				Reuter, M; Schneider-Mergener, D; Kupper, D; Meisel, A; Mackeldanz, P; Kruger, DH; Schroeder, C			Regions of endonuclease EcoRII involved in DNA target recognition identified by membrane-bound peptide repertoires	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RESTRICTION ENDONUCLEASES; CRYSTAL-STRUCTURE; REFRACTORY DNA; SEQUENCE; SITES; BINDING; CLEAVAGE; COMPLEX; DNA-(CYTOSINE-C5)-METHYLTRANSFERASES; SPECIFICITY	Target sequence-specific DNA binding regions of the restriction endonuclease EcoRII were identified by screening a membrane-bound EcoRII-derived peptide scan with an EcoRII recognition site (CCWGG) oligonucleotide duplex, Dodecapeptides overlapping by nine amino acids and representing the complete protein were prepared by spot synthesis. Two separate DNA binding regions, amino acids 88-102 and amino acids 256-273, which share the consensus motif KXRXXK, emerged. Screening 570 single substitution analogues obtained by exchanging every residue of both binding sites for all other amino acids demonstrated that replacing basic residues in the consensus motifs significantly reduced DNA binding. EcoRII mutant enzymes generated by substituting alanine or glutamic acid for the consensus lysine residues in DNA binding site I expressed attenuated DNA binding, whereas corresponding substitutions in DNA binding site II caused impaired cleavage, but enzyme secondary structure was unaffected. Furthermore, Glu(96), which is part of a potential catalytic motif and also locates to DNA binding site I, was demonstrated to be critical for DNA cleavage and binding. Homology studies of DNA binding site II revealed strong local homology to SsoII (recognition sequence, CCNGG) and patterns of sequence conservation, suggesting the existence of functionally related DNA binding sites in diverse restriction endonucleases with recognition sequences containing terminal C:G or G:C pairs.	Humboldt Univ, Med Sch Charite, Inst Virol, D-10098 Berlin, Germany; Humboldt Univ, Med Sch Charite, Inst Med Immunol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reuter, M (corresponding author), Humboldt Univ, Med Sch Charite, Inst Virol, D-10098 Berlin, Germany.			Meisel, Andreas/0000-0001-7233-5342				Aggarwal AK, 1998, CURR OPIN STRUC BIOL, V8, P19, DOI 10.1016/S0959-440X(98)80005-5; BHAGWAT AS, 1990, J BIOL CHEM, V265, P767; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; FRANK R, 1992, TETRAHEDRON, V48, P9211; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GOPAL J, 1994, NUCLEIC ACIDS RES, V22, P4482, DOI 10.1093/nar/22.21.4482; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6051, DOI 10.1093/nar/20.22.6051; JANULAITIS A, 1996, BIOLOGIJA, V2, P28; JELTSCH A, 1995, GENE, V160, P7, DOI 10.1016/0378-1119(95)00181-5; JELTSCH A, 1995, J BIOL CHEM, V270, P5122, DOI 10.1074/jbc.270.10.5122; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KOSSYKH V, 1989, BIOCHIM BIOPHYS ACTA, V1009, P290, DOI 10.1016/0167-4781(89)90117-6; KOSSYKH VG, 1993, GENE, V125, P65, DOI 10.1016/0378-1119(93)90746-P; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; KUPPER D, 1995, PROTEIN EXPRES PURIF, V6, P1, DOI 10.1006/prep.1995.1001; Lange C, 1996, EMBO J, V15, P1443, DOI 10.1002/j.1460-2075.1996.tb00486.x; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; MCLANE KE, 1995, P NATL ACAD SCI USA, V92, P5214, DOI 10.1073/pnas.92.11.5214; Morgenstern B, 1996, P NATL ACAD SCI USA, V93, P12098, DOI 10.1073/pnas.93.22.12098; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; OSULLIVAN DJ, 1995, J BACTERIOL, V177, P134, DOI 10.1128/jb.177.1.134-143.1995; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PEIN CD, 1989, FEBS LETT, V245, P141, DOI 10.1016/0014-5793(89)80208-X; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Reineke U, 1998, PROTEIN SCI, V7, P951; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Roberts RJ, 1998, NUCLEIC ACIDS RES, V26, P338, DOI 10.1093/nar/26.1.338; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAMBROOK J, 1989, MOL CLONING, V1, P7; SIKSNYS V, 1995, GENE, V157, P311, DOI 10.1016/0378-1119(94)00632-3; STANOJEVIC D, 1995, NAT STRUCT BIOL, V2, P450, DOI 10.1038/nsb0695-450; Swaminathan N, 1996, NUCLEIC ACIDS RES, V24, P2463, DOI 10.1093/nar/24.13.2463; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; Trautner TA, 1996, EMBO J, V15, P1434, DOI 10.1002/j.1460-2075.1996.tb00485.x; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565	53	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5213	5221		10.1074/jbc.274.8.5213	http://dx.doi.org/10.1074/jbc.274.8.5213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988771	hybrid			2022-12-27	WOS:000078698200096
J	Shworak, NW; Liu, JA; Petros, LM; Zhang, LJ; Kobayashi, M; Copeland, NG; Jenkins, NA; Rosenberg, RD				Shworak, NW; Liu, JA; Petros, LM; Zhang, LJ; Kobayashi, M; Copeland, NG; Jenkins, NA; Rosenberg, RD			Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase - Isolation, characterization, and expression of human cDNAs and identification of distinct genomic loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; INTEGRATED MOLECULAR ANALYSIS; GENE CONVERSION; MESSENGER-RNA; CELL-LINE; CLONING; MOUSE; SEQUENCE; PROTEIN; BINDING	3-O-Sulfated glucosaminyl residues are rare constituents of heparan sulfate and are essential for the activity of anticoagulant heparan sulfate. Cellular production of the critical active structure is controlled by the rate-limiting enzyme, heparan sulfate D-glucosaminyl 3-O-sulfotransferase-1 (3-OST-1) (EC 2.8.2.23). We have probed the expressed sequence tag data base with the carboxyl-terminal sulfotransferase domain of 3-OST-1 to reveal three novel, incomplete human cDNAs. These were utilized in library screens to isolate full-length cDNAs. Clones corresponding to predominant transcripts were obtained for the 367-, 406-, and 390-amino acid enzymes 3-OST-2, 3-OST-3(A), and 3-OST-3(B), respectively. These type II integral membrane proteins are comprised of a divergent amino-terminal region and a very homologous carboxyl-terminal sulfotransferase domain of similar to 260 residues. Also recovered were partial length clones for 3-OST-4. Expression of the full-length enzymes confirms the 3-O-sulfation of specific glucosaminyl residues within heparan sulfate (Liu, J., Shworak, N. W., Sinay, P., Schwartz, J. J. Zhang, L., Fritze, L. M. S., and Rosenberg, R. D. (1999) J. Biol. Chem. 274, 5185-5192). Southern analyses suggest the human 3OST1, 3OST2, and 3OST4 genes, and the corresponding mouse isologs, are single copy. However, 3OST3A and 3OST3B genes are each duplicated in humans and show at least one copy each in mice. Intriguingly, the entire sulfotransferase domain sequence of the 3-OST-3(B) cDNA (774 base pairs) was 99.2% identical to the same region of 3-OST-3(A). Together, these data argue that the structure of this functionally important region is actively maintained by gene conversion between 3OST3A and 3OST3B loci. Interspecific mouse back-cross analysis identified the loci for mouse 3Ost genes and syntenic assignments of corresponding human isologs were confirmed by the identification of mapped sequence-tagged site markers, Northern blot analyses indicate brain exclusive and brain predominant expression of 3-OST-4 and 3-OST-2 transcripts, respectively; whereas, 3-OST-3(A) and 3-OST-3(B) isoforms show widespread expression of multiple transcripts. The reiteration and conservation of the 3-OST sulfotransferase domain suggest that this structure is a self-contained functional unit. Moreover, the extensive number of 3OST genes with diverse expression patterns of multiple transcripts suggests that the novel 3-OST enzymes, like 3-OST-1, regulate important biologic properties of heparan sulfate proteoglycans.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shworak, NW (corresponding author), Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, SL-418,330 Brookline Ave, Boston, MA 02215 USA.	nshworak@caregroup.harvard.edu	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [5-PO1-HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1995, NATURE, V377, P3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; AVRAHAM KB, 1994, GENOMICS, V21, P656, DOI 10.1006/geno.1994.1330; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BUCHBERG AM, 1989, GENETICS, V122, P153; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carey DJ, 1997, BIOCHEM J, V327, P1; CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Chopra R, 1996, EXP HEMATOL, V24, P755; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Pathak BG, 1996, GENOMICS, V33, P124, DOI 10.1006/geno.1996.0168; POWERS PA, 1991, GENETICS, V129, P133; RAU C, 1995, PHYSIOL CHEM PHYS M, V27, P55; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1995, PROTEIN SCI, V4, P521; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SCHIMENTI JC, 1994, SOC GEN PHY, V49, P85; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; SHWORAK NW, 1995, ENDOTHELIAL CELL HLT, P119; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHL GM, 1987, METHOD ENZYMOL, V152, P399; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	64	191	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5170	5184		10.1074/jbc.274.8.5170	http://dx.doi.org/10.1074/jbc.274.8.5170			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988767	hybrid			2022-12-27	WOS:000078698200092
J	Ray, A; Schatten, H; Ray, BK				Ray, A; Schatten, H; Ray, BK			Activation of Sp1 and its functional co-operation with serum amyloid a-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR; REACTIVE PROTEIN; POSTTRANSCRIPTIONAL MECHANISMS; RHEUMATOID-ARTHRITIS; FAMILY PROTEINS; NUCLEAR FACTOR; MESSENGER-RNA; C/EBP-BETA	The serum amyloid A (SAA) protein has been implicated in the progression and pathogenesis of rheumatoid arthritis through induction of collagenase activity in synovial fibroblast cells that line the joint tissues. We demonstrate that SAA is synergistically induced in synovial cells by interleukin (IL)-1 and IES that are present at significantly high level in the synovial fluid of arthritis patients. These cytokines induced phenotypic changes in synovial cells, promoting protrusion and increased cellular contact. Induction of SAA under this condition is mediated by promoter elements located between -254 and -226, which contains binding sites for transcription factors Sp1 and SAA activating sequence binding factor (SAF). Mutation of these sequences abolishes SAA promoter response to IL-1 and IL-6. The role of Spl in SAA induction was demonstrated by increased DNA binding activity, phosphorylation, and increased protein content of Spl during cytokine treatment. Spl interacts with the SAA promoter in association with SAF as an SAF Spl heteromeric complex. Furthermore, using a phosphatase inhibitor, we demonstrated increased transactivation potential of both Spl and SAF as a consequence of a phosphorylation event. These results provide first evidence for cytokine-mediated activation of Spl in synovial fibroblast cells and its participation in regulating SAA expression by acting in conjunction with SAF.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205, R56DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BENSON MD, 1979, ARTHRITIS RHEUM, V22, P36, DOI 10.1002/art.1780220106; BETTS JC, 1993, J BIOL CHEM, V268, P25624; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CLINE CA, 1983, CELL MOTIL CYTOSKEL, V3, P513, DOI 10.1002/cm.970030518; CONTI P, 1995, IMMUNOL INVEST, V24, P523, DOI 10.3109/08820139509066848; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; Horackova M, 1997, EXP CELL RES, V237, P158, DOI 10.1006/excr.1997.3775; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jensen LE, 1997, J IMMUNOL, V158, P384; JIANG SL, 1995, J CLIN INVEST, V95, P1253, DOI 10.1172/JCI117775; JIANG SL, 1995, J IMMUNOL, V154, P825; Koj A, 1985, ACUTE PHASE RESPONSE, P139; Kumon Y, 1997, SCAND J IMMUNOL, V46, P284, DOI 10.1046/j.1365-3083.1997.d01-128.x; Kumon Y, 1997, J RHEUMATOL, V24, P14; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 1997, DNA CELL BIOL, V16, P1, DOI 10.1089/dna.1997.16.1; Ray Alpana, 1993, Gene Expression, V3, P151; Ray BK, 1997, J BIOL CHEM, V272, P28948, DOI 10.1074/jbc.272.46.28948; RAY BK, 1993, BIOCHEM BIOPH RES CO, V193, P1159, DOI 10.1006/bbrc.1993.1747; RIENHOFF HY, 1988, MOL CELL BIOL, V8, P3710, DOI 10.1128/MCB.8.9.3710; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; Strissel KJ, 1997, EXP CELL RES, V237, P275, DOI 10.1006/excr.1997.3783; SUKENIK S, 1988, J RHEUMATOL, V15, P942; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; YANNI G, 1994, ANN RHEUM DIS, V53, P39, DOI 10.1136/ard.53.1.39; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	55	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4300	4308		10.1074/jbc.274.7.4300	http://dx.doi.org/10.1074/jbc.274.7.4300			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933631	hybrid			2022-12-27	WOS:000078575500055
J	Charron, MJ; Katz, EB; Olson, AL				Charron, MJ; Katz, EB; Olson, AL			GLUT4 gene regulation and manipulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLUCOSE-TRANSPORTER GENE; WHITE SKELETAL-MUSCLE; TRANSGENIC MICE; ADIPOSE-TISSUE; MESSENGER-RNA; DIFFERENTIAL REGULATION; INSULIN-RESISTANCE; TRANSCRIPTIONAL REGULATION; EXPRESSION; ADIPOCYTES		Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Yeshiva University; Albert Einstein College of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	charron@aecom.yu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047894, R01DK047425, R55DK047894] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58119] Funding Source: Medline; NIDDK NIH HHS [DK47894, DK47425] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; Charron MJ, 1997, BIOCHEM SOC T, V25, P963, DOI 10.1042/bst0250963; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; Charron MJ, 1998, MOL CELL BIOCHEM, V182, P143, DOI 10.1023/A:1006809611658; Cooke DW, 1998, J BIOL CHEM, V273, P6210, DOI 10.1074/jbc.273.11.6210; CUSIN I, 1990, ENDOCRINOLOGY, V127, P3246, DOI 10.1210/endo-127-6-3246; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; GERRITS PM, 1993, J BIOL CHEM, V268, P640; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; LIU ML, 1992, J BIOL CHEM, V267, P11673; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; OLSON AL, 1993, J BIOL CHEM, V268, P9839; OLSON AL, 1995, ENDOCRINOLOGY, V136, P1962, DOI 10.1210/en.136.5.1962; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; Prins JB, 1997, CLIN SCI, V92, P3, DOI 10.1042/cs0920003; RANDLE PJ, 1963, LANCET, V1, P785; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; Rossetti L, 1997, J CLIN INVEST, V100, P1831, DOI 10.1172/JCI119711; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; VRANIC M, 1990, DIABETES MELLITUS TH, P198; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WEILAND M, 1990, BIOCHEM J, P331; WHITE MF, 1994, J BIOL CHEM, V269, P1; Zierath JR, 1998, J BIOL CHEM, V273, P20910, DOI 10.1074/jbc.273.33.20910	37	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3253	3256		10.1074/jbc.274.6.3253	http://dx.doi.org/10.1074/jbc.274.6.3253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920861	hybrid			2022-12-27	WOS:000078428200001
J	Huang, CF; Buu, LM; Yu, WL; Lee, FJS				Huang, CF; Buu, LM; Yu, WL; Lee, FJS			Characterization of a novel ADP-ribosylation factor-like protein (yARL3) in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; STIMULATORY REGULATORY COMPONENT; PHOSPHOLIPASE-D ACTIVITY; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; CHOLERA-TOXIN; ARF PROTEINS; ADENYLATE-CYCLASE; ESCHERICHIA-COLI; GENE DISRUPTION	ADP-ribosylation factors (ARFs) are highly conserved, similar to 20-kDa guanine nucleotide-binding proteins that enhance the ADP-ribosyltransferase activity of cholera toxin and have an important role in vesicular transport. Several cDNAs for ARF-like proteins (ARLs) have been cloned from human, Drosophila, rat, and yeast, although the biological function(s) of ARLs is unknown. We have identified a yeast gene (yARL3) encoding a protein that is structurally related (>43% identical) to the mammalian ARF-like protein ARP. Biochemical studies of purified recombinant yARL3 protein revealed properties similar to those of ARF and ARL proteins, including the ability to bind and hydrolyze GTP. Like other ARLs, recombinant yARL3 did not stimulate cholera toxin-catalyzed auto-ADP-ribosylation. Anti-yARL3 antibodies did not cross-react with yARFs or yARL1. yARL3 was not essential for cell viability, but disruption of yARL3 resulted in cold-sensitive cell growth. At the nonpermissive temperature, processing of alkaline phosphatase and carboxypeptidase Y in arl3 mutant was slowed. yARL3 might be required for protein transport from endoplasmic reticulum to Golgi or from Golgis to vacuole at nonpermissive temperatures. On subcellular fractionation, unlike its mammalian homologue ARP, yARL3 was detected in the soluble fraction but not in the plasma membrane. Indirect immunofluorescence analysis revealed that yARL3 when overexpressed was associated in part with the endoplasmic reticulum-nuclear envelope. Thus, the structural and functional characteristics of yARL3 indicate that it may have a unique role(s) in vesicular trafficking.	Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University	Lee, FJS (corresponding author), Natl Taiwan Univ, Sch Med, Inst Mol Med, 7 Chang Shan S Rd, Taipei, Taiwan.	fangjen@ha.mc.ntu.edu.tw		LEE, FANG-JEN/0000-0002-2167-2426				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUKIC V, 1991, METHOD ENZYMOL, V194, P697; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Lowe SL, 1996, J CELL SCI, V109, P209; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Schurmann A, 1995, J BIOL CHEM, V270, P30657, DOI 10.1074/jbc.270.51.30657; SEGEV N, 1987, MOL CELL BIOL, V7, P2367, DOI 10.1128/MCB.7.7.2367; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wang XM, 1996, MOL CELL BIOL, V16, P5375; WHITNEY JA, 1995, CELL, V83, P703; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	60	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3819	3827		10.1074/jbc.274.6.3819	http://dx.doi.org/10.1074/jbc.274.6.3819			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920936	hybrid			2022-12-27	WOS:000078428200076
J	Monnet, C; Laune, D; Laroche-Traineau, J; Biard-Piechaczyk, M; Briant, L; Bes, C; Pugniere, M; Mani, JC; Pau, B; Cerutti, R; Devauchelle, G; Devaux, C; Granier, C; Chardes, T				Monnet, C; Laune, D; Laroche-Traineau, J; Biard-Piechaczyk, M; Briant, L; Bes, C; Pugniere, M; Mani, JC; Pau, B; Cerutti, R; Devauchelle, G; Devaux, C; Granier, C; Chardes, T			Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARITY-DETERMINING REGION; IMMUNOGLOBULIN CDR3-LIKE REGION; CLASS-II MHC; SYNCYTIUM FORMATION; GP120 BINDING; LYMPHOCYTES-T; ANTIGEN; TYPE-1; ENVELOPE; RECEPTOR	The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides from the ST40 paratope that could mimic these biological properties, a set of 220 overlapping 12-mer peptides frameshifted by one residue, corresponding to the deduced ST40 amino acid sequence, was synthesized by the Spot method and tested for binding to recombinant soluble CD4 antigen. Several peptides that included in their sequences amino acids from the CDRs of the antibody and framework residues flanking the CDRs were found to bind soluble CD4, Eleven paratope-derived peptides (termed CM1-CM11) were synthesized in a cyclic and soluble form. All the synthetic peptides showed CD4 binding capacity with affinities ranging from 1.6 to 86.4 nM. Moreover, peptides CM2, CM6, CM7, CM9, and CM11 were able to bind a cyclic peptide corresponding to the CDR3-like loop in domain 1 of CD4 (amino acids 81-92 of CD4), Peptide CM9 from the light chain variable region of mAb ST40 and, to a lesser extent, peptides CM2 and CM11 were able to inhibit HIV-1 promoter long terminal repeat-driven beta-galactosidase gene expression in the HeLa P4 HIV-1 long terminal repeat beta-galactosidase indicator cell line infected with HIV-1, The binding of mAb ST40 to CD4 was also efficiently displaced by peptides CM2, CM9, and CM11, Our results indicate that the information gained from a systematic exploration of the antigen binding capacity of synthetic peptides from immunoglobulin variable sequences can lead to the identification of bioactive paratope-derived peptides of potential pharmacological interest.	INRA, CNRS, URA 2209, Lab Pathol Comparee, F-30380 St Christol Les Ales, France; Fac Pharm Montpellier, CNRS, UMR 9921, F-34060 Montpellier, France; CRBM, CNRS, UPR 1086, Lab Infect Retrovirales & Signalisation Cellulair, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Chardes, T (corresponding author), INRA, CNRS, URA 2209, Lab Pathol Comparee, F-30380 St Christol Les Ales, France.		Chardès, Thierry/B-5420-2019; PUGNIERE, Martine/AAD-4315-2020; GRANIER, Claude/A-8841-2008; Pugniere, Martine/T-1355-2017; Briant, Laurence/AAB-9281-2021	Chardès, Thierry/0000-0002-1836-7439; PUGNIERE, Martine/0000-0002-2049-2909; Pugniere, Martine/0000-0002-2049-2909; MONNET, Celine/0000-0003-0492-5062; Briant, Laurence/0000-0002-1995-3501				ALANEN A, 1989, EUR J IMMUNOL, V19, P1961, DOI 10.1002/eji.1830191031; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BATINIC D, 1992, J BIOL CHEM, V267, P6664; BENKIRANE M, 1995, J VIROL, V69, P6898, DOI 10.1128/JVI.69.11.6898-6903.1995; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Briant L, 1997, J BIOL CHEM, V272, P19441, DOI 10.1074/jbc.272.31.19441; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CARRIERE D, 1994, CLIN CHEM, V40, P30; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DOUGALL WC, 1994, TRENDS BIOTECHNOL, V12, P372, DOI 10.1016/0167-7799(94)90038-8; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; IDZIOREK T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P39, DOI 10.1016/0005-2736(91)90332-3; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JARRIN A, 1994, FEBS LETT, V354, P169, DOI 10.1016/0014-5793(94)01113-3; Kabat EA, 1991, SEQUENCES PROTEINS I; KALYANARAMAN VS, 1990, J IMMUNOL, V145, P4072; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; Koch U, 1997, BLOOD, V89, P2880, DOI 10.1182/blood.V89.8.2880; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; LASARTE JJ, 1994, J ACQ IMMUN DEF SYND, V7, P129; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; LEAHY DJ, 1995, FASEB J, V9, P17, DOI 10.1096/fasebj.9.1.7821755; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOHMAN KL, 1992, J IMMUNOL, V149, P3247; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MCDONNELL JM, 1992, IMMUNOMETHODS, V1, P33; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; Molina F, 1996, PEPTIDE RES, V9, P151; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; PRESS JL, 1993, J IMMUNOL, V151, P1998; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SMITH JW, 1994, J BIOL CHEM, V269, P32788; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAUB R, 1989, J BIOL CHEM, V264, P259; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WELLING GW, 1991, J CHROMATOGR, V548, P235, DOI 10.1016/S0021-9673(01)88605-2; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	57	52	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3789	3796		10.1074/jbc.274.6.3789	http://dx.doi.org/10.1074/jbc.274.6.3789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920932	hybrid, Green Published			2022-12-27	WOS:000078428200072
J	Wallis, R; Drickamer, K				Wallis, R; Drickamer, K			Molecular determinants of oligomer formation and complement fixation in mannose-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; ENDOPLASMIC-RETICULUM; ACTIVATES COMPLEMENT; BACTERICIDAL FACTOR; CLASSICAL PATHWAY; MANNAN; SERUM; COLLAGEN; LECTIN; HYDROXYLYSINE	Rat serum mannose-binding protein (MBP-A) functions as part of the innate immune system by targetting complement toward potentially pathogenic microorganisms. In order to examine the molecular basis for complement activation, rat MBP-A has been overproduced in Chinese hamster ovary cells, Recombinant protein is post-translationally modified in the same way as the native lectin, Hydrodynamic studies indicate that MBP-A consists predominantly of covalent oligomers containing one to four copies of a subunit that comprises a trimer of polypeptides. These oligomers are non-interconverting and do not assemble into higher order structures at concentrations in excess of those normally found in serum. Disulfide bonds formed between cysteine residues at the N-terminal end of the collagen-like domain link polypeptides to form covalent oligomers, Analysis of wild-type MBP-A and MBP-A containing the substitution Cys(6) --> Ser suggests that polypeptides within each trimeric structural unit are mostly linked by disulfide bonds between cysteine residues at positions 13 and 18 arranged in an asymmetrical configuration. Disulfide bonds involving Cys(6) connect polypeptides within separate trimers. Analysis of chimeras between MBP-A and rat liver MBP (MBP-C) indicates that residues within the N-terminal region of the collagenous domain and the cysteine-rich domain of MBP-A enable assembly of trimers into higher order oligomers. The activity of MBP-A in a hemolytic complement fixation assay using mannan-coated sheep erythrocytes was approximately 20-fold greater than the activity of MBP-C. Analysis of the MBP chimeras and isolated oligomers of MBP-A reveals that the larger oligomers are more efficient at complement activation. These data indicate that the overall complement fixing activity of MBP-A is a function of the individual molecular activities of oligomers and their relative abundance within the serum.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.			Wallis, Russell/0000-0002-8705-5295				BUTLER WT, 1982, METHOD ENZYMOL, V82, P339; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1986, J BIOL CHEM, V261, P6578; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HULMES DJS, 1973, J MOL BIOL, V79, P137, DOI 10.1016/0022-2836(73)90275-1; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JI YH, 1993, J IMMUNOL, V150, P571; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; KOZUTSUMI Y, 1980, BIOCHEM BIOPH RES CO, V95, P658, DOI 10.1016/0006-291X(80)90836-0; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ST, 1975, J MOL BIOL, V98, P835, DOI 10.1016/S0022-2836(75)80015-5; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; LU J, 1990, J IMMUNOL, V144, P2287; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; PERUCCA PJ, 1969, J IMMUNOL, V102, P812; Quesenberry MS, 1997, BIOCHEMISTRY-US, V36, P2724, DOI 10.1021/bi9622635; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1989, LANCET, V2, P1236; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TAKAHASHI A, 1993, BIOCHEM BIOPH RES CO, V190, P681, DOI 10.1006/bbrc.1993.1103; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; WALLACE DG, 1990, BIOPOLYMERS, V29, P1015, DOI 10.1002/bip.360290613; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	35	90	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3580	3589		10.1074/jbc.274.6.3580	http://dx.doi.org/10.1074/jbc.274.6.3580			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920905	hybrid			2022-12-27	WOS:000078428200045
J	Goalstone, ML; Leitner, JW; Golovchenko, I; Stjernholm, MR; Cormont, M; Le Marchand-Brustel, Y; Draznin, B				Goalstone, ML; Leitner, JW; Golovchenko, I; Stjernholm, MR; Cormont, M; Le Marchand-Brustel, Y; Draznin, B			Insulin promotes phosphorylation and activation of geranylgeranyltransferase II - Studies with geranylgeranylation of Rab-3 and Rab-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; 3T3-L1 ADIPOCYTES; ALPHA-SUBUNIT; FARNESYLTRANSFERASE; TRANSFERASE; MEMBRANE; REDISTRIBUTION; LOCALIZATION; PRENYLATION	Rab proteins play a crucial role in the trafficking of intracellular vesicles, Rab proteins are GTPases that cycle between an inactive GDP-bound form and an active GTP-bound conformation. A prerequisite to Rab activation by GTP loading is its post-translational modification by the addition of geranylgeranyl moieties to highly conserved C-terminal cysteine residues. We examined the effect of insulin on the activity of geranylgeranyltransferase II (GGTase II) in 3T3-L1 fibroblasts and adipocytes. In fibroblasts, insulin increased the enzymatic activity of GGTase II 2.5-fold after 1 h of incubation, an effect that is blocked by perillyl alcohol, an inhibitor of prenyltransferases, but not by the geranylgeranyltransferase I inhibitor, GGTI-298, or the farnesyltransferase inhibitor, alpha-hydroxyfarnesylphosphonic acid. Concomitantly, insulin stimulated the phosphorylation of the GGTase II alpha-subunit without any effect on the GGTase II beta-subunit, At the same time, insulin also increased the amounts of geranylgeranylated Rab-3 in 3T3-L1 fibroblasts from 44 +/- 1.2% in control cells to 63 +/- 3.8 and 64 +/- 6.1% after 1 and 24 h of incubation, respectively. In adipocytes, insulin increased the amounts of geranylgeranylated Rab-4 from 38 +/- 0.6% in control cells to 56 +/- 1.7 and 60 +/- 2.6% after 1 and 24 h of incubation, respectively. In both fibroblasts and adipocytes, the presence of perillyl alcohol blocked the ability of insulin to increase geranylgeranylation of Rab-4, whereas GGTI-298 and alpha-hydroxyfarnesylphosphonic acid were without effect, indicating that insulin activates GGTase II. In summary, insulin promotes phosphorylation and activation of GGTase II in both 3T3 L1 fibroblasts and adipocytes and increases the amounts of geranylgeranylated Rab-S and Rab-4 proteins.	Vet Affairs Med Ctr, Res Serv 151, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA; Fac Med, INSERM U145, F-06107 Nice, France	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Draznin, B (corresponding author), Vet Affairs Med Ctr, Res Serv 151, 1055 Clermont St, Denver, CO 80220 USA.	DRAZNINB@den-res.org		CORMONT, Mireille/0000-0001-6918-2410				ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bortoluzzi MN, 1996, DIABETOLOGIA, V39, P899, DOI 10.1007/BF00403908; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; Chinni SR, 1998, EXP CELL RES, V242, P373, DOI 10.1006/excr.1998.4105; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CORMONT M, 1994, EUR J BIOCHEM, V219, P1081, DOI 10.1111/j.1432-1033.1994.tb18591.x; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Goud B, 1992, Semin Cell Biol, V3, P301; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2880	2884		10.1074/jbc.274.5.2880	http://dx.doi.org/10.1074/jbc.274.5.2880			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915824	hybrid			2022-12-27	WOS:000078319500042
J	Hong, SH; Privalsky, ML				Hong, SH; Privalsky, ML			Retinoid isomers differ in the ability to induce release of SMRT corepressor from retinoic acid receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; X-RECEPTOR; CRYSTAL-STRUCTURE; ONCOGENE PRODUCT; RAR-ALPHA; N-COR	Nuclear hormone receptors are ligand-regulated transcription factors that modulate the expression of specific target genes in response to the binding of small, hydrophobic hormone ligands. Many nuclear hormone receptors, such as the retinoic acid receptors, can both repress and activate target gene expression; these bimodal transcription properties are mediated by the ability of these receptors to tether auxiliary factors, denoted corepressors and coactivators. Corepressors are typically bound by receptors in the absence of cognate hormone, whereas binding of an appropriate hormone agonist induces an allosteric alteration in the receptor resulting in release of the corepressor and recruitment of coactivator, Structural analysis indicates that there is a close induced fit between the hormone ligand and the receptor polypeptide chain. This observation suggests that different ligands, once bound, may confer distinct conformations on the receptor that may invoke, in turn, distinct functional consequences. We report here that different retinoids do differ in the ability to release corepressor once bound to retinoic acid receptor and suggest that these differences in corepressor release may manifest as differences in transcriptional regulation.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu		Hong, Suk-Hyun/0000-0001-7541-4847	NCI NIH HHS [R37 CA053394, R37 CA053394-06S1, R37 CA-53394] Funding Source: Medline; NIDDK NIH HHS [R01 DK053528, R01 DK-53528, R01 DK053528-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; Chen H, 1998, DRUG METAB DISPOS, V26, P222; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Claret FX, 1996, MOL CELL BIOL, V16, P219; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIBEIRO RC, 1993, ANN NY ACAD SCI, V758, P366; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shih TW, 1997, DRUG METAB DISPOS, V25, P27; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	60	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2885	2892		10.1074/jbc.274.5.2885	http://dx.doi.org/10.1074/jbc.274.5.2885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915825	hybrid, Green Accepted			2022-12-27	WOS:000078319500043
J	Karantzoulis-Fegaras, F; Antoniou, H; Lai, SLM; Kulkarni, G; D'Abreo, C; Wong, GKT; Miller, TL; Chan, Y; Atkins, J; Wang, Y; Marsden, PA				Karantzoulis-Fegaras, F; Antoniou, H; Lai, SLM; Kulkarni, G; D'Abreo, C; Wong, GKT; Miller, TL; Chan, Y; Atkins, J; Wang, Y; Marsden, PA			Characterization of the human endothelial nitric-oxide synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ZINC-FINGER PROTEIN; TATA-LESS PROMOTER; T-CELL LEUKEMIA; VIRUS TYPE-I; NF-KAPPA-B; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ETS-DOMAIN; POTENTIAL ROLE	Understanding transcription initiation of the endothelial nitric-oxide synthase (eNOS) gene appears pivotal to gaining a comprehensive view of NO biology in the blood vessel wall. The present study therefore focused upon a detailed dissection of the functionally important cis-DNA elements and the multiprotein complexes implicated in the cooperative control of constitutive expression of the human eNOS gene in vascular endothelium, Two tightly clustered cis-regulatory regions were identified in the proximal enhancer of the TATA-less eNOS promoter using deletion analysis and linker-scanning mutagenesis: positive regulatory domains I (-104/-95 relative to transcription initiation) and II (-144/-115), Analysis of trans-factor binding and functional expression studies revealed a surprising degree of cooperativity and complexity. The nucleoprotein complexes that form upon these regions in endothelial cells contained Ets family members, Spl, variants of Sp3, MAZ, and YY1. Functional domain studies in Drosophila Schneider cells and endothelial cells revealed examples of positive and negative protein-protein cooperativity involving Sp1, variants of Sp3, Ets-1, Elf-1, and MAZ, Therefore, multiprotein complexes are formed on the activator recognition sites within this 50-base pair region of the human eNOS promoter in vascular endothelium.	Univ Toronto, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Rm 7358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Marsden, Philip A/B-1441-2012					Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; Ernst P, 1996, MOL CELL BIOL, V16, P6121; Fadel BM, 1998, BIOCHEM J, V330, P335; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; Fuks F, 1996, J VIROL, V70, P1331, DOI 10.1128/JVI.70.3.1331-1339.1996; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; Graef IA, 1997, SCIENCE, V277, P193, DOI 10.1126/science.277.5323.193; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; SCHRODER FH, 1989, PROSTATE, P17; Seelan RS, 1997, J BIOL CHEM, V272, P10175, DOI 10.1074/jbc.272.15.10175; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Vassias I, 1998, J BIOL CHEM, V273, P8287, DOI 10.1074/jbc.273.14.8287; VENEMA RC, 1994, BBA-GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167-4781(94)90195-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WARIISHI S, 1995, BIOCHEM BIOPH RES CO, V216, P729, DOI 10.1006/bbrc.1995.2682; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNERT N, 1992, AM J PATHOL, V140, P119; WERNERT N, 1994, CANCER RES, V54, P5638; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Wilkinson DA, 1997, LEUKEMIA, V11, P86, DOI 10.1038/sj.leu.2400516; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	90	175	182	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3076	3093		10.1074/jbc.274.5.3076	http://dx.doi.org/10.1074/jbc.274.5.3076			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915847	hybrid			2022-12-27	WOS:000078319500065
J	Shao, R; Yan, W; Rockey, DC				Shao, R; Yan, W; Rockey, DC			Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC-FIBROSIS; RAT-LIVER; POSSIBLE INVOLVEMENT; CELL LINES; ITO CELLS; EXPRESSION; LIPOCYTES; GENE; RECEPTORS; CIRRHOSIS	Endothelin-1 (ET-1) is involved in the pathogenesis of a number of diseases, including wound healing. In cirrhosis, the wounding response of the liver, circulating ET-1 levels are elevated; moreover, ET-1 has potent effects on hepatic stellate cells, the key effecters of cirrhosis. In this study, we have examined the regulatory role of ECE-1, a critical enzyme involved in ET-1 synthesis, in the two major cellular sources of hepatic ET-1, ET-1 release from normal hepatic endothelial cells was 25-fold higher than that from normal stellate cells. However, after liver injury, ET-1 release was increased in stellate cells but markedly decreased in endothelial cells. The two major isoforms of ECE-1, ECE-1 alpha/1 beta, made up 80% and 20%, respectively, of total ECE-1 in both stellate and endothelial cells. Following liver injury, ECE-1 alpha mRNA was decreased by 44.2% in stellate cells, and by 16.1% in endothelial cells. ECE-1 beta mRNA expression remained unchanged after injury. In contrast to ECE-1 mRNA, ECE-1 protein expression was increased by 43.9% in stellate cells but decreased in endothelial cells, while relative ECE-1 enzymatic activity was unchanged. In mRNA stability experiments, the half-life of ECE-alpha mRNA in normal stellate cells was 13 h compared with 38 h in cells from injured livers. Thus, during hepatic wound healing, differential regulation of ECE-1 mRNA and protein appears to be critical in controlling ET-1 production.	Duke Univ, Med Ctr, Ctr Liver, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Ctr Liver, Sands Bldg,Box 3083,Rm 334, Durham, NC 27710 USA.	dcrockey@acpub.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002124, R01DK050574] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02124, DK 50574] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARDINI G, 1988, VIRCHOWS ARCH B, V56, P45, DOI 10.1007/BF02890000; Barnes K, 1997, J NEUROCHEM, V68, P570; BAUER M, 1994, AM J PHYSIOL, V267, pG143, DOI 10.1152/ajpgi.1994.267.1.G143; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; GANDHI CR, 1995, LIFE SCI, V58, P55, DOI 10.1016/0024-3205(95)02255-4; GUI GJ, 1993, J CARDIOVASC PHARM, V22, pS53, DOI 10.1097/00005344-199322008-00016; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KAWADA N, 1993, EUR J BIOCHEM, V213, P815, DOI 10.1111/j.1432-1033.1993.tb17824.x; KENT G, 1976, P NATL ACAD SCI USA, V73, P3719, DOI 10.1073/pnas.73.10.3719; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; Matsuura A, 1997, BIOCHEM BIOPH RES CO, V235, P713, DOI 10.1006/bbrc.1997.6885; Minamino T, 1997, CIRCULATION, V95, P221, DOI 10.1161/01.CIR.95.1.221; MOLLER S, 1995, J HEPATOL, V23, P135, DOI 10.1016/0168-8278(95)80327-0; MOORE K, 1992, NEW ENGL J MED, V327, P1774, DOI 10.1056/NEJM199212173272502; OKUMURA S, 1994, HEPATOLOGY, V19, P155, DOI 10.1002/hep.1840190125; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Rockey DC, 1998, HEPATOLOGY, V27, P472, DOI 10.1002/hep.510270222; Rockey DC, 1996, J CLIN INVEST, V98, P1381, DOI 10.1172/JCI118925; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; Saleh D, 1997, AM J RESP CELL MOL, V16, P187, DOI 10.1165/ajrcmb.16.2.9032126; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; STEWART DJ, 1991, J AM COLL CARDIOL, V18, P38, DOI 10.1016/S0735-1097(10)80214-1; TAKADA J, 1992, BIOCHEM BIOPH RES CO, V182, P1383, DOI 10.1016/0006-291X(92)91886-U; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YORIMITSU K, 1995, BIOCHEM BIOPH RES CO, V208, P721, DOI 10.1006/bbrc.1995.1397; Yoshimura H, 1997, AM J RESP CELL MOL, V17, P471, DOI 10.1165/ajrcmb.17.4.2832; ZHANG JX, 1995, AM J PHYSIOL-GASTR L, V269, pG269, DOI 10.1152/ajpgi.1995.269.2.G269; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624	44	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3228	3234		10.1074/jbc.274.5.3228	http://dx.doi.org/10.1074/jbc.274.5.3228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915864	hybrid			2022-12-27	WOS:000078319500082
J	Purcarea, C; Evans, DR; Herve, G				Purcarea, C; Evans, DR; Herve, G			Channeling of carbamoyl phosphate to the pyrimidine and arginine biosynthetic pathways in the deep sea hyperthermophilic archaeon Pyrococcus abyssi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE-TRANSCARBAMYLASE; ENZYME-ENZYME INTERACTIONS; ESCHERICHIA-COLI; MULTIFUNCTIONAL PROTEIN; HAMSTER-CELLS; ORNITHINE CARBAMOYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; REGULATORY PROPERTIES; MULTIENZYME COMPLEX; TIME ANALYSIS	The kinetics of the coupled reactions between carbamoyl-phosphate synthetase (CPSase) and both aspartate transcarbamoylase (ATCase) and ornithine transcarbamoylase (OTCase) hom the deep sea hyperthermophilic archaeon Pyrococcus abyssi demonstrate the existence of carbamoyl phosphate channeling in both the pyrimidine and arginine biosynthetic pathways. Isotopic dilution experiments and coupled reaction kinetics analyzed within the context of the formalism proposed by Ovadi et al. (Ovadi, J., Tompa, P., Vertessy, B., Orosz, F., Keleti, T., and Welch, G. R (1989) Biochem J. 257, 187-190) are consistent with a partial channehng of the intermediate at 37 degrees C, but channeling efficiency increases dramatically at elevated temperatures. There is no preferential partitioning of carbamoyl phosphate between the arginine and pyrimidine biosynthetic pathways. Gel filtration chromatography at high and low temperature and in the presence and absence of substrates did not reveal stable complexes between P. abyssi CPSase and either ATCase or OTCase. Thus, channeling must occur during the dynamic association of coupled enzymes pairs. The interaction of CPSase-ATCase was further demonstrated by the unexpectedly weak inhibition of the coupled reaction by the bisubstrate analog, N-(phosphonacetyl)-L- aspartate (PALA). The anomalous effect of PALA suggests that, in the coupled reaction, the effective concentration of carbamoyl phosphate in the vicinity of the ATCase active site is 96-fold higher than the concentration in the bulk phase. Channeling probably plays an essential role in protecting this very unstable intermediate of metabolic pathways performing at extreme temperatures.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France	Wayne State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Purcarea, C (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.				NIGMS NIH HHS [GM-74399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELAL AT, 1975, ANAL BIOCHEM, V69, P652, DOI 10.1016/0003-2697(75)90174-8; ABDELAL ATH, 1977, J BACTERIOL, V129, P1387, DOI 10.1128/JB.129.3.1387-1396.1977; ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; BAUR H, 1990, J BIOL CHEM, V265, P14728; BELKAID M, 1988, ARCH BIOCHEM BIOPHYS, V262, P171, DOI 10.1016/0003-9861(88)90179-8; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COHEN NS, 1992, BIOCHEM J, V282, P173, DOI 10.1042/bj2820173; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; EASTERBY JS, 1973, BIOCHIM BIOPHYS ACTA, V293, P552, DOI 10.1016/0005-2744(73)90362-8; ERAUSO G, 1993, ARCH MICROBIOL, V160, P338; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; GUY HI, 1994, J BIOL CHEM, V269, P23808; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; Kim JH, 1996, J BIOL CHEM, V271, P15549, DOI 10.1074/jbc.271.26.15549; KUO LC, 1985, BIOCHEMISTRY-US, V24, P4754, DOI 10.1021/bi00339a007; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LOWE SE, 1993, MICROBIOL REV, V57, P451, DOI 10.1128/MMBR.57.2.451-509.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUE P F, 1970, Biochimica et Biophysica Acta, V220, P365, DOI 10.1016/0005-2744(70)90268-8; MAKOFF AJ, 1978, MICROBIOL REV, V42, P307, DOI 10.1128/MMBR.42.2.307-328.1978; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MORI M, 1978, EUR J BIOCHEM, V86, P381, DOI 10.1111/j.1432-1033.1978.tb12320.x; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; OVADI J, 1989, BIOCHEM J, V257, P187, DOI 10.1042/bj2570187; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; PURCAREA C, 1994, MICROBIOL-SGM, V140, P1967, DOI 10.1099/13500872-140-8-1967; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; PURCAREA C, 1995, THESIS PARIS SUD; ROBIN JP, 1989, EUR J BIOCHEM, V183, P519, DOI 10.1111/j.1432-1033.1989.tb21080.x; SMOLEN P, 1990, BIOPHYS CHEM, V38, P241, DOI 10.1016/0301-4622(90)87006-7; SRERE PA, 1990, FEBS LETT, V268, P360, DOI 10.1016/0014-5793(90)81286-W; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; VANDECASTEELE M, 1990, J GEN MICROBIOL, V136, P1177, DOI 10.1099/00221287-136-7-1177; VANDECASTEELE M, 1994, BIOCATALYSIS, V11, P165, DOI 10.3109/10242429409034386; WANDERS RJA, 1984, EUR J BIOCHEM, V142, P247, DOI 10.1111/j.1432-1033.1984.tb08278.x; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WILLIAMS LG, 1970, BIOCHEMISTRY-US, V9, P4329, DOI 10.1021/bi00824a013; WILLIAMS LG, 1971, J BIOL CHEM, V246, P973; YANOFSKY C, 1989, BIOCHIM BIOPHYS ACTA, V1000, P133, DOI 10.1016/S0006-3002(89)80013-7	45	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6122	6129		10.1074/jbc.274.10.6122	http://dx.doi.org/10.1074/jbc.274.10.6122			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037695	hybrid			2022-12-27	WOS:000078902800017
J	Lu-Kuo, JM; Joyal, DM; Austen, KF; Katz, HR				Lu-Kuo, JM; Joyal, DM; Austen, KF; Katz, HR			gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; FC-GAMMA-RIIB; IMMUNOGLOBULIN SUPERFAMILY; NEGATIVE REGULATION; LEUKOTRIENE C-4; RECEPTOR; CLONING; ANTIGEN; GENE; PHOSPHORYLATION	We define by molecular, pharmacologic, and physiologic approaches the proximal mechanism by which the immunoglobulin superfamily member gp49B1 inhibits mast cell activation mediated by the high affinity Fc receptor for IgE (Fc epsilon RI). In rat basophilic leukemia-2H3 cells expressing transfected mouse gp49B1, mutation of tyrosine to phenylalanine in either of the two immunoreceptor tyrosine-based inhibitory motifs of the gp49B1 cytoplasmic domain partially suppressed gp49B1-mediated inhibition of exocytosis, whereas mutation of both abolished inhibitory capacity. Sodium pervanadate elicited tyrosine phosphorylation of native gp49B1 and association of the tyrosine phosphatases src homology 2 domain-containing phosphatase-1 (SHP-1) and SHP-2 in mouse bone marrow-derived mast cells (mBMMCs). SHP-1 associated transiently with gp49B1 within 1 min after coligation of gp49B1 with cross-linked Fc epsilon RI in mBMMCs. SHP-1-deficient mBMMCs exhibited a partial loss of gp49B1-mediated inhibition of Fc epsilon RI-induced exocytosis at concentrations of IgE providing optimal exocytosis, revealing a central, but not exclusive, SHP-1 requirement in the counter-regulatory pathway. Coligation of gp49B1 with cross-linked Fc epsilon RI on mBMMCs inhibited early release of calcium from intracellular stores and subsequent influx of extracellular calcium, consistent with SHP-1 participation. Because exocytosis is complete within 2 min in mBMMCs, our studies establish a role for SHP-1 in the initial counter-regulatory cellular responses whereby gp49B1 immunoreceptor tyrosine-based inhibition motifs rapidly transmit inhibition of Fc epsilon RI-mediated exocytosis.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Katz, HR (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 638A,1 Jimmy Fund Way, Boston, MA 02115 USA.	hrkatz@mbcrr.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041144, U19AI031599, U01AI031599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-41144, AI-31599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARM JP, 1991, J BIOL CHEM, V266, P15966; Arm JP, 1997, J IMMUNOL, V159, P2342; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Borges L, 1997, J IMMUNOL, V159, P5192; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Colonna M, 1998, J IMMUNOL, V160, P3096; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HULETT MD, 1994, ADV IMMUNOLOGY; Katz HR, 1997, J IMMUNOL, V158, P5065; KATZ HR, 1989, J IMMUNOL, V142, P919; KATZ HR, 1990, J IMMUNOL, V145, P3412; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KATZ HR, 1983, P NATL ACAD SCI-BIOL, V80, P5916, DOI 10.1073/pnas.80.19.5916; Katz HR, 1998, ASTHMA AND ALLERGIC DISEASES, P97, DOI 10.1016/B978-012473340-4/50011-4; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; LAM BK, 1989, J BIOL CHEM, V264, P12885; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LuKuo JM, 1996, J BIOL CHEM, V271, P22169, DOI 10.1074/jbc.271.36.22169; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Yamashita Y, 1998, J IMMUNOL, V161, P4042	45	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5791	5796		10.1074/jbc.274.9.5791	http://dx.doi.org/10.1074/jbc.274.9.5791			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026201	hybrid			2022-12-27	WOS:000078804400072
J	Schliebs, W; Saidowsky, J; Agianian, B; Dodt, G; Herberg, FW; Kunau, WH				Schliebs, W; Saidowsky, J; Agianian, B; Dodt, G; Herberg, FW; Kunau, WH			Recombinant human peroxisomal targeting signal receptor PEX5 - Structural basis for interaction of PEX5 with PEX14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; PTS1 RECEPTOR; SNAP HELIX; MEMBRANE; BINDING; IMPORT; BIOGENESIS; DISORDERS; DOMAINS	Import of matrix proteins into peroxisomes requires two targeting signal-specific import receptors, Pex5p and Pex7p, and their binding partners at the peroxisomal membrane, Pex13p and Pex14p. Several constructs of human PEX5 have been overexpressed and purified by affinity chromatography in order to determine functionally important interactions and provide initial structural information. Sizing chromatography and electron microscopy suggest that the two isoforms of the human PTS1 receptor, PEX5L and PEX5S, form homotetramers. Surface plasmon resonance analysis indicates that PEX5 binds to the N-terminal fragment of PEX14-(1-78) with a very high affinity in the low nanomolar range. Stable complexes between recombinant PEX14-(1-78) and both the full-length and truncated versions of PEX5 were formed in vitro. Analysis of these complexes revealed that PEX5 possesses multiple binding sites for PEX14, which appear to be distributed throughout its N-terminal half. Coincidentally, this part of the molecule is also responsible for oligomerization, whereas the C-terminal half with its seven tetratricopeptide repeats has been reported to bind PTS1-proteins. A pentapeptide motif that is reiterated seven times in PEX5 is proposed as a determinant for the interaction with PEX14.	Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	Ruhr University Bochum; European Molecular Biology Laboratory (EMBL)	Kunau, WH (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany.	wolf-h.kunau@ruhr-uni-bochum.de	Agianian, Bogos/O-8019-2016; Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653; Agianian, Bogos/0000-0003-1295-6846; Schliebs, Wolfgang/0000-0003-2762-3403				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Gale M, 1996, MOL CELL BIOL, V16, P4172; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Waterham HR, 1997, BIOESSAYS, V19, P57, DOI 10.1002/bies.950190110; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51	32	144	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5666	5673		10.1074/jbc.274.9.5666	http://dx.doi.org/10.1074/jbc.274.9.5666			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026185	hybrid			2022-12-27	WOS:000078804400056
J	Zhang, LJ; Yoshida, K; Liu, J; Rosenberg, RD				Zhang, LJ; Yoshida, K; Liu, J; Rosenberg, RD			Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; DEACETYLASE N-SULFOTRANSFERASE; ANTITHROMBIN-BINDING SEQUENCE; HEPATOCYTE GROWTH-FACTOR; MOLECULAR-CLONING; HIGH-AFFINITY; PROTEOGLYCANS; BIOSYNTHESIS; EXPRESSION; OLIGOSACCHARIDES	To understand the mechanisms that control anticoagulant heparan sulfate (HSact) biosynthesis, we previously showed that HSact production in the F9 system is determined by the abundance of 3-O-sulfotransferase-1 as well as the size of the HSact precursor pool. In this study, HSact precursor structures have been studied by characterizing [6-H-3]GlcN metabolically labeled F9 HS tagged with 3-O-sulfates in vitro by 3'-phosphoadenosine 5'-phospho-S-35 and purified 3-O-sulfotransferase-1. This later in vitro labeling allows the regions of HS destined to become the antithrombin (AT)-binding sites to be tagged for subsequent structural studies. It was shown that sig 3-O-sulfation sites exist per HSact precursor chain. At least five out of six 3-O-sulfate-tagged oligosaccharides in HSact precursors bind AT, whereas none of 3-O-sulfate-tagged oligosaccharides from HSinact precursors bind AT. When treated with low pH nitrous or heparitinase, 3-O-sulfate-tagged HSact and HSinact precursors exhibit clearly different structural features. 3-O-Sulfate-tagged HSact hexasaccharides were AT affinity purified and sequenced by chemical and enzymatic degradations. The 3-O-sulfate-tagged HSact hexasaccharides exhibited the following structures, Delta UA-[6-H-3]GlcNAc6S-GlcUA-[6-H-3]GlcNS3(35)S +/- 6S-IdceA2S-[6-H-3]GlcNS6S. The underlined 6- and 3-O-sulfates constitute the most critical groups for AT binding in view of the fact that the precursor hexasaccharides possess all the elements for AT binding except for the 3-O-sulfate moiety. The presence of five potential AT-binding precursor hexasaccharides in all HSact precursor chains demonstrates for the first time the processive assembly of specific sequence in HS. The difference in structures around potential 3-O-sulfate acceptor sites in HSact and HSinact precursors suggests that these precursors might be generated by different concerted assembly mechanisms in the same cell. This study permits us to understand better the nature of the HS biosynthetic pathway that leads to the generation of specific saccharide sequences.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Hosp, Sch Med, Dept Med, Boston, MA 02215 USA; Seikagaku Corp, Tokyo Res Inst, Tokyo 207, Japan	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Seikagaku Corporation	Rosenberg, RD (corresponding author), MIT, Dept Biol, Bldg 68-480,77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdrrosen@MIT.EDU			NHLBI NIH HHS [R-PO1-HL41484, HL66385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066385, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1993, J BIOL CHEM, V268, P19956; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; IOZZO RV, 1989, J BIOL CHEM, V264, P2690; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V69, P158, DOI 10.1016/S0006-291X(76)80286-0; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARCUM JA, 1989, ANN NY ACAD SCI, V556, P81; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rostand KS, 1997, INFECT IMMUN, V65, P1; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VARKI A, 1997, J CLIN INVEST, V100, P31; VLODAVSKY I, 1983, CANCER RES, V43, P2704; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	61	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5681	5691		10.1074/jbc.274.9.5681	http://dx.doi.org/10.1074/jbc.274.9.5681			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026187	hybrid			2022-12-27	WOS:000078804400058
J	Dong, MQ; Dings, XQ; Pinon, DI; Hadac, EM; Oda, RP; Landers, JP; Miller, LJ				Dong, MQ; Dings, XQ; Pinon, DI; Hadac, EM; Oda, RP; Landers, JP; Miller, LJ			Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor - Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER-INDUCED FLUORESCENCE; GEL-ELECTROPHORESIS; PROTEIN; SITE; IDENTIFICATION; GLYCOPROTEIN; MOLECULES; ENZYME	The molecular basis of ligand binding to receptors provides important insights for drug development. Here, we explore domains of the cholecystokinin (CCK) receptor that are critical for ligand binding, using a novel series of fluorescent photolabile probes, receptor proteolysis, and rapid high resolution separation of peptide fragments by capillary electrophoresis, Each probe incorporated the same fluorophore and a photolabile p-benzoylphenylalanine at the amino terminus of the pharmacophoric domain (residue 24 of CCK-33) of CCK analogues representing full agonist, partial agonist, and antagonist of this receptor. Each was used to label the CCK receptor expressed on Chinese hamster ovary-CCKR cells, with the labeled domain then released by cyanogen bromide cleavage. Capillary electrophoresis with laser-induced fluorescence detection achieved an on-capillary mass sensitivity of 1.6 attomoles (10(-18) mol), with an excellent signal to-noise ratio, Each of the biologically divergent, but structurally similar probes saturably and specifically labeled the same receptor domain, consistent with conservation of "docking" determinants. This had an apparent mass of 2.9 kDa, most consistent with the first extracellular loop domain. An additional probe having its site of covalent attachment in a different region of the probe (residue 29 of CCK-33) labeled a distinct receptor fragment with differential migration on capillary electrophoresis (third extracellular loop). Identification of the specific receptor residue(s) covalently linked to the amino-terminal probes must await further fragmentation and sequence analysis.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Prot Core Facil, Rochester, MN 55905 USA; Univ Pittsburgh, Dept Chem, Analyt Div, Pittsburgh, PA 15260 USA	Mayo Clinic; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, MQ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32878] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARRIAGA E, 1993, J CHROMATOGR A, V652, P347, DOI 10.1016/0021-9673(93)83252-N; CHEN DY, 1994, J CHROMATOGR B, V657, P265; CHEN DY, 1994, ANALYST, V119, P349, DOI 10.1039/an9941900349; CHENG YF, 1988, SCIENCE, V242, P562, DOI 10.1126/science.3140381; Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875; Dong MQ, 1997, ELECTROPHORESIS, V18, P1767, DOI 10.1002/elps.1150181010; FADDEN P, 1995, ANAL BIOCHEM, V225, P81, DOI 10.1006/abio.1995.1111; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GALARDY RE, 1977, MOL PHARMACOL, V13, P852; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JORGENSON JW, 1981, J CHROMATOGR, V218, P209, DOI 10.1016/S0021-9673(00)82057-9; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; LANDERS JP, 1997, CAPILLARY ELECTROPHO; MONNIG CA, 1994, ANAL CHEM, V66, pR280, DOI 10.1021/ac00084a013; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SWERDLOW H, 1991, ANAL CHEM, V63, P2835, DOI 10.1021/ac00024a006; WILLIAMS DC, 1995, ANAL CHEM, V67, P3427, DOI 10.1021/ac00115a010; XUE QF, 1994, ANAL CHEM, V66, P1175, DOI 10.1021/ac00079a036; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	31	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4778	4785		10.1074/jbc.274.8.4778	http://dx.doi.org/10.1074/jbc.274.8.4778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988716	hybrid			2022-12-27	WOS:000078698200041
J	Hanson, SRA; Chen, AA; Smith, JB; Lou, MF				Hanson, SRA; Chen, AA; Smith, JB; Lou, MF			Thiolation of the gamma B-crystallins in intact bovine lens exposed to hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE MIXED DISULFIDE; MASS-SPECTROMETRY; ALPHA-CRYSTALLINS; POSTTRANSLATIONAL MODIFICATIONS; BETA-CRYSTALLINS; FREE CYSTEINE; EYE-LENS; PROTEIN; STABILITY; CATARACT	Oxidative damage of the lens causes disulfide bonds between cysteinyl residues of lens proteins and thiols such as glutathione and cysteine, which may lead to cataract. The effect of H2O2 oxidation was determined by comparing bovine lenses incubated with and without 30 mM H2O2. The H2O2 treatment decreased the glutathione and increased the protein-glutathione and proteincysteine disulfides in the lens. The molecular mass of the gamma B-crystallin isolated from lenses, not treated with H2O2, agreed with the published sequence (M-r 20,966). Some lenses also had a less abundant gamma B-crystallin component 305 Da higher (M-r 21,270), suggesting the presence of a glutathione adduct. The gamma B-crystallins from H2O2 treated lenses had three components, the major one with one GSH adduct, another one with the mass of unmodified gamma B-crystallin, and a third with a mass consistent with addition of two GSH adducts. Mass spectrometric analysis of tryptic peptides of gamma B-crystallins from different lenses indicated that the +305 Da modifications were not at a specific cysteine, For the lenses incubated without H2O2, there was evidence of adducts at Cys-41 and in peptide 10-31, which includes 3 cysteines. Analysis of modified peptide 10-31 by tandem mass spectrometry showed GSH adducts at Cys-15, Cys-18, and Cys-22, In addition, gamma B-crystallins from H2O2-treated lenses had an adduct at Cys-109, partial oxidation at all 7 Met residues, and evidence for two disulfide bonds.	Univ Nebraska, Dept Vet & Biomed Sci, Ctr Biotechnol, Lincoln, NE 68583 USA; Univ Nebraska, Dept Chem, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Lou, MF (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, Ctr Biotechnol, 134 VBS, Lincoln, NE 68583 USA.				NEI NIH HHS [EY RO1 07609] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY U, IN PRESS PRINCIPLES; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; Blundell T.L., 1983, LENS RES, V1, P109; CU XL, 1993, EXP EYE RES, V57, P157, DOI 10.1006/exer.1993.1111; Dickerson JE, 1997, EXP EYE RES, V65, P451, DOI 10.1006/exer.1997.0343; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; GIBLIN FJ, 1995, EXP EYE RES, V60, P219, DOI 10.1016/S0014-4835(05)80105-8; HAY RE, 1987, BIOCHEM BIOPH RES CO, V146, P332, DOI 10.1016/0006-291X(87)90729-7; Jiang XY, 1996, J MASS SPECTROM, V31, P1309, DOI 10.1002/(SICI)1096-9888(199611)31:11<1309::AID-JMS423>3.0.CO;2-R; KILBY GW, 1995, EXP EYE RES, V60, P465, DOI 10.1016/S0014-4835(05)80061-2; KILBY GW, 1995, EUR MASS SPECTROM, V1, P203, DOI 10.1255/ejms.126; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; LIANG JN, 1988, EXP EYE RES, V47, P17, DOI 10.1016/0014-4835(88)90020-6; LOU MF, 1989, CURR EYE RES, V8, P883; Lou MF, 1997, ADVANCES IN OCULAR TOXICOLOGY, P27; LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F; LOU MF, 1986, EXP EYE RES, V42, P607, DOI 10.1016/0014-4835(86)90050-3; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; LOU MF, 1993, INVEST OPHTH VIS SCI, V34, P987; LOU MF, 1986, P INT SOC EYE RES, V4, P87; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; MILBERG R M, 1990, P305; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; Qin CA, 1996, CURR EYE RES, V15, P719, DOI 10.3109/02713689609003454; SIEZEN RJ, 1989, EXP EYE RES, V48, P225, DOI 10.1016/S0014-4835(89)80072-7; SLINGSBY C, 1985, BIOCHEM J, V230, P143, DOI 10.1042/bj2300143; SMITH JB, 1991, INT J MASS SPECTROM, V111, P229, DOI 10.1016/0168-1176(91)85057-S; SMITH JB, 1991, ANAL BIOCHEM, V193, P118, DOI 10.1016/0003-2697(91)90050-4; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; Smith JB, 1997, FREE RADICAL RES, V26, P103, DOI 10.3109/10715769709097789; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Takemoto L, 1996, EXP EYE RES, V63, P585, DOI 10.1006/exer.1996.0149; Takemoto LJ, 1997, CURR EYE RES, V16, P719, DOI 10.1076/ceyr.16.7.719.5055; Takemoto LJ, 1997, EXP EYE RES, V64, P609, DOI 10.1006/exer.1996.0247; VELTMAN J, 1993, INVEST OPHTH VIS SCI, V34, P758; Wang GM, 1997, EXP EYE RES, V64, P693, DOI 10.1006/exer.1996.0251; WEN Q, 1992, EXP EYE RES, V54, P23, DOI 10.1016/0014-4835(92)90065-Z; XU GT, 1992, EXP EYE RES, V54, P63, DOI 10.1016/0014-4835(92)90070-9; ZIGLER JS, 1985, EXP EYE RES, V41, P67, DOI 10.1016/0014-4835(85)90095-8; ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723	45	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4735	4742		10.1074/jbc.274.8.4735	http://dx.doi.org/10.1074/jbc.274.8.4735			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988710	hybrid			2022-12-27	WOS:000078698200035
J	Kim, SJ; Jansson, S; Hoffman, NE; Robinson, C; Mant, A				Kim, SJ; Jansson, S; Hoffman, NE; Robinson, C; Mant, A			Distinct "assisted" and "spontaneous" mechanisms for the insertion of polytopic chlorophyll-binding proteins into the thylakoid membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; CHLOROPLAST HOMOLOG; PRECURSOR PROTEIN; INNER MEMBRANE; PHOTOSYSTEM-II; INTEGRATION; TRANSPORT; POLYPEPTIDE; MACHINERY	The biogenesis of several bacterial polytopic membrane proteins has been shown to require signal recognition particle (SRP) and protein transport machinery, and one such protein, the major light-harvesting chlorophyll-binding protein (LHCP) exhibits these requirements in chloroplasts. In this report we have used in vitro insertion assays to analyze four additional members of the chlorophyll-alb-binding protein family. We show that two members, Lhca1 and Lhcb5, display an absolute requirement for stroma, nucleoside triphosphates, and protein transport apparatus, indicating an "assisted" pathway that probably resembles that of LHCP. Two other members, however, namely an early light-inducible protein 2 (Elip2) and photosystem II subunit S (PsbS), can insert efficiently in the complete absence of SRP, SecA activity, nucleoside triphosphates, or a functional Sec system. The data suggest a possibly spontaneous insertion mechanism that, to date, has been characterized only for simple single-span proteins. Of the membrane proteins whose insertion into thylakoids has been analyzed, five have now been shown to insert by a SRP/Sec-independent mechanism, suggesting that this is a mainstream form of targeting pathway. We also show that PsbS and Elip2 molecules are capable of following either "unassisted" or assisted pathways, and we discuss the implications for the mechanism and role of SRP in chloroplasts.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Umea Univ, Dept Plant Physiol, S-90187 Umea, Sweden; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	University of Warwick; Umea University; Carnegie Institution for Science	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	CG@dna.bio.warwick.ac.uk	Jansson, Stefan/A-1119-2009	Jansson, Stefan/0000-0002-7906-6891; Hoffman, Neil/0000-0002-4057-555X; Mant, Alexandra/0000-0001-7169-209X				BREYTON C, 1994, J BIOL CHEM, V269, P7597; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLINE K, 1992, J BIOL CHEM, V267, P2688; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DeGier JWL, 1997, FEBS LETT, V408, P1, DOI 10.1016/S0014-5793(97)00402-X; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HOFFMAN NE, IN PRESS RES PHOTOSY; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 1998, FEBS LETT, V423, P183, DOI 10.1016/S0014-5793(98)00089-1; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; NAKAI M, 1994, J BIOL CHEM, V269, P31338; Robinson C, 1998, PLANT MOL BIOL, V38, P209, DOI 10.1023/A:1006041917853; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	38	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4715	4721		10.1074/jbc.274.8.4715	http://dx.doi.org/10.1074/jbc.274.8.4715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988708	hybrid			2022-12-27	WOS:000078698200033
J	Le Beyec, J; Chauffeton, V; Kan, HY; Janvier, PL; Cywiner-Golenzer, C; Chatelet, FP; Kalopissis, AD; Zannis, V; Chambaz, J; Pincon-Raymond, M; Cardot, P				Le Beyec, J; Chauffeton, V; Kan, HY; Janvier, PL; Cywiner-Golenzer, C; Chatelet, FP; Kalopissis, AD; Zannis, V; Chambaz, J; Pincon-Raymond, M; Cardot, P			The -700/-310 fragment of the apolipoprotein A-IV gene combined with the -890/-500 apolipoprotein C-III enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN GENE; CIS-ACTING ELEMENTS; HUMAN APOCIII GENE; TRANSGENIC MICE; GUT EPITHELIUM; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; INTESTINAL EPITHELIUM; PROXIMAL PROMOTER; DIFFERENTIATION	Spatial gene expression in the intestine is mediated by specific regulatory sequences. The three genes of the apoA-I/C-III/A-IV cluster are expressed in the intestine following cephalocaudal and crypt-to-villus axes. Previous studies have shown that the -780/-520 enhancer region of the apoC-III gene directs the expression of the apoA-I gene in both small intestinal villi and crypts, implying that other unidentified elements are necessary for a normal intestinal pattern of apoA-I gene expression. In this study, we have characterized transgenic mice expressing the chloramphenicol acetyltransferase gene under the control of different regions of the apoC-III and apoA-IV promoters. We found that the -890/+24 apoC-III promoter directed the expression of the reporter gene in crypts and villi and did not follow a cephalocaudal gradient of expression. In contrast, the -700/+10 apoA-IV promoter linked to the -500/-890 apoC-III enhancer directed the expression of the reporter gene in enterocytes with a pattern of expression similar to that of the endogenous apoA-IV gene. Furthermore, linkage of the -700/-310 apoA-IV distal promoter region to the -890/+24 apoC-III promoter was sufficient to restore the appropriate pattern of intestinal expression of the reporter gene. These findings demonstrate that the -700/-310 distal region of the apoA-IV promoter contains regulatory elements that, in combination with proximal promoter elements and the -500/-890 enhancer, are necessary and sufficient to restrict apoC-III and apoA-IV gene expression to villus enterocytes of the small intestine along the cephalocaudal axis.	INSERM, U505, F-75006 Paris, France; CNRS, UPRESA 7079, F-75006 Paris, France; Boston Univ, Med Ctr, Cardiovasc Inst, Mol Genet Sect, Boston, MA 02118 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Boston University	Le Beyec, J (corresponding author), INSERM, U505, 15 Rue Ecole med, F-75006 Paris, France.			Le Beyec - Le Bihan, johanne/0000-0002-5647-2002				BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTIERREZ ED, 1995, AM J PHYSIOL-GASTR L, V269, pG500, DOI 10.1152/ajpgi.1995.269.4.G500; Henning Susan J., 1994, P571; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, AM J PHYSIOL-GASTR L, V268, pG813, DOI 10.1152/ajpgi.1995.268.5.G813; JANUZZI JL, 1992, GENOMICS, V14, P1081, DOI 10.1016/S0888-7543(05)80133-8; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUER SJ, 1991, CIRCULATION, V84, P1390; Le Beyec J, 1998, TRANSGENICS, V2, P211; LI Z, 1993, DEVELOPMENT, V117, P947; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; OGAMI K, 1990, J BIOL CHEM, V265, P9808; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; REUE K, 1991, J BIOL CHEM, V266, P12715; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; RUBIN DC, 1992, AM J PHYSIOL, V263, pG853, DOI 10.1152/ajpgi.1992.263.6.G853; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Steinmetz A, 1998, J BIOL CHEM, V273, P10543, DOI 10.1074/jbc.273.17.10543; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Vergnes L, 1997, BBA-LIPID LIPID MET, V1348, P299, DOI 10.1016/S0005-2760(97)00071-4; WALSH A, 1989, J BIOL CHEM, V264, P6488; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	38	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4954	4961		10.1074/jbc.274.8.4954	http://dx.doi.org/10.1074/jbc.274.8.4954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988739	hybrid			2022-12-27	WOS:000078698200064
J	Evans, TC; Benner, J; Xu, MQ				Evans, TC; Benner, J; Xu, MQ			The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; SPLICING ELEMENT	The smallest known intein, found in the ribonucleoside diphosphate reductase gene of Methanobacterium thermoautotrophicum (Mth RIR1 intein), was found to splice poorly in Escherichia coli with the naturally occurring proline residue adjacent to the N-terminal cysteine of the intein. Splicing proficiency increased when this proline was replaced with an alanine residue, However, constructs that displayed efficient N- and C-terminal cleavage were created by replacing either the C-terminal asparagine or N-terminal cysteine of the intein, respectively, with an alanine. Furthermore, these constructs were used to specifically generate complementary reactive groups on protein sequences for use in ligation reactions. Reaction between an intein-generated C-terminal thioester on E. coli maltose-binding protein (43 kDa) and an intein-generated cysteine at the N terminus of either T4 DNA ligase (56 kDa) or thioredoxin (12 kDa) resulted in the ligation of the proteins through a native peptide bond. Thus the smallest of the known inteins is capable of splicing and its unique properties extend the utility of intein-mediated protein ligation to include the in vitro fusion of large, bacterially expressed proteins.	New England Biolabs Inc, Beverly, MA 01915 USA		Evans, TC (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	xum@neb.com	Wood, David W/B-2992-2012					Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DUPLAY P, 1984, J BIOL CHEM, V259, P606; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Gimble FS, 1998, CHEM BIOL, V5, pR251, DOI 10.1016/S1074-5521(98)90109-0; Holford M, 1998, STRUCTURE, V6, P951, DOI 10.1016/S0969-2126(98)00097-5; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PERLER FB, 1999, IN PRESS NUCL ACIDS, V27; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	22	128	147	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3923	3926		10.1074/jbc.274.7.3923	http://dx.doi.org/10.1074/jbc.274.7.3923			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933578	hybrid			2022-12-27	WOS:000078575500002
J	Bodeau-Pean, S; Ravassard, P; Neuner-Jehle, M; Faucheux, B; Mallet, J; Dumas, S				Bodeau-Pean, S; Ravassard, P; Neuner-Jehle, M; Faucheux, B; Mallet, J; Dumas, S			A human tyrosine hydroxylase isoform associated with progressive supranuclear palsy shows altered enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEASE CALPAIN; DOPA-RESPONSIVE DYSTONIA; MESSENGER-RNA; LIMITED PROTEOLYSIS; ADRENAL-MEDULLA; GENE; PHOSPHORYLATION; ACTIVATION; BINDING; REGION	A novel human tyrosine hydroxylase (HTH) messenger RNA subgroup generated by alternative splicing and characterized by the absence of the third exon was recently identified. The corresponding putative protein lacks 74 amino acids including Ser(31) and Ser(40), two major phosphorylation sites implicated in the regulation of HTH activity. These mRNA species are detected in adrenal medulla and are overexpressed in patients suffering from progressive supranuclear palsy, a neurodegenerative disease mostly affecting catecholaminergic neurons of the basal ganglia. In the present work, an HTH protein isoform lacking exon 3 was identified in human adrenal medulla. For this purpose, an antibody was raised against the HTH exon 3, The effect of the removal of exon 3 on the enzymatic activity of HTH was studied in vitro by comparing a purified recombinant fusion protein without exon 3 (glutathione S-transferase (GST)-HTH Delta 3) to the equivalent protein containing exon 3 (GST-HTH3). In initial velocity conditions, GST-HTH Delta 3 has 30% of the maximal velocity of GST-HTH3. Moreover, the skipping of exon 3 results in the absence of activation of GST-HTH by heparin and increases by 10-fold the retroinhibition constant for dopamine, demonstrating the involvement of exon 3 in the regulation of HTH enzymatic activity. The identification of a variably expressed HTH isoform that lacks an exon implicated in activity regulation supports the view that HTH alternative splicing contributes to the functional diversity within the catecholaminergic system and may be implicated in some neurological diseases.	Hop La Pitie Salpetriere, CNRS, UMR 9923, Lab Genet Mol Neurotransmiss & Proc Neurodigenera, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Dumas, S (corresponding author), Hop La Pitie Salpetriere, LGN, Batiment CERVI Etage 5,83 Bd Hop, F-75013 Paris, France.			ravassard, philippe/0000-0002-0393-9262				ABATE C, 1991, J MOL NEUROSCI, V2, P203; ALMAS B, 1992, EUR J BIOCHEM, V209, P249, DOI 10.1111/j.1432-1033.1992.tb17283.x; Alterio J, 1998, J BIOL CHEM, V273, P10196, DOI 10.1074/jbc.273.17.10196; ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; BIRMAN S, 1994, J BIOL CHEM, V269, P26559; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; COKER GT, 1990, MOL BRAIN RES, V8, P93, DOI 10.1016/0169-328X(90)90052-F; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DANIEL SE, 1995, BRAIN, V118, P759, DOI 10.1093/brain/118.3.759; DAUBNER SC, 1995, PROTEIN SCI, V4, P538; DEYEBENES JG, 1995, BRAIN, V118, P1095, DOI 10.1093/brain/118.5.1095; DIXON M, 1964, ENZYMES, P81; Dumas S, 1996, J NEUROCHEM, V67, P19; GAHN LG, 1993, BIOCHEM J, V295, P189, DOI 10.1042/bj2950189; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Haavik J, 1997, J NEUROCHEM, V68, P328; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1993, J NEUROCHEM, V60, P493, DOI 10.1111/j.1471-4159.1993.tb03177.x; HAYCOCK JW, 1991, J NEUROCHEM, V56, P2139, DOI 10.1111/j.1471-4159.1991.tb03477.x; HAYKALCOATES N, 1991, BRAIN RES, V556, P353, DOI 10.1016/0006-8993(91)90330-X; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V213, P645, DOI 10.1006/bbrc.1995.2180; Joh T H, 1998, Adv Pharmacol, V42, P33; KATZ IR, 1976, BIOCHIM BIOPHYS ACTA, V429, P84, DOI 10.1016/0005-2744(76)90032-2; KIUCHI K, 1991, BIOCHEMISTRY-US, V30, P10416, DOI 10.1021/bi00107a008; KNAPPSKOG PM, 1995, HUM MOL GENET, V4, P1209, DOI 10.1093/hmg/4.7.1209; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kumer SC, 1996, J NEUROCHEM, V67, P443; Laniece P, 1996, J NEUROCHEM, V66, P1819; LEBOURDELLES B, 1988, J NEUROCHEM, V50, P988; LEWIS DA, 1993, NEUROSCIENCE, V54, P477, DOI 10.1016/0306-4522(93)90267-J; LIU X, 1991, NEUROCHEM INT, V18, P27, DOI 10.1016/0197-0186(91)90031-8; Ludecke B, 1996, HUM MOL GENET, V5, P1023, DOI 10.1093/hmg/5.7.1023; Nagatsu T, 1995, ESSAYS BIOCHEM, V30, P15; OKUNO S, 1991, J NEUROCHEM, V57, P53, DOI 10.1111/j.1471-4159.1991.tb02098.x; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P2910; OTA A, 1995, BIOCHEM BIOPH RES CO, V213, P1099, DOI 10.1006/bbrc.1995.2240; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; TOGARI A, 1986, BIOCHEM BIOPH RES CO, V134, P749, DOI 10.1016/S0006-291X(86)80484-3; VRANA KE, 1994, J NEUROCHEM, V63, P2014; WU J, 1992, J BIOL CHEM, V267, P25754	43	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3469	3475		10.1074/jbc.274.6.3469	http://dx.doi.org/10.1074/jbc.274.6.3469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920892	hybrid			2022-12-27	WOS:000078428200032
J	Chen, H; Slepnev, VI; Di Fiore, PP; De Camilli, P				Chen, H; Slepnev, VI; Di Fiore, PP; De Camilli, P			The interaction of epsin and Eps15 with the clathrin adaptor AP-2 is inhibited by mitotic phosphorylation and enhanced by stimulation-dependent dephosphorylation in nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; COATED PITS; VESICLE FORMATION; PROTEIN; DOMAIN; DYNAMIN; EH; PHOSPHOPROTEINS; ENDOCYTOSIS; CELLS	Clathrin-mediated endocytosis was shown to be arrested in mitosis due to a block in the invagination of clathrin-coated pits. A Xenopus mitotic phosphoprotein, MP90, is very similar to an abundant mammalian nerve terminal protein, epsin, which binds the Eps15 homology (EH) domain of Eps15 and the alpha-adaptin subunit of the clathrin adaptor AP-2, We show here that both rat epsin and Eps15 are mitotic phosphoproteins and that their mitotic phosphorylation inhibits binding to the appendage domain of alpha-adaptin. Both epsin and Eps15, like other cytosolic components of the synaptic vesicle endocytic machinery, undergo constitutive phosphorylation and depolarization-dependent dephosphorylation in nerve terminals. Furthermore, their binding to AP-2 in brain extracts is enhanced by dephosphorylation, Epsin together with Eps15 was proposed to assist the clathrin coat in its dynamic rearrangements during the invagination/fission reactions. Their mitotic phosphorylation may be one of the mechanisms by which the invagination of clathrin-coated pits is blocked in mitosis and their stimulation-dependent dephosphorylation at synapses may contribute to the compensatory burst of endocytosis after a secretory stimulus.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Bari, Ist Microbiol, I-70124 Bari, Italy	Howard Hughes Medical Institute; Yale University; IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu	Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Gad H, 1998, NEURON, V21, P607, DOI 10.1016/S0896-6273(00)80570-X; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Iannolo G, 1997, CANCER RES, V57, P240; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Nigg E A, 1991, Semin Cell Biol, V2, P261; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	34	110	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3257	3260		10.1074/jbc.274.6.3257	http://dx.doi.org/10.1074/jbc.274.6.3257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920862	hybrid			2022-12-27	WOS:000078428200002
J	Heyduk, E; Heyduk, T				Heyduk, E; Heyduk, T			Architecture of a complex between the sigma(70) subunit of Escherichia coli RNA polymerase and the nontemplate strand oligonucleotide - Luminescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER RECOGNITION; BACILLUS-SUBTILIS; TRANSCRIPTION INITIATION; SIGMA-70 SUBUNIT; FACTOR MUTATIONS; MISMATCH BUBBLE; AMINO-ACIDS; DNA; BINDING; SPECIFICITY	We used luminescence energy transfer measurements to determine the localization of 5'- and 3'-ends of a 12-nucleotide nontemplate strand oligonucleotide bound to sigma(70) holoenzyme, Five single reactive cysteine mutants of sigma(70) (cysteine residues at positions 1, 59, 366, 442, and 596) were labeled with a europium chelate fluorochrome (donor). The oligonucleotide was modified at the 5'- or at the S'-end with Cy5 fluorochrome (acceptor). The energy transfer was observed upon complex formation between the donor-labeled sigma(70) holoenzyme and the acceptor-labeled nontemplate strand oligonucleotide, whereas no interaction was observed with the template strand oligonucleotide. The oligonucleotide was bound in one preferred orientation. This observation together with the sequence specificity of single-stranded oligonucleotide interaction suggests that two mechanisms of discrimination between the template and nontemplate strand are used by sigma(70): sequence specificity and strand polarity specificity. The bound oligonucleotide was found to be close to residue 442, confirming that the single-stranded DNA binding site of sigma(70) is located in an cu-helix containing residue 442. The 5'-end of the oligonucleotide was oriented toward the COOH terminus of the helix.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@wpogate.slu.edu			NIGMS NIH HHS [GM50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; AIYAR SE, 1994, J BIOL CHEM, V269, P13179; BURGESS RR, 1970, FED PROC, V29, P1164; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEYDUK E, 1992, BIOCHEMISTRY-US, V31, P3682, DOI 10.1021/bi00129a017; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; Ishihama A, 1990, Adv Biophys, V26, P19, DOI 10.1016/0065-227X(90)90005-E; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; LEIRMO S, 1990, NUCLEIC ACIDS MOL BI, P123; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Savinkova L. K., 1996, Molekulyarnaya Biologiya (Moscow), V30, P188; SAVINKOVA LK, 1983, DOKL AKAD NAUK SSSR+, V270, P1501; SAVINKOVA LK, 1993, MOL BIOL+, V27, P33; SAVINKOVA LK, 1988, MOL BIOL+, V22, P651; Selvin PR, 1996, IEEE J SEL TOP QUANT, V2, P1077, DOI 10.1109/2944.577339; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; TRIPATARA A, 1993, J MOL BIOL, V233, P349, DOI 10.1006/jmbi.1993.1516; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	45	31	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3315	3322		10.1074/jbc.274.6.3315	http://dx.doi.org/10.1074/jbc.274.6.3315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920872	hybrid			2022-12-27	WOS:000078428200012
J	Krasnoperov, V; Bittner, MA; Holz, RW; Chepurny, O; Petrenko, AG				Krasnoperov, V; Bittner, MA; Holz, RW; Chepurny, O; Petrenko, AG			Structural requirements for alpha-latrotoxin binding and alpha-latrotoxin-stimulated secretion - A study with calcium-independent receptor of alpha-latrotoxin (CIRL) deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CATIONS; FAMILY	Stimulation of neurotransmitter release by alpha-latrotoxin requires its binding to the calcium-independent receptor of alpha-latrotoxin (CIRL), an orphan neuronal G protein-coupled receptor. CIRL consists of two noncovalently bound subunits, p85, a heptahelical integral membrane protein, and p120, a large extracellular polypeptide with domains homologous to lectin, olfactomedin, mucin, the secretin receptor family, and a novel structural motif common for large orphan G protein-coupled receptors, The analysis of CIRL deletion mutants indicates that the high affinity alpha-latrotoxin-binding site is located within residues 467-891, which comprise the first transmembrane segment of p85 and the C-terminal half of p120, The N-terminal lectin, olfactomedin, and mucin domains of p120 are not required for the interaction with alpha-latrotoxin. Soluble p120 and all its fragments, which include the 467-770 residues, bind alpha-latrotoxin with low affinity suggesting the importance of membrane-embedded p85 for the stabilization of the complex of the toxin with p120, Two COOH-terminal deletion mutants of CIRL, one with the truncated cytoplasmic domain and the other with only one transmembrane segment left of seven, supported both alpha-latrotoxin-induced calcium uptake in HEK293 cells and alpha-latrotoxin-stimulated secretion when expressed in chromaffin cells, although with a different dose dependence than wild-type CIRL and its N-terminal deletion mutant, Thus the signaling domains of CIRL are not critically important for the stimulation of exocytosis in intact chromaffin cells by alpha-latrotoxin.	NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU Med Ctr, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU Med Ctr, Dept Environm Med, New York, NY 10016 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	New York University; New York University; New York University; University of Michigan System; University of Michigan	Petrenko, AG (corresponding author), NYU Med Ctr, Dept Pharmacol, 550 1st Ave,MSB 202, New York, NY 10016 USA.			Petrenko, Alexander/0000-0002-6689-6546	NIDDK NIH HHS [R01DK27959] Funding Source: Medline; NINDS NIH HHS [R01NS34937, R01NS35098] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098, R01NS034937] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; ICHTCHENKO K, 1999, IN PRESS J BIOL CHEM; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094	20	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3590	3596		10.1074/jbc.274.6.3590	http://dx.doi.org/10.1074/jbc.274.6.3590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920906	hybrid			2022-12-27	WOS:000078428200046
J	Bradbury, P; Mann, CJ; Kochl, S; Anderson, TA; Chester, SA; Hancock, JM; Ritchie, PJ; Amey, J; Harrison, GB; Levitt, DG; Banaszak, LJ; Scott, J; Shoulders, CC				Bradbury, P; Mann, CJ; Kochl, S; Anderson, TA; Chester, SA; Hancock, JM; Ritchie, PJ; Amey, J; Harrison, GB; Levitt, DG; Banaszak, LJ; Scott, J; Shoulders, CC			A common binding site on the microsomal triglyceride transfer protein for apolipoprotein B and protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CONTAINING LIPOPROTEINS; ABETALIPOPROTEINEMIA GENE; HEPG2 CELLS; VITELLOGENIN; DEGRADATION; EXPRESSION; SECRETION; SEQUENCE; PRODUCT	The assembly of triglyceride-rich lipoproteins requires the formation in the endoplasmic reticulum of a complex between apolipoprotein B (apoB), a microsomal triglyceride transfer protein (MTP), and protein disulfide isomerase (PDI). In the MTP complex, the aminoterminal region of MTP (residues 22-303) interacts with the amino-terminal region of apoB (residues 1-264). Here, we report the identification and characterization of a site on apoB between residues 512 and 721, which interacts with residues 517-603 of MTP. PDI binds in close proximity to this apoB binding site on MTP. The proximity of these binding sites on MTP for PDI and amino acids 512-721 of apoB was evident from studies carried out in a yeast two-hybrid system and by coimmunoprecipitation. The expression of PDI with MTP and apoB16 (residues 1-721) in the baculovirus expression system reduced the amount of MTP co-immunoprecipitated with apoB by 73%. The interaction of residues 512-721 of apoB with MTP facilitates lipoprotein production. Mutations of apoB that markedly reduced this interaction also reduced the level of apoB-containing lipoprotein secretion.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, MRC Mol Med Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, Gene Genome Evolut Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Natl Heart & Lung Inst, London W12 0NN, England; Inst Gerichtliche Med, A-6020 Innsbruck, Austria; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA	Imperial College London; Imperial College London; Imperial College London; University of Minnesota System; University of Minnesota Twin Cities	Shoulders, CC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, MRC Mol Med Grp, Du Cane Rd, London W12 0NN, England.		Hancock, John/A-2442-2009	Hancock, John/0000-0003-2991-2217				Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GERBERHUBER S, 1987, NUCLEIC ACIDS RES, V15, P4737, DOI 10.1093/nar/15.12.4737; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; REYNOLDS A, 1992, SHORT PROTOCOLS MOL; ROST B, 1992, NATURE, V360, P540, DOI 10.1038/360540b0; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, ARTERIOSCL THROM VAS, V17, P3347, DOI 10.1161/01.ATV.17.11.3347; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	26	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3159	3164		10.1074/jbc.274.5.3159	http://dx.doi.org/10.1074/jbc.274.5.3159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915855	hybrid			2022-12-27	WOS:000078319500073
J	Barton, VA; Hudson, KR; Heath, JK				Barton, VA; Hudson, KR; Heath, JK			Identification of three distinct receptor binding sites of murine interleukin-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; LEUKEMIA INHIBITORY FACTOR; MOLECULAR-CLONING; HUMAN IL-6; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RATIONAL DESIGN; GP130; MUTAGENESIS	Interleukin-11 (IL-11) is a member of the gp130 family of cytokines. These cytokines drive the assembly of multisubunit receptor complexes, all of which contain at least one molecule of the transmembrane signaling receptor gp130. A complex of IL-11 and the IL-11 receptor (IL-11R) has been shown to interact with gp130, with high affinity, and to induce gp130- dependent signaling. In this study, we have identified residues crucial for the binding of murine IL-11 (mIL-11) to both the IL-11R and gp130 by examining the activities of mIL-11 mutants in receptor binding and cell proliferation assays. The location of these residues, as predicted from structural studies and a model of IL-11, reveals that mIL-11 has three distinct receptor binding sites. These are structurally and functionally analogous to the previously defined receptor binding sites I, II, and III of interleukin-6 (IL-6). This supports the hypothesis that IL-11 signals via the formation of a hexameric receptor complex and indicates that site III is a generic feature of cytokines that signal via association with gp130.	Univ Birmingham, Dept Biochem, Canc Res Campaign, Growth Factor Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Heath, JK (corresponding author), Univ Birmingham, Dept Biochem, Canc Res Campaign, Growth Factor Grp, Birmingham B15 2TT, W Midlands, England.	j.k.heath@bham.ac.uk						BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Czupryn M, 1995, ANN NY ACAD SCI, V762, P152; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiMarco A, 1997, J BIOL CHEM, V272, P23069, DOI 10.1074/jbc.272.37.23069; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EHLERS M, 1994, J IMMUNOL, V153, P1744; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; Harlow E., 1988, ANTIBODIES LABORATOR, P341; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Karow J, 1996, BIOCHEM J, V318, P489, DOI 10.1042/bj3180489; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nandurkar HH, 1996, ONCOGENE, V12, P585; NEBEN TY, 1993, BLOOD, V81, P901; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; SAITO M, 1992, J IMMUNOL, V148, P4066; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SONIS S, 1995, ORAL ONCOL, V31B, P261, DOI 10.1016/0964-1955(95)00015-A; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; WANG XY, 1995, J BIOL CHEM, V270, P27999; WARD LD, 1994, J BIOL CHEM, V269, P23286; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467	46	53	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5755	5761		10.1074/jbc.274.9.5755	http://dx.doi.org/10.1074/jbc.274.9.5755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026196	hybrid			2022-12-27	WOS:000078804400067
J	Carraway, KL; Rossi, EA; Komatsu, M; Price-Schiavi, SA; Huang, DM; Guy, PM; Carvajal, ME; Fregien, N; Carraway, CAC; Carraway, KL				Carraway, KL; Rossi, EA; Komatsu, M; Price-Schiavi, SA; Huang, DM; Guy, PM; Carvajal, ME; Fregien, N; Carraway, CAC; Carraway, KL			An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY ADENOCARCINOMA; SIALOMUCIN COMPLEX; ASCITES ADENOCARCINOMA; NEURAL DEVELOPMENT; BREAST-CANCER; ONCOGENE; HETERODIMERIZATION; PHOSPHORYLATION; HEREGULIN; LIGAND	The ErbB2 receptor tyrosine kinase plays a critical role in a variety of developmental processes, and its aberrant activation may contribute to the progression of some breast and ovarian tumors. ASGP2, a transmembrane glycoprotein found on the surface of the highly metastatic ascites 13762 rat mammary adenocarcinoma cell line, is constitutively associated with ErbB2 in these cells and in mammary tissue from pregnant rats. Expression studies indicate that ASGP2 interacts directly and specifically with ErbB2 through one of its epidermal growth factor-like domains and that the co-expression of the two proteins in the same cell dramatically facilitates their direct stable interaction. Ectopic expression of ASGP2 in human melanoma tumor cells potentiates the response of endogenous ErbB2 to the neuregulin-1 growth factor. These observations point to a novel intramembrane mechanism for the modulation of receptor tyrosine kinase activity.	Beth Israel Hosp, Harvard Inst Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33101 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; University of Miami; University of Miami; University of California System; University of California San Diego	Carraway, KL (corresponding author), Beth Israel Hosp, Harvard Inst Med, Div Signal Transduct, Rm 1018,330 Brookline Ave, Boston, MA 02215 USA.			Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA14395, CA52498, CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014395, R01CA074072, R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1992, J BIOL CHEM, V267, P13851; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Juang SH, 1996, ONCOGENE, V12, P1033; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LONARDO F, 1990, New Biologist, V2, P992; MORIARTY J, 1990, CANCER RES, V50, P6800; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969	28	166	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5263	5266		10.1074/jbc.274.9.5263	http://dx.doi.org/10.1074/jbc.274.9.5263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026131	hybrid			2022-12-27	WOS:000078804400002
J	Fanger, CM; Ghanshani, S; Logsdon, NJ; Rauer, H; Kalman, K; Zhou, JM; Beckingham, K; Chandy, KG; Cahalan, MD; Aiyar, J				Fanger, CM; Ghanshani, S; Logsdon, NJ; Rauer, H; Kalman, K; Zhou, JM; Beckingham, K; Chandy, KG; Cahalan, MD; Aiyar, J			Calmodulin mediates calcium-dependent activation of the intermediate conductance K-Ca channel, IKCa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; POTASSIUM CHANNELS; ION CHANNELS; BETA-SUBUNIT; RYANODINE RECEPTOR; T-LYMPHOCYTES; BINDING SITES; EXPRESSION; BRAIN; MODULATION	Small and intermediate conductance Ca2+-activated K+ channels play a crucial role in hyperpolarizing the membrane potential of excitable and nonexcitable cells. These channels are exquisitely sensitive to cytoplasmic Ca2+, yet their protein-coding regions do not contain consensus Ca2+-binding motifs. me investigated the involvement of an accessory protein in the Ca2+-dependent gating of hIKCa1, a human intermediate conductance channel expressed in peripheral tissues. Calmodulin was found to interact strongly with the cytoplasmic carboxyl (C)-tail of hIKCa1 in a yeast two-hybrid system. Deletion analyses defined a requirement for the first 62 amino acids of the C-tail, and the binding of calmodulin to this region did not require Ca2+. The C-tail of hSKCa3, a human neuronal small conductance channel, also bound calmodulin, whereas that of a voltage-gated K+ channel, mKv1.3, did not. Calmodulin coprecipitated with the channel in cell lines transfected with hIKCa1, but not with mKv1.3-transfected Lines. A mutant calmodulin, defective in Ca2+ sensing but retaining binding to the channel, dramatically reduced current amplitudes when co-expressed with hIKCa1 in mammalian cells. Co-expression with varying amounts of wild-type and mutant calmodulin resulted in a dominant-negative suppression of current, consistent with four calmodulin molecules being associated with the channel. Taken together, our results suggest that Ca2+ calmodulin-induced conformational changes in all four subunits are necessary for the channel to open.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Zeneca Pharmaceut, Target Discovery Dept, Wilmington, DE 19850 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	University of California System; University of California Irvine; Rice University	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Joan Irvine Smith Hall,Rm 291, Irvine, CA 92697 USA.	gchandy@uci.edu		Fanger, Christopher/0000-0002-8268-9053	NIGMS NIH HHS [GM41514, GMOD54872] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872, R01GM041514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R56NS014609, R37NS014609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BENDER PK, 1988, J BIOL CHEM, V263, P9733; Bowen T, 1998, MOL PSYCHIATR, V3, P266, DOI 10.1038/sj.mp.4000400; BRUGNARA C, 1995, J MEMBRANE BIOL, V147, P71, DOI 10.1007/BF00235398; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Cox DH, 1997, J GEN PHYSIOL, V110, P257, DOI 10.1085/jgp.110.3.257; DECOURSEY TE, 1985, J NEUROIMMUNOL, V10, P71, DOI 10.1016/0165-5728(85)90035-9; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GUERRINI R, 1995, BIOCHEMISTRY-US, V34, P5120, DOI 10.1021/bi00015a024; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Hanselmann C, 1996, J PHYSIOL-LONDON, V496, P627, DOI 10.1113/jphysiol.1996.sp021714; HILLE B, 1993, IONIC CHANNELS EXCIT, P121; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MAHAUTSMITH MP, 1995, J PHYSIOL-LONDON, V484, P15, DOI 10.1113/jphysiol.1995.sp020644; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MCMANUS OB, 1991, J PHYSIOL-LONDON, V443, P739, DOI 10.1113/jphysiol.1991.sp018861; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Mukherjea P, 1996, PROTEIN SCI, V5, P468; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Vergara C, 1997, EXP NEUROL, V146, P282, DOI 10.1006/exnr.1997.6486; Verheugen JAH, 1998, J PHYSIOL-LONDON, V508, P167, DOI 10.1111/j.1469-7793.1998.167br.x; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	56	251	262	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5746	5754		10.1074/jbc.274.9.5746	http://dx.doi.org/10.1074/jbc.274.9.5746			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026195	hybrid			2022-12-27	WOS:000078804400066
J	Hilpert, J; Nykjaer, A; Jacobsen, C; Wallukat, G; Nielsen, R; Moestrup, SK; Haller, H; Luft, FC; Christensen, EI; Willnow, TE				Hilpert, J; Nykjaer, A; Jacobsen, C; Wallukat, G; Nielsen, R; Moestrup, SK; Haller, H; Luft, FC; Christensen, EI; Willnow, TE			Megalin antagonizes activation of the parathyroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OPOSSUM KIDNEY-CELLS; MEDIATED ENDOCYTOSIS; EPITHELIAL-CELLS; DEGRADATION; BINDING; GENE; PEPTIDE; PROTEIN; GROWTH	Parathyroid hormone(PTH) is predominantly cleared from the circulation by glomerular filtration and degradation in the renal proximal tubules. Here, we demonstrate that megalin, a multifunctional endocytic receptor in the proximal tubular epithelium, mediates the uptake and degradation of PTH. Megalin was purified from kidney membranes as the major PTH-binding protein and shown in BIAcore analysis to specifically bind full-length PTH and amino-terminal PTH fragments (K-d 0.5 mu M) Absence of the receptor in megalin knockout mice resulted in 4-fold increased levels of amino-terminal PTH fragments in the urine, In F9 cells expressing both megalin and the PTH/PTH-related peptide receptor (PTH/PTHrP receptor), uptake and lysosomal degradation of the hormone was mediated through megalin. Blocking megalin-mediated clearance of PTH resulted in 3-fold increased stimulation of the PTH/PTRrP receptor. These data provide evidence that megalin is involved in the renal catabolism of PTH and potentially antagonizes PTH/PTHrP receptor activity in the proximal tubular epithelium.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Franz Volhard Clin, D-13125 Berlin, Germany; Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus, Denmark; Univ Aarhus, Dept Cell Biol, DK-8000 Aarhus C, Denmark	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Humboldt University of Berlin; Aarhus University; Aarhus University	Willnow, TE (corresponding author), Max Delbruck Ctr Mol Med, R Roessle Str 10, D-13125 Berlin, Germany.	willnow@mdc-berlin.de	Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Nielsen, Rikke/0000-0003-3105-3474; Nykjaer, Anders/0000-0001-6422-6736; Willnow, Thomas/0000-0001-9515-7921; Luft, Friedrich/0000-0002-8635-1199				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BROWN RC, 1991, AM J PHYSIOL, V260, pE544, DOI 10.1152/ajpendo.1991.260.4.E544; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; DAUGAARD H, 1994, ENDOCRINOLOGY, V134, P1373, DOI 10.1210/en.134.3.1373; DAUGAARD H, 1988, AM J PHYSIOL, V254, pE740, DOI 10.1152/ajpendo.1988.254.6.E740; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEMAY M, 1985, AM J PHYSIOL, V249, pE437, DOI 10.1152/ajpendo.1985.249.5.E437; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAU ST, 1977, AM J PHYSIOL, V223, pF445; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Lepage R, 1998, CLIN CHEM, V44, P805; Lewin E, 1995, Curr Opin Nephrol Hypertens, V4, P324, DOI 10.1097/00041552-199507000-00007; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MAHONEY CA, 1983, J CLIN INVEST, V72, P411, DOI 10.1172/JCI110989; MARTIN KJ, 1979, NEW ENGL J MED, V301, P1092, DOI 10.1056/NEJM197911153012005; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Morales CR, 1996, BIOL REPROD, V55, P676, DOI 10.1095/biolreprod55.3.676; RIZZOLI RE, 1983, ENDOCRINOLOGY, V112, P1303, DOI 10.1210/endo-112-4-1303; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Silver J, 1994, Curr Opin Nephrol Hypertens, V3, P379, DOI 10.1097/00041552-199407000-00003; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STJOHN A, 1992, NEPHRON, V61, P422; TEITELBAUM AP, 1982, ENDOCRINOLOGY, V111, P1524, DOI 10.1210/endo-111-5-1524; TEITELBAUM AP, 1986, ENDOCRINOLOGY, V118, P595, DOI 10.1210/endo-118-2-595; VANDESTOLPE A, 1993, J CELL BIOL, V120, P235, DOI 10.1083/jcb.120.1.235; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEAVER CA, 1984, GENE, V28, P319, DOI 10.1016/0378-1119(84)90149-5; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; YAMAGUCHI T, 1992, ACTA ENDOCRINOL-COP, V127, P267, DOI 10.1530/acta.0.1270267; YAMAGUCHI T, 1988, ENDOCRINOLOGY, V123, P2812, DOI 10.1210/endo-123-6-2812	38	87	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5620	5625		10.1074/jbc.274.9.5620	http://dx.doi.org/10.1074/jbc.274.9.5620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026179	hybrid			2022-12-27	WOS:000078804400050
J	Kyriakis, JM				Kyriakis, JM			Signaling by the germinal center kinase family of protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							C-JUN; TRANSDUCTION PATHWAY; OXIDANT STRESS; ACTIVATION; CASCADE; P38; SAPK/JNK; CLONING; GTPASES; CDC42		Massachusetts Gen Hosp E, Diabet Res Lab, Charlestown, MA 02129 USA; Harvard Med Sch, Dept Med, Charlestown, MA 02129 USA		Kyriakis, JM (corresponding author), Massachusetts Gen Hosp E, Diabet Res Lab, 149 13th St, Charlestown, MA 02129 USA.	kyriakis@helix.mgh.harvard.edu			NIGMS NIH HHS [GM46577] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046577, R01GM046577] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerutti A, 1998, IMMUNITY, V9, P247, DOI 10.1016/S1074-7613(00)80607-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PHILLIPSEN P, 1991, YEAST, V7, P265; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	55	135	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5259	5262		10.1074/jbc.274.9.5259	http://dx.doi.org/10.1074/jbc.274.9.5259			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026130	hybrid			2022-12-27	WOS:000078804400001
J	Yang, B; Gonzalez, L; Prekeris, R; Steegmaier, M; Advani, RJ; Scheller, RH				Yang, B; Gonzalez, L; Prekeris, R; Steegmaier, M; Advani, RJ; Scheller, RH			SNARE interactions are not selective - Implications for membrane fusion specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTIONS; SYNTAXIN-BINDING; GOLGI-APPARATUS; T-SNARE; V-SNARE; TRANSPORT; COMPLEX; EXOCYTOSIS; RECEPTORS; CLEAVAGE	The SNARE hypothesis proposes that membrane trafficking specificity is mediated by preferential high affinity interactions between particular v (vesicle membrane)- and t (target membrane)-SNARE combinations. The specificity of interactions among a diverse set of SNAREs, however, is unknown. We have tested the SNARE hypothesis by analyzing potential SNARE complexes between five proteins of the vesicle-associated membrane protein (VAMP) family, three members of the synaptosome-associated protein-25 (SNAP-25) family and three members of the syntaxin family, All of the 21 combinations of SNAREs tested formed stable complexes, Sixteen were resistant to SDS denaturation, and most complexes thermally denatured between 70 and 90 degrees C, These results suggest that the specificity of membrane fusion is not encoded by the interactions between SNAREs.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Gonzalez, Lino/E-4102-2012	Gonzalez, Lino/0000-0003-3817-6450				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1998, P NATL ACAD SCI USA, V95, P9274, DOI 10.1073/pnas.95.16.9274; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; MOLLARD GF, 1997, J CELL BIOL, V137, P1511; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9	39	258	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 26	1999	274	9					5649	5653		10.1074/jbc.274.9.5649	http://dx.doi.org/10.1074/jbc.274.9.5649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	170KG	10026182	hybrid			2022-12-27	WOS:000078804400053
J	Lee, SR; Kim, JR; Kwon, KS; Yoon, HW; Levine, RL; Ginsburg, A; Rhee, SG				Lee, SR; Kim, JR; Kwon, KS; Yoon, HW; Levine, RL; Ginsburg, A; Rhee, SG			Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG ADENOCARCINOMA CELLS; GLUTATHIONE-REDUCTASE; DISULFIDE OXIDOREDUCTASES; LIPOAMIDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; REDOX REGULATION; SELENOPROTEIN-W; SECIS ELEMENTS; C-ELEGANS	A thioredoxin reductase (TrxR), named here TrxR2, that did not react with antibodies to the previously identified TrxR (now named TrxR1) was purified from rat liver. Like TrxR1, TrxR2 was a dimeric enzyme containing selenocysteine (Secys) as the COOH-terminal penultimate residue. A cDNA encoding TrxRa was cloned from rat liver; the open reading frame predicts a polypeptide of 526 amino acids with a COOH-terminal Gly-Cys-Secys-Gly motif provided that an in-frame TGA codon encodes Secys. The 3'-untranslated region of the cDNA contains a canonical Secys insertion sequence element, The deduced amino acid sequence of TrxR1 shows 54% identity to that of TrxR1 and contained 36 additional residues upstream of the experimentally determined NH2-terminal sequence. The sequence of this 36-residue region is typical of that of a mitochondrial leader peptide. Immunoblot analysis confirmed that TrxR2 is localized almost exclusively in mitochondria, whereas TrxR1 is a cytosolic protein. Unlike TrxR1, which was expressed at a level of 0.6 to 1.6 mu g/mill/gram of total soluble protein in all rat tissues examined, TrxRa was relatively abundant (0.3 to 0.6 mu g/mg) only in liver, kidney, adrenal gland, and heart. The specific localization of TrxR2 in mitochondria, together with the previous identification of mitochondria-specific thioredoxin and thioredoxin-dependent peroxidase, suggest that these three proteins provide a primary line of defense against H2O2 produced by the mitochondrial respiratory chain.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.	sgrhee@nih.gov	Levine, Rodney L/D-9885-2011					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BROWN NL, 1983, BIOCHEMISTRY-US, V22, P4089, DOI 10.1021/bi00286a015; Candas M, 1997, ARCH BIOCHEM BIOPHYS, V339, P323, DOI 10.1006/abbi.1996.9872; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; DAHER R, 1994, CLIN CHEM, V40, P62; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu QP, 1997, GENE, V193, P187, DOI 10.1016/S0378-1119(97)00113-3; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KLUK RM, 1997, SCIENCE, V275, P1132; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; KROEMER G, 1997, CELL DEATH DIFFER, V4, P449; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu SY, 1997, P NATL ACAD SCI USA, V94, P6138, DOI 10.1073/pnas.94.12.6138; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stafford Walter F., 1996, Biophysical Journal, V70, pA231; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Tamura T, 1995, BIOFACTORS, V5, P99; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO T, 1989, GENE, V80, P337; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	63	233	240	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4722	4734		10.1074/jbc.274.8.4722	http://dx.doi.org/10.1074/jbc.274.8.4722			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988709	hybrid			2022-12-27	WOS:000078698200034
J	Levine, J; Etter, J; Apostol, I				Levine, J; Etter, J; Apostol, I			Nickel-catalyzed N-terminal oxidative deamination in peptides containing histidine at position 2 coupled with sulfite oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CROSS-LINKING; PROTEIN OXIDATION; HYDROXYL RADICALS; DECARBOXYLATION; PEROXIDATION; AUTOXIDATION; (BI)SULFITE; METHIONINE; COMPLEX	Peptides containing histidine at position 2 were observed to undergo spontaneous N-terminal oxidative deamination in aqueous solution in the presence of Ni(II), sulfite, and ambient oxygen. The reaction resulted in the formation of a free carbonyl on the N-terminal alpha-carbon (alpha-ketoamide) and was catalytic with respect to nickel. This oxidative deamination was confirmed by C-13 NMR, H-1 MMR, mass spectrometry, and chemical tests. No evidence of modification of histidine was found. It was demonstrated that the nickel-dependent N-terminal oxidative deamination also occurred in His-2 peptides using potassium peroxymonosulfate (oxone) as an oxidant. When oxone was used, oxygen was not required for the deamination to proceed. The results suggest that both nickel-catalyzed reactions (sulfite and oxygen, and oxone) produce an imine intermediate that spontaneously hydrolyzes to form the free carbonyl, These findings may provide a physiologically relevant model for oxidative carbonyl formation in vivo, as well as a useful method for producing a site-specific carbonyl on peptides and proteins.	Baxter Hemoglobin Therapeut Inc, Boulder, CO 80301 USA		Apostol, I (corresponding author), Baxter Hemoglobin Therapeut Inc, 2545 Cent Ave, Boulder, CO 80301 USA.							AMICI A, 1989, J BIOL CHEM, V264, P3341; Apostol I, 1997, J BIOL CHEM, V272, P28980, DOI 10.1074/jbc.272.46.28980; ATHAR M, 1987, BIOCHEM BIOPH RES CO, V147, P1276, DOI 10.1016/S0006-291X(87)80208-5; BAL W, 1994, J CHEM SOC CHEM COMM, P1889, DOI 10.1039/c39940001889; BRANDT C, 1995, CHEM REV, V95, P119, DOI 10.1021/cr00033a006; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; Brown KC, 1998, BIOCHEMISTRY-US, V37, P4397, DOI 10.1021/bi9728046; CHEN K, 1991, J AM CHEM SOC, V113, P5884; Cornish VW, 1996, J AM CHEM SOC, V118, P8150, DOI 10.1021/ja961216x; Davies MJ, 1996, ARCH BIOCHEM BIOPHYS, V336, P163, DOI 10.1006/abbi.1996.0545; Dean RT, 1997, BIOCHEM J, V324, P1; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; Gaertner HF, 1996, BIOCONJUGATE CHEM, V7, P38, DOI 10.1021/bc950074d; Gill G, 1997, CHEM RES TOXICOL, V10, P302, DOI 10.1021/tx960170i; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; INOUE S, 1989, BIOCHEM BIOPH RES CO, V159, P445, DOI 10.1016/0006-291X(89)90012-0; Levine J, 1998, J BIOL CHEM, V273, P13037, DOI 10.1074/jbc.273.21.13037; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Liang Q, 1998, J AM CHEM SOC, V120, P248, DOI 10.1021/ja9720218; March J., 1992, REACTIONS MECH STRUC, V4th; MERKLER DJ, 1995, FEBS LETT, V366, P165, DOI 10.1016/0014-5793(95)00516-C; MOTTLEY C, 1988, ARCH BIOCHEM BIOPHYS, V267, P681, DOI 10.1016/0003-9861(88)90077-X; Muller JG, 1997, J AM CHEM SOC, V119, P1501, DOI 10.1021/ja963701y; NETA P, 1985, ENVIRON HEALTH PERSP, V64, P209, DOI 10.2307/3430011; REED GA, 1986, P NATL ACAD SCI USA, V83, P7499, DOI 10.1073/pnas.83.19.7499; SAKURAI T, 1979, INORG CHIM ACTA, V34, pL243, DOI 10.1016/S0020-1693(00)94648-6; SCHONEICH C, 1993, BIOCHIM BIOPHYS ACTA, V1158, P307, DOI 10.1016/0304-4165(93)90030-C; SHIEMKE AK, 1989, J BIOL CHEM, V264, P7276; SHULLENBERGER DF, 1993, J AM CHEM SOC, V115, P11038, DOI 10.1021/ja00076a091; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; THORNE GC, 1990, J AM SOC MASS SPECTR, V1, P249, DOI 10.1016/1044-0305(90)85042-K; TORREILLES J, 1990, FREE RADICAL RES COM, V11, P159, DOI 10.3109/10715769009109679; ZHUANG ZX, 1994, TOXICOL APPL PHARM, V126, P319, DOI 10.1006/taap.1994.1122	34	10	10	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4848	4857		10.1074/jbc.274.8.4848	http://dx.doi.org/10.1074/jbc.274.8.4848			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988725	hybrid			2022-12-27	WOS:000078698200050
J	Liu, Y; Samuel, CE				Liu, Y; Samuel, CE			Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; GLUR-B; UNWINDING ACTIVITY; MOLECULAR-CLONING; HUMAN-CELLS; ION FLOW; 2 FORMS; Z-DNA; CHANNELS; BINDING	The interferon-inducible RNA-specific adenosine deaminase (ADAR1) is an RNA-editing enzyme that catalyzes the deamination of adenosine in double-stranded RNA structures. Three alternative splice-site variants of ADAR1 (ADAR1-a, -b, and -c) occur that possess functionally distinct double-stranded RNA-binding motifs as measured with synthetic double-stranded RNA substrates, The pre-mRNA transcript encoding the B subunit of glutamate receptor (GluR-B) has two functionally important editing sites (Q/R and R/G sites) that undergo selective A-to-I conversions. We have examined the ability of the three ADAR1 splice-site variants to catalyze the editing of GluR-B pre-mRNA at the Q/R and R/G sites as well as an intron hotspot (+60) of unknown function. Measurement of GluR-B pre-mRNA editing in vitro revealed different site-specific deamination catalyzed by the three ADAR1 variants. The ADAR1-a, -b, and -c splice variants all efficiently edited the R/G site and the intron +60 hotspot but exhibited little editing activity at the Q/R site, ADAR1-b and -c showed higher editing activity than ADAR1-a for the R/G site, whereas the intron +60 site was edited with comparable efficiency by all three ADAR1 splice variants. Mutational analysis revealed that the functional importance of each of the three RNA-binding motifs of ADAR1 varied with the specific target editing site in GluR-B RNA. Quantitative reverse transcription-polymerase chain reaction analyses of GluR-B RNA from dissected regions of rat brain showed significant expression and editing at the R/G site in all brain regions examined except the choroid plexus. The relative levels of the alternatively spliced flip and flop isoforms of GluR-B RNA varied among the choroid plexus, cortex, hippocampus, olfactory bulb, and striatum, but in all regions of rat brain the editing of the flip isoform was greater than that of the flop isoform.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Grad Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI012520] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; Belcher SM, 1997, MOL BRAIN RES, V52, P130, DOI 10.1016/S0169-328X(97)00252-0; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Brooks R, 1998, FEBS LETT, V434, P121, DOI 10.1016/S0014-5793(98)00963-6; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CATTANEO R, 1994, CURR OPIN GENET DEV, V4, P895, DOI 10.1016/0959-437X(94)90076-0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; Gerber A, 1997, RNA, V3, P453; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1994, J BIOL CHEM, V269, P17367; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Lai F, 1997, J NEUROCHEM, V69, P43; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; Liu Y, 1998, METHODS, V15, P199, DOI 10.1006/meth.1998.0624; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Mittaz L, 1997, GENOMICS, V41, P210, DOI 10.1006/geno.1997.4655; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Polson AG, 1996, NATURE, V380, P454; Rueter S.M., 1998, MODIFICATION EDITING, P343; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Villard L, 1997, SOMAT CELL MOLEC GEN, V23, P135, DOI 10.1007/BF02679972; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WATHELET MG, 1988, SOMAT CELL MOLEC GEN, V14, P415, DOI 10.1007/BF01534709; WEIER HUG, 1995, GENOMICS, V30, P372, DOI 10.1006/geno.1995.0034; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	51	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5070	5077		10.1074/jbc.274.8.5070	http://dx.doi.org/10.1074/jbc.274.8.5070			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988754	hybrid			2022-12-27	WOS:000078698200079
J	Nakaar, V; Samuel, BU; Ngo, EO; Joiner, KA				Nakaar, V; Samuel, BU; Ngo, EO; Joiner, KA			Targeted reduction of nucleoside triphosphate hydrolase by antisense RNA inhibits Toxoplasma gondii proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE MEMBRANE; ANTI-SENSE RNA; GENE-EXPRESSION; SELECTABLE MARKER; SYNTHASE GENE; PROTEIN; CELLS; RIBOZYMES; NUCLEAR; TRANSFORMATION	Nucleoside triphosphate hydrolase (NTPase) is a very abundant protein secreted by the obligate intracellular parasite Toxoplasma gondii shortly after invasion of the host cell, When activated by dithiols, NTPase is one of the most potent apyrases known to date, but its physiological function remains unknown. The genes encoding NTPase have been cloned (Bermudes, D., Peck, K. R., Afifi-Afifi, M., Beckers, C. J. M., and Joiner, K. A. (1994) J. Biol. Chem. 269, 29252-29260), We have recently shown that the enzyme is tightly controlled within the vacuolar space and may influence parasite exit from the host cell (Silverman, J. A., Qi, H., Riehl, A., Beckers, C., Nakaar, V., and Joiner, K. A (1998) J. Biol. Chem. 273, 12352-12359). In the present study, we have generated an antisense NTP RNA construct in which the 3'-untranslated region is replaced by a hammerhead ribozyme, The constitutive synthesis of the chimeric antisense RNA-ribozyme construct in parasites that were stably transfected with this construct resulted in a dramatic reduction in the steady-state levels of NTPase, This inhibition was accompanied by a decrease in the capacity of the parasites to replicate. The reduction in parasite proliferation was due to a specific effect of antisense NTP RNA, since a drastic inhibition of hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT) expression by a chimeric antisense HXGPRT RNA-ribozyme construct did not alter NTPase expression nor compromise parasite replication. These data implicate NTPase in an essential parasite function and suggest that NTPase may have more than one function in vivo, These results also establish that it is possible to study gene function in apicomplexan parasites using antisense RNA coupled to ribozymes.	Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA	Yale University	Joiner, KA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, 333 Cedar St,808 LCI, New Haven, CT 06520 USA.		Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X				ASAI T, 1983, J BIOL CHEM, V258, P6816; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; ASAI T, 1996, 4 INT BIENN TOX C JU; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CORNELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P7203, DOI 10.1093/nar/17.18.7203; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; ECKER JR, 1986, P NATL ACAD SCI USA, V83, P5372, DOI 10.1073/pnas.83.15.5372; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GU JL, 1995, CIRC RES, V77, P14, DOI 10.1161/01.RES.77.1.14; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUIPERS AGJ, 1995, MOL GEN GENET, V246, P745, DOI 10.1007/BF00290722; LIU Z, 1994, P NATL ACAD SCI USA, V91, P4258, DOI 10.1073/pnas.91.10.4258; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; Nakaar V, 1998, MOL BIOCHEM PARASIT, V92, P229, DOI 10.1016/S0166-6851(97)00220-X; OSSORIO PN, 1994, J BIOL CHEM, V269, P15350; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; RODERMEL SR, 1988, CELL, V55, P673, DOI 10.1016/0092-8674(88)90226-7; ROTHSTEIN SJ, 1987, P NATL ACAD SCI USA, V84, P8439, DOI 10.1073/pnas.84.23.8439; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SIBLEY LD, 1994, EXP PARASITOL, V79, P301, DOI 10.1006/expr.1994.1093; Silverman JA, 1998, J BIOL CHEM, V273, P12352, DOI 10.1074/jbc.273.20.12352; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; Tilley M, 1997, INFECT IMMUN, V65, P4598, DOI 10.1128/IAI.65.11.4598-4605.1997; VANDERKROL AR, 1988, NATURE, V333, P866, DOI 10.1038/333866a0; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807	42	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5083	5087		10.1074/jbc.274.8.5083	http://dx.doi.org/10.1074/jbc.274.8.5083			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988756	hybrid			2022-12-27	WOS:000078698200081
J	Mock, HP; Heller, W; Molina, A; Neubohn, B; Sandermann, H; Grimm, B				Mock, HP; Heller, W; Molina, A; Neubohn, B; Sandermann, H; Grimm, B			Expression of uroporphyrinogen decarboxylase or coproporphyrinogen oxidase antisense RNA in tobacco induces pathogen defense responses conferring increased resistance to tobacco mosaic virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; PROGRAMMED CELL-DEATH; SALICYLIC-ACID; DISEASE RESISTANCE; GENE-EXPRESSION; TRANSGENIC TOBACCO; ACCUMULATION; SCOPOLETIN; PROTEINS; NECROSIS	Transgenic tobacco plants with reduced activity of either uroporphyrinogen decarboxylase or coproporphyrinogen oxidase, two enzymes of the tetrapyrrole biosynthetic pathway, are characterized by the accumulation of photosensitizing tetrapyrrole intermediates, antioxidative responses, and necrotic leaf lesions, In this study we report on cellular responses in uroporphyrinogen decarboxylase and coproporphyrinogen oxidase antisense plants, normally associated with pathogen defense. These plants accumulate the highly fluorescent coumarin scopolin in their leaves. They also display increased pathogenesis-related protein expression and higher levels of free and conjugated salicylic acid. Upon tobacco mosaic virus inoculation, the plants with leaf lesions and high levels of PR-I mRNA expression show reduced accumulation of virus RNA relative to wild-type controls. This result is indicative of an increased resistance to tobacco mosaic virus. We conclude that porphyrinogenesis as a result of deregulated tetrapyrrole synthesis induces a set of defense responses that resemble the hypersensitive reaction observed after pathogen attack.	Inst Pflanzengenet & Kulturpflanzenforsch, D-06466 Gatersleben, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Biochem Pflanzenpathol, D-85764 Oberschleissheim, Germany; Novartis Crop Protect Inc, Biotechnol & Genomics Ctr, Res Triangle Pk, NC 27709 USA	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mock, HP (corresponding author), Inst Pflanzengenet & Kulturpflanzenforsch, Corrensstr 3, D-06466 Gatersleben, Germany.	mock@ipk-gatersleben.de	Molina, Antonio/G-9789-2015; Mock, Hans-Peter/C-8202-2019	Molina, Antonio/0000-0003-3137-7938; Mock, Hans-Peter/0000-0002-3983-3099				Abad MS, 1997, MOL PLANT MICROBE IN, V10, P635, DOI 10.1094/MPMI.1997.10.5.635; ALVAREZ ME, 1997, OXIDATIVE STRESS MOL, P815; ANTONIW JF, 1986, PLANT MOL BIOL, V6, P145, DOI 10.1007/BF00021483; Arakane K, 1996, BIOCHEM BIOPH RES CO, V223, P578, DOI 10.1006/bbrc.1996.0937; Asada K, 1996, PHOTOSYNTHESIS ENV, P123, DOI DOI 10.1007/0-306-48135-9_5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEFFA R, 1995, EMBO J, V14, P5753, DOI 10.1002/j.1460-2075.1995.tb00264.x; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BORS W, 1990, METHOD ENZYMOL, V186, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; Chamnongpol S, 1996, PLANT J, V10, P491, DOI 10.1046/j.1365-313X.1996.10030491.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; Dellinger M, 1996, PHOTOCHEM PHOTOBIOL, V64, P182, DOI 10.1111/j.1751-1097.1996.tb02440.x; DIETERMAN LJ, 1964, ARCH BIOCHEM BIOPHYS, V106, P275, DOI 10.1016/0003-9861(64)90188-2; DIETERMAN LJ, 1964, ANAL BIOCHEM, V9, P139, DOI 10.1016/0003-2697(64)90095-8; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; DOKE N, 1997, OXIDATIVE STRESS MOL, P815; Durner J, 1997, TRENDS PLANT SCI, V2, P266, DOI 10.1016/S1360-1385(97)86349-2; ELMODAFAR C, 1995, EUR J PLANT PATHOL, V101, P503, DOI 10.1007/BF01874474; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Foyer C. H., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P1; Friedrich L, 1996, PLANT J, V10, P61, DOI 10.1046/j.1365-313X.1996.10010061.x; FRITIG B, 1971, Acta Phytopathologica Academiae Scientiarum Hungaricae, V6, P21; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GOY PA, 1993, PLANTA, V191, P200; HASELOFF RF, 1989, J PHOTOCH PHOTOBIO B, V3, P593, DOI 10.1016/1011-1344(89)80082-X; HEITZ T, 1994, MOL PLANT MICROBE IN, V7, P776, DOI 10.1094/MPMI-7-0776; HELLER W, 1990, ENVIRON POLLUT, V64, P353, DOI 10.1016/0269-7491(90)90057-J; Herbers K, 1996, PLANT CELL, V8, P793, DOI 10.1105/tpc.8.5.793; HOSEL W, 1987, ARCH BIOCHEM BIOPHYS, V252, P152, DOI 10.1016/0003-9861(87)90019-1; HUGHES JC, 1960, PHYTOPATHOLOGY, V50, P398; JURD L, 1971, PHYTOCHEMISTRY, V10, P2971, DOI 10.1016/S0031-9422(00)97334-5; KRUSE E, 1995, EMBO J, V14, P3712, DOI 10.1002/j.1460-2075.1995.tb00041.x; LAGRIMINI LM, 1987, P NATL ACAD SCI USA, V84, P7542, DOI 10.1073/pnas.84.21.7542; LUMMERZHEIM M, 1995, PLANT CELL ENVIRON, V18, P499, DOI 10.1111/j.1365-3040.1995.tb00550.x; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MCINTYRE JL, 1981, PHYTOPATHOLOGY, V71, P297, DOI 10.1094/Phyto-71-297; MCMURCHY RA, 1984, PHYSIOL PLANT PATHOL, V25, P229, DOI 10.1016/0048-4059(84)90061-4; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MEUWLY P, 1993, ANAL BIOCHEM, V214, P500, DOI 10.1006/abio.1993.1529; Mittler R, 1996, PLANT CELL, V8, P1991, DOI 10.1105/tpc.8.11.1991; Mittler R, 1997, J CELL SCI, V110, P1333; Mock HP, 1998, PLANT PHYSIOL, V116, P107, DOI 10.1104/pp.116.1.107; Mock HP, 1997, PLANT PHYSIOL, V113, P1101, DOI 10.1104/pp.113.4.1101; OKAZAKI M, 1982, AGR BIOL CHEM TOKYO, V46, P601, DOI 10.1080/00021369.1982.10865137; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; REBEIZ CA, 1984, ENZYME MICROB TECH, V6, P390, DOI 10.1016/0141-0229(84)90012-7; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SCHUSTER B, 1986, Z NATURFORSCH C, V41, P511; SPIKES JD, 1991, CHLOROPHYLLS, P1181; STEIN A, 1985, PHYTOPATHOL Z, V114, P295; Takahashi H, 1997, PLANT J, V11, P993, DOI 10.1046/j.1365-313X.1997.11050993.x; TAL B, 1986, PLANT PHYSIOL, V82, P167, DOI 10.1104/pp.82.1.167; TAL B, 1986, PHYTOCHEMISTRY, V25, P2913, DOI 10.1016/S0031-9422(00)94505-9; TANGUY J, 1972, PHYTOCHEMISTRY, V11, P19, DOI 10.1016/S0031-9422(00)89962-8; Thalmair M, 1996, J PLANT PHYSIOL, V148, P222, DOI 10.1016/S0176-1617(96)80318-X; Valle T, 1997, PLANT SCI, V125, P97, DOI 10.1016/S0168-9452(97)00057-5; VANETTEN HD, 1994, PLANT CELL, V6, P1191; Vereecke D, 1997, PLANTA, V201, P342, DOI 10.1007/s004250050076; VERNOOIJ B, 1995, MOL PLANT MICROBE IN, V8, P228, DOI 10.1094/MPMI-8-0228; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WERNER C, 1985, J PLANT PHYSIOL, V118, P237, DOI 10.1016/S0176-1617(85)80225-X; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621	69	70	77	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4231	4238		10.1074/jbc.274.7.4231	http://dx.doi.org/10.1074/jbc.274.7.4231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933622	hybrid			2022-12-27	WOS:000078575500046
J	Silver, DL; Jiang, XC; Tall, AR				Silver, DL; Jiang, XC; Tall, AR			Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice - Possible role of leptin in stimulation of HDL turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; GENETICALLY-OBESE MICE; TRANSGENIC MICE; INCREASED PLASMA; SR-BI; RECEPTOR; GENE; CHOLESTEROL; PROTEIN; ATHEROSCLEROSIS	Abnormalities of plasma high density lipoprotein (HDL) levels commonly reflect altered metabolism of the major HDL apolipoproteins, apoA-I and apoA-II, but the regulation of apolipoprotein metabolism is poorly understood. Two mouse models of obesity, ob/ob and db/db, have markedly increased plasma HDL cholesterol levels. The purpose of this study was to evaluate mechanisms responsible for increased HDL in ob/ob mice and to assess potential reversibility by leptin administration. ob/ob mice were found to have increased HDL cholesterol (2-fold), apoA-I (1.3-fold), and apoA-II (4-fold). ApoA-I mRNA was markedly decreased (to 25% of wildtype) and apoA-II mRNA was unchanged, suggesting a defect in HDL catabolism, HDL apoprotein turnover studies using nondegradable radiolabels confirmed a decrease in catabolism of apoA-I and apoA-II and a 4-fold decrease in hepatic uptake in ob/ob mice compared with wild-type, but similar renal uptake, Low dose leptin treatment markedly lowered HDL cholesterol and apoA-II levels in both ob/ob mice and in lean wild-type mice, and it restored apoA-I mRNA to normal levels in ob/ob mice. These changes occurred without significant alteration in body weight, Moreover, ob/ob neuropeptide Y-/- mice, despite marked attenuation of diabetes and obesity phenotypes, showed no change in HDL cholesterol levels relative to ob/ob mice. Thus, increased HDL levels in ob/ob mice reflect a marked hepatic catabolic defect for apoA-I and apoA-II, In the case of apoA-I, this is offset by decreased apoA-I mRNA, resulting in apoA-II-rich HDL particles. The studies reveal a specific HDL particle catabolic pathway that is downregulated in ob/ob mice and suggest that HDL apolipoprotein turnover may be regulated by obesity and/or leptin signaling.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 622 W 168th St, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682, F32HL009928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22682, HL09928-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AZROLAN N, 1995, J BIOL CHEM, V270, P19833, DOI 10.1074/jbc.270.34.19833; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Breslow Jan L., 1994, Current Opinion in Lipidology, V5, P175, DOI 10.1097/00041433-199405030-00004; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHENG CF, 1985, J BIOL CHEM, V260, P720; Cohen SM, 1998, P NATL ACAD SCI USA, V95, P7385, DOI 10.1073/pnas.95.13.7385; Cooper AD, 1997, J LIPID RES, V38, P2173; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; FIDGE N, 1980, METABOLISM, V29, P643, DOI 10.1016/0026-0495(80)90109-2; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hamann A, 1998, Z ERNAHRUNGSWISS, V37, P1; HILDENBRANDT GR, 1979, BIOCHIM BIOPHYS ACTA, V587, P373, DOI 10.1016/0304-4165(79)90441-0; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; Huang QL, 1998, ENDOCRINOLOGY, V139, P1524, DOI 10.1210/en.139.4.1524; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; JOOSTEN HFP, 1974, METABOLISM, V23, P59, DOI 10.1016/0026-0495(74)90104-8; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Le N A, 1986, Methods Enzymol, V129, P384; LE NA, 1988, METABOLISM, V37, P614, DOI 10.1016/0026-0495(88)90077-7; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LIU AC, 1994, J LIPID RES, V35, P2263; LIU MS, 1994, J BIOL CHEM, V269, P11417; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; Miller N. E., 1980, Atherosclerosis 5. Proceedings of the Fifth International Symposium, P500; Mooradian AD, 1996, AM J PHYSIOL-REG I, V271, pR1602, DOI 10.1152/ajpregu.1996.271.6.R1602; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RATH EA, 1974, DIABETOLOGIA, V10, P261; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Sarmiento U, 1997, LAB INVEST, V77, P243; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1996, ATHEROSCLEROSIS CORO, P105; Taylor AH, 1996, BIOCHEMISTRY-US, V35, P8281, DOI 10.1021/bi960269o; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WALSH A, 1989, J BIOL CHEM, V264, P6488; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Zaiou M, 1998, J CLIN INVEST, V101, P1699, DOI 10.1172/JCI2166; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4140	4146		10.1074/jbc.274.7.4140	http://dx.doi.org/10.1074/jbc.274.7.4140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933608	hybrid			2022-12-27	WOS:000078575500032
J	Simpson, PJ; Nighorn, A; Morton, DB				Simpson, PJ; Nighorn, A; Morton, DB			Identification of a novel guanylyl cyclase that is related to receptor guanylyl cyclases, but lacks extracellular and transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; MANDUCA-SEXTA; EXPRESSION; NEURONS; CONTAINS; FORM	We have identified a novel guanylyl cyclase, named MsGC-I, that is expressed in the nervous system of Manduca sexta. MsGC-I shows highest sequence identity with receptor guanylyl cyclases throughout its catalytic and dimerization domains but does not contain the ligand-binding, transmembrane, or kinase-like domains characteristic of receptor guanylyl cyclases. In addition, MsGC-I contains a C-terminal extension of 149 amino acids that is not present in other receptor guanylyl cyclases; The sequence of MsGC-I contains no regions that show similarity to the regulatory domain of soluble guanylyl cyclases, Thus, MsGC-I appears to represent a member of a new class of guanylyl cyclases, We show that both a transcript and a protein of the sizes predicted from the MsGC-I cDNA are present in the nervous system of Manduca and that MsGC-I is expressed in a small population of neurons within the abdominal ganglia, When expressed in COS-7 cells, MsGC-I appears to exist as a soluble homodimer with high levels of basal guanylyl cyclase activity that is insensitive to stimulation by nitric oxide. Western blot analysis, however, shows that MsGC-I is localized to the particulate fraction of nervous system homogenates, suggesting that it may be membrane-associated in vivo.	Oregon Hlth & Sci Univ, Sch Dent, Dept Biol Struct & Funct, Portland, OR 97201 USA; Univ Arizona, Arizona Res Labs, Div Neurobiol, Tucson, AZ 85721 USA	Oregon Health & Science University; University of Arizona	Morton, DB (corresponding author), Oregon Hlth & Sci Univ, Sch Dent, Dept Biol Struct & Funct, 611 SW Campus Dr,SD, Portland, OR 97201 USA.	mortonda@ohsu.edu			NINDS NIH HHS [NS29740] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029740, R29NS029740] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; Bhatt TR, 1997, BIOTECHNIQUES, V23, P1000, DOI 10.2144/97236bm06; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; DAVIS NT, 1993, J COMP NEUROL, V338, P612, DOI 10.1002/cne.903380410; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Kojima M, 1995, BIOCHEM BIOPH RES CO, V217, P993, DOI 10.1006/bbrc.1995.2868; Komminoth P., 1996, NONRADIOACTIVE IN SI, P126; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Moon C, 1998, J NEUROSCI, V18, P3195; Nighorn A, 1998, J NEUROSCI, V18, P7244; NIGHORN AJ, 1999, IN PRESS J BIOL CHEM; Prabhakar S, 1997, J NEUROCHEM, V69, P1650; Schulz S, 1998, J BIOL CHEM, V273, P1032, DOI 10.1074/jbc.273.2.1032; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; THORPE DS, 1990, J BIOL CHEM, V265, P14717; TREMBLAY J, 1988, ADV SEC MESS PHOSPH, V22, P319; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	26	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4440	4446		10.1074/jbc.274.7.4440	http://dx.doi.org/10.1074/jbc.274.7.4440			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933648	hybrid			2022-12-27	WOS:000078575500072
J	Li, Q; Subbulakshmi, V; Fields, AP; Murray, NR; Cathcart, MK				Li, Q; Subbulakshmi, V; Fields, AP; Murray, NR; Cathcart, MK			Protein kinase C alpha regulates human monocyte O-2(center dot-) production and low density lipoprotein lipid oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; ACTIVATED HUMAN MONOCYTES; ADENINE-DINUCLEOTIDE PHOSPHATE; SUPEROXIDE ANION PRODUCTION; HUMAN-NEUTROPHILS; NADPH-OXIDASE; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; PHOSPHORYLATION	Our previous studies have shown that human native low density lipoprotein (LDL) can be oxidized by activated human monocytes, In this process, both activation of protein kinase C (PKC) and induction of superoxide anion (O-2(radical anion)) production are required. PKC is a family of isoenzymes, and the functional roles of individual PKC isoenzymes are believed to differ based on subcellular location and distinct responses to regulatory signals. We have shown that the PKC isoenzyme that is required for both monocyte O-2(radical anion) production and oxidation of LDL is a member of the conventional PKC group of PKC isoenzymes (Li, Q., and Cathcart, M.K. (1994) J. Biol. Chem, 269, 17508-17515), The conventional PKC group includes PKC alpha, PKC beta I, PKC beta II, and PKC gamma. With the exception of PKC gamma, each of these isoenzymes was detected in human monocytes, in these studies, we investigated the requirement for select PKC isoenzymes in the process of monocyte-mediated LDL lipid oxidation, Our data indicate that PKC activity was rapidly induced upon monocyte activation with the majority of the activity residing in the membrane/particulate fraction. This enhanced PRC activity was sustained for up to 24 h after activation. PKC alpha, PKC beta I, and PKC beta II protein levels were induced upon monocyte activation, and PKC alpha and PKC beta II substantially shifted their location from the cytosol to the particulate/ membrane fraction. To distinguish between these isoenzymes for regulating monocyte O-2(radical anion) production and LDL oxidation, PKC alpha or PKC beta isoenzyme-specific antisense oligonucleotides were used to selectively suppress isoenzyme expression. We found that suppression of PKC alpha expression inhibited both monocyte-mediated O-2(radical anion) production and LDL lipid oxidation by activated human monocytes, In contrast, inhibition of PKC beta expression (including both PKC beta I and PKC beta II) did not affect O-2(radical anion) production or LDL lipid oxidation, Further studies demonstrated that the respiratory burst oxidase responsible for O-2(radical anion) production remained functionally intact in monocytes with depressed levels of PKC alpha because O-2(radical anion) production could be restored by treating the monocytes with arachidonic acid. Taken together, our data reveal that PKC alpha, and not PKC beta I or PKC beta II, is the predominant isoenzyme required for O-2(radical anion) production and maximal oxidation of LDL by activated human monocytes.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA	Cleveland Clinic Foundation; University of Texas System; University of Texas Medical Branch Galveston	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	cathcam@esmtp.ccf.org			NCI NIH HHS [CA56869] Funding Source: Medline; NHLBI NIH HHS [HL51068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHISOLM GM, 1996, ATHEROSCLEROSIS CORO, P129; COSTACASNELLIE MR, 1986, J CELL PHYSIOL, V129, P336, DOI 10.1002/jcp.1041290311; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Hatch F T, 1968, Adv Lipid Res, V6, P1; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; HOCEVAR BA, 1992, J CELL SCI, V101, P671; JACOB T, 1994, J LEUKOCYTE BIOL, V55, P310, DOI 10.1002/jlb.55.3.310; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; KADRIHASSANI N, 1995, J BIOL CHEM, V270, P15111, DOI 10.1074/jbc.270.25.15111; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAKE DS, 1990, BIOCHEM J, V270, P741, DOI 10.1042/bj2700741; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; Li Q, 1997, J LIPID MEDIAT CELL, V17, P175, DOI 10.1016/S0929-7855(97)00030-8; LI Q, 1994, J BIOL CHEM, V269, P17508; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MYERS MA, 1985, J IMMUNOL, V135, P3411; Park JW, 1998, EXP HEMATOL, V26, P37; Park JW, 1997, J BIOL CHEM, V272, P11035; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PRABHAKAR U, 1993, EUR CYTOKINE NETW, V4, P31; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; SAKATA A, 1987, J IMMUNOL, V138, P4353; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; STEINMAN RM, 1972, J CELL BIOL, V55, P186, DOI 10.1083/jcb.55.1.186; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZHENG L, 1995, J IMMUNOL, V155, P776	47	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3764	3771		10.1074/jbc.274.6.3764	http://dx.doi.org/10.1074/jbc.274.6.3764			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920929	hybrid			2022-12-27	WOS:000078428200069
J	Morris, SNK; Harkins, TT; Tennyson, RB; Lindsley, JE				Morris, SNK; Harkins, TT; Tennyson, RB; Lindsley, JE			Kinetic and thermodynamic analysis of mutant type II DNA topoisomerases that cannot covalently cleave DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; BINDING; MECHANISM; PURIFICATION; RELAXATION; TRANSPORT; CLAMP	DNA topoisomerase II catalyzes two different chemical reactions as part of its DNA transport cycle: ATP hydrolysis and DNA breakage/religation, The coordination between these reactions was studied using mutants of yeast topoisomerase II that are unable to covalently cleave DNA. In the absence of DNA, the ATPase activities of these mutant enzymes are identical to the wild type activity. DNA binding stimulates the ATPase activity of the mutant enzymes, but with steady-state parameters different from those of the wild type enzyme. These differences were examined through DNA binding experiments and pre-steady-state ATPase assays. One mutant protein, Y782F, binds DNA with the same affinity as wild type protein. This mutant topologically traps one DNA circle in the presence of a nonhydrolyzable ATP analog under the same conditions that the wild type protein catenates two circles. Rapid chemical quench and pulse-chase ATPase experiments reveal that the mutant proteins bound to DNA have the same sequential hydrolysis reaction cycle as the wild type enzyme. Binding of ATP to the mutants is not notably impaired, but hydrolysis of the first ATP is slower than for the wild type enzyme. Models to explain these results in the context of the entire DNA topoisomerase II reaction cycle are discussed.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.	Janet.Lindsley@hsc.utah.edu			NCI NIH HHS [CA09602-06] Funding Source: Medline; NIGMS NIH HHS [GM51194, 5T32GM08753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051194, T32GM008753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Alsner J, 1996, J MOL BIOL, V259, P317, DOI 10.1006/jmbi.1996.0321; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; FREIFELDER D, 1982, PHYSICAL BIOCH APPL, P430; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1994, ADV PHARM B, V29; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Tennyson RB, 1997, BIOCHEMISTRY-US, V36, P6107, DOI 10.1021/bi970152f; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3446	3452		10.1074/jbc.274.6.3446	http://dx.doi.org/10.1074/jbc.274.6.3446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920889	hybrid			2022-12-27	WOS:000078428200029
J	Seol, DW; Chen, QY; Smith, ML; Zarnegar, R				Seol, DW; Chen, QY; Smith, ML; Zarnegar, R			Regulation of the c-met proto-oncogene promoter by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; TYROSINE KINASE; TUMOR-SUPPRESSOR; FACTOR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; EPITHELIAL-CELLS; GENE PROMOTER; BINDING-SITE; FACTOR-ALPHA	In the present study, we have investigated the possible involvement of p53 in the transcriptional regulation of the c-met gene. Cotransfection of various c-met promoter reporter vectors with p53 expression plasmids demonstrated that only wild-type p53 but not tumor-derived mutant forms of p53 resulted in a significant enhancement of c-met promoter activity. Functional assays revealed that the p53 responsive element in the c-met promoter region is located at position -278 to -216 and confers p53 responsiveness not only in the context of the c-met promoter but also in the context of a heterologous promoter. Electrophoretic mobility shift assays using purified recombinant p53 protein showed that the p53 binding element identified within the c-met promoter specifically binds to p53 protein. Induction of p53 by UV irradiation in RKO cells that express wildtype p53 increased the level of the endogenous c-met gene product and p21(WAF1/CIP1), a known target of p53 regulation. On the other hand, in RKO cells in which the function of p53 is impaired either by stable transfection of a dominant negative form of p53 or by HPV-E6 viral protein, no induction of the endogenous c-met gene or p21(WAF1/CIP1) was noted by UV irradiation. These results suggest that the c-met gene is also a target of p53 gene regulation.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Indiana University System; Indiana University-Purdue University Indianapolis	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, BST S 419, Pittsburgh, PA 15261 USA.	rezazar+@pitt.edu						Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BELL A, 1989, IN PRESS ONCOGENE; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; MIYASHITA T, 1995, CELL, V80, P293; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, ONCOGENE, V6, P501; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PONZETTO C, 1991, ONCOGENE, V6, P553; RONG S, 1993, CANCER RES, V53, P5355; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SAXENA A, 1992, ONCOGENE, V7, P243; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Thorgeirsson SS, 1997, MUTAT RES-FUND MOL M, V376, P221, DOI 10.1016/S0027-5107(97)00047-X; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	50	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3565	3572		10.1074/jbc.274.6.3565	http://dx.doi.org/10.1074/jbc.274.6.3565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920903	hybrid			2022-12-27	WOS:000078428200043
J	Hook, VYH; Sei, C; Yasothornsrikul, S; Toneff, T; Kang, YH; Efthimiopoulos, S; Robakis, NK; Van Nostrand, W				Hook, VYH; Sei, C; Yasothornsrikul, S; Toneff, T; Kang, YH; Efthimiopoulos, S; Robakis, NK; Van Nostrand, W			The kunitz protease inhibitor form of the amyloid precursor protein (KPI/APP) inhibits the proneuropeptide processing enzyme prohormone thiol protease (PTP) - Colocalization of KPI/APP and PTP in secretory vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-CONTAINING PEPTIDES; ALZHEIMERS-DISEASE; CHROMAFFIN GRANULES; ADRENAL-MEDULLA; NEXIN-II; CYSTEINE PROTEASE; NERVE-TERMINALS; FULL-LENGTH; PURIFICATION; DOMAIN	Proteolytic processing of proenkephalin and proneuropeptides is required for the production of active neurotransmitters and peptide hormones. Variations in the extent of proenkephalin processing in vivo suggest involvement of endogenous protease inhibitors. This study demonstrates that "protease nexin 2 (PN2)," the secreted form of the kunitz protease inhibitor (KPI) of the amyloid precursor protein (APP), potently inhibited the proenkephalin processing enzyme known as prohormone thiol protease (PTP), with a K-i,K-app of 400 nM. Moreover, PTP and PN2 formed SDS-stable complexes that are typical of kunitz protease inhibitor interactions with target proteases, In vivo, KPI/APP (120 kDa), as well as a truncated form of KPI/APP that resembles PN2 in apparent molecular mass (110 kDa), were colocalized with PTP and (Met)enkephalin in secretary vesicles of adrenal medulla (chromaffin granules). KPI/APP (110-120 kDa) was also detected in pituitary secretory vesicles that contain PTP, In chromaffin cells, calcium-dependent secretion of KPI/APP with PTP and (Met)enkephalin demonstrated the colocalization of these components in functional secretory vesicles. These results suggest a role for KPI/APP inhibition of PTP in regulated secretory vesicles. In addition, these results are the first to identify an endogenous protease target of KPI/APP, which is developmentally regulated in aging and Alzheimer's disease.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; USN, Med Res Inst, Bethesda, MD 20892 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY 10029 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Med, Stony Brook, NY 11794 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hook, VYH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr 0822, La Jolla, CA 92093 USA.	vhook@ucsd.edu	Robakis, Nikolaos/AAA-1838-2021; Efthimiopoulos, Spiros/H-3956-2013	Efthimiopoulos, Spiros/0000-0001-9244-4570	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49566] Funding Source: Medline; NIDA NIH HHS [DA04271] Funding Source: Medline; NINDS NIH HHS [NS24553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON JP, 1989, EMBO J, V8, P3627, DOI 10.1002/j.1460-2075.1989.tb08536.x; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; AZARYAN AV, 1995, J NEUROCHEM, V65, P1771; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; BEESON JG, 1994, J COMP NEUROL, V342, P78, DOI 10.1002/cne.903420109; BJORKLUND A, 1990, HDB CHEM NEUROANAT, V9, P1; BJORKLUND A, 1990, HDB CHEM NEUROANATOM, V9, P287; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; CARMICHAEL SW, 1985, SCI AM, V253, P40, DOI 10.1038/scientificamerican0885-40; Efthimiopoulos S, 1996, P NATL ACAD SCI USA, V93, P8046, DOI 10.1073/pnas.93.15.8046; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; FLEMINGER G, 1983, P NATL ACAD SCI-BIOL, V80, P6418, DOI 10.1073/pnas.80.20.6418; FURUYA S, 1989, J ELECTRON MICROSC, V38, P143; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gottfries CG, 1995, EUR NEUROPSYCHOPHARM, V5, P491, DOI 10.1016/0924-977X(95)00038-Q; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1985, J BIOL CHEM, V260, P5991; HOOK VYH, 1998, MOL B INT U, V2, P89; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; LEWIS ME, 1985, PEPTIDES, V6, P37, DOI 10.1016/0196-9781(85)90010-5; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Loh Y. P., 1993, MECHANISMS INTRACELL, P179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MERCHENTHALER I, 1986, NEUROSCIENCE, V17, P325, DOI 10.1016/0306-4522(86)90250-2; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MOYA KL, 1994, J NEUROCHEM, V63, P1971; NORRIS DO, 1997, VERTEBRATE ENDOCRINO, P104; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; Robakis Nikolaos K., 1994, P317; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Roeske LC, 1995, REV NEUROSCIENCE, V6, P317; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; SCHULTZBERG M, 1978, ACTA PHYSIOL SCAND, V103, P475, DOI 10.1111/j.1748-1716.1978.tb06243.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SINHA S, 1990, J BIOL CHEM, V265, P8983; SOLA C, 1993, NEUROSCIENCE, V53, P267, DOI 10.1016/0306-4522(93)90304-X; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Tezapsidis N, 1998, BIOCHEMISTRY-US, V37, P1274, DOI 10.1021/bi9714159; TEZAPSIDIS N, 1995, J BIOL CHEM, V270, P13285, DOI 10.1074/jbc.270.22.13285; TOOMIM CS, 1992, BIOCHEM BIOPH RES CO, V183, P449, DOI 10.1016/0006-291X(92)90502-C; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VASSILACOPOULOU D, 1995, J NEUROCHEM, V64, P2140; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yasothornsrikul S, 1998, J NEUROCHEM, V70, P153; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	70	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3165	3172		10.1074/jbc.274.5.3165	http://dx.doi.org/10.1074/jbc.274.5.3165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915856	hybrid			2022-12-27	WOS:000078319500074
J	Nagano, K; Fukami, K; Minagawa, T; Watanabe, Y; Ozaki, C; Takenawa, T				Nagano, K; Fukami, K; Minagawa, T; Watanabe, Y; Ozaki, C; Takenawa, T			A novel phospholipase C delta 4 (PLC delta 4) splice variant as a negative regulator of PLC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDE BINDING-SPECIFICITY; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; EXPRESSION; C-BETA(1)	It has been reported that there are two alternatively spliced variants of phospholipase C-delta 4 (PLC delta 4), termed ALT I and II, that contain an additional 32 and 14 amino acids in their respective sequences in the linker region between the catalytic X and Y domains (Lee, S. B., and Rhee, S. G. (1996) J. Biol. Chem. 271, 25-31). We report here the isolation and characterization of a novel alternative splicing isoform of PLC delta 4, termed ALT III, as a negative regulator of PLC. In ALT III, alternative splicing occurred in the catalytic X domain, i.e. 63 amino acids (residues 424-486) containing the C-terminal of the X domain and linker region were substituted for 32 amino acids corresponding to the insert sequence of ALT I. Although the expression level of ALT III was found to be much lower in most tissues and cells compared with that of PLC delta 4, it was significantly higher in some neural cells, such as NIE-115 cells and p19 cells differentiated to neural cells by retinoic acid. Interestingly, recombinant ALT III protein did not retain enzymatic activity, and the activity of PLC delta 4 overexpressed in COS7 cells was markedly decreased by the co-expression of ALT III but not by ALT I or II. Moreover, N-terminal pleckstrin homology domain (PH domain) of ALT III alone could inhibit the increase of inositol-1,4,5-trisphosphate levels in PLC delta 4-overexpressing NIH3T3 cells, whereas a PH domain deletion mutant could not, indicating that the PH domain is necessary and sufficient for its inhibitory effect. The ALT III PH domain specifically bound to phosphatidylinositol (PtdIns)-4,5-P-2 and PtdIns-3,4,5-P-3 but not PtdIns, PtdIns-4-P, or inositol phosphates, and the mutant R36G, which retained only weak affinity for PtdIns-4,5-P-2, could not inhibit the activity of PLC delta 4. These results indicate that PtdIns-4,5-P-2 binding to PH domain is essential for the inhibitory effect of ALT III. ALT III also inhibited PLC delta 1 activity and partially suppressed PLC gamma 1 activity, but not PLC beta 1 in vitro; it did inhibit all types of isozymes tested in vivo. Taken together, our results indicate that ALT III is a negative regulator of PLC that is most effective against the PLC delta-type isozymes, and its PH domain is essential for its function.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Ehime Univ, Fac Technol, Matsuyama, Ehime 7908577, Japan	University of Tokyo; Ehime University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; BAHK YY, 1994, J BIOL CHEM, V269, P8240; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KENNEDY CRJ, 1995, BBA-LIPID LIPID MET, V1258, P206, DOI 10.1016/0005-2760(95)00049-I; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; KIM S, 1995, J BIOL CHEM, V270, P14376, DOI 10.1074/jbc.270.24.14376; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; Sims CE, 1998, J BIOL CHEM, V273, P4052, DOI 10.1074/jbc.273.7.4052; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Takeuchi H, 1996, BIOCHEM J, V318, P561, DOI 10.1042/bj3180561; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	41	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2872	2879		10.1074/jbc.274.5.2872	http://dx.doi.org/10.1074/jbc.274.5.2872			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915823	hybrid			2022-12-27	WOS:000078319500041
